

# Polar Capital Funds plc

Annual Report and Audited Financial Statements For the year ended 31 December 2021





# Contents

### **Business Review**

Investment Manager's Reports	
Asian Stars Fund	01
Automation & Artificial Intelligence Fund	04
Biotechnology Fund	07
China Stars Fund	12
Emerging Markets Income Fund	14
Emerging Markets Stars Fund	15
European ex UK Income Fund	19
Financial Opportunities Fund	22
Global Absolute Return Fund	23
Global Convertible Fund	26
Global Insurance Fund	29
Global Technology Fund	32
Healthcare Blue Chip Fund	38
Healthcare Discovery Fund	41
Healthcare Opportunities Fund	44
Income Opportunities Fund	46
Japan Value Fund	48
North American Fund	51
Smart Energy Fund	54
Smart Mobility Fund	56
UK Absolute Equity Fund	58
UK Value Opportunities Fund	59
Report of the Directors	61
Report of the Depositary to the Shareholders	65

### Financial Statements and Notes

Independent Auditor's Report	66
Portfolio Statements	
Asian Stars Fund	72
Automation & Artificial Intelligence Fund	75
Biotechnology Fund	79
China Stars Fund	83
Emerging Markets Income Fund	86
Emerging Markets Stars Fund	87
European ex UK Income Fund	91
Financial Opportunities Fund	94
Global Absolute Return Fund	98
Global Convertible Fund	104
Global Insurance Fund	116
Global Technology Fund	119
Healthcare Blue Chip Fund	128
Healthcare Discovery Fund	132
Healthcare Opportunities Fund	137
Income Opportunities Fund	141
Japan Value Fund	146
North American Fund	150

Smart Energy Fund	155
Smart Mobility Fund	158
UK Absolute Equity Fund	161
UK Value Opportunities Fund	162
Statement of Financial Position	166
Statement of Comprehensive Income	174
Statement of Changes in Net Assets Attributable	
to Holders of Redeemable Participating Shares	182
Statement of Cash Flows	186
Notes to the Financial Statements	194
Statement of Significant Portfolio Movements (Unaudited)	
Asian Opportunities Fund	361
Automation & Artificial Intelligence Fund	362
Biotechnology Fund	364
China Stars Fund	365
Emerging Markets Income Fund	366
Emerging Markets Stars Fund	368
European ex UK Income Fund	369
Financial Opportunities Fund	370
Global Absolute Return Fund	372
Global Convertible Fund	374
Global Insurance Fund	375
Global Technology Fund	376
Healthcare Blue Chip Fund	378
Healthcare Discovery Fund	380
Healthcare Opportunities Fund	382
Income Opportunities Fund	383
Japan Value Fund	385
North American Fund	386
Smart Energy Fund	387
Smart Mobility Fund	388
UK Value Opportunities Fund	390
Information for Investors (unaudited)	
Information for Investors in the Federal Republic of Germany (unaudited)	392
Information for Investors in Switzerland (unaudited)	392
Total Expense Ratio	393
PEA Compliance (unaudited)	393
Appendix I – Remuneration Disclosures (unaudited)	394
Appendix II – Securities Financing Transactions	
Regulation (unaudited)	395
Article 8 SFDR Asian Stars Fund Annual Report	397
Article 8 SFDR China Stars Annual Report	404
Article 8 SFDR Emerging Markets Stars Annual Report	407
Article 8 SFDR Global Insurance Annual Report	415
Article 9 SFDR Smart Energy Annual Report	426
Article 9 SFDR Smart Mobility Annual Report	430
Management and Administration	434



For the financial year ended 31 December 2021

# **Asian Stars Fund**

### **Fund Performance**

For the full year 2021, we returned 3.7% (Class I US Dollar Accumulation Shares) compared to returns for the MSCI AC Asia ex Japan Total Return Index of -4.7% (in dollar terms), giving us an excess return of 8.4%, net of fees, which we are pleased with given this was generally a strong value year and a weaker one for our style of growth and quality. It was a very disappointing year for Asia as an asset class, witnessing one of the biggest differentials with developed markets. Asia was in particular dragged down by weak performance in China (including Hong Kong) as well as a general fear around the Fed taper, both topics we commented on throughout the year.

We are pleased we provided positive absolute returns, driven by our stock picking, during a year when the Asian market was down, but given the potential we see in Asian equities and the bottom-up cases we have, a return of 'just' 3.7% still feels disappointing.

Our growth and quality bias, linked to our fully integrated sustainability investment process, in the way we select and invest in companies means 2021 was a difficult year for us, in fact for any quality/ESG fund in emerging markets with a growth bias.

There is of course a slightly different calculation for the performance of growth versus value as a style, though using data from Bloomberg, value in Asia for 2021 outperformed growth by 12.9% (value 2.7%; growth -10.3%, in dollar terms). Therefore, we feel it is ok to outperform by nearly 8.5%, given our bias alongside our integrated suitability process where we do not invest in fossil fuel, coal and so on, all areas that performed well during 2021. In a year of constant headwinds, at times the occasional one felt more like a hurricane.

For the full year 2021, we had a positive contribution from our selection as well as our allocation effect, though the biggest positive contribution came from our selection effect. We had a strong, positive performance contribution from a stock selection effect in South Korea, Taiwan, China and India. In Taiwan and China we also had a good allocation effect, with these being our two best absolute contributors from a country perspective, closely followed by South Korea and India.

Despite all the negative issues, China ended up a positive contributor for us during 2021, which we are very pleased by given how 'topical' and centre stage it has been. However, the overall positive contribution has primarily been driven by the allocation effect, having been underweight the market. The selection effect for us in China was 1.4% (gross of fees), which we find acceptable given our profound growth bias here, precisely where a great deal of panic sentiment hit hard. Hopefully, this is in part due to our ability to identify the higher quality part of the market as well as having risk management capabilities at a portfolio level. Our off-benchmark exposure in Vietnam also paid off well during 2021, with our stock picks returning more than 20%, making it one of the bright spots in an otherwise disappointing year. We remain positive on the return outlook in Vietnam and for our stock picks there.

We did not have any significantly bad countries from an allocation perspective, with Hong Kong – that we fully consider to be part of China – performing ok, driven by the old value names, though we did see a small allocation drag from not owning anything there.

Myanmar was also a drag on relative performance, down to the investment we had in Yoma Strategic Holdings early in the year (we have been a long-term shareholder here going back many years). The military coup totally changed the investment case and we find the situation for Yoma Strategic Holdings, its employees and the population there dreadful.

Our performance from a sector perspective shows our overall outperformance was purely driven by our selection effect (alpha). We ended up with a positive contribution effect from allocation.

We had good, positive selection effect within industrials, real estate and IT. The allocation effect was also positive for IT, leading to IT and industrials being our two strongest contributing sectors overall. We see these two as core sectors so are pleased that in a difficult year like 2021 we can still derive value added and alpha when things get tough.

The good selection effect in real estate was very much driven by our core stock picks in India and Vietnam.

We do not have a huge exposure to materials, but we had a good selection effect from our position in Ivanhoe Mines which we still believe is one of the best ways to gain exposure to what we call 'green metals'.

On the negative side, dragging down relative performance from a sector perspective, were financials and consumer discretionary. Financials was mostly related to not owning the right companies (banks in the value markets did well compared to those in the more growth-oriented markets). From a stock-specific perspective, Ping An Insurance in China was a significant drag.

Communication services (including internet companies) has historically been one of our strongest performing sectors and a key alpha generator. Given the growth scare on the back of the Fed's proposed taper actions, and particularly the Chinese internet regulation we ended up with a positive contribution of 1.1%, gross of fees, very much driven by a positive selection effect.

# Asian Stars Fund continued

### Fund Performance continued

Sea was the main positive contributing stock over the year, but our significant reduction in exposure early in 2021 and concentrating our portfolio around what we believe are the high-quality names and business models for the longer term, helped us survive this out of favour area. To be clear, we still structurally believe in a world where most emerging market countries will in the coming decade more significantly move towards greater digital living, so this is certainly not an ex-growth area. In our view, it is becoming attractively priced.

The best contributing stocks were eMemory Technology (Taiwan technology, embedded memory/semiconductors), EcoPro (Korea specialised battery material), Sungrow Power Supply (China inverters for renewable energy), Prestige Estates Projects (India property) and Binjiang Service Group (China property management).

The worst contributors to relative performance for 2021 were Alibaba Health Information Technology (China digital healthcare services), MicroPort CardioFlow (China medtech), Ping An Insurance (China insurance/financial supermarket), Land Mark Optoelectronics (Taiwan technology) and ITM Semiconductor (South Korea battery technology).

eMemory Technology is a company we have invested in for many years now. The case has taken longer to play out than we had hoped but returned well over 200% in 2021 and was the standout company for us last year. It is great when patience is rewarded. This company is at the forefront of semiconductor design and has created a unique security solution that will be built into the wafer (chip) and thereby give it unique security properties which will be essential for our digital world going forward. This is still only a \$5bn market-cap company so with the right execution it has a long way to go.

Another name we want to highlight is Prestige Estates Projects, our key Indian property company. It has not been easy to talk positively about Indian property over the past 18 months, so we are pleased to demonstrate there were return opportunities available there. We still believe we are at the beginning of a multiyear property cycle in India and see Prestige Estates Projects as one of the best positioned companies to turn this growth opportunity into sustainable shareholder value. Our other highlighted and long-term India name – Phoenix Mills (malls and hotels) – also gave a solid contribution to performance last year, though struggled because of COVID-19.

Looking at the weaker areas, one company stands out – Alibaba Health Information Technology (China). A mixture of strong market and sector sentiment headwinds created a strong negative backdrop, combined with questionable strategic decisions the market had a hard time understanding, leading to significant selloffs. Alibaba Health Information Technology increased its capital expenditure while preparing for the opening up of online prescription drugs and the related services and infrastructure needed. This resulted in shorterterm reduced growth and the inflection point moving out to reach breakeven, a problem as the company is still in the early growth stage. This was clearly not the year to be a high growth company, especially when it then had to disappoint the market on lowering growth guidance during a period with very high risk aversion.

As we mentioned earlier, China was a difficult place to invest during 2021 and the negative sentiment around technology, healthcare and medtech contributed to the weak contribution from MicroPort CardioFlow. Ping An Insurance in China was another drag on performance as the market became frustrated with its growth profile as the year progressed.

### **Market Outlook**

We are bullish for 2022 for our Fund as, put simply, we feel little has changed from a structural long-term perspective over the past 6–12 months, while many of our companies have become cheaper relative to their fundamentals (long-term EVA creation). We have, therefore, become more positive on our view of the return prospects for the portfolio over the next 12–18 months, and beyond.

There are big risks in the market for 2022 though our view is they are already guite well understood and priced in by the market to the extent that some are overshooting the longer-term fundamentals on the downside. We obviously cannot spot the unknown unknowns that the market has paid absolutely no attention to, nor can we see any large or broad-based bubble areas either. There are still pockets where a large proportion of companies have high valuations - electric vehicles (EV), Indian consumer names or some of the robotics/ automation areas, for example – but these are also areas where the long-term growth opportunities are high and where we see earlystage growth opportunities for significant alpha over the coming decade. We do not have structural concerns here and still believe that even these 'hot' areas will offer the potential for attractive alpha generation. We also believe a great deal of negative sentiment is already priced into emerging markets in general, and we are faced with one of the largest ever valuation spreads between the US/ developed markets and emerging markets.

We maintain our view that we are now around peak inflation in the US. The supply-chain bottleneck has been more significant than we originally forecast and moved our original peak inflation point from Q3/Q4 2021 to Q1/Q2 2022. Over the next 12 months we expect to see the inflation scare fade away and think it is likely that by Q4 2022 we will be looking at inflation (US Core CPI and US Core PCE) at around 2.5–3%, with consensus at 2% for 2023 and 2024 that should be supportive for emerging market equities. An increase in inflation from here in the range of 0.2–0.4% per month should take us there – we think this is realistic and the most likely outcome.

Why will inflation go down in 2023–24? The Fed taper combined with reduced stimuli will have an impact on demand as long as consumers continue to behave rationally. There is a lag in fiscal and monetary policy and as most people are forward looking they will price expectations for goods and services faster, in our view.

We are also seeing more indications of supply bottlenecks being eased so as 1H 2022 plays out we see a high likelihood of supply again being stronger than demand which will reduce inflation pressure. The big moving part for inflation will be energy while a potential structural risk to inflation – which is not our base case view – is 'greenflation' if politicians push for too unrealistic an agenda on carbon reduction.

Around 6 January, we saw panic in the market when the Fed minutes were released because it now looks like the first rate hike will be moved from May to March. This news sent the MSCI Global Growth index down by 2.7% and the MSCI Global Value index up by 1.2% – a spread of 4% on the back of a potential two-month difference in timing a rate hike. This seems crazy to us, though it also seems people now believe in five US rate hikes in 2022 and an additional three in 2023 which would take real rates into positive territory. We believe the taper and a few rate hikes will do the job for the Fed as has been the case before – just think back to H2 2018.

We mention this as we expect emerging market equities as an asset class to continue for some time to be significantly influenced by US monetary policy. We therefore expect a high likelihood of a repeat of 2021 in 2022 in the US economy, with a great deal of cyclical and value hype in the early part of the year that will then fade away during H1 as it becomes clear supply is outstripping demand. The Fed will be able to show a projection to get itself back to its target inflation level, then the market will move back and favour growth. During this, the 10-year yield will flirt with 2%+ but structurally we do not see it moving beyond 2–2.5%, though we acknowledge the Fed has been a big buyer in the market and there is uncertainty about what a Treasury market looks like without the Fed being there.

Sticking our neck out, we see today's COVID-19 panic being a thing of the past quite soon. We believe Omicron will burn itself out in the developed world in 1Q22 and the early part of 2Q22 and, unless we get a further mutation that is more deadly (not necessarily more infectious), then we think we are quickly moving towards a pre-COVID-19 normal. The world simply cannot keep going on as it is now. We also think that working from home (WFH) as a new standard will quickly move to working one day per week from home and that people will return to the office. We are increasingly seeing companies complaining that WFH is good for a short period but they cannot grow a business this way and the cost to culture and new employees is just too high.

In general, we are not making large changes to our current positioning. Of the hotter topics, we feel we will reach the bottom for Chinese internet companies and we are now selectively starting to slowly add back exposure as we see favourable risks/rewards for certain companies. This also spills over to other internet-related companies in ASEAN and Korea, such as Sea and Naver, that seem lately to have suffered collateral damage without any real change to their operational fundamentals. The same goes for technology, particularly semiconductors, an area we are still bullish on. We strongly believe we have seen the right strategic fundamentals play out to give us comfort that we are moving into an upcycle that is clearly not being fully priced in by the broader market. We see a cyclical tailwind coming into play as well as a strong structural underlying trend with technology leaders getting stronger, creating a favourable supply-side relative to demand in the years to come. We believe we have a good mix of strong large-cap names as well as emerging leaders.

We retain a structural positive towards India, acknowledging that it had a great year in 2021 relative to the rest of the emerging world. Seen from a broader market perspective its valuation looks expensive. However, we see the stars aligning for India in terms of its structural growth and we also see the emergence of a housing uptrend, strong underlying consumption trends, a significant infrastructure uptick and a corporate capex cycle that will be codeveloping with growth in manufacturing in India, admittedly from a low base. We still find a large amount of exciting stock picks in India and foresee us having high relative exposure here throughout 2022. Short-term risk will be a likely rate hike around March as the Reserve Bank of India (RBI) will keep a conservative view on inflation as growth momentum builds. As of now, we will see any selloff on the back of such a move by the RBI as a buying opportunity from a long-term perspective.

We also see a significant move within North Asia for advances in manufacturing and automation – we believe we already have some great stock picks here that offer the potential for great returns – so we will maintain our exposure. If anything, if the opportunity emerges we will be happy to add exposure from a structural perspective.

We maintain our positive view on Vietnam and again will be a buyer on any interesting opportunity that appears. We also believe that in 2022 we will have an announcement that Vietnam will be moved into the emerging market universe from its frontier market status in 2023.

The slightly more problematic areas for us into 2022 include EVs (battery technology and battery materials), not because we do not see great growth potential but due to valuation levels for many of these companies. This area will be all about stock picking. Looking more broadly, we increasingly see better supply versus demand dynamics appearing more upstream in the value chain, so expect potential activity from us here.

The bottom line is we see great opportunities for our Asian Stars portfolio, with significant return potential for anyone with a 12–18-month investment horizon. We have historically been good at taking advantages of 'panic periods' and turning them into sustainable, responsible returns – we believe one of those periods is coming again.

#### **Emerging Markets and Asia Team**

Polar Capital LLP

# Automation & Artificial Intelligence Fund

### **Fund Performance**

The Fund's NAV (Class I US Dollar Accumulation Shares) returned 16.6% in 2021, compared to its global equity benchmark, the MSCI AC World Index TR Net, which returned 18.5% (in dollar terms).

Our artificial intelligence (AI) theme delivered strong returns, with our AI Enablers subtheme performing particularly well. Our holdings, which include NVIDIA, Advanced Micro Devices (AMD) and Tokyo Electron, benefited from strong investment tailwinds as Fortune 500 companies further accelerated their AI-related projects and moved these into the early stages of commercialisation. While this same tailwind helped our AI Applications' holdings generate a respectable return, the subtheme's returns were somewhat negatively impacted by the sharp rotations from growth to value stocks seen sporadically through the year. Companies such as Guardant Health, Spotify and Snap, to name a few, either in their early stages or with little or no profit, were particularly impacted.

Our Automation theme had a challenging year in a volatile macro backdrop. Recurring COVID-19 waves culminating in the Omicron variant, aggressive deleveraging and regulatory crackdowns the Chinese government pursued through the year, and unprecedented supply-chain shortages combined to produce an environment in which visibility into and execution of orders were seriously compromised, despite generally strong demand levels in many parts of the economy. At the same time, rising expectations of an acceleration in the rate at which central banks tighten monetary policy pressured valuation multiples of high growth stocks, a number of which we own in our Digital Transformation subtheme. Although the Factory Automation subtheme underperformed the overall market, the accelerated adoption of industrial IoT and digital twin technology helped several of our large, key holdings, which delivered strong returns over the year.

Emerging Themes, a relatively small group of holdings that supplement the above-mentioned two key themes, performed broadly in line with the overall market. The strong performance in MediaTek, DexCom and Givaudan was partially offset by weaker performance from Alfen Beheer, Amyris and TDK.

The top three relative performance contributors in 2021 were NVIDIA, eMemory Technology and Tokyo Electron. The bottom three, as relative detractors, were Daifuku, Harmonic Drive Systems and TDK.

#### **Market Review**

2021 began with a contested US presidential election and the storming of the Capitol Building, surging COVID-19 infections and uncertainty around the efficacy and uptake of vaccines. Two major, new COVID-19 variants, supply-chain dislocations, commodity shortages, the Taliban reconquest of Afghanistan, persistently high inflation and the onset of global central bank tightening, could not, however, curtail equity market returns. If the previous year owed everything to policymakers and unprecedented stimulus, 2021 belongs to science. It is now two years since COVID-19 began to reshape the world we live in, and after a tragic first 18 months, there was clear light emerging at the end of the tunnel in 2021, with spectacular medical vaccine and anti-viral innovations aiding this process. World governments have managed to distribute the vaccine to nearly 5 billion people and the Commonwealth Fund estimates this has saved 1.1 million lives in the US alone.

Equity markets reached new highs by mid-February, driven by the prospect of an economic recovery, progress on vaccine rollouts and optimism around further US fiscal stimulus following Democratic victories in the Georgia runoffs. Economic activity indicators pointed to a robust expansion and the successful passage of President Biden's \$1.9trn COVID-19 Relief bill, strong jobs data, and the early success of vaccine rollouts supported expectations for a rapid economic recovery. The speed of the macroeconomic demand recovery pushed the global economy into outright shortages across components, commodities and labour. Supply chains remained tight following lengthy lockdowns, and labour shortages were exacerbated by the continued US stimulus programs in the first quarter and the extension of enhanced unemployment benefits through September.

A pick-up in inflation had been anticipated by the market in response to the reopening and shortages of raw materials, intermediate inputs and labour, but the extent of the surge in CPI inflation in April and May surprised to the upside. A 5% year-over-year increase for May was an acceleration from the already elevated 4.2% in the previous month and represented the fastest growth since August 2008. The core personal consumption expenditure (PCE) price index – the Fed's preferred inflation gauge – was up 3.6% y/y in April, the highest level since 1992. Commodity prices continued to surge and copper prices reached their highest level in a decade.

Financial markets focused on the degree to which inflation was transitory, with the Federal Reserve (Fed) maintaining that 'aboveaverage' inflation is both transitory and somewhat welcome, having spent the post-global financial crisis period fighting deflationary impulses. This consistent, dovish message from the Fed, repeated by the ECB, combined with keeping asset purchases steady at \$120bn per month allowed equity markets to shrug off concerns about inflation, forcing the central banks to tighten policy ahead of schedule. That said, a slightly more hawkish June FOMC saw the so-called 'dot plot' imply two hikes in 2023 from zero in March and October. Fed Chair Jerome Powell indicated the Fed could begin scaling back asset purchases (tapering) as soon as November and complete the process by mid-2022. As inflation readings remained elevated (October CPI +6.2% y/y, November +6.8% - the fastest pace since 1982), the US five-year breakeven reached 3% during November - for the first time based on data going back to 2002 - and the yield curve flattened materially due to a move higher in two-year rates as investors become more concerned about tighter Fed policies.

Powell was re-nominated as Fed chair, and the tone turned more hawkish still, with Powell stressing it was time to 'retire' the word 'transitory' and the December FOMC meeting saw the announcement of a doubling in the pace of tapering from \$15bn to \$30bn per month, which indicates the Fed will stop adding to its balance sheet by March 2022. The median dot plot now suggests three rate hikes in 2022.

Late November also saw South Africa begin to report surging cases of the new Omicron variant. The pace with which the virus has engulfed the world, becoming the dominant strain in many countries due to its high transmissibility, is mind-blowing. During the three previous COVID-19 waves, peak new cases were between 700–900 thousand; in early January, new cases were reported to be 2.5 million daily, with the US alone exceeding one million.

The combination of an apparently less deadly variant and greater immunity (natural or via vaccines) may have broken the link between infection and death. However, the sheer volume of cases and the ability of Omicron to at least partially evade prior immunity threatens significant worldwide disruption. Initially this caused panic, leading the US 10-year Treasury to fall to 1.34% while the VIX Index (an option-implied measure of market volatility) exceeded 30. Since then, a more optimistic view has emerged with this 'weaker' variant the potential bridge between pandemic and endemic phases. This led equity markets to fully recover into year end. Commodity markets also rebounded strongly, and oil prices came close to recovering all their earlier losses, with WTI Oil gaining 14.2%. The US 10-year Treasury yield also recovered sharply, ending the year around 1.5% and surging towards a post-pandemic peak of 1.7% during the first week of 2022.

2021 was another strong year for risk asset returns, reflecting successful vaccine rollouts, a still-supportive fiscal and monetary policy backdrop, strong corporate earnings and record equity inflows. US returns (S&P 500 +29%) once again drove global returns (MSCI ACWI +19%), eclipsing those achieved in Europe (Eurostoxx 600 +17%) and offsetting Japanese (TOPIX +1%), Asian (MSCI Asian ex-Japan: -5%) and emerging market (MSCI EM: -2%) weakness.

The S&P 500's 29% total return was delivered with below-average volatility (largest peak-to-trough drawdown just -5%), and was composed of around c33% growth in earnings and 1.8% in dividend income, offset by around c7% compression in its P/E multiple. The market also saw a decline in breadth as the five largest S&P 500 stocks at the start of the year returned 37% and accounted for almost a third of the Index's total return. Large-cap stocks outperformed small caps, the Russell 1000 Index (LARGE) returning 26% against the Russell 2000 Index's (SMALL) 15%.

There was particular weakness in small-cap growth stocks (Russell 2000 Growth Index), returning just 3% after a strong start to the year. Strong index-level returns belied material volatility under the surface with 92% of S&P 500 companies and 89% of NASDAQ companies experiencing greater than 10% corrections from year-to-date (YTD) highs, while the average company drawdown from YTD highs was -18% for the S&P and -40% for the NASDAQ. US performance also benefitted from dollar strength, the trade-weighted dollar basket gaining 6% during the year. The weakness in Asian stocks reflected the region's struggle with the Delta variant, low vaccination rates, soaring energy prices and a deluge of regulatory changes and market unfriendly developments in China that took their toll on investor sentiment and stock prices alike.

Equity inflows were extraordinarily robust at \$1trn, exceeding the combined total of the past 19 years. Corporate buyback authorisations also passed \$1trn. Equity issuance was a record, with more than \$530bn of total issuance (\$146bn of which was Special Purpose Acquisition Companies or SPACs) as companies looked to take advantage of seemingly insatiable investor demand.

### **Fund Activity**

While we do not allocate capital on a subtheme basis and the weighting of each bucket is a result of our bottom-up stock-picking approach, the size of each bucket remained broadly the same throughout the year. In a changing macro environment, our focus was on maintaining a high-quality portfolio and incrementally adding to areas of greatest opportunity, rather than making wholesale changes to our investment approach.

We closed successful positions in stocks that performed well such as Airtac, Equifax, Adyen, Cerence and Axon Enterprise, to name a few, and recycled the proceeds in initiating several new positions including Duerr, Micron, Siemens Healthineers and Sandvik. We exited several positions in which our conviction level reduced over the year such as Alibaba, Pinduoduo, Spotify, Delivery Hero and Stone. Lastly, we reduced our weighting in stocks the investment cases for which are being challenged but where we remain confident in the thesis over the mid-term, such as Paypal, Fanuc, Covestro, Samsung Electro-Mechanics and Ansys. Through the year we continued to use dips in the market to build positions in stocks that we believe offer earnings potential over and above consensus estimates – UnitedHealth, Thermo Fisher and Hamamatsu Photonics to name just a few.

Throughout 2021, the cash on average remained just over 2% to enable us to deal with fund flows that were understandably volatile in 2021.

# Automation & Artificial Intelligence Fund continued

### **Market Outlook**

Looking into 2022, we see a number of factors at play that leave us cautiously constructive on equity markets, but with expectations of volatility ahead. 2021 was a year in which macro factors dominated equity prices, with multiples rerating alongside style rotations as inflationary pressures dominated the discourse and markets adjusted to new monetary policy regimes. While we do not underestimate the potential for further shocks and indeed do not intend to take major macro bets, we believe central bank actions could become less disruptive to market dynamics as the year progresses.

It is our expectation that 2022 may prove more of a stock-picker's market and that earnings revisions will be a major determinant of stock performance. Although the contraction in high valuation stocks has continued since the recent November peak, we continue to look for a greater pullback before stepping into the highest growth opportunities; the rotation from growth to value in the first few days of January proved our fears that many of the best stocks are still on a high base even after recent weakness. We continue to believe the portfolio is of a high quality and well positioned in any serious correction, having taken steps during the inflationary shocks to position ourselves alongside names that are best in breed. The Fund has always been averse to highly indebted names or those with uncertain cash flow or balance sheet outlooks, a position we think is particularly pertinent in a rising rate environment.

While 2021 proved premature for those calling an end to some industrial cycles, we are cognisant that the easing of supply-side pressures might lead to more normalised demand trends later in 2022 and hence expect to hear more concern around early-cycle peaks, even as China moves to provide greater stimulus in some areas. That said, there has been no softening in demand outlooks from the conversations we have had with companies recently, with backlog builds supported by the structural tailwind of the adoption of AI and automation technologies. Both our cyclical and late-cycle industrial exposures are well aligned with those technologies that are most in demand when balance sheets are healthy and companies are facing wage and labour pressures, as is the current environment. US Census Bureau research suggests that, for an average manufacturing facility, even small-scale investment in automation technologies (<\$1m/year) brings productivity improvements such that the payback period is only one year. As a result, and in the absence of new information around double ordering or cancellations, we do not plan to greatly reduce our cyclical exposure in the near term.

With regards to the enterprise adoption of these technologies, 2021 was the year when Fortune 500 companies really started to embrace the transformational power of AI. Technological advancements continue the democratisation of AI, with more companies exploring these new technologies at greater scale across their businesses. Research from McKinsey & Co suggests initial applications have predominantly focused more on cost cutting as the economy recovered from the pandemic while facing labour and inflationary pressures. More companies are feeling the benefit of adopting these technologies, as measured by contribution to profits, while the scale of contribution is also increasing year over year; some surveys suggest Al contributed 20% more to operating profits on a year-over-year basis. Despite these results, this is still a nascent technology for most businesses, and we are excited to see greater progression as companies increasingly turn their attentions to using AI to generate new products and higher growth. We look forward to partaking in the opportunities that greater adoption of these technologies provides, both through a widening of the investable universe and through greater contribution to earnings growth in the highest quality assets.

#### **Technology Team**

Polar Capital LLP

### **Biotechnology Fund**

### **Fund Performance**

The Fund returned 4.7% (Class I US Dollar Distribution Shares) in the 12 months to the end of December 2021, modestly ahead of the benchmark's -0.2% for a relative outperformance of 4.9% (all returns in dollar terms, unless otherwise stated). The biotechnology sector underperformed the broader market with the S&P500 Index returning 28.7% over the period.

The start of 2021 was marked by the deployment of the COVID-19 vaccines, but also a return to lockdowns for many countries in the face of resurging infection rates and concern over the emergence of new coronavirus variants. However, the stock market soon started to look ahead towards the potential for a strong economic rebound as the accelerating cadence of mass vaccination strategies in major developed markets offered the prospect of a release from lockdown restrictions within months and a return to normal economic activity.

After a wild start to the year, growth-flavoured equity assets started to relinguish their leadership as investors sought value and cyclical stocks to gain exposure to the impending global economic reopening as well as for protection against an anticipated surge in inflation that most assumed would result in central banks moving to raise interest rates and taper asset purchasing. Overlaid on top of these macro factors was the unprecedented noise and chaos caused by the surging - but then later receding- involvement in the stock market by retail investors. After the middle part of the year was marked by a steadily appreciating market, the run into the end of the year became challenging for equity investors attempting to position portfolios correctly. While investors grappled with the timing and impact of central banks reining in asset purchases and debated the pace of likely interest rate increases in the face of the increasingly alarming inflation picture, the emergence of a new coronavirus variant of concern, subsequently labelled Omicron, had investors wrestling again with the prospects of new lockdowns and potentially fresh disruption of recently normalising economic activity. Along with these overwhelming macroeconomic headwinds, the biotechnology sector continued to struggle as a run of disappointing clinical and regulatory news flow for companies starting the year in many cases with excessive valuations and expectations, coupled with an uncertain regulatory environment and, perhaps most problematically of all, continued excessive new paper issuance, whether from IPOs or follow-on financing activity, weighed on enthusiasm and appetite for the asset class.

### Market Review Q1 2021

The new calendar year of 2021 started to some degree as 2020 finished, with the Fund struggling to keep up with a sector driven higher from investor enthusiasm for earlier-stage concept technology stories as well as renewed enthusiasm for the leading COVID-19 vaccine biotechnology names. In addition, it is not probably unreasonable to say that the biotechnology sector was contaminated by the hedge fund 'degrossing' phenomenon as the GameStop 'retail investor versus Wall Street' short-squeeze situation became front-page news. This 'degrossing' saw hedge funds scramble to buy back short positions in companies perceived to have unattractive fundamental prospects and/or valuations, at the same time as selling down long positions in companies perceived to have attractive fundamental prospects and/or valuations. Given some degree of commonality of view and ownership across specialist funds, this made for especially frustrating investment conditions, probably not just for us but other biotechnology specialists as well.

As with in January, the biotechnology sector started February very strongly but gave back gains into month-end. From a broader market perspective, it felt like investors were torn between wanting to reduce holdings in growth and momentum assets with the global economic reopening trade building momentum, while at the same time reluctant to give up on these same assets that have served them so well for so long, while lingering issues of COVID-19 vaccine deployment and worries over the emergence of new virus strains threatened the tactical asset allocation repositioning. With the biotechnology sector trading wildly day-to-day driven by the push-pull of opposing quantitative factors, largely irrespective of fundamentals, it was an exhausting few weeks for specialist investors in the sector.

The Fund started to eke out relative outperformance largely by avoiding high-profile setbacks for a couple of the sector's gene therapy stories, an area we had been avoiding due to what we perceived to be high expectations and the market distortions created by a recently fashionable investment approach that seems almost to completely fail to consider risks involved in investing in new medical technologies that are just finding their feet. Biotech IPOs continued, typically affording very early-stage companies multi-billion-dollar valuations, reflecting the continued availability of risk capital. That phenomenon aside, we continued to detect a moderating of sentiment towards the sector from institutional investors. We also started to detect a calming of the frenzied appetite of retail investors for the sector's genomics-themed technology concept stories.

# Biotechnology Fund continued

### Market Review Q1 2021 continued

March saw continued underperformance for the sector versus the broader market, with defensive growth and momentum assets slipping further as the rotation into value and cyclical stocks continued to gain support from a market increasingly expecting a surge in global economic demand from increased consumer spending and business activity as coronavirus pandemic-driven restrictions eased. It is probably fair to say that most of the sector's relative underperformance during the month was driven by the market's evolving inflation expectations and the move in long-term interest rates in response, raising the discount rate and thus reducing the present value of long-dated cash flows, such as those typically offered by the majority of biotechnology stories. However, it should also be noted that the sector year-to-date had already experienced a run of negative stock-specific news, both in terms of disappointing clinical trial results as well as unexpected regulatory setbacks, which served to temper sentiment. It appeared that US retail investor interest in biotechnology was starting to wane (presumably not coincidentally with the improving cadence of the vaccination effort in the US as well as the easing of lockdown restrictions), leading to the start of outflows from a group of popular thematic actively managed ETFs, which dragged down technology concept stories. Meanwhile, institutional investors seem inclined to let this phenomenon wash out, while also waiting on some colour on the new Biden administration's healthcare reform agenda, particularly as it pertained to prescription drug pricing.

### Q2 2021

The relative underperformance of the biotechnology sector continued through April in another month where defensive growth and momentum assets again struggled as the rotation into value and cyclical stocks continued to gain support. This support largely came from a market increasingly confident in a surge in global economic demand from increased consumer spending and business activity as coronavirus pandemic-driven restrictions ease. Again, the sector itself struggled to deliver positive fundamental news flow with disappointing clinical trial results as well as unexpected regulatory setbacks continuing to erode sentiment. A lacklustre start to firstquarter earnings season - while traditionally the weakest quarter due to seasonal factors, it appeared to have also suffered from COVID-19 disruption – did not create any urgency to own or add to investments in some of the sector's commercial-stage pharmaceutical and biotechnology companies either. It was more of the same in May, with an adverse macro environment failing to offer the sector the right conditions to find sustained support. Again, there was little positive news flow to lift investors' malaise. That aside, investors seemed content to keep chasing the share prices of mRNA vaccine names higher, which continued to exist in their own unique bubble of investor appetite.

June was a different story entirely as the sector snapped back to outperform the broader market in a sharp reversal of the recent propensity for growth and momentum assets to struggle against the investor preference for value and cyclical stocks. In May, we mused on the conditions that we thought needed to change for the sector to escape the downward pressure it had been experiencing year-todate. At a high level, we thought inflation concerns and interest rate expectations needed to moderate or even reverse and that the global economic recovery narrative needed to falter (perhaps in the face of the emergence of new coronavirus variants of concern threatening the durable success of vaccination and lockdown release strategies), but most importantly, that the sector needed to string together a series of significant positive fundamental developments for investors to remember the returns possible when innovation succeeds and crystallizes real significant value. Well, all that happened in June.

At a high level, markets were calmed by the Federal Reserve with respect to inflation and recently rising long-term interest rates fell. The pro-cyclicals' economic recovery/re-opening trade faltered in the face of mounting concern over the rapid spread of the new Delta variant of coronavirus. Growth, and what were last year labelled 'momentum', assets quickly reasserted themselves and the recently deflating bubbles in ownership and valuation for the highest profile technology (and biotechnology) stories rapidly re-inflated. Within the biotechnology sector itself, the controversial shock FDA approval early in the month of Biogen's Alzheimer's drug aducanumab caught many healthcare specialist investors offside and scrambling to come to terms with the possibility of a new regulatory paradigm where any new medicine is approvable on the most marginal of clinical evidence if the need is great enough. Towards the end of the month, we witnessed a true landmark in medical research with the first very early clinical data for an in-vivo (in body) gene editing approach to treating disease being pioneered by Intellia Therapeutics.

The mRNA vaccine platform stories led by Moderna continued to surge higher in the face of clear negative fundamental developments in the form of emerging safety issues, the fading of mass vaccination momentum, the dismantling of pandemic vaccine delivery infrastructure, increasing COVID-19 vaccine competition, as well as longer-term mRNA platform modality competition from new investment programmes announced by experienced vaccine competitors. With valuations starting to rival long-established pharmaceutical companies, we felt the stocks of these companies had become dangerously divorced from reality, having merely become tools to express technical positioning in equity markets flooded with capital. We were certainly not alone in struggling to rationalise ownership of these types of company, but with bubbles of valuation excess forming everywhere many investors seemed loath (or unable) to identify the catalysts for them to pop. Away from these stocks, many biotechnology companies, large and small, ended the period still struggling to maintain a bid, and certainly fundamental updates such as clinical data and business development activity continued to be met with neutral to negative - sometimes excessively negative share price reactions.

#### Q3 2021

The sector underperformed the broader market in July, reverting to the trend for the sector to lose ground versus a broader stock market that appeared inclined to melt higher irrespective of what is going on in the world. Notably, the sector failed to build on June's material outperformance, driven by high-profile fundamental events, which indicated to us a sector where positioning or ownership continued to remain fuller than perhaps the broader investment community felt comfortable. Interestingly, investors continued to show almost no tangible interest in wanting to own more commercial-stage pharmaceutical and biotechnology companies with real products generating revenues and cash flow today. Instead, interest was still focused on technology concept stocks and companies harnessing cutting edge drug discovery and development tools but where real products remain years away, if ever. Even those stories seemed increasingly unable to keep the attention of investors. Indeed, the only biotechnology stories that seemed to be working from a performance perspective were the mRNA COVID-19 vaccine companies that, while the pandemic burned on, still thematically seemed able to command the attention of the investment community.

With its baffling inclusion into the S&P 500 in early July, Moderna's share price surged higher during the month – the major driver of the Fund's relative underperformance versus the benchmark – leaving the company with a \$140bn valuation at month end. This is greater than biotechnology leaders Regeneron and Vertex combined, greater than industry bellwethers Amgen and Gilead, and effectively at par with pharmaceutical majors AstraZeneca and Bristol Myers Squib. Fundamentally this made no sense whatsoever, but apparently intoxicated and mesmerised investors seemed perfectly content to chase the share price higher. The combined impact of the immense passive buying impact of index-linked funds, agnostic to either fundamentals or valuations, and frenetic call option buying activity by retail investors, pumped the company's valuation far beyond what any kind of rational investment valuation framework could support.

In August, the broader biotechnology sector managed to outperform the broader market, something we felt was more related to technical trends and hedge funds covering over-shorted positioning, and perhaps some retail averaging down/bargain hunting, rather than reflecting any material shift towards more positive sentiment on the part of institutional investors.

#### Q4 2021

The sector fell again in September, though performance was essentially in line with the broader market suggesting a degree of investor ambivalence (or even weariness) towards the sector in the short term. This is in line with our view that August's relative outperformance was more technical in nature. Accordingly, the sector's relative performance fading resumed in October as investors started to give up on the year, with the month marked by the start of material tax loss selling as well as hedge fund de-grossing, which particularly afflicted the struggling smaller-cap segment of the biotechnology sector. Share prices across the sector continued to struggle to react constructively to companies announcing news flow of any kind, which made it especially tricky for investors attempting to navigate a seasonally busy period for clinical and corporate updates.

The dynamics in place in October seemed to accelerate in November, with specialist investors seemingly capitulating, and we heard reports of hedge fund investment portfolios being deleveraged, tidied and even closed down. Towards the end of the month, and somewhat awkwardly over the Thanksgiving holiday period in the US, reports from South Africa of the arrival of Omicron sparked wild market gyrations as investors grappled with the potential implications. With the emerging evidence of Omicron's milder severity (albeit with much higher transmissibility), coupled with the suggestion that vaccinated, boosted, and pre-infected people seemed to be protected against serious disease, in December, the market settled back to trend, which meant for the biotechnology sector an almost predictably downbeat and wearisome end to what for many specialist investors was a year to forget.

#### **Fund Activity**

Within the portfolio, investments in Valneva, Regeneron Pharmaceuticals and BioNTech were among the top absolute contributors to performance, with Y-mAbs Therapeutics, NanoString Technologies and Deciphera Pharmaceuticals among the main absolute detractors from performance. With respect to relative performance versus the benchmark, Valneva, Biohaven Pharmaceutical Holding and Acceleron were the largest positive contributors while Moderna, Gilead Sciences and Y-mAbs Therapeutics were the largest negative contributors. Two Fund investments - Oxford Immunotec and Acceleron - were acquired during the period, bringing the number of Fund investments acquired since its inception to 33. Relative performance versus the benchmark was strong at the start of the year with correct topdown positioning as well as good bottom-up stock-picking and risk management. However, through the middle part of the year, the Fund was overwhelmed by the share price performance of Moderna after the company's successful development of one of the first COVID-19 vaccines and on subsequent investor interest and expectations for the technology platform.

# Biotechnology Fund continued

### Fund Activity continued

The company became an investment phenomenon – the biotechnology sector's own Tesla in the eyes of the Fund's manager – as investors clamoured to own a perceived long-term beneficiary of the COVID-19 pandemic at almost any price. It took several months for this ludicrous situation to normalise, and while the company's share price gave back a significant proportion of its gains into the end of the calendar year, which helped the Fund's relative performance, a material reduction in the stock's oversized weighting in the benchmark in September had frustratingly already locked in material relative underperformance versus the benchmark.

The Fund's manager continues to be negative on Moderna, believing there is significant risk to current expectations that the company will be a material beneficiary of any need for regular COVID-19 vaccine boosters; that expectations for what the mRNA platform technology is capable of delivering remain excessive (along with the valuation being afforded to it); and, in addition, has corporate governance and corporate responsibility concerns. Aside from the challenge presented by the performance of Moderna, the period was a positive one in terms of top-down positioning and bottom-up stock selection, as well as risk management. Trading turnover gradually decreased over the period; the number of portfolio investments stayed consistently in the range of between 45–50 and active share versus the benchmark remained high in the range of 70–75%. Over the course of 2021, the Fund manager started to incorporate ESG and sustainability factors into the investment decision-making process on a more comprehensive and rigorous basis.

### **Market Outlook**

The biotechnology sector presently seems to be struggling with the evolving macroeconomic environment for equities that is seeing growth and momentum assets slip as investors rotate portfolios towards having greater exposure to value and cyclical stocks. This reflects their expectation of growth in global economic demand from increased consumer spending and business activity as pandemicdriven restrictions ease. It is probably fair to say that most of the sector's relative underperformance during the period was driven by the market's evolving inflation expectations and the move in longterm interest rates in response, raising the discount rate and thus reducing the present value of long-dated cash flows, such as those typically offered by many biotechnology stories. It should also be noted, however, that the sector had a run of negative stock-specific news in 2021, both in terms of disappointing clinical trial results as well as unexpected regulatory setbacks, which tempered - and continues to undermine - sentiment, as well as the inclination of investors to deploy more capital into the biotechnology sector, the macroeconomic environment aside. For a sector that has attracted so much investor capital in recent years, and where market expectations have been raised so high based on thematic narratives pitching the transformative potential of exciting new technologies to discover and develop new medicines, it has not been terribly surprising to see investor appetite for high-risk early-stage companies sporting enthusiastic valuations faltering in the face of disappointing news flow.

Furthermore, in the short term, violently variable and significant capital flows into and out of sector-specific, guantitative and thematic strategies is introducing significant volatility into share prices, making short-term trading dynamics challenging. This is particularly true for earlier-stage technology concept stories where we feel the quantity of liquidity injected into capital markets by central banks in recent times, as well as the increasingly pernicious involvement of retail investors through online trading platforms, often has the effect of divorcing the valuations and trading behaviour of many of these companies far beyond any rational analysis. Indeed, the area of concern for us remains squarely the capital markets environment, specifically how the biotechnology sector as an asset class behaves in the context of global economic growth trends as we emerge from the pandemic. We can add to this continued central bank interventions and evolving interest rate and inflation expectations, not to mention the toxic participation of retail investors influenced by social media and enabled by online trading platforms. The rise of the arguably asinine 'meme stock' phenomenon over the past couple of years undermines the core price discovery efforts and ability of professional and tightly regulated investors. The biotechnology sector seems to be especially vulnerable given the complexity of the science and technologies involved in creating innovative new products in what is already an emotive industry.

We continue to detect a shift of investor interest towards larger-cap quality within the biotechnology sector, particularly revenue growthstage companies with robust new product cycles, R&D pipeline potential and M&A possibilities. Recent market volatility caused by evolving monetary policy in the US as well as the emergence of Omicron has clouded the trend to a degree. However, sentiment towards pharmaceutical and larger biotechnology companies seems to be firming as healthcare reform legislative clarity appears to be developing in Washington, providing some comfort on the drug pricing environment for the coming few years. Our sense is that beneath the surface institutional investors are starting to position portfolios more defensively in response to recent geopolitical developments as well as, and perhaps more importantly, in preparation for a changing liquidity environment, given expectations that the Fed will start to taper asset purchases in early 2022, and to increase interest rates through the year. We feel the likely imminent transition from a pandemic to endemic phase for COVID-19, and epidemiology will drive a normalisation of prescription drug trends, which, especially for companies selling medicines for chronic illnesses or attempting to garner physician and patient attention early in product launch cycles, could create a robust environment for a 'beat and raise' dynamic to be established versus investor expectations. This would be positive for commercial-stage

#### biopharma stories.

Reassuringly too, the pace of successful innovation remains high. Despite the string of high-profile clinical and regulatory setbacks during the year, the FDA approved 50 new medicines in 2021, and we expect a similar number in 2022; new drug approvals are one of the more important building blocks for sustainable value creation for investors in the biotechnology sector, in our view.

By contrast, we feel the recent record-breaking IPO and equity issuance for the sector has stretched specialist capital thinly across a large number of early-stage, unprofitable companies. Many of these stories appear to be 'build-a-bear' attempts by specialist crossover investors to game the recent appetite of the public markets for innovation and disruptive technologies by creating look-a-like private companies, injecting significant capital and flipping them public almost instantly. Many of these companies appear to be undifferentiated or are otherwise so early in their development that it is extremely hard to discern whether they have the credentials to create real medical breakthroughs with truly sustainable competitive advantage. Certainly over 2021 the market seemed to tire of the constant stream of almost impossible-to-decipher clinical development updates involving very small numbers of patients and often efficacy measures of debatable clinical relevance. For us, this stretching of risk-tolerant capital across early-stage companies in an intensely crowded and competitive environment is a bigger, stickier, pernicious issue for the sector that is likely to keep downward pressure on the share prices of earlier-stage companies in the near term, especially given the tightening macro environment. Therapeutic areas that we feel have become particularly crowded include oncology and inflammation, and from a technology platform perspective we continue to largely avoid cell and gene therapy as well as gene editing companies for the time being.

With this in mind, in terms of positioning, the Fund continues to focus more on late clinical development or revenue growth-stage companies, particularly those with either close-to-market or recently launched unique breakthrough therapies. With the record level of biotech IPO activity in recent years introducing many early-stage unprofitable companies to the public markets, we have started to contemplate the concomitant increased R&D spend for the industry versus current cash balances and future funding requirements, set against what we believe to be a tightening capital markets environment. Taking a step back from the challenges posed by the current nature of the capital markets, the fundamentals of the biotechnology sector responsible for the significant real value creation seen for investors in recent years in our view remain intact. Accumulating scientific insight and understanding into human biology and powerful new drug development technologies continue to create exciting new medicines that in early-stage clinical trials are generating provocative and encouraging data.

Despite a difficult start to the year driven by the macroeconomic environment, 2022 looks set to be another strong year in terms of new drug approvals, which would be a significant positive for the sector. The importance and value of continued investment in biomedical research and the more effective delivery of healthcare has been heightened over the past two years with the pandemic, in our view. We continue to invest in what we believe to be the best people, using the best technologies, to develop the best new medicines.

#### **Healthcare Team**

Polar Capital LLP

For the financial year ended 31 December 2021

# **China Stars Fund**

### **Fund Performance**

The Fund's full-year 2021 return (Class I US Dollar Accumulation Shares) was -15.3%, compared to -12.9% for the benchmark, the MSCI China All Shares Net Total Return Index (all figures in dollar terms).

In 2021, the Chinese economy can be defined by one word: tightening – tightening of regulations, tightening of policies and tightening of the credit cycle. Much of the tightening is justified and, in many cases, long overdue.

'Innovate first, regulate later' has been the implicit guiding principle for China's growth model for the past few decades. It is no different this time for the consumer internet industry. As the industry graduates from adolescence to adulthood with flattening penetration levels, maturing technologies and slowing innovations, proper regulations and oversight are put in place. Instead of spelling the end of value creation in the consumer internet industry, having these institutionalised guardrails will cement its place as a core pillar of China's economy and ensure more profitable and sustainable growth in its next stage of development.

Similarly, we should also celebrate the downfall of Evergrande in 2021. Chinese policymakers are obsessed with stability and risk – runaway inflation and rampant speculation in the '80s and '90s ran deep in the institutional memory of the top echelon of policymakers. The property sector is the epitome of their fear with its reckless appetite for credit, dizzyingly high leverage ratio and ever-increasing housing prices. Policymakers have attempted to tame the overleveraged industry a few times in the past five years but, each time when it started to hurt overall growth, they blinked. However, this year, with more resolve, determination and a higher pain threshold, we finally witnessed the much-anticipated demise of the colossal Evergrande – short-term pain, long-term gain.

This is of course a tricky balancing act. Too much tightening in regulation, policy and credit runs the risk of sapping what John Maynard Keynes calls the 'animal spirits'. The shroud of uncertainty dampens consumer and business confidence. Many in the business and investment community are taking a 'wait and see' approach before deploying their talent and capital. Some steps have been taken by politicians to boost business confidence but more needs to be done in 2022.

The overarching vision is clear – the Chinese economy is transitioning yet again from a free-wheeling robber baron version of capitalism to a more inclusive model of capitalism. In China 3.0, we are going to see new sources of growth and innovation, and sustainability and ESG will become ever more important.

The top contributors to relative performance in 2021 were Binjiang Service Group, China Resources Sanjiu Medical and China Meidong Auto Holdings; among the biggest detractors were iQIYI, Alibaba Group Holding and Ping An Insurance. Binjiang Service Group (Binjiang), a high-end property management services provider that is well positioned to capitalise on the growing demand for a premium service from China's burgeoning upper/ middle-class consumers, saw its shares increase by 52% as it delivered a strong set of earnings growth. Binjiang is a well-run company with a great reputation for high quality service. It is a mid-size holding.

China Resources Sanjiu Medical, a consumer health company with a portfolio of popular OTC (over the counter) drug brands, appreciated 41%. Its OTC business proved its resilience and quality during the year. We were positively surprised by a management incentive scheme in Q4 which, together with favourable industry news, drove a significant rerating of its shares. We took advantage of the strong performance to reduce our position size. It is a mid-size holding

China Meidong Auto Holdings (Meidong), a luxury car dealership run by an exceptional owner-operator, advanced by 27%. Since our initial investment in Meidong almost exactly three years ago, it has evolved from a small-cap hidden gem with barely any sell-side research coverage to a well-respected mid-cap company with a loyal and strong shareholder base. We believe it can continue to deliver more than 25% EPS CAGR over the next three years. Meidong is currently a large holding.

iQIYI, the leading video streaming platform suffered from tightening content censorship and balance sheet stress. We reduced iQIYI significantly at the beginning of 2021. During the Archegos liquidation saga at the end of March, we refilled our position. Subsequently, China tightened its content censorship, which added to concerns about iQIYI's cash burn and financing given its stretched balance sheet. We have reduced our position materially and it is a small position.

Alibaba Group Holding (Alibaba), China's largest e-commerce platform experienced a horrid year. Tighter regulatory measures on anti-trust and anti-competitive business practices not only undermined sentiment and growth but also weakened Alibaba's competitive positioning. We still believe its competitive positioning remains strong and that it can generate strong and sustainable cash flow in the medium to long term, despite high short-term uncertainty. Given the very favourable risk/reward, we have added to our position. It is a mid-size overweight.

Ping An Insurance, a financial conglomerate with life insurance at its core, continues to disappoint. It became apparent to us that a combination of potential challenges from fintech, generational leadership transition and execution risk had changed the risk/ reward proposition of the business. We reduced our exposure materially during the quarter. It is a small overweight.

### **Market Review**

China equity was one of the worst performing asset classes in 2021 after being one of the best in 2020, primarily driven by multiple derating. MSCI China All Shares 12-month forward earnings multiple contracted from 15.5x at the beginning of the year to 13x as the year ended, a 16% depression compared to the total return of -13% by the index. This derating should be viewed in the context of tightening policy this year given low growth pressure.

#### **Fund Activity**

During 2021, there were a few noteworthy new positions and exits.

We reinitiated a position in China State Construction Development (CSCD), a Hong Kong-based leading exterior engineering solution provider; OPT Machine Vision Tech, an emerging champion in machine vision benefiting from explosive growth in electric vehicle batteries; and KE Holdings, a leading digital platform serving the property market vertical.

We exited positions in Geely and VNET Group, as we found better opportunities elsewhere for the capital.

#### **Market Outlook**

2021 was a year of regulation, policy tightening and financial derisking in China. The scale and speed of regulatory actions created a crescendo of panic, which was then further augmented by rising default risk at a few recklessly leveraged property developers. The rhetoric on regulation has changed and we believe the systematic risk from the Evergrande implosion is very low.

Thanks to these tightening regulatory and macro policies, China will exit 2021 with slowing growth momentum. Growth will return as a top priority again as we enter 2022 and we expect to see a more decisive pro-growth shift soon. After a more than 20% pullback, China equity is valued attractively in both absolute and relative terms, in our opinion. A receding regulatory cycle and loosening macro policy will provide confidence on corporate earnings growth and drive a meaningful rerating.

Some of the worst hit sectors are likely to drive performance in 2022. There are signs of stabilisation and reduced competitive intensity in the internet and technology sectors. For healthcare, the worst pricing environment is likely over, but recovery is subject to COVID-19 developments. In the consumer segment, a pro-growth policy shift is supportive of consumption, but China's zero COVID-19 policy creates short-term volatility. The strong trends in the adoption of factory automation and rising penetration of electric vehicles are likely to continue for many years to come. As such, while valuations are less compelling, we still see attractive stocks capable of delivering robust growth with the potential for significant upside.

As China picks itself up off the floor, there are plenty of opportunities in well priced and high-quality companies with high structural growth.

We are confident that our portfolio companies will continue to deliver strong earnings growth, and they are trading at a material discount to their intrinsic value. We believe the portfolio is well positioned to deliver good performance in 2022.

Thank you for keeping your eyes on the horizon.

#### **Emerging Markets and Asia Team**

Polar Capital LLP

For the financial year ended 31 December 2021

# **Emerging Markets Income Fund**

Due to the retirement of the fund manager, the Fund was merged into the Polar Capital Emerging Markets Stars Fund with effect from 8 June 2021.

# **Emerging Markets Stars Fund**

### **Fund Performance**

For the full year 2021, we returned -0.5% (Class I US Dollar Accumulation Shares), compared to -2.5% for the MSCI Emerging Market Net Total Return Index (in dollar terms), which we are pleased with given this was generally a strong value year and a weaker one for our style of growth and quality. It was a disappointing year for the emerging market asset class, witnessing one of the biggest differentials with developed markets.

We are disappointed to end with a negative absolute return, however small, though pleased we managed to reduce the negative return, through good stock selection, and to demonstrate that active management can add value when we are not in a bull market.

Our growth and quality bias, in the way we select and invest in companies linked, to our fully integrated sustainability investment process, means 2021 was a difficult year for us, in fact for any SFDR Article 8 fund in emerging markets with a growth bias. There is of course a slightly different calculation for the performance of growth versus value as a style, though using data from Bloomberg, value in emerging markets for 2021 outperformed growth by 12.4% (value 4%; growth -8.4%, in dollar terms). Therefore, we feel it is ok to outperform by nearly 2%, given our bias and our integrated suitability process where we do not invest in fossil fuel, coal and so on, all areas that performed well during 2021. In a year of constant headwinds, at times the occasional one felt more like a hurricane.

For the full year 2021, we had a positive contribution from our country selection (mainly South Korea, Taiwan and India) but our main outperformance came from our allocation effect. Taiwan and India benefited from both, with South Korea following closely from a country perspective.

Despite all the negative issues, China ended up a positive contributor for us during 2021, which we are very pleased by given how 'topical' and centre stage it has been. However, the overall positive contribution has primarily been driven by the allocation effect, having been underweight the market. The selection effect for us in China was only -0.1% (gross of fees), which we find acceptable given our profound growth bias here, precisely where a great deal of panic sentiment hit hard. Hopefully, this is in part due to our ability to identify the higher quality part of the market as well as having risk management capabilities at a portfolio level.

Our off-benchmark exposure in Vietnam also paid off well during 2021, with our stock picks returning more than 20%, making it one of the bright spots in an otherwise disappointing year. We remain positive on the return outlook in Vietnam and for our stock picks there.

The negatives came from Brazil, Saudi Arabia and Russia that hit us relatively hard and which explain most, if not all of, the broader headwinds we faced last year. Brazil was the biggest negative contributing country, driven by selection effect. Our allocation effect was positive, having been underweight the Brazilian market throughout the year. From a selection perspective we had exposure to a number of so-called new, high growth technology and consumer (fintech/ecommerce)-related companies, which had weak performance on the back of weaker overall growth in the economy, the COVID-19 panic and a spike in interest rates, causing these types of company to perform badly. On the other hand, Brazil still has a relatively large number of more value-related names which held up much better; not having exposure here also cost us relative performance.

We often hit significant ESG issues within Brazil's so-called valuerelated companies, best illustrated with the massive corruption scandals in Petrobras over the years and the significant lack of safety in a company like Vale, which has had fatal consequences for its workers. We believe Brazil's digitalisation online development is at an inflection point and there are good companies that will take advantage, which is why we are maintaining an exposure there. Clearly, macroeconomics and politics are a significant factor when it comes to investing in Brazil.

Saudi Arabia was the second biggest negative contributing country for 2021. We have a zero weight here, driven to a large degree by ESG considerations. With 'oil on fire' and expectations of US rate hikes, the Saudi market managed to return more than 34%, making it one of the best performing emerging markets in 2021. In our view, this performance seems top-down driven and as stock-pickers we are having a hard time getting excited.

The third most negative contributing country was Russia. Again, we do not have a great deal of exposure, but the exposure we do have is growth-oriented (like Yandex) where performance was poor, as was the case for most growth stocks in emerging markets. On the other hand, there was strong performance in Russian energy and commodities, where we not involved for ESG reasons. Russia does have quality assets if looked at objectively (lifting costs and so on), but there are huge governance issues. Within base materials, we find interesting opportunities in copper and nickel but here we often have environment issues on top of governance issues. We strongly believe in our ESG-bias investment process and, therefore, the types of company we invest in.

We strongly believe our integrated sustainability process helps to generate alpha, but there are periods where style swings can lead to significant dislocations from the true longer-term fundamentals. We would appeal to investors to join us in focusing over the longer term and allowing the fundaments to play out over time.

Our performance from a sector perspective shows our overall outperformance was purely driven by selection effect. We ended up with a small negative allocation effect.

# Emerging Markets Stars Fund continued

### Fund Performance continued

We had good, positive selection effect within industrials, real estate and IT. The allocation effect was also positive for IT, leading to IT and industrials being our two strongest contributing sectors overall. We see these two as core sectors so are pleased that in a difficult year like 2021, we can still derive value added and alpha when things get tough.

The good selection effect in real estate was very much driven by our core stock picks in India and Vietnam.

We do not have a huge exposure to materials, but we had a good selection effect from our position in Ivanhoe Mines which we still believe is one of the best ways to gain exposure to what we call 'green metals'.

On the negative side, financials and consumer discretionary dragged down relative performance from a sector perspective. Financials was mostly related to not owning the right companies (banks in the value markets did well compared to those in the more growth-oriented markets). From a stock-specific perspective, Ping An Insurance in China was a significant drag. The weak performance within consumer discretionary was explained by our exposure in Brazil and to some degree China, where e-commerce is classified as consumer discretionary.

Communication services (including internet companies) has historically been one of our strongest performing sectors and a key alpha generator. Given the growth scare on the back of the Fed's proposed taper actions, and particularly the Chinese internet regulation, we ended up 'only' losing -0.2%, gross of fees. We had a small positive selection effect, so the drag was from our overweight in this sector.

Sea was the main positive contributing stock over the year, but our significant reduction in exposure early in 2021 and concentrating our portfolio around what we believe are the high-quality names and business models for the longer term, helped us survive this out of favour area. To be clear, we still structurally believe in a world where most emerging market countries will in the coming decade more significantly move towards greater digital living, so this is certainly not an ex-growth area. In our view, it is becoming attractively priced.

The best contributing stocks were eMemory Technology (Taiwan technology, embedded memory/semiconductors), EcoPro (Korea specialised battery material), Sungrow Power Supply (China inverters for renewable energy), Ivanhoe Mines (DRC and South Africa copper mining), and Prestige Estates Projects (India property).

The worst contributors to relative performance for 2021 were StoneCo (Brazil fintech), Alibaba Health Information Technology (China digital healthcare services), B2W (Americanas, Brazil e-commerce/fintech), MicroPort CardioFlow (China medtech), and Ping An Insurance (China insurance/financial supermarket).

eMemory Technology is a company we have invested in for many years now. The case has taken longer to play out than we had hoped but returned well over 200% in 2021 and was the standout company for us last year. It is great when patience is rewarded. This company is at the forefront of semiconductor design and has created a unique security solution that will be built into the wafer (chip) and thereby give it unique security properties which will be essential for our digital world going forward. This is still only a \$5bn market-cap company so with the right execution it has a long way to go.

Another name we want to highlight is Prestige Estates Projects, our key Indian property company. It has not been easy to talk positively about Indian property over the past 18 months, so we are pleased to demonstrate there were return opportunities available there. We still believe we are at the beginning of a multi-year property cycle in India and see Prestige Estates Projects as one of the best positioned companies to turn this growth opportunity into sustainable shareholder value. Our other highlighted and long-term India name – Phoenix Mills (malls and hotels) – also gave a solid contribution to performance last year, though struggled because of COVID-19.

Looking at the weaker areas, two companies stand out – StoneCo (Brazil) and Alibaba Heath Information Technology (China). A mixture of strong market and sector sentiment headwinds created a strong negative backdrop for both that, combined with questionable strategic decisions the market had a hard time understanding, led to significant selloffs. For StoneCo, it was company-specific and weak execution around their new credit portfolio, while for Alibaba Health Information Technology it was around their bigger capex move into preparing for the opening up of online prescription drugs and the related services and infrastructure needed. This resulted in shorterterm reduced growth and the inflection point moving out for them to reach breakeven, a problem as they are still in their early growth stage. This was clearly not the year to be a high growth company, especially when they then had to disappoint the market on lowering growth guidance during a period with very high risk aversion.

Having ended November with a first quartile Lipper ranking versus our peers, our weak December nudged us into the best third of the Lipper peer group over the course of the year. Saying that, we beat most of those we consider to be our core competitors and are within the top third percentile over the past three years, and top fourth percentile since inception, according to Lipper data (Lipper figures representative of the Class I US Dollar Accumulation Shares).

### **Market Outlook**

We are bullish for 2022 for our Fund as, put simply, we feel little has changed from a structural long-term perspective over the past 6–12 months while many of our companies have become cheaper relative to their fundamentals (long-term EVA creation). We have, therefore, become more positive on our view of the return prospects for the portfolio over the next 12–18 months, and beyond.

There are big risks in the market for 2022, though our view is they are already quite well understood and priced in by the market to the extent that some are overshooting the longer-term fundamentals on the downside. We obviously cannot spot the unknown unknowns that the market has paid absolutely no attention to, nor can we see any large or broad-based bubble areas either. There are still pockets where a large proportion of companies have high valuations – electric vehicles (EV), Indian consumer names or some of the robotics/ automation areas, for example – but these are also areas where the long-term growth opportunities are high and where we see earlystage growth opportunities for significant alpha over the coming decade. We do not have structural concerns here and still believe that even these 'hot' areas will offer the potential for attractive alpha generation. We also believe a great deal of negative sentiment is already priced into emerging markets in general, and we are faced with one of the largest ever valuation spreads between the US/ developed markets and emerging markets.

We maintain our view that we are now around peak inflation in the US. The supply-chain bottleneck has been more significant than we originally forecast and moved our original peak inflation point from Q3/Q4 2021 to Q1/Q2 2022. Over the next 12 months we expect to see the inflation scare fade away and it is likely that by Q4 2022 we will be looking at inflation (US Core CPI and US Core PCE) at around 2.5–3%, with consensus at 2% for 2023 and 2024 that should be supportive for emerging market equites. An increase in inflation from here in the range of 0.2–0.4% per month should take us there – we think this is realistic and the most likely outcome.

Why will inflation go down in 2023–24? The Fed taper combined with reduced stimuli will have an impact on demand as long as consumers continue to behave rationally. There is a lag in fiscal and monetary policy and as most people are forward looking they will price expectations for goods and services faster, in our view. We are also seeing more indications of supply bottle necks being eased so as 1H 2022 plays out we see a high likelihood of supply again being stronger than demand which will reduce inflation pressure. The big moving part for inflation will be energy while a potential structural risk to inflation – which is not our base case view – is 'greenflation' if politicians push for too unrealistic an agenda on carbon reduction. Around 6 January, we saw panic in the market when the Fed minutes were released because it now looks like the first rate hike will be moved from May to March. This news sent the MSCI Global Growth index down by 2.7% and the MSCI Global Value index up by 1.2% – a spread of 4% on the back of a potential two-month difference in timing a rate hike. This seems crazy to us, though it also seems people now believe in five US rate hikes in 2022 and an additional three in 2023 which would take real rates into positive territory. We believe the taper and a few rate hikes will do the job for the Fed as has been the case before – just think back to H2 2018.

We mention this as we expect emerging market equities as an asset class to continue for some time to be significantly influenced by US monetary policy. We therefore expect a high likelihood of a repeat of 2021 in the US economy in 2022, a great deal of cyclical and value hype in the early part of the year that will then fade away during H1 as it becomes clear supply is outstripping demand. The Fed will then be able to show a projection to get back on its target inflation level, and the market will move back and favour growth. During this, the 10-year yield will flirt with 2%+ but structurally we do not see it moving beyond 2–2.5%, though we acknowledge the Fed has been a big buyer in the market and there is uncertainty about what a Treasury market looks like without the Fed being there.

Sticking our neck out, we see today's COVID-19 panic being a thing of the past quite soon. We believe Omicron will burn itself out in the developed world in 1Q22 and the early part of 2Q22 and, unless we get a further mutation that is more deadly (not necessarily more infectious), then we think we are quickly moving towards a pre-COVID-19 normal. The world simply cannot keep going on as it is now. We also think that working from home (WFH) as a new standard will quickly move to working one day per week from home and that people will return to the office. We are increasingly seeing companies complaining that WFH is good for a short period but they cannot grow a business this way and the cost to culture and new employees is just too high.

In general, we are not making large changes to our current positioning. Of the hotter topics, we feel we will reach the bottom for Chinese internet companies and we are now selectively starting to slowly add back exposure as we see favourable risks/rewards for certain companies. This also spills over to other internet-related companies in ASEAN and Korea, such as Sea and Naver, that seem lately to have suffered collateral damage without any real change to their operational fundamentals.

The same goes for technology, particularly semiconductors, an area we are still bullish on. We strongly believe we have seen the right strategic fundamentals play out to give us comfort that we are moving into an upcycle that is clearly not being fully priced in by the broader market. We see a cyclical tailwind coming into play as well as a strong structural underlying trend with technology leaders getting stronger, creating a favourable supply-side relative to demand in the years to come. We believe we have a good mix of strong large-cap names as well as emerging leaders.

# Emerging Markets Stars Fund continued

We retain a structural positive towards India, acknowledging that it had a great year in 2021 relative to the rest of the emerging world. Seen from a broader market perspective its valuation looks expensive. However we see the stars aligning for India in terms of its structural growth and we also see the emergence of a housing uptrend, strong underlying consumption trends, a significant infrastructure uptick and a corporate capex cycle that will be codeveloping with – growth in manufacturing in India, admittedly from a low base. We still find a large amount of exciting stock picks in India and foresee us having high relative exposure here throughout 2022. Short-term risk will be a likely rate hike around March as the Reserve Bank of India (RBI) will keep a conservative view on inflation as growth momentum builds. As of now, we will see any selloff on the back of such a move by the RBI as a buying opportunity from a long-term perspective.

We also see a significant move within North Asia for advances in manufacturing and automation – we believe we already have some great stock picks here that offer the potential for great returns – so we will maintain our exposure. If anything, if the opportunity emerges we will be happy to add exposure from a structural perspective.

We maintain our positive view on Vietnam and again will be a buyer on any interesting opportunity that appears. We also believe that in 2022 we will have the announcement that Vietnam will be moved into the emerging market universe from its frontier market status in 2023.

The slightly more problematic areas for us into 2022 include EVs (battery technology and battery materials), not because we do not see great growth potential but due to valuation levels for many of these companies. This area will be all about stock picking. Looking more broadly, we increasingly see better supply versus demand dynamics appearing more upstream in the value chain, so expect potential activity from us here.

The really difficult spot this year, as we see it right now, is Brazil. Clearly a great many interesting company cases are flagging given the aggressive selloff in Brazil, particularly of newer digital growth names. As one of the few emerging market countries that has had inflation issues and an aggressive rate-hike cycle, combined with what is a complex political environment, it looks like Brazil will have to choose between keeping Jai Bolsonaro ('Trump in LatAm' who has mishandled the economy for the past few years) as its president or elect Luiz Inácio Lula da Silva (the former president who spent eight years destroying all reforms and misusing the massive windfall Brazil had from the commodity cycle in the 2000s). This will be a really ugly contest. We are stock-pickers by heart and there are great companies in Brazil that are cheap but we have to navigate the country risk carefully to make sure we do not get a repeat of 2021. The bottom line is we see great opportunities for our Emerging Market Stars portfolio, with significant return potential for anyone with a 12–18-month investment horizon. We have historically been good at taking advantages of 'panic periods' and turning them into sustainable, responsible returns – we believe one of those periods is coming again.

**Emerging Markets and Asia Team** Polar Capital LLP

### European ex UK Income Fund

### **Fund Performance**

In 2021, the Fund returned (Class I GBP Accumulation Shares) 11.4% on an absolute basis but underperformed by 5.3% relative to the MSCI Europe Daily Total Net Return, excluding UK, Euro Index (in sterling terms).

The top relative contributors to performance were Total, Deutsche Post, Enel\*, Iberdrola\* and Adidas\*. Contrastingly, the top relative detractors were ASML Holding\*, Unilever, Anheuser-Busch InBev (ABI), Novo Nordisk\* and Orange.

### **Market Review**

The year began with crazy moves in the market because of a long period of very easy monetary policy and a steady build-up of moral hazard as many assumed the Fed would never let asset prices fall. This had two effects: a de-anchoring of valuations based on low rates forever (some sell-side analysts barely mention valuation these days or reference expensive stocks to each other) and a buy-any-dip mentality. Below the surface of markets, there continued to be signs of excessive risk-taking being revealed at even small signs of liquidity tightening. Credit Suisse\* was hit by two separate scandals: the collapse of Greensill and heavy losses in its prime broking exposure to the Archegos margin call blow-up.

The main risks to markets were more endogenous (ie about leverage, excess valuation and speculation within financial markets as taper talk builds, or a change in the correlation of equities and bonds) than from the pandemic. Markets are always riskier when the inflation picture limits the scope of central banks to do 'whatever it takes'. While much talk was of bubbles, there remained a massive bifurcation in valuation between loved and unloved sectors and between loved and unloved stocks within sectors. The valuation of our defensive blue-chip, cash-generative stocks continued to make no sense relative to other parts of the equity market and other asset classes.

While there remained plenty of volatility in the pandemic news flow, the broad trend remained towards normalisation with improving pharma interventions (vaccines and new drug treatments) reducing the need for non-pharma interventions (mobility restrictions and lockdowns). Early evidence from South Africa and the UK indicated that the Omicron variant resulted in less severe hospitalisations and lower mortality risk than earlier variants. The main development in pandemic policy, considering both the higher transmissibility and vaccine efficacy, was a trend towards countries reducing selfisolation periods.

In November, Fed Chair Jerome Powell was renominated for a new term by a president under political pressure around inflation. Due to the sequencing pathway of it not raising rates until the taper was complete, the Fed was in a position where inflation was above 6%, unemployment at 4.2%, real rates were deeply negative, and interest rates were unlikely to start to move away from zero until the middle of this year.

Furthermore, commentary from the Fed implied the risk to inflation from new coronavirus variants was to the upside (from further supply chain and labour shortages) rather than downside (demand destruction). The latest policy implied that the Fed was in tightening mode. The yield curve has continued to flatten. While the ECB may come under pressure if inflationary pressures persist in 2022, we continue to not expect Eurozone rate rises for the foreseeable future. Central banks were making tentative efforts to tighten monetary policy at a time when analysis from strategists at Société Genérale shows the stocks most negatively correlated to bond yields currently trade at a 40+% valuation premium (versus no valuation premium prior to the QE era). As such, further violent rotations within markets should be expected even if index headline moves are most measured.

Our central scenario for European equities in 2022 is that European politics will be broadly dull, inflation in Europe will ease faster than other regions, economic stimulus will be steadily withdrawn absent a large macro slowdown and the pandemic policy response will continue to be less draconian (less non-pharma interventions). The starting valuation of European equities (around 15x forward earnings) means there is sufficient risk premium for us to be compensated for any negative surprises to this scenario. We would be more cautious of the most expensive sub-segments within Europe's markets. We continued to prefer recovery plays that broadly sit in two camps: those that benefit from higher global bond yields (not reliant on European ones) or from economies reopening (some of our usual recession defensives like brewers are more reopening/recovery plays this time around).

Despite considerable absolute recovery year to date, the valuations of our portfolio remain striking. We only own seven stocks on P/ Es above 20x (the multiple of global equities) or 5% earnings yield (Air Liquide, Tryg, Heineken, Assa Abloy, Nestle, Industria de Diseno Textil [Inditex] and ABI). These should deliver unusually fast mediumterm earnings growth as they directly benefit from reopening tailwinds over the next three years (due to exposure to bars, hotels, travel and retail). The median 2022 P/E of the portfolio is 15x. The median 2022 EV/EBITDA of the portfolio is just below 10x. These remarkable valuation characteristics are despite the fact the Fund has no exposure to traditional value sectors like banks or autos and only invests in companies that make 10% through-cycle returns on equity. Defensive dividend equities had become deep value versus growth equities (the NASDAQ at around all-time highs), cyclical equities (European autos are at a 20-year high relative to the index) and other asset classes. In our view, global defensive equities with dividend yields above 2.5% are materially the wrong price versus individual government bonds. This is because global defensive equities have an ability to grow yields over the medium term in a more uncertain inflation backdrop, and diversification protects these yields from single country pandemic setbacks and foreign exchange risk.

\* not held

### European ex UK Income Fund continued

### **Fund Activity**

Our low portfolio activity was lower than usual in 2021 reflecting two things. First, the Fund's defensive holdings were currently out of favour and tended to be good companies benefitting from reopening, rather than stocks benefitting from monetary reflation of lower quality cyclicals. Given that most economies are in the early stages of reopening, plus the extended nature of the reflation trade, there are few compelling switch ideas between these two camps. Second, we were very active in 2020 repositioning the Fund for the new dividend reality. The Fund's dividend yield grew faster than the index before the pandemic (7.8% CAGR 2016–19) and was more resilient last year (down 14% versus the index down roughly a third). The wide dividend yield of the Fund versus the index is a function of these two factors rather than reaching for yield, but we are not looking to extend this premium even further by rotating from lower yielders into higher yielders.

Our stock sales were dominated by those we felt had reached expensive valuations. In February, we sold our position in Brenntag (German chemical distributor) on valuation grounds. The new management team was trying to drive significant change through the business to improve organic growth trends and better tap opportunities in specialist chemicals distribution. After a strong run since late 2018, we felt there was insufficient upside given what we perceive as underappreciated execution risk to their initiatives. In October, we decided to tender our share in Naturgy Energy Group in the tender offer carried about by an infrastructure fund. We became more sceptical on the ability of utility stocks, such as Naturgy, to maintain such high dividend payouts relative to free cash flow generation while investing so much capex in renewables. We also exited our position in BASF (German chemicals group). We lost conviction in the ability of management to allocate capital in an attractive way. The current macro backdrop seemed challenging given issues around China, auto supply chains and moderating PMIs and we are wary of cyclically exposed stocks where there are doubts around execution. We continued to review companies as potential Fund purchases that are executing well but are becoming cheaper for these reasons. In December, we exited two positions. We sold Pernod Ricard (spirits business) on valuation grounds. The shares had performed strongly since purchase and materially outperformed other reopening stocks despite travel retail remaining subdued and the key Chinese end market continuing to pursue a zero-COVID-19 policy. We also sold our position in Scandinavian Tobacco Group (STG) (cigars business) after reviewing the position as part of our dividend sustainability score work (see ESG below). The shares still look cheap despite performing well, but we see less scope for a rerating from here and are cautious on growth prospects.

We found several interesting ideas later in the year. After attending its impressive capital markets day, we started a position in Tryg (Scandinavian insurer). The company expects to double its technical result by 2024. Management has an impressive track record in pursuing efficiencies in the business and extracting synergies from acquisitions. The company is focused on retail (commercial and private) to drive future value creation, while the corporate business is being repositioned towards more attractive smaller customer portfolios while reducing less profitable clients. Tryg has also laid out an attractive shareholder returns program combining attractive and growing dividends plus a buyback starting next year. We took profits on our position in Cie Financiere Richemont (Swiss luxury branded goods) as the shares performed strongly on the back of activist investor headlines around realising value in the online business, strong trading and speculation around the metaverse being bullish for luxury stocks.

In December, we started positions in two stocks. First, we bought Air Liquide (industrial gases business). We have long admired the company as a very solid, defensive compounder in an attractive industry that has significantly consolidated in the past 20 years. The index dividend reset has made the stock's dividend look cheap relative to the index given its growth of 6% 5-year CAGR. Second, we bought Siemens (German industrial business), a stock we have consistently liked and previously owned. The business is executing very well both operationally and in terms of portfolio rotation. The group has delivered 8% dividend CAGR since 2009 and consistently augmented a solid ordinary dividend with share buybacks. We see the diversified growth profile as highly compelling in the context of the current 6% free cash flow yield.

#### ESG

We are in the process of applying to move the Fund to an Article 8 status under the SFDR (Sustainable Finance Disclosure Regulation). We have spent time building a dividend sustainability score methodology for each of the Fund's holdings and potential purchases going forward. We believe a bottom-up score method has two advantages for our approach relative to a sector exclusion methodology. Divestment approaches do not really solve problems like energy transition. Additionally, we expect the score approach to have more longevity as all industries implement ESG measures over time.

Having integrated ESG into our process more than two years ago, there is relatively little change to our stock research template and therefore stock picking. The aim of the dividend sustainability score is threefold. First, we want to improve the transparency to our clients of how we see our stocks' ESG profiles to our clients given third-party ESG scores are only an input into our ESG view. Second, we want to better quantify the metrics on which we seek to engage with our companies. Last, we want to create a binding constraint to meet the requirements of SFDR Article 8 funds. We do not expect this process to require any further stock divestments, apart from our sale of Scandinavian Tobacco Group (see above).

### **Market Outlook**

Volatility and uncertainty are likely to remain in the near term as markets process the implications of the pandemic and subsequent policy responses. We are optimistic on the opportunities the market will inevitably present us with while continuing to relentlessly focus on protecting capital and dividend streams as best we can.

Stocks with defensive business models and resilient dividend yields look increasingly appealing in the current backdrop against overvalued growth stocks, vulnerable deep value sectors and other asset classes with little yield.

### **European Income Team**

Polar Capital LLP

# **Financial Opportunities Fund**

### **Fund Performance**

Markets saw a strong recovery in 2021 but remained volatile given the unpredictable nature of the COVID-19 virus. Consequently, there were a number of conflicting market forces with new virus variants causing moderation in the pace of economic recovery while progress on vaccinations provided reassurance on the longer-term outlook.

Global financials saw a relatively strong recovery, with the MSCI ACWI Financials Net TR Index rising 24.3% in the year, outperforming broader markets (MSCI ACWI Index +19.0%) (all returns in dollar terms, unless otherwise stated). The Fund's NAV (Class I US Dollar Accumulation Shares) rose 19.7%, with the relative performance affected primarily by our mix of holdings in Asia (bias to emerging Asia and underweight developed Asia) along with the underweight position in diversified financials and a drag from the cash position.

#### **Market Review**

US financials outperformed (MSCI US Financials +35.8% in the year), led by diversified financials (+38%), with the banking and insurance sectors rising 35% and 31% respectively. While COVID-19 developments led to heightened volatility, the banking sector benefited from a pick-up in bond yields which bottomed in August and started to increase meaningfully in late September as market expectations shifted on the extent to which inflationary pressures were transitory or durable. The Federal Reserve announced in December that given upside surprises in both inflation and the labour market they would double the speed of tapering (to conclude in March 2022) with the dot plot moving from half a hike in 2022 to three hikes (three hikes maintained for 2023).

European financials saw a strong recovery in 2021, the MSCI European Financials rising 29.5% (in euro terms) although underperforming in dollar terms given significant currency movements during the year. The banking sector was relatively strong (+39%, in euro terms) as while COVID-19 infection rates picked up in the latter part of the year, the progress on vaccinations reduced the requirement for a reimposition of widespread restrictions. As with US banks, European bank results typically came in ahead of expectations (primarily on lower provisioning but also stronger fee income), leading to material earnings upgrades in the year, while a lifting of remaining regulatory restrictions led to the confirmation of high yields.

The MSCI Emerging Market Financials rose 8.2% in 2021, underperforming peers due to a combination of escalating pandemic concerns, expectations for tighter US monetary policy and heightened political risk (US-Russia rhetoric in relation to Ukraine became increasingly heated). Turkey's unconventional approach to tackling soaring inflation through lower interest rates (associated with 'Erdonomics') also brought into focus the risks for countries reliant on external financing.

### **Fund Activity**

While COVID-19-related uncertainties limited visibility on the near-term economic trajectory leading to abrupt shifts in market expectations, we have been encouraged by operating trends in the banking sector where fundamentals remain attractive. Management feedback points to a pick-up in lending activity, low levels of provisioning and elevated capital markets activity. Costs are also expected to see upward pressure (primarily linked to wages) but, overall, the sector is a significant net beneficiary of higher inflation leading to higher interest rates. Consequently, we raised our exposure to the banking sector during the year in both the US and Europe with a focus on adding to companies whose earnings are particularly sensitive to higher interest rates.

Emerging markets look less vulnerable than in previous cycles to rising US interest rates, given lower current account deficits, contained inflation levels and lower reliance on FX debt. However, the combination of rising COVID-19 infection levels (and slower vaccine rollouts) along with the prospect of tighter US monetary policy has raised risks relative to developed markets. We materially lowered our emerging market exposure during the year through reductions in Asia, Eastern Europe and Latin America.

Fintech companies saw selling pressure in the latter part of the year alongside a reassessment of the monetary policy outlook and a broader rotation out of growth and towards value sectors, with loss-making companies seeing particular weakness. Payment companies also underperformed, with concerns on competition (from account-toaccount transfer and Buy Now/Pay Later providers), pricing (following Amazon's decision to stop accepting UK Visa credit cards) and strategic positioning (PayPal's potential takeover of Pinterest). We continue to view payment companies, such as Mastercard, as a strong reopening play as cross-border revenues rebound but reduced our overall fintech exposure during the year in light of elevated valuations, a shift in the interest rate outlook and the potential for tighter regulation.

### **Market Outlook**

Omicron, the latest COVID-19 variant, has raised uncertainty, added to market volatility and is set to weigh on economic activity in 1Q22. However, we have been encouraged by recent data that points to a milder infection which, along with an acceleration in vaccine programs, suggests the impact on mobility will be significantly lower than in previous waves. The prospect of receding Omicron fears (South African cases have peaked), above-trend global growth and rising interest rates creates a positive setup for the sector in 2022. Within financials, the banking sector (which remains the core of the Fund and the key overweight) looks particularly well placed given its earnings sensitivity to interest rates and strong correlation to bond yields, while valuations remain undemanding (supported by earnings upgrades) despite the strong recovery in 2021.

#### **Financials Team**

Polar Capital LLP

### **Global Absolute Return Fund**

### **Fund Performance**

The Polar Capital Global Absolute Return Fund returned 4.3% (Class I US Dollar Accumulation Shares) in 2021, taking its return since inception to 30.8% (Class I US Dollar Accumulation Shares).

### **Market Review**

We believe 2021 can be reviewed in the context of the following five events:

- 1. Stimulus levels and policy in the US
- 2. COVID-19 cases, variants and restrictions
- 3. Inflation levels, expectations and the need of the central banks to tighten monetary policy
- 4. Strong corporate earnings growth
- 5. Global supply chain crisis

Despite starting the year in the face of political uncertainty in the US, the presidential inauguration and an eventual Democrat Congressional majority led to agreement on further fiscal stimulus. Given the positive development along with a rollout of vaccines by the middle of the first quarter, value names, particularly smaller-cap recovery beneficiaries, were once again leading risk assets higher. The positive macro outlook also tightened credit spreads.

On the flip side, with elevated personal disposable income and savings levels in the US, another round of fiscal stimulus led to higher inflation expectations and contributed to a further steepening in the US yield curve to levels not seen since 2017. In fact, Q1 finished with the 10-year treasury bonds suffering their worst quarterly performance since 1980, when interest rates were raised significantly in the US to fight double-digit levels of inflation. Elevated inflation levels were supported by bottlenecks at multiple levels of the supply chain, stemming from a paucity of raw materials, port congestion and difficulty finding labour supply, the latter likely being a result of the generous benefits-related component of financial stimulus.

At the same time, central bank sentiment shifted as US policymakers opened the discussion about an eventual reduction of the bank's \$120bn-a-month bond purchases, with 190 US companies citing inflation on their first quarter earnings, the highest number in at least 10 years, according to FactSet.

Rising real yields and the strong main street rebound continued to prove challenging for long-duration, high-growth companies while supporting more cyclical equities through Q1 and the first two months of Q2 (Russell 2000 Value: +26.7% (in dollar terms); Russell 2000 Growth: 3.9% (in dollar terms) through May). However, in the final month of the first half of the year, the Fed decided to re-emphasise its willingness to let inflation run hot before taking action. This which helped yields revert back to where we were in February with the 10-year US treasury yield back to 1.47% from a peak of 1.74% and the 2s/10s curve 36bps flatter than at its steepest point, reached at the end of Q1. On the back of this reversion in yields, equities started to see a pullback in value versus growth.

The second half faced a backdrop of resurging COVID-19 cases, softening economic data, ongoing cost pressures and lower leverage levels among market participants. Yet, in August, markets generally moved higher over the month driven by strong Q2 earnings. Per the Financial Times, European companies reported aggregate second quarter net income growth of 249% year-on-year while the percentage of European companies beating analysts' estimates hit a five-year high.

At the 26–28 August Jackson Hole meeting, Fed officials leaned towards reigning in US monetary stimulus in the form of tapering the bank's crisis-era \$120bn-per-month asset purchase program, while keeping the effort to taper bond buying decidedly separate from potential future increases to US interest rates.

Supply chain constraints only worsened with complications remaining for many in sourcing enough key materials, such as semiconductor devices, as well as sourcing the necessary human capital to process demand. With the possibility of prolonged higher inflation, major central banks tilted towards a more hawkish monetary policy stance and a slowdown in growth during September. Labour, supply and inflation conditions continued into October, as companies such as McDonald's commented on the need for a 15% increase in employee wages, as well as the need to pass some of these costs to consumers. Additionally, Ford and Apple both commented on semiconductor chip shortages hampering their respective ability to meet demand, with the former expecting the current environment to last well into 2023. These supply-chain disruptions and labour difficulties, as well as further increases in the prices of various important commodities (copper: +9.7%; crude oil: +11.4%; platinum: +5.7%; S&P Agricultural Index (SPCGAG): +3.8%) led to expectations of inflation remaining at more elevated levels for longer, as seen in US treasury 5yr breakeven rates (+40bp to 2.9%). Nevertheless, while yields increased and credit spreads widened modestly, equity markets largely shrugged off these fears in October, with many indices retracing to near record levels (S&P 500: +6.9% (in dollar terms); Eurostoxx600: +4.6% (in euro terms); MSCI Emerging Market Index: +0.9% (in dollar terms)). We believe this was mainly due to a general sense of strong corporate earnings combined with a lowering of real rates, helping higher growth assets (Russell 2000 Growth Index: +8.4% (in dollar terms)).

# Global Absolute Return Fund continued

#### Market Review continued

Towards the end of November, this sense of calm was shattered as Omicron emerged. Market moves were exacerbated when Fed Chair Jerome Powell signalled an intention to reduce asset purchases more quickly than expected to fight stubbornly persistent inflation.

Financial markets recovered in December in the wake of early signs of relatively positive data pertaining to the virulence of the latest strain. This relief was also bolstered by news of ongoing strength both of consumers and corporates. A US personal consumption increase of 4.7% year on year for November came in higher than anticipated, while staff lay-offs remained low as highlighted by US jobless claims. According to data from Goldman Sachs, US financial conditions in December were near the most accommodative on record.

Despite all the headwinds faced in 2021, most headline equity indices rallied meaningfully for the year (S&P 500: +26.9% (in dollar terms); EuroStoxx 600: +22.3 (in euro terms); TOPIX: +10.4% (in yen terms)). This was driven substantially by ongoing asset flows into mega-cap stocks which, due to how they are represented within indices, have an outsized impact on returns. Indeed, the Financial Times reported that, as of year-end, the top six contributors to the S&P 500 performance were all big tech names. This can be seen most clearly in the chart below, which shows an increasing number of securities hitting 52-week lows while only a few are hitting 52-week highs within the Russell 3000 index, which represents more than 95% of listed US companies.

Convertibles' issuance remained strong in 2021. By the end of the first half, there had been \$99bn of new convertible issuance, an increase of 6.8% from the already high bar set during the same period in the previous year. The US contributed approximately 56.5% of the issuance, followed by Asia with 22.5%, Europe with 19.1% and Japan with 1.9% (source: BAML). Though the monthly level of convertible primary activity closely resembled levels seen during the height of the pandemic, issuance was driven much more by companies seeking opportunistic financing as opposed to rescue financing. The cheapening of the secondary convertible market, despite a positive equity and credit backdrop, was a material headwind to the Fund's performance and explains much of the disappointing result for the first half.

### **Fund Activity**

Looking back at 2021, while the Fund modestly underperformed its 5-8% return target, we are pleased to have been able to post positive numbers following an exceptionally strong 2020. At the end of the year, the Fund had a net equity sensitivity of 11.7%. With regards to investment categories, asymmetric investments and equity hedged drove performance with contributions of 496 bps and 318 bps respectively versus having spent 89 bps on put trades and 42 bps on a credit hedge. As we reflect on the Fund's three-year track record, we are pleased to be able to report a compound net annual return of 9.4% with a volatility of return of 5.4% (against our target of 5–8% net return with approximately 6% volatility of return). Moreover, that we have been able to provide these risk/return metrics with generally very low net equity sensitivity is, we believe, testament to our approach of utilising the Fund's differentiated investment categories to provide a highly asymmetric investment opportunity with limited downside risk.

The Fund enjoyed a strong start to the year, with performance driven primarily by the Fund's equity hedged and asymmetric investment categories as elevated volatility and ongoing attractive new convertible issuance continued to present profit-generating opportunity. Additionally, the Fund was able to take advantage of the above-mentioned cyclical strength, evidenced by consumer discretionary being the largest contributing sector to Fund Performance in February and March. During the same timeframe, IT was the largest detractor, largely due to the level of issuance from this sector weighing on convertible valuations. Fund Performance in March suffered from both the widening of credit spreads and a general decline in convertible valuations, with the latter being driven by the extraordinary level of convertible issuance. Despite these headwinds, the Fund was able to maintain most of its returns as it de-grossed substantially in anticipation of the convertible valuation contraction. Notably, the Fund's gross exposure had declined from 218% in June 2020 and 172% at the beginning of 2021 to less than 150% at the end of the first half. This enabled the Fund to avoid the worst impacts from the cheapening of the secondary market. Indeed, valuations began to stabilise towards the end of the first half and we increased the Fund's gross exposures in response to this attractive risk/ reward backdrop. The Fund has adhered to its philosophy of strong risk discipline and management throughout this turbulent period, maintaining a modest equity exposure throughout.

The Fund generated positive returns in August driven both by the equity hedged and asymmetric investment categories. In particular, the equity hedged category benefitted from the stabilisation of convertible valuations as well as the Fund's lack of exposure to Chinese ADR-linked convertibles. Additionally, the broader equity market appreciation benefitted the Fund's asymmetric investment category, while causing some losses in the put profile category.

Against a volatile backdrop, Fund Performance was mixed in September. In particular, the Fund's asymmetric investment category, which is most closely correlated with broader equity moves, provided a negative return. Conversely, the Fund's equity hedged investment category, which largely has very limited positive or negative equity sensitivity, contributed modestly to performance, while the Fund's put profile investment category, which benefits most during declining markets, contributed most positively during the month. However, given an overall modestly positive net equity exposure across all investment categories, Fund Performance was in aggregate slightly negative in September.

The Fund benefitted from the theme of rising inflation and rates as energy, materials and financials were the largest contributors to performance during October. Notably, it benefitted from a modest long exposure in cryptocurrency exchange, Coinbase, whose equity rose 40.4% in October and second, a modest long exposure to US neo bank Sofi Technologies, whose stock rose 26.5%. This was offset by small losses in some consumer discretionary and IT names, though these were generally small and no individual name caused an outsized loss.

Against this risk-off backdrop, the Fund performed well in November driven by several factors, including a partial credit hedge, maintenance of a very modest equity sensitivity and good security selection. No investment category detracted materially from performance during the month. The Fund performed moderately in December given a volatile backdrop.

#### **Market Outlook**

As mentioned above, with few mega-cap names, the convertible asset class lacked a source of the support enjoyed by the broader equity market this year. We note that in recent times, when headline indices were advancing contemporaneously with such narrow breadth (such as March 2020 and December 2019, the latter during fears over a premature tightening cycle from the Fed which has a similar ring to today's backdrop), these smaller stocks rebounded strongly in the months following months. While we remain cautious on the outlook as discussed below, we believe that, coupled with an asymmetric exposure to their underlying securities this backdrop, offers some comfort that the convertible universe will provide a solid risk/reward ratio in the months ahead.

While we are generally constructive, we are also cognisant that there are risks. These include credit spreads that remain historically tight, interest rates that could rise, a further rotation away from longerduration growth equities and the potential that risk assets in general are late cycle and supported by a declining amount of supra-normal liquidity. However, these are risks investors in general must address, not just those in the convertibles market. Convertibles have historically been well placed to address each of these, as their low duration protects against interest rates and credit spreads and their bond floors provide late-cycle protection and defensiveness. Also, the breadth of the opportunity set noted above provides convertible investors with more ability to navigate equity market rotations than they have ever had – and arguably more than the mega-cap-centric equity indices provide.

Consequently, despite the challenges of 2021, we believe the asset class remains well positioned to provide both fixed income and equity investors with superior risk-adjusted return potential than their native asset classes.

#### **Convertibles Team**

Polar Capital LLP January 2022 For the financial year ended 31 December 2021

# **Global Convertible Fund**

### **Fund Performance**

The Polar Capital Global Convertible Fund returned -7.5% (Class I US Dollar Accumulation Shares) in 2021, taking its return since inception to 61.0% (Class I US Dollar Accumulation Shares). In comparison, the Refinitiv Global Focus Convertible Bond Index returned -3.8% and 49.3% (both in dollar terms) for the same periods respectively.

### **Market Review**

We believe 2021 can be reviewed in the context of the following five events:

- 1. Stimulus levels and policy in the US
- 2. COVID-19 cases, variants and restrictions
- 3. Inflation levels, expectations and the need of the central banks to tighten monetary policy
- 4. Strong corporate earnings growth
- 5. Global supply chain crisis

Despite starting the year in the face of political uncertainty in the US, the presidential inauguration and an eventual Democrat Congressional majority led to agreement on further fiscal stimulus. Given the positive development along with a rollout of vaccines by the middle of the first quarter, value names, particularly smaller-cap recovery beneficiaries, were once again leading risk assets higher. The positive macro-outlook also tightened credit spreads.

On the flip side, with elevated personal disposable income and savings levels in the US, another round of fiscal stimulus led to higher inflation expectations and contributed to a further steepening in the US yield curve to levels not seen since 2017. In fact, Q1 finished with the 10-year treasury bonds suffering their worst quarterly performance since 1980, when interest rates were raised significantly in the US to fight double-digit levels of inflation. Elevated inflation levels were supported by bottlenecks at multiple levels of the supply chain, stemming from a paucity of raw materials, port congestion and difficulty finding labour supply, the latter likely being a result of the generous benefits-related component of financial stimulus.

At the same time, central bank sentiment shifted as US policymakers opened the discussion about an eventual reduction of the bank's \$120bn-a-month bond purchases, with 190 US companies citing inflation on their first quarter earnings, the highest number in at least 10 years, according to FactSet.

Rising real yields and the strong main street rebound continued to prove challenging for long-duration, high-growth companies while supporting more cyclical equities through Q1 and the first two months of Q2 (Russell 2000 Value: +26.7% (in dollar terms); Russell 2000 Growth: 3.9% (in dollar terms) through May). However, in the final month of the first half of the year, the Fed decided to re-emphasise its willingness to let inflation run hot before taking action this helped yields revert back to where we were in February with the 10-year US treasury yield back to 1.47% from a peak of 1.74% and the 2s/10s curve 36bps flatter than at its steepest point, reached at the end of Q1. On the back of this reversion in yields, equities started to see a pullback in value versus growth.

The second half faced a backdrop of resurging COVID-19 cases, softening economic data, ongoing cost pressures and lower leverage levels among market participants. Yet, in August, markets generally moved higher over the month driven by strong Q2 earnings. Per the Financial Times, European companies reported aggregate second quarter net income growth of 249% year-on-year while the percentage of European companies beating analysts' estimates hit a five-year high.

At the 26–28 August Jackson Hole meeting, Fed officials leaned towards reigning in US monetary stimulus in the form of tapering the bank's crisis-era \$120bn-per-month asset purchase program, while keeping the effort to taper bond buying decidedly separate from potential future increases to US interest rates.

Supply chain constraints only worsened with complications remaining for many in sourcing enough key materials, such as semiconductor devices, as well as sourcing the necessary human capital to process demand. With the possibility of prolonged higher inflation, major central banks tilted towards a more hawkish monetary policy stance and a slowdown in growth during September. Labour, supply and inflation conditions continued into October, as companies such as McDonald's commented on the need for a 15% increase in employee wages, as well as the need to pass some of these costs to consumers. Additionally, Ford and Apple both commented on semiconductor chip shortages hampering their respective ability to meet demand, with the former expecting the current environment to last well into 2023. These supply-chain disruptions and labour difficulties, as well as further increases in the prices of various important commodities (copper: +9.7%; crude oil: +11.4%; platinum: +5.7%; S&P Agricultural Index (SPCGAG): +3.8%) led to expectations of inflation remaining at more elevated levels for longer, as seen in US treasury 5yr breakeven rates (+40bp to 2.9%). Nevertheless, while yields increased and credit spreads widened modestly, equity markets largely shrugged off these fears in October, with many indices retracing to near record levels (S&P 500: +6.9% (in dollar terms); Eurostoxx600: +4.6% (in euro terms); MSCI Emerging Market Index: +0.9% (in dollar terms)). We believe this was mainly due to a general sense of strong corporate earnings combined with a lowering of real rates, helping higher growth assets (Russell 2000 Growth Index: +8.4% (in dollar terms)).

Towards the end of November, this sense of calm was shattered as Omicron emerged. Market moves were exacerbated when Fed Chair Jerome Powell signalled an intention to reduce asset purchases more quickly than expected to fight stubbornly persistent inflation.

Financial markets recovered in December in the wake of early signs of relatively positive data pertaining to the virulence of the latest strain. This relief was also bolstered by news of ongoing strength both of consumers and corporates. A US personal consumption increase of 4.7% year on year for November came in higher than anticipated, while staff lay-offs remained low as highlighted by US jobless claims. According to data from Goldman Sachs, US financial conditions in December were near the most accommodative on record.

Despite all the headwinds faced in 2021, most headline equity indices rallied meaningfully for the year (S&P 500: +26.9% (in dollar terms); EuroStoxx 600: +22.3 (in euro terms); TOPIX: +10.4% (in yen terms)). This was driven substantially by ongoing asset flows into mega-cap stocks which, due to how they are represented within indices, have an outsized impact on returns. Indeed, the Financial Times reported that, as of year-end, the top six contributors to the S&P 500 performance were all big tech names. This can be seen most clearly in the chart below, which shows an increasing number of securities hitting 52-week lows while only a few are hitting 52-week highs within the Russell 3000 index, which represents more than 95% of listed US companies.

Convertibles' issuance remained strong in 2021. By the end of the first half, there had been \$99bn of new convertible issuance, an increase of 6.8% from the already high bar set during the same period in the previous year. The US contributed approximately 56.5% of the issuance, followed by Asia with 22.5%, Europe with 19.1% and Japan with 1.9% (source: BAML). Though the monthly level of convertible primary activity closely resembled levels seen during the height of the pandemic, issuance was driven much more by companies seeking opportunistic financing as opposed to rescue financing. The cheapening of the secondary convertible market, despite a positive equity and credit backdrop, was a material headwind to the Fund's performance and explains much of the disappointing result for the first half.

### **Fund Activity**

After the exceptional strength of 2020, 2021 was a much more challenging year for convertibles, with many of the tailwinds from 2020 turning into headwinds in 2021. Convertibles are often used by mid-cap companies transitioning from equity-financing to straight debt-financing. Although there are some mega-cap names, these are under-represented.

The Fund began the year by taking profits on the reopening names which had generated strong outperformance in the second half of 2020. With fiscal and monetary policies both being simultaneously expansionary in the most marked fashion since the 1970s, we harboured concerns that there could be near-term inflationary spikes. As a result, we rotated from our reopening trades of 2020 into names that should be more direct beneficiaries of inflation, such as miners, materials and industrial companies, while maintaining an underweight in growth. However, absent the overweight in materials and the underweight in IT, the Fund generally maintained a neutral exposure both by geography and sector. With market volatility and dispersion increasing, and given the multitude of crosscurrents, we believed it unwise to run significant macro or factor exposures. In general, this view was borne out even if our single-stock performance has been disappointing. With some cyclical equities trading above their pre-COVID-19 levels, this created an unfavourable risk/reward relative to that of our preferred defensive growth investments, whose convertibles and underlying equities traded at more attractive valuations in the first half of the year.

The Fund generated positive returns in August, with all regions contributing. Moreover, returns were broad-based, with no sector or individual position contributing an outsized profit. Additionally, the Fund did not hold any Chinese ADR-linked convertible positions at month end as, although many of these names had fallen precipitously in earlier months, we felt the risk-to-reward remained sub-optimal in many cases.

While convertible bonds were moderately pressured by rising credit spreads and interest rates as well as declining equity markets, the convertible universe in general fared well given a lower sensitivity to equity markets in September, helped by more balanced recent new convertible issuance (source: BAML).

In October, the Fund benefitted from the broader moves in equity markets, with IT (duration), materials (inflation beneficiaries) and financials contributing most to performance.

The convertible asset class was similarly influenced by the previously mentioned themes in November, with higher-beta names underperforming lower-risk assets. With the Federal Reserve signalling a faster pace of monetary policy tightening, coupled with elevated valuations, we lowered the overall equity sensitivity of the Fund in November. This proved beneficial when news of the emergence of the Omicron variant spread through markets. In addition, we also reduced our technology exposure and slightly increased our exposure to the utility sector to further reduce the risk profile of the Fund.

Amid easing fears of the new Omicron variant, the Fund performed well in December. Performance was strong in the industrial sector as cyclicals outperformed.

# Global Convertible Fund continued

### **Market Outlook**

As mentioned above, with few mega-cap names, the convertible asset class lacked a source of the support enjoyed by the broader equity market this year. We note that in recent times, when headline indices were advancing contemporaneously with such narrow breadth (such as March 2020 and December 2019, the latter during fears over a premature tightening cycle from the Fed which has a similar ring to today's backdrop), these smaller stocks rebounded strongly in the months following months. While we remain cautious on the outlook as discussed below, we believe that, this backdrop coupled with an asymmetric exposure to their underlying securities, offers some comfort that the convertible universe will provide a solid risk/reward ratio in the months ahead.

While we are generally constructive, we are also cognisant that there are risks. These include credit spreads that remain historically tight, interest rates that could rise, a further rotation away from longerduration growth equities and the potential that risk assets in general are late cycle and supported by a declining amount of supra-normal liquidity. However, these are risks investors in general must address, not just those in the convertibles market.

Convertibles have historically been well placed to address each of these, as their low duration protects against interest rates and credit spreads and their bond floors provide late-cycle protection and defensiveness. Also, the breadth of the opportunity set noted above provides convertible investors with more ability to navigate equity market rotations than they have ever had – and arguably more than the mega-cap-centric equity indices provide.

Consequently, despite the challenges of 2021, we believe the asset class remains well positioned to provide both fixed income and equity investors with superior risk-adjusted return potential than their native asset classes.

#### **Convertibles Team**

Polar Capital LLP

### **Global Insurance Fund**

### **Fund Performance**

For 2021, the Fund returned 15.7% (Class R GBP Accumulation Shares) versus 19.0% for the MSCI World Insurance Index benchmark, 22.9% for the MSCI World Index (both net total return in GBP terms), 18.3% for the FTSE All Share Index and 29.8% for the S&P 500 Index (both total return in GBP terms).

Fund Performance was largely driven by our estimate of bookvalue growth in 2021 with only a modest increase in price-to-book valuations despite the material improvement in underwriting conditions and strong equity market performance. Sentiment to non-life insurance has not been helped by another year of elevated catastrophe losses, discussed further below, and market rotation. The latter helped life insurer stock prices accelerate their recovery from post-COVID-19 lows which impacted the Fund's relative performance over the year. Non-life insurance is typically neglected in favour of the banks and life companies as bond yields move higher. However, rising bond yields and inflation expectations are a positive for our companies given their focus on annual policies with short-duration liabilities and this adds further upward momentum to already rising earnings estimates. Given our companies' 2.5x investment leverage to shareholders' equity, the recent rise in short-term bond yields should translate into a meaningful 1% increase in our prospective bookvalue growth.

We entered 2021 expecting book values to grow by double digits for the year with better underwriting margins offsetting modestly lower investment returns. While we will not know the outcome for 2021 until the year-end results are published our expectation is that our companies grew book values by c-3% in the fourth quarter making -11% for the full year and achieving our 10%+ expectation at the start of 2021. Catastrophe frequency was marginally above 'normal' expectations and the average of the past 10 years, although our prudent catastrophe weighting meant the portfolio was not materially impacted. The Fund was up -16% in 2021 with FX contributing a marginal c1%. We estimate the 15% constant FX return comprises 11% book-value growth with a further 4% from rising price-to-book valuations. Multiple expansion for our companies in the aggregate lagged what we saw for the US industry overall. The Dowling & Partners industry price-to-book multiple increased from 132% to 145% during 2021 but still ended the year below the pre-pandemic levels of 150%.

In the end, what drives long-term Fund Performance is our companies' ability to compound book value per share and dividends at an attractive rate over time. Over the 23 years of the Fund, we estimate this metric has compounded at close to 11% per annum which is almost identical to the Fund Performance over the same period. Constructing a 30–35 stock diversified portfolio focused on specialty underwriters that can deliver double-digit book value per share growth over time remains core to our investment process.

### **Market Review**

Given recent experience, perhaps it is not surprising that each passing year feels like it again breaks climate-related records, and that we see the world suffering a barrage of ever more unusual weather events. 2021 sadly was another active year with Swiss Re's preliminary estimate for global insured natural catastrophe losses standing at \$105bn (excluding the December events such as the US tornadoes which will likely add another \$3-5bn to this total). 2021 was the fourth year of \$100bn+ insured losses in the past 20 and exceeded our normalised \$85-90bn expected level. Losses were led by Hurricane Ida (\$30–32bn), the Texas Winter Storm Uri (\$15bn) and the July European flooding losses (\$13bn). Managing and insuring risk is becoming more and more complex given rising climate change volatility, a proliferation of cyber threats, increasing jury verdicts and social inflation. In a world of relentlessly increasing risk, the value the insurance industry provides has never been greater. Risk globally continues to be re-evaluated and repriced, providing excellent underwriting and growth opportunities for our companies.

The strong underwriting market conditions are well illustrated by the quarterly Global Insurance Market Index published by insurance broker Marsh. In 2019, rate rises progressively rose from 3% in 1Q19 ending 2019 at 11%. Pricing accelerated throughout 2020 with 14% in 1Q20 rising to 22% by 4Q20 which was the greatest increase since the survey begun. In 2021, rates rose again in the mid/high-teens resulting in a third year of rate-on-rate increases. For the three years to 3Q21, the compounded rate rise has been a significant 49% which we believe is materially ahead of loss cost inflation. This has led to improving underwriting margins since mid-2020. Insurance is a lagged industry and the profits being reported today mostly reflect the underwriting environment of 12–18 months ago. Given the extent of premium rate rises we have seen the best is still to come with regards to underwriting margins for our portfolio companies.

Rob Berkley, CEO of WR Berkley, nicely summarised the current market opportunity on Berkley's 3Q21 earnings call: 'It's just a good moment for the P&C space, quite frankly, ex-most of the workers comp market, which continues to feel a bit of a growing headwind. Obviously, property felt some pain in the quarter, but just general market conditions are reasonably attractive, and we don't see that trend changing. More specifically, it is a good moment for specialty writers, particularly casualty-related specialty writers and even more so the E&S [Excess & Surplus Lines] market. We continue to see a growing flow of opportunities both in specialty and even more so in E&S, and there is nothing that leads us to believe that that tide is going to reverse anytime soon, so that's definitely encouraging.'

# Global Insurance Fund continued

### Market Review continued

Against this backdrop we also expect to see improved reinsurance pricing as 2022 develops which will further support the already strong rating environment we see in commercial insurance. This is also discussed further below.

In recent years, we have seen a huge shift in public company disclosures given the growth in ESG investing, supplemented by new disclosure frameworks like the Taskforce on Climate-related Financial Disclosures (TCFD). The UK is on track to become the first G20 country to make TCFD mandatory for Britain's largest companies with rules coming into force from April 2022 and we hope other countries will guickly follow suit. Importantly, as we saw at COP26, the emphasis is moving beyond purely climate change to something more holistic where other considerations such as biodiversity are given their due recognition. The risks that many companies are now publicly disclosing have mostly always been there but encouragingly we see a renewed effort by company managements to demonstrate they are appropriately managing risks that have been highlighted to stakeholders. The good news for the sector is that insurance is one of the key tools in managing risk and volatility and therefore rising disclosures alongside ongoing regulatory change will likely act as a tailwind for insurance demand for many years to come. Helping communities build resilience is a core competency of the insurance industry and it has a critical role to play in this effort.

In May, we published our inaugural dedicated ESG and Sustainability presentation. This brought together and expanded on many of the themes we have discussed in our factsheets, presentations and webcasts including topics such as climate change, biodiversity and nature-based solutions. We addressed the role of the insurance industry within an ESG context and described the key role both the Fund and the industry are playing, now and in the future, as part of the transition to a greener and more sustainable world: "The Fund's proprietary ESG scoring methodology and context on how we assess the impact of individual companies through the lenses of the UN's Sustainable Development Goals (SDGs) is provided in more detail in the Fund's prospectus, website and annual report SFDR disclosures pursuant to Article 8 of the SFDR. The mapping of the Fund's underlying underwriting exposures to the SDGs forms the basis of these disclosures under the SFDR."

We believe the non-life insurance sector is currently underappreciated within most ESG and sustainability-led portfolios. However, we are somewhat encouraged by the ongoing improvement in how thirdparty ESG rating companies are assessing the industry, but it will take time. The Fund is A-rated by MSCI with strong positive momentum as our companies continue to improve their broader ESG approach and disclosures which complement their strong governance.

### **Fund Activity**

The Fund continues to have a low turnover and we did not change our overall positioning materially during the period. One new holding was initiated in Ryan Specialty Group Holdings, a wholesale insurance broker that listed in the US in July. No positions were fully sold.

### **Market Outlook**

In December 2020, we revised our prospective book-value growth assumption back to 10%+ having marginally lowered it at the onset of COVID-19. Our current expectations are that industry COVID-19 losses will come below the lower end of our initial \$60-70bn base case estimate (2% industry capital) given in April 2020. Many companies have yet to recognise the lower claims experience in 2020 in their financial results which will likely see material favourable reserve development benefiting future earnings. The vast majority of COVID-19 underwriting losses were borne in the 2020 financial results with very little impact in 2021. Elevated COVID-19 deaths will continue to impact RGA, the Fund's life reinsurer (2.6% holding) but we would not expect any material underwriting impacts from Omicron, nor any other variant, on our non-life companies. Industry losses to COVID-19 in 2020 were led by event cancellation and business interruption within commercial property policies. The latter was specific to certain geographies such as the UK and policy language has since been tightened up where necessary with exposure having now largely run off the books.

In recent years, a growing proportion of catastrophe reinsurance risk has been borne by the broader capital markets, rather than by traditional reinsurers through Insurance Linked Securities (ILS) such as catastrophe bonds and other reinsurance capital structures. However, following the elevated catastrophe losses since 2017, the appetite for catastrophe risk from these capital providers, as well as a growing number of traditional reinsurers, is declining. At the same time demand for catastrophe reinsurance is rising and consequently premium rates are moving higher.

Around 50–60% of property catastrophe business is placed at the 1 January renewal with a bias to European and global accounts, given Japanese risk largely renews 1 April and US domestic accounts at the mid-year ahead of the Atlantic hurricane season. Early market commentary has suggested that the 1 January 2022 renewal was 'very late' with some reinsurance buyers struggling to buy the catastrophe protection they wanted. Deployable ILS capital (excluding catastrophe bonds) is thought to be down 20–25% from the previous year, adding to the upwards pressure on catastrophe pricing, particularly for retrocession. 'Retro' is the reinsurance bought by reinsurers and is a market that is majority supported by ILS capital. Overall, we believe property catastrophe pricing rose by low double digits depending on geography. Guy Carpenter, the reinsurance broking subsidiary of Marsh McLennan, announced its Global Property Catastrophe Rate-on-Line Index rose by 10.8% for the 1 January renewals. Several commentators suggested that retro saw rate rises of 15%+. We expect catastrophe reinsurance pricing to continue to harden as we move through 2022 particularly towards the mid-year with the US renewals. This will add even more pricing discipline to the already strong primary insurance market condition.

Although catastrophe reinsurance rates are now 30% above 2017 levels, we are maintaining our current prudent low level of catastrophe exposure, given the heightened level of activity in recent years and the excellent underwriting margins we expect in many non-catastrophe classes of business. The economics of non-catastrophe-related reinsurance follows insurance market profitability which is strong and continues to improve. We expect catastrophe reinsurance pricing to continue to harden as we move through 2022 particularly towards the mid-year with the US renewals. This will add even more pricing discipline to the already strong primary insurance market conditions.

The US industry price to book is currently around 145% still below the pre-pandemic levels of 150%, despite the increasing earnings power of our companies. Historically, the weighted average price to book for the Fund's companies (excluding brokers) has been at a meaningful premium to industry averages, which is what you would expect given the quality bias of the portfolio to best-in-class underwriters. However, that historic premium has disappeared, and the Fund now trades in line with the US average and at a modest discount to the benchmark price-to-book multiple.

We believe our quality companies remain on sale and it is no surprise to have seen significant share buybacks in 2021. Chubb, Arch Capital, RenaissanceRe Holdings and Fairfax Financial Holdings all repurchased 5%+ of their outstanding shares during the year and Berkshire Hathaway and Travelers could join this list depending on their 4Q21 activity. With earnings power rising, balance sheets in great shape and valuations attractive, we believe material buyback activity will continue benefiting future financial results. We expect our companies to report double digit book-value growth in the aggregate for the foreseeable future. It is looking increasingly likely that earnings power will be further increased by rising shortterm bond yields as markets react to growing inflationary pressures. The four key building blocks of book-value growth – namely underwriting leverage, underwriting margin, investment income return and investment leverage – are all moving favourably higher. Insider buying, M&A and robust share repurchase activity suggest the non-life insurance sector remains on sale. The growing disconnect between fundamentals and valuations is why we believe the Fund is very well placed to deliver good returns in 2022 and beyond.

#### **Financials Team**

Polar Capital LLP

# **Global Technology Fund**

### **Fund Performance**

The Fund's NAV increased 10.1% (Class I US Dollar Distribution Shares) during 2021, a solid absolute return, but notably lagging behind its benchmark, the Dow Jones Global Technology Net Total Return Index, which returned 26.9% (all returns in dollar terms, unless otherwise stated). Relative underperformance was driven by multiple headwinds, which we discuss below, many of which we expect will subside in 2022, hopefully allowing stock selection and fundamentals to play a greater role in Fund returns this year.

Large caps materially outperformed, the Russell 1000 Technology Index returning +37.2%, while the small-cap Russell 2000 Technology Index returned +14.2%. The Fund is structurally underweight mega-caps and, as such, their strength was a meaningful headwind to relative performance (despite our use of out of the money (OTM) call options to reduce our underweight positions at various points during the year) with Apple (+35%), Microsoft (+53%), Alphabet (+65%) and Facebook (+23%) representing around 39% of our benchmark. Our more global approach, especially relative to peers, also proved deleterious with the Dow Jones Technology (ex US) W2TEC Index returning only 1.8%.

However, the most significant headwind to both absolute and relative returns during 2021 was a reversal in many of the trends that powered the Fund in 2020, when many of its existing core themes benefited from work from home (WFH) and other related behaviour changes. What were tailwinds leading to multiple expansion in 2020 became headwinds and multiple compression in 2021. In that context, we prefer to look at underlying returns over the entire pandemic period, which have lagged the benchmark a little but remained robust, largely due to the strong underlying growth of our holdings which persisted more evenly during both years.

A good example of this was the reversal in investor sentiment around small and mid-cap growth companies, outside a small group of the highest growth companies trading at very elevated valuations: Russell 3000 constituents with high sales growth but low margins saw EV/sales multiples compress from 16x EV/FY2E sales in February to just 8x by the end of the calendar year. Another example was the full-year performance of next-generation technology stocks, especially the unprofitable stocks and concentrated funds investing aggressively in these areas, many of which ended the year in substantially negative territory.

While our holdings largely delivered robust results ahead of expectations, there were pockets of disappointment and slowing growth against difficult growth comparisons for e-commerce/ payments and other direct WFH beneficiaries such as Peloton\* and Zoom, where we very recently reinitiated a position. Some of these stocks are now back at pre-pandemic levels with much greater levels of sales. In addition, we encountered a few stock-specific execution issues at holdings such as Everbridge, Zendesk and Zillow\*. Payments and fintech companies also came under sustained pressure as the benefits of elevated e-commerce activity and support from government stimulus measures rolled off and concerns mounted about the perceived increased threat of disruption from new payment modalities, including account to account payments, BNPL (buy now/ pay later) and cryptocurrencies. Fortunately, we have limited exposure here due to these and other potential risks.

However, our concerns about high-growth valuations and exuberance in certain areas – recently borne out by market weakness – proved premature. As such, our decision to hold cash and deep OTM NDX put options reduced the beta of the Fund in a rising market and dragged on returns. That said, cash and our NDX puts should not be viewed in isolation because by ameliorating downside risk during market setbacks (as per 1Q20 and 4Q18), they positively influence stock selection and embolden overall portfolio construction. This has benefitted the Fund relative to growth-centric peers which have proven even more volatile recently (December 2021 and early 2022).

For the full year, the top contributors to relative performance were Alibaba\* (u/w), Advanced Micro Devices (AMD), Marvell Technology, Applied Materials and E Ink Holdings. The biggest detractors to relative performance during the year were our cash holdings and NDX index puts, Microsoft (u/w), Everbridge, Zendesk and Peloton\*.

### **Market Review**

2021 began with a contested US presidential election and the storming of the Capitol Building, surging COVID-19 infections and uncertainty around the efficacy and uptake of vaccines. Two major new COVID-19 variants, supply-chain dislocations, commodity shortages, the Taliban reconquest of Afghanistan, persistently high inflation and the onset of global central bank tightening could not, however, curtail equity market returns. If the previous year owed everything to policymakers and unprecedented stimulus, 2021 belongs to science. It is now two years since COVID-19 began to reshape the world we live in, and after a tragic first 18 months, there was clear light emerging at the end of the tunnel in 2021, with spectacular medical vaccine and anti-viral innovations aiding this process. World governments have managed to distribute the vaccine to nearly 5 billion people and the Commonwealth Fund estimates this has saved 1.1 million lives in the US alone.

Equity markets reached new highs by mid-February, driven by the prospect of an economic recovery, progress on vaccine rollouts and optimism around further US fiscal stimulus following Democratic victories in the Georgia runoffs. Economic activity indicators pointed to a robust expansion and the successful passage of President Biden's \$1.9trn COVID-19 Relief bill, strong jobs data and the early success of vaccine rollouts supported expectations for a rapid economic recovery.

\* not held

The speed of the macroeconomic demand recovery pushed the global economy into outright shortages across components, commodities and labour. Supply chains remained tight following lengthy lockdowns, and labour shortages were exacerbated by the continued US stimulus programs in the first quarter and the extension of enhanced unemployment benefits through September.

A pick-up in inflation had been anticipated by the market in response to the reopening and shortages of raw materials, intermediate inputs and labour, but the extent of the surge in CPI inflation in April and May surprised to the upside. A 5% year-over-year increase for May was an acceleration from the already elevated 4.2% in the previous month and represented the fastest growth since August 2008. The core personal consumption expenditure (PCE) price index – the Fed's preferred inflation gauge – was up 3.6% y/y in April, the highest level since 1992. Commodity prices continued to surge and copper prices reached their highest level in a decade.

Financial markets focused on the degree to which inflation was transitory, with the Federal Reserve (Fed) maintaining that 'aboveaverage' inflation is both transitory and somewhat welcome, having spent the post-global financial crisis period fighting deflationary impulses. This consistent dovish message from the Fed, repeated by the ECB, combined with keeping asset purchases steady at \$120bn per month allowed equity markets to shrug off concerns about inflation, forcing the central banks to tighten policy ahead of schedule. That said, a slightly more hawkish June FOMC saw the so-called 'dot plot' imply two hikes in 2023 from zero in March and October. Fed Chair Jerome Powell indicated the Fed could begin scaling back asset purchases (tapering) as soon as November and complete the process by mid-2022. As inflation readings remained elevated (October CPI +6.2% y/y, November +6.8% - the fastest pace since 1982), the US five-year breakeven reached 3% during November - for the first time based on data going back to 2002 - and the yield curve flattened materially due to a move higher in two-year rates as investors become more concerned about tighter Fed policies. Powell was re-nominated as Fed chair and the tone turned more hawkish still, with Powell stressing it was time to 'retire' the word 'transitory' and the December FOMC meeting saw the announcement of a doubling in the pace of tapering from \$15bn to \$30bn per month, which indicates the Fed will stop adding to its balance sheet by March 2022. The median dot plot now suggests three rate hikes in 2022.

Late November also saw South Africa begin to report surging cases of the new Omicron variant. The pace with which the virus has engulfed the world, becoming the dominant strain in many countries due to its high transmissibility, is mind-blowing. During the three previous COVID-19 waves, peak new cases were between 700–900 thousand; in early January, new cases were reported to be 2.5 million daily, with the US alone exceeding one million. The combination of an apparently less deadly variant and greater immunity (natural or via vaccines) may have broken the link between infection and death. However, the sheer volume of cases and the ability of Omicron to at least partially evade prior immunity threatens significant worldwide disruption. Initially this caused panic, leading the US 10-year Treasury to fall to 1.34% while the VIX Index (an option-implied measure of market volatility) exceeded 30. Since then, a more optimistic view has emerged with this 'weaker' variant the potential bridge between pandemic and endemic phases. This led equity markets to fully recover into year-end. Commodity markets also rebounded strongly, and oil prices came close to recovering all their earlier losses, with WTI Oil gaining 14.2%. The US 10-year Treasury yield also recovered sharply, ending the year around 1.5% and surging towards a post-pandemic peak of 1.7% during the first week of 2022.

2021 was another strong year for risk asset returns reflecting successful vaccine rollouts, a still-supportive fiscal and monetary policy backdrop, strong corporate earnings and record equity inflows. US returns (S&P 500 +29%) once again drove global returns (MSCI ACWI +19%), eclipsing those achieved in Europe (Eurostoxx 600 +17%) and offsetting Japanese (TOPIX +1%), Asian (MSCI Asian ex-Japan: -5%) and emerging market (MSCI EM: -2%) weakness.

The S&P 500's 29% total return was delivered with below-average volatility (largest peak-to-trough drawdown just -5%), and was composed of 33% growth in earnings and 1.8% in dividend income, offset by a 7% compression in its P/E multiple. The market also saw a decline in breadth as the five largest S&P 500 stocks at the start of the year returned 37% and accounted for almost a third of the Index's total return. Large-cap stocks outperformed small caps, the Russell 1000 Index (large-cap) returning 26% against the Russell 2000 Index's (small-cap) 15%. There was particular weakness in small-cap growth stocks (Russell 2000 Growth Index), returning just 3% after a strong start to the year. Strong index-level returns belied material volatility under the surface with 92% of S&P 500 companies and 89% of NASDAQ companies experiencing greater than 10% corrections from year-to-date (YTD) highs, while the average company drawdown from YTD highs was -18% for the S&P and -40% for the NASDAQ. US performance also benefitted from dollar strength, the tradeweighted dollar basket gaining 6% during the year. The weakness in Asian stocks reflected the region's struggle with the Delta variant, low vaccination rates, soaring energy prices and a deluge of regulatory changes and market unfriendly developments in China that took their toll on investor sentiment and stock prices alike.

Equity inflows were extraordinarily robust at \$1trn, exceeding the combined total of the past 19 years. Corporate buyback authorisations also passed \$1trn. Equity issuance was a record, with more than \$530bn of total issuance (\$146bn of which was special purchase acquisition companies or SPACs), as companies looked to take advantage of seemingly insatiable investor demand.

# Global Technology Fund continued

### **Technology review**

The technology sector posted another strong year in 2021, after a phenomenal 2020, the Dow Jones Global Technology Index gaining +26.9% supported by strong underlying growth in revenue and earnings. Having been at the heart of the response to the COVID-19 pandemic, the sector performed in line with the broader market during the reopening phase, against the MSCI All Company World Index's +19% and the S&P 500's +29%. Larger technology companies (Russell 1000 Technology Index) returned +37%, significantly ahead of the smaller technology companies' (Russell 2000 Technology Index) +14% return, led by strong performance from Microsoft (+52%), Alphabet (+65%), Apple (+35%) and NVIDIA (+125%). The technology sector contributed one third of the S&P 500's 29% total return in 2021, and the sector made up 29% of the index by year-end while contributing 22% of total index earnings. This remains in stark contrast with the dot.com bubble years when the sector accounted for 33% of market cap and just 14% of earnings.

Strong headline returns led by the largest companies belied bifurcated subsector returns. Semiconductors were the strongest performing subsector, the Philadelphia Semiconductor Index (SOX) returning 43% as strong demand from cloud data centre capex and economic reopening met constrained supply, despite earlier concerns about double ordering and the durability of the cycle. The semiconductor industry is estimated to have grown +26% (per SIA billings data) during 2021 and is on course to reach \$1trn over the next five years as semiconductor spending as a percentage of GDP and economic profitability continues to trend higher. Memory stocks were lacklustre for most of the year, with Hynix\*, Micron and Samsung tracking the DRAM spot price lower, but recovered in Q4 on hopes the cycle had bottomed, metaverse excitement and an expected increase in the ratio of memory-to-compute with increasing core counts, memory channels and DDR5 coming in.

Strong growth at the hyperscale companies led to continued strength in cloud data centre capex benefitting AMD (+57%) and NVIDIA (+125%). Both were also perceived to be winners from the emergence of the metaverse as an investment theme. In contrast, Intel\* (+6%) underperformed as it continued to lose market share while a more detailed plan to turn the business around made the enormity of the task all too apparent. Semiconductor capital equipment stocks performed particularly well as the industry continued to invest in technology to combat Moore's Stress, add capacity and build out domestic manufacturing to reduce reliance on Taiwan. In June, the US Senate passed the \$250bn US Innovation and Competition Act to provide subsidies for domestic manufacturing. The WFE market is expected to have grown 40% in 2021 to near \$90bn, three times the historical annual run rate and up from c\$33bn in 2015. While most of the automotive industry struggled with the global chip shortages, Tesla (+50%) enjoyed a stellar period, delivering a record number of vehicles – and record margins – in Q3 and Q4 against a supportive backdrop for electric vehicles. Apple (+35%) struggled early in the year with chip shortages, blaming 'larger than expected supply constraints' for a c\$6bn headwind when the company missed revenue expectations in Q3 despite growing sales 29% y/y in the quarter. Still, the stock recovered strongly in Q4 (+26%) as investors moved into large, liquid, profitable, ESG-friendly names as higher growth/less profitable technology companies sold off aggressively. Despite its focus on app stores, the US regulatory backdrop remained relatively benign during the period, with the Federal Trade Commission suffering a small setback in its case against Facebook. Unfortunately, the same was not true in China where a regulatory crackdown has been both unexpected and unwelcome. President Xi's bid for a third term by adopting a populist agenda saw wealthy elites and technology billionaires targeted under the guise of 'common prosperity'.

Software returns were reasonable in absolute terms (IGV: +12%) but lagged other sectors and trailed the S&P 500 for the first time in five years due to valuation compression during the second half of the year. For the full year, software underperformed the S&P 500 by 15% in 2021, having outperformed by 36% during 2020 – its best relative performance in two decades. Multiples compressed by 10% in 2021 having expanded by 80% in 2020 and 37% in 2019. Sector underperformance was most acute into year-end (continuing into 2022) as concerns about a more hawkish Fed put downward pressure on historically elevated software valuations. Returns were led by Microsoft (+53%) and a narrower group of next-generation winners, especially high growth companies tied to the ongoing adoption of public cloud.

Internet returns were weak as the NASDAQ Internet Index returned -5% during the year. Having been well positioned during lockdown, the internet sector was challenged by reopening dynamics which initially impacted engagement trends. Pinterest had exploded into relevance during 2020 but in 2Q21, the company announced that its US monthly active user (MAU) had declined 7% y/y amid reopening, and it declined to offer Q3 MAU guidance due to their lack of visibility. In hindsight, Pinterest was the proverbial canary in the coalmine, but at the time most of its peers continued to deliver strong growth. However, many of the key e-commerce and payment-related stocks such as Amazon (+2%) and PayPal (-19%) saw their stock prices peak in the summer and trail into year-end. Third-quarter earnings season once again saw Amazon's retail results fall short of consensus with weaker trends (exacerbated by several billion dollars of additional costs due to labour shortages and supply-chain issues). PayPal missed lowered expectations on greater eBay\* headwinds and weaker back to school spending and took down guidance for Q4 and 2022. Even Shopify\*, who were certain in June that they saw 'no slowdown whatsoever', missed revenue forecasts for the first time in at least five years.

Online advertising stocks initially performed significantly better than e-commerce, led by Alphabet (+65%) as any drag from e-commerce normalisation was lost in easier comparisons, the rebounding travel vertical (said to represent 10-15% of Google's revenue prepandemic) and the broader ad spend recovery with the advertising market forecast at \$669bn this year, representing 11.2% y/y and \$40bn ahead of pre-pandemic levels. However, privacy changes made by Apple to its Identifier for Advertisers (IDFA) - intended to give users the options of not sharing their personal data - created a new challenge to user targeting and RoI measurement. Meta Platforms (Facebook) had previously warned about the risk posed by the removal of personalised ads which materialised in Q3 when Snap (-6%) results and guidance missed on larger than expected headwinds from Apple's IDFA changes as well as weaker ad demand from some of its customers due to supply-chain disruption and cost inflation. Facebook themselves also underestimated the IDFA impact with Q3 advertising revenue 'only' growing 32% y/y in constant currency (cc) during the quarter. However, this disappointment was overshadowed by capex guidance for 2022 which at \$29-34bn is higher than TSMC, reflecting Meta's confidence in future growth and push into the metaverse.

While some would dismiss this as an over-hyped extension of multi-player gaming (and right now, perhaps be correct), we are optimistic about the metaverse opportunity longer term due to its huge disruptive potential which, along with AI, is huge. Following its recent earnings, Facebook rebranded itself Meta Platforms to reflect its growing focus on this area with existing brands (Facebook, Instagram, WhatsApp etc) positioned under a parent company. We like the stock longer term, but remain cautious here (IDFA headwinds, regulatory risks and a multi-year AR/VR investment cycle) despite the undemanding headline valuation.

So, what is the metaverse? Facebook would call it 'the next evolution of social technology' more generally, though it is perceived as a collection of persistent online worlds where people interact via digital avatars. While that sounds futuristic, it is happening today in forms mostly within games platforms like Robox (a holding) or Minecraft (owned by Microsoft, a holding). While it is early days, this is an exciting trend to which we believe investors will want some exposure to and we are already seeing other Fund holdings, such as NVIDIA, Advanced Micro Devices, Arista Networks, Adobe and many other management teams, talk much more about their involvement and the stocks are garnering greater attention as a result. Some see this as the next evolution of digital connectivity (ie what follows the screenaccessed internet), and a natural progression as the growth of our 'digital lives' outpaces the growth of our 'physical lives'. The global digital economy makes up around 17% of global GDP today, so there is ample room for further penetration.

### **Fund Activity**

We entered the year positioned in a more balanced way across our eight core themes, reflecting our desire to position for a strong economic rebound (adding more pro-cyclical growth exposure) and tempering our exposure to some of the high growth/highest multiple names for a strong economic recovery (characterised by rising bond yields), anticipating that robust fundamentals for our sector (strong revenue growth) may be partially offset by some multiple compression. As our confidence in the recovery grew, we exited a number of stay/work-at-home beneficiaries such as Ocado, Just Eat Takeaway, TakeTwo and DoorDash while significantly reducing our position size in others facing tough year-on-year growth comparisons such as Amazon, Netflix, Activision Blizzard, HelloFresh and Zalando.

Following strong first quarter earnings results and company outlooks, we moved the portfolio to a more acute barbell shape. We witnessed muted share price reactions to many fundamentally strong technology earnings reports and as many as 75% of technology companies traded down post-earnings, the worst of all GICS sectors. We continued to add to cyclical stocks with secular tailwinds and strong balance sheets, including Marvell Technology, Seagate Technology and Western Digital, and started adding back modestly to ultra-high-growth names which have sold off indiscriminately despite strong results and company outlooks, including DocuSign, Twilio, ROBLOX and CrowdStrike.

While strong headline results and guidance was a common theme, some WFH and other pandemic winners gave disappointing user growth or engagement commentary with the economy reopening. We sold our positions in Netflix and Spotify and reduced Pinterest. As market breadth narrowed into the back half of the year there was a compression in software and other high-growth multiples which continued into 2022. Mega-cap stocks continued to hold up well, which was a headwind for relative performance. The semiconductor sector performed well based on still-strong demand and we added to our exposure here, ending the year as our largest sectoral overweight at +4.1% from +1.1% at the end of 2020. We reduced our internet and direct marketing retail (e-commerce) exposure versus our benchmark during the period to +1.7% from +3.8% at the start of the year, along with our relative data processing (payments) exposure to +0.6% from +3.9% as these segments struggled with tough comps. We remained underweight software during the year finishing at -4% from -4.1% at the start.

The shape of the portfolio narrowed somewhat during the year as we moved from 85 total positions at the end of 2020 to 70 at the end of 2021, and the top-10 holdings increased from 37.3% to 41.1% of the Fund over the same period.

# Global Technology Fund continued

#### Fund Activity continued

While we have increased our positions in some of the largest index constituents, these remain large underweights versus our benchmark. Incorporating our delta-adjusted call exposures in Apple, Microsoft and Alphabet, Microsoft has increased to 7.9% from 5.7% at the end of 2020 and Alphabet has increased to 8.3% from 4.6%. Our Apple weighting has reduced to 6.4% from 7% over the same period. Several names are no longer in our top-10 holdings, including Samsung which is now 1.8% (versus 3.9% at the end of 2020), Tencent 1% (2.5%), and PayPal now 0.4% (2%). These have been replaced by NVIDIA at 3.3% (versus 1.5% at the end of 2020), Marvell 2.4% (0%) and Seagate 2% (0%).

From a geographical perspective, our exposure has moved modestly away from Asia and Europe in favour of the US, reflecting the reduction in our Chinese internet exposure and increased weights in some of the largest US technology companies described above. The US accounts for 77.8% of the Fund (69.6% at end 2020), Asia Pacific 9.3% (13%), Europe 7.7% (9.4%), and Japan 3.4% (6.1%).

#### **Market Outlook**

Rapid vaccination/booster campaigns in developed countries appear for now to have broken the link between COVID-19 case numbers and hospitalizations and deaths. However, the Omicron variant has proved a sobering reminder of the inherent unpredictability of macroeconomic and market conditions, and a reminder of the need for a highly liquid and well-diversified portfolio.

The tensions between more macroeconomic growth, where we assume the fiscal impulse moderates and financial conditions tighten somewhat during the reopening, and perhaps easing inflationary fears – as supply further recovers, demand normalises – remain. A stronger economy will increase inflationary pressure and should, within reason, be positive for equities. Meanwhile, a slower recovery will reduce the likelihood of materially higher bond yields and could support growth/risk assets.

At the end of the year and early into 2022, high-growth software companies came under intense pressure, seeing multiple compression of >25% as a rapid rebound in the 10-year US Treasury yield back towards 2021 highs (1.7%) and a 'bear steepening' in the yield curve raised concerns about the tightening of financial conditions and the susceptibility of high multiple stocks to a reduction in the Fed's balance sheet.

While valuations for growth companies are normalising and the fundamental outlook for our sector remains encouraging, one large uncertainty remains – the impact of Omicron on countries such as China who continue to pursue a zero COVID-19 strategy. It feels like there is a limit to how long these countries can hold back the tidal wave of Omicron. Either way, continued headwinds to economic growth will remain either in the form of waves of tight restrictions or the impact of the virus itself. This also has potential to create further supply-chain disruption and market volatility if the situation becomes more acute.

Encouragingly, Goldman Sachs' Effective Lockdown Index (ELI) has indicated that new COVID-19 variants have seen policy responses and impacted mobility, but by less each time and the impact on GDP growth has become less pronounced. The fiscal impulse is waning in the US but remains supportive in Europe and potentially in China.

Labour market tightness has been widely reported given the 'Great Resignation' currently underway, and 4.5 million Americans quit their jobs in November, the highest in the two decades of tracking. Job openings remain near record levels. Attracting and retaining skilled staff has come up at many of our recent company meetings. Competition for talent has long been a feature of the technology landscape and runs all the way up to the largest companies. We expect many of our holdings to continue to be able to compete effectively in a tight labour market, and the wider shortages and wage inflation to act as a meaningful driver for the adoption of automation and artificial intelligence (AI) in every industry.

We remain constructive on the fundamental outlook for the technology sector and continue to expect the portfolio to deliver strong growth as the necessity of digital transformation continues to drive IT spending, cloud adoption and the increasing integration of AI into the world. Morgan Stanley's 3Q21 CIO survey indicated that 45% of CIOs expect IT spend to increase as a percentage of revenues in their organisations over the next three years (versus 5% who are expecting a decline). A December 2021 survey by McKinsey found 56% of respondents reported AI adoption in at least one corporate function and 27% reported at least 5% of EBIT attributable to AI. We also continue to believe the pandemic spurred even laggards to adopt the cloud and digitally transform in order to support vast numbers of remote workers and customers alike.

Structural drivers for the sector remain strong: annual software spending has expanded to 3% of US GDP from 2.25% in 2018; our conversations with many company management teams indicate a strong demand environment; and R&D as a percentage of US capex has reached 20% from a low to mid-teens level over the past 20 years, while software capex has reached a new high of 16.9% of total US capex from 10–11% pre-GFC and just 7% in the early 1990s.

It is also worth noting from a long-term structural perspective that many of the most acute pressures in the economy and society today can be best alleviated, if not totally solved, by the application of more technology rather than less: labour shortages call for a higher degree of automation, online skills training, the ability to work from anywhere and deeper online labour markets; climate change requires creative and ambitious technological solutions, products and services delivered with greater energy efficiency and ever more data to understand the world we wish to preserve; an aging population requires remote health provision, personalised medicine and greater connectivity. This ties into the deeper integration of ESG into our investment process and the planned application for Article 8 status under the SFDR (Sustainable Finance Disclosure Regulation) in Q1 2022.

All these things will benefit from ongoing advances up and down the technological stack, but most significantly from the adoption and proliferation of Al. The pandemic has demonstrated the extraordinary power of innovative technology at scale, with everything from mRNA-based vaccines invented and deployed within a year to a cloud infrastructure and technology-supported economy that did not break down.

The Fed's recent more hawkish pivot has driven a sharp growth to value rotation that has little to do with technology fundamentals. We do not believe valuation excesses have fully unwound yet, but good progress has been made. Significant corrections in many stock prices are beginning to create more attractive investment opportunities. Fourth quarter earnings season is just getting under way and we expect solid results, albeit probably tempered by conservative guidance given the uncertainties. As we progress through earnings, as long as the tone from our meetings and calls with companies remains positive as we expect, we intend to use any further weakness to begin to move back to a more growth-centric and fully invested position.

#### **Technology Team**

Polar Capital LLP

# Healthcare Blue Chip Fund

#### **Fund Performance**

The Fund returned 22.3% (Class I US Dollar Accumulation Shares) versus 17.5% for the MSCI AC World Daily Total Return Net Health Care Index (in dollar terms) during 2021.

Geographically, the biggest drivers of performance were Europe, Asia Pacific ex-Japan and Japan. Stock selection was key to driving the performance in Europe, whereas allocation was the key driver behind the Asia Pacific and Japan performance, with the Fund underweight versus the benchmark in both regions. The US and Canada detracted from performance with stock selection being the challenge. In terms of subsectors, life sciences tools and services, healthcare equipment, biotechnology and healthcare supplies were positive contributors, with stock selection the overwhelming driver. On the negative side, healthcare services and facilities were the biggest drags on performance, with selection the primary issue. On a market-cap basis, the large caps (>\$10bn) were the biggest contributors, although the mid-caps (>\$1bn to \$10bn) were also positive. Cash and 'others' detracted from performance during the reporting period. The Fund comprises a concentrated portfolio, with an active share of 73.5% and 34 positions at the end of 2021.

In terms of individual holdings, the most significant contributors to relative attribution were Biohaven Pharmaceutical Holding, Sartorius and Medtronic.

Biohaven Pharmaceutical Holding performed strongly thanks to approval by the FDA of its drug Nurtec ODT for migraine prevention. The approval was based on the results of a Phase III study that revealed Nurtec ODT reduced migraine days by 30% after just one week of every-other-day treatment. Further, after three months of treatment, approximately half the patients experienced at least a 50% reduction in moderate-to-severe migraine days. The company executed excellently after the approval, announcing impressive sets of revenues for Nurtec ODT during the second and third quarters of 2021, which boosted the already robust momentum of the shares.

Sartorius, a life sciences tools and services company which manufactures capital equipment and consumables for the biopharma industry, benefitted from the general strength of its subsector. However, management also executed superbly throughout the financial year, leading analysts to upgrade financial estimates with the shares following suit. It is worth noting that Sartorius, along with a number of life sciences peers, benefitted from the COVID-19 pandemic through the supply of capital equipment needed for the manufacture of vaccines.

Medtronic performed strongly during the first half of 2021, with the relatively new management team delivering not just operationally, but also with a simplified message to the financial community. Several pipeline setbacks towards the end of the year, however, derailed that momentum with the Fund benefitting from having exited the position.

The most significant detractors to relative performance were Pfizer, Amedisys and Encompass Health.

The Fund's lack of exposure to Pfizer negatively impacted relative performance. Pfizer's strong performance in 2021 was primarily driven by its significant contribution to the pandemic. First, in partnership with BioNTech, they were the first company to receive US FDA approval for their mRNA-based vaccine Comirnaty. Expected to generate sales of approximately \$36bn in 2021, the vaccine had a materially positive impact on the company's financial health. Further, in November 2021 Pfizer disclosed positive data for its oral antiviral Paxlovid. Paxlovid was found to reduce the risk of hospitalisation or death by 89% compared to a placebo in non-hospitalised, high-risk adults with COVID-19. The positive update put more upward pressure on Pfizer's share price.

Amedisys operates home health facilities and hospices. Unfortunately, the company announced in their 2Q21 results that they were facing near-term challenges due to the high level of staff turnover in its hospice business and to wage inflation for nurses and carers. Although the issues can be attributed to the pandemic, investors felt the growth prospect and trajectory for 2022 might also be impacted, causing the stock to materially underperform the overall healthcare sector.

Encompass Health operates in-patient rehabilitation hospitals, out-patient and rehabilitation satellites and hospice and home health agencies. The disappointing performance is a combination of similar challenges faced by Amedisys, but also frustration that the strategic repositioning of the hospice and home health business is being delayed. As a reminder, in December 2020, Encompass Health announced it was exploring strategic alternatives for its home health and hospice business.

### **Market Review**

With the exception of September and the latter half of November, global stock markets enjoyed positive momentum throughout most of 2021, perhaps not too surprising given we entered the year with effective COVID-19 vaccines, considerable fiscal and monetary stimulus and a CPI reading below 1.5%. Importantly, and focusing on the US, the key driver behind the impressive performance appeared to be earnings growth as opposed to multiple expansion. With regards to the more challenging periods mentioned above, September was impacted by COVID-19 Delta variant-fuelled growth concerns, inflation worries and a Fed update that was perceived to be relatively hawkish versus consensus expectations. Those same concerns were elevated in November, with the appearance of a new, heavily mutated COVID-19 variant, Omicron, and a hawkish update from the Chair of the Federal Reserve. Both were catalysts for a sharp market sell-off towards the month-end. Thankfully, December witnessed a robust recovery with a more optimistic stance towards Omicron, one of the key drivers. Early data, and subsequent real-world evidence, point to Omicron leading to milder disease compared to the Delta variant (67-73% lower risk of severe disease). Further, it appears that Omicron is more likely to impact the nose and throat as opposed to the lungs, as seen with Delta, which could help explain the reduced number of hospital admissions.

Switching gears to healthcare, which modestly underperformed the broader market in the year, the best performing subsectors were life sciences tools and services, managed care and facilities. The life sciences tools and services industry was not only involved in developing and distributing COVID-19 testing kits, but also in the successful development and manufacture of the much-needed vaccines. Both were key contributors of positive top-line performance for the industry. The managed care industry enjoyed a strong year of performance, especially in the fourth quarter. The main drivers were cancelled elective procedures (reducing medical costs), rising interest rates (as insurance companies, managed care companies have large investment portfolios that benefit from rising rates) and comfort on consensus expectations for 2022 earnings. The positive performance for healthcare facilities reflects strong operational performance despite the challenges of the pandemic. The most noticeable underperformer in 2021 was the biotechnology sector which struggled for a number of reasons. On the macro side, the prospect of higher real yields and reduced terminal values impacted the sector but there were also a number of clinical and regulatory setbacks that adversely impacted sentiment.

#### **Fund Activity**

While stock-picking is central to the team's process, allocation was also an important factor in driving 2021's performance, especially when one reflects on subsector and regional attribution. COVID-19 was also a key component behind some of the allocation decisions, as we tried to assess the key opportunities and risks. As we entered 2021, life sciences tools and services was the Fund's biggest relative overweight versus the benchmark, taking a view that not only would COVID-19 provide a tailwind for the industry but that base businesses would eventually recover. By the end of the reporting period, life sciences tools and services was the second biggest relative underweight with valuations having become very stretched. As of 31 December 2021, healthcare facilities was the biggest relative overweight having been a modest overweight entering 2021. As we navigate through the Omicron wave, and hopefully move into a more endemic phase, then logic dictates that patients will start to reengage with healthcare systems globally. In that scenario, addressing the ever-growing backlog of patients will become an important investment consideration, not just for deferred elective procedures, but also treating those who might have missed important diagnoses during the pandemic.

Another noticeable shift in positioning sits within healthcare supplies where the Fund has moved to an overweight versus an underweight stance at the beginning of the reporting period. This stance reflects our view on exciting new innovations and recoveries in the ophthalmology and dental arenas. On the ophthalmology side, a key new market which should see dramatic growth globally over many years is the treatment of myopia. Myopia is a relatively new focus for relevant companies with new contact lens products being launched. The Fund's biggest relative underweight continues to be pharmaceuticals, reflecting our view on their anaemic growth profile, mature margins and patent expirations. We would note, however, that greater exposure to these stocks could be justified in a more defensive market as we enter the latter stages of the economic cycle.

#### **Market Outlook**

COVID-19 aside, there are few similarities between early 2022 and early 2021. Early 2022 brings with it more uncertainty given Omicron's high transmissibility, a failed attempt to pass Biden's 'Build Back Better' package and inflation north of 6%. Further, tighter monetary policy and a hawkish update from the Fed will likely put upwards pressure on interest rates, an observation that brings two challenges for the healthcare sector. First, a rising rate environment could encourage a switch out of growth sectors like healthcare into more value-oriented areas of the market. Second, rising rates put pressure on highly rated growth stocks and those that carry high terminal values, both of which are relevant for healthcare subsectors such as medical technology, medical devices and biotechnology.

On a more positive note, most Omicron updates offer cause for cautious optimism. The scientific community continues to be vigilant, but the early signs appear to be encouraging, not just the reduced burden on healthcare systems, but the hope that the daily cases peak-to-trough could be rapid (this was approximately four weeks in South Africa) and we start to move away from a pandemic and towards an endemic.

If Omicron does indeed turn out to be less harmful to its host and cases quickly move from peak to trough, the next big decision could well be how healthcare systems deal with an ever-increasing backlog of patients waiting for medical intervention, having postponed procedures in 2020 and 2021. We anticipate a reversal of this in 2022, with companies that have previously been held back delivering better than expected growth and potentially positive earnings revisions as utilisation rates return to pre-COVID-19 levels.

The other consideration for the healthcare sector in 2022 is the US mid-term elections in November. If the Republicans gain control of the House of Representatives, which feels like a distinct possibility, then we may well be faced with legislative gridlock. Legislative gridlock, and the status quo, would be perceived as a positive for the healthcare sector, especially the bio-pharmaceuticals industry, given the reduced likelihood of draconian drug pricing changes.

# Healthcare Blue Chip Fund continued

#### **Healthcare outlook**

The impact of the COVID-19 pandemic on healthcare will be felt for many years, even if the virus becomes endemic. On the labour side, it has driven a sea change in what employees want and expect from their jobs, which is having a real impact on healthcare. A recently published survey highlighted that 18% of US healthcare workers quit their jobs during the pandemic, with 79% of healthcare professionals saying the national employee shortage has affected them and their place of work. Not only are positions being left vacant, but providers are also seeing a significant spike in wages. This is likely to remain a challenge for many organisations for the next 12–18 months.

The disruption in healthcare delivery that started several years ago has been another area that has seen an acceleration driven by the pandemic. The shift of care to lower cost settings and away from the large in-patient hospitals is a must if healthcare systems are to become more efficient. Obviously, with hospitals being at the centre of managing patients affected by COVID-19, care has naturally moved towards other providers such as ambulatory care, outpatient and home healthcare who have experienced a significant boost in demand for their products and services.

Backlogs have increased dramatically due to the pressure of the pandemic on healthcare systems. The most visible is on the elective procedure side, such as hips and knees, with the UK an example of the large increase in a backlog which will take years to clear. The 'invisible' backlog is the impact of the lack of screening and testing for diseases such as cancer during the past 18 months which, sadly, will likely cause an increase of more serious and later-stage disease in the months and years ahead. Both these dynamics will lead to high levels of demand for healthcare services for many years to come.

In summary, despite the macro and sector-specific challenges, we continue to be optimistic about the near and medium-term opportunity set that healthcare offers. The industry's fundamentals are in rude health, with many subsectors with even stronger foundations now than before the pandemic. The sector also continues to feel under-owned and underappreciated, with allocations to the sector near decade lows and ETF outflows underpinning that view. Last, but not least, relative and absolute valuations in the US are attractive and supportive, respectively. As we look forward into the next financial year, we remain confident that the diverse and creative nature of the healthcare industry will yield a multitude of compelling investments that we hope will generate attractive returns.

#### **Healthcare Team**

Polar Capital LLP

# Healthcare Discovery Fund

### **Fund Performance**

The Fund (Class I US Dollar Accumulation Shares) delivered 2.8% compared to the MSCI World Small Healthcare Net TR Index of -6.8% (in dollar terms). While we were pleased to come in ahead of the index, the weak absolute performance is not lost on us relative to broader market returns on offer and that of our large-cap healthcare brethren. This was due to a combination of factors at both a market and sector level: the former becoming less supportive over the year as inflation was deemed less 'transitional' than previously believed, and the latter, at least down the market cap scale, from an IPO window that had remained open long past its prime. We did well to be defensively positioned from a market, sector and company maturity perspective though the frequent market rotation did its level best to undermine confidence. A case in point is we could have added to performance by selling what worked over one month and investing that what had lagged into the next – easy to say in hindsight, difficult to do in practice. Last, but certainly not least, we received a number of bids for portfolio holdings, the majority at a significant premium to our investment and where we had meaningful active exposure.

#### **Market Review**

As frequently cited in our reports over the year, the index figures belied the rotation tussle going on beneath the surface. Much of this comes down to the unforged territory of a pandemic-led recession and the lack of clarity along the subsequent road to recovery, bouncing frequently from one economic 'wall of worry' to the next and then frequently to the opposite extreme.

After the past 18 months, it is fair to say that a bipolar equity market should not be all that surprising as we saw economic stresses unique to the pandemic. Poor vaccine distribution, the global supply chain, the 'Great Resignation' – mostly among the US workforce – all conspired against a smoother transition toward normalcy. We were certainly too optimistic that as the global economy came back online, there would be increasingly less top-down market influence and more to company fundamentals as the year progressed. Instead, the market seemed stuck in forecast mode, constantly analysing the evolving economic and FOMC tea leaves, seeking to position itself relative to the prevailing monetary policy stance of the moment. All this resulted in more rather than less rotation indigestion over the year.

A rising interest rate environment that would support a more cyclically geared investment position is generally not ideal for the more defensive attributes of the healthcare sector. There are cyclical elements of the healthcare investment universe, healthcare services and in turn medical equipment companies, which have historically outperformed in such a market backdrop. Timing in this instance has been somewhat challenging as healthcare staff were simply exhausted at this juncture, and rightly so. Many medically-related service companies are still very much people-driven businesses professionals and other staff are required to keep the business of care delivery up and running. This also had a knock-on effect to medical devices and supplies – if procedures and surgeries are being deferred then it is not hard to follow the knock-on effect on supplies and equipment consumption. Fortunately, the immunity afforded from either the vaccine and/or Omicron infection should lessen the burden of demand going forward, while healthcare staffing is likely a longerterm issue of note for future investment and positioning.

Smaller healthcare investor challenges included those of the broader healthcare sector relative to more cyclical areas of the market. This is evident when comparing the performance of small-cap indices, either the MSCI World Healthcare Small Cap Net TR Index or the Russell 2000 Index, to their respective small-cap healthcare subindices. In addition, and as raised coming into 2021, we were concerned about the public funding window that was increasingly becoming unselective but prolific for emerging healthcare companies, particularly biopharmaceuticals, though new healthcare IT and service listings joined in as well, being very late to the party. Comparing the S&P 600 Index (small cap) to the MSCI World Small Cap Net TR Index or Russell 2000 Index gives a better picture; however, new technology issues had resulted in a notable new issue 'hangover' for their smallcap index performance relative to the more financially mature smallcap constituents of the S&P 600. Though investors may view smaller companies at large as having significantly lagged the S&P 500 Index this year, the S&P 600 Index offers a different perspective.

# Healthcare Discovery Fund continued

### **Fund Activity**

We exited 2020 being cautious about the overzealous fundraising for the biotechnology sector, particularly the earlier stage nature of 'platform' and 'concept' companies that had very little to show other than the ability to consume cash. As it turns out, we were not wrong in our thinking - though perhaps a bit early - nonetheless, our underweight stance over the year performed well. Selection was also our best here, given a leg up by M&A, and while we did well on selection across the board, when taken together with allocation biotechnology was our best attribution to performance by far. In addition, their largest competitor, Medtronic, announced a significant setback with the US regulator in relation to their own next-generation insulin pump product. This is not only timely for Tandem Diabetes Care's existing business, but also their new product launches set for 2022. On the flip side, the largest subsector detractor was healthcare supplies and our only area of negative selection effect, though clearly meaningful. This was down to our most disappointing single stock performance over the period, when Haemonetics unexpectedly lost a major contract delivering a significant blow to their financial guidance, and, as a result, their shares were marked down accordingly.

The market-cap attribution reflects the defensive nature of our positioning – an overweight in mid-caps (>\$5–10bn) where allocation and selection led to the better attribution effect. Second to that was our micro-cap (less than \$1bn) allocation, where we were underweight. Along with selection, this was positive. While we could have improved contribution further having increased our large-cap exposure (>\$10bn), we were more of the mind that we run a small-cap fund despite being allowed to invest in, for example, those companies with market caps as large as the most mature benchmark member, currently up to \$10bn market cap.

We were significantly underweight small-caps (>\$1–5bn) which was a positive though our selection let us down. Our total regional attribution effect was positive, though selection for Japan detracted. Currency was slightly negative, by less than 20 basis points.

A total of seven M&A were received during the year: United Healthcare sought to acquire Change Healthcare (healthcare IT), Centene acquired Magellan Healthcare (managed care), Medtronic made an offer for IntersectENT (healthcare equipment), Baxter Inc acquired Hill-Rom Inc (healthcare supplies), private equity sought to take out Swedish Orphan Biovitrum (biotechnology), Merck and Co acquired Acceleron (biotechnology) and December brought an offer from Pfizer for Arena Pharmaceuticals (biotechnology).

# **Market Outlook**

The year ahead is likely to see more of a move back to a macroeconomic environment like 2005 and 2011, when the markets had to digest what monetary policy and global growth would look like following a historic coordinated easing cycle by the global central banks. Long-term inflation break-evens suggest the Fed's current tightening bias and potential actions may be enough to prevent sustained high inflation – what some have dubbed, an 'immaculate' tightening. Whatever the longer-term outcome may be, nearer-term fear of the Fed, global growth and policy uncertainty will likely conspire to keep market enthusiasm in check as we move through a 'normal' correction following strong equity market years.

Concerning the healthcare sector, and certainly for smaller companies, valuations have continued to come in relative to the market. Even for larger healthcare companies, despite the better performance seen over the year, shares remain reasonably valued. We do not think this will go unnoticed by the more generalist investor along with the optionality of the sector bringing both defensive and cyclical qualities to a broader equity portfolio. So much of the routine healthcare consumption has been put on hold that the upcoming spring and summer may bring with them increasing volume pull-through across the spectrum of healthcare goods and services. Companies are just beginning to report their fourth quarter earnings and give an initial outlook so the market will soon have more information shortly.

In addition, we believe the pandemic has shown investors what the sector can do well and where there is significant room for improvement. In successfully developing the coronavirus vaccines, the biopharmaceutical industry produced a modern-day medical miracle which is central to prevent further health and economic destruction. Having said that, no one can deny that our care infrastructure and delivery systems could use an innovative re-think and investment. The emerging biotechnology sector has significantly de-rated and as such we find it much more interesting now at current valuations to selectively pick up quality companies that have been painted with the same negative brush as the rest.

More significant, in our view, is the pandemic has shown us a patient's post code says much more about their healthcare needs than their genetic code. The social disparities of care that were in place prior to the pandemic have subsequently been laid bare in plain view – 21st century cures are of no use for the greater good if we are not able to administer them to those who need them most. If we are unable to cover off the very basics of good health and wellbeing first, what is the point of the rest?

While biopharmaceutical innovation will always be part of our investments, we see the poor current state of the global healthcare delivery system, as well as basic healthcare needs of patients, as the greater focus right now. The healthcare system and marketplace historically have been very much built on acute care-setting (hospital-based compared to the ability to deliver care to the patient), wherever they may be. Going forward, we should see an increasing combination of avenues for caregivers and patients such as telemedicine, ambulatory centres or patients' own homes. Further, there is a need for more efficient and artificial intelligence-driven smart systems able to lend better support to staff who can then focus on what only humans are able to do, leaving the administrative or repetitive tasks to automated and machine-learning processes. There remains a tremendous amount of paper and human back-office work that has yet to come out of the healthcare systems globally. Finally, certain common medical problems and related data decisions should further incorporate sophisticated algorithms that may be routinely applied to reserve human intervention for the more challenging and serious judgement calls - there are a few in place today, though this should continue to grow. In sum, these are a few examples of innovation to add to traditional medication and device opportunities within the healthcare universe where the Fund is currently invested and seeks to do more.

It may take time for smaller healthcare investors to find their feet again, particularly with inflation still working out which way it is going to go. Until then, quality is key as monetary policy seeks to run a tightening-biased playbook which typically leads to more challenging market conditions for longer-duration opportunities, such as emerging platform or concept companies. We have yet to see signs of inflationary expectations becoming unhinged, resulting in a wage-price spiral, though the tightness of the labour market suggests risk here has increased. With that in mind, smaller-cap investors will need to remain on the front foot in the short term, and with any luck, healthcare should finish 2022 on much firmer footing. When the sector has previously finished at the back of the pack for smallercompany investors, the following year has resulted in a double-digit recovery. We believe M&A should remain as active as in 2021, if not more so. In the interim, we will stick to our knitting - investing in high calibre management working to solve the critical healthcare challenges of today, backed by clear and precise data that in turn commands a positive price for the delivery of meaningful outcomes.

#### Healthcare Team

Polar Capital LLP

# Healthcare Opportunities Fund

#### **Fund Performance**

The Fund returned 9% (Class I US Dollar Distribution Shares) compared to 17.5% (in dollar terms) for the MSCI AC World Daily Net Total Return Health Care Index during the year of 2021.

The sector lagged the broader market, with the prominent macroeconomic driver being increasing inflation which drove investment flows out of healthcare into other sectors. The real challenge for the Fund, with its multi-cap strategy, was the fact that large-cap healthcare outperformed small/mid-cap stocks by an astonishing 35% in 2021. With an average exposure of 60% to small/ mid-cap stocks over the year, the differential versus large caps meant the strategy lagged the benchmark. The Fund was slightly behind the benchmark at the end of September, but weakness in October, and more notably November in small and mid-cap healthcare stocks, caused the Fund to significantly underperform.

From a market-cap perspective, allocation was negative, whereas stock selection was highly positive. The significant underweight in large caps and overweight in small and mid-caps were the real driver of underperformance over the year. Geography-wise, investments in India and zero exposure to China were significant positives, while US performance was a significant drag due to most of the small and mid-cap investments being in companies based there. On a subsector basis, allocation was most positive for the overweight in healthcare facilities and most negative for the underweight in managed care. From a stock selection perspective, the life sciences tools and services was the most positive subsector, while biotechnology was the most negative, with more detail below on the two stocks that caused this underperformance.

The most positive contributors in the Fund were Cytokinetics, Uniphar and Surgery Partners. Cytokinetics is a US-based biotechnology company focused on cardiovascular disease which was rewarded for its pipeline progression. Uniphar, a healthcare services company based in Ireland, delivered better than expected growth and continued to acquire companies throughout the year. Surgery Partners is a US facilities company operating ambulatory surgical centres that continued to generate strong growth from the trend of procedures shifting to the outpatient setting, which accelerated due to the pandemic.

The most negative contributors were Medley, ChemoCentryx and Immunovant. Medley de-rated despite strong revenue growth as the company continues to invest ahead of expanding margins in the short term. ChemoCentryx, a US-based biotechnology company, underperformed after negative regulatory news flow from the FDA in the US. Immunovant, another US-based biotechnology business, unfortunately had to halt the clinical trial for its lead development candidate due to a surprising side-effect causing the stock to pull back dramatically.

#### **Market Review**

Markets began 2021 with more speculative stocks moving aggressively higher, following the strength seen from the lows of March 2020 into year end. However, these stocks peaked in January and February and began a significant decline into the end of the year.

The rebound from the lows of the market in March 2020 through to February 2021 typified performance during the early stages of an economic cycle, supported this time by significant monetary and fiscal stimulus to offset the impact of COVID-19. From the second quarter of 2021 onwards, the cycle moved into its mid-stage, with investors focused on buying higher quality large-cap stocks and selling small caps, mid-caps, investments in unprofitable companies and expensive stocks. The Delta wave of COVID-19 over the summer caused markets to become much more defensive through to mid-August when there was a small rebound in underperformers through to early September. Trends then continued with higher quality stocks outperforming into the year end.

In November, investors in small and mid-cap companies suffered from a significant decline in these stocks, with volatility spiking aggressively through to early December. While more speculative areas of the market had been derating since the highs for these stocks seen early in the year, other small and mid-cap stocks had performed in a satisfactory manner until November. There was a collapse on a broad basis with extreme selling, with suggestion that some investors were being forced to sell down positions. Following the collapse in small and mid-cap stocks in November, December saw a rebound with the seasonal Santa rally in the back half of the month.

In healthcare, large-cap stocks performed well considering the macroenvironment; however, small and mid-cap stocks finished the year more than 35% behind large-cap healthcare stocks, an astonishing number, highlighting just what a challenge 2021 was for investors.

### **Fund Activity**

The first quarter of 2021 started well with an offer from a corporate for Oxford Immunotec, which had been a long-term holding for the Fund. However, a surprise negative side-effect for the lead drug development candidate Immunovant caused the stock to move aggressively lower. The position was sold due to doubts over the future of the program. Also, profits were taken in Horizon Therapeutics after a strong run, and the position in Roche Holding was sold due to building concerns over potential pricing policy changes in the US. New positions were built in Kyowa Hakko Kirin over the potential for their drug candidate to treat atopic dermatitis, and Max Healthcare, a hospital operator based in India.

In the second quarter, the Fund took part in a number of financings, including the IPOs of Treace Medical, Privia, Polypeptide and Krishna Institute of Medical Sciences. The Fund also participated in a financing for Angle, based in the UK. Positions sold included Haemonetics and Chemocentryx. Haemonetics surprised investors with the loss of their main customer causing the stock to derate significantly.

The position was sold as the fundamental buy thesis was broken following this news. Chemocentryx was sold after risks over regulatory action increased dramatically.

In the third quarter, new positions added to the Fund included Bristol-Myers Squibb, AngioDynamics, UCB, Genmab and Iveric. The exposure to Max Healthcare was increased following a secondary offering. We sold positions in ArgenX, Align and Atricure following significant outperformance. The position in Johnson & Johnson was reduced.

During the last quarter of 2021, the Fund took part in an IPO for Skan Group and Surgery Partners. Stocks added to during the extreme volatility at year end included Medley and Ship Healthcare. Other new positions included Xenon Pharmaceuticals, following positive epilepsy data from their development candidate in a mid-stage clinical trial, and United Therapeutics, based on its strong growth potential. The position in Revance was also increased following a disappointing regulatory update and purchase of shares in the company by the CEO. The position in Johnson & Johnson was sold out of the Fund alongside the holding in Teleflex, following a disappointing reimbursement update for the latter company.

#### Market Outlook

The healthcare sector looks attractive in many ways and thus supports a positive outlook for 2022. First, healthcare stocks are trading at a significant discount historically. Second, fundamentals are robust despite the challenges of the pandemic and demand should accelerate if the situation with COVID-19 improves. Third, positioning in healthcare by US mutual funds is historically light and ETF flows are negative, both suggestive of a contrarian buy signal. Last, healthcare remains the most fragmented industry and M&A is expected to continue. It is worth noting that activity was slow between pharmaceuticals and biotechnology in 2021, potentially suggesting a rebound for 2022.

The key challenge is the macroeconomic outlook. Increasing inflation drives flows out of sectors like healthcare into areas such as financials and energy, in part driven by elevated economic activity but also increasing interest rates. Until inflation trends moderate, as in the rate of change, healthcare will likely be a laggard. There is rationale for inflation to slow in 2022, in part driven by an improved outlook for the pandemic which would improve supply chains, manufacturing and shifts in employment trends. Challenges on all these increased inflation in 2021, ultimately driven by the impact of COVID-19. We are hopeful that infections will drop significantly in 2022, thus allowing a return to normal life. With this, over the year inflation should slow, thus reducing the need for higher interest rates and causing funds to shift back to areas like healthcare.

One of the most significant effects of COVID-19 on healthcare has been the build-up in backlogs of procedures for patients across the world. We are seeing a significant backlog build in elective surgeries and activity levels in certain areas of healthcare, including oncology and dermatology, are still well below pre-COVID-19 levels as measured by patient visits and diagnostic testing. We are seeing anecdotal evidence of patients turning up at healthcare providers with much more serious illness at a later stage than would have been the case pre-pandemic. Hopefully, if COVID-19 infections fall away in 2022, there will be a significant pick-up in healthcare utilisation as patients receive better care than has been available through the pandemic.

#### **Healthcare Team**

Polar Capital LLP

For the financial year ended 31 December 2021

# **Income Opportunities Fund**

#### **Fund Performance**

The Fund's unit price rose 22.4% (Class B2 I GBP Accumulation Shares) over the year while in comparison our benchmark index, the STOXX Financials Index, rose by 21.6% (in sterling terms).

#### **Market Review**

The 12 months covered by this report were excellent for financials in both absolute terms and relative to wider equity markets. The news in November 2020 of the efficacy of Pfizer's coronavirus vaccine, in collaboration with BioNTech, as well as those being developed by others, provided the catalyst for sentiment to turn much more positive on the sector.

As a result, a quicker rollout of vaccines than had been previously expected led to a belief that economies would open up more quickly. Coupled with continued positive economic data underpinned by governments and central banks' fiscal and monetary stimulus, financials, in particular bank stocks, were seen as key beneficiaries of the recovery.

A combination of lower political risk with the UK and the EU reaching an agreement on Brexit, the election of Jo Biden as US President leading to an expectation of further fiscal stimulus and Janet Yellen, former Governor of the Federal Reserve, being appointed as US Treasury Secretary helped underpin the positive sentiment. Pent-up demand from the huge fiscal and monetary stimulus, rising commodity prices and supply-side issues led to rising inflation expectations.

Government bond yields consequently rose over the year, with yield curves initially steepening as central banks indicated they would keep monetary policy loose for the foreseeable future despite concerns around inflation pressures. As concerns rose around the impact of COVID-19 variants on economic growth, bond yields did give up some of their rise, with yield curves flattening in the second half of the year before bond yields started to tick higher again on more hawkish commentary from central banks.

### **Sector review**

Banks led the sector over the first six months of the year before handing the baton to the diversified financials subsector on the back of strong results that significantly exceeded analyst expectations due to lower provisions for loan losses as well as continued strong investment banking and trading income. This resulted in positive earnings revisions, and the increased investor interest due to the sector's sensitivity to rising bond yields against the background of rising inflation expectations provided a strong tailwind to share prices. US banks led the rally in bank shares, followed by those in Canada and the Eurozone, reflecting the stronger economic tailwinds in the US from a faster rollout of vaccines than nearly all other major economies, more significant fiscal stimulus and a sharper rise in government bond yields than most other countries. Conversely, Japanese and emerging market banks, having performed much more strongly over the initial stages of the pandemic and recovery, in part reflecting Asian countries' more robust handling of it from a health perspective, lagged the rally in bank shares.

Diversified financials, which include asset managers, consumer finance companies, custody banks and stock exchanges, performed extremely strongly. Alternative asset managers led the sector on the back of continued strong inflows and buoyant financial markets. Also, traditional asset managers, which have struggled in recent years due to weaker investment performance and pressure on fees as flows have shifted increasingly to passive funds or alternative assets, saw a sharp turnaround in flows which led to a strong rally in their share prices.

Insurance stocks lagged the sector materially, despite decent results and evidence of a continued increase in insurance rates. This performance reflected the lower sensitivity of the sector, except for life assurance companies, to economic cycles and therefore seen as less attractive at this point in the economic cycle as investors shifted their financials weighting towards more cyclical stocks such as banks. However, concern around the impact of rising inflation on reserves, and the potential for climate change to increase the frequency and severity of losses, also hit sentiment.

Business development companies and investment companies where the underlying assets are loans or bonds also produced strong returns, reflecting the improvement in outlook for underlying borrowers and a rerating in their share prices relative to book value. Fixed income securities of financial companies eked out only modest returns due to the headwind of rising government bond yields and low yields on offer at the start of the year following a strong performance in 2020.

# **Fund Activity**

At the beginning of the period, the opportunity was taken to increase the Fund's exposure to banks to take advantage of the cyclical rally in equity markets, but over the following months, a number of holdings were sold while profits were taken on others as share prices hit price targets and exposure to bank shares reduced to below where it started the year. The Fund's exposure to fixed income securities was also reduced materially as prices rose and yields fell sharply to less attractive levels as well as a number of holdings being called by their issuers, resulting in the level of cash in the Fund rising to 15.2% by the year-end. Among others, new holdings were purchased in East West Bancorp, a US bank, Skandinaviska Enskilda Banken, a Swedish bank, Shinhan Financial, a Korean bank, XPS Pensions, a UK pensions consultancy, and Schroders, a UK wealth and asset management firm. Holdings in KasikornBank, a Thai bank, KBC Groep, a Belgian bank, Bank of America, PNC Financial Services and First Republic, all US banks, were sold. The Fund's holding in JP Morgan was also reduced. New holdings were purchased in a Tier 2 bond issued by Provident Financial as well as Singapore government bonds and US Treasury inflation-linked bonds.

#### **Market Outlook**

On 5 December 2006, 15 years ago, HSBC Holdings gave the first hint of trouble to the market on its US mortgage business in what would morph into the biggest financial crisis since the 1930s. Two months later, in February, the conservative lender warned on profits, raising provisions by \$2bn, as sub-prime borrowers in the US were hit by much higher interest costs on their adjustable-rate mortgages as initial teaser rates fell away. The seriousness of the situation was not appreciated, with the bank's shares falling by around a mere 1.5% that day in December and by even less on the February announcement. US bank share prices were similarly unaffected.

HSBC was widely criticised at the time for its 2002 acquisition of Household Finance, a US sub-prime lender that turned out to be the driver of its woes. However, the strength of its balance sheet meant the bank weathered the global financial crisis well, so well in fact that anyone who had bought its shares on that day in 2006, after taking into account dividends, would not have lost any money, assuming the shares had been held to the end of 2009. By comparison, the average US or European bank's share price was still down by over 50%, with many much worse.

At that time the 'smart' money on Wall Street was also packaging up and selling, to unsuspecting German bank treasury departments and Norwegian municipalities, sub-prime mortgages and an alphabet soup of structured products. Either way it was too late for regulators to have acted even if they had seen what was coming. For example, the Bank of England had reduced staffing in its financial stability department in 2004 so it was not surprising it did not see what was coming. In a May 2007 report, it stated: 'The UK financial system remains highly resilient'.

Moving on to today, the resilience of the banking sector during the pandemic highlights the steps regulators have taken since the global financial crisis that have made a significant difference. Today, banks are more like HSBC in that they have strong balance sheets, plenty of liquidity and are more cautious in their lending appetite. Consequently, in 2020 they were able to facilitate governmentguaranteed lending programs such as the Coronavirus Business Interruption Loan Scheme ('CBILS') in the UK and Paycheck Protection Program ('PPP') loans in the US and are well positioned to benefit from the continuing recovery of economies. Furthermore, we expect monetary policy to remain centre stage, as central banks continue to react to rising inflationary pressures. According to analysis by Bank of America Merrill Lynch, December saw 15 interest rate hikes, taking the total to 44 for the fourth quarter, close to the largest ever quarterly amount. The sector is a net beneficiary of rising interest rates, with banks the biggest beneficiaries, and this continues to result in a strong tailwind for the sector. Estimates for the sector assume fewer interest rate rises than that suggested by the Fed dot plot, for example, suggesting further material upside to earnings, all things being equal.

Reassuringly, US household deposits are by some calculations over \$3trn more than they would otherwise have been if not for the pandemic. More importantly, as a consequence of the fall in interest rates and sharp fall in the levels of household debt since 2007, debt service ratios are at 40+ year lows. Equally, corporate cash levels over the past year hit levels not seen for 70+ years. Thanks in part to government and central bank largesse, consumers and corporates are in incredibly robust health, and that means defaults should not be rising in any meaningful way in the short term.

Therefore, looking forwards, we remain constructive on the outlook for the sector as we believe the tailwinds remain very positive for the foreseeable future. The sector has also shown a degree of diversification benefits from higher growth sectors such as technology which have come under pressure from rising bond yields. While valuations for the sector have recovered to their pre-pandemic levels, those of wider equity markets have increased further, highlighting the relative value of financial stocks at this point in the cycle, notwithstanding any short-term impact on activity from COVID-19 variants.

# Financials Team

Polar Capital LLP

For the financial year ended 31 December 2021

# Japan Value Fund

#### **Fund Performance**

The Fund increased by 15.2% (Class S Japanese Yen Distribution Shares) versus a 12.7% (in Japanese Yen terms) increase in the TOPIX Total Return Index over the year.

The Fund modestly outperformed the benchmark having been heavily impacted by the pandemic in the previous year. Relative outperformance was driven by a combination of sector allocation and stock selection. Stylistically, while the Fund benefited from its value bias, it also faced a headwind from its high level of exposure to outof-favour small and mid-caps. The TOPIX Value Index outperformed the TOPIX Growth Index by 9.5% while the TOPIX Small Index underperformed the TOPIX Core 30 Index by 7.2%. Since the start of the pandemic, both the value and small-cap indices are notably lagging their respective growth and large-cap counterparts.

The value style tailwind was only evident across the first half of the year, with value significantly outperforming as valuations had fallen to extremely depressed levels prior to the positive news on vaccines in late 2020. However, from the start of June onwards, growth once again became the dominant factor in the market with value giving up approximately half its earlier gains. The Fund also faced stylistic headwinds from its small-cap exposure over the course of the year, with the majority of underperformance coming in the final quarter.

The largest contributors to relative performance were Secom Joshinetsu and Inpex Corporation. The largest contributor, Secom Joshinetsu, provides security services and is a listed subsidiary of its parent, Secom. During the period, Secom submitted a tender offer to buy out Secom Joshinetsu minority shareholders at a 65% premium. In general, listed subsidiaries have been a key part of our portfolio strategy given the ongoing corporate governance reform in Japan which is increasingly making it harder for corporates to maintain these structures. The Secom Joshinetsu takeout was one of two tender offers for portfolio holdings from their parent company during the period. The other, Toppan Forms, was acquired by its parent Toppan Printing during the final quarter of the year. The second largest contributor, Inpex Corp, is a Japanese oil and gas producer. The shares outperformed as they correlated with the rise in the oil price following the global economic rebound and partial normalisation.

The largest detractors to relative performance were Cosel and Alps Alpine. Cosel, a diversified electronics manufacturer, has materially underperformed its peers due to greater sensitivity to semiconductor supply shortages globally. The share price underperformed as investors focussed on clearer short-term winners within the electronics industry. Alps Alpine, an electronics manufacturer in the smartphone and auto industries, saw its share price come under pressure as the business continued to invest into auto electrification while their smartphone business was at a cyclical low. The prospects for Alps Alpine's new automotive business remain encouraging in the long term, however investors have been unwilling to apply value to the growth prospects that should start to contribute from the second half of next year.

### **Market Review**

Although 2021 has been a strong year for equities in general, it has also been a volatile year for investors with market leadership heavily rotating throughout the year. Over the first half of 2021, global equities trended higher as vaccination campaigns began to roll out. Investors had much to digest as these vaccination campaigns, in addition to the low level of cases in light of the social restrictions, significantly improved the outlook for the more economically sensitive businesses that had been adversely affected by the COVID-19 pandemic. As a result, it is of no surprise that market leadership rotated to cyclical value across the majority of global indices. However, the tailwind for value was brief and by the second half we saw growth once again become the primary market driver. The rising yields, persistent inflation concerns, and changes in central bank policy did little to cause a rotation back to value in the final quarter of the year although investor sentiment to value was improving as the year came to a close.

In Japan, the vaccination campaign lagged its peers, and we believe this had a material impact on market leadership. The domestic economy has therefore not enjoyed as strong an economic rebound as many of its western peers. As a result, leadership of the Japanese market was largely determined by exposure to global trade with companies exposed to the quicker overseas re-opening performing strongly. The ongoing yen sensitivity also had a marked impact on equity returns in the second half. In such an environment, it was primarily the cyclical and financial areas of the market that performed strongly. Stocks more highly geared to domestic consumption continued to underperform for the majority of the year. This was highly evident with small-cap companies where stocks, which are typically more exposed to the domestic economy, materially underperformed their larger counterparts.

### **Fund Activity**

Portfolio strategy remained consistent during 2021 and, as always, we purchased shares where we believe there is a mismatch between the quality of the underlying business and the share price performance. In the first half of the year, we saw exposure to both the auto and medical equipment industries increase as continued short-term issues in both sectors led to a number of investment opportunities. In the second half, the Fund found various opportunities in technology, both software and hardware, by focusing on areas that were not fully participating in the short-term reopening trade and therefore were selling off despite excellent longer-term outlooks.

Portfolio sales over the period included many names that had reached our target valuations. In addition, we conducted a review into longer-term holdings that had not yet seen the investment case come to fruition. Although we retain our conviction in some of these long-term holdings, we sold down a number of names in favour of new holdings which we believe offer a superior risk/ return profile. Significant new purchases over the second half of the year (please reference the Polar Capital Fund Interim Report 2021 for a discussion of significant first-half purchases) included:

Mitsubishi Research Institute (MRI): a new holding was taken in MRI following a research meeting with the company. Management are keen to leverage existing relationships in their consulting/think-tank proposition to further expand their IT service given the large potential growth opportunity from an acceleration in digital transformation in Japan. The business is highly cash generative in nature and offers significant optionality from the use of their existing cash pile. A recent secondary offering, due to the unwinding of cross-held shares by other Mitsubishi group companies, presented an opportunity to initiate a holding at an attractive valuation.

Ines: following the meeting with MRI, we conducted further research on related companies and ultimately decided to initiate a holding in their equity method affiliate, Ines. Ines offers cheap exposure to IT spending and the digital transformation at a local government level in Japan. Its large net cash position relative to market capitalisation provides capital allocation optionality with the company announcing plans to buy back up to 10% of their shares outstanding at the first quarter results announcement. We are also interested in the potential for the company to become a takeover target with the most likely suitor being MRI, given the potential synergies.

Shimamura: a new holding was taken in Shimamura following a research meeting with the company. They operate a bricks-andmortar retail business which has done surprisingly well during the pandemic. The combination of the lockdown and the shift to a remote working model is leading to increased footfall in suburban shopping arcades at the expense of city centre locations. The shift in consumer behaviour is positive for Shimamura and our view is that a hybrid working model going forward will continue to support this trend. In addition, a new president has recently evolved its capital management policies and we expect an increase in allocation towards shareholder returns in the future.

Bank of Kyoto: we elected to return to Bank of Kyoto, a regional bank with substantial equity cross-shareholdings, having sold the shares in 2020. Bank of Kyoto's share price has significantly lagged the performance of the TOPIX, Japanese banks and, more importantly, its collection of cross-shareholdings biased to the technology sector, since our decision to sell. This means the discount on the underlying stub trade has reached extreme levels once again, hence our decision to re-enter the shares. SoftBank Group: a new position was initiated in SoftBank Group following a period of share price weakness due to concerns regulatory changes in China would negatively impact the value of their substantial Chinese investment holdings. Although short term visibility is poor with regards developments in China, we believe the current 50% discount to reported NAV provides a significant margin of safety. The most likely near-term catalyst for a turnaround in the share price is the restart of a large-scale share buyback programme aimed at narrowing the discount to NAV given the founder and leading shareholder's sensitivity to the share price level.

Toyo Tire & Rubber: we invested in Toyo Tire, a tyre manufacturer with significant exposure to the US where the business is well placed to enjoy industry growth. Demand for extra large diameter tyres, in which the company specialises, is quickly outstripping supply growth. Industry prices have been moving higher and, although Toyo Tire is yet to follow, gives it significant room to increase prices in the second half. The business trades on an attractive forward P/E multiple and in the long term will benefit from increasing mileage, penetration of larger-sized tyres and potential synergies following its recent tie up with Mitsubishi Corp.

Mabuchi Motor: we elected to return to Mabuchi Motor, a company manufacturing small and mid-sized motors for the auto sector, having sold the shares in April 2020. The business came under significant pressure in 2021 given the semiconductor shortage and its impact on the auto sector. Over the long term, the company stands to benefit significantly from the electrification of autos in addition to increasing penetration of advanced driver-assistance systems (ADAS). A weakness in its share price provided us with an opportunity to gain exposure to a high-quality parts manufacturer that stands to benefit from both a short-term recovery in auto volumes and a longer-term driver with electric vehicle and ADAS tailwinds.

Optex: a new position was taken in Optex, a sensor manufacturer, following two research meetings conducted with the company in 2021. The company have been expanding their factory automation capabilities through a series of sensibly priced, small-scale acquisitions over the past five years. The share price derated significantly during the initial phase of the pandemic given high operational gearing but has failed to recover in line with the sharp rebound in profitability this year. We believe the current valuation does not fully reflect the company's growth potential and were encouraged to see management undertake a new buyback programme at the recent earnings release given the low share price.

# Japan Value Fund continued

Lifedrink: The Fund participated in the initial public offering of Lifedrink. The company is a manufacturer of bottled mineral water and commands a 16% market share in the in the industry which they have successfully increased in recent years by monopolising the lower-priced segment of the market. Going forward, we expect the aggressive pricing strategy to continue to deliver results. In addition, we expect the overall market to grow as Japan's consumption of mineral water, which is approximately a quarter of the level seen in the west, continues to increase. Valuations are extremely attractive on forward-looking measures.

### **Outlook and strategy**

Although the emergence of the Omicron variant has clouded the short-term economic outlook it is clear that initial data on the severity of the disease is better than it has been for previous variants. If we assume that governments continue to tolerate higher case levels, then the year ahead will likely be more favourable to global business.

In Japan, COVID-19 case numbers fell back to very low levels and the positive economic impact from initial reopening is starting to emerge. Looking forward to 2022, a combination of the pent-up demand linked to reopening and the government's large fiscal stimulus plan, we believe, is likely to support a period of significantly above-trend growth which should be a tailwind to corporate profit growth at a time when the yen is trading at a favourable level for the manufacturing sector.

Portfolio strategy was little changed in 2021 but at the margin the Fund has been increasing exposure into the anticipated postpandemic recovery. The Fund has targeted names where we expect an almost full recovery in the short or medium term, while avoiding names where we believe there has been a more structural and longerterm impact. Although the recovery rally has been evident in many global markets, we have yet to see the same recovery in Japan with only large-cap exporters fully participating in the global reopening trade. We would expect this effect to filter through to the domestic economy and a wider selection of smaller and mid-sized companies in 2022 where the Fund is well positioned to benefit.

Longer term, the Fund remains highly geared to the wider corporate governance reform that continues at pace in Japan. It has been encouraging to see both Secom Joshinetsu and Toppan Forms being acquired at a significant premium by their respective parents. The portfolio has now enjoyed seven corporate transactions related to listed subsidiaries under the current value strategy initiated in mid-2016 and typically retains approximately 10 names accounting for close to 20% of the portfolio in this theme. There have been a number of interesting corporate governance developments over the past year. First, the upcoming restructuring of the TOPIX Index is forcing many companies to adopt structural changes in order to be considered for the new Prime Index and we are seeing more companies willing to engage with investors as a result. In addition, as of the 2022 AGM season, proxy advisers will call for institutional investors to vote against the management of corporates with excessive cross-shareholders irrespective of their reasoning. Finally, any corporates listed on the Prime Index who have controlling shareholders need to either appoint a majority independent board or establish an independent special committee to discuss any issues where a conflict exists for minority shareholders. The upcoming changes, and further pressures that will almost certainly be faced by corporates, remains the largest catalyst in unlocking the deep value opportunity inherent in the Fund.

#### Japan Team

Polar Capital LLP

# North American Fund

#### **Fund Performance**

The Fund returned 23.6% (Class I US Dollar Distribution Shares) over 2021, compared with 26.4% for the MSCI North America Net Total Return Index (in dollar terms).

We are pleased with the absolute performance of the Fund, particularly the operational performance of its holdings which for the most part have been strong and better than we would have expected at the beginning of 2021. This recent operational performance has continued the trend of strong and, we believe, superior business compounding (measured by growth in earnings per share plus dividend yield) of the holdings since launch just over 10 years ago.

A prime example of this strong operational performance is Alphabet, the Fund's largest holding and biggest contributor to relative performance in 2021, which, despite its size, will have approximately doubled its earnings per share in 2021 versus 2019 (prior to the pandemic).

Good operational performance was not restricted to technology businesses, nor was it restricted to the world's largest companies. Other notable positive operational and stock-price performances over the year include Canadian Natural Resources, which is seeing attractive cash-flow growth given its high quality, low decline-rate asset base and higher commodity prices, and Affiliated Managers Group, the asset manager holding company, which not only benefited from the recovery in asset prices but also started to see an improvement in organic inflows and the benefits of deploying its significant cash flow into acquisitions and buybacks.

These two had been disappointing performers earlier in the Fund's ownership. In such instances, we evaluate whether it is the long-term potential of the business or simply the valuation applied to the longterm potential that has changed. In both instances, we felt the stocks had been punitively devalued versus their potential so we stuck with them. It is pleasing to see this patience has been rewarded. We continue to believe they are still attractively valued despite the recent strong share-price performance.

Also notable were the performances of two long-standing healthcare holdings, Anthem, a health benefits company, and Icon, a provider of contract clinical research to the biopharma industry, which both continue to exhibit appealing free cash-flow compounding. The Fund got off to a good start to the year, helped to some degree by exposure to those companies most hit by the pandemic experiencing a recovery, as well as its small and mid-cap bias. However, the same characteristics turned out to be headwinds for relative performance after the first quarter. This was partially driven by the elongation of the pandemic with the advent first of the Delta and then of the Omicron variants which hurt businesses with recovery potential, particularly in the fourth quarter. Such businesses include US Foods Holding, the food distributor to restaurants; Medtronic, a producer of medical devices often used in elective surgery; Uber, the ride-hailing platform; and Booking Holdings, the hotel booking platform. With the pandemic on the cusp of becoming endemic, we think the buoyant outlook for such businesses is currently not reflected in their share prices.

Aside from the above-mentioned stocks, other notable weak stock performers over the year included T-Mobile, the wireless telecoms operator; LiveRamp Holdings, an online advertising technology provider; and Shift Technologies, an online used car retailer.

T-Mobile suffered due to a pick-up in competitive activity in the industry. This is a concern to us. However, we still think the industry is stable and largely rational while the company offers the best value combination of superior spectrum at the lowest cost. The combination of industry-leading growth, ramping synergies from its acquisition of Sprint and future capital return could see the shares on a teensfree cash flow yield 2–3 years out. LiveRamp Holdings and Shift Technologies are examples of two small positions in the portfolio which we believed had above average operational risk as well as attractively skewed upside given their high growth potential and reasonable entry valuations. Both businesses saw good operational progress. However, LiveRamp delivered growth that was perhaps a little lower than some investors had hoped for, while concern about the impact that lower used car prices will have on Shift's profitability (at the same time as the business will require further capital to sustain its rapid growth) overwhelmed otherwise remarkable operating results.

Overall, we are encouraged to see that some of the acute stylistic headwinds the Fund has faced in recent years were less strong in 2021 and may in fact have peaked in 2020 when the Fund's relative performance troughed. More importantly, we believe the outlook for the businesses held in the portfolio is bright and we expect them to continue to compound business value at a double-digit rate, in excess of the rate of the performance benchmark.

# North American Fund continued

#### **Market Review**

2021 marked the third year in a row of exceptionally strong equity market returns. Despite the setback in war against COVID-19 caused by the arrival of the Delta and Omicron variants, increasing vaccination rates, prior infections and continued scientific progress meant the virus wrought a less severe a toll on public health systems in 2021 than it did in 2020. Nonetheless, 2021 can hardly be described as a 'normal' year. The first quarter was spent in lockdowns in most countries around the world and ongoing Covid-related shutdowns, or a plain lack of investment in certain areas, led to notable supply-chain imbalances in the global economy.

Meanwhile, the sheer force of monetary and fiscal policy in response to the pandemic and, perhaps more importantly, an apparent mind set change at the Federal Reserve and other central banks towards a tolerance of higher inflation, resulted in monetary policy remaining very easy throughout 2021. Loose monetary policy and the tailwinds fiscal stimulus was a partial contributor to the robust demand for goods and services throughout the year – though some areas of demand in the economy remain under-normalised due to the pandemic. The inevitable inflation that loose monetary policy, tight supply and strong demand caused has started to look more persistent, with the US economy beginning to witness greater pressure on wages towards the end of the year. Wage inflation has historically been less transitory than the inflation we saw last year in items such as used car prices and certain industrial commodities.

This is perhaps one reason why the valuation multiples of the longest duration, highest valued companies in the market started compressing from extreme levels later in the year. We have been highlighting for some time that equity market positioning reflects the status quo environment of disinflation from the past half decade as well as a concern that extreme valuations in parts of the market may not be sustainable. Given the starting point, this unwinding process may have further to run.

While the valuations of the highest valued stocks in the market compressed significantly towards the end of the year, for the year as a whole the S&P 500 also saw some modest multiple compression. This reflects the remarkably strong rebound in corporate earnings that we have seen in the past 18 months. It looks likely that earnings growth will be around 50% in 2021. Clearly, such a result is flattered by the easy comparison from 2020, but it is remarkable that S&P earnings in 2021 are likely to be 20% higher than they were in 2019 – a reflection of the stimulus put in place in the aftermath of the pandemic as well as the impressive productivity and global market-share gains generated by many companies.

The rate of economic recovery and the associated operating leverage seen at many companies will of course inevitably slow down. However, we still see attractive and broader growth prospects for a larger cohort of businesses, especially ones that were able to adapt and innovate during the downturn, than we have seen for the vast majority of the past decade. We remain optimistic about the prospects for the portfolio's value creation potential in the near, medium and long term.

### **Fund Activity**

After elevated turnover in 2020, activity was more muted than last year with the number of complete sales of a position or purchases of a new position falling back to their historic average. New stocks added to the portfolio hail from a variety of different industries and included Zuora, a software business; MKS Instruments, a manufacturer of critical components to a variety of industries; Signature Bank, a commercial bank; Service Corp International, a provider of funeral services; LPL Financial Services, a provider of processing and services to financial advisers and Littelfuse, a manufacturer of fuses and other electronic components. Nearly all the new additions would not be considered large-cap stocks, reflecting what we consider to be a key attraction of the US stock market - its depth and breadth. Indeed, the portfolio continues to exhibit a small or mid-cap bias compared to the most commonly used benchmarks. This skew has not been helpful for relative performance in recent years, given spectacular returns from a number of the largest American businesses which have contributed disproportionately to the returns of the most commonly used indices. However, we think the most sensible investment approach is one that takes advantage of the best investment opportunities across the market cap spectrum and expect this approach to reassert itself as a positive contributor to performance in the future.

For a more detailed write up of the rationale of some of the key buys and sells, please see our most recent investment update for Q4 2021.

# **Market Outlook**

A new calendar year inevitably brings with it prophecies of what the next 12 months might hold as well as a list of investment risks that lie on the horizon. While we are fully aware of the holistic environment in which the businesses held in the portfolio operate, we have found that over time it is rarely the case that the most commonly cited near-term macro risks dictate the longer-term path of most businesses' fundamentals. Overall, there is nothing to suggest corporate America will not continue to grow and prosper in the near, mid or long term. We expect American businesses will continue to expand their share of global profits as they have done over the past decade. This is happening more and more in industries that were once considered localised and where that localisation is being disrupted due to technological change. One prominent and perhaps more significant concern for both fundamentals as well as valuations is the trend of higher inflation in goods, services and wages. A tight labour market and ongoing supply chain issues, as well as companies' intentions to increase prices and wages, suggest to us that inflation is unlikely to go away in the near term. Whether it persists for longer is too difficult to forecast.

The equity market has, in many respects, been pricing in a continuation of the previous environment of low inflation and interest rates. Any sustained period of higher inflation could result in a somewhat different interest rate and investing environment to what we have been used to in recent years. As a result, valuation could reassert itself as playing a more important role, more so than it has done in recent years. We believe our process, which focuses on long-term value creation with an overlay of valuation discipline, is well placed to take advantage of the evolving investment opportunity set.

While there are parts of the equity market that look overextended from a valuation perspective, there remain plenty of opportunities to invest in well-run businesses demonstrating strong compounding potential at attractive valuations. The wide selection of such companies is an ongoing clear competitive strength of the American market and one we look to take advantage of with our multi-cap approach. We continue to find attractively valued opportunities from a variety of industries, including businesses with appealing secular growth prospects, those with solid cashflow compounding characteristics as well as companies with strong recovery potential.

In summary, we believe the outlook for the businesses held in the portfolio is very bright. We expect the underlying businesses held in the portfolio should continue to compound at a double-digit rate and in excess of the rate of the performance benchmark. We expect the valuation discipline inherent in our process will naturally reassert itself as an asset in the future and complement the underlying business compounding of the portfolio.

#### **North American Team**

Polar Capital LLP

# Smart Energy Fund

#### **Fund Performance**

Launched at the beginning of October, the Fund returned 6.4% (Class I US Dollar Accumulation Shares) in its first three months, slightly underperforming the broader MSCI AC World Index TR Net, which returned 6.7% during the same period (in dollar terms).

The strongest positive performance contribution was delivered by our Energy Efficiency cluster, followed by the Energy Conversion and Storage and Energy Transmission and Distribution clusters. Clean Power Generation delivered an absolute negative performance contribution.

At an individual stock level, ON Semiconductor, Marvell Technology, Xilinx and Lattice Semiconductor were the strongest positive contributors. The strongest negative contributors were NIO, Renova, Apple\* and Alstom.

#### **Market Review**

In the last quarter of the year, the stock markets continued to be strongly impacted by the coronavirus pandemic, causing supply disruptions which drove up inflation in the middle of increasingly tight labour markets. Consequently, the comments from the US Fed became increasingly hawkish, with Fed Chair Jerome Powell retiring the word 'transitory' for inflation and announcing a faster bond tapering before increasing interest rates again during 2022.

The corporate earnings season delivered strong results, with most companies able to beat earnings estimates amid improving margins.

The clean energy sector remained in focus with investors, with the COP26 climate summit in Glasgow creating substantial media coverage. More countries announced commitments on net-zero emissions, and a common agreement was found to phase down coal as well as 'inefficient fossil-fuel subsidies'. To the surprise of many, a compromise was also found to develop a framework for a global carbon market, which has the potential to reduce emission-reduction costs significantly. At the same time, the news flows of new deals being announced, notably around green hydrogen infrastructure, gave additional support. Renewable power generation is seen as improving the resilience of a country's energy sector in times of rising energy commodity prices.

# **Fund Activity**

In October 2021, we successfully launched the Fund, with investments spread broadly over the four investment clusters mentioned above. Care was taken to start with a concentrated portfolio while maintaining geographical and thematic diversification.

Investments in the energy efficiency cluster had the greatest share, spread over four sub-clusters of big data, transportation, industrial processes and buildings. Given the solid business perspectives, companies addressing the energy consumption of big data like Marvell, Xilinx and Lattice Semiconductor had a decent weight in the portfolio. Inside the transportation sector, focus was put on Chinese electric vehicle (EV) manufacturers XPeng and Nio, and on the train systems developers Alstom and Stadler Rail. Companies addressing the energy efficiencies of industrial processes, such as Schneider Electric, were also represented with a solid weight in the portfolio. This is equally true for the building efficiency sector, where hardware improvements in HVACs (heating, ventilation and air-conditioning), lighting and controls are delivering strong efficiency gains and an improved user experience. Investments in this sub-cluster included Johnson Controls, Azbil and Resideo Technologies.

The exposure to semiconductor power management companies increased during the quarter as they are considered to particularly profit from the strong electrification trends in the global energy sector. Energy-efficient power conversion devices are becoming omnipresent across the clean energy value chains, with new strong growth drivers being the electrification of the transportation sector and battery management systems as well as the energy efficiency of big data. Notably, the positions in ON Semiconductor, Power Integrations, Rohm and Navitas Semiconductor were reinforced during the quarter.

Investments in hydrogen were maintained in the high single-digit percentage range and included pure play companies like Plug Power, ITM Power and NEL ASA, but also legacy hydrogen infrastructure equipment providers Linde and Air Liquide.

Towards the end of the year, exposure to clean power generation was reduced through selling the renewable power producers Neoen, Encavis and Boralex, as the sector continued to be negatively impacted by supply-chain delays and rising costs. The position in the poly-silicon supplier Wacker Chemie was sold.

\* not held

### **Market Outlook**

Inflationary pressures caused by supply-chain bottlenecks, tight labour markets and higher energy costs are likely to persist at least into the first half of 2022. All this is likely to push the Fed to take a more aggressive stance, advancing interest rate increases.

On a positive note, the less virulent Omicron variant may signal the beginning of the end of the pandemic, making more extensive lockdowns increasingly unlikely. The Fund's management expects current tight supply chains to gradually normalise going into 2022, thereby lessening inflationary pressure. All this would be supportive for the markets.

We remain constructive on the underlying themes as reflected by the Fund's investment strategy. Driven by favourable governmental frameworks and better economics, the deployment of clean energy solutions will further gain momentum.

Concerning the deployment of clean power generation, we expect another record of new installations for 2022, driven by solar deployments, as falling input raw material costs will improve the economics again, notably towards the second half of the year.

2022 should also see record investments in energy storage as it offers a strong complement to distributed generation, especially in solar PV (photovoltaics). Similarly, the building efficiency sector is likely to remain very strong.

In line with the overall strong underlying electrification trend, we expect the key technology enablers in power semiconductors to continue to see strong demand. The current tense supply situation is not likely to abate soon, and this will allow companies to continue to expand their top and bottom line.

As in the past, the Fund will continue to invest across the clean energy value chain, focusing on segments with strong structural growth drivers like clean power production, smart grid and storage solutions, the buildout of a green hydrogen infrastructure, power electronic components, electric vehicles, building efficiencies and the energy efficiency of big data.

#### **Financials Team**

Polar Capital LLP

For the financial year ended 31 December 2021

# **Smart Mobility Fund**

#### **Fund Performance**

Launched at the beginning of October, the Fund returned 5.7% (Class I US Dollar Accumulation Shares) in its first three months, slightly underperforming the broader MSCI AC World Index TR Net, which returned 6.7% during the same period (in dollar terms).

At the outset, investments were spread broadly over four thematic investment clusters. All four contributed positively, with the strongest positive performance contribution coming from the EV (electric vehicles) Technologies cluster, followed by the Mobility Infrastructure, EV Manufacturing and Autonomous Driving clusters.

At an individual stock level, ON Semiconductor, Xpeng, Plug Power and Denso were the strongest positive contributors. The strongest negative contributors were NIO, Umicore, Apple\* and Uber Technologies.

#### **Market Review**

In the last quarter of the year, the stock markets continued to be strongly impacted by the coronavirus pandemic, causing supply disruptions which drove up inflation in the middle of increasingly tight labour markets. Consequently, the comments from the US Fed became increasingly hawkish, with Fed Chair Jerome Powell retiring the word 'transitory' for inflation and announcing a faster bond tapering before increasing interest rates again during 2022.

The corporate earnings season delivered strong results, with most companies able to beat earnings estimates amid improving margins.

The news flow for the smart mobility sector during the quarter was supportive, notably around strong EV sales numbers worldwide, and company partnerships announced that targeted the buildout of green hydrogen infrastructure. In addition, the COP26 Climate Change Conference in Glasgow confirmed the strong global support to decarbonise the transportation sector as more countries announced commitments on net-zero emissions.

### **Fund Activity**

In October 2021, we successfully launched the Fund, with investments spread broadly over the four investment clusters mentioned above. Care was taken to start with a concentrated portfolio while maintaining geographical and thematic diversification.

EV Technologies had the strongest cluster weight in the portfolio. A particular focus was put on companies supplying the electric powertrain such as ON Semiconductor, Infineon Technologies, Rohm and Power Integrations, as they benefited from significant revenue opportunities for on-board chargers, battery management systems and, notably, traction inverters. Investments in the battery value chain included lithium mining companies Livent, Albemarle and Sociedad Química y Minera de Chile (SQM), as well as battery cells producers such as Panasonic and GS Yuasa. The Mobility Infrastructure cluster represented the second strongest weight of the portfolio. Investments were spread over the smart grid and charging sub-cluster with holdings like ABB and Schneider Electric, the green hydrogen and sustainable fuels sub-cluster through Linde, Air Liquide, NEL ASA and ITM Power, as well as the public transport and vehicle sharing sub-cluster through Alstom, Stadler Rail as well as Uber Technologies.

The exposure to EV manufacturers was more limited and included Chinese car OEMs XPeng, NIO and BYD, some tier-one OEM suppliers like the Japanese suppliers Denso and Nidec, and South Korean suppliers Hyundai Mobis and Mando.

Finally, investments in Autonomous Driving included the sensor and micro-controller companies Renesas Electronics and NXP Semiconductor, the autonomous driving solutions company APTIV, as well as connectivity players Visteon and U-blox Holding.

### **Market Outlook**

Inflationary pressures caused by supply-chain bottlenecks, tight labour markets and higher energy costs are likely to persist at least into the first half of 2022. All this is likely to push the Fed to take a more aggressive stance, advancing interest rate increases.

On a positive note, the less virulent Omicron variant may signal the beginning of the end of the pandemic, making more extensive lockdowns increasingly unlikely. The Fund's management expects current tight supply chains to gradually normalise going into 2022, thereby lessening inflationary pressure. All this would be supportive for the markets.

Following an already successful 2021, we expect the strong growth of electric vehicles to continue. With global auto production capacity recovering as a result of lessening-supply chain disruptions, we expect to see sales growth for EVs vehicles of at least 60% in 2022, which would give them a market share of 12% worldwide. The global penetration will thereby continue to be driven by Europe and China, but we have seen a recent acceleration in US EV developments.

In the area of autonomous driving, 2022 will mark a major milestone with 'level 3' cars on public roads after authorities granted system approval for the first time in December 2021. Level 3 autonomy will conditionally allow the driver to focus on other activities such as processing emails, online shopping and web browsing. Furthermore, in 2022 we expect to witness various fully automated robo-taxi projects worldwide to make further progress towards a public-facing commercial setting.

\* not held

Overall, we remain very constructive on the Fund given the strong fundamentals of the smart mobility sector, with the entire transportation sector having engaged in an unprecedented transformation towards electrification. We will continue to invest across the smart mobility value chain, seeking exposure to market segments including EV manufacturers and suppliers, power semiconductors, batteries, hydrogen and EV charging infrastructure, sensor and data processing technologies for automated driving, shared mobility solutions or new developments in the area of driverless mobility.

#### **Financials Team**

Polar Capital LLP

# **UK Absolute Equity Fund**

Due to the ill health of the fund manager, the Fund was suspended in mid-April 2020, and money returned to investors by mid-May 2020.

# **UK Value Opportunities Fund**

### **Fund Performance**

The Fund returned 20.1% (Class I GBP Accumulation Shares) in 2021 compared to 17.8% (in GBP terms) for the FTSE All Share Total Return benchmark. Since inception, the Fund has returned 46.4% (Class I GBP Accumulation Shares) compared to 29.6% (in GBP terms) for the benchmark.

The outlook for the global and the UK economy was volatile over the year. Initially, hopes of continued rapid economic recovery from COVID-19 in the first half of the year, driven by successful vaccine rollouts and a reduction of enforced economic lockdowns gave way to concerns over inflation and supply chains and then new emerging COVID-19 variants. Broadly speaking, the first half of the year saw the 10-year Treasury and sterling strengthen while small and midcaps outperformed large caps. All of this tends to provide beneficial stylistic tailwinds for the Fund. The second half of the year saw those tailwinds turn to headwinds and become a more challenging backdrop, especially in Q4.

The strongest performing sectors by contribution to the Fund were retail and capital goods, with the weakest performing sectors being household and personal goods and consumer durables. Looking at individual stocks, there is a clear picture of those that delivered consistent profit upgrades over the year being the Fund's best performing shares, while those shares that proved to be the most difficult from a performance perspective all had to deliver more difficult news.

The strongest performing shares by contribution were Morgan Sindall Group, Investec, Marks & Spencer Group, Watches of Switzerland Group and MW Morrison Supermarkets. Morrison was one of three shares sold and exited during the year after receiving successful takeover approaches. The other four benefitted from starting the year on modest valuations and delivered a number of strong profit upgrades over the course of 2021.

The weakest performing shares were IG Design Group, Lancashire Holdings, QinetiQ Group, Vesuvius and Mitchells & Butlers. All of these companies had to downgrade profit expectations in 2021, thanks to a combination of tougher supply chains and more difficult end markets.

#### **Market Review**

We assess the period on our three investment criteria: valuation, durability of profits and our financial safety check.

In late 2020, we saw the re-emergence of value as a style with the announcement of the successful vaccines and their rollout. Value had a mixed 2021, initially outperforming before growth started to perform better in the summer months. Within the Fund we can clearly see that cheaper shares outperformed over the year as whole. If we can navigate through the Omicron scare with only minor economic restrictions, then the outlook for value looks set fair as we should see an acceleration again in economic data over the course of the first half of 2022. The valuation of the UK market remains highly attractive in the context of other global markets, and the Fund remains at a healthy discount to the UK market as a whole.

The durability of companies' profits was easier to forecast than in 2020, though in many cases they were still subject to volatile changes in expectations. While businesses often experienced large variations in top-line sales, depending on the impact of lockdowns, most companies in the portfolio coped admirably when dealing with the huge challenges that 2021 presented. Companies were faced with having to guide the market with an unknown future while coping with inflation, supply-chain disruption and, in some cases, extreme shortages of basic inputs, including labour. We have commented previously that the COVID 19 crisis has exaggerated and sped up change across many sectors and companies and we feel particularly excited to see a number of businesses well placed to keep taking substantial market share.

The premise of our financial safety check is that businesses generating decent positive retained cash with a robust balance sheet are best placed to weather storms and seize opportunities whenever they present themselves. The past two years have perhaps shown more than ever its benefit to our process. Many of the Fund's companies have been able to accelerate capital spending plans and were able to come strongly back onto the dividend list. When analysing those we believe are taking the greatest market share within their sectors, it is clear they start from the basis of a strong financing position.

# UK Value Opportunities Fund continued

### **Fund Activity**

The portfolio benefitted from three shares being taken over at acceptable valuations that were above or approaching our target price. MW Morrison Supermarkets (see above), Stock Spirits Group and Ultra Electronics Holdings. Additionally, our holdings in Watches of Switzerland Group, Marlowe, Johnson Service Group, Pennon Group, Prudential, Discoverie Group and On the Beach Group were all sold when the shares reached our estimation of fair value. As a value fund, we will always seek to exit a holding at fair value (or better) and recycle capital into cheaper areas of the portfolio. Many of these businesses are investments that have been great friends to the Fund and we will happily revisit them if valuations come back towards more reasonable levels. We continually monitor all holdings for adherence to our three investment criteria - valuation, durability of profits and our financial safety check - and if any one of those criteria are challenged then we exit the holding. Over the course of the year our analysis changed surrounding the durability of the profit streams for Polymetal International, Barratt Developments, Ashmore Group and James Fisher & Sons. While they were difficult decisions to take, on average it has been the right decision to keep the portfolio focused on those shares in which we have higher conviction.

One advantage of the sizeable discount the UK market is trading at, is there is no shortage of great value shares to choose from. Indeed, the new holdings that have come into the Fund are a mix of market cap, sector as well as both internationally and domestically-focused shares. Over the course of the year, new holdings were added on valuation grounds in AstraZeneca, Beazley, Taylor Wimpey, Atalaya Mining, Dunelm Group, WPP and Tesco. Additionally, we used capital-raising events to acquire holdings at attractive prices in Rathbone Brothers, Kier Group and SigmaRoc.

We still have a healthy pipeline of possible shares to consider for the fund into 2022.

#### Market Outlook

There are three clear risks the market will have to continue to grapple with at the start of 2022. First, continued supply-chain disruption and bottlenecks will keep inflationary pressures high and leave the profit outlook for business more challenging. In particular, while China continues to follow an unrealistic policy of zero COVID-19, its economy will be subject to significant shutdowns which will impact global GDP and maintain supply-chain disruption. Second, tightening monetary policy. Third, we are faced with continuing ongoing variants of COVID-19.

The valuation of the UK market and the Fund remains highly attractive and it is a source of frustration but also opportunity that the UK valuation discount did not close in 2021. The UK remains on a material valuation discount to the rest of the world even when sector-adjusted, despite the most dramatic downside risks of a new relationship with the EU failing to materialise and an advanced vaccine program. As long as the UK remains out of favour, it is a particularly good place to go bargain hunting, in our view, and the Fund itself remains at a significant discount to the market, creating a double discount.

There was a significant amount of M&A in 2021 and, if the UK valuation discount continues, this level of elevated takeover activity is likely to continue. There is little good news priced into large parts of the UK stock market and certain domestic shares stand at incredibly attractive valuations. Should the vaccination booster program prove successful, we believe the UK market and domestic shares should be well placed to outperform.

In assessing our outlook for return on invested capital, its already clear that the significant vaccination effort in the UK and the rollout of the booster program is thankfully insulating the healthcare system from the worst-case outcomes. We are starting to see tentative signs that supply-chain disruptions for freight and input commodities is easing. However the labour market both in the UK and around the world remains tight. While this is a challenge, it is becoming increasingly clear that 'winning' businesses are navigating these challenges better than weaker impaired businesses. We have seen some of our holdings take five years' worth of market share in five months. We continue to think this is a hugely exciting investment opportunity.

The balance sheet position of UK companies and UK consumers remains extremely healthy which bodes well for the outlook for corporate capex spend and consumption over the course of 2022. There will be plenty of challenges ahead, but we feel the valuation of both the UK and the Fund remains highly attractive and we strongly believe that should be the basis for generating meaningful returns.

#### **UK Value Team**

Polar Capital LLP

Report of the Directors For the financial year ended 31 December 2021

The Directors of Polar Capital Funds plc (the 'Company') have pleasure in submitting their Annual Report and Audited Financial Statements for the financial year ended 31 December 2021 to the Shareholders.

#### **Directors Responsibilities Statement**

The Directors are responsible for preparing the Directors' report and the financial statements in accordance with the Companies Act 2014 (including amendments made by the Companies (Accounting) Act 2017, hereinafter 'Companies Act 2014') and the applicable regulations.

Irish company law requires the Directors to prepare financial statements for each financial year. Under the law, the Directors have elected to prepare the financial statements in accordance with International Financial Reporting Standards as adopted by the European Union ('IFRS').

Under company law, the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the Company as at the financial year end date and of the profit or loss of the Company for the financial year and otherwise comply with the Companies Act 2014.

In preparing those financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with the applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for ensuring that the Company keeps or causes to be kept adequate accounting records which: correctly explain and record the transactions of the Company; enable at any time the assets, liabilities, financial position and profit or loss of the Company to be determined with reasonable accuracy; enable the financial statements and Directors' report to comply with the Companies Act 2014 and with the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (as amended) (the 'UCITS Regulations') and Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (the 'Central Bank UCITS Regulations') and the Listing Rules of Euronext Dublin; and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In this regard, Bridge Fund Management Limited (the 'Manager') has been appointed as the Company's UCITS management company, with overall responsibility for the administration of the Company and the management of its investments. The Manager has in turn appointed Polar Capital LLP (the 'Investment Manager') as investment manager of the Company's sub-funds and Northern Trust International Fund Administration Services (Ireland) Limited (the 'Administrator') for the purpose of, among others, maintaining adequate accounting records. Northern Trust Fiduciary Services (Ireland) Limited (the 'Depositary') has been appointed for the purpose of safeguarding the assets of the Company.

#### **Basis of Presentation**

The format and certain wording in the Financial Statements has been adapted from those contained in the Companies Act 2014 and IFRS so that, in the opinion of the Directors, they more appropriately reflect the nature of the Company's business as an investment fund.

# Directors' Statement on adequate accounting records

The Directors believe that they have complied with the requirements of sections 281 to 285 of the Companies Act 2014 with regard to adequate accounting records by employing personnel with appropriate expertise and by providing adequate resources to the finance function. The accounting records of the Company are maintained by the Administrator at Georges Court, 54–62 Townsend Street, Dublin 2, Ireland.

#### **Business Review and Future Developments**

The Company is an open-ended investment company with variable capital and segregated liability between its sub-funds (the 'Funds'), organised under the laws of Ireland. The Company was incorporated on 28 September 2001.

During the financial year ended 31 December 2021:

- Asian Opportunities Fund terminated on 1 March 2021.
- Emerging Markets Income Fund merged with the Emerging Markets Stars Fund on 8 June 2021.
- Barbara Healy was appointed as Director 11 June 2020 and resigned on 16 February 2021.
- Karen Nolan was appointed as Director on 16 February 2021.
- Smart Energy Fund launched on 30 September 2021.
- Smart Mobility Fund launched on 30 September 2021.

The Company will continue to act as an investment vehicle as set out in its Prospectus.

A detailed review of the Company's activities for the financial year ended 31 December 2021 is included in the Investment Manager's Report.

For the financial year ended 31 December 2021

### **Risk Management Objectives and Policies**

The principal risks and uncertainties faced by the Company are the investment risks associated with the portfolio of investments held for the account of each Fund and the operational risks associated with their management and administration. A more detailed analysis of some of the risks facing the Company is included in Note 10 of the Notes to the Financial Statements.

#### **Directors' Interests in Shares of the Company**

Other than as disclosed in Note 8 to the Financial Statements, there were no contracts or agreements of any significance in relation to the business of the Company in which the Directors had any interest, as defined in the Companies Act 2014, at any time during the financial year.

### **Transactions with Connected Persons**

Regulation 43(1) of the Central Bank UCITS Regulations requires that any transaction carried out with the Company by a management company or depositary to the Company, their respective delegates, and associated or group companies ('connected persons') must be carried out as if negotiated at arm's length. Transactions must be in the best interests of the shareholders.

The Directors are satisfied that there are arrangements (evidenced by written procedures) in place, to ensure that this obligation is applied to all transactions with connected persons, and are satisfied that transactions with connected persons entered into during the year complied with this obligation.

#### Distributions

Distributions declared for the financial year are as set out in Note 13.

#### **Corporate Governance Statement**

The Company is subject to corporate governance practices imposed by:

- (i) The Memorandum and Articles of Association of the Company;
- (ii) The Companies Act 2014;
- (iii) The UCITS Regulations;
- (iv) The Euronext Dublin Code of Listing Requirements and Procedures.

Copies of the above are all available for inspection at the Company's registered office at Georges Court, 54–62 Townsend Street, Dublin 2.

The Company has adopted the Corporate Governance Code for Collective Investment Schemes and Management Companies (the 'Code') issued by Irish Funds. The Company is organised in such a way to meet all the provisions of the Code and there are no exceptions to be noted. The Directors are responsible for establishing and maintaining adequate internal control and risk management systems in relation to the financial reporting process of the Company. Such systems are designed to manage, rather than eliminate, the risk of error or fraud in achieving the Company's financial reporting objectives and can only provide reasonable and not absolute assurance against material misstatement or loss.

The Company has procedures in place to ensure all relevant accounting records are properly maintained and are readily available, including production of annual and half-yearly financial statements. The annual and half-yearly financial statements of the Company are required to be approved by the Directors of the Company and filed with the Central Bank of Ireland and Euronext Dublin.

The accounting information provided in the annual financial statements is required to be audited by an independent auditor who reports annually to the Shareholders of the Company on the audit process and their findings. The auditor's report on the financial statements, including any qualifications, is reproduced in full in the annual report of the Company.

The business of the Company is managed by the Directors, who are responsible for the Company's overall direction and strategy, including review of investment management performance, administration of the Company's funds and compliance with the Company's regulatory requirements. Custody of the Company's assets is overseen by the Depositary, which is independent of the Company.

The Board meets at least four times a financial year to review the operations of the Company, to address matters of strategic importance and to receive reports from the Manager, Administrator, the Depositary and the Investment Manager. However, a Director may call a meeting of Directors at any time.

Questions arising at any meeting of the Directors are generally decided by consensus, but majority voting can be used if necessary to reach a decision. If there are an equal number of votes for or against a resolution the Chairman of the meeting can effectively decide the matter by exercising a second or casting vote.

The minimum required number of Directors is two, which is also the minimum number of Directors required for a meeting to take place. Currently there are six non-executive Directors, five of whom are independent of the Investment Manager. The Directors are listed on page 434.

#### **Diversity Statement**

The Board of Directors strives to ensure that its membership reflects diversity in the broadest sense (capturing a combination of skills, experience, age, educational and professional backgrounds). The Board has established a nominations committee the remit of which is to monitor the composition of the board, satisfy itself with regard to succession planning and ensure it adheres to the Code and applicable legislation with regard to diversity.

The Company believes that there is a strong business case for boardroom diversity, which helps to promote good governance and challenge 'group think' mentality. A diverse board should also help to ensure that the board continues to remain objective in its decision making and to exercise good judgement on behalf of the Shareholders. When appointing members to the board, the Company will consider whether the candidates have the knowledge, qualifications and skills necessary to safeguard proper and prudent management of the institution.

The Company has no employees. It is the opinion of the Board that the current Directors represent an appropriate mix of skills, knowledge and experience commensurate with governing a UCITS investment company of this scale, while meeting regulatory requirements as to the composition of the board and the experience and qualifications of its members.

The convening and conduct of Shareholders' meetings are governed by company law and the Memorandum and Articles of Association. Shareholders together holding 5 per cent or more in aggregate of the shares of the Company in issue may at any time request that the Directors convene a meeting of Shareholders to consider any matters that may be proposed by the Shareholders requesting the meeting.

A meeting of Shareholders held in accordance with the provisions of the Memorandum and Articles of Association may by a 75% majority of those voting approve a change to the Memorandum and Articles of Association or a proposal to wind up the Company. A simple majority vote is required for most other proposals, including proposals to determine that the Directors shall retire, or to terminate any of its Funds, and any material change in the investment objective and policies or the investment restrictions set out in the Prospectus issued by the Company. Twenty one days' notice at least of every meeting shall be given to Shareholders in the manner provided in the Memorandum and Articles of Association. At any meeting any matter put to a vote shall be decided on a show of hands unless a poll is (before or on the declaration of the result of the show of hands) demanded by the Chairman or by one or more Shareholders present in person or by proxy and holding or representing one-twentieth of the number of shares for the time being in issue. Unless a poll is so demanded, a declaration by the Chairman that a resolution has been carried or carried unanimously or by a particular majority or lost shall be conclusive evidence of the fact without proof of the number or proportion of the votes recorded in favour of or against such resolution.

If a poll is duly demanded, it shall be taken in such manner as the Chairman may direct and the result of a poll shall be deemed to be the resolution of the meeting at which the poll was demanded.

#### Results

The results of operations for the financial year are set out in the Statement of Comprehensive Income.

#### Significant Events during the financial year

Events which were significant during the financial year are detailed in Note 17.

#### Subsequent Events

Significant events since the financial year end date are set out above and detailed in Note 18.

#### **UCITS Remuneration Report**

The Company has established a remuneration policy in accordance with the Central Bank UCITS Regulations and the Guidelines on Sound Remuneration Policies issued by the European Securities and Markets Authority under the UCITS Directive (the 'ESMA Guidelines'). A copy of this policy is available on www.polarcapital.co.uk. Report of the Directors continued For the financial year ended 31 December 2021

### Directors Compliance Statement made in accordance with Section 225 of the Companies Act 2014

The Directors acknowledge that they are responsible for securing compliance by the Company with its Relevant Obligations as defined with the Companies Act 2014 (hereinafter called the 'Relevant Obligations').

The Directors confirm that they have drawn up and adopted a Compliance Policy Statement setting out the Company's policies that, in the Directors' opinion, are appropriate to the Company in respect of its compliance with its Relevant Obligations.

The Directors further confirm the Company has put into place appropriate arrangements or structures that are, in the Directors' opinion, designed to secure material compliance with its Relevant Obligations including reliance on the advice of persons employed by the Company and external legal and tax advisers as considered appropriate from time to time and that they have reviewed the effectiveness of these arrangements or structures during the financial year to which this Report relates.

### **Brexit and Associated Risks**

The decision by the United Kingdom ('UK') to leave the European Union ('EU') has led to political instability and economic uncertainty, volatility in the financial markets of the UK and more broadly across Europe and a decline in the value of Sterling. The terms of withdrawal appear now to have been largely settled, but there remains a number of uncertainties in connection with the UK's relationship with the EU which may continue for a time to affect economies in the UK, the EU and the rest of Europe and create volatility in the securities and foreign exchange markets in which many of the Sub-Funds invest.

### **Audit Committee**

During the financial year ended 31 December 2021 the Company did not have an audit committee in place. The Board has decided not to establish an audit committee as this was deemed most appropriate to the Company's structure as a UCITS fund and the nature, scale and complexity of the Company's operations at this time.

# **Statement on Relevant Audit Information**

So far as the Directors are aware, there is no relevant audit information of which the Company's auditors are unaware. The Directors have taken all the steps that should have been taken as Directors in order to make themselves aware of any relevant audit information and to establish that the Company's auditors are aware of that information.

#### **Independent Auditor**

Deloitte LLP, Chartered Accountants and Statutory Audit Firm, was appointed as the auditors of the Company on 22 October 2014. In accordance with Section 383 (2) of the Companies Act 2014, the auditors have indicated their willingness to continue in office.

On behalf of the Board

#### **David Hammond**

Karen Nolan

31 March 2022

Directors

Report of the Depositary to the Shareholders For the financial year ended 31 December 2021

We, Northern Trust Fiduciary Services (Ireland) Limited, appointed Depositary to Polar Capital Funds plc ('the Fund') provide this report solely in favour of the shareholders of the Fund for the year ended 31 December 2021 ('the Annual Accounting Period'). This report is provided in accordance with the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 (SI No 352 of 2011), as amended, which implemented Directive 2009/65/ EU into Irish Law ('the Regulations'). We do not, in the provision of this report, accept nor assume responsibility for any other purpose or person to whom this report is shown.

In accordance with our Depositary obligation as provided for under the Regulations, we have enquired into the conduct of the Fund for the Accounting Period and we hereby report thereon to the shareholders of the Fund as follows;

We are of the opinion that the Fund has been managed during the Annual Accounting Period, in all material respects:

- (i) in accordance with the limitations imposed on the investment and borrowing powers of the Fund by the constitutional documents and by the Regulations; and
- (ii) otherwise in accordance with the provisions of the constitutional document and the Regulations.

For and on behalf of

#### Northern Trust Fiduciary Services (Ireland) Limited

Georges Court 54–62 Townsend Street Dublin 2

31 March 2022

Independent Auditor's Report to the Shareholders of Polar Capital Funds plc

### Report on the audit of the financial statements

#### Opinion on the financial statements of Polar Capital Funds Plc (the 'company')

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2021 and of the profit for the financial year then ended; and
- have been properly prepared in accordance with the relevant financial reporting framework and, in particular, with the requirements of the Companies Act 2014 and the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations 2011 and Central Bank (Supervision and Enforcement) Act 2013 (Section 48(1)) (Undertakings for Collective Investment in Transferable Securities) Regulations 2019 (as amended).

The financial statements we have audited comprise:

- the Statement of Financial Position;
- the Statement of Comprehensive Income;
- the Statement of Changes in Net Assets to Holders of Redeemable Participating Shares;
- the Statement of Cash Flows; and
- the related notes 1 to 19, including a summary of significant accounting policies as set out in note 2.

The relevant financial reporting framework that has been applied in their preparation is the Companies Act 2014 and International Financial Reporting Standards (IFRS) as adopted by the European Union ('the relevant financial reporting framework').

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland, including the Ethical Standard issued by the Irish Auditing and Accounting Supervisory Authority, as applied to listed entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Summary of our audit approach

Key audit matters	The key audit matters that we identified in the current year were:
	Valuation of Financial Assets and Liabilities at Fair Value Through Profit or Loss;
	• Existence of Financial Assets and Liabilities at Fair Value Through Profit or Loss; and
	Accuracy of Performance Fees
	Within this report, any new key audit matters are identified with $\uparrow$ and any key audit matters which are the same as the prior year identified with $\rightarrow$ .
Materiality	The materiality that we used in the current year was 1% of the average net assets for each sub-fund.
Scoping	Our audit is a risk based approach taking into account the structure of the company, types of investments, the involvement of the third parties service providers, the accounting processes and controls in place and the industry in which the company operates.
Significant changes in our approach	There have been no significant changes in our approach from our prior year audit.

#### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Our evaluation of the directors' assessment of the company's ability to continue to adopt the going concern basis of accounting included:

- Reviewed and assessed the liquidity position of each sub-fund.
- Assessment of overall market performance and assessment of current year performance and year-end position of the company.
- Obtaining and challenging the directors assessment of going concern including key assumptions.
- Evaluating the adequacy of the relevant disclosures made in the financial statements.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

#### **Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current financial year and include the most significant assessed risks of material misstatement (whether or not due to fraud) we identified, including those which had the greatest effect on: the overall audit strategy, the allocation of resources in the audit; and directing the efforts of the engagement team.

These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

#### Valuation of Financial Assets and Liabilities at Fair Value Through Profit or Loss

Key audit matter description	The valuation of financial assets and liabilities at fair value through profit or loss is considered a key audit matter as they represents a significant balance on the Statement of Financial Position.
	There is a risk that financial assets and liabilities at fair value through profit or loss are valued incorrectly, inappropriate valuation methodology applied and the use of inappropriate assumptions could result in the valuation being materially misstated.
	Refer also to note 2 and 10 in the financial statements.
How the scope of our audit responded to the key audit matter	We have performed the following audit procedures to address the key audit matter: We obtained an understanding and evaluated the key controls that have been implemented over the valuation process for financial assets and liabilities at fair value through profit or loss.
	We obtained the Northern Trust International Fund Administration Services (Ireland) Limited (the 'Administrator') SOC 1 Report and identified the key controls in place over the valuation process and reviewed those key controls for any exceptions.
	We compared the prices of equities, warrants, contracts for difference, bonds, futures, swaps and forward foreign exchange contracts in the investment portfolio at year end to prices published by independent pricing sources.

Independent Auditor's Report continued

to the Shareholders of Polar Capital Funds plc

#### Existence of Financial Assets and Liabilities at Fair Value Through Profit or Loss

Key audit matter description	The existence of financial assets and liabilities at fair value through profit or loss is considered a key audit matter as they represents a significant balance on the Statement of Financial Position.
	There is a risk that financial assets and liabilities at fair value through profit or loss do not exist.
	Refer also to note 2 and 10 in the financial statements.
How the scope of our audit responded to the key audit matter	We have performed the following audit procedures to address the key audit matter:
	• We obtained an understanding and evaluated the key controls that have been implemented over the reconciliation process for existence from the Administrator to the depositary and counterparties.
	• We obtained the Administrator's SOC 1 Report and identified the key controls in place over the reconciliation process and reviewed those key controls for any exceptions.
	• We obtained independent confirmations from the depositary and counterparties at the financial year- end and agreed the amounts held to the investment portfolio.
	We tested a sample of reconciling trades to ensure that they have been recorded in the correct period including a review of a sample of unsettled trades
Accuracy of Performance Fees	
Key audit matter description	The performance fee crystallises on an annual basis. The accuracy of performance fees are considered a ke audit matter because the performance fee is a related party transaction and a significant expense in the Statement of Comprehensive Income.
	There is a risk that performance fee is not calculated correctly in accordance with the prospectus and input used in the calculation is incorrect.
	Refer also to note 3 in the financial statements.
How the scope of our audit	We have performed the following audit procedures to address the key audit matter:
responded to the key audit matter	• We obtained an understanding and assessed the design of the key controls over the calculation and approval of the performance fees.
	• We reviewed the prospectus of the company to understand the calculation methodology.
	• We reviewed the inputs used in the performance fee calculation to ensure compliance with the prospectus.
	• We recalculated performance fees in accordance with the prospectus and compared to recorded

performance fee to ensure accuracy.

Our audit procedures relating to these matters were designed in the context of our audit of the financial statements as a whole, and not to express an opinion on individual accounts or disclosures. Our opinion on the financial statements is not modified with respect to any of the risks described above, and we do not express an opinion on these individual matters.

#### Our application of materiality

We define materiality as the magnitude of misstatement that makes it probable that the economic decisions of a reasonably knowledgeable person, relying on the financial statements, would be changed or influenced. We use materiality both in planning the scope of our audit work and in evaluating the results of our work.

As the company is set up as an umbrella fund with segregated liabilities between sub-funds, we determined materiality on a sub-fund basis to be 1% of average net assets. We have considered the average net assets to be the critical component for determining materiality because the main objective of the sub funds is to provide investors with a total return. We have considered quantitative and qualitative factors such as understanding the company and its environment, history of mistatetements, complexity of the company and reliability of control environment.

We agreed with the directors that we would report to them any audit differences in excess of 5% of materiality, as well as differences below that threshold which, in our view, warranted reporting on qualitative grounds. We also report to the Board of Directors on disclosure matters that we identified when assessing the overall presentation of the financial statements.

#### An overview of the scope of our audit

Our audit is a risk based approach taking into account the structure of the company, types of investments, the involvement of the third party service providers, the accounting processes and controls in place and the industry in which the company operates. The company is incorporated as an open-ended investment company with variable capital and is organised under the laws of Ireland as a public limited company pursuant to the Irish Companies Act 2014. The company is authorised by the Central Bank of Ireland (the "Central Bank") as a UCITS (Undertaking for Collective Investment in Transferable Securities) pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Pursuant to the Irish Stock Exchange (the "ISE"). At 31 December 2021, the company had twenty active sub funds. We assess the risks of each sub-fund separately. We have conducted our audit based on the books and records maintained by the administrator, Northern Trust International Fund Administration Services (Ireland) Limited, Georges Court, 54–62 Townsend Street, Dublin 2, Ireland.

#### **Other information**

The other information comprises the information included in the Annual Report and Audited Financial Statements, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the Annual Report and Audited Financial Statements.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Independent Auditor's Report continued to the Shareholders of Polar Capital Funds plc

#### **Responsibilities of directors**

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view and otherwise comply with the Companies Act 2014, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

#### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (Ireland), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit
  procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk
  of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion,
  forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of the auditor's report. However, future events or conditions may cause the entity (or where relevant, the group) to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that the auditor identifies during the audit.

For listed entities and public interest entities, the auditor also provides those charged with governance with a statement that the auditor has complied with relevant ethical requirements regarding independence, including the Ethical Standard for Auditors (Ireland), and communicates with them all relationships and other matters that may reasonably be thought to bear on the auditor's independence, and where applicable, related safeguards.

Where the auditor is required to report on key audit matters, from the matters communicated with those charged with governance, the auditor determines those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. The auditor describes these matters in the auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, the auditor determines that a matter should not be communicated in the auditor's report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### Report on other legal and regulatory requirements

Opinion on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited.
- The financial statements are in agreement with the accounting records.
- In our opinion the information given in the directors' report is consistent with the financial statements and the directors' report has been prepared in accordance with the Companies Act 2014.

#### Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report

We have nothing to report in respect of the provisions in the Companies Act 2014 which require us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions specified by law are not made.

#### Use of our report

This report is made solely to the company's members, as a body, in accordance with Section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

#### **Christian MacManus**

For and on behalf of Deloitte Ireland LLP Chartered Accountants and Statutory Audit Firm Deloitte & Touche House, Earlsfort Terrace, Dublin 2

7 April 2022



#### **Asian Stars Fund**

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 99.43% (2020: 99.46%)		
	Australia: 1.71% (2020: Nil)		
140,848	OZ Minerals	2,889,828	1.71
	Total Australia	2,889,828	1.71
	Bermuda: 0.59% (2020: 1.25%)		
1,186,000	Alibaba Health Information Technology	1,002,493	0.59
	Total Bermuda	1,002,493	0.59
	Cayman Islands: 21.58% (2020: 33.05%)		
439,812	Alibaba	6,707,495	3.97
25,113	Bilibili ADR	1,155,102	0.68
253,000	JD Health International	1,994,132	1.18
126,248	JD.Com Inc	4,436,970	2.63
360,500	Longfor	1,697,004	1.01
142,400	Meituan	4,116,948	2.44
23,063	Sea ADR	5,159,424	3.05
190,900	Tencent	11,185,193	6.62
	Total Cayman Islands	36,452,268	21.58
	Hong Kong: 2.89% (2020: 3.06%)		
484,600	AIA	4,885,594	2.89
	Total Hong Kong	4,885,594	2.89
	India: 19.24% (2020: 14.11%)		
35,392	Apollo Hospitals	2,386,933	1.41
34,758	Coforge	2,754,221	1.63
26,999	Dixon Technologies	2,001,090	1.18
101,416	Housing Development Finance	3,528,689	2.09
530,941	ICICI Bank	5,286,508	3.13
225,395	ICICI Prudential Life Insurance	1,700,416	1.01
18,553	Info Edge	1,391,856	0.82
344,676	Phoenix Mills	4,568,824	2.70
483,098	Prestige Estates Projects	3,085,340	1.83
182,184	Reliance Industries	5,803,932	3.44
	Total India	32,507,809	19.24

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 99.43% (2020: 99.46%) continued		
	Japan: 1.60% (2020: Nil)		
4,700	Tokyo Electron	2,705,189	1.60
	Total Japan	2,705,189	1.60
	People's Republic of China: 5.83% (2020: 4.57%)		
141,900	Glodon	1,427,692	0.85
340,500	Ping An Insurance	2,452,327	1.45
218,900	Shenzhen Inovance Technology	2,361,444	1.40
96,100	Sungrow Power Supply	2,203,376	1.30
367,500	Venus MedTech (HangZhou) Inc	1,395,277	0.83
	Total People's Republic of China	9,840,116	5.83
	Republic of South Korea: 20.01% (2020: 22.73%)		
6,132	Ecopro BM	2,583,307	1.53
40,954	ITM Semiconductor	1,467,626	0.87
143,698	Koh Young Technology	2,864,894	1.69
14,730	NAVER	4,690,057	2.78
200,318	Samsung Electronics	13,194,447	7.81
3,590	Samsung SDI	1,978,086	1.17
124,077	Seoul Viosys	1,382,982	0.82
51,229	SK Hynix	5,645,425	3.34
	Total Republic of South Korea	33,806,824	20.01
	Singapore: 3.46% (2020: 1.08%)		
71,713	CLSA Global Market	1,964,151	1.16
43,980	OPT Machine Vision Tech	1,947,145	1.15
242,392	Zhejiang Heda Technology	1,932,032	1.15
	Total Singapore	5,843,328	3.46
	Taiwan: 19.32% (2020: 15.77%)		
105,000	Andes Technology	2,034,192	1.20
376,000	Chroma ATE	2,718,040	1.61
49,000	eMemory Technology	3,878,628	2.30
370,000	LandMark Optoelectronics	2,627,860	1.56
134,000	MediaTek	5,763,545	3.41
702,000	Taiwan Semiconductor Manufacturing	15,604,511	9.24
	Total Taiwan	32,626,776	19.32



#### Asian Stars Fund continued

Other Net Liabilities

		Fair Value	% of
Holdings	Financial assets at fair value through profit or loss	US\$	Net Assets
	Equities: 99.43% (2020: 99.46%) continued		
	Vietnam: 3.20% (2020: 3.84%)		
583,120	Vietnam Technological & Commercial Joint Stock Bank	1,279,333	0.76
1,414,200	Vincom Retail	1,867,811	1.11
625,812	Vinhomes	2,251,715	1.33
	Total Vietnam	5,398,859	3.20
	Total Equities	167,959,084	99.43
	Total Transferable Securities	167,959,084	99.43
		Fair Value US\$	% of Net Assets
	Total Value of Investments (Cost: US\$ 171,665,582)	167,959,084	99.43
	Cash at Bank	2,707,513	1.60

All securities are transferable securities and are admitted to an official stock exchange or dealt on a regulated market at the financial year end.

Net Assets Attributable to Holders of Redeemable Participating Shares

(1.03)

100.00

(1,743,383)

168,923,214

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	98.22	98.06
Other assets	1.78	1.94
	100.00	100.00

# Automation & Artificial Intelligence Fund

the following	Financial and the investor the structure in the second	Fair Value	% of
Holdings	Financial assets at fair value through profit or loss Equities: 97.99% (2020: 96.73%)	US\$	Net Assets
	Cayman Islands: Nil (2020: 2.62%)		
	France: 3.13% (2020: 2.39%)		
122,855	Schneider Electric	24,094,511	3.13
	Total France	24,094,511	3.13
	Germany: 3.55% (2020: 3.22%)		
83,753	Covestro	5,162,220	0.67
88,391	Duerr AG	4,032,792	0.52
256,774	Infineon Technologies	11,902,060	1.55
83,226	Siemens Healthineers	6,229,509	0.81
	Total Germany	27,326,581	3.55
	Ireland: 1.63% (2020: Nil)		
110,958	Seagate Technology	12,536,035	1.63
	Total Ireland	12,536,035	1.63
	Italy: 0.75% (2020: 0.63%)		
405,341	Brembo	5,775,752	0.75
	Total Italy	5,775,752	0.75
	Japan: 16.70% (2020: 19.94%)		
79,700	Daifuku	6,505,840	0.85
46,700	FANUC	9,887,074	1.29
155,650	Fuji Machine Manufacturing	3,489,977	0.45
129,300	Hamamatsu Photonics	8,241,605	1.07
95,450	Harmonic Drive Systems	4,028,370	0.52
106,800	Ноуа	15,868,595	2.06
25,200	Keyence	15,817,429	2.06
237,300	Shima Seiki Manufacturing	4,069,884	0.53
100,200	Shin-Etsu Chemical	17,333,021	2.26
38,700	Sysmex Corp	5,225,869	0.68
214,400	TDK	8,359,654	1.09
33,924	Tokyo Electron	19,525,706	2.54
82,800	Toyota Industries	6,607,894	0.86
105,700	Zuken	3,396,205	0.44
	Total Japan	128,357,123	16.70

# Automation & Artificial Intelligence Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 97.99% (2020: 96.73%) continued		
	Jersey: 0.71% (2020: (0.54%))		
1,766,624	Man Group plc	5,441,236	0.71
	Total Jersey	5,441,236	0.71
	Luxembourg: Nil (2020: 1.25%)		
	Netherlands: 2.22% (2020: 3.58%)		
16,554	ASML	13,303,777	1.73
79,859	Corbion	3,763,401	0.49
	Total Netherlands	17,067,178	2.22
	People's Republic of China: 2.03% (2020: 1.84%)		
455,500	BYD Company	15,576,145	2.03
	Total People's Republic of China	15,576,145	2.03
	Republic of South Korea: 1.12% (2020: 1.44%)		
13,250	NAVER	4,218,822	0.55
26,594	Samsung Electro-Mechanics	4,418,351	0.57
	Total Republic of South Korea	8,637,173	1.12
	Sweden: 5.68% (2020: 3.18%)		
273,074	Atlas Copco	18,874,811	2.45
625,763	Epiroc AB	15,841,314	2.06
321,162	Sandvik AB	8,960,334	1.17
	Total Sweden	43,676,459	5.68
	Switzerland: 0.96% (2020: 1.63%)		
1,406	Givaudan	7,394,559	0.96
	Total Switzerland	7,394,559	0.96
	Taiwan: 6.57% (2020: 5.62%)		
244,000	eMemory Technology	19,313,984	2.51
252,000	MediaTek	10,838,906	1.41
914,000	Taiwan Semiconductor Manufacturing	20,316,984	2.65
	Total Taiwan	50,469,874	6.57
	United Kingdom: 2.21% (2020: 2.48%)		
370,819	RELX	12,064,185	1.57
76,193	Renishaw	4,932,942	0.64
	Total United Kingdom	16,997,127	2.21

23,469 137,156 37,572	Equities: 97.99% (2020: 96.73%) continuedUnited States: 50.73% (2020: 47.44%)10x GenomicsAdvanced Micro DevicesAirbnb Inc.AlphabetAmazon.com	3,495,942 19,736,748 6,255,362 31,230,091	0.45 2.57
137,156	10x Genomics       Advanced Micro Devices       Airbnb Inc.       Alphabet	19,736,748 6,255,362	2.57
137,156	Advanced Micro Devices Airbnb Inc. Alphabet	19,736,748 6,255,362	2.57
	Airbnb Inc. Alphabet	6,255,362	
37,572	Alphabet		0.01
		31.230.091	0.81
10,780	Amazon.com	0.1200,001	4.06
8,373		27,918,429	3.63
75,208	Analog Devices	13,219,310	1.72
10,387	Ansys Inc	4,166,433	0.54
21,990	Block Inc	3,551,605	0.46
86,380	Cognex	6,716,909	0.87
21,152	DexCom Inc	11,357,566	1.48
47,276	Dolby Laboratories	4,501,621	0.59
165,812	Emerson Electric	15,415,542	2.01
23,442	Guardant Health	2,344,669	0.31
22,077	Intuitive Surgical	7,932,266	1.03
31,632	KLA Corp	13,605,240	1.77
17,405	Littelfuse	5,477,005	0.71
13,544	Masimo Corporation	3,965,412	0.52
27,274	Mastercard	9,800,094	1.27
4,399	MercadoLibre	5,931,612	0.77
12,228	Meta Platforms	4,112,888	0.53
171,482	Micron Technology	15,973,548	2.08
107,996	Microsoft	36,321,215	4.72
18,216	Netflix	10,974,047	1.43
120,194	NVIDIA	35,350,257	4.60
10,300	PayPal	1,942,374	0.25
67,058	Qualcomm	12,262,896	1.60
55,142	Rockwell Automation	19,236,287	2.50
226,452	Snap	10,650,038	1.39
23,558	Thermo Fisher Scientific	15,718,840	2.04
45,501	UnitedHealth Group Inc	22,847,872	2.97
41,279	Unity Software Inc	5,902,484	0.77
14,046	Upstart	2,125,160	0.28
	Total United States	390,039,762	50.73
	Total Equities	753,389,515	97.99
	Total Transferable Securities	753,389,515	97.99

#### Portfolio Statements continued As at 31 December 2021

# Automation & Artificial Intelligence Fund continued

Open Forward C	Open Forward Currency Contracts: Nil (2020: Nil)					
Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain US	% of Net Assets	
USD 100,879	GBP 75,253	1.3405	04/01/2022	1,047	_	
USD 29,055	EUR 25,684	1.1313	04/01/2022	152	_	
USD 6,901	GBP 5,148	1.3405	04/01/2022	72	-	
USD 586	GBP 437	1.3401	04/01/2022	6	_	
USD 327	EUR 289	1.1311	04/01/2022	2	_	
USD 1	GBP 1	1.3333	04/01/2022	_	_	
Total unrealised	gain on forward f	oreign currency co	ntracts	1,279	0.00	
Total Financial A	ssets at fair value	through profit or l	055	753,390,794	97.99	

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 506,863,383)	753,390,794	97.99
Cash at Bank	17,264,656	2.25
Other Net Liabilities	(1,826,143)	(0.24)
Net Assets Attributable to Holders of Redeemable Participating Shares	768,829,307	100.00

All securities are transferable and are admitted to an official stock exchange or dealt on a regulated market at year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	96.91	92.83
Other assets	3.09	7.17
	100.00	100.00

# **Biotechnology Fund**

Haldinga	Financial and the fair value through mustiting lass	Fair Value	% of
Holdings	Financial assets at fair value through profit or loss Equities: 99.67% (2020: 92.76%)	US\$	Net Assets
	Diagnostic Equipment: 0.06% (2020: 1.57%)		
1,500,000	Verici Dx	1,076,788	0.06
1,300,000	Total Diagnostic Equipment	1,076,788	0.06
		1,070,788	0.00
	Diagnostic Kits: 1.01% (2020: 1.20%)		
30,000,000	C4X Discovery	17,269,239	1.01
	Total Diagnostic Kits	17,269,239	1.01
	Diversified Operations: 2.17% (2020: 3.26%)		
13,190,948	Synairgen	37,162,280	2.17
	Total Diversified Operations	37,162,280	2.17
	Medical Labs & Testing Services: 3.52% (2020: 2.95%)		
1,250,000	Evotec	60,413,757	3.52
1,230,000	Total Medical Labs & Testing Services	60,413,757	3.52
		00,413,737	5.52
	Medical Products: 3.63% (2020: 2.13%)		
1,050,000	NanoString Technologies	44,341,500	2.59
2,118,100	Renalytix	17,786,937	1.04
	Total Medical Products	62,128,437	3.63
	Medical-Biomedical/Gene: 66.46% (2020: 71.82%)		
1,500,000	Adicet Bio	26,235,000	1.53
1,000,000	Akoya Biosciences	15,310,000	0.89
375,000	Alnylam Pharmaceuticals	63,592,500	3.71
1,500,000	Arcutis Biotherapeutics	31,110,000	1.82
150,000	Argenx	53,783,880	3.14
675,000	Bavarian Nordic	27,742,059	1.62
2,000,000	BELLUS Health	16,100,000	0.94
150,000	Biogen	35,988,000	2.10
525,000	Biohaven Pharmaceutical	72,350,250	4.22
125,000	BioMarin Pharmaceutical	11,043,750	0.64
250,000	Blueprint Medicines	26,777,500	1.56
750,000	Calliditas Therapeutics	9,344,091	0.55
1,000,000	Celldex Therapeutics	38,640,000	2.25
750,000	Cerevel Therapeutics	24,315,000	1.42
20,000,000	Diurnal	15,440,731	0.90
3,750,000	Exelixis	68,550,000	4.00
150,000	Genmab	60,318,795	3.52
750,000	Global Blood Therapeutics	21,952,500	1.28



# Biotechnology Fund continued

		Fair Value	% of
Holdings	Financial assets at fair value through profit or loss	US\$	Net Assets
	Equities: 99.67% (2020: 92.76%) continued		
006 100	Medical-Biomedical/Gene: 66.46% (2020: 71.82%) continued	4 000 014	0.20
906,133	Heidelberg Pharma AG	4,899,811	0.29
425,000	Incyte	31,195,000	1.82
5,000,000	Infinity Pharmaceuticals	11,250,000	0.66
1,750,000	Insmed	47,670,000	2.78
1,000,000	Inventiva SA	13,350,730	0.78
170,000	Regeneron Pharmaceuticals	107,358,400	6.26
425,000	Seagen	65,705,000	3.83
150,000	United Therapeutics	32,412,000	1.89
2,000,000	Valneva	55,722,806	3.25
375,000	Vertex Pharmaceuticals	82,350,000	4.81
1,000,000	Xenon Pharmaceuticals	31,240,000	1.82
1,000,000	Y-mAbs Therapeutics	16,210,000	0.95
250,000	Zentalis Pharmaceuticals	21,015,000	1.23
	Total Medical-Biomedical/Gene	1,138,972,803	66.46
	Medical-Drugs: 22.82% (2020: 9.83%)		
1,000,000	AstraZeneca	117,539,181	6.86
750,000	Bristol-Myers Squibb	46,762,500	2.73
750,000	Cytokinetics	34,185,000	1.99
500,000	Fulcrum Therapeutics	8,845,000	0.52
550,000	Horizon Therapeutics	59,268,000	3.46
350,000	Jazz Pharma Plc	44,590,000	2.60
325,000	Morphic Holding	15,398,500	0.90
6,117,911	Summit Therapeutics	16,457,181	0.96
500,000	Supernus Pharmaceuticals	14,580,000	0.85
250,000	UCB	28,529,508	1.66
225,000	Zealand Pharma	4,991,782	0.29
	Total Medical-Drugs	391,146,652	22.82
	Total Equities	1,708,169,956	99.67
	Warrants: 0.22% (2020: Nil)		
19,000,000	Wts. C4X Discovery 31-Dec-2040	3,731,510	0.22
	Total Warrants	3,731,510	0.22
	Total Transferable Securities	1,711,901,466	99.89

#### Open Forward Currency Contracts: 0.21% (2020: 0.02%) **Unrealised Gain** % of **Currency Sold Currency Bought Currency Rate Maturity Date** US\$ Net Assets USD 142,273,318 GBP 107,601,606 1.3222 31/01/2022 3,460,363 0.20 USD 7,497,800 GBP 5,669,718 31/01/2022 0.01 1.3224 181,165 USD 233,554 GBP 174,211 05/01/2022 1.3406 2,406 \_ USD 103,505 GBP 77,548 04/01/2022 1.3347 1,530 USD 209,727 EUR 185,205 04/01/2022 1.1324 888 \_ USD 157,496 EUR 139,213 05/01/2022 1.1313 816 \_ USD 222,361 GBP 164,758 1.3496 31/01/2022 784 \_ USD 23,850 GBP 17,790 1.3406 05/01/2022 246 USD 11,736 GBP 8,792 1.3348 04/01/2022 173 USD 11,542 GBP 8,647 04/01/2022 1.3347 171 \_ 31/01/2022 GBP 10,000 USD 13,409 1.3409 135 \_ USD 28,729 EUR 25,370 1.1324 04/01/2022 122 USD 2,906 GBP 2,198 1.3221 31/01/2022 71 USD 10,689 GBP 7,920 1.3496 31/01/2022 38 USD 942 GBP 712 1.3233 31/01/2022 22 05/01/2022 USD 4,113 EUR 3,635 1.1313 21 \_ USD 1,502 GBP 1,121 05/01/2022 1.3402 16 \_ USD 1,968 EUR 1,740 1.1313 05/01/2022 10 USD 1,029 GBP 768 1.3409 05/01/2022 10 USD 616 GBP 462 1.3348 31/01/2022 9 USD 1,071 EUR 946 1.1324 04/01/2022 4 USD 206 GBP 153 04/01/2022 2 1.3411 \_ USD 134 GBP 101 04/01/2022 2 1.3348 \_ USD 161 GBP 120 1.3402 05/01/2022 2 USD 145 EUR 128 1.1324 04/01/2022 1 USD 5 GBP 3 1.3217 31/01/2022 USD 51 EUR 45 1.1314 05/01/2022 \_ USD – 04/01/2022 GBP -1.0000 \_ \_ USD 11 GBP 8 1.3414 05/01/2022 \_ \_ Total unrealised gain on forward foreign currency contracts 3,649,007 0.21 Total Financial Assets at fair value through profit or loss 1,715,550,473 100.10

Financial assets at fair value through profit or loss

Portfolio Statements continued As at 31 December 2021

## Biotechnology Fund continued

Open Forward O	Currency Contracts:	Nil (2020: Nil)			
Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss US\$	% of Net Assets
EUR 265,161	USD 299,969	1.1313	04/01/2022	(1,572)	-
EUR 126,903	USD 143,561	1.1313	04/01/2022	(753)	-
GBP 52,361	USD 70,192	1.3405	04/01/2022	(729)	-
GBP 15,000	USD 20,108	1.3405	04/01/2022	(209)	_
GBP 8,792	USD 11,736	1.3348	31/01/2022	(172)	_
GBP 10,000	USD 13,408	1.3408	04/01/2022	(136)	_
GBP 1,421	USD 1,878	1.3221	31/01/2022	(46)	_
EUR 2,726	USD 3,083	1.1311	04/01/2022	(17)	_
GBP 432	USD 571	1.3234	31/01/2022	(13)	_
GBP 768	USD 1,029	1.3409	31/01/2022	(10)	_
GBP 1,302	USD 1,757	1.3496	31/01/2022	(6)	_
GBP 101	USD 134	1.3348	31/01/2022	(2)	_
GBP 5	USD 6	1.3262	31/01/2022	_	-
GBP 4	USD 5	1.3223	31/01/2022	_	-
GBP 8	USD 11	1.3414	31/01/2022	_	_
EUR 7	USD 7	1.1318	04/01/2022	_	-
Total unrealised	l loss on forward fo	reign currency coi	ntracts	(3,665)	-

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 1,623,369,783)	1,715,546,808	100.10
Cash at Bank	10,138,766	0.59
Other Net Liabilities	(11,781,475)	(0.69)
Net Assets Attributable to Holders of Redeemable Participating Shares	1,713,904,099	100.00

All securities are transferable and are admitted to an official stock exchange or dealt on a regulated market at year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	98.82	91.20
OTC Financial derivative instruments	0.21	0.02
Other assets	0.97	8.78
	100.00	100.00

### **China Stars Fund**

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 95.21% (2020: 95.21%)		
	Communications: 27.70% (2020: 29.17%)		
7,905	51job ADR	386,792	1.94
6,345	Alibaba ADR	753,723	3.77
42,200	Alibaba Group	643,585	3.22
6,945	iQIYI ADR	31,669	0.16
8,160	JD.com Inc	571,771	2.86
7,656	Kuaishou Technology	70,753	0.36
22,000	Meituan Dianping Class B	636,045	3.18
3,000	NetEase	60,606	0.30
84,282	Phoenix New Media ADR	72,651	0.36
3,908	Prosus	326,780	1.64
33,800	Tencent	1,980,406	9.91
	Total Communications	5,534,781	27.70
	Consumer Discretionary: 1.25% (2020: Nil)		
7,100	JD.com Inc Class A	249,529	1.25
	Total Consumer Discretionary	249,529	1.25
	Consumer, Cyclical: 13.68% (2020: 12.47%)		
22,500	BYD	769,403	3.85
104,000	China Meidong Auto	536,254	2.68
74,600	Gree Electric Appliancesof Zhuhai	434,411	2.17
54,800	Haier Smart Home	231,605	1.16
15,700	Mango Excellent Media Co Ltd	141,272	0.71
42,500	Midea	493,301	2.47
62,400	Samsonite International	126,780	0.64
	Total Consumer, Cyclical	2,733,026	13.68
	Consumer, Non-cyclical: 16.12% (2020: 18.13%)		
18,600	Centre Testing International	78,594	0.39
64,776	China Building Material Test & Certification	196,598	0.98
809,292	China Foods	316,604	1.58
124,576	China Resources Sanjiu Medical & Pharmaceutical	670,774	3.36
9,410	Foshan Haitian Flavouring & Food	155,540	0.78
40,786	Jiangsu Hengrui Medicine	325,246	1.63
440,000	ManpowerGreater China	506,805	2.54
125,001	Microport Cardioflow Medtech	62,049	0.31
56,500	Venus MedTech (HangZhou) Inc	214,512	1.07
26,800	Yunnan Baiyao	441,044	2.21
335,500	Zhou Hei Ya International Holdings Co Ltd	253,035	1.27
	Total Consumer, Non-cyclical	3,220,801	16.12



### China Stars Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 95.21% (2020: 95.21%) continued		
	Energy: 0.46% (2020: Nil)		
1,000	Contemporary Amperex Technology Co Ltd	92,467	0.46
	Total Energy	92,467	0.46
	Financial: 14.05% (2020: 17.74%)		
150,355	Binjiang Service Group Co Ltd	422,351	2.12
1,409,000	China Construction Bank	975,925	4.89
20,700	China Merchants Bank Class A	158,561	0.79
18,500	China Merchants Bank Class H	143,680	0.72
5,200	Hong Kong Exchanges & Clearing	303,744	1.52
107,000	Longfor	503,688	2.52
24,500	Ping An Insurance Groupof China Class A	194,218	0.97
14,500	Ping An Insurance Groupof China Class H	104,431	0.52
	Total Financial	2,806,598	14.05
	Industrial: 9.00% (2020: 5.32%)		
1,848,000	China State Construction Development	379,257	1.90
7,500	Guangdong Kinlong Hardware Products	214,171	1.07
41,000	Hainan Meilan International Airport Co Ltd	126,477	0.63
24,300	Hefei Meiya Optoelectronic Technology	143,147	0.72
33,400	S.F. Holding Co Ltd	361,992	1.81
34,650	Shenzhen Inovance Technology	373,796	1.87
598,000	Xin Point	199,428	1.00
	Total Industrial	1,798,268	9.00
	Participatory Notes: 3.28% (2020: Nil)		
5,127	CLSA Global Market	140,424	0.70
6,410	CLSA OPT Machine Vision Tech	283,793	1.42
28,923	Zhejiang Heda Technology Co Ltd	230,536	1.16
	Total Participatory Notes	654,753	3.28
	Real Estate: 1.12% (2020: Nil)		
11,137	KE Holdings Inc	224,076	1.12
	Total Real Estate	224,076	1.12

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 95.21% (2020: 95.21%) continued		
	Technology: 8.55% (2020: 12.38%)		
1,504	Agora Inc	24,380	0.12
3,952	Bilibili ADR	183,373	0.92
94,250	Dadi Early-Childhood Education	497,361	2.49
29,188	Glodon	293,668	1.47
2,000	MediaTek Inc	86,023	0.43
4,371	NetEase ADR	444,880	2.23
8,000	Taiwan Semiconductor Manufacturing	177,829	0.89
	Total Technology	1,707,514	8.55
	Total Equities	19,021,813	95.21
	Total Transferable Securities	19,021,813	95.21

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 20,200,184)	19,021,813	95.21
Cash at Bank	986,829	4.94
Margin Cash	6,461	0.03
Other Net Liabilities	(35,774)	(0.18)
Net Assets Attributable to Holders of Redeemable Participating Shares	19,979,329	100.00

All securities are transferable and are admitted to an official stock exchange or dealt on a regulated market at year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	95.00	93.00
Other assets	5.00	7.00
	100.00	100.00



## Emerging Markets Income Fund\*

\* The Fund was merged with the Emerging Markets Stars Fund on 8 June 2021. There were no investments held by the Fund on the last valuation day of the reporting period.

# **Emerging Markets Stars Fund**

Holdings	Financial assets at fair value through profit or loss	Fair Value US <b>\$</b>	% of Net Assets
Tiolalitys	Equities: 98.50% (2020: 97.94%)		Netrosets
	Bermuda: 0.64% (2020: 1.14%)		
9,724,000	Alibaba Health Information Technology	8,219,432	0.64
	Total Bermuda	8,219,432	0.64
	Brazil: 0.89% (2020: 1.25%)		
2,025,100	Americanas SA	11,481,626	0.89
	Total Brazil	11,481,626	0.89
	Canada: 3.06% (2020: 2.23%)		
4,821,982	Ivanhoe Mines	39,395,839	3.06
	Total Canada	39,395,839	3.06
	Cayman Islands: 21.46% (2020: 29.90%)		
3,119,692	Alibaba Group Holdings	47,577,874	3.69
448,963	Arco Platform	9,378,837	0.73
176,105	Bilibili ADR	8,100,157	0.63
1,846,250	JD Health International	14,552,039	1.13
933,626	JD.Com Inc	32,812,170	2.55
2,871,000	Longfor	13,514,834	1.05
1,027,700	Meituan Dianping	29,711,989	2.30
154,494	Sea ADR	34,561,853	2.68
1,472,400	Tencent	86,270,708	6.70
	Total Cayman Islands	276,480,461	21.46
	Cyprus: 0.81% (2020: Nil)		
124,029	TCS Group GDR	10,458,125	0.81
	Total Cyprus	10,458,125	0.81
	Hong Kong: 1.08% (2020: 1.06%)		
1,387,600	AIA	13,989,374	1.08
	Total Hong Kong	13,989,374	1.08

Portfolio Statements continued As at 31 December 2021

# Emerging Markets Stars Fund continued

the fellowing	The state of the s	Fair Value	% of
Holdings	Financial assets at fair value through profit or loss Equities: 98.50% (2020: 97.94%) continued	US\$	Net Assets
	India: 18.53% (2020: 12.93%)		
337,788	Apollo Hospitals	22,781,349	1.77
296,262	Coforge Ltd	23,475,773	1.77
137,017	Dixon Technologies	10,155,316	0.79
714,401	Housing Development Finance	24,857,016	1.93
4,047,716	ICICI Bank	40,302,560	3.13
	ICICI Balik ICICI Prudential Life Insurance		0.85
1,444,945		10,900,896	
131,069	Info Edge	9,832,866	0.76
2,632,270	Phoenix Mills	34,891,835	2.71
3,421,428	Prestige Estates Projects	21,851,197	1.69
1,244,860	Reliance Industries – Restricted	39,658,162	3.08
	Total India	238,706,970	18.53
	Luxembourg: Nil (2020: 0.78%)		
	Netherlands: 0.98% (2020: 2.71%)		
209,361	Yandex	12,666,341	0.98
	Total Netherlands	12,666,341	0.98
	People's Republic of China: 4.66% (2020: 4.45%)		
2,378,000	Ping An Insurance	17,126,675	1.33
1,263,334	Shenzhen Inovance Technology	13,628,563	1.06
807,715	Sungrow Power Supply	18,519,252	1.44
2,835,000	Venus MedTech (HangZhou) Inc	10,763,567	0.83
	Total People's Republic of China	60,038,057	4.66
	Republic of South Korea: 18.65% (2020: 20.51%)		
51,566	Ecopro BM	21,723,872	1.68
384,191	ITM Semiconductor	13,767,854	1.07
865,304	Koh Young Technology	17,251,487	1.34
99,012	Naver	31,525,587	2.45
1,481,896	Samsung Electronics	97,608,797	7.58
29,258	Samsung SDI	16,121,127	1.25
866,680	Seoul Viosys	9,660,156	0.75
296,363	SK Hynix	32,659,140	2.53

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 98.50% (2020: 97.94%) continued		
	Singapore: 2.05% (2020: 1.00%)		
545,580	Leader Harmonious Drive Systems	14,942,918	1.16
259,245	OPT Machine Vision Tech	11,477,663	0.89
	Total Singapore	26,420,581	2.05
	Taiwan: 18.14% (2020: 13.91%)		
814,000	Andes Technology	15,769,834	1.22
2,344,000	Chroma ATE	16,944,374	1.32
484,000	eMemory Technology	38,311,346	2.97
2,337,000	LandMark Optoelectronics	16,598,131	1.29
903,000	MediaTek	38,839,412	3.02
4,824,000	Taiwan Semiconductor Manufacturing	107,230,997	8.32
	Total Taiwan	233,694,094	18.14
	United States: 4.03% (2020: 2.20%)		
36,664	EPAM Systems	24,508,051	1.90
20,336	MercadoLibre	27,421,062	2.13
	Total United States	51,929,113	4.03
	Vietnam: 2.80% (2020: 3.03%)		
4,824,450	Vietnam Technological & Commercial Joint Stock Bank	10,584,576	0.82
6,742,110	Vincom Retail	8,904,674	0.69
4,595,691	Vinhomes	16,535,615	1.29
	Total Vietnam	36,024,865	2.80
	Virgin Islands: 0.72% (2020: 0.84%)		
1,222,845	Fix Price Group Ltd	9,232,480	0.72
	Total Virgin Islands	9,232,480	0.72
	Total Equities	1,269,055,378	98.50
	Total Transferable Securities	1,269,055,378	98.50

Portfolio Statements continued As at 31 December 2021

# Emerging Markets Stars Fund continued

#### Financial assets at fair value through profit or loss **Open Forward Currency Contracts: Nil (2020: Nil) Unrealised Gain** % of **Currency Sold Currency Bought Currency Rate Maturity Date** US\$ Net Assets USD 173,865 758 SEK 1,581,003 0.1100 04/01/2022 USD 1,643 SEK 14,900 0.1103 04/01/2022 2 \_ Total unrealised gain on forward foreign currency contracts 760 0.00 Total Financial Assets at fair value through profit or loss 1,269,056,138 98.50 Fair Value % of

	US\$	Net Assets
Total Value of Investments (Cost: US\$ 1,235,581,872)	1,269,056,138	98.50
Cash at Bank	25,601,477	1.99
Other Net Liabilities	(6,304,200)	(0.49)
Net Assets Attributable to Holders of Redeemable Participating Shares	1,288,353,415	100.00

All securities are transferable and are admitted to an official stock exchange or dealt on a regulated market at year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	97.87	96.59
Other assets	2.13	3.41
	100.00	100.00

# European ex UK Income Fund

Holdings	Financial assets at fair value through profit or loss	Fair Value EUR€	% of Net Assets
	Equities: 97.44% (2020: 99.34%)		
	Basic Materials: 3.21% (2020: 8.67%)		
114,451	UPM-Kymmene	3,829,530	3.21
	Total Basic Materials	3,829,530	3.21
	Communications: 15.20% (2020: 14.63%)		
160,936	Deutsche Telekom	2,623,257	2.20
1,407,734	Koninklijke KPN	3,843,114	3.23
1,029,942	NOS	3,512,102	2.95
460,083	Orange	4,330,761	3.63
302,739	Telenet	3,795,985	3.19
	Total Communications	18,105,219	15.20
	Consumer, Cyclical: 3.01% (2020: 4.60%)		
125,724	Industria de Diseno Textil	3,586,906	3.01
	Total Consumer, Cyclical	3,586,906	3.01
	Consumer, Non-cyclical: 37.00% (2020: 34.66%)		
69,760	Anheuser-Busch InBev	3,709,139	3.11
81,853	Danone	4,468,355	3.75
41,572	Heineken	4,109,808	3.45
42,464	Nestle	5,222,758	4.39
78,193	Novartis	6,058,268	5.09
16,424	Roche	6,009,052	5.04
63,833	Sanofi	5,654,327	4.75
76,086	Societe BIC	3,600,389	3.02
111,455	Unilever Plc	5,244,515	4.40
	Total Consumer, Non-cyclical	44,076,611	37.00
	Energy: 5.08% (2020: 1.99%)		
135,733	TotalEnergies	6,057,764	5.08
	Total Energy	6,057,764	5.08
	Financial: 17.31% (2020: 16.59%)		
93,717	AXA	2,453,980	2.06
16,313	Muenchener Rueckversicherungs-Gesellschaftin Muenchen	4,249,536	3.57
59,648	Sampo Plc	2,628,091	2.21
136,578	SCOR	3,747,700	3.14
47,605	Swiss Re	4,146,877	3.48
156,666	TRYG	3,401,857	2.85
	Total Financial	20,628,041	17.31

Portfolio Statements continued As at 31 December 2021

## European ex UK Income Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value EUR€	% of Net Assets
	Equities: 97.44% (2020: 99.34%) continued		
	Industrial: 13.56% (2020: 13.75%)		
126,235	Assa Abloy	3,386,361	2.84
200,354	Cia de Distribucion Integral Logista	3,512,206	2.95
53,304	Deutsche Post	3,013,808	2.53
12,419	Siemens	1,896,133	1.59
46,788	Vinci	4,347,073	3.65
	Total Industrial	16,155,581	13.56
	Utilities: 3.07% (2020: 4.45%)		
192,003	Red Electrica	3,652,857	3.07
	Total Utilities	3,652,857	3.07
	Total Equities	116,092,509	97.44
	Warrants: 0.10% (2020: 0.01%)		
123,252	Richemont Financi	118,951	0.10
	Total Warrants	118,951	0.10
	Total Transferable Securities	116,211,460	97.54

#### Financial assets at fair value through profit or loss

```
Open Forward Currency Contracts: 0.02% (2020: 0.45%)
```

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain EUR€	% of Net Assets
EUR 801,003	GBP 684,586	1.1701	31/01/2022	13,968	0.01
EUR 176,187	GBP 150,580	1.1701	31/01/2022	3,072	0.01
EUR 98,787	GBP 84,430	1.1701	31/01/2022	1,723	_
EUR 17,075	GBP 14,500	1.1776	31/01/2022	186	-
EUR 14,808	GBP 12,500	1.1847	31/01/2022	72	_
EUR 14,217	GBP 12,000	1.1848	31/01/2022	68	_
EUR 3,089	GBP 2,640	1.1699	31/01/2022	54	-
EUR 1,571	GBP 1,343	1.1701	31/01/2022	28	_
EUR 6,667	GBP 5,600	1.1905	31/01/2022	_	_
EUR 5,952	GBP 5,000	1.1905	31/01/2022	_	_
Total unrealise	ed gain on forward for	eign currency cont	racts	19,171	0.02
Total Financial	Assets at fair value th	rough profit or los	s	116,230,631	97.56



	Fair Value EUR€	% of Net Assets
Total Value of Investments (Cost: EUR€ 105,517,900)	116,230,631	97.56
Cash at Bank	(2,476,589)	(2.08)
Other Net Assets	5,385,461	4.52
Net Assets Attributable to Holders of Redeemable Participating Shares	119,139,503	100.00

All securities are transferable and are admitted to an official stock exchange or dealt on a regulated market at year end.

The counterparty for the forward foreign currency contracts is The Northern Trust Company.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	95.36	99.04
OTC Financial derivative instruments	0.02	0.45
Other assets	4.62	0.51
	100.00	100.00



# **Financial Opportunities Fund**

		Fair Value	% of
Holdings	Financial assets at fair value through profit or loss	US\$	Net Assets
	Equities: 93.73% (2020: 96.43%)		
C 0 44	Banking: 2.60% (2020: Nil)	244.024	1.02
6,041	Pacific Premier Bancorp	241,821	1.03
3,419	Western Alliance Bancorp	368,055	1.57
	Total Banking	609,876	2.60
	Banks: 53.25% (2020: 57.96%)		
757,300	Bank Central Asia	387,882	1.65
22,347	Bank of America	994,218	4.23
887,000	Bank Rakyat Indonesia Persero	255,785	1.09
6,448	BNP Paribas	445,606	1.90
14,098	Citizens Financial	666,130	2.84
6,383	East West Bancorp	502,214	2.14
7,851	Enterprise Financial Services	369,704	1.57
8,774	Esquire Financial	277,434	1.18
1,101	First Republic Bank	227,368	0.97
30,000	Grupo Financiero Banorte	194,996	0.83
9,786	HDFC Bank ADR	636,775	2.71
23,722	ING Groep	330,248	1.41
160,278	Intesa Sanpaolo SPA	414,478	1.77
71,838	Joint Stock Commercial Bank for Foreign Trade of Vietnam	248,391	1.06
7,998	JPMorgan Chase	1,266,483	5.39
1,436	Macquarie Group	214,447	0.91
46,259	Nordea Bank Abp	564,580	2.40
30,000	Oversea-Chinese Banking	253,681	1.08
8,000	PacWest Bancorp	361,360	1.54
3,108	PNC Financial Services Group	623,216	2.65
7,529	Shinhan Financial	233,074	0.99
1,376	Signature Bank	445,095	1.89
14,100	Sumitomo Mitsui Financial	482,795	2.05
687	SVB Financial	465,951	1.98
1,382	TCS Group GDR	112,955	0.48
8,566	Toronto-Dominion Bank	657,666	2.80
30,514	UBS	549,898	2.34
5,909	Webster Financial	329,959	1.40
	Total Banks	12,512,389	53.25

Holdings	Financial assets at fair value through profit or loss	Fair Value US <b>\$</b>	% of Net Assets
	Equities: 93.73% (2020: 96.43%) continued		
	Commercial Services: 4.90% (2020: 4.17%)		
18,403	Allfunds	361,969	1.54
2,435	PayPal	459,192	1.95
700	S&P Global	330,351	1.41
	Total Commercial Services	1,151,512	4.90
	Common Stock: 0.67% (2020: 1.88%)		
194,444	Atom Bank	158,019	0.67
	Total Common Stock	158,019	0.67
	Diversified Financial Services: 10.34% (2020: 15.89%)		
4,382	Banca Generali	193,099	0.82
22,164	Chailease	211,090	0.90
4,400	Hong Kong Exchanges & Clearing	257,014	1.09
10,966	Housing Development Finance	381,553	1.62
111,998	Manappuram Finance	247,995	1.06
1,333	Mastercard	478,974	2.04
68,973	Pensionbee	124,903	0.53
127,800	Srisawad PCL	236,242	1.00
104,400	Tisco Financial	300,027	1.28
	Total Diversified Financial Services	2,430,897	10.34
	Financial: 6.92% (2020: Nil)		
76,751	HSBC	466,396	1.99
96,580	Natwest	295,245	1.26
72,015	OSB	540,863	2.30
53,173	Standard Chartered	322,938	1.37
	Total Financial	1,625,442	6.92
	Financial Services: 3.11% (2020: Nil)		
16,525	Gresham House	201,441	0.86
4,733	Morgan Stanley	464,591	1.98
95,923	VEF AB	64,098	0.27
	Total Financial Services	730,130	3.11
	Insurance: Nil (2020: 1.95%)	-	-
	Internet: 0.39% (2020: 1.08%)		
6,000	Alibaba Group Holdings	91,505	0.39
	Total Internet	91,505	0.39

Portfolio Statements continued As at 31 December 2021

# Financial Opportunities Fund continued

		Fair Value	% of
Holdings	Financial assets at fair value through profit or loss	US\$	Net Assets
	Equities: 93.73% (2020: 96.43%) continued		
	Life/Health Insurance: 1.73% (2020: 4.77%)		
40,209	AIA	405,376	1.73
	Total Life/Health Insurance	405,376	1.73
	Multi-line Insurance: 3.86% (2020: 1.96%)		
3,079	Chubb	595,202	2.53
6,242	Sampo Plc	312,755	1.33
	Total Multi-line Insurance	907,957	3.86
	Private Equity: 1.45% (2020: 1.75%)		
2,631	Blackstone Group	340,425	1.45
	Total Private Equity	340,425	1.45
	Property/Casualty Insurance: 4.29% (2020: 5.02%)		
14,766	Arch Capital	656,349	2.79
48,946	Lancashire	351,363	1.50
	Total Property/Casualty Insurance	1,007,712	4.29
	Software & Tech Services: 0.22% (2020: Nil)		
2,898	One 97 Communications	52,028	0.22
	Total Software & Tech Services	52,028	0.22
	Total Equities	22,023,268	93.73
	Total Transferable Securities	22,023,268	93.73

#### Financial assets at fair value through profit or loss

Open Forward Currency Contracts: Nil (2020: Nil)

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain US\$	% of Net Assets
USD 10,794	GBP 8,052	1.3405	04/01/2022	112	-
USD 25	GBP 19	1.3399	04/01/2022	_	-
USD 1	GBP 1	1.3367	04/01/2022	_	_
Total unrealised g	ain on forward fore	ign currency conti	acts	112	0.00
Total Financial Assets at fair value through profit or loss				22,023,380	93.73

Fair Value % of US\$ Net Assets Total Value of Investments (Cost: US\$ 20,948,411) 22,023,380 93.73 Cash at Bank 1,447,277 6.16 Other Net Assets 26,105 0.11 Net Assets Attributable to Holders of Redeemable Participating Shares 23,496,762 100.00

All securities are transferable and are admitted to an official stock exchange or dealt on a regulated market at year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	93.53	96.12
Other assets	6.47	3.88
	100.00	100.00

Portfolio Statements continued As at 31 December 2021

#### **Global Absolute Return Fund**

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Corporate Bonds: 119.83% (2020: 109.65%)		
	Australia: Nil (2020: 1.86%)	-	-
	Belgium: 3.21% (2020: Nil)		
2,000,000	Umicore 0.000% 23/06/2025	2,256,269	3.21
	Total Belgium	2,256,269	3.21
	Canada: 0.48% (2020: 0.89%)		
250,000	Ivanhoe Mines 2.500% 15/04/2026	336,250	0.48
	Total Canada	336,250	0.48
	Cayman Islands: Nil (2020: 6.54%)	_	_
	France: Nil (2020: 4.13%)	-	-
	Germany: Nil (2020: 14.98%)	-	-
	Israel: 3.02% (2020: 3.86%)		
2,000,000	Camtek 0.000% 01/12/2026	2,125,000	3.02
	Total Israel	2,125,000	3.02
	Japan: 3.19% (2020: 1.12%)		
100,000,000	Nippon Steel Class A 0.000% 04/10/2024	892,276	1.27
150,000,000	Nippon Steel Class B 0.000% 05/10/2026	1,354,044	1.92
	Total Japan	2,246,320	3.19
	Liberia: Nil (2020: 2.55%)	-	-
	Luxembourg: 1.59% (2020: 1.75%)		
15,000	ArcelorMittal 5.500% 18/05/2023	1,115,400	1.59
	Total Luxembourg	1,115,400	1.59
	Netherlands: 12.53% (2020: 7.97%)		
1,300,000	Basic-Fit 1.500% 17/06/2028	1,601,713	2.28
2,000,000	Dufry One 0.750% 30/03/2026	2,088,821	2.97
2,000,000	Mondelez International 0.000% 20/09/2024	2,378,511	3.38
2,000,000	QIAGEN 0.500% 13/09/2023	2,745,618	3.90
	Total Netherlands	8,814,663	12.53
	People's Republic of China: 2.13% (2020: Nil)		
10,000,000	China Conch Venture International 0.000% 05/09/2023	1,494,299	2.13
	Total People's Republic of China	1,494,299	2.13
	Spain: 6.05% (2020: Nil)		
1,000,000	Cellnex Telecom 0.500% 05/07/2028	1,522,688	2.16
2,600,000	International Consolidated Airlines 1.125% 18/05/2028	2,732,630	3.89
	Total Spain	4,255,318	6.05

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Corporate Bonds: 119.83% (2020: 109.65%) continued		
	United Kingdom: 10.71% (2020: 2.20%)		
2,000,000	BP Capital Markets 1.000% 28/04/2023	2,768,295	3.93
1,000,000	Capital & Counties Properties 2.000% 30/03/2026	1,426,442	2.03
2,500,000	JET2 1.625% 10/06/2026	3,338,177	4.75
	Total United Kingdom	7,532,914	10.71
	United States: 76.92% (2020: 57.40%)		
1,150,000	2U 2.250% 01/05/2025	1,221,660	1.74
800,000	3D Systems % 15/11/2026	764,000	1.09
3,500,000	Array Technologies 1.000% 01/12/2028	3,326,750	4.73
1,000,000	Bandwidth 0.250% 01/03/2026	1,063,000	1.51
3,500,000	BigBear.ai 6.000% 15/12/2026	3,342,500	4.75
1,750,000	Chegg 0.125% 15/03/2025	1,732,500	2.46
1,800,000	Coinbase Global 0.500% 01/06/2026	1,935,900	2.75
1,500,000	Cryoport 0.750% 01/12/2026	1,385,973	1.97
2,500,000	CSG Systems International 4.250% 15/03/2036	2,654,688	3.78
1,500,000	Dexcom 0.250% 15/11/2025	1,787,813	2.54
5,000,000	Global Blood Therapeutics 1.875% 15/12/2028	5,825,000	8.28
750,000	Guardant Health 0.000% 15/11/2027	762,450	1.08
1,000,000	Live Nation Entertainment 2.500% 15/03/2023	1,810,000	2.57
3,500,000	MGP Ingredients 1.875% 15/11/2041	4,009,600	5.70
2,250,000	MP Materials 0.250% 01/04/2026	2,851,875	4.06
4,000,000	Nutanix 0.250% 01/10/2027	3,660,000	5.20
1,500,000	Perficient 0.125% 15/11/2026	1,426,963	2.03
1,000,000	Pioneer Natural Resources 0.250% 15/05/2025	1,786,875	2.54
1,500,000	Shift4 Payments 0.500% 01/08/2027	1,324,650	1.88
2,500,000	SoFi Technologies 0.000% 15/10/2026	2,593,875	3.69
1,500,000	Stride 1.125% 01/09/2027	1,466,808	2.09
2,500,000	Veritone One 1.750% 15/11/2026	2,397,661	3.41
3,000,000	Vertex Energy 6.250% 01/10/2027	3,168,228	4.51
1,500,000	Zendesk 0.625% 15/06/2025	1,797,150	2.56
	Total United States	54,095,919	76.92
	Virgin Islands: Nil (2020: 4.40%)	-	-
	Total Corporate Bonds	84,272,352	119.83
	Total Transferable Securities	84,272,352	119.83



### Global Absolute Return Fund continued

Holdings	Financial assets at fair value through profit or loss	Unrealised Gain US\$	% of Net Assets
	Contracts for Difference (on Equities) – Unrealised Gains: 0.48% (2020: 0.38%	()	
	Australia: Nil (2020: 0.05%)	-	-
	Cayman Islands: Nil (2020: 0.12%)	-	-
	Germany: Nil (2020: 0.01%)	-	-
	Liberia: Nil (2020: 0.04%)	-	-
	United States: 0.48% (2020: 0.16%)		
(111,000)	Array Technologies	61,050	0.09
(6,250)	Bandwidth	17,250	0.02
(1,700)	Dexcom	49,215	0.07
(92,500)	GBL. Blood Therapeutics	172,975	0.25
(3,100)	Guardant Health	3,131	_
904	Illumina	886	_
(30,752)	MGP Ingredients	31,060	0.04
(8,412)	Zendesk	3,785	0.01
	Total United States	339,352	0.48
	Total Contracts for Difference (on Equities) – Unrealised Gains	339,352	0.48

#### Financial assets at fair value through profit or loss

Open Forward Currency Contracts: 1.34% (2020: 1.88%)

				Unrealised Gain	% of
Currency Sold	Currency Bought	Currency Rate	Maturity Date	US\$	Net Assets
USD 32,266,700	GBP 24,403,372	1.3222	31/01/2022	784,789	1.12
USD 5,606,475	GBP 4,240,189	1.3222	31/01/2022	136,360	0.20
USD 2,299,508	EUR 2,034,956	1.1300	31/01/2022	15,657	0.02
USD 243,903	EUR 215,842	1.1300	31/01/2022	1,661	_
USD 3,874	GBP 2,903	1.3348	31/01/2022	57	_
USD 1,542	GBP 1,165	1.3234	31/01/2022	36	_
USD 1,637	GBP 1,226	1.3348	04/01/2022	24	_
USD 39	GBP 30	1.3224	31/01/2022	1	_
USD 2	GBP 2	1.3333	31/01/2022	-	_
USD 1	GBP 1	1.3284	04/01/2022	_	_
USD 3	GBP 3	1.3242	31/01/2022	_	_
Total unrealised g	ain on forward fore	ign currency conti	racts	938,585	1.34
Total Financial As	sets at fair value thr	ough profit or los	5	85,550,289	121.65

Holdings	Financial liabilities at fair value through profit or loss	Fair Value US <b>\$</b>	% of Net Assets
	Corporate Bonds: (3.26%) (2020: Nil)		
	United States: (3.26%) (2020: Nil)		
(2,000,000)	Illumina	(2,291,250)	(3.26)
	Total United States	(2,291,250)	(3.26)
	Options: (0.66%) (2020: Nil)		
	United States: (0.66%) (2020: Nil)		
5,000,000	CDX CCP 5% 20/12/2026	(459,826)	(0.66)
	Total United States	(459,826)	(0.66)
	Total Corporate Bonds	(2,751,076)	(3.92)
Holdings	Financial liabilities at fair value through profit or loss	Unrealised Loss US\$	% of Net Assets
	Contracts for Difference (on Equities) – Unrealised Losses: (0.92	%) (2020: (8.97%))	
	Belgium: (0.01%) (2020: Nil)		
(18,800)	Umicore	(6,842)	(0.01)
	Total Belgium	(6,842)	(0.01)
	Canada: Nil (2020: Nil)	-	-
	Cayman Islands: Nil (2020: (1.73%))	-	_
	France: Nil (2020: (0.21%))	-	-
	Germany: (0.04%) (2020: (0.51%))		
(42,847)	QIAGEN	(24,915)	(0.04)
	Total Germany	(24,915)	(0.04)
	Hong Kong: Nil (2020: Nil)		
(60,000)	China Conch Venture International	(770)	-
	Total Hong Kong	(770)	-
	Israel: Nil (2020: (0.54%))	-	-
	Japan: Nil (2020: (0.01%))	-	-
	Luxembourg: (0.13%) (2020: Nil)		
(24,000)	ArcelorMittal	(94,134)	(0.13)
	Total Luxembourg	(94,134)	(0.13)
	Netherlands: (0.06%) (2020: (0.05%))		
(8,800)	Basic-Fit	(42,031)	(0.06)
	Total Netherlands	(42,031)	(0.06)



## Global Absolute Return Fund continued

Holdings	Financial liabilities at fair value through profit or loss	Unrealised Loss US\$	% of Net Assets
	Contracts for Difference (on Equities) – Unrealised Losses: (0.92%) (2020: (8.97%)) continued		
	Spain: (0.06%) (2020: Nil)		
(14,400)	Cellnex Telecom	(43,559)	(0.06)
	Total Spain	(43,559)	(0.06)
	Switzerland: Nil (2020: (0.18%))	_	-
	United Kingdom: (0.07%) (2020: Nil)		
(23,423)	JET2	(35,374)	(0.05)
(46,307)	Shaftesbury Reits	(14,112)	(0.02)
	Total United Kingdom	(49,486)	(0.07)
	United States: (0.55%) (2020: (5.74%))		
(20,734)	Camtek	(74,228)	(0.11)
(14,500)	Chegg	(4,350)	(0.01)
(3,150)	Coinbase Global	(14,742)	(0.02)
(7,000)	Cryoport	(7,980)	(0.01)
(30,000)	CSG Systems International	(16,200)	(0.02)
(20,700)	Live Nation	(113,229)	(0.16)
(21,000)	MP Materials	(36,120)	(0.05)
(5,500)	Perficient	(15,125)	(0.02)
(8,630)	Pioneer Natural Resources	(34,088)	(0.05)
(33,849)	SoFi Technologies	(28,433)	(0.04)
(11,304)	Stride	(4,748)	(0.01)
(25,000)	Veritone One	(15,500)	(0.02)
(121,179)	Vertex Energy	(21,812)	(0.03)
	Total United States	(386,555)	(0.55)
	Total Contracts for Difference (on Equities) – Unrealised Losses	(648,292)	(0.92)

#### Financial liabilities at fair value through profit or loss Futures Contracts – Unrealised Losses: (0.23%) (2020: (0.09%)) No. of **Unrealised Loss** % of Description Country Currency Contracts Net Assets US\$ United Kingdom: (0.20%) (2020: Nil) Future IMM GBP Mar22 (139,562) (0.20) UK USD (70) Total United Kingdom (139,562) (0.20) United States: (0.03%) (2020: (0.09%)) Future Euro CME Mar22 USD (20) (0.03) US (22,875) **Total United States** (22,875) (0.03) **Total Futures Contracts – Unrealised Losses** (162,437) (0.23)

#### Open Forward Currency Contracts: Nil (2020: (0.03%))

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss US\$	% of Net Assets
GBP 11,407	USD 15,081	1.3221	31/01/2022	(368)	-
GBP 1,226	USD 1,637	1.3348	31/01/2022	(24)	_
GBP 160	USD 216	1.3496	31/01/2022	(1)	_
GBP 1	USD 1	1.3284	31/01/2022	_	_
Total unrealised	loss on forward fore	eign currency cont	racts	(393)	-
Total Financial Liabilities at fair value through profit or loss				(3,562,198)	(5.07)

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 45,083,116)	81,988,091	116.58
Cash at Bank	(12,015,492)	(17.09)
Margin Cash	711,785	1.01
Other Net Liabilities	(359,000)	(0.50)
Net Assets Attributable to Holders of Redeemable Participating Shares	70,325,384	100.00

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	93.79	92.04
Exchange traded financial derivative instruments	0.39	0.31
OTC Financial derivative instruments	1.07	1.57
Other assets	4.75	6.08
	100.00	100.00

Portfolio Statements continued As at 31 December 2021

### **Global Convertible Fund**

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Corporate Bonds: 91.19% (2020: 98.07%)		
	Belgium: 1.55% (2020: Nil)		
11,500,000	Oliver Capital 0.000% 29/12/2023	16,494,859	1.55
	Total Belgium	16,494,859	1.55
	Bermuda: Nil (2020: 1.94%)	-	_
	Canada: 2.59% (2020: 3.04%)		
12,650,000	Ivanhoe Mines 2.500% 15/04/2026	17,014,250	1.59
8,539,000	SSR Mining 2.500% 01/04/2039	10,647,066	1.00
	Total Canada	27,661,316	2.59
	Cayman Islands: 1.73% (2020: 0.81%)		
18,000,000	Kingsoft 0.625% 29/04/2025	2,769,391	0.26
16,500,000	Meituan 0.000% 27/04/2027	15,662,625	1.47
	Total Cayman Islands	18,432,016	1.73
	Cyprus: Nil (2020: 0.33%)	-	_
	France: 5.48% (2020: 7.38%)		
1,100,000	Electricite de France 0.000% 14/09/2024	17,380,082	1.63
50,000	Engie 0.000% 02/06/2024	5,305,501	0.50
3,000,000	Kering 0.000% 30/09/2022	4,098,749	0.39
31,647	Safran 0.875% 15/05/2027	4,929,665	0.46
25,000	SOITEC 0.000% 01/10/2025	6,976,925	0.65
460,000	Veolia Environnement 0.000% 01/01/2025	19,738,086	1.85
	Total France	58,429,008	5.48
	Germany: 2.58% (2020: 6.34%)		
2,000,000	Delivery Hero 0.875% 15/07/2025	2,206,354	0.21
8,000,000	Deutsche Post 0.050% 30/06/2025	10,878,884	1.02
9,800,000	MorphoSys 0.625% 16/10/2025	8,661,107	0.81
4,600,000	Zalando 0.050% 06/08/2025	5,721,474	0.54
	Total Germany	27,467,819	2.58
	Hong Kong: Nil (2020: 0.67%)	_	-
	India: 0.12% (2020: Nil)		
1,000,000	Bharti Airtel 1.500% 17/02/2025	1,303,500	0.12
	Total India	1,303,500	0.12
	Italy: Nil (2020: 0.49%)	_	_

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Corporate Bonds: 91.19% (2020: 98.07%) continued		
	Japan: 4.22% (2020: 2.22%)		
500,000,000	CyberAgent 0.000% 17/02/2023	5,420,954	0.51
1,700,000,000	DMG Mori 0.000% 16/07/2024	15,703,834	1.47
1,300,000,000	Nippon Steel Class A 0.000% 04/10/2024	11,599,583	1.09
1,200,000,000	SBI 0.000% 25/07/2025	12,322,522	1.15
	Total Japan	45,046,893	4.22
	Luxembourg: 0.47% (2020: 10.57%)		
68,000	ArcelorMittal 5.500% 18/05/2023	5,056,480	0.47
	Total Luxembourg	5,056,480	0.47
	Malaysia: Nil (2020: 1.54%)	-	-
	Maritius: 0.88% (2020: Nil)		
8,800,000	HTA /Mauritius 2.875% 18/03/2027	9,395,772	0.88
	Total Maritius	9,395,772	0.88
	Netherlands: 8.66% (2020: 3.57%)		
9,200,000	Basic-Fit 1.500% 17/06/2028	11,335,200	1.06
41,000,000	Dufry One 0.750% 30/03/2026	42,820,827	4.02
18,000,000	ELM 3.250% 13/06/2024	19,967,400	1.87
7,000,000	STMicroelectronics 0.000% 04/08/2025	9,202,204	0.86
8,000,000	Yandex 0.750% 03/03/2025	9,096,400	0.85
	Total Netherlands	92,422,031	8.66
	New Zealand: Nil (2020: 0.62%)	-	-
	Panama: Nil (2020: 0.49%)	-	_
	People's Republic of China: 2.04% (2020: Nil)		
90,000,000	China Conch Venture International 0.000% 05/09/2023	13,448,687	1.26
10,000,000	Micorport Scientific 0.000% 11/06/2026	8,310,000	0.78
	Total People's Republic of China	21,758,687	2.04
	Republic of South Korea: 1.17% (2020: Nil)		
10,000,000	LG Display 1.500% 22/08/2024	12,505,000	1.17
	Total Republic of South Korea	12,505,000	1.17
	Singapore: Nil (2020: 2.56%)	-	-
	Spain: 3.14% (2020: 2.21%)		
5,800,000	Cellnex Telecom 0.500% 05/07/2028	8,831,587	0.83
23,500,000	International Consolidated Airlines 1.125% 18/05/2028	24,698,774	2.31
	Total Spain	33,530,361	3.14



### Global Convertible Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value US <b>\$</b>	% of Net Assets
Holdings	Corporate Bonds: 91.19% (2020: 98.07%) continued	033	Net Assets
	Switzerland: Nil (2020: 1.51%)	_	_
22.000.000	Taiwan: 3.43% (2020: Nil)	22.640.642	2.22
22,000,000	Globalwafers 0.000% 01/06/2026	23,649,542	2.22
14,000,000	Sea 0.250% 15/09/2026 Total Taiwan	12,941,600	3.43
		36,591,142	5.45
	United Kingdom: 5.43% (2020: 8.81%)		
20,000,000	Capital & Counties Properties 2.000% 30/03/2026	28,528,837	2.68
22,000,000	JET2 1.625% 10/06/2026	29,375,963	2.75
	Total United Kingdom	57,904,800	5.43
	United States: 46.45% (2020: 41.52%)		
19,615,000	Air Transport Services 1.125% 15/10/2024	21,919,763	2.05
10,000,000	Airbnb 0.000% 15/03/2026	9,810,000	0.92
15,000,000	Akamai Technologies 0.375% 01/09/2027	17,616,000	1.65
9,500,000	Array Technologies 1.000% 01/12/2028	9,029,750	0.85
9,000,000	BigBear.ai 6.000% 15/12/2026	8,595,000	0.81
14,000,000	Bill.com 0.000% 01/04/2027	14,385,000	1.35
6,000,000	Blackline 0.000% 15/03/2026	5,604,000	0.52
7,000,000	Block 0.000% 01/05/2026	7,214,249	0.68
15,500,000	Cloudflare 0.000% 15/08/2026	16,555,937	1.55
7,000,000	Coinbase Global 0.500% 01/06/2026	7,528,500	0.71
24,500,000	CSG Systems International 4.250% 15/03/2036	26,015,937	2.44
3,000,000	CyberArk Software 0.000% 15/11/2024	3,795,000	0.36
30,895,000	Dermira 3.000% 15/05/2022	31,227,121	2.93
6,000,000	Dexcom 0.250% 15/11/2025	7,151,250	0.67
17,000,000	DISH Network 0.000% 15/12/2025	17,170,000	1.61
4,500,000	Etsy 0.250% 15/06/2028	5,312,700	0.50
2,200,000	Fiverr International 0.000% 01/11/2025	2,053,700	0.19
13,500,000	Ford Motor 0.000% 15/03/2026	18,638,438	1.75
8,500,000	Global Blood Therapeutics 1.875% 15/12/2028	9,902,500	0.93
5,000,000	Guardant Health 0.000% 15/11/2027	5,083,000	0.48
18,000,000	Ionis Pharmaceuticals 0.000% 01/04/2026	15,919,200	1.49
15,000,000	JPMorgan Chase Bank NA 0.000% 18/02/2024	19,768,086	1.85
13,500,000	JPMorgan Chase Bank NA 0.000% 10/06/2024	17,834,273	1.67
5,500,000	Lumentum 0.500% 15/12/2026	6,868,125	0.64
15,000,000	Marriott Vacations 0.000% 15/01/2026	17,628,605	1.65
20,500,000	MP Materials 0.250% 01/04/2026	25,983,750	2.43
6,000,000	NextEra Energy Partners 0.000% 15/06/2024	6,213,788	0.58
2,500,000	Novocure 0.000% 01/11/2025	2,297,000	0.21

Holdings	Financial assets at fair value through profit or loss	Fair Value US <b>\$</b>	% of Net Assets
	Corporate Bonds: 91.19% (2020: 98.07%) continued		
	United States: 46.45% (2020: 41.52%) continued		
25,010,000	Nutanix 0.250% 01/10/2027	22,884,150	2.14
4,000,000	ON Semiconductor 0.000% 01/05/2027	5,840,000	0.55
3,800,000	Palo Alto Networks 0.375% 01/06/2025	7,217,720	0.68
4,400,000	QIAGEN 1.000% 13/11/2024	5,735,848	0.54
3,142,000	Rapid7 0.250% 15/03/2027	4,065,120	0.38
8,000,000	RingCentral 0.000% 01/03/2025	7,555,680	0.71
8,500,000	Royal Caribbean Cruises 2.875% 15/11/2023	10,055,500	0.94
5,500,000	Shift4 Payments 0.000% 15/12/2025	5,826,700	0.55
9,941,000	Silicon Laboratories 0.625% 15/06/2025	17,477,272	1.64
6,000,000	Snap 0.000% 01/05/2027	5,832,244	0.55
14,000,000	SoFi Technologies 0.000% 15/10/2026	14,525,700	1.36
13,453,000	Supernus Pharmaceuticals 0.625% 01/04/2023	13,326,878	1.25
10,000,000	Vail Resorts 0.000% 01/01/2026	10,707,762	1.00
7,000,000	Vertex Energy 6.250% 01/10/2027	7,392,533	0.69
	Total United States	495,563,779	46.45
	Vietnam: 0.86% (2020: Nil)		
9,000,000	VinJSC 3.000% 20/04/2026	9,132,750	0.86
	Total Vietnam	9,132,750	0.86
	Virgin Islands: 0.39% (2020: 1.45%)		
5,000,000	Viva Biotech Investment Management 1.000% 30/12/2025	4,166,535	0.39
	Total Virgin Islands	4,166,535	0.39
	Total Corporate Bonds	972,862,748	91.19
	Equities: 25.81% (2020: 10.76%)		
	United States: 25.81% (2020: 10.76%)		
100,000	2020 Cash Mandatory Exchangeable Trust	104,521,000	9.80
12,000	2020 Mandatory Exchangeable Trust	16,229,520	1.52
553,452	Change Healthcare	38,891,072	3.65
1,000,000	PG&E	115,680,000	10.84
	Total United States	275,321,592	25.81
	Total Equities	275,321,592	25.81
	Warrants: Nil (2020: Nil)		
	United Kingdom: Nil (2020: Nil)		
5,345,707	Premier Oil	-	-
	Total Warrants	-	-
	Total Transferable Securities	1,248,184,340	117.00



Portfolio Statements continued As at 31 December 2021

### Global Convertible Fund continued

Holdings	Financial assets at fair value through				Unrealised Gain US\$	% of Net Assets
	Contracts for Difference (on Equi Cayman Islands: Nil (2020: 0.01%		ed Gains: 0.51	% (2020: 0.15%)		
		)				
	Germany: 0.01% (2020: 0.14%)					
(5,200)	Delivery Hero				1,649	_
(28,000)	Zalando				111,793	0.01
	Total Germany				113,442	0.01
	Netherlands: 0.06% (2020: Nil)					
(70,000)	Yandex				684,531	0.06
	Total Netherlands				684,531	0.06
	United Kingdom: Nil (2020: Nil)					
(21,103)	Shaftesbury				10,290	_
	Total United Kingdom				10,290	-
	United States: 0.44% (2020: Nil)					
(251,400)	Chewy Class A				2,043,882	0.19
(8,242,500)	PG&E				2,637,600	0.25
	Total United States				4,681,482	0.44
	Total Contracts for Difference (o	n Equities) – U	Inrealised Gai	าร	5,489,745	0.51
	Futures Contracts – Unrealised G	iains: 0.16% (2	020: 0.11%)			
	Description	Country	Currency	No. of Contracts	Unrealised Gain US <b>\$</b>	% of Net Assets
	United States: 0.16% (2020: 0.11%	%)				
	Future Euro CME Mar22	US	USD	1574	1,753,042	0.16
	Total United States				1,753,043	0.16

1,753,043

0.16

**Total Futures Contracts – Unrealised Gains** 

### Financial assets at fair value through profit or loss

Open Forward Currency Contracts: 0.59% (2020: 0.43%)

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain US\$	% of Net Assets
USD 71,779,570	GBP 54,157,810	1.3254	12/01/2022	1,573,979	0.15
USD 55,892,415	GBP 42,272,892	1.3222	31/01/2022	1,361,231	0.13
USD 45,316,544	GBP 34,279,711	1.3220	24/01/2022	1,112,023	0.10
USD 37,964,519	GBP 28,713,557	1.3222	31/01/2022	924,606	0.09
EUR 22,093,887	GBP 18,884,772	1.1372	12/01/2022	451,635	0.04
JPY 774,866,392	GBP 5,187,821	0.0087	12/01/2022	297,540	0.03
EUR 13,372,510	GBP 11,407,714	1.1372	24/01/2022	238,888	0.02
JPY 491,146,198	GBP 3,266,838	0.0087	24/01/2022	159,033	0.02
USD 2,394,728	GBP 1,811,195	1.3222	31/01/2022	58,322	0.01
USD 7,031,759	EUR 6,222,294	1.1301	18/01/2022	45,503	_
USD 1,076,999	GBP 814,562	1.3222	31/01/2022	26,230	_
USD 2,427,763	GBP 1,808,605	1.3423	12/01/2022	21,886	_
JPY 76,029,864	EUR 592,616	0.0087	18/01/2022	13,758	_
USD 1,898,023	EUR 1,679,362	1.1302	31/01/2022	12,584	_
USD 1,055,279	CHF 970,614	1.0872	31/01/2022	10,586	_
USD 1,169,670	GBP 871,360	1.3423	24/01/2022	10,503	-
JPY 20,218,391	GBP 133,477	0.0087	12/01/2022	5,208	_
USD 206,978	GBP 156,324	1.3240	12/01/2022	4,754	_
USD 166,242	GBP 125,485	1.3248	31/01/2022	3,712	-
USD 147,806	GBP 111,384	1.3270	12/01/2022	3,057	_
USD 84,000	GBP 62,932	1.3348	31/01/2022	1,234	_
USD 46,221	GBP 34,954	1.3224	12/01/2022	1,122	-
EUR 60,822	GBP 51,840	1.1372	12/01/2022	1,043	-
USD 42,039	GBP 31,796	1.3222	12/01/2022	1,027	_
EUR 43,360	GBP 37,029	1.1372	12/01/2022	841	-
JPY 2,230,019	GBP 14,826	0.0087	12/01/2022	715	-
USD 30,611	GBP 23,123	1.3239	12/01/2022	707	_
USD 63,565	GBP 47,442	1.3398	31/01/2022	690	_
JPY 1,581,550	GBP 10,523	0.0087	12/01/2022	518	-
USD 33,098	GBP 24,797	1.3348	31/01/2022	486	_
USD 19,329	GBP 14,590	1.3248	31/01/2022	432	-
EUR 14,344	GBP 12,307	1.1372	12/01/2022	356	_
USD 10,615	GBP 8,028	1.3222	12/01/2022	259	-
EUR 12,975	GBP 11,086	1.1372	12/01/2022	259	_
USD 8,489	GBP 6,425	1.3212	31/01/2022	213	_
USD 63,959	GBP 47,378	1.3500	31/01/2022	209	-
USD 20,517	GBP 15,285	1.3423	04/01/2022	186	_

Portfolio Statements continued As at 31 December 2021

### Global Convertible Fund continued

Open Forward C	urrency Contracts: 0	.59% (2020: 0.43%	) continued		
Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain US\$	% of Net Assets
JPY 502,324	GBP 3,337	0.0087	12/01/2022	158	_
USD 14,464	GBP 10,795	1.3398	31/01/2022	157	-
JPY 454,483	GBP 3,028	0.0087	12/01/2022	154	_
EUR 9,524	GBP 8,102	1.1372	12/01/2022	143	-
EUR 7,767	GBP 6,621	1.1372	18/01/2022	133	-
JPY 611,281	GBP 4,007	0.0087	04/01/2022	119	-
JPY 333,948	GBP 2,222	0.0087	12/01/2022	110	-
EUR 5,079	GBP 4,344	1.1372	18/01/2022	107	-
USD 4,659	GBP 3,518	1.3245	12/01/2022	105	-
JPY 12,347,290	GBP 79,246	0.0087	24/01/2022	95	_
USD 3,484	GBP 2,629	1.3254	12/01/2022	76	_
EUR 3,105	GBP 2,653	1.1372	12/01/2022	62	-
USD 5,920	GBP 4,410	1.3423	04/01/2022	54	_
USD 5,891	GBP 4,389	1.3423	04/01/2022	53	_
JPY 248,208	GBP 1,628	0.0087	04/01/2022	50	-
EUR 5,938	GBP 5,017	1.1372	04/01/2022	42	_
JPY 115,266	GBP 769	0.0087	12/01/2022	41	_
USD 4,291	GBP 3,197	1.3422	31/01/2022	39	-
JPY 218,774	GBP 1,425	0.0087	04/01/2022	30	-
USD 1,942	GBP 1,455	1.3348	31/01/2022	29	-
EUR 1,446	GBP 1,232	1.1372	12/01/2022	24	_
USD 982	GBP 741	1.3248	31/01/2022	22	-
EUR 1,070	GBP 915	1.1372	12/01/2022	22	-
USD 813	GBP 613	1.3256	12/01/2022	18	-
JPY 51,208	GBP 341	0.0087	12/01/2022	17	-
JPY 37,639	GBP 252	0.0087	12/01/2022	15	-
EUR 1,706	GBP 1,441	1.1372	04/01/2022	12	-
EUR 1,714	GBP 1,448	1.1372	04/01/2022	12	-
JPY 62,940	GBP 410	0.0087	04/01/2022	9	-
JPY 63,247	GBP 412	0.0087	04/01/2022	9	-
USD 379	GBP 286	1.3239	12/01/2022	9	-
USD 653	CHF 601	1.0872	31/01/2022	7	-

	Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain US\$	% of Net Assets
	JPY 8,892	GBP 59	0.0087	12/01/2022	3	_
	USD 122	GBP 92	1.3248	31/01/2022	3	_
	EUR 238	GBP 202	1.1372	12/01/2022	3	-
	GBP 1,873	EUR 2,233	1.3545	24/01/2022	3	-
	USD 242	GBP 180	1.3422	31/01/2022	2	-
	JPY 10,520	GBP 69	0.0087	04/01/2022	2	_
	USD 86	GBP 65	1.3248	31/01/2022	2	_
	EUR 111	GBP 95	1.1372	12/01/2022	2	-
	USD 72	GBP 54	1.3396	04/01/2022	1	_
	USD 52	GBP 39	1.3221	24/01/2022	1	_
	JPY 4,212	GBP 28	0.0087	12/01/2022	1	-
	USD 82	GBP 61	1.3397	04/01/2022	1	-
	USD 91	GBP 68	1.3397	04/01/2022	1	_
	JPY 601	GBP 4	0.0087	24/01/2022	_	_
	JPY 766	GBP 5	0.0087	04/01/2022	_	-
	EUR 26	GBP 22	1.1372	04/01/2022	_	_
	EUR 24	GBP 20	1.1372	04/01/2022	_	_
	JPY 766	GBP 5	0.0087	04/01/2022	_	-
	EUR 15	GBP 13	1.1372	24/01/2022	_	-
	JPY 2,287	GBP 15	0.0087	04/01/2022	_	_
	JPY 3,224	GBP 21	0.0087	04/01/2022	_	_
	JPY 919	GBP 6	0.0087	04/01/2022	_	-
	JPY 614	GBP 4	0.0087	04/01/2022	_	_
	GBP 246	EUR 293	1.3545	12/01/2022	_	-
	EUR 20	GBP 17	1.1372	04/01/2022	_	-
	Total unrealised	l gain on forward for	eign currency cont	racts	6,347,293	0.59
_	Total Financial A	Assets at fair value th	rough profit or los	s	1,261,774,421	118.26

Financial assets at fair value through profit or loss



Portfolio Statements continued As at 31 December 2021

### Global Convertible Fund continued

Holdings	Financial liabilities at fair value throu	ah profit or loss			Unrealised Loss USS	% of Net Assets
noiuings	Contracts for Difference (on Equit	5 1		(2020: (4,27		Net Assets
	France: Nil (2020: Nil)					
(2,430)	LVMH Moet Hennessy Louis Vuitton				(5,063)	_
	Total France				(5,063)	-
	Luxembourg: (0.04%) (2020: (2.92	20/))				
(156,000)	Arcelor Mittal	. /0//			(403,915)	(0.04)
(100/000)	Total Luxembourg				(403,915)	(0.04)
	Spain: Nil (2020: (0.01%))				· · · · · · · · · · · · · · · · · · ·	
	Switzerland: Nil (2020: (0.03%))					
	United Kingdom: Nil (2020: (0.049					
	United States: (0.19%) (2020: (1.27	7%))				
(1,688,679)	Change Healthcare				(1,046,981)	(0.10)
(693,000)	T-Mobile US				(1,039,500)	(0.09)
	Total United States				(2,086,481)	(0.19)
	Total Officed States					
	Total Contracts for Difference (or	n Equities) – U	nrealised Loss	es	(2,495,459)	(0.23)
	Total Contracts for Difference (or			es	(2,495,459) Fair Value	(0.23) % of
Holdings	Total Contracts for Difference (or Financial liabilities at fair value throug	gh profit or loss		es		
	Total Contracts for Difference (or Financial liabilities at fair value throug Credit Default Swaps: (0.43%) (20	gh profit or loss		es	Fair Value US\$	% of Net Assets
	Total Contracts for Difference (or Financial liabilities at fair value throug Credit Default Swaps: (0.43%) (20 CDX CCP 5% 20-Dec-2026	gh profit or loss		es	<b>Fair Value</b> US\$ (4,598,265)	% of Net Assets (0.43)
	Total Contracts for Difference (or Financial liabilities at fair value throug Credit Default Swaps: (0.43%) (20	gh profit or loss		es	Fair Value US\$	% of Net Assets (0.43)
Holdings 50,000,000	Total Contracts for Difference (or Financial liabilities at fair value throug Credit Default Swaps: (0.43%) (20 CDX CCP 5% 20-Dec-2026	gh profit or loss		es	<b>Fair Value</b> US\$ (4,598,265)	% of Net Assets
	Total Contracts for Difference (or         Financial liabilities at fair value throug         Credit Default Swaps: (0.43%) (20         CDX CCP 5% 20-Dec-2026         Total Credit Default Swaps	gh profit or loss D20: Nil)	; 		<b>Fair Value</b> US\$ (4,598,265) (4,598,265)	% of Net Assets (0.43) (0.43)
	Total Contracts for Difference (or         Financial liabilities at fair value throug         Credit Default Swaps: (0.43%) (20         CDX CCP 5% 20-Dec-2026         Total Credit Default Swaps         Total Credit Default Swaps	gh profit or loss D20: Nil)	; 		<b>Fair Value</b> US\$ (4,598,265) (4,598,265)	% of Net Assets (0.43) (0.43)
	Total Contracts for Difference (or         Financial liabilities at fair value throug         Credit Default Swaps: (0.43%) (20         CDX CCP 5% 20-Dec-2026         Total Credit Default Swaps         Total Credit Default Swaps         Futures Contracts – Unrealised Local	gh profit or loss 020: Nil) osses: (0.09%) Country	; (2020: (0.04%	)) No. of	Fair Value US\$           (4,598,265)           (4,598,265)           (4,598,265)           (4,598,265)           Unrealised Loss	% of Net Assets (0.43) (0.43) (0.43) (0.43)
	Total Contracts for Difference (or         Financial liabilities at fair value througe         Credit Default Swaps: (0.43%) (20         CDX CCP 5% 20-Dec-2026         Total Credit Default Swaps         Total Credit Default Swaps         Futures Contracts – Unrealised Log         Description	gh profit or loss 020: Nil) osses: (0.09%) Country	; (2020: (0.04%	)) No. of	Fair Value US\$           (4,598,265)           (4,598,265)           (4,598,265)           (4,598,265)           Unrealised Loss	% of Net Assets (0.43) (0.43) (0.43) (0.43) % of Net Assets
	Total Contracts for Difference (or         Financial liabilities at fair value throug         Credit Default Swaps: (0.43%) (20         CDX CCP 5% 20-Dec-2026         Total Credit Default Swaps         Total Credit Default Swaps         Futures Contracts – Unrealised Loc         Description         United Kingdom: (0.01%) (2020: No	gh profit or loss D2O: Nil) Dsses: (0.09%) Country Nil)	; (2020: (0.04% Currency	)) No. of Contracts	Fair Value         US\$         (4,598,265)         (4,598,265)         (4,598,265)         (4,598,265)         Unrealised Loss         US\$	% of Net Assets (0.43) (0.43) (0.43) (0.43)
	Total Contracts for Difference (or         Financial liabilities at fair value throug         Credit Default Swaps: (0.43%) (20         CDX CCP 5% 20-Dec-2026         Total Credit Default Swaps         Total Credit Default Swaps         Futures Contracts – Unrealised Loc         Description         United Kingdom: (0.01%) (2020: N         Future IMM GBP Mar22	gh profit or loss D20: Nil) Dosses: (0.09%) Country Nil) UK	; (2020: (0.04% Currency	)) No. of Contracts	Fair Value         US\$         (4,598,265)         (4,598,265)         (4,598,265)         (4,598,265)         Unrealised Loss         US\$         (123,613)	% of Net Assets (0.43) (0.43) (0.43) (0.43) (0.43) % of Net Assets (0.01)
	Total Contracts for Difference (or         Financial liabilities at fair value throug         Credit Default Swaps: (0.43%) (20         CDX CCP 5% 20-Dec-2026         Total Credit Default Swaps         Total Credit Default Swaps         Futures Contracts – Unrealised Loc         Description         United Kingdom: (0.01%) (2020: N         Future IMM GBP Mar22         Total United Kingdom	gh profit or loss D20: Nil) Dosses: (0.09%) Country Nil) UK	; (2020: (0.04% Currency	)) No. of Contracts	Fair Value         US\$         (4,598,265)         (4,598,265)         (4,598,265)         (4,598,265)         Unrealised Loss         US\$         (123,613)	% of Net Assets (0.43) (0.43) (0.43) (0.43) % of Net Assets (0.01) (0.01)
	Total Contracts for Difference (or         Financial liabilities at fair value throug         Credit Default Swaps: (0.43%) (20         CDX CCP 5% 20-Dec-2026         Total Credit Default Swaps         Total Credit Default Swaps         Futures Contracts – Unrealised Loc         Description         United Kingdom: (0.01%) (2020: N         Future IMM GBP Mar22         Total United Kingdom         United States: (0.08%) (2020: (0.0)	gh profit or loss 020: Nil) 0555es: (0.09%) 0555es: (0.09%) 0557 0577 0577 0577 0577 0577 0577 057	; (2020: (0.04% Currency USD	)) No. of Contracts (62)	Fair Value         US\$         (4,598,265)         (4,598,265)         (4,598,265)         (4,598,265)         (4,598,265)         (4,598,265)         (4,598,265)         (123,613)         (123,613)	% of Net Assets (0.43) (0.43) (0.43) (0.43) (0.43) % of Net Assets (0.01)
	Total Contracts for Difference (or         Financial liabilities at fair value throug         Credit Default Swaps: (0.43%) (20         CDX CCP 5% 20-Dec-2026         Total Credit Default Swaps         Total Credit Default Swaps         Futures Contracts – Unrealised Loc         Description         United Kingdom: (0.01%) (2020: N         Future IMM GBP Mar22         Total United Kingdom         United States: (0.08%) (2020: (0.0)         Future Japan Yen CME Mar22	gh profit or loss D20: Nil) Dosses: (0.09%) Country Nil) UK 4%)) US	; (2020: (0.04% Currency USD	)) No. of Contracts (62) 480	Fair Value         US\$         (4,598,265)         (4,598,265)         (4,598,265)         (4,598,265)         (123,613)         (123,613)         (123,613)         (765,000)	% of Net Assets (0.43) (0.43) (0.43) (0.43) % of Net Assets (0.01) (0.01)

# Financial liabilities at fair value through profit or loss Open Forward Currency Contracts: Nil (2020: (0.01%))

% of Net Assets	Unrealised Loss US\$	Maturity Date	Currency Rate	Currency Bought	Currency Sold
-	(11,300)	12/01/2022	1.3545	EUR 580,910	GBP 496,109
_	(3,188)	18/01/2022	1.3545	EUR 159,602	GBP 136,383
-	(1,822)	12/01/2022	1.3237	USD 78,374	GBP 59,210
-	(941)	24/01/2022	1.3248	USD 42,077	GBP 31,761
-	(835)	12/01/2022	1.3348	USD 56,845	GBP 42,586
-	(746)	04/01/2022	1.3397	USD 67,834	GBP 50,633
-	(556)	04/01/2022	1.3397	USD 50,558	GBP 37,738
_	(527)	12/01/2022	1.3397	USD 48,044	GBP 35,861
_	(456)	31/01/2022	1.3398	USD 42,021	GBP 31,363
-	(412)	12/01/2022	1.3545	EUR 23,143	GBP 19,736
-	(333)	31/01/2022	1.3212	USD 13,230	GBP 10,014
_	(308)	12/01/2022	1.3248	USD 13,789	GBP 10,408
-	(279)	12/01/2022	0.0087	JPY 842,860	GBP 5,610
_	(269)	24/01/2022	1.3255	USD 12,326	GBP 9,299
_	(206)	12/01/2022	1.3545	EUR 16,572	GBP 14,067
-	(192)	24/01/2022	1.3545	EUR 12,292	GBP 10,466
-	(186)	12/01/2022	1.3423	USD 20,517	GBP 15,285
-	(158)	18/01/2022	1.3545	EUR 7,730	GBP 6,608
-	(148)	04/01/2022	0.0087	JPY 1,064,921	GBP 6,937
-	(135)	04/01/2022	1.3397	USD 12,288	GBP 9,172
-	(133)	04/01/2022	1.3545	EUR 19,826	GBP 16,744
-	(127)	24/01/2022	1.3223	USD 5,230	GBP 3,955
-	(124)	24/01/2022	0.0087	JPY 453,752	GBP 3,001
-	(119)	12/01/2022	0.0087	JPY 611,203	GBP 4,007
-	(117)	04/01/2022	0.0087	JPY 736,569	GBP 4,809
-	(99)	04/01/2022	1.3545	EUR 14,776	GBP 12,479
-	(96)	12/01/2022	1.3545	EUR 13,927	GBP 11,765
-	(96)	04/01/2022	0.0087	JPY 689,735	GBP 4,493
-	(87)	04/01/2022	0.0087	JPY 548,942	GBP 3,584
-	(82)	12/01/2022	0.0087	JPY 514,019	GBP 3,356
-	(77)	04/01/2022	0.0087	JPY 554,490	GBP 3,612
-	(77)	31/01/2022	1.3422	USD 8,521	GBP 6,348
_	(63)	12/01/2022	1.3545	EUR 4,030	GBP 3,430
_	(50)	24/01/2022	1.3545	EUR 3,609	GBP 3,068
_	(46)	12/01/2022	1.3222	USD 1,878	GBP 1,420
_	(43)	12/01/2022	1.3545	EUR 5,937	GBP 5,017

Portfolio Statements continued As at 31 December 2021

### Global Convertible Fund continued

Open Forward O	Currency Contracts: N	lil (2020: (0.01%)) o	ontinued		
Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss US\$	% of Net Assets
 GBP 984	JPY 148,796	0.0087	12/01/2022	(41)	
GBP 891	JPY 134,247	0.0087	24/01/2022	(41)	_
GBP 1,950	USD 2,601	1.3337	12/01/2022	(40)	
GBP 2,542	USD 3,406	1.3397	04/01/2022	(37)	_
GBP 8,436	USD 11,388	1.3500	31/01/2022	(37)	_
GBP 4,422	EUR 5,234	1.3545	18/01/2022	(36)	_
GBP 1,524	USD 2,033	1.3337	24/01/2022	(32)	_
GBP 1,425	JPY 218,742	0.0087	12/01/2022	(31)	_
GBP 1,314	EUR 1,542	1.3545	24/01/2022	(25)	_
GBP 5,683	USD 7,672	1.3499	24/01/2022	(25)	_
GBP 3,033	EUR 3,591	1.3545	04/01/2022	(24)	_
GBP 872	JPY 133,560	0.0087	04/01/2022	(21)	_
GBP 377	JPY 56,703	0.0087	24/01/2022	(18)	_
GBP 406	USD 537	1.3222	12/01/2022	(13)	_
GBP 648	EUR 764	1.3545	12/01/2022	(9)	_
GBP 472	EUR 554	1.3545	12/01/2022	(9)	_
GBP 507	EUR 597	1.3545	24/01/2022	(7)	_
GBP 187	JPY 28,350	0.0087	12/01/2022	(7)	_
GBP 135	JPY 20,307	0.0087	12/01/2022	(7)	_
GBP 841	EUR 996	1.3545	04/01/2022	(7)	-
GBP 356	USD 475	1.3348	24/01/2022	(7)	_
GBP 146	JPY 22,132	0.0087	24/01/2022	(6)	_
GBP 242	JPY 37,066	0.0087	04/01/2022	(6)	_
GBP 210	JPY 32,238	0.0087	04/01/2022	(5)	_
GBP 226	USD 303	1.3423	12/01/2022	(3)	_
GBP 135	EUR 158	1.3545	12/01/2022	(3)	_
GBP 146	USD 195	1.3348	12/01/2022	(3)	_
GBP 747	USD 1,008	1.3500	12/01/2022	(3)	_
GBP 530	JPY 82,345	0.0087	24/01/2022	(3)	_
GBP 39	JPY 5,866	0.0087	12/01/2022	(2)	-
GBP 117	EUR 138	1.3545	24/01/2022	(2)	_
GBP 33	JPY 5,033	0.0087	24/01/2022	(1)	_
GBP 61	USD 82	1.3397	12/01/2022	(1)	_
GBP 74	EUR 88	1.3545	12/01/2022	(1)	_

#### Financial liabilities at fair value through profit or loss

Open Forward Currency Contracts: Nil (2020: (0.01%)) continued

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss US\$	% of Net Assets
GBP 48	EUR 57	1.3545	12/01/2022	(1)	_
GBP 5	JPY 766	0.0087	12/01/2022	-	_
GBP 21	JPY 3,224	0.0087	12/01/2022	_	-
GBP 20	EUR 24	1.3545	12/01/2022	_	-
GBP 13	JPY 1,983	0.0087	12/01/2022	-	-
GBP 70	JPY 10,877	0.0087	12/01/2022	_	-
Total unrealise	ed loss on forward fore	eign currency cont	acts	(24,947)	-
Total Financial	Liabilities at fair value	(8,019,278)	(0.75)		

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 1,256,364,031)	1,253,755,143	117.51
Cash at Bank	(188,288,471)	(17.65)
Other Net Liabilities	1,437,734	0.14
Net Assets Attributable to Holders of Redeemable Participating Shares	1,066,904,406	100.00

All securities are transferable securities and are admitted to an official stock exchange or dealt on a regulated market at the financial year end.

Counterparty for the contracts for difference is UBS AG.

The counterparty for the forward currency contracts is The Northern Trust Company.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	95.62	93.59
Exchange traded financial derivative instruments	0.55	0.23
OTC Financial derivative instruments	0.49	0.37
Other assets	3.34	5.81
	100.00	100.00

The % of Net Assets has been rounded to Nil if the amount is less than 0.01%.



Portfolio Statements continued As at 31 December 2021

### **Global Insurance Fund**

Holdings	Financial assets at fair value through profit or loss	Fair Value GBP£	% of Net Assets
	Investment Funds: 1.82% (2020: 1.52%)		
	Bermuda: 0.36% (2020: Nil)		
10,000	Lodgepine 2021	6,150,255	0.36
	Total Bermuda	6,150,255	0.36
	United States: 1.46% (2020: 1.52%)		
21,016	AlphaCat Opportunities	11,662,631	0.68
2,384,817	Kinesis	13,217,322	0.78
	Total United States	24,879,953	1.46
	Total Investment Funds	31,030,208	1.82
	Equities: 98.16% (2020: 95.77%)		
	Insurance Brokers: 13.15% (2020: 10.72%)		
337,500	Aon	74,893,124	4.40
1,060,000	Marsh & McLennan Cos	136,032,474	7.99
435,000	Ryan Specialty Group	12,958,949	0.76
	Total Insurance Brokers	223,884,547	13.15
	Life/Health Insurance: 4.09% (2020: 4.64%)		
427,500	Aflac	18,429,416	1.08
4,580,000	AIA	34,090,743	2.00
1,350,000	Prudential	17,205,750	1.01
	Total Life/Health Insurance	69,725,909	4.09
	Multi-line Insurance: 12.31% (2020: 12.85%)		
925,000	Chubb	132,017,966	7.76
19,285,000	Direct Line Insurance	53,805,150	3.16
641,000	Sampo Plc	23,712,449	1.39
	Total Multi-line Insurance	209,535,565	12.31
	Property/Casualty Insurance: 47.59% (2020: 48.27%)		
163,300	Alleghany	80,488,344	4.73
4,200,000	Arch Capital	137,834,534	8.10
7,770,000	Beazley	36,231,510	2.13
225,000	Berkshire Hathaway	49,669,604	2.92
519,500	First American Financial	30,005,155	1.76
4,440,000	Hiscox	38,219,520	2.25

Holdings	Financial assets at fair value through profit or loss	Fair Value GBP£	% of Net Assets
	Property/Casualty Insurance: 47.59% (2020: 48.27%) continued		
689,500	Intact Financial	66,262,982	3.89
900,000	James River	19,143,562	1.12
7,432,500	Lancashire	39,392,250	2.31
100,050	Markel	91,152,637	5.36
1,200,000	ProAssurance	22,415,001	1.32
609,250	Progressive Corp	46,173,360	2.71
275,000	RLI	22,760,159	1.34
501,000	Travelers Companies	57,862,175	3.40
1,188,750	WR Berkley	72,310,609	4.25
	Total Property/Casualty Insurance	809,921,402	47.59
	Reinsurance: 21.02% (2020: 19.29%)		
2,172,000	Essent	73,012,036	4.29
253,250	Everest Re	51,216,534	3.01
231,150	Fairfax Financial	84,068,613	4.94
9,875,000	Helios Underwriting	16,540,625	0.98
542,500	Reinsurance of America	43,854,199	2.58
710,000	RenaissanceRe	88,762,442	5.22
	Total Reinsurance	357,454,449	21.02
	Total Equities	1,670,521,872	98.16
	Total Transferable Securities	1,701,552,080	99.98

### Open Forward Currency Contracts: Nil (2020: Nil)

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain GBP£	% of Net Assets
EUR 61,559	GBP 51,939	0.8437	04/01/2022	254	-
EUR 200	GBP 169	0.8438	04/01/2022	1	_
GBP 1	EUR 1	0.8395	05/01/2022	_	_
Total unrealised	gain on forward for	eign currency cont	racts	255	_
Total Financial A	ssets at fair value th	rough profit or los	S	1,701,552,335	99.98

Portfolio Statements continued As at 31 December 2021

### Global Insurance Fund continued

Open Forward Cu	rrency Contracts: (0	0.01%) (2020: (0.02	%))		
Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss GBP£	% of Net Assets
GBP 12,028,449	EUR 14,073,941	0.8547	31/01/2022	(206,158)	(0.01)
GBP 679,487	USD 898,433	0.7563	31/01/2022	(16,134)	_
GBP 3,038	USD 4,055	0.7492	04/01/2022	(44)	_
GBP 91	EUR 108	0.8438	05/01/2022	(1)	_
GBP 24	USD 33	0.7456	04/01/2022	-	_
Total unrealised lo	oss on forward fore	ign currency contr	acts	(222,337)	(0.01)
Total Financial Lia	bilities at fair value	through profit or	loss	(222,337)	(0.01

	Fair Value GBP£	% of Net Assets
Total Value of Investments (Cost: GBP£ 1,339,920,939)	1,701,329,998	99.97
Cash at Bank	5,787,298	0.34
Other Net Liabilities	(5,284,572)	(0.31)
Net Assets Attributable to Holders of Redeemable Participating Shares	1,701,832,724	100.00

All securities are transferable securities and are admitted to an official stock exchange or dealt on a regulated market at the financial year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	98.90	96.67
Other assets	1.10	3.33
	100.00	100.00

The % of Net Assets has been rounded to Nil if the amount is less than 0.01%.

## Global Technology Fund

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 95.60% (2020: 90.47%)		
	Communications: 16.67% (2020: 17.30%)		
123,287	Alphabet	356,742,030	3.93
123,651	Alphabet	358,221,893	3.95
65,629	Amazon.com	218,829,400	2.41
689,859	Meta Platforms	232,034,074	2.56
93,812	Monolithic Power Systems	46,280,274	0.51
168,015	Naver	53,496,259	0.59
1,613,550	Tencent	94,540,954	1.04
1,368,603	Uber	57,385,524	0.63
918,948	Zendesk	95,837,087	1.05
	Total Communications	1,513,367,495	16.67
	Consumer, Cyclical: 3.89% (2020: 3.42%)		
537,609	Dolby Laboratories	51,191,129	0.57
1,524,075	Lattice Semiconductor	117,445,220	1.29
256,502	Match Group	33,922,389	0.37
3,201,809	Snap	150,581,077	1.66
	Total Consumer, Cyclical	353,139,815	3.89
	Consumer, Non-cyclical: 4.50% (2020: 7.43%)		
1,261,986	HelloFresh SE	96,928,723	1.07
233,155	Netflix	140,461,898	1.55
205,918	PayPal	38,832,017	0.43
1,428,798	Tenable	78,683,906	0.86
50,441	Tesla Inc.	53,305,040	0.59
	Total Consumer, Non-cyclical	408,211,584	4.50
	Financial: 6.91% (2020: 13.54%)		
670,526	Airbnb Inc.	111,635,874	1.23
402,361	Aptiv PLC	66,369,447	0.73
2,310,500	BYD Company	79,009,184	0.87
301,570	Crowdstrike	61,746,458	0.68
535,090	CyberArk Software	92,720,395	1.02
1,949,637	Infineon Technologies	90,370,114	0.99
120,133	Mastercard	43,166,190	0.48
511,789	TE Connectivity	82,572,037	0.91
	Total Financial	627,589,699	6.91



Portfolio Statements continued As at 31 December 2021

### Global Technology Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
noidings	Equities: 95.60% (2020: 90.47%) continued		Net Abets
	Industrial: 3.10% (2020: 5.24%)		
263,224	DocuSign	40,091,647	0.44
528,600	Ноуа	78,540,628	0.86
379,456	Kornit Digital	57,772,176	0.64
3,854,988	TripAdvisor	105,086,973	1.16
	Total Industrial	281,491,424	3.10
	Technology: 60.53% (2020: 42.44%)		
219,533	Adobe	124,488,383	1.37
2,157,719	Advanced Micro Devices	310,495,764	3.42
332,129	Ambarella	67,385,653	0.74
2,505,048	Apple	444,821,373	4.90
882,523	Applied Materials	138,873,819	1.53
1,242,500	Arista Networks	178,609,375	1.97
196,382	ASML	157,824,226	1.74
239,364	Coupa Software	37,831,480	0.42
21,369,405	E Ink	116,629,203	1.28
788,541	Elastic	97,061,512	1.07
876,371	Everbridge	59,006,059	0.65
826,951	Five9	113,556,911	1.25
171,157	HubSpot	112,818,137	1.24
226,746	KLA Corp	97,525,722	1.07
2,459,302	Marvell Technology	215,164,332	2.37
2,097,400	MediaTek	90,212,383	0.99
1,496,718	Micron Technology	139,419,282	1.54
1,878,071	Microsoft	631,632,839	6.96
169,500	MongoDB	89,724,825	0.99
183,100	Nintendo	85,305,154	0.94
1,026,511	NVIDIA	301,907,150	3.33
581,824	Okta	130,427,486	1.44
1,961,700	ON Semiconductor	133,238,664	1.47
593,309	Power Integrations	55,112,473	0.61
2,938,969	Pure Storage	95,663,441	1.05
578,956	Qualcomm	105,873,684	1.17
864,102	Roblox	89,140,762	0.98
244,286	salesforce.com	62,080,401	0.68

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 95.60% (2020: 90.47%) continued		
2,494,190	Samsung Electronics	164,286,080	1.81
1,605,713	Seagate Technology	181,413,455	2.00
277,177	ServiceNow	179,918,362	1.98
701,412	Smartsheet Inc.	54,324,359	0.60
97,764	Snowflake Inc.	33,117,555	0.36
9,812,350	Taiwan Semiconductor Manufacturing	218,115,273	2.40
231,900	Tokyo Electron	133,475,160	1.47
185,289	Twilio	48,794,005	0.54
1,163,127	Western Digital	75,847,512	0.84
287,343	Workday	78,496,361	0.86
249,395	Zoom Video Communications	45,866,234	0.50
	Total Technology	5,495,484,849	60.53
	Total Equities	8,679,284,866	95.60
	Total Transferable Securities	8,679,284,866	95.60

#### Options Purchased: 0.28% (2020: 0.58%)

Base Description         Base Currency         Strike Price         No. of Contracts         Maturity Date         Fair Value USS         % of Net Assets           Option Alphabet Call 3300         USD         3,300.00         1,575         18/02/2022         1,582,875         0.02           Option Microsoft Call 365         USD         365.00         14,250         18/02/2022         3,633,750         0.04           Option Nasdaq 100 Put 13500         USD         13,500.00         575         18/02/2022         8,452,500         0.09           Option Nasdaq 100 Put 15000         USD         15,000.00         575         18/02/2022         8,452,500         0.09           Option Apple Call 200         USD         200.00         40,000         18/03/2022         9,040,000         0.10           Total Options Purchased         USD         200.00         40,000         18/03/2022         9,040,000         0.28							
Option Microsoft Call 365         USD         365.00         14,250         18/02/2022         3,633,750         0.04           Option Nasdaq 100 Put 13500         USD         13,500.00         575         18/02/2022         2,587,500         0.03           Option Nasdaq 100 Put 15000         USD         15,000.00         575         18/02/2022         8,452,500         0.09           Option Apple Call 200         USD         200.00         40,000         18/03/2022         9,040,000         0.10	Description						
Option Nasdaq 100 Put 13500         USD         13,500.00         575         18/02/2022         2,587,500         0.03           Option Nasdaq 100 Put 15000         USD         15,000.00         575         18/02/2022         8,452,500         0.09           Option Apple Call 200         USD         200.00         40,000         18/03/2022         9,040,000         0.10	Option Alphabet Call	3300 USD	3,300.00	1,575	18/02/2022	1,582,875	0.02
Option Nasdaq 100 Put 15000         USD         15,000.00         575         18/02/2022         8,452,500         0.09           Option Apple Call 200         USD         200.00         40,000         18/03/2022         9,040,000         0.10	Option Microsoft Cal	1365 USD	365.00	14,250	18/02/2022	3,633,750	0.04
Option Apple Call 200         USD         200.00         40,000         18/03/2022         9,040,000         0.10	Option Nasdaq 100 P	ut 13500 USD	13,500.00	575	18/02/2022	2,587,500	0.03
	Option Nasdaq 100 P	ut 15000 USD	15,000.00	575	18/02/2022	8,452,500	0.09
Total Options Purchased         25,296,625         0.28	Option Apple Call 20	0 USD	200.00	40,000	18/03/2022	9,040,000	0.10
	Total Options Purch	ased				25,296,625	0.28

Portfolio Statements continued As at 31 December 2021

### Global Technology Fund continued

Open Forward Cu	rrency Contracts: 0.	13% (2020: 0.08%)			
				Unrealised Gain	% o
Currency Sold	Currency Bought	Currency Rate	Maturity Date	US\$	Net Asset
USD 263,565,331	GBP 199,335,007	1.3222	31/01/2022	6,410,420	0.07
USD 208,764,768	EUR 184,746,929	1.1300	31/01/2022	1,421,486	0.02
USD 129,412,118	CHF 119,056,819	1.0870	31/01/2022	1,328,370	0.02
USD 172,716,151	EUR 152,845,610	1.1300	31/01/2022	1,176,030	0.0
USD 100,936,257	EUR 89,323,805	1.1300	31/01/2022	687,278	0.0
USD 37,059,990	CHF 34,094,524	1.0870	31/01/2022	380,408	
USD 7,012,478	GBP 5,253,875	1.3347	04/01/2022	103,633	
USD 11,012,592	EUR 9,724,976	1.1324	04/01/2022	46,652	
USD 2,453,949	GBP 1,830,434	1.3406	05/01/2022	25,282	
USD 3,220,825	EUR 2,849,927	1.1301	31/01/2022	21,532	
USD 140,798	GBP 106,395	1.3234	31/01/2022	3,301	
USD 774,801	EUR 683,412	1.1337	31/01/2022	2,716	
USD 317,041	EUR 280,247	1.1313	05/01/2022	1,657	
USD 589,550	CHF 538,300	1.0952	31/01/2022	1,576	
USD 392,728	EUR 346,493	1.1334	31/01/2022	1,477	
USD 347,019	EUR 306,445	1.1324	04/01/2022	1,470	
USD 71,039	GBP 53,220	1.3348	31/01/2022	1,041	
USD 41,178	GBP 31,145	1.3221	31/01/2022	1,005	
USD 105,152	EUR 93,276	1.1273	31/01/2022	968	
USD 270,841	EUR 238,895	1.1337	31/01/2022	949	
USD 94,394	CHF 86,814	1.0873	05/01/2022	886	
USD 166,148	EUR 146,793	1.1319	31/01/2022	858	
USD 150,689	EUR 133,196	1.1313	05/01/2022	781	
USD 81,709	CHF 75,148	1.0873	05/01/2022	767	
USD 213,705	GBP 158,344	1.3496	31/01/2022	754	
USD 98,850	EUR 87,467	1.1301	31/01/2022	661	
USD 110,974	EUR 98,095	1.1313	05/01/2022	580	
USD 149,348	EUR 131,732	1.1337	31/01/2022	524	
USD 101,113	EUR 89,334	1.1319	31/01/2022	522	
USD 83,027	EUR 73,355	1.1319	31/01/2022	429	
USD 45,720	EUR 40,556	1.1273	31/01/2022	421	
USD 79,313	EUR 70,106	1.1313	05/01/2022	411	
USD 64,638	EUR 57,137	1.1313	05/01/2022	338	
USD 83,649	EUR 73,846	1.1328	04/01/2022	328	
USD 68,596	EUR 60,520	1.1334	31/01/2022	258	
USD 63,303	EUR 55,885	1.1328	04/01/2022	249	
USD 45,254	EUR 40,000	1.1313	05/01/2022	234	

#### Open Forward Currency Contracts: 0.13% (2020: 0.08%) continued % of **Unrealised Gain Currency Sold Currency Bought Currency Rate Maturity Date** US\$ Net Assets USD 13,040 GBP 9,769 1.3348 04/01/2022 192 USD 12,140 GBP 9,095 04/01/2022 179 1.3347 1.1324 USD 41,754 EUR 36,872 04/01/2022 177 \_ USD 14,079 CHF 12,949 31/01/2022 1.0873 140 \_ 04/01/2022 USD 11,258 CHF 10,363 1.0864 115 \_ USD 7,477 CHF 6,909 1.0822 31/01/2022 110 USD 8,938 GBP 6,666 1.3409 31/01/2022 90 USD 3,859 GBP 2,916 1.3234 31/01/2022 90 USD 20,526 EUR 18,126 1.1324 04/01/2022 87 USD 7,996 CHF 7,354 31/01/2022 80 1.0873 \_ USD 18,675 04/01/2022 79 EUR 16,492 1.1324 USD 7,109 GBP 5,304 1.3402 05/01/2022 76 USD 2,280 GBP 1,724 1.3224 31/01/2022 55 USD 5,636 EUR 5,000 1.1273 31/01/2022 52 USD 3,524 GBP 2,627 1.3411 04/01/2022 35 \_ USD 3,329 GBP 2,483 1.3406 05/01/2022 34 \_ 24 USD 3,570 EUR 3,158 1.1302 31/01/2022 \_ USD 5,799 EUR 5,119 1.1328 04/01/2022 23 USD 2,914 EUR 2,582 1.1286 31/01/2022 23 GBP 1,614 USD 2,164 1.3409 05/01/2022 22 USD 2,568 05/01/2022 EUR 2,270 13 1.1313 USD 3,931 CHF 3,589 1.0952 31/01/2022 11 \_ 31/01/2022 10 USD 2,792 EUR 2,463 1.1334 \_ USD 824 CHF 759 1.0869 31/01/2022 9 USD 459 GBP 344 1.3348 31/01/2022 7 7 USD 717 CHF 660 1.0873 05/01/2022 USD 1,369 05/01/2022 7 EUR 1,211 1.1313 \_ USD 617 CHF 567 1.0873 05/01/2022 6 \_ USD 872 EUR 772 31/01/2022 6 1.1302 \_ USD 1,013 EUR 894 1.1324 04/01/2022 4 USD 1,533 CHF 1,400 1.0952 31/01/2022 4 USD 841 EUR 744 1.1313 05/01/2022 4 05/01/2022 3 USD 487 EUR 431 1.1313 USD 716 EUR 632 04/01/2022 3 1.1328 \_

Financial assets at fair value through profit or loss

USD 218

USD 274

USD 760

CHF 201

CHF 252

EUR 670

1.0822

1.0869

1.1334

31/01/2022

31/01/2022

31/01/2022

3

3

3

Portfolio Statements continued As at 31 December 2021

### Global Technology Fund continued

Open Forward O	Currency Contracts: 0	.13% (2020: 0.08%)	continued		
Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain US <b>\$</b>	% o Net Asset
 USD 362	EUR 320	1.1313	05/01/2022	2	Net Asset
USD 432	EUR 382	1.1313	05/01/2022	2	
USD 579	EUR 511	1.1327	04/01/2022	2	
USD 265	EUR 235	1.1273	31/01/2022	2	
USD 59	GBP 44	1.3266	31/01/2022	1	
USD 60	GBP 45	1.3348	04/01/2022	1	
USD 347	EUR 306	1.1337	31/01/2022	1	
USD 85	EUR 76	1.1287	31/01/2022	1	
USD 69	EUR 61	1.1286	31/01/2022	1	
USD 74	CHF 68	1.0874	31/01/2022	1	
USD 374	EUR 330	1.1334	31/01/2022	1	
USD 101	CHF 93	1.0864	04/01/2022	1	
USD 234	EUR 207	1.1337	31/01/2022	1	
USD 52	EUR 46	1.1327	04/01/2022		
USD 15	GBP 11	1.3407	05/01/2022	_	
USD 131	EUR 116	1.1338	31/01/2022	_	
USD 3	EUR 3	1.1322	05/01/2022	_	
USD 75	EUR 66	1.1324	04/01/2022	_	
USD 121	GBP 90	1.3496	31/01/2022	_	
EUR –	USD –	1.0000	05/01/2022	_	
USD –	GBP –	1.0000	04/01/2022	_	
USD 57	EUR 50	1.1334	31/01/2022	_	
USD 8	GBP 6	1.3397	05/01/2022	_	
USD 23	EUR 20	1.1304	31/01/2022	_	
USD 20	CHF 19	1.0857	31/01/2022	-	
USD 80	EUR 70	1.1324	04/01/2022	_	
USD 9	CHF 9	1.0949	31/01/2022	_	
Total unrealised	gain on forward for	eign currency cont	racts	11,628,055	0.1
Total Financial /	Assets at fair value th	rough profit or los	s	8,716,209,546	96.0
rotar i maricial P	issets at full value th	i sagii pione oi los		0,,10,200,040	50.0

# Financial liabilities at fair value through profit or loss Open Forward Currency Contracts: (0.01%) (2020: Nil)

% of Net Assets	Unrealised Loss US\$	Maturity Date	Currency Rate	Currency Bought	Currency Sold
(0.01)	(321,010)	31/01/2022	0.7550	USD 14,248,538	GBP 10,757,340
_	(100,545)	31/01/2022	0.9235	USD 7,110,690	CHF 6,566,801
-	(100,134)	31/01/2022	0.8866	USD 11,493,523	EUR 10,190,450
-	(48,099)	31/01/2022	0.8866	USD 5,520,903	EUR 4,894,973
-	(12,248)	04/01/2022	0.7460	USD 1,180,242	GBP 880,423
_	(6,087)	31/01/2022	0.8820	USD 1,736,375	EUR 1,531,567
_	(5,123)	31/01/2022	0.7564	USD 209,986	GBP 158,825
_	(4,757)	31/01/2022	0.8820	USD 1,357,078	EUR 1,197,009
_	(2,723)	31/01/2022	0.8871	USD 295,770	EUR 262,365
_	(2,151)	31/01/2022	0.8848	USD 321,765	EUR 284,712
_	(2,002)	04/01/2022	0.8840	USD 381,916	EUR 337,599
_	(1,959)	31/01/2022	0.8871	USD 212,794	EUR 188,761
-	(1,637)	31/01/2022	0.8835	USD 317,200	EUR 280,247
_	(1,507)	04/01/2022	0.8840	USD 287,529	EUR 254,165
-	(1,307)	04/01/2022	0.8840	USD 249,297	EUR 220,369
-	(1,003)	31/01/2022	0.7557	USD 42,776	GBP 32,324
_	(884)	31/01/2022	0.9192	USD 94,449	CHF 86,814
_	(878)	04/01/2022	0.8840	USD 166,055	EUR 146,793
_	(766)	31/01/2022	0.9192	USD 81,757	CHF 75,148
-	(757)	31/01/2022	0.9199	USD 74,735	CHF 68,746
_	(727)	31/01/2022	0.8871	USD 78,973	EUR 70,053
_	(706)	31/01/2022	0.8820	USD 201,373	EUR 177,621
_	(612)	31/01/2022	0.9131	USD 228,909	CHF 209,010
_	(573)	31/01/2022	0.8835	USD 111,030	EUR 98,095
_	(549)	04/01/2022	0.7460	USD 52,866	GBP 39,436
_	(537)	31/01/2022	0.8848	USD 80,375	EUR 71,119
_	(534)	04/01/2022	0.8840	USD 101,057	EUR 89,334
_	(533)	31/01/2022	0.9131	USD 199,585	CHF 182,235
-	(476)	04/01/2022	0.7460	USD 45,908	GBP 34,246
_	(438)	04/01/2022	0.8840	USD 82,981	EUR 73,355
_	(339)	31/01/2022	0.7409	USD 96,047	GBP 71,166
-	(334)	31/01/2022	0.8835	USD 64,670	EUR 57,137
_	(315)	31/01/2022	0.8823	USD 83,699	EUR 73,846

Portfolio Statements continued As at 31 December 2021

### Global Technology Fund continued

Open Forward O	Open Forward Currency Contracts: (0.01%) (2020: Nil) continued					
Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss US\$	% of Net Assets	
CHF 18,307	USD 19,811	0.9241	31/01/2022	(292)	_	
CHF 22,762	USD 24,745	0.9199	31/01/2022	(251)	_	
EUR 55,885	USD 63,342	0.8823	31/01/2022	(238)	_	
EUR 30,753	USD 34,756	0.8848	31/01/2022	(232)	_	
GBP 9,769	USD 13,040	0.7492	31/01/2022	(191)	-	
CHF 10,363	USD 11,267	0.9197	31/01/2022	(112)	_	
GBP 6,666	USD 8,938	0.7458	04/01/2022	(91)	-	
EUR 7,667	USD 8,643	0.8871	31/01/2022	(80)	-	
EUR 5,481	USD 6,179	0.8871	31/01/2022	(57)	-	
GBP 883	USD 1,168	0.7557	31/01/2022	(27)	-	
EUR 5,119	USD 5,802	0.8823	31/01/2022	(22)	-	
GBP 1,614	USD 2,164	0.7458	31/01/2022	(22)	-	
EUR 2,031	USD 2,290	0.8871	31/01/2022	(21)	-	
EUR 4,580	USD 5,193	0.8820	31/01/2022	(18)	-	
EUR 1,812	USD 2,048	0.8848	31/01/2022	(14)	-	
EUR 2,270	USD 2,569	0.8835	31/01/2022	(13)	-	
EUR 2,174	USD 2,459	0.8841	04/01/2022	(13)	-	
EUR 3,073	USD 3,484	0.8820	31/01/2022	(12)	-	
EUR 1,589	USD 1,798	0.8841	04/01/2022	(10)	-	
EUR 1,461	USD 1,653	0.8840	04/01/2022	(9)	-	
CHF 533	USD 577	0.9241	31/01/2022	(8)	-	
GBP 466	USD 625	0.7462	04/01/2022	(7)	-	
CHF 660	USD 718	0.9192	31/01/2022	(7)	-	
CHF 567	USD 617	0.9192	31/01/2022	(6)	-	
EUR 744	USD 842	0.8835	31/01/2022	(4)	-	
EUR 460	USD 519	0.8860	31/01/2022	(4)	-	
EUR 632	USD 717	0.8823	31/01/2022	(3)	-	
GBP 112	USD 148	0.7539	31/01/2022	(3)		
EUR 670	USD 759	0.8828	04/01/2022	(3)	-	
EUR 431	USD 488	0.8835	31/01/2022	(2)	-	
EUR 511	USD 579	0.8823	31/01/2022	(2)		
EUR 183	USD 206	0.8860	31/01/2022	(2)	-	
EUR 436	USD 494	0.8820	31/01/2022	(2)		

#### Financial liabilities at fair value through profit or loss

Open Forward Currency Contracts: (0.01%) (2020: Nil) continued

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss US\$	% of Net Assets
EUR 76	USD 85	0.8860	31/01/2022	(1)	_
CHF 474	USD 519	0.9131	31/01/2022	(1)	_
EUR 330	USD 374	0.8828	04/01/2022	(1)	_
GBP 45	USD 60	0.7492	31/01/2022	(1)	_
CHF 93	USD 101	0.9197	31/01/2022	(1)	_
CHF 503	USD 551	0.9131	31/01/2022	(1)	_
GBP 133	USD 179	0.7409	31/01/2022	(1)	_
EUR 46	USD 52	0.8824	31/01/2022	-	-
CHF 17	USD 19	0.9211	31/01/2022	-	_
GBP 11	USD 15	0.7459	31/01/2022	_	_
Total unrealised	l loss on forward fore	eign currency contr	acts	(624,035)	(0.01)
Total Financial L	iabilities at fair value	through profit or	loss	(624,035)	(0.01)

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 7,302,481,606)	8,715,585,511	96.00
Cash at Bank	405,019,610	4.46
Margin Cash	14,322,512	0.16
Other Net Liabilities	(56,530,487)	(0.62)
Net Assets Attributable to Holders of Redeemable Participating Shares	9,078,397,146	100.00

All securities are transferable securities and are admitted to an official stock exchange or dealt on a regulated market at the financial year end.

The counterparty for the options is Credit Suisse Securities (Europe) Limited.

The counterparty for the forward currency contracts is The Northern Trust Company.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	94.80	88.53
Exchange traded financial derivative instruments	0.28	0.57
OTC Financial derivative instruments	0.13	0.07
Other assets	4.79	10.83
	100.00	100.00

The % of Net Assets was rounded to Nil if the amount is less than 0.01.

Portfolio Statements continued As at 31 December 2021

### Healthcare Bluechip Fund

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 95.63% (2020: 93.85%)		
	Containers-Paper/Plastic: 2.68% (2020: Nil)		
25,414	AptarGroup	3,112,707	2.68
	Total Containers-Paper/Plastic	3,112,707	2.68
	Dental Supplies & Equipment: 2.72% (2020: 1.64%)		
4,800	Align Technology	3,154,464	2.72
	Total Dental Supplies & Equipment	3,154,464	2.72
	Diagnostic Equipment: 2.53% (2020: 2.27%)		
69,839	Avantor	2,943,015	2.53
	Total Diagnostic Equipment	2,943,015	2.53
	Diagnostic Kits: 2.30% (2020: Nil)		
34,937	Hologic	2,674,777	2.30
	Total Diagnostic Kits	2,674,777	2.30
	Dialysis Centers: Nil (2020: 3.04%)		
	Drug Delivery Systems: Nil (2020: 3.73%)	-	_
	Electronic Measuring Instruments: Nil (2020: 2.26%)	-	-
	Medical Instruments: 4.67% (2020: 4.31%)		
20,575	Alcon	1,823,218	1.57
84,768	Boston Scientific	3,600,945	3.10
	Total Medical Instruments	5,424,163	4.67
	Medical Labs & Testing Services: Nil (2020: 5.45%)	-	-
	Medical Products: 20.22% (2020: 13.83%)		
32,937	Abbott Laboratories	4,635,553	3.99
44,220	Baxter International	3,795,845	3.27
51,491	Envista	2,320,184	2.00
36,213	Siemens Healthineers	2,710,562	2.33
14,298	STERIS Plc	3,480,276	3.00
8,659	The Cooper Companies	3,627,602	3.12
22,936	Zimmer Biomet	2,913,789	2.51
	Total Medical Products	23,483,811	20.22

Holdings	Financial assets at fair value through profit or loss	Fair Value US <b>\$</b>	% of Net Assets
	Equities: 95.63% (2020: 93.85%) continued		
	Medical-Biomedical/Gene: 15.20% (2020: 14.77%)		
14,298	Alnylam Pharmaceuticals	2,424,655	2.09
2,595	Argenx	930,461	0.80
23,489	Biohaven Pharmaceutical	3,237,019	2.79
4,819	Bio-Rad Laboratories	3,641,092	3.13
6,857	Genmab	2,757,373	2.38
13,000	Seagen	2,009,800	1.73
12,255	United Therapeutics	2,648,060	2.28
	Total Medical-Biomedical/Gene	17,648,460	15.20
	Medical-Drugs: 23.68% (2020: 25.29%)		
46,814	AstraZeneca	5,502,479	4.74
50,754	Bristol-Myers Squibb	3,164,512	2.72
30,857	Horizon Therapeutics	3,325,150	2.86
51,575	Johnson & Johnson	8,822,935	7.60
40,400	Sanofi	4,069,621	3.50
22,967	UCB	2,620,949	2.26
	Total Medical-Drugs	27,505,646	23.68
	Medical-HMO: 10.64% (2020: 11.28%)		
21,800	Centene	1,796,320	1.55
8,681	Molina Healthcare	2,761,253	2.38
15,523	UnitedHealth Group Inc	7,794,719	6.71
	Total Medical-HMO	12,352,292	10.64
	Medical-Hospitals: 4.71% (2020: Nil)		
46,979	Acadia Healthcare	2,851,625	2.45
50,507	Ramsay Health Care	2,625,560	2.26
	Total Medical-Hospitals	5,477,185	4.71
	Medical-Outpatient/Home Med: 1.85% (2020: Nil)		
13,276	Amedisys	2,149,119	1.85
	Total Medical-Outpatient/Home Med	2,149,119	1.85
	Medical-Wholesale Drug Distribution: 2.35% (2020: 1.72%)		
20,532	AmerisourceBergen	2,728,498	2.35
	Total Medical-Wholesale Drug Distribution	2,728,498	2.35



Portfolio Statements continued As at 31 December 2021

### Healthcare Bluechip Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 95.63% (2020: 93.85%) continued		
	Physical Therapy/Rehab Centers: 2.08% (2020: 1.98%)		
36,996	Encompass Health	2,414,359	2.08
	Total Physical Therapy/Rehab Centers	2,414,359	2.08
	Therapeutics: Nil (2020: 2.28%)	-	-
	Total Equities	111,068,496	95.63
	Total Transferable Securities	111,068,496	95.63

#### Open Forward Currency Contracts: Nil (2020: Nil)

Currency SoldCurrency BoughtCurrency RateMaturity DateUSSUSD 433,262GBP 324,6081.334704/01/20226,403USD 27,714GBP 20,6721.340605/01/2022285USD 18,755GBP 14,0521.334704/01/2022277USD 22,440GBP 16,7391.340605/01/2022231USD 2,215GBP 1,6751.322231/01/202254USD 3,371GBP 2,5151.340605/01/202235USD 2,302GBP 1,7251.334704/01/202234	Net Assets
USD 27,714GBP 20,6721.340605/01/2022285USD 18,755GBP 14,0521.334704/01/2022277USD 22,440GBP 16,7391.340605/01/2022231USD 2,215GBP 1,6751.322231/01/202254USD 3,371GBP 2,5151.340605/01/202235	
USD 22,440         GBP 16,739         1.3406         05/01/2022         231           USD 2,215         GBP 1,675         1.3222         31/01/2022         54           USD 3,371         GBP 2,515         1.3406         05/01/2022         35	
USD 2,215         GBP 1,675         1.3222         31/01/2022         54           USD 3,371         GBP 2,515         1.3406         05/01/2022         35	-
USD 3,371 GBP 2,515 1.3406 05/01/2022 35	-
	_
USD 2,302 GBP 1,725 1.3347 04/01/2022 34	
	-
USD 1,412 GBP 1,053 1.3411 04/01/2022 14	-
USD 493 GBP 369 1.3347 04/01/2022 7	_
USD 91 GBP 68 1.3411 04/01/2022 1	-
USD 55 GBP 41 1.3401 05/01/2022 1	-
USD 76 GBP 57 1.3402 05/01/2022 1	_
USD 53 GBP 39 1.3406 05/01/2022 1	_
USD 121 GBP 91 1.3408 31/01/2022 1	-
USD – GBP – 1.3750 05/01/2022 –	_
USD 10 GBP 8 1.3417 04/01/2022 -	_
USD – GBP – 1.0000 05/01/2022 –	-
GBP – USD – 1.2857 04/01/2022 –	_
USD 2 GBP 2 1.3416 04/01/2022 –	_
Total unrealised gain on forward foreign currency contracts7,345	0.00
Total Financial Assets at fair value through profit or loss       111,075,841	95.63

#### Financial liabilities at fair value through profit or loss Open Forward Currency Contracts: Nil (2020: Nil)

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss US\$	% of Net Assets
GBP 59,651	USD 79,964	1.3405	04/01/2022	(830)	-
GBP 3,409	USD 4,570	1.3405	04/01/2022	(48)	_
GBP 3,207	USD 4,299	1.3405	04/01/2022	(45)	_
GBP 599	USD 804	1.3405	04/01/2022	(8)	_
GBP 9	USD 12	1.3401	04/01/2022	_	-
GBP 8	USD 11	1.3405	04/01/2022	-	_
Total unrealised	loss on forward fore	eign currency conti	acts	(931)	-
Total Financial L	iabilities at fair value	through profit or	loss	(931)	-

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 103,556,700)	111,074,910	95.63
Cash at Bank	4,560,436	3.93
Other Net Assets	512,779	0.44
Net Assets Attributable to Holders of Redeemable Participating Shares	116,148,125	100.00

All securities are transferable and are admitted to an official stock exchange or dealt on a regulated market at year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	94.67	91.66
OTC Financial derivative instruments	0.01	-
Other assets	5.32	8.34
	100.00	100.00

The % of Net Assets has been rounded to Nil if the amount is less than 0.01%.

Portfolio Statements continued As at 31 December 2021

### Healthcare Discovery Fund

Holdings	Financial assets at fair value through profit or loss	Fair Value US <b>\$</b>	% of Net Assets
	Equities: 95.54% (2020: 93.42%)		
	Commercial Services: 2.35% (2020: 1.03%)		
38,450	Medley	792,006	1.09
18,175	Progyny	915,111	1.26
	Total Commercial Services	1,707,117	2.35
	Consulting Services: 2.48% (2020: 1.06%)		
70,754	R1 RCM	1,803,519	2.48
	Total Consulting Services	1,803,519	2.48
	Containers-Metal/Glass: 2.19% (2020: 2.34%)		
16,504	Gerresheimer	1,589,679	2.19
	Total Containers-Metal/Glass	1,589,679	2.19
	Diagnostic Equipment: 0.03% (2020: 0.66%)		
34,847	Verici Dx	25,015	0.03
	Total Diagnostic Equipment	25,015	0.03
	Diagnostic Kits: 3.24% (2020: 3.27%)		
33,463	Meridian Bioscience	682,645	0.94
17,854	Natera	1,667,385	2.30
	Total Diagnostic Kits	2,350,030	3.24
	Disposable Medical Product: 1.95% (2020: 2.43%)		
9,969	Conmed	1,413,205	1.95
	Total Disposable Medical Product	1,413,205	1.95
	Drug Delivery Systems: 0.79% (2020: 1.27%)		
35,341	Revance Therapeutics	576,765	0.79
	Total Drug Delivery Systems	576,765	0.79
	Enterprise Software/Serv: 1.49% (2020: Nil)		
39,188	Evolent Health	1,084,332	1.49
	Total Enterprise Software/Serv	1,084,332	1.49
	Health Care Cost Contain: 0.66% (2020: 0.63%)		
10,770	HealthEquity	476,465	0.66
	Total Health Care Cost Contain	476,465	0.66

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 95.54% (2020: 93.42%) continued		
	Healthcare Safety Device: 3.14% (2020: 2.11%)		
15,173	Tandem Diabetes Care	2,283,840	3.14
	Total Healthcare Safety Device	2,283,840	3.14
	Insurance Brokers: Nil (2020: 0.58%)	-	_
	Medical Information System: 2.19% (2020: 1.70%)		
7,000	Health Catalyst	277,340	0.38
45,543	Lantheus	1,315,737	1.81
	Total Medical Information System	1,593,077	2.19
	Medical Instruments: 0.65% (2020: 4.46%)		
76,687	Stereotaxis	475,459	0.65
	Total Medical Instruments	475,459	0.65
	Medical Labs & Testing Services: 4.08% (2020: 6.81%)		
38,113	Evotec	1,842,040	2.54
10,917	Syneos Health	1,120,958	1.54
	Total Medical Labs & Testing Services	2,962,998	4.08
	Medical Products: 15.51% (2020: 12.61%)		
15,698	AtriCure	1,091,482	1.50
9,398	Castle Biosciences	402,892	0.55
33,846	Envista	1,525,101	2.10
9,847	Establishment Labs	665,559	0.92
20,929	Globus Medical	1,511,074	2.08
2,075	Inspire Medical Systems	477,375	0.66
17,399	LivaNova	1,521,195	2.10
34,650	NanoString Technologies	1,463,270	2.01
5,887	Omnicell	1,062,250	1.46
3,944	Penumbra	1,133,190	1.56
2,310	Shockwave Medical	411,942	0.57
	Total Medical Products	11,265,330	15.51
	Medical Wholesale Drug Distribution: Nil (2020: 1.41%)	-	-

Portfolio Statements continued As at 31 December 2021

### Healthcare Discovery Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value US <b>\$</b>	% of Net Assets
Holdings	Equities: 95.54% (2020: 93.42%) continued	033	Net Assets
	Medical-Biomedical/Gene: 25.75% (2020: 22.26%)		
27,273	Adjcet Bio	477,005	0.66
49,651	Arcutis Biotherapeutics	1,029,762	1.42
17,936	Arena Pharmaceuticals	1,666,972	2.30
17,182	Arrowhead	1,139,167	1.57
16,020	Biohaven Pharmaceutical	2,207,716	3.04
		714,849	0.98
16,028	Denali Therapeutics		
100,842	Exelixis	1,843,392	2.54
4,862	Horizon Therapeutics	523,929	0.72
48,209	Insmed	1,313,213	1.81
51,302	IVERIC bio	857,769	1.18
5,587	Mirati Therapeutics	819,557	1.13
106,422	Oncocyte	230,936	0.32
9,893	United Therapeutics	2,137,679	2.94
34,500	Valneva	961,218	1.32
17,160	Vericel	674,388	0.93
21,486	Xenon Pharmaceuticals	671,223	0.92
41,929	Y-mAbs Therapeutics	679,669	0.94
11,939	Zai Lab	750,366	1.03
	Total Medical-Biomedical/Gene	18,698,810	25.75
	Medical-Drugs: 11.69% (2020: 11.49%)		
3,490	ALK-Abello	1,830,312	2.52
48,790	Avadel	394,223	0.55
46,000	Hikma Pharmaceuticals	1,382,541	1.90
16,254	Laboratorios Farmaceuticos Rovi	1,364,123	1.88
37,790	Ocular Therapeutix	263,396	0.36
17,368	Pacira BioSciences	1,045,033	1.44
57,301	Richter Gedeon Nyrt	1,542,590	2.12
13,200	uniQure	273,768	0.38
17,712	Zealand Pharma	392,953	0.54
	Total Medical-Drugs	8,488,939	11.69
	Medical-HMO: Nil (2020: 2.50%)		_
	Medical-HMU: NII (2020: 2.50%)	-	

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 95.54% (2020: 93.42%) continued		
	Medical-Hospitals: 6.16% (2020: 3.58%)		
35,004	Acadia Healthcare	2,124,743	2.93
36,101	Krishna Institute of Medical Sciences	692,365	0.95
177,353	Max Healthcare Institute	1,056,689	1.46
11,090	Surgery Partners	592,317	0.82
	Total Medical-Hospitals	4,466,114	6.16
	Medical-Nursing Homes: 1.20% (2020: Nil)		
27,519	Korian	871,242	1.20
	Total Medical-Nursing Homes	871,242	1.20
	Medical-Outpatient/Home Med: 1.03% (2020: 1.23%)		
8,011	Addus HomeCare	749,109	1.03
	Total Medical-Outpatient/Home Med	749,109	1.03
	Medical-Output/Home Med: Nil (2020: 3.05%)	-	-
	Medical-Wholesale Drug Dististribution: Nil (2020: 3.16%)	-	_
	Medical-Wholesale Drug Distribution: 3.78% (2020: Nil)		
33,026	Owens & Minor	1,436,631	1.98
56,000	Ship Healthcare	1,303,287	1.80
	Total Medical-Wholesale Drug Distribution	2,739,918	3.78
	Pharmacy Services: 2.42% (2020: 1.13%)		
61,780	Option Care Health	1,757,023	2.42
	Total Pharmacy Services	1,757,023	2.42
	Physical Therapy/Rehab Centers: 2.05% (2020: 2.65%)		
22,797	Encompass Health	1,487,732	2.05
	Total Physical Therapy/Rehab Centers	1,487,732	2.05
	Therapeutics: 0.71% (2020: Nil)		
300,747	Recro Pharma	514,277	0.71
	Total Therapeutics	514,277	0.71
	Total Equities	69,379,995	95.54
	Total Transferable Securities	69,379,995	95.54

Portfolio Statements continued As at 31 December 2021

### Healthcare Discovery Fund continued

Open Forward	Currency Contracts: N	lil (2020: Nil)			
Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain US <b>\$</b>	% o Net Asset
USD 139	GBP 104	1.3405	04/01/2022	1	
Total unrealise	d gain on forward for	eign currency cont	racts	1	0.0
	-				
	Assets at fair value th		S	69,379,996	95.5
Financial liabiliti	Assets at fair value th es at fair value through p Currency Contracts: N	rofit or loss	S	69,379,996	95.5
Financial liabiliti	es at fair value through p	rofit or loss	s Maturity Date	69,379,996 Unrealised Loss US\$	95.54 % o Net Asset
Financial liabiliti Open Forward	es at fair value through p Currency Contracts: N	rofit or loss lil (2020: Nil)		Unrealised Loss	% 0
Financial liabiliti Open Forward Currency Sold GBP 104	es at fair value through p Currency Contracts: N Currency Bought	rofit or loss lil (2020: Nil) Currency Rate 1.3408	<b>Maturity Date</b> 04/01/2022	Unrealised Loss US\$	% 0

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 64,973,397)	69,379,995	95.54
Cash at Bank	4,037,118	5.56
Other Net Liabilities	(797,521)	(1.10)
Net Assets Attributable to Holders of Redeemable Participating Shares	72,619,592	100.00

All securities are transferable securities and are admitted to an official stock exchange or dealt on a regulated market at the financial year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	94.24	92.89
Other assets	5.76	7.11
	100.00	100.00

The % of Net Assets was rounded to Nil if the amount is less than 0.01.

## Healthcare Opportunities Fund

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 96.65% (2020: 99.05%)		
	Belgium: 2.78% (2020: Nil)		
521,850	UCB	59,552,495	2.78
	Total Belgium	59,552,495	2.78
	British Virgin Islands: 3.30% (2020: 2.13%)		
512,113	Biohaven Pharmaceutical	70,574,292	3.30
	Total British Virgin Islands	70,574,292	3.30
	Canada: 0.97% (2020: 1.06%)		
666,558	Xenon Pharmaceuticals	20,823,272	0.97
	Total Canada	20,823,272	0.97
	Denmark: 5.46% (2020: 3.71%)		
86,141	ALK-Abello	45,176,198	2.11
96,703	Genmab	38,886,723	1.82
1,469,559	Zealand Pharma	32,603,190	1.53
, ,	Total Denmark	116,666,111	5.46
	France: Nil (2020: 2.92%)	_	_
	Hungary: 1.69% (2020: 1.68%)		
1,339,663	Richter Gedeon Nyrt	36,064,815	1.69
	Total Hungary	36,064,815	1.69
	India: 4.69% (2020: Nil)		
3,015,648	Glenmark Life Sciences	25,600,431	1.20
1,497,296	Krishna Institute of Medical Sciences	28,715,967	1.34
7,700,284	Max Healthcare Institute	45,879,141	2.15
	Total India	100,195,539	4.69
	Ireland: 13.14% (2020: 9.57%)		
2,467,314	Avadel	19,935,897	0.93
912,149	Horizon Therapeutics	98,293,176	4.60
265,963	STERIS PIC	64,738,054	3.03
17,241,848	Uniphar – En Dublin	98,037,159	4.58
	Total Ireland	281,004,286	13.14
	Japan: 3.19% (2020: 3.45%)		
1,472,552	Medley	30,332,103	1.42
1,629,037	Ship Healthcare	37,912,545	1.77
	Total Japan	68,244,648	3.19
	Jersey: 0.97% (2020: 1.72%)		
8,028,149	Quotient	20,792,906	0.97
	Total Jersey	20,792,906	0.97

Portfolio Statements continued As at 31 December 2021

### Healthcare Opportunities Fund continued

Switzerland: 2:56% (2020: 6.53%)         54,684,591           617,115         Alcon         54,684,591           Total Switzerland         54,684,591           0,206,896         Angle         10,004,248           754,536         AstraZeneca         88,687,544           536,168         LivaNova         46,877,168           13,571,429         Redx Pharma         15,808,368           Total United Kingdom         161,377,328           011ted States: 50,35% (2020: 60,65%)         91,722           4,adia Healthcare         41,987,525           425,066         Addus HomeCare         39,747,922           1,432,920         AngioDynamics         39,519,934           322,299         AptarGroup         39,475,182           511,060         AtriCure         35,534,002           1,233,203         Avantor         51,967,174           658,805         Axonics Modulation Technologies         37,285,080           63,280         Bio-Rad Laboratories         47,812,470           1,493,350         Boston Scientific         63,437,508           63,280         Bio-Rad Laboratories         47,812,470           1,493,350         Boston Scientific         63,283,318           674,608	Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
Total Switzerland         \$4,684,591           United Kingdom: 7.55% (2020: 5.63%)         10,004,248           6,206,896         Angle         10,004,248           754,536         AstraZeneca         88,687,544           536,168         LivaNova         46,877,168           13,571,429         Redx Pharma         15,808,368           Total United Kingdom         161,377,328           United states: 50.35% (2020: 60.65%)         161,377,328           691,722         Acadia Healthcare         41,987,525           425,066         Addus HomeCare         39,747,922           1,432,920         AngioDynamics         39,519,934           322,299         AptarGroup         39,519,934           322,299         AptarGroup         39,5534,002           1,233,203         Avantor         51,967,174           665,805         Axonics Modulation Technologies         37,285,080           63,280         Bio-Rad Laboratories         47,812,470           1,493,350         Boston Scientific         63,437,508           701,805         CVS Health         44,024,918           1,004,868         Envista         45,279,352           540,116         Globus Medical         38,396,375		Switzerland: 2.56% (2020: 6.53%)		
United Kingdom: 7.55% (2020: 5.63%)           6,206.896         Angle         10,004,248           754,536         AstraZeneca         88,687,544           536,168         LivaNova         46,877,168           13,571,429         Redx Pharma         15,808,368           Total United Kingdom         161,377,328           United States: 50.35% (2020: 60.65%)         691,772         Acadia Healthcare         41,987,525           425,066         Addus HomeCare         39,747,922         1,432,920           1,432,920         AngioDynamics         39,519,934         322,299           AptarGroup         39,475,182         511,060         AtriCure         35,534,002           1,233,203         Avantor         51,967,174         655,805         Axonics Modulation Technologies         37,285,080         63,280         Bio-Rad Laboratories         47,812,470           1,493,350         Boston Scientific         63,437,508         701,805         CVS Health         72,398,204         2,120,875         Cytokinetics         96,699,482         674,608         Encompass Health         44,024,918         1,004,868         Envista         38,353,188         77,056         ModivCare         40,868,171           1,916,951         IVERIC bio         30,238,371	617,115	Alcon	54,684,591	2.56
6,205,896         Angle         10,004,248           754,536         AstraZeneca         88,687,544           536,168         LivaNova         46,877,168           13,571,429         Redx Pharma         15,808,368           Total United Kingdom         161,377,328           United States: 50.35% (2020: 60.65%)         601,977,328           691,722         Acadia Healthcare         41,987,525           425,066         Addus HomeCare         39,747,922           1,432,920         AngioDynamics         39,519,934           322,299         AptarGroup         39,475,182           511,060         AtriCure         35,534,002           1,233,203         Avantor         51,967,174           665,805         Axonics Modulation Technologies         37,285,080           665,805         Axonics Modulation Technologies         37,285,080           701,805         CVS Health         72,398,204           2,120,875         Cytokinetics         96,659,482           674,608         Encompass Health         44,024,918           1,004,868         Envista         45,279,352           1,004,868         Envista         36,353,188           277,066         Modiral         38,965,375 </td <td></td> <td>Total Switzerland</td> <td>54,684,591</td> <td>2.56</td>		Total Switzerland	54,684,591	2.56
7.54,536       AstraZeneca       88,687,544         536,168       LivaNova       46,877,168         13,571,429       Redx Pharma       15,808,368         Total United Kingdom       161,377,328         United States: 50.35% (2020: 60.65%)         691,722       Acadia Healthcare       41,987,525         425,066       Addus HomeCare       39,747,922         1,432,920       AngioDynamics       39,519,934         322,299       AptarGroup       39,519,812         11,065,805       Axonics Modulation Technologies       37,285,080         63,280       Bio-Rad Laboratories       34,37,08         1		United Kingdom: 7.55% (2020: 5.63%)		
S36,168         LivaNova         46,877,168           13,571,429         Redx Pharma         15,808,368           Total United Kingdom         161,377,328           United States: 50.35% (2020: 60.65%)           691,722         Acadia Healthcare         41,987,525           425,066         Addus HomeCare         39,747,922           1,432,920         AngioDynamics         39,519,934           322,299         AptarGroup         39,475,182           11,233,203         Avantor         51,967,174           665,805         Axonics Modulation Technologies         37,285,080           63,280         Bio-Rad Laboratories         47,812,470           1,439,350         Boston Scientific         63,437,508           701,805         Cytokinetics         96,669,482           724,508         Encompass Health         44,024,918           1,004,868         Envista         45,279,352           540,016         Globus Medical         38,956,375           1,808,515         IVERIC bio         30,238,371           615,621         Merit Medical Systems         38,353,188           277,064         ModioxCare Health         54,844,123           1,916,958         Revance Therapeutics	6,206,896	Angle	10,004,248	0.47
13,571,429       Redx Pharma       15,808,368         Total United Kingdom         United States: 50.35% (2020: 60.65%)         691,722       Acadia Healthcare       41,987,525         425,066       Addus HomeCare       39,747,922         1,432,920       AngioDynamics       39,747,922         1,432,920       AngioDynamics       39,747,922         1,432,920       AngioDynamics       39,747,922         1,233,203       Avantor       51,967,174         665,805       Axonics Modulation Technologies       37,285,080         612,280       Bio-Rad Laboratories       47,812,470         1,493,350       Boston Scientific       63,437,508         701,805       CVS Health       72,398,204         2,120,875       Cytokinetics       96,669,482         674,608       Encompass Health       44,024,918         1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         165,621       Merit Medical Systems       38,353,188         277,066       Modina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123 </td <td>754,536</td> <td>AstraZeneca</td> <td>88,687,544</td> <td>4.15</td>	754,536	AstraZeneca	88,687,544	4.15
Total United Kingdom         161,377,328           United States: 50.35% (2020: 60.65%)         4           691,722         Acadia Healthcare         41,987,525           425,066         Addus HomeCare         39,747,922           1,432,920         AngioDynamics         39,519,934           322,299         AptarGroup         39,475,182           511,060         AtriCure         35,534,002           1,233,203         Avantor         51,967,174           665,805         Axonics Modulation Technologies         37,285,080           63,280         Bio-Rad Laboratories         47,812,470           1,493,350         Boston Scientific         63,437,508           701,805         CVS Health         72,398,204           2,120,875         Cytokinetics         96,669,482           674,608         Encompass Health         44,024,918           1,004,868         Envista         45,279,352           540,116         Globus Medical         38,956,375           1,808,515         IVERIC bio         30,238,371           615,621         Merit Medical Systems         38,353,188           27,066         ModivCare         41,086,117           21,43872         Option Care Health         54,584,	536,168	LivaNova	46,877,168	2.19
United States: 50.35% (2020: 60.65%)           691,722         Acadia Healthcare         41,987,525           425,066         Addus HomeCare         39,747,922           1,432,920         AngioDynamics         39,519,934           322,299         AptarGroup         39,475,182           511,060         AtriCure         35,534,002           1,233,203         Avantor         51,967,174           665,805         Axonics Modulation Technologies         37,285,080           63,280         Bio-Rad Laboratories         47,812,470           1,493,350         Boston Scientific         63,437,508           701,805         CVS Health         72,398,204           2,120,875         Cytokinetics         96,669,482           674,608         Encompass Health         44,024,918           1,004,868         Envista         45,279,352           540,116         Globus Medical         38,996,375           1,808,515         IVERIC bio         30,238,371           615,621         Merit Medical Systems         38,353,188           277,066         ModivCare         41,086,117           214,532         Molina Healthcare         68,238,339           1,928,415         Option Care Health         52,	13,571,429	Redx Pharma	15,808,368	0.74
691,722Acadia Healthcare41,987,525425,066Addus HomeCare39,747,9221,432,920AngioDynamics39,519,934322,299AptarGroup39,475,182511,060AtriCure35,534,0021,233,203Avantor51,967,174665,805Axonics Modulation Technologies37,285,08063,280Bio-Rad Laboratories47,812,4701,493,350Boston Scientific63,437,508701,805CVS Health72,398,2042,120,875Cytokinetics96,669,48274,408Encompass Health44,024,9181,004,868Envista45,279,352540,116Globus Medical38,996,3751,808,515IVERIC bio30,238,371615,621Merit Medical Systems38,353,188277,066ModivCare41,086,117214,532Molina Healthcare68,238,3391,928,415Option Care Health54,844,1231,916,958Revance Therapeutics31,284,755125,459The Cooper Companies52,559,793220,038United Therapeutics43,656,371125,459The Cooper Companies52,559,793220,203United Therapeutics1,076,501,088Total United States1,076,501,088		Total United Kingdom	161,377,328	7.55
425,066       Addus HomeCare       39,747,922         1,432,920       AngioDynamics       39,519,934         322,299       AptarGroup       39,475,182         511,060       AtriCure       35,534,002         1,233,203       Avantor       51,967,174         665,805       Axonics Modulation Technologies       37,285,080         63,280       Bio-Rad Laboratories       47,812,470         1,493,350       Boston Scientific       63,437,508         701,805       CVS Health       72,398,204         2,120,875       Cytokinetics       96,669,482         674,608       Encompass Health       44,024,918         1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       43,247,553         1,916,958       Revance Therapeutics       31,284,755         215,459       The Cooper Companies       52,559,793         202,038       Uni		United States: 50.35% (2020: 60.65%)		
1,432,920       AngioDynamics       39,475,182         1,432,920       AptarGroup       39,475,182         511,060       AtriCure       35,534,002         1,233,203       Avantor       51,967,174         665,805       Axonics Modulation Technologies       37,285,080         63,280       Bio-Rad Laboratories       47,812,470         1,493,350       Boston Scientific       63,437,508         701,805       CVS Health       72,398,204         2,120,875       Cytokinetics       96,669,482         674,608       Encompass Health       44,024,918         1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         213,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038 <td< td=""><td>691,722</td><td>Acadia Healthcare</td><td>41,987,525</td><td>1.96</td></td<>	691,722	Acadia Healthcare	41,987,525	1.96
322,299       AptarGroup       39,475,182         511,060       AtriCure       35,534,002         1,233,203       Avantor       51,967,174         665,805       Axonics Modulation Technologies       37,285,080         63,280       Bio-Rad Laboratories       47,812,470         1,493,350       Boston Scientific       63,437,508         701,805       CVS Health       72,398,204         2,120,875       Cytokinetics       96,669,482         674,608       Encompass Health       44,024,918         1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         10,76,501,088	425,066	Addus HomeCare	39,747,922	1.86
AtriCure       35,534,002         1,233,203       Avantor       51,967,174         665,805       Axonics Modulation Technologies       37,285,080         63,280       Bio-Rad Laboratories       47,812,470         1,493,350       Boston Scientific       63,437,508         701,805       CVS Health       72,398,204         2,120,875       Cytokinetics       96,669,482         674,608       Encompass Health       44,024,918         1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         Total United States       1,076,501,088	1,432,920	AngioDynamics	39,519,934	1.85
1,233,203       Avantor       51,967,174         1,233,203       Avanics Modulation Technologies       37,285,080         665,805       Axonics Modulation Technologies       37,285,080         63,280       Bio-Rad Laboratories       47,812,470         1,493,350       Boston Scientific       63,437,508         701,805       CVS Health       72,398,204         2,120,875       Cytokinetics       96,669,482         674,608       Encompass Health       44,024,918         1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         Total Equities       2,066,481,371	322,299	AptarGroup	39,475,182	1.85
Axonics Modulation Technologies       37,285,080         63,280       Bio-Rad Laboratories       47,812,470         1,493,350       Boston Scientific       63,437,508         701,805       CVS Health       72,398,204         2,120,875       Cytokinetics       96,669,482         674,608       Encompass Health       44,024,918         1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         Total Equities       2,066,481,371	511,060	AtriCure	35,534,002	1.66
63,280         Bio-Rad Laboratories         47,812,470           1,493,350         Boston Scientific         63,437,508           701,805         CVS Health         72,398,204           2,120,875         Cytokinetics         96,669,482           674,608         Encompass Health         44,024,918           1,004,868         Envista         45,279,352           540,116         Globus Medical         38,996,375           1,808,515         IVERIC bio         30,238,371           615,621         Merit Medical Systems         38,353,188           277,066         ModivCare         41,086,117           214,532         Molina Healthcare         68,238,339           1,928,415         Option Care Health         54,844,123           1,916,958         Revance Therapeutics         31,284,755           212,038         United Therapeutics         43,656,371           202,038         United States         1,076,501,088           Total Equities         2,066,481,371	1,233,203	Avantor	51,967,174	2.43
1,493,350       Boston Scientific       63,437,508         701,805       CVS Health       72,398,204         2,120,875       Cytokinetics       96,669,482         674,608       Encompass Health       44,024,918         1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         Total Equities       2,066,481,371	665,805	Axonics Modulation Technologies	37,285,080	1.74
701,805       CVS Health       72,398,204         721,20,875       Cytokinetics       96,669,482         674,608       Encompass Health       44,024,918         1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         125,459       Total United States       1,076,501,088	63,280	Bio-Rad Laboratories	47,812,470	2.24
2,120,875       Cytokinetics       96,669,482         674,608       Encompass Health       44,024,918         1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         202,038       United Therapeutics       43,656,371         202,038       United Therapeutics       43,656,371         Total United States       2,066,481,371	1,493,350	Boston Scientific	63,437,508	2.97
Addition         Addition           674,608         Encompass Health         44,024,918           1,004,868         Envista         45,279,352           540,116         Globus Medical         38,996,375           1,808,515         IVERIC bio         30,238,371           615,621         Merit Medical Systems         38,353,188           277,066         ModivCare         41,086,117           214,532         Molina Healthcare         68,238,339           1,928,415         Option Care Health         54,844,123           1,916,958         Revance Therapeutics         31,284,755           413,872         Surgery Partners         22,104,903           125,459         The Cooper Companies         52,559,793           202,038         United Therapeutics         43,656,371           Total United States           Total Equities	701,805	CVS Health	72,398,204	3.39
1,004,868       Envista       45,279,352         540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         Total United States       1,076,501,088	2,120,875	Cytokinetics	96,669,482	4.52
540,116       Globus Medical       38,996,375         1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         Total United States       1,076,501,088	674,608	Encompass Health	44,024,918	2.06
1,808,515       IVERIC bio       30,238,371         615,621       Merit Medical Systems       38,353,188         277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         Total Equities       2,066,481,371	1,004,868	Envista	45,279,352	2.12
615,621Merit Medical Systems38,353,188277,066ModivCare41,086,117214,532Molina Healthcare68,238,3391,928,415Option Care Health54,844,1231,916,958Revance Therapeutics31,284,755413,872Surgery Partners22,104,903125,459The Cooper Companies52,559,793202,038United Therapeutics43,656,371Total United States1,076,501,088	540,116	Globus Medical	38,996,375	1.82
277,066       ModivCare       41,086,117         214,532       Molina Healthcare       68,238,339         1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         Total United States       1,076,501,088	1,808,515	IVERIC bio	30,238,371	1.42
214,532Molina Healthcare68,238,3391,928,415Option Care Health54,844,1231,916,958Revance Therapeutics31,284,755413,872Surgery Partners22,104,903125,459The Cooper Companies52,559,793202,038United Therapeutics43,656,371Total United States1,076,501,088Total Equities2,066,481,371	615,621	Merit Medical Systems	38,353,188	1.79
1,928,415       Option Care Health       54,844,123         1,916,958       Revance Therapeutics       31,284,755         413,872       Surgery Partners       22,104,903         125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         Total United States         Total Equities	277,066	ModivCare	41,086,117	1.92
1,916,958Revance Therapeutics31,284,755413,872Surgery Partners22,104,903125,459The Cooper Companies52,559,793202,038United Therapeutics43,656,371Total United States1,076,501,088Total Equities2,066,481,371	214,532	Molina Healthcare	68,238,339	3.19
413,872Surgery Partners22,104,903125,459The Cooper Companies52,559,793202,038United Therapeutics43,656,371Total United StatesTotal Equities2,066,481,371	1,928,415	Option Care Health	54,844,123	2.57
125,459       The Cooper Companies       52,559,793         202,038       United Therapeutics       43,656,371         Total United States         Total Equities         2,066,481,371	1,916,958	Revance Therapeutics	31,284,755	1.46
202,038 United Therapeutics 43,656,371 Total United States 1,076,501,088 Total Equities 2,066,481,371	413,872	Surgery Partners	22,104,903	1.03
Total United States         1,076,501,088           Total Equities         2,066,481,371	125,459	The Cooper Companies	52,559,793	2.46
<b>Total Equities</b> 2,066,481,371	202,038	United Therapeutics	43,656,371	2.04
		Total United States	1,076,501,088	50.35
		Total Equities	2,066,481,371	96.65
Total Transferable Securities2,066,481,371		Total Transferable Securities	2,066,481,371	96.65

# Financial assets at fair value through profit or loss Open Forward Currency Contracts: Nil (2020: Nil)

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain US\$	% of Net Assets
USD 3,964,084	EUR 3,508,026	1.1300	31/01/2022	26,991	_
USD 677,854	GBP 507,860	1.3347	04/01/2022	10,017	_
USD 771,231	GBP 575,272	1.3406	05/01/2022	7,946	_
USD 432,973	GBP 322,960	1.3406	05/01/2022	4,461	-
USD 259,698	EUR 229,333	1.1324	04/01/2022	1,100	_
USD 211,758	EUR 186,926	1.1328	31/01/2022	907	-
USD 40,485	EUR 35,785	1.1313	05/01/2022	210	-
USD 41,697	EUR 36,822	1.1324	04/01/2022	177	-
USD 27,446	EUR 24,260	1.1313	05/01/2022	142	-
USD 8,472	GBP 6,317	1.3411	04/01/2022	84	-
USD 2,974	GBP 2,219	1.3402	05/01/2022	32	_
USD 4,261	EUR 3,763	1.1324	04/01/2022	18	_
USD 560	EUR 495	1.1313	05/01/2022	3	_
USD 703	EUR 621	1.1324	04/01/2022	3	_
USD 373	EUR 329	1.1313	05/01/2022	2	_
EUR –	USD –	1.1250	05/01/2022	_	_
GBP –	USD –	1.3333	05/01/2022	_	_
Total unrealised	gain on forward for	eign currency cont	racts	52,093	0.00
Total Financial A	ssets at fair value th	rough profit or los	S	2,066,533,464	96.65

#### Financial liabilities at fair value through profit or loss Open Forward Currency Contracts: Nil (2020: Nil)

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss US <b>\$</b>	% of Net Assets
 GBP 1,438,299	USD 1,928,096	1.3405	04/01/2022	(20,008)	_
EUR 167,156	USD 189,099	1.1313	04/01/2022	(991)	_
EUR 54,396	USD 61,537	1.1313	04/01/2022	(322)	_
EUR 2,262	USD 2,559	1.1311	04/01/2022	(14)	_
GBP 647	USD 867	1.3401	04/01/2022	(9)	_
EUR 753	USD 851	1.1311	04/01/2022	(5)	_
EUR 100	USD 113	1.1313	04/01/2022	(1)	_
EUR 18	USD 21	1.1311	05/01/2022	-	_
Total unrealised	loss on forward fore	eign currency contr	acts	(21,350)	-
Total Financial Li	abilities at fair value	through profit or	loss	(21,350)	-



Portfolio Statements continued As at 31 December 2021

### Healthcare Opportunities Fund continued

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 1,685,606,298)	2,066,512,114	96.65
Cash at Bank	67,611,320	3.16
Margin Cash	100	_
Other Net Assets	4,099,910	0.19
Net Assets Attributable to Holders of Redeemable Participating Shares	2,138,223,444	100.00

All securities are transferable securities and are admitted to an official stock exchange or dealt on a regulated market at the financial year end.

The counterparty for the forward currency contracts is The Northern Trust Company.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	96.13	98.35
Other assets	3.87	1.65
	100.00	100.00

The % of Net Assets was rounded to Nil if the amount is less than 0.01.

### Income Opportunities Fund

Holdings	Financial assets at fair value through profit or loss	Fair Value GBP£	% of Net Assets
nolulings	Corporate Bonds: 15.58% (2020: 32.10%)	GDF1	Net Assets
	Cyprus: 0.69% (2020: Nil)		
750,000	Hellenic Bank 10.000% 31/12/2049	401,120	0.69
	Total Cyprus	401,120	0.69
	Marshall Islands: Nil (2020: 1.22%)		
	Mauritius: 1.75% (2020: 1.69%)		
300,000	Bayport Management 10.500% 19/12/2022	211,940	0.36
1,100,000	Bayport Management 11.500% 14/06/2022	806,385	1.39
	Total Mauritius	1,018,325	1.75
	Netherlands: 2.11% (2020: 4.71%)		
1,055,525	Stichting AK Rabobank Certificaten FRN 31/12/2049	1,222,986	2.11
	Total Netherlands	1,222,986	2.11
	Portugal: 0.57% (2020: Nil)		
400,000	Banco Comercial Portugues 4.000% 17/05/2032	331,223	0.57
	Total Portugal	331,223	0.57
	United Kingdom: 9.15% (2020: 16.18%)		
50,000	HDL Debenture 10.375% 31/07/2023	56,375	0.10
8,000,000	International Personal Finance 7.000% 21/10/2024	653,924	1.13
700,000	International Personal Finance 9.750% 12/11/2025	631,199	1.09
750,000	Jupiter Fund Management FRN 27/07/2030	879,844	1.51
400,000	Pension Insurance FRN (Perpetual)	477,061	0.82
1,100,000	Provident Financial 8.875% 13/01/2032	1,173,342	2.02
450,000	Rothesay Life FRN (Perpetual)	510,169	0.88
600,000	Shawbrook FRN 10/10/2030	630,675	1.09
300,000	Shawbrook FRN (Perpetual)	298,409	0.51
	Total United Kingdom	5,310,998	9.15
	United States: 1.31% (2020: 8.30%)		
999,700	Burford Capital Finance 6.125% 12/08/2025	760,487	1.31
	Total United States	760,487	1.31
	Total Corporate Bonds	9,045,139	15.58

Portfolio Statements continued As at 31 December 2021

### Income Opportunities Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value GBP£	% of Net Assets
	Government Bonds: 4.90% (2020: Nil)		
	Singapore: 2.55% (2020: Nil)		
1,500,000	Singapore Government Bond 2.750% 01/07/2023	846,412	1.46
1,100,000	Singapore Government Bond 3.000% 01/09/2024	633,983	1.09
	Total Singapore	1,480,395	2.55
	United States: 2.35% (2020: Nil)		
850,000	United States Treasury Inflation Indexed Bonds 0.132% 15/04/2026	714,931	1.23
530,000	United States Treasury Inflation Indexed Bonds 3.259% 15/01/2027	648,829	1.12
	Total United States	1,363,760	2.35
	Total Government Bonds	2,844,155	4.90
	Equities: 63.95% (2020: 68.64%)		
	Australia: 1.12% (2020: 0.66%)		
650,000	Litigation Capital Management	651,300	1.12
	Total Australia	651,300	1.12
	Belgium: Nil (2020: 2.05%)		
	Bermuda: 2.69% (2020: 4.26%)		
47,500	Arch Capital	1,558,843	2.69
	Total Bermuda	1,558,843	2.69
	Canada: 1.95% (2020: 1.42%)		
20,000	Toronto-Dominion Bank	1,133,690	1.95
	Total Canada	1,133,690	1.95
	Finland: 3.50% (2020: 3.27%)		
55,000	Sampo	2,034,609	3.50
	Total Finland	2,034,609	3.50
	France: Nil (2020: 0.71%)		
	Germany: 1.92% (2020: 2.01%)		
6,400	Allianz	1,115,798	1.92
	Total Germany	1,115,798	1.92
	Guernsey: 6.07% (2020: 5.37%)		
137,916	Chenavari Capital Solutions Red Ord	-	-
330,000	Doric Nimrod Air Two	227,700	0.39
2,350,000	DP Aircraft I	26,025	0.04
575,000	ICG-Longbow Senior Secured UK Property Debt Investments	467,475	0.81
575,000	Real Estate Credit Investments	882,625	1.52
1,100,000	Tufton Oceanic Assets Fund	1,112,629	1.92
1,100,000	UK Mortgages	806,300	1.39
	Total Guernsey	3,522,754	6.07

Holdings	Financial assets at fair value through profit or loss	Fair Value GBP£	% of Net Assets
	Equities: 63.95% (2020: 68.64%) continued		
	Netherlands: 3.35% (2020: 1.83%)		
22,500	Flow Traders	608,292	1.05
130,000	ING Groep	1,336,194	2.30
	Total Netherlands	1,944,486	3.35
	Norway: 1.50% (2020: 2.06%)		
70,000	SpareBank 1 SMN	873,246	1.50
	Total Norway	873,246	1.50
	Republic of South Korea: 0.94% (2020: Nil)		
23,850	Shinhan Financial	545,108	0.94
	Total Republic of South Korea	545,108	0.94
	Singapore: 1.95% (2020: 2.24%)		
770,000	Fortune Real Estate Investment Trust REIT	584,079	1.01
87,500	Oversea-Chinese Banking	546,276	0.94
	Total Singapore	1,130,355	1.95
	Sweden: 1.33% (2020: Nil)		
75,000	Skandinaviska Enskilda Banken	769,694	1.33
	Total Sweden	769,694	1.33
	Switzerland: 4.82% (2020: 4.33%)		
14,000	Chubb	1,998,110	3.44
60,000	UBS	798,310	1.38
	Total Switzerland	2,796,420	4.82
	Thailand: 1.48% (2020: 2.39%)		
405,500	Tisco Financial	860,375	1.48
	Total Thailand	860,375	1.48
	United Kingdom: 20.78% (2020: 18.41%)		
180,000	Beazley	839,340	1.44
114,000	City of London Investment	570,000	0.98
270,000	Direct Line Insurance	753,300	1.30
700,000	Distribution Finance Capital	343,000	0.59
1,275,000	Ground Rents Income Fund	892,500	1.54
575,000	International Personal Finance	741,750	1.28
53,400	Orchard Funding	27,501	0.05
225,000	OSB	1,247,625	2.15
390,000	Personal	1,267,500	2.18
100,000	Provident Financial	359,200	0.62

 $\bigcirc$ 

Portfolio Statements continued As at 31 December 2021

# Income Opportunities Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value GBP£	% of Net Assets
	Equities: 63.95% (2020: 68.64%) continued		
	United Kingdom: 20.78% (2020: 18.41%) continued		
2,750,000	Riverstone Credit Opportunities Income Fund	1,766,400	3.04
750,000	RM Secured Direct Lending	712,500	1.23
14,908	Schroders	343,629	0.59
1,475,000	VPC Specialty Lending	1,359,950	2.34
600,000	XPS Pensions	840,000	1.45
	Total United Kingdom	12,064,195	20.78
	United States: 10.55% (2020: 17.63%)		
60,000	Ares Capital	938,683	1.62
5,000	Blackstone Group	477,648	0.82
7,750	East West Bancorp	450,197	0.78
15,000	Esquire Financial	350,179	0.60
87,850	Golub Capital BDC	1,001,443	1.73
8,000	JPMorgan Chase	935,287	1.61
50,000	SLR Investment	680,350	1.17
22,149	SLR Senior Investment	228,612	0.39
30,000	Wells Fargo	1,062,719	1.83
	Total United States	6,125,118	10.55
	Total Equities	37,125,991	63.95
	Total Transferable Securities	49,015,285	84.43
	Financial assets at fair value through profit or loss		

Futures Contracts – Unrealised Gains: 0.05% (2020: Nil)

			No. of	Unrealised	% of
Description	Country	Currency	Contracts	Gain	Net Assets
Germany: 0.05% (2020: Nil)					
Future Euro-Bund Eux Mar22	DE	GBP	(10)	24,852	0.05
Total Germany				24,852	0.05
United Kingdom: Nil (2020: Nil)					
	UK	GBP	_	_	-
Future LIF Long Gilt Mar22	UK	GBP	(10)	1,000	-
Total United Kingdom				1,000	-
Total Futures Contracts – Unrea	lised Gains			25,852	0.05
Total Financial Assets at fair va	lue through pro	fit or loss		49,041,137	84.48

#### Financial liabilities at fair value through profit or loss

Futures Contracts – Unrealised Losses: Nil (2020: (0.03%))

United Kingdom: Nil (2020: (0.03%))

#### Open Forward Currency Contracts: (0.77%) (2020: (0.96%))

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss GBP£	% of Net Assets
GBP 12,638,839	USD 16,711,364	0.7563	31/01/2022	(300,102)	(0.52)
GBP 4,375,696	USD 5,785,646	0.7563	31/01/2022	(103,898)	(0.18)
GBP 1,093,808	EUR 1,279,814	0.8547	31/01/2022	(18,747)	(0.03)
GBP 968,351	EUR 1,133,024	0.8547	31/01/2022	(16,597)	(0.03)
GBP 237,863	EUR 278,313	0.8547	31/01/2022	(4,077)	(0.01)
GBP 9,713	EUR 11,365	0.8547	31/01/2022	(166)	_
Total unrealised	loss on forward fore	ign currency conti	acts	(443,587)	(0.77)
Total Financial Lia	abilities at fair value	through profit or	loss	(443,587)	(0.77)

	Fair Value GBP£	% of Net Assets
Total Value of Investments (Cost: GBP£ 42,183,357)	48,597,550	83.71
Cash at Bank	9,817,635	16.91
Margin Cash	97,949	0.17
Other Net Liabilities	(460,435)	(0.79)
Net Assets Attributable to Holders of Redeemable Participating Shares	58,052,699	100.00

All securities are transferable and are admitted to an official stock exchange or dealt on a regulated market at year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	78.01	98.05
Other assets	21.95	1.95
	100.00	100.00

The % of Net Assets has been rounded to Nil if the amount is less than 0.01%.



# Japan Value Fund

		Fair Value	% of
Holdings	Financial assets at fair value through profit or loss	JPY	Net Assets
	Equities: 98.91% (2020: 98.33%)		
	Basic Materials: 5.85% (2020: 5.31%)		
390,000	Nihon Parkerizing	438,750,000	1.86
25,000	SK Kaken	945,000,000	3.99
	Total Basic Materials	1,383,750,000	5.85
	Communications: 11.03% (2020: 12.14%)		
180,000	Amuse	377,100,000	1.59
270,000	CONEXIO	398,520,000	1.68
820,000	SKY Perfect JSAT	344,400,000	1.46
140,000	SoftBank Group	760,760,000	3.22
240,000	Tokyo Broadcasting System	400,560,000	1.69
230,000	TV Asahi	329,590,000	1.39
	Total Communications	2,610,930,000	11.03
	Consumer Discretionary: 3.35% (2020: Nil)		
45,000	Shimamura	434,700,000	1.84
200,000	Toyo Tire	358,800,000	1.51
	Total Consumer Discretionary	793,500,000	3.35
	Consumer Staples: 1.80% (2020: Nil)		
369,400	Lifedrink	425,918,200	1.80
	Total Consumer Staples	425,918,200	1.80
	Consumer, Cyclical: 11.85% (2020: 9.63%)		
230,000	Honda Motor	742,900,000	3.14
215,000	Suzuki Motor	952,235,000	4.02
229,700	Торге	273,572,700	1.16
300,000	TS Tech	424,200,000	1.79
225,000	United Arrows	411,975,000	1.74
	Total Consumer, Cyclical	2,804,882,700	11.85

Holdings	Financial assets at fair value through profit or loss	Fair Value JPY	% of Net Assets
	Equities: 98.91% (2020: 98.33%) continued		
	Consumer, Non-cyclical: 19.76% (2020: 16.84%)		
100,000	Aeon Delight	337,000,000	1.42
145,000	Benesse Holdings	327,555,000	1.38
130,000	Hogy Medical	423,800,000	1.79
165,000	Kissei Pharmaceutical	371,910,000	1.57
200,000	Medikit	570,400,000	2.41
145,000	San-A	606,100,000	2.56
110,000	Secom	878,460,000	3.71
100,000	Suntory Beverage & Food	416,000,000	1.76
400,000	Tanseisha	314,000,000	1.33
535,000	Vital KSK Holdings	431,745,000	1.83
	Total Consumer, Non-cyclical	4,676,970,000	19.76
	Energy: Nil (2020: 1.61%)		
	Financial: 12.39% (2020: 14.47%)		
200,000	Aeon Mall	328,200,000	1.39
100,000	Bank of Kyoto	533,000,000	2.25
750,000	Mitsubishi UFJ Lease & Finance	426,750,000	1.80
190,000	Sumitomo Mitsui Financial	749,170,000	3.17
140,000	Tokio Marine	894,880,000	3.78
	Total Financial	2,932,000,000	12.39
	Industrial: 20.65% (2020: 29.41%)		
575,000	Alps Alpine	623,875,000	2.64
427,300	Cosel	364,914,200	1.54
755,000	Daiwa Industries	955,075,000	4.03
355,000	INFRONEER Holdings	372,040,000	1.57
230,000	JSP	376,050,000	1.59
275,000	METAWATER	556,325,000	2.35
155,000	Nitto Kohki	283,805,000	1.20
210,000	Nohmi Bosai	472,710,000	2.00
235,000	Optex	386,105,000	1.63
52,200	Pasco	70,731,000	0.30
90,000	Toshiba	425,700,000	1.80
	Total Industrial	4,887,330,200	20.65



# Japan Value Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value JPY	% of Net Assets
	Equities: 98.91% (2020: 98.33%) continued		
	Technology: 12.23% (2020: 8.92%)		
180,000	DTS	454,320,000	1.92
800,000	Forum Engineering	668,800,000	2.82
157,200	Ines	237,529,200	1.00
225,000	Jastec	238,050,000	1.01
100,000	Mabuchi Motor	380,000,000	1.60
61,000	Mitsubishi Research Institute	246,440,000	1.04
120,000	NS Solutions	425,400,000	1.80
85,000	SRA Holdings	245,480,000	1.04
	Total Technology	2,896,019,200	12.23
	Total Equities	23,411,300,300	98.91
	Total Transferable Securities	23,411,300,300	98.91

#### Open Forward Currency Contracts: 0.79% (2020: 0.22%)

Curre	ncy Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain JPY	% of Net Assets
JPY 1	,810,425,381	GBP 12,091,639	149.7300	31/01/2022	63,008,205	0.27
JPY 2	,865,469,225	USD 25,278,771	113.3500	31/01/2022	45,082,571	0.19
JPY 2	,065,217,940	USD 18,219,065	113.3500	31/01/2022	32,492,177	0.14
JPY 3	70,365,429	GBP 2,473,631	149.7300	31/01/2022	12,889,823	0.05
JPY 6	25,133,665	EUR 4,888,619	127.8800	31/01/2022	11,353,899	0.05
JPY 5	38,221,347	EUR 4,208,955	127.8800	31/01/2022	9,775,367	0.04
JPY 3	02,550,218	CHF 2,460,375	122.9700	31/01/2022	6,276,710	0.03
JPY 2	66,557,978	CHF 2,167,682	122.9700	31/01/2022	5,530,014	0.02
JPY 4	3,760,349	USD 386,048	113.3500	31/01/2022	688,483	_
JPY 8	,459,759	GBP 56,502	149.7300	31/01/2022	294,425	_
JPY 2	,988,423	GBP 19,542	152.9200	31/01/2022	39,401	-
JPY 3	71,275	GBP 2,428	152.9100	04/01/2022	5,014	-
JPY 1	35,028	CHF 1,098	122.9700	31/01/2022	2,801	-
JPY 1	22,777	EUR 960	127.8800	31/01/2022	2,230	-
JPY 4	9,096	USD 432	113.5500	31/01/2022	689	-
JPY 3	,211	EUR 25	128.4400	31/01/2022	44	_
Total	unrealised ga	ain on forward fore	eign currency cont	racts	187,441,853	0.79
Total	Financial Ass	ets at fair value th	rough profit or los	S	23,598,742,153	99.70

#### Financial liabilities at fair value through profit or loss Open Forward Currency Contracts: (0.02%) (2020: (0.04%)) **Unrealised Loss** % of **Currency Sold Currency Bought Currency Rate Maturity Date** JPY Net Assets GBP 348,264 JPY 52,245,274 150.0200 31/01/2022 (1,713,418) (0.01) (1,153,394) USD 749,744 JPY 85,170,722 113.6000 31/01/2022 (0.01) USD 519,841 JPY 59,053,859 113.6000 31/01/2022 (799, 715)\_ GBP 72,340 JPY 10,852,216 150.0200 31/01/2022 (355,906) \_ 128.2400 EUR 144,178 JPY 18,489,059 31/01/2022 (282,651) \_ EUR 123,182 JPY 15,796,530 128.2400 31/01/2022 (241,489) \_ CHF 72,576 JPY 8,956,991 123.4200 31/01/2022 (152,764) \_ CHF 63,374 JPY 7,821,370 123.4200 31/01/2022 (133,396) USD 45,876 JPY 5,241,316 114.2500 31/01/2022 (40,746)USD 23,059 JPY 2,618,229 113.5500 31/01/2022 (36,704) \_ USD 11,050 JPY 1,255,316 113.6000 31/01/2022 (17,000) \_ GBP 1,655 JPY 248,261 150.0200 31/01/2022 (8,142) USD 259 JPY 29,547 114.2500 31/01/2022 (230) CHF 32 JPY 3,975 123.4100 31/01/2022 (68) EUR 28 JPY 3,620 128.2300 31/01/2022 (55) GBP 13 JPY 2,029 153.3600 04/01/2022 (21) \_ GBP 1 JPY 209 150.3600 31/01/2022 (6) \_ Total unrealised loss on forward foreign currency contracts (4,935,705)(0.02) Total Financial Liabilities at fair value through profit or loss (4,935,705) (0.02)

	Fair Value JPY	% of Net Assets
Total Value of Investments (Cost: JPY 23,796,194,776)	23,593,806,448	99.68
Cash at Bank	74,991,593	0.32
Other Net Liabilities	(344,583)	_
Net Assets Attributable to Holders of Redeemable Participating Shares	23,668,453,458	100.00

All securities are transferable securities and are admitted to an official stock exchange or dealt on a regulated market at the financial year end. The counterparty for the forward currency contracts is The Northern Trust Company.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	98.58	97.62
OTC Financial derivative instruments	0.79	0.22
Other assets	0.63	2.16
	100.00	100.00

The % of Net Assets has been rounded to Nil if the amount is less than 0.01%.



### North American Fund

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets	
	Equities: 97.47% (2020: 97.34%)			
	Communications: 23.45% (2020: 23.30%)			
27,552	Alphabet	79,724,192	6.37	
20,270	Amazon.com	67,587,072	5.40	
5,486	Booking	13,162,176	1.05	
148,741	IAC/InterActiveCorp	19,441,936	1.55	
254,791	Liberty Media	16,112,983	1.29	
129,753	Meta Platforms	43,642,421	3.49	
235,942	Stitch Fix	4,464,023	0.36	
293,371	T-Mobile US	34,025,168	2.72	
363,599	Uber	15,245,706	1.22	
	Total Communications	293,405,677	23.45	
	Consumer Discretionary: 2.26% (2020: Nil)			
397,823	Service Corporation International	28,241,455	2.26	
	Total Consumer Discretionary	28,241,455	2.26	
	Consumer, Cyclical: 7.16% (2020: 6.83%)			
503,086	Cannae	17,683,473	1.41	
204,391	Dolby Laboratories	19,462,111	1.55	
61,084	Mohawk Industries	11,128,283	0.89	
7,196,100	Samsonite International	14,620,554	1.17	
753,820	Shift Technologies	2,570,526	0.21	
691,818	Taylor Morrison Home	24,185,957	1.93	
	Total Consumer, Cyclical	89,650,904	7.16	
	Consumer, Non-Cyclical: 21.20% (2020: 20.96%)			
80,760	Anthem	37,435,490	2.99	
267,312	Centene	22,026,509	1.76	
521,961	Envista	23,519,563	1.88	
104,039	ICON	32,220,878	2.57	
228,642	LiveRamp Holdings	10,963,384	0.88	
163,901	Medtronic	16,955,558	1.36	
39,064	S&P Global	18,435,474	1.47	
105,072	United Rentals	34,914,375	2.79	
904,733	US Foods	31,511,850	2.52	
172,008	Visa	37,275,854	2.98	
	Total Consumer, Non-Cyclical	265,258,935	21.20	

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
-	Equities: 97.47% (2020: 97.34%) continued		
	Energy: 2.18% (2020: 0.85%)		
644,149	Canadian Natural Resources	27,257,067	2.18
	Total Energy	27,257,067	2.18
	Financial: 14.09% (2020: 18.19%)		
143,012	Affiliated Managers	23,526,904	1.88
849,023	Arch Capital	37,739,072	3.02
244,915	Citigroup	14,790,417	1.18
153,523	Intercontinental Exchange	20,997,341	1.68
129,858	LPL Financial	20,788,967	1.66
107,716	Signature Bank	34,842,895	2.78
151,538	Travelers Companies	23,705,089	1.89
	Total Financial	176,390,685	14.09
	Industrial: 5.92% (2020: 8.57%)		
146,250	Ametek	21,504,600	1.72
1,513,600	Grupo Cementos de Chihuahua	11,719,029	0.93
65,227	Littelfuse	20,525,632	1.64
126,355	TE Connectivity	20,386,116	1.63
	Total Industrial	74,135,377	5.92
	Technology: 21.21% (2020: 18.64%)		
124,059	Analog Devices	21,805,850	1.74
19,721	Constellation Software	36,641,732	2.93
188,040	Fiserv	19,516,672	1.56
211,701	Microsoft	71,199,280	5.69
153,450	MKS Instruments	26,726,386	2.14
196,672	Qualcomm	35,965,409	2.87
397,760	SS&C Technologies	32,608,365	2.61
1,120,764	Zuora	20,935,872	1.67
	Total Technology	265,399,566	21.21
	Total Equities	1,219,739,666	97.47
	Total Transferable Securities	1,219,739,666	97.47

 $\bigcirc$ 

Portfolio Statements continued As at 31 December 2021

# North American Fund continued

Open Forward Cu	Open Forward Currency Contracts: 0.24% (2020: 0.16%)							
				Unrealised Gain	% of			
Currency Sold	Currency Bought	Currency Rate	Maturity Date	US\$	Net Assets			
USD 65,273,813	GBP 49,366,720	1.3222	31/01/2022	1,587,586	0.13			
USD 27,722,244	GBP 20,966,391	1.3222	31/01/2022	674,259	0.05			
USD 90,287,613	EUR 79,900,260	1.1300	31/01/2022	614,771	0.05			
USD 2,113,657	GBP 1,598,563	1.3222	31/01/2022	51,408	0.01			
USD 6,577,021	EUR 5,820,352	1.1300	31/01/2022	44,783	-			
USD 2,096,570	CHF 1,928,807	1.0870	31/01/2022	21,521	-			
USD 802,706	EUR 710,357	1.1300	31/01/2022	5,466	-			
USD 786,900	EUR 694,680	1.1328	04/01/2022	3,090	-			
USD 442,390	EUR 391,446	1.1301	31/01/2022	2,958	-			
USD 232,257	EUR 206,025	1.1273	31/01/2022	2,138	-			
USD 131,419	GBP 98,027	1.3406	05/01/2022	1,354	-			
USD 69,873	GBP 52,346	1.3348	31/01/2022	1,024	-			
USD 233,005	EUR 205,574	1.1334	31/01/2022	876	-			
USD 55,623	GBP 41,674	1.3347	04/01/2022	822				
USD 81,446	EUR 72,248	1.1273	31/01/2022	750				
USD 45,484	GBP 33,927	1.3406	05/01/2022	469				
USD 24,170	GBP 18,109	1.3347	04/01/2022	357				
USD 87,545	EUR 77,219	1.1337	31/01/2022	307				
USD 58,455	EUR 51,671	1.1313	05/01/2022	305				
USD 56,842	EUR 50,220	1.1319	31/01/2022	293				
USD 16,586	GBP 12,369	1.3409	31/01/2022	167				
USD 6,299	GBP 4,764	1.3221	31/01/2022	154				
USD 12,699	GBP 9,409	1.3496	31/01/2022	45				
USD 11,761	GBP 8,715	1.3496	31/01/2022	42				
USD 9,515	EUR 8,400	1.1328	04/01/2022	37				
USD 1,231	GBP 918	1.3409	31/01/2022	12				
USD 1,748	EUR 1,546	1.1302	31/01/2022	12				
USD 283	GBP 213	1.3265	31/01/2022	6				
USD 202	GBP 153	1.3234	31/01/2022	5				
USD 183	GBP 138	1.3224	31/01/2022	4				
USD 94	GBP 71	1.3224	31/01/2022	2				
USD 384	EUR 340	1.1313	05/01/2022	2				
USD 166	GBP 124	1.3402	05/01/2022	2				
USD 164	GBP 123	1.3349	31/01/2022	2				
USD 198	GBP 148	1.3411	04/01/2022	2				
USD 62	GBP 46	1.3266	31/01/2022	1				



### Financial liabilities at fair value through profit or loss

#### **Open Forward Currency Contracts: Nil (2020: Nil)**

% of Net Assets	Unrealised Loss US\$	Maturity Date	Currency Rate	Currency Bought	Currency Sold
_	(10,247)	31/01/2022	1.1273	USD 1,113,150	EUR 987,429
_	(2,960)	31/01/2022	1.1334	USD 787,376	EUR 694,680
_	(2,012)	31/01/2022	1.1337	USD 574,063	EUR 506,352
_	(1,119)	04/01/2022	1.3405	USD 107,841	GBP 80,446
_	(814)	31/01/2022	1.1301	USD 121,805	EUR 107,778
_	(463)	31/01/2022	1.3221	USD 18,965	GBP 14,344
_	(302)	31/01/2022	1.1319	USD 58,484	EUR 51,671
_	(300)	04/01/2022	1.1312	USD 56,810	EUR 50,220
_	(251)	31/01/2022	1.1273	USD 27,234	EUR 24,158
_	(168)	04/01/2022	1.3408	USD 16,585	GBP 12,369
_	(156)	31/01/2022	1.3221	USD 6,403	GBP 4,843
_	(49)	04/01/2022	1.3405	USD 4,684	GBP 3,494
_	(36)	31/01/2022	1.1334	USD 9,521	EUR 8,400
_	(34)	31/01/2022	1.1302	USD 5,046	EUR 4,465
_	(13)	31/01/2022	1.1337	USD 3,577	EUR 3,155

 $\bigcirc$ 

Portfolio Statements continued As at 31 December 2021

### North American Fund continued

Open Forward Cu	urrency Contracts: N	il (2020: Nil) contin	bed		
Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Loss US\$	% of Net Assets
GBP 918	USD 1,231	1.3408	04/01/2022	(13)	_
GBP 1,234	USD 1,666	1.3496	31/01/2022	(6)	-
GBP 77	USD 102	1.3265	31/01/2022	(2)	_
EUR 340	USD 384	1.1319	31/01/2022	(2)	_
GBP 70	USD 92	1.3234	31/01/2022	(2)	_
GBP 81	USD 108	1.3409	04/01/2022	(1)	_
GBP 76	USD 102	1.3409	31/01/2022	(1)	_
GBP 57	USD 77	1.3349	31/01/2022	(1)	-
GBP 58	USD 78	1.3402	04/01/2022	(1)	_
EUR 330	USD 374	1.1328	04/01/2022	(1)	_
GBP 1	USD 1	1.3382	31/01/2022	-	_
GBP 7	USD 10	1.3403	04/01/2022	-	-
GBP 2	USD 2	1.3256	31/01/2022	_	_
GBP 6	USD 8	1.3416	04/01/2022	-	_
GBP 3	USD 4	1.3224	31/01/2022	-	-
	loss on forward fore	ian currency contr	acts	(18,954)	0.00

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 868,525,426)	1,222,735,752	97.71
Cash at Bank	27,650,901	2.21
Other Net Liabilities	1,047,388	0.08
Net Assets Attributable to Holders of Redeemable Participating Shares	1,251,434,041	100.00

All securities are transferable and are admitted to an official stock exchange or dealt on a regulated market at year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	97.16	97.09
OTC Financial derivative instruments	0.24	0.17
Other assets	2.60	2.74
	100.00	100.00

The % of Net Assets has been rounded to Nil if the amount is less than 0.01%.

# Smart Energy Fund

		Fair Value	% of
Holdings	Financial assets at fair value through profit or loss	US\$	Net Assets
	Equities: 99.58% (2020: Nil) Canada: 0.66% (2020: Nil)		
7,000	Hydro One	182,377	0.66
7,000	Total Canada	182,377	0.66
3,200	Cayman Islands: 2.10% (2020: Nil) Silergy	581,198	2.10
5,200	Total Cayman Islands	581,198	2.10
250	Denmark: 0.55% (2020: Nil) Rockwool	152.052	0.55
350	Total Denmark	153,052	0.55
	Total Definiark	153,052	0.55
	France: 11.99% (2020: Nil)		
4,700	Air Liquide	819,471	2.97
20,900	Alstom	742,021	2.68
5,800	Nexans	566,246	2.05
6,050	Schneider Electric	1,186,535	4.29
	Total France	3,314,273	11.99
	Germany: 6.93% (2020: Nil)		
19,000	Infineon Technologies	880,693	3.18
30,000	Nordex	474,554	1.72
8,000	SMA Solar Technology	340,068	1.23
1,700	Varta	221,356	0.80
	Total Germany	1,916,671	6.93
	Japan: 12.01% (2020: Nil)		
10,500	Azbil	477,791	1.73
8,500	Fuji Electric	463,549	1.68
7,400	Mabuchi Motor	244,192	0.88
3,150	Nidec	369,832	1.34
59,000	Renesas Electronics	729,078	2.64
9,500	RENOVA	171,760	0.62
9,500	Rohm	863,749	3.12
	Total Japan	3,319,951	12.01
	Netherlands: 2.44% (2020: Nil)		
13,700	STMicroelectronics	675,689	2.44
	Total Netherlands	675,689	2.44



# Smart Energy Fund continued

Haldinga		Fair Value US <b>\$</b>	% of Net Assets
Holdings	Financial assets at fair value through profit or loss Equities: 99.58% (2020: Nil) continued	053	Net Assets
	Norway: 1.60% (2020: Nil)		
100,000	Nel	172,482	0.62
8,000	Nordic Semiconductor	269,984	0.98
0,000	Total Norway	442,466	1.60
	People's Republic of China: 4.76% (2020: Nil)		
12,000	NIO ADR	380,160	1.37
18,600	Xpeng Motors ADR	936,138	3.39
	Total People's Republic of China	1,316,298	4.76
	South Africa: 1.25% (2020: Nil)		
20,000	Scatec	346,439	1.25
	Total South Africa	346,439	1.25
	Spain: 0.94% (2020: Nil)		
7,000	Acciona Energias Renovables	259,350	0.94
	Total Spain	259,350	0.94
	Sweden: 1.26% (2020: Nil)		
23,000	Nibe Industrier	347,394	1.26
	Total Sweden	347,394	1.26
	Switzerland: 2.14% (2020: Nil)		
6,100	ABB	233,650	0.84
8,200	Stadler Rail	359,445	1.30
	Total Switzerland	593,095	2.14
	Taiwan: 0.54% (2020: Nil)		
15,000	Delta Electronics	149,095	0.54
	Total Taiwan	149,095	0.54
	United Kingdom: 3.03% (2020: Nil)		
30,000	ITM Power	160,096	0.58
1,950	Linde	678,567	2.45
	Total United Kingdom	838,663	3.03
	United States: 47.38% (2020: Nil)		
1,400	Albemarle	327,278	1.18
3,000	Analog Devices	527,310	1.91
11,800	EnerSys	932,908	3.37
3,600	ltron	246,672	0.89
11,500	Johnson Controls International	935,065	3.38
11,000	Lattice Semiconductor	847,660	3.07

		Fair Value	% of
Holdings	Financial assets at fair value through profit or loss	US\$	Net Assets
	Equities: 99.58% (2020: Nil) continued		
	United States: 47.38% (2020: Nil) continued		
6,500	Lumentum	687,505	2.49
9,300	Marvell Technology	813,657	2.94
1,650	Monolithic Power Systems	813,995	2.94
31,000	Navitas Semiconductor	527,310	1.91
21,000	ON Semiconductor	1,426,320	5.16
19,500	Plug Power	550,485	1.99
14,750	Power Integrations	1,370,128	4.95
4,850	Qorvo	758,491	2.74
1,150	Regal Rexnord	195,707	0.71
11,000	Resideo Technologies	286,330	1.04
3,400	Skyworks Solutions	527,476	1.91
800	SolarEdge Technologies	224,456	0.81
10,200	Vertiv Holdings	254,694	0.92
4,000	Xilinx	848,120	3.07
	Total United States	13,101,567	47.38
	Total Equities	27,537,578	99.58
	Total Transferable Securities	27,537,578	99.58

#### Open Forward Currency Contracts: Nil (2020: Nil)

Currency Sold	Currency Bought	Currency Rate	Maturity Date	Unrealised Gain US\$	% of Net Assets
USD 11	GBP 8	1.3405	04/01/2022	_	_
Total unrealised	l gain on forward for	eign currency cont	tracts	0	-
Total Financial A	27,537,578	99.58			

All securities are transferable and are admitted to an official stock exchange or dealt on a regulated market at year end.

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 27,524,884)	27,537,578	99.58
Cash at Bank	386,949	1.40
Other Net Liabilities	(271,856)	(0.98)
Net Assets Attributable to Holders of Redeemable Participating Shares	27,652,671	100.00

The % of Net Assets was rounded to Nil if the amount is less than 0.01.



# Smart Mobility Fund

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
liolaligs	Equities: 99.53% (2020: Nil)		incertaisets
	Chile: 1.37% (2020: Nil)		
2,000	Sociedad Quimica y Minera de Chile	100,860	1.37
	Total Chile	100,860	1.37
	France: 12.69% (2020: Nil)		
1,200	Air Liquide	209,227	2.84
8,000	Alstom	284,027	3.85
2,500	Dassault Systemes	148,717	2.02
500	Legrand	58,509	0.79
1,200	Schneider Electric	235,346	3.19
	Total France	935,826	12.69
	Germany: 4.71% (2020: Nil)		
7,500	Infineon Technologies	347,642	4.71
	Total Germany	347,642	4.71
	Ireland: 2.83% (2020: Nil)		
600	Linde	208,790	2.83
	Total Ireland	208,790	2.83
	Japan: 16.47% (2020: Nil)		
3,200	Denso	264,798	3.59
1,800	Fuji Electric	98,163	1.33
2,100	GS Yuasa	46,648	0.63
1,300	Nidec	152,629	2.07
16,000	Panasonic	175,763	2.38
18,000	Renesas Electronics	222,431	3.02
2,800	Rohm	254,579	3.45
	Total Japan	1,215,011	16.47
	Jersey: 4.25% (2020: Nil)		
1,900	Aptiv	313,405	4.25
	Total Jersey	313,405	4.25
	Netherlands: 3.22% (2020: Nil)		
500	NXP Semiconductors	113,890	1.55
2,500	STMicroelectronics	123,301	1.67
	Total Netherlands	237,191	3.22
	Norway: 0.70% (2020: Nil)		
30,000	NEL	51,745	0.70
	Total Norway	51,745	0.70

Holdings	Financial assets at fair value through profit or loss	Fair Value US\$	% of Net Assets
	Equities: 99.53% (2020: Nil) continued		
	People's Republic of China: 6.91% (2020: Nil)		
3,000	BYD	102,587	1.39
3,000	NIO	95,040	1.29
6,200	XPeng	312,046	4.23
	Total People's Republic of China	509,673	6.91
	Republic of South Korea: 2.54% (2020: Nil)		
500	Hyundai Mobis	107,045	1.45
1,500	Mando	80,000	1.09
	Total Republic of South Korea	187,045	2.54
	Switzerland: 6.38% (2020: Nil)		
5,200	ABB	199,177	2.70
3,200	Stadler Rail	140,271	1.90
450	TE Connectivity	72,603	0.98
760	u-blox	58,763	0.80
	Total Switzerland	470,814	6.38
	Taiwan: 4.08% (2020: Nil)		
8,000	Chroma ATE	57,831	0.79
5,000	Delta Electronics	49,698	0.67
43,000	Hota Industrial Manufacturing	141,898	1.92
5,000	Sinbon Electronics	51,325	0.70
	Total Taiwan	300,752	4.08
	United Kingdom: 0.72% (2020: Nil)		
10,000	ITM Power	53,365	0.72
	Total United Kingdom	53,365	0.72
	United States: 32.66% (2020: Nil)		
750	Albemarle	175,328	2.38
1,200	Analog Devices	210,924	2.86
12,000	Livent	292,560	3.97
500	Monolithic Power Systems	246,665	3.34
6,500	ON Semiconductor	441,480	5.99
4,500	Plug Power	127,035	1.72
3,100	Power Integrations	287,959	3.90
7,000	Uber Technologies	293,510	3.98
3,000	Visteon	333,420	4.52
	Total United States	2,408,881	32.66
	Total Equities	7,341,000	99.53
	Total Transferable Securities	7,341,000	99.53



# Smart Mobility Fund continued

	Fair Value US\$	% of Net Assets
Total Value of Investments (Cost: US\$ 7,143,928)	7,341,000	99.53
Cash at Bank	263,160	3.57
Other Net Liabilities	(228,290)	(3.10)
Net Assets Attributable to Holders of Redeemable Participating Shares	7,375,870	100.00

All securities are transferable securities and are admitted to an official stock exchange or dealt on a regulated market at the financial year end.

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	95.46	_
Other assets	4.54	_
	100.00	100.00

The % of Net Assets was rounded to Nil if the amount is less than 0.01.

# UK Absolute Equity Fund\*

\* UK Absolute Equity Fund terminated on 15 May 2020. There were no investments held by the Fund on the last valuation day of the reporting period.



# **UK Value Opportunities Fund**

Holdings	Financial assets at fair value through profit or loss	Fair Value GBP	% of Net Assets
	Equities: 97.51% (2020: 98.03%)		
	Basic Materials: 6.52% (2020: 7.24%)		
838,076	Anglo American	25,330,847	1.57
10,047,367	Central Asia Metals	25,498,208	1.59
1,684,304	Mondi	30,906,979	1.92
475,336	Rio Tinto	23,127,473	1.44
	Total Basic Materials	104,863,507	6.52
	Communications: 2.71% (2020: 1.01%)		
10,082,664	Spirent Communications	27,888,649	1.73
1,408,661	WPP	15,777,003	0.98
	Total Communications	43,665,652	2.71
	Consumer Discretionary: 0.59% (2020: Nil)		
690,752	Dunelm	9,587,638	0.59
	Total Consumer Discretionary	9,587,638	0.59
	Consumer Staples: 2.26% (2020: Nil)		
8,123,103	J Sainsbury	22,354,779	1.39
4,816,090	Tesco	13,947,397	0.87
	Total Consumer Staples	36,302,176	2.26
	Consumer, Cyclical: 14.51% (2020: 19.84%)		
3,579,478	B&M European Value Retail	22,901,500	1.42
1,028,399	Bellway	34,451,367	2.14
2,541,361	Grafton	31,284,154	1.95
5,554,133	IG Design	14,440,746	0.90
2,367,352	Inchcape	21,732,291	1.35
9,222,009	Mitchells & Butlers	23,497,679	1.46
2,303,453	MJ Gleeson	17,644,450	1.10
12,168,951	Rank	19,275,618	1.20
13,051,107	Taylor Wimpey	22,887,752	1.42
6,953,634	Wincanton	25,311,228	1.57
	Total Consumer, Cyclical	233,426,785	14.51

Holdings	Financial assets at fair value through profit or loss	Fair Value GBP	% of Net Assets
	Equities: 97.51% (2020: 98.03%) continued		
	Consumer, Non-cyclical: 25.38% (2020: 23.85%)		
3,893,180	A.G. Barr	20,127,741	1.25
17,915,062	Alliance Pharma	19,706,568	1.22
320,391	AstraZeneca	27,610,404	1.72
825,915	Cranswick	30,724,038	1.91
14,255,119	Greencore	18,431,869	1.15
5,093,411	Henry Boot	14,057,814	0.87
1,529,774	Hikma Pharmaceuticals	33,716,219	2.10
2,669,911	Hilton Food	30,383,587	1.89
14,932,494	Marks & Spencer	34,553,791	2.15
30,362,344	Premier Foods	33,769,272	2.10
9,386,801	PZ Cussons	19,149,074	1.19
8,418,283	QinetiQ	22,350,541	1.39
264,805	Reckitt Benckiser	16,717,140	1.04
6,597,968	Restore	32,257,466	2.01
38,942,013	Speedy Hire	24,416,642	1.52
4,293,092	SThree	20,005,809	1.24
657,721	Young & Co's Brewery	10,194,675	0.63
	Total Consumer, Non-cyclical	408,172,650	25.38
	Energy: 2.66% (2020: 2.08%)		
22,440,273	Jadestone Energy	19,060,768	1.19
10,045,466	Serica Energy	23,709,419	1.47
	Total Energy	42,770,187	2.66
	Financial: 22.79% (2020: 23.75%)		
2,309,474	Зі	33,602,847	2.09
9,801,662	Barclays	18,333,009	1.14
5,170,455	Beazley	23,985,741	1.49
4,437,643	Brewin Dolphin	16,308,338	1.01
4,774,192	HSBC	21,321,541	1.33
5,065,514	Investec	20,419,087	1.27
4,320,293	Lancashire	22,919,154	1.43

 $\bigcirc$ 

Portfolio Statements continued As at 31 December 2021

# UK Value Opportunities Fund continued

Holdings	Financial assets at fair value through profit or loss	Fair Value GBP	% of Net Assets
	Equities: 97.51% (2020: 98.03%) continued		
	Financial: 22.79% (2020: 23.75%) continued		
7,508,972	Legal & General	22,226,557	1.38
13,029,943	Natwest	29,330,402	1.82
4,528,736	Numis	15,533,564	0.97
3,915,238	OSB Group Plc	21,690,419	1.35
850,393	Rathbone Brothers	16,888,805	1.05
1,068,003	Schroders	24,777,670	1.54
4,998,652	Standard Chartered	22,328,978	1.39
12,373,040	Virgin Money UK	21,999,265	1.37
13,145,324	Watkin Jones	34,769,382	2.16
	Total Financial	366,434,759	22.79
	Financials: 1.10% (2020: Nil)		
6,645,654	CMC Markets	17,655,509	1.10
	Total Financials	17,655,509	1.10
	Industrial: 14.03% (2020: 18.41%)		
33,752,166	Breedon	32,267,071	2.01
6,712,478	Forterra	18,325,065	1.14
1,207,409	Hill & Smith	21,709,214	1.35
17,606,224	Kier	19,437,271	1.21
8,930,995	Morgan Advanced Materials	31,838,997	1.98
1,407,712	Morgan Sindall	35,615,113	2.21
2,639,153	Renew	21,920,805	1.36
8,064,240	TT Electronics	20,375,512	1.27
5,373,561	Vesuvius	24,127,289	1.50
	Total Industrial	225,616,337	14.03
	Materials: 3.02% (2020: Nil)		
6,537,603	Atalaya Mining	26,712,646	1.66
25,983,914	SigmaRoc	21,816,094	1.36
	Total Materials	48,528,740	3.02
	Technology: 1.94% (2020: 1.85%)		
1,073,214	Computacenter	31,251,992	1.94
	Total Technology	31,251,992	1.94
	Total Equities	1,568,275,932	97.51
	Total Transferable Securities	1,568,275,932	97.51

	Fair Value GBP	% of Net Assets
Total Value of Investments (Cost: GBP 1,387,909,965)	1,568,275,932	97.51
Cash at Bank	42,216,589	2.62
Margin Cash	(2)	_
Other Net Liabilities	(2,234,730)	(0.13)
Net Assets Attributable to Holders of Redeemable Participating Shares	1,608,257,789	100.00

Analysis of total assets	31 December 2021 % of Total Assets	31 December 2020 % of Total Assets
Transferable securities admitted to official stock exchange listing	97.15	97.25
Other assets	2.85	2.75
	100.00	100.00

The % of Net Assets was rounded to Nil if the amount is less than 0.01.



### Statement of Financial Position As at 31 December 2021

#### As at 31 December 2021

	Notes	Asian Opportunities Fund* US\$	Asian Stars Fund US\$	Automation & Artificial Intelligence Fund US\$	Biotechnology Fund US\$	
Assets						
Transferable securities	10	_	167,959,084	753,389,515	1,711,901,465	
Financial derivative instruments	10	_	_	1,279	3,649,007	
Dividends and interest receivable		_	216,278	196,295	_	
Amounts receivable on sale of securities		_	84,771	_	347,928	
Amounts receivable on sale of redeemable participating shares		_	36,625	757,164	4,405,693	
Sundry debtors		279	1,067	7,848	20,040	
Cash at bank	10	14,913	2,707,513	23,037,351	11,989,544	
Margin cash	10	-	_	_	_	
Total Assets		15,192	171,005,338	777,389,452	1,732,313,677	
Liabilities						
Financial derivative instruments	10	_	_	_	(3,664)	
Bank overdraft	4	_	_	(5,772,695)	(1,873,888)	
Amounts payable on redemption of redeemable participating shares		_	(118,089)	(1,598,126)	(5,703,086)	
Amounts payable on purchase of securities		_	_	(549,402)	(623,580)	
Dividends and interest payable		_	(51)	(5,313)	(2,497)	
Investment management fee payable	3	_	(55,024)	(444,026)	(2,318,762)	
Performance fee payable	3	-	(992,104)	_	(7,476,886)	
Sundry creditors	3	(15,192)	(916,856)	(190,583)	(407,215)	
Total liabilities (excluding net assets attributable to holders of redeemable participating shares)		(15,192)	(2,082,124)	(8,560,145)	(18,409,578)	
Net assets attributable to holders of redeemable participating shares		_	168,923,214	768,829,307	1,713,904,099	

\* Asian Opportunities Fund terminated on 01 March 2021.

\*\* Emerging Markets Income Fund terminated on 08 June 2021.



China Stars Fund US\$	Emerging Markets Income Fund** US\$	Emerging Markets Stars Fund US\$	European (ex UK) Income Fund EUR	Financial Opportunities Fund US\$	Global Absolute Return Fund US\$	Global Convertible Fund US\$	Global Insurance Fund GBP
19,021,813	_	1,269,055,378	118,058,199	22,023,268	81,981,102	1,248,184,340	1,701,552,080
_	_	760	19,171	112	1,277,937	13,590,081	255
6,412	_	1,591,009	_	14,416	143,826	2,905,181	401,875
-	-	_	3,770,524	-	-	_	1,677,461
1,624	_	402,108	_	60,356	_	699,087	2,101,947
32	_	7,233	1,324	161	70	51,883	12,174
986,829	153,108	25,601,477	1,950,890	1,447,277	1,000,347	39,982,640	14,751,983
6,461	-	-	-	-	711,785	-	-
20,023,171	153,108	1,296,657,965	123,800,108	23,545,590	85,115,067	1,305,413,212	1,720,497,775
_	_	_	_	_	(1,270,948)	(8,019,278)	(222,337)
_	(26,670)	_	(4,427,479)	_	(13,015,839)	(228,309,056)	(9,052,423)
(782)	_	(826,444)	_	(18,932)	-	(707,411)	(7,863,868)
(11,603)	_	_	-	_	-	_	_
(175)	_	(74)	(1,518)	(160)	(3,235)	(83,333)	(9,862)
(6,587)	(18,467)	(1,246,505)	(208,137)	(22,261)	(70,080)	(839,936)	(1,260,403)
_	_	(1,023,961)	_	-	(382,160)	_	_
(24,695)	(107,971)	(5,207,566)	(23,471)	(7,475)	(47,421)	(549,792)	(256,158)
(43,842)	(153,108)	(8,304,550)	(4,660,605)	(48,828)	(14,789,683)	(238,508,806)	(18,665,051)
19,979,329	_	1,288,353,415	119,139,503	23,496,762	70,325,384	1,066,904,406	1,701,832,724
13,323		1,200,333,413	0,00,000	25,450,702	10,525,504	1,000,504,400	1,701,052,724

### Statement of Financial Position continued As at 31 December 2021

#### As at 31 December 2021

		Global Technology Fund	Healthcare Blue Chip Fund	Healthcare Discovery Fund	Healthcare Opportunities Fund	
	Notes	US\$	US\$	US\$	US\$	
Assets						
Transferable securities	10	8,679,284,866	111,068,496	69,379,995	2,066,481,371	
Financial derivative instruments	10	36,924,680	7,345	1	52,093	
Dividends and interest receivable		2,732,465	19,772	5,864	132,222	
Amounts receivable on sale of securities		-	1,243,788	_	_	
Amounts receivable on sale of redeemable participating shares		15,432,776	422,226	179,472	15,449,126	
Sundry debtors		97,715	2.523	16,950	35,345	
Cash at bank	10	406,286,817	4,560,436	4,037,118	67,605,464	
Margin cash	10	14,322,512	_	_	100	
Total Assets		9,155,081,831	117,324,586	73,619,400	2,149,755,721	
Liabilities						
Financial derivative instruments	10	(624,035)	(930)	(1)	(21,350)	
Bank overdraft	4	(1,414,870)	_	-	_	
Amounts payable on redemption of redeemable participating shares		(50,206,824)	(598,426)	(148,305)	(4,907,452)	
Amounts payable on purchase of securities		(9,038,809)	(480,580)	_	_	
Dividends and interest payable		(3,040)	(56)	(10)	(7,784)	
Investment management fee payable	3	(13,243,240)	(58,470)	(41,785)	(2,109,763)	
Performance fee payable	3	_	_	(678,160)	_	
Sundry creditors	3	(2,153,867)	(37,999)	(131,547)	(4,485,928)	
Total liabilities (excluding net assets attributable to holders of redeemable participating shares)		(76,684,685)	(1,176,461)	(999,808)	(11,532,277)	
Net assets attributable to holders of redeemable participating shares		9,078,397,146	116,148,125	72,619,592	2,138,223,444	

\* Smart Energy Fund launched on 30 September 2021.

\*\* Smart Mobility Fund launched on 30 September 2021.

The Financial Statements were approved by the Board of Directors of Polar Capital Funds plc on 31 March 2022 and signed on its behalf by:

David Hammond Director

Karen Nolan Director

The accompanying notes form an integral part of these Financial Statements.



Income Opportunities Fund GBP	Japan Value Fund JPY	North American Fund US\$	Smart Energy Fund * US\$	Smart Mobility Fund** US\$	UK Absolute Equity Fund GBP	UK Value Opportunities Fund GBP	Total GBP
49,015,285	23,411,300,300	1,219,739,666	27,537,578	7,341,000	-	1,568,275,932	22,287,115,874
25,852	187,441,853	3,015,040	-	-	-	-	60,203,242
213,000	41,318,415	342,936	6,754	3,946	_	3,092,484	13,697,618
-	_	_	74,391	55,793	_	1,176	8,368,145
12,750	2,991,991	2,712,426	2,727,359	16,513	-	639,295	47,058,682
83	81,735	6,796	22,356	9,640	149	2,688	302,597
9,817,635	106,030,217	29,548,576	471,527	263,160	96,447	42,256,929	713,477,267
97,949	-	-	_	-	_	(2)	15,173,522
59,182,554	23,749,164,511	1,255,365,440	30,839,965	7,690,052	96,596	1,614,268,502	23,145,396,947
(443,587)	(4,935,705)	(18,954)	_	_	_	-	(10,903,982)
_	(31,038,624)	(1,897,676)	(84,578)	_	(8,512)	(40,340)	(270,026,967)
(84,508)	(2,370,088)	(1,053,235)	(1,394)	_	_	(4,304,983)	(82,505,650)
(401,435)	(6,504,700)	-	(3,069,677)	(307,656)	_	(480,082)	(15,331,765)
(135)	(128,665)	(684)	(348)	(62)	(5)	(42)	(123,270)
(92,919)	(24,273,156)	(807,674)	(16,645)	(4,675)	_	(900,930)	(24,804,653)
(95,588)	-	-	_	-	_	_	(10,682,740)
(11,683)	(11,460,115)	(153,176)	(14,652)	(1,789)	(88,079)	(284,336)	(15,447,130)
(1,129,855)	(80,711,053)	(3,931,399)	(3,187,294)	(314,182)	(96,596)	(6,010,713)	(429,826,157)
58,052,699	23,668,453,458	1,251,434,041	27,652,671	7,375,870	_	1,608,257,789	22,715,570,790

### Comparative Statement of Financial Position As at 31 December 2020

#### As at 31 December 2020

	Notes	Asian Opportunities Fund US\$	Asian Stars Fund US\$	Automation & Artificial Intelligence Fund US\$	Biotechnology Fund US\$	
Assets						
Transferable securities	10	8,030,649	17,352,888	728,735,691	1,165,403,819	
Financial derivative instruments	10	6,111	_	_	245,891	
Dividends and interest receivable		6,299	18,552	183,041	_	
Amounts receivable on sale of securities		_	_	2,023,185	_	
Amounts receivable on sale of redeemable participating shares		_	1,279	1,293,404	10,060,801	
Sundry debtors		43	46	14,348	39,174	
Cash at bank	10	430,296	323,398	52,730,677	102,055,535	
Margin cash	10	_	_	_	_	
Total Assets		8,473,398	17,696,163	784,980,346	1,277,805,220	
Liabilities						
Financial derivative instruments	10	(6)	_	_	(1,171)	
Bank overdraft	4	_	_	(21,259,046)	(1,994,610)	
Amounts payable on redemption of redeemable participating shares		(2,482)	_	(448,232)	(2,250,899)	
Amounts payable on purchase of securities		_	_	(2,008,097)	(4,583,634)	
Dividends and interest payable		(1)	(68)	(14,351)	(2,010)	
Investment management fee payable	3	(8,054)	(5,779)	(354,188)	(1,636,277)	
Performance fee payable	3	(83,075)	(160,566)	(7,253,623)	(10,486,483)	
Sundry creditors	3	(7,417)	(82,155)	(281,709)	(412,129)	
Total liabilities (excluding net assets attributable to holders of redeemable participating shares)		(101,035)	(248,568)	(31,619,246)	(21,367,213)	
Net Assets Attributable to holders of redeemable participating shares		8,372,363	17,447,595	753,361,100	1,256,438,007	

China Star Fun US	d Fund	Emerging Markets Stars Fund US <b>\$</b>	European ex UK Income Fund EUR	Financial Opportunities Fund US\$	Global Absolute Return Fund US\$	Global Convertible Fund US <b>\$</b>	Global Insurance Fund GBP
13,305,34	1 103,152,112	362,968,186	189,728,564	10,420,659	51,610,726	1,140,320,729	1,544,769,994
9	0 7,030	-	866,971	-	1,058,225	7,252,796	1,054
4,97	4 638,529	354,073	-	3,982	111,299	3,760,238	433,150
31,01	3 –	-	961,717	_	-	13,694,099	_
33,49	9 35,709	738,923	_	33,042	-	1,277,215	3,377,584
18	7 11,695	7,256	741	323	1,910	125,141	7,530
924,48	8 1,426,888	11,697,452	-	383,063	3,294,741	51,960,950	49,422,268
6,47	0 –	_	_	_	-	_	_
14,306,06	2 105,271,963	375,765,890	191,557,993	10,841,069	56,076,901	1,218,391,168	1,598,011,580
	- (6,893)	_	_	_	(4,278,042)	(45,346,789)	(354,981)
		_	(254,206)	_	(3,080,696)	(116,048,142)	_
(35,58	2) (690,235)	_	-	(12,541)	-	(408,974)	(6,310,305)
(179,28	5) —	_	_	_	_	(7,289,691)	(2,077,659)
(16	3) (1)	(46)	(1,268)	(48)	(7,859)	(33,629)	(8,011)
(5,98	8) (125,445)	(174,775)	(298,072)	(9,654)	(50,689)	(797,714)	(1,176,074)
(92,20	9) –	(2,558,924)	_	(6,693)	(1,547,256)	(23)	_
(18,35	5) (36,920)	(2,428,396)	(26,215)	(6,640)	(46,018)	(636,605)	(252,119)
(331,58	2) (859,494)	(5,162,141)	(579,761)	(35,576)	(9,010,560)	(170,561,567)	(10,179,149)
13,974,48	0 104,412,469	370,603,749	190,978,232	10,805,493	47,066,341	1,047,829,601	1,587,832,431
-,,-	. , , ,		, ,	.,,	1	, , , , , , , , , , , , , , , , , , , ,	

### Comparative Statement of Financial Position continued As at 31 December 2020

#### As at 31 December 2020

		Global Technology	Healthcare Blue Chip	Healthcare	Healthcare Opportunities	
		Fund	Fund	Discovery Fund*	Fund	
	Notes	US\$	US\$	US\$	US\$	
Assets						
Transferable securities	10	7,831,220,695	86,369,420	45,272,115	2,104,298,240	
Financial derivative instruments	10	56,877,906	48	_	92,664	
Dividends and interest receivable		2,418,410	67,432	5,550	179,647	
Amounts receivable on sale of securities		132,571,861	1,052,537	_	5,262,529	
Amounts receivable on sale of						
redeemable participating shares		28,245,040	185,522	100,021	7,187,577	
Sundry debtors		86,603	1,591	21,774	30,853	
Cash at bank	10	784,391,029	6,553,011	3,338,624	1,941,735	
Margin cash	10	9,919,032	_	_	20,502,228	
Total Assets		8,845,730,576	94,229,561	48,738,084	2,139,495,473	
Liabilities						
Financial derivative instruments	10	(27,157)	_	_	(7)	
Bank overdraft	4	_	(1,980,003)	-	_	
Amounts payable on redemption of						
redeemable participating shares		(25,805,450)	(131,900)	(4,334)	(10,523,130)	
Amounts payable on purchase of securities		(120,150,463)	_	-	(600,255)	
Dividends and interest payable		(4,505)	(1,881)	(104)	(5,662)	
Investment management fee payable	3	(11,075,893)	(46,553)	(26,423)	(2,132,947)	
Performance fee payable	3	(31,044,272)	_	(234,272)	(766,974)	
Sundry creditors	3	(1,827,007)	(38,977)	(16,155)	(885,153)	
Total liabilities (excluding net assets attributable to holders of redeemable participating shares)		(189,934,747)	(2,199,314)	(281,288)	(14,914,128)	
Net Assets Attributable to holders of redeemable participating shares		8,655,795,829	92,030,247	48,456,796	2,124,581,345	

\* Healthcare Discovery Fund launched on 31 January 2020.

\*\* UK Absolute Equity Fund terminated on 15 May 2020.

The accompanying notes form an integral part of these Financial Statements.



Income Opportunities Fund GBP	Japan Value Fund JPY	North American Fund US\$	UK Absolute Equity Fund** GBP	UK Value Opportunities Fund GBP	Total US <b>\$</b>
60,122,208	17,653,006,900	1,027,053,531	_	1,125,618,319	18,831,113,854
_	39,004,928	1,745,802	_	_	68,726,577
213,249	42,189,325	462,904	_	2,177,630	12,483,873
210,122	_	_	_	619,289	156,945,699
2,200	17,112,403	2,855,597	-	1,677,512	59,126,451
2,201	102,573	10,026	-	3,512	370,973
617,784	331,247,746	25,721,198	97,914	27,353,593	1,156,308,632
71,626	-	-	-	17,668	30,549,791
61,239,390	18,082,663,875	1,057,849,058	97,914	1,157,467,523	20,315,625,850
(577,225)	(6,355,778)	(578)	-	-	(50,996,483)
_	(75,316,023)	(378,941)	(8,938)	(38,779)	(145,847,187)
(359,467)	(13,877,794)	(1,513,089)	-	(549,034)	(51,829,020)
-	_	-	_	(5,559,002)	(145,250,368)
(138)	(153,087)	(611)	_	(40)	(85,167)
(77,222)	(19,822,035)	(655,041)	_	(633,968)	(20,241,915)
(493,358)	-	_	_	(2,307,788)	(58,063,400)
(52,366)	(13,843,719)	(139,081)	(88,976)	(185,006)	(7,819,615)
(1,559,776)	(129,368,436)	(2,687,341)	(97,914)	(9,273,617)	(480,133,155)
59,679,614	17,953,295,439	1,055,161,717	-	1,148,193,906	19,835,492,695

 $\langle \rangle$ 

Statement of Comprehensive Income

For the financial year ended 31 December 2021

#### As at 31 December 2021

	Notes	Asian Opportunities Fund* US\$	Asian Stars Fund US\$	Automation & Artificial Intelligence Fund US\$	Biotechnology Fund US\$	
Investment income						
Investment income	2H	8,387	1,143,496	6,178,847	815,821	
Net realised and unrealised gain/(loss) on investments	2D	669,604	(1,460,143)	117,311,204	77,930,909	
Income equalisation	2E	_	27,640	(201,328)	_	
Net investment income/(expense)		677,991	(289,007)	123,288,723	78,746,730	
Expenses						
Investment management fees	3	(11,751)	(436,149)	(3,792,408)	(18,380,899)	
Administration fees	3	(466)	(39,216)	(270,553)	(549,759)	
General expenses	3	(10,556)	(104,949)	(165,296)	(317,061)	
Performance fees	3	(50,573)	(992,104)	_	(7,476,885)	
Depositary's fees	3	(909)	(59,537)	(178,739)	(254,812)	
Research fees		_	(5,647)	(132,640)	(390,415)	
Legal fees		(13,288)	(5,636)	(32,266)	(69,761)	
Directors' fees	8	(363)	(4,967)	(34,478)	(68,565)	
Auditor's fees		12	(1,503)	(6,950)	(16,499)	
Operating expenses		(87,894)	(1,649,708)	(4,613,330)	(27,524,656)	
Net income/(expense) from operations before finance co	osts	590,097	(1,938,715)	118,675,393	51,222,074	
Finance costs						
Bank interest/financing charges	2H	(4)	(1,864)	(194,259)	(26,111)	
Distributions to holders of redeemable participating shares	13	_	_	-	_	
Total finance costs		(4)	(1,864)	(194,259)	(26,111)	
Profit/(loss) for the year before tax		590,093	(1,940,579)	118,481,134	51,195,963	
Withholding tax		(1,793)	(174,323)	(1,194,362)	(110,250)	
Change in net assets attributable to holders of redeemable participating shares		588,300	(2,114,902)	117,286,772	51,085,713	

\* Asian Opportunities Fund terminated on 01 March 2021.

\*\* Emerging Markets Income Fund merged with the Emerging Markets Stars Fund on 08 June 2021.

China Stars Fund US <b>\$</b>	Emerging Markets Income Fund** US\$	Emerging Markets Stars Fund US <b>\$</b>	European (ex UK) Income Fund EUR	Financial Opportunities Fund US <b>\$</b>	Global Absolute Return Fund US\$	Global Convertible Fund US\$	Global Insurance Fund GBP
201,167	1,059,447	6,582,210	7,868,489	415,229	1,449,933	44,744,020	29,077,081
(2,757,930)	6,902,274	(38,335,045)	23,303,166	2,114,623	1,118,434	(116,506,823)	245,735,386
58,924	(1,079,820)	78,741	(965,317)	98,959	161,542	3,523,299	(2,098,029)
(2,497,839)	6,881,901	(31,674,094)	30,206,338	2,628,811	2,729,909	(68,239,504)	272,714,438
(74,433)	(214,085)	(5,195,726)	(1,574,347)	(154,594)	(407,662)	(8,788,205)	(13,272,603)
(5,586)	(11,273)	(280,249)	(57,482)	(6,106)	(18,590)	(384,916)	(615,382)
(71,075)	(57,519)	(291,760)	(47,262)	(55,555)	(30,926)	(1,293,766)	(294,474)
-	_	(1,023,961)	_	_	(382,160)	_	_
(4,869)	(35,929)	(388,697)	(36,518)	(4,289)	(8,758)	(169,230)	(288,769)
(1,286)	(18,830)	(33,860)	_	(1,134)	(10,342)	(228,161)	(107,628)
(677)	(29,695)	(41,262)	(6,150)	(818)	(2,097)	(45,591)	(73,040)
(708)	(1,792)	(35,056)	(7,370)	(728)	(3,030)	(49,072)	(76,814)
(149)	(546)	(11,786)	(974)	(197)	(475)	(9,633)	(14,902)
(158,783)	(369,669)	(7,302,357)	(1,730,103)	(223,421)	(864,040)	(10,968,574)	(14,743,612)
(2,656,622)	6,512,232	(38,976,451)	28,476,235	2,405,390	1,865,869	(79,208,078)	257,970,826
(2,148)	(2)	(6,471)	(12,365)	(1,107)	(75,231)	(528)	(96,010)
 -	(2,012,462)	-	(5,627,689)	(187,304)		(34,011,104)	(11,359,000)
(2,148)	(2,012,464)	(6,471)	(5,640,054)	(188,411)	(75,231)	(34,011,632)	(11,455,010)
(2,658,770)	4,499,768	(38,982,922)	22,836,181	2,216,979	1,790,638	(113,219,710)	246,515,816
(13,670)	(196,109)	(1,085,592)	(834,422)	(75,538)	(3,127)	(206,109)	(4,226,581)
(2,672,440)	4,303,659	(40,068,514)	22,001,759	2,141,441	1,787,511	(113,425,819)	242,289,235

### Statement of Comprehensive Income continued For the financial year ended 31 December 2021

#### As at 31 December 2021

	Notes	Global Technology Fund US\$	Healthcare Blue Chip Fund US\$	Healthcare Discovery Fund US\$	Healthcare Opportunities Fund US\$	
Investment income						
Investment income	2H	45,816,041	1,033,251	141,646	10,235,725	
Net realised and unrealised gain/(loss) on investments	2D	852,947,428	20,920,667	2,399,074	196,476,252	
Income equalisation	2E	_	21,016	-	_	
Net investment income/(expense)		898,763,469	21,974,934	2,540,720	206,711,977	
Expenses						
Investment management fees	3	(108,980,103)	(605,468)	(456,485)	(22,469,683)	
Administration fees	3	(3,331,496)	(37,137)	(23,409)	(761,442)	
General expenses	3	(1,559,898)	(49,319)	(42,170)	(379,029)	
Performance fees	3	_	_	(678,160)	_	
Depositary's fees	3	(2,008,346)	(18,209)	(12,798)	(424,241)	
Research fees		(1,605,059)	(25,127)	(11,152)	(512,991)	
Legal fees		(403,996)	(4,534)	(3,050)	(89,787)	
Directors' fees	8	(423,805)	(4,707)	(2,978)	(97,824)	
Auditor's fees		(88,756)	(993)	(711)	(17,902)	
Operating expenses		(118,401,459)	(745,494)	(1,230,913)	(24,752,899)	
Net income/(expense) from operations before finance co	osts	780,362,010	21,229,440	1,309,807	181,959,078	
Finance costs						
Bank interest/financing charges	2H	(56,128)	(5,082)	(537)	(282,985)	
Distributions to holders of redeemable participating shares	13	_	(465,527)	-	_	
Total finance costs		(56,128)	(470,609)	(537)	(282,985)	
Profit/(loss) for the year before tax		780,305,882	20,758,831	1,309,270	181,676,093	
Withholding tax		(9,323,213)	(203,363)	(19,195)	(1,493,638)	
Change in net assets attributable to holders of redeemable participating shares		770,982,669	20,555,468	1,290,075	180,182,455	

\* Smart Energy Fund launched on 30 September 2021.

\*\* Smart Mobility Fund launched on 30 September 2021.

The accompanying notes form an integral part of these Financial Statements.



Total US\$	UK Value Opportunities Fund GBP	UK Absolute Equity Fund GBP	Smart Mobility Fund** US\$	Smart Energy Fund* US <b>\$</b>	North American Fund US\$	Japan Value Fund JPY	Income Opportunities Fund GBP
241,269,388	39,974,138	_	7,944	17,242	7,906,250	558,437,951	2,999,747
2,096,945,477	238,804,892	427	202,733	(27,321)	240,381,092	3,245,942,241	9,424,653
(2,077,691)	(200,135)	_	-	_	1,286	29,975,676	(536,356)
2,336,137,174	278,578,895	427	210,677	(10,079)	248,288,628	3,834,355,868	11,888,044
(212,559,903)	(8,774,340)	-	(12,294)	(32,545)	(7,908,691)	(178,651,052)	(595,987)
(7,901,488)	(534,191)	_	(532)	(1,332)	(427,564)	(8,036,420)	(21,259)
(5,608,218)	(274,720)	(330)	(3,490)	(6,295)	(236,439)	(6,118,776)	(27,615)
(15,030,176)	(3,195,129)	_	_	_	_	_	(22,595)
(4,517,855)	(177,941)	_	(210)	(522)	(203,052)	(4,966,481)	(10,342)
(3,322,660)	(116,384)	_	(294)	(648)	_	(3,681,733)	(2,444)
(1,007,647)	(67,143)	_	(79)	(227)	(52,463)	(999,011)	(2,327)
(1,000,970)	(66,651)	_	(63)	(185)	(53,679)	(1,010,679)	(2,680)
(213,675)	(15,955)	_	(52)	(153)	(11,243)	(225,013)	(355)
(251,162,592)	(13,222,454)	(330)	(17,014)	(41,907)	(8,893,131)	(203,689,165)	(685,604)
2,084,974,582	265,356,441	97	193,663	(51,986)	239,395,497	3,630,666,703	11,202,440
(834,018)	(700)	(97)	(96)	(503)	(8,614)	(2,072,070)	(4,118)
(66,515,716)	(4,455,214)	(57)	(50)	(505)	(0,014)	(2,072,070)	(1,037,712)
(67,349,734)	(4,455,914)	(97)	(96)	(503)	(8,614)	(2,072,070)	(1,041,830)
	( ,,,,	(577		(000)	(0)011)		(1,0.1,000)
2,017,624,848	260,900,527	-	193,567	(52,489)	239,386,883	3,628,594,633	10,160,610
(24,155,629)	(303,060)	_	(1,911)	(3,223)	(1,929,035)	(83,762,652)	(101,430)
1,993,469,219	260,597,467	-	191,656	(55,712)	237,457,848	3,544,831,981	10,059,180

# Comparative Statement of Comprehensive Income

For the financial year ended 31 December 2020

#### As at 31 December 2020

	Notes	Asian Opportunities Fund US\$	Asian Stars Fund US\$	Automation & Artificial Intelligence Fund US\$	Biotechnology Fund US\$	
Investment income						
Investment income	2H	437,574	80,795	4,799,510	599,331	
Net realised and unrealised (loss)/gain on investments	2D	(749,750)	3,886,334	214,911,072	322,029,287	
Income equalisation	2E	(119,908)	_	(117,181)	_	
Net investment (loss)/income		(432,084)	3,967,129	219,593,401	322,628,618	
Expenses						
Investment management fees	3	(194,896)	(38,668)	(2,226,400)	(9,161,955)	
Administration fees	3	(9,183)	(4,102)	(242,359)	(346,295)	
General expenses	3	(55,182)	(37,556)	(130,713)	(184,339)	
Performance fees	3	(83,074)	(160,566)	(7,253,623)	(10,485,339)	
Depositary's fees	3	(15,535)	(6,641)	(184,995)	(184,694)	
Research fees		(1,215)	(2,306)	(118,337)	(277,298)	
Legal fees		(513)	(655)	(39,553)	(57,368)	
Directors' fees	8	(1,248)	(579)	(34,819)	(48,603)	
Auditor's fees		(28)	(127)	(7,492)	(12,168)	
Operating expenses		(360,874)	(251,200)	(10,238,291)	(20,758,059)	
Net (expense)/income from operations before finance of	osts	(792,958)	3,715,929	209,355,110	301,870,559	
Finance costs						
Bank interest/financing charges	2H	(3)	(109)	(114,985)	(162,900)	
Distributions to holders of redeemable participating shares	13	_	_	-	_	
Total finance costs		(3)	(109)	(114,985)	(162,900)	
(Loss)/profit for the year before tax		(792,961)	3,715,820	209,240,125	301,707,659	
Withholding tax		(58,383)	(13,224)	(874,539)	(173,221)	
Change in net assets attributable to holders of redeemable participating shares		(851,344)	3,702,596	208,365,586	301,534,438	



China Stars Fund US\$	Markets Income Fund	Emerging Markets Stars Fund US\$	European ex UK Income Fund EUR	Financial Opportunities Fund US\$	Global Absolute Return Fund US\$	Global Convertible Fund US\$	Global Insurance Fund GBP
140,652	5,561,678	1,243,440	10,413,745	191,845	1,411,662	37,600,109	25,894,077
3,856,231	(9,968,960)	84,620,064	(46,227,604)	(2,587,321)	9,874,176	200,646,391	(115,141,003)
5,246	(453,589)	21,883	328,898	(25,174)	(18,315)	(3,839,501)	(433,302)
4,002,129	(4,860,871)	85,885,387	(35,484,961)	(2,420,650)	11,267,523	234,406,999	(89,680,228)
(42,879	) (743,034)	(745,066)	(1,910,808)	(95,142)	(325,743)	(7,276,903)	(10,832,795)
(4,316		(69,426)	(101,854)	(4,415)	(19,432)	(402,662)	(630,712)
(57,734		(106,213)	(28,195)	(46,540)	(117,918)	(448,146)	(211,886)
(92,209		(2,558,924)	(20).00)	(6,693)	(1,521,702)	(23)	933
(4,815	•	(113,329)	(75,575)	(3,741)	(9,262)	(205,511)	(341,719)
(2,220		(32,273)	-	(770)	(4,456)	(113,828)	(147,280)
(690)		(11,711)	(17,013)	(490)	(3,352)	(67,150)	(107,937)
(623		(9,866)	(14,932)	(629)	(2,954)	(72,878)	(92,075)
(142)	) (613)	(4,166)	(1,199)	_	(470)	(9,249)	(14,353)
(205,628		(3,650,974)	(2,149,576)	(158,420)	(2,005,289)	(8,596,350)	(12,377,824)
3,796,501	(5,947,893)	82,234,413	(37,634,537)	(2,579,070)	9,262,234	225,810,649	(102,058,052)
(14,440	) (4,772)	(10,699)	(34,969)	(424)	(32,267)	(385,857)	(132,293)
	(	(10,055)	(8,438,293)	(160,699)	(52,207)	(27,795,727)	(8,820,811)
(14,440)		(10,699)	(8,473,262)	(161,123)	(32,267)	(28,181,584)	(8,953,104)
(14,440)	, (3,131,401)	(10,099)	(0,473,202)	(101,125)	(32,207)	(20,101,304)	(0,900,104)
3,782,061	(11,139,374)	82,223,714	(46,107,799)	(2,740,193)	9,229,967	197,629,065	(111,011,156)
(10,417	) (523,953)	(203,592)	(921,913)	(2,145)	(556)	(192,494)	(3,428,612)
3,771,644	(11,663,327)	82,020,122	(47,029,712)	(2,742,338)	9,229,411	197,436,571	(114,439,768)

# Comparative Statement of Comprehensive Income continued For the financial year ended 31 December 2020

## As at 31 December 2020

		Global Technology	Healthcare Blue Chip	Healthcare Discovery	Healthcare Opportunities	
		Fund	Fund	Fund*	Fund	
	Notes	US\$	US\$	US\$	US\$	
Investment income						
Investment income	2H	27,928,268	841,185	45,003	11,825,151	
Net realised and unrealised (loss)/gain on investments	2D	2,972,566,278	5,383,498	12,421,781	347,906,439	
Income equalisation	2E	_	12,996	(82)	2,576	
Net investment (loss)/income		3,000,494,546	6,237,679	12,466,702	359,734,166	
Expenses						
Investment management fees	3	(67,064,282)	(495,178)	(164,311)	(18,826,064)	
Administration fees	3	(2,634,022)	(37,142)	(11,088)	(810,177)	
General expenses	3	(1,452,301)	(49,356)	(34,495)	(324,172)	
Performance fees	3	(30,980,309)	_	(234,272)	(766,974)	
Depositary's fees	3	(1,815,837)	(20,554)	(6,961)	(456,692)	
Research fees		(1,243,996)	(27,468)	(10,029)	(691,014)	
Legal fees		(417,627)	(6,416)	(1,712)	(132,147)	
Directors' fees	8	(382,549)	(5,476)	(1,511)	(116,255)	
Auditor's fees		(93,185)	(784)	(494)	(21,203)	
Operating expenses		(106,084,108)	(642,374)	(464,873)	(22,144,698)	
Net (expense)/income from operations before finance c	osts	2,894,410,438	5,595,305	12,001,829	337,589,468	
Finance costs						
Bank interest/financing charges	2H	(20,542)	(23,769)	(1,406)	(32,068)	
Distributions to holders of redeemable participating shares	13	_	(652,419)	_	_	
Total finance costs		(20,542)	(676,188)	(1,406)	(32,068)	
(Loss)/profit for the year before tax		2,894,389,896	4,919,117	12,000,423	337,557,400	
Withholding tax		(6,172,526)	(223,601)	(9,300)	(2,575,580)	
Change in net assets attributable to holders of redeemable participating shares		2,888,217,370	4,695,516	11,991,123	334,981,820	
· · · · · · · · · · · · · · · · · · ·		, , - , - , 0	.,,0		,, - 20	

\* Healthcare Discovery Fund launched on 31 January 2020.

\*\* UK Absolute Equity Fund terminated on 15 May 2020.

The accompanying notes form an integral part of these Financial Statements.



Total US\$	UK Value Opportunities Fund GBP	UK Absolute Equity Fund** GBP	North American Fund US\$	Japan Value Fund JPY	Income Opportunities Fund GBP
185,946,566	17,721,458	1,184,070	12,923,667	528,860,051	4,651,824
3,572,235,308	(121,386,972)	(133,051,055)	17,044,522	(7,383,010,406)	(10,348,013)
(8,782,043)	46,591	_	(340,848)	(80,346,555)	(2,365,581)
3,749,399,831	(103,618,923)	(131,866,985)	29,627,341	(6,934,496,910)	(8,061,770)
(143,104,974)	(5,590,386)	(1,291,041)	(8,283,049)	(191,444,593)	(814,752)
(6,983,156)	(461,529)	(65,792)	(587,194)	(10,811,425)	(38,068)
(4,137,927)	(179,290)	148,846	(112,771)	(7,332,295)	(34,261)
(57,744,766)	(2,307,788)	_	_	_	(498,569)
(4,175,789)	(151,463)	(21,159)	(309,647)	(7,559,631)	(20,254)
(3,440,693)	(132,536)	(260,264)	_	(12,136,281)	(8,482)
(1,163,401)	(78,730)	(14,971)	(107,836)	(2,125,814)	(7,484)
(1,044,863)	(67,397)	(23,706)	(85,954)	(1,591,610)	(5,416)
(184,275)	(9,642)	(2,080)	619	(108,651)	844
(221,979,844)	(8,978,761)	(1,530,167)	(9,485,832)	(233,110,300)	(1,426,442)
3,527,419,987	(112,597,684)	(133,397,152)	20,141,509	(7,167,607,210)	(9,488,212)
(3,446,063)	(613)	(1,846,404)	(1,669)	(5,056,256)	(9,519)
(77,058,211)	(15,656,304)	_	_	_	(1,723,491)
(80,504,274)	(15,656,917)	(1,846,404)	(1,669)	(5,056,256)	(1,733,010)
3,446,915,713	(128,254,601)	(135,243,556)	20,139,840	(7,172,663,466)	(11,221,222)
(20,408,736)	(150,770)	_	(3,102,389)	(95,611,526)	210,078
3,426,506,977	(128,405,371)	(135,243,556)	17,037,451	(7,268,274,992)	(11,011,144)

# Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares

For the financial year ended 31 December 2021

## As at 31 December 2021

	Notes	Asian Opportunities Fund US\$	Asian Stars Fund US\$	Automation & Artificial Intelligence Fund US\$	Biotechnology Fund US\$	
Net assets attributable to holders of redeemable participating shares at the beginning of the financial year		8,372,363	17,447,595	753,361,100	1,256,438,007	
Issue of redeemable shares during the financial year	9	72,598	195,670,182	124,475,620	851,579,878	
Fx gain on consolidation	9	_	_	_	_	
Redemption of redeemable shares during the financial year	9	(9,033,261)	(42,079,661)	(226,294,185)	(445,199,499)	
Change in net assets attributable to holders of redeemable participating shares		588,300	(2,114,902)	117,286,772	51,085,713	
Net assets attributable to holders of redeemable participating shares at the end of the financial year		_	168,923,214	768,829,307	1,713,904,099	

	Notes	Global Technology Fund US\$	Healthcare Blue Chip Fund US\$	Healthcare Discovery Fund US\$	Healthcare Opportunities Fund US\$	
Net assets attributable to holders of redeemable participating shares at the beginning of the financial year		8,655,795,829	92,030,247	48,456,796	2,124,581,345	
Issue of redeemable shares during the financial year	9	2,932,766,804	21,571,885	28,843,889	485,125,747	
Fx gain on consolidation	2	_	_	_	_	
Redemption of redeemable shares during the financial year	9	(3,281,148,156)	(18,009,475)	(5,971,168)	(651,666,103)	
Change in net assets attributable to holders of redeemable participating shares		770,982,669	20,555,468	1,290,075	180,182,455	
Net assets attributable to holders of redeemable participating shares at the end of the financial year		9,078,397,146	116,148,125	72,619,592	2,138,223,444	

\* Asian Opportunities Fund terminated on 01 March 2021.

\*\* Emerging Markets Income Fund merged with the Emerging Markets Stars Fund on 08 June 2021.

\*\*\* Smart Energy Fund launched on 30 September 2021.

\*\*\*\* Smart Mobility Fund launched on 30 September 2021.

The accompanying notes form an integral part of these Financial Statements.



\_\_\_\_

China Stars Fund US <b>\$</b>	Emerging Markets Income Fund US\$	Emerging Markets Stars Fund US\$	European (ex UK) Income Fund EUR	Financial Opportunities Fund US\$	Global Absolute Return Fund US <b>\$</b>	Global Convertible Fund US\$	Global Insurance Fund GBP
13,974,480	104,412,469	370,603,749	190,978,232	10,805,493	47,066,341	1,047,829,601	1,587,832,431
12,041,071	3,676,063	1,081,577,517	23,512,624	21,924,862	41,585,735	361,783,823	464,751,344
_	-	_	_	_	-	-	-
(3,363,782)	(112,392,191)	(123,759,337)	(117,353,112)	(11,375,034)	(20,114,203)	(229,283,199)	(593,040,286)
(2,672,440)	4,303,659	(40,068,514)	22,001,759	2,141,441	1,787,511	(113,425,819)	242,289,235
19,979,329	_	1,288,353,415	119,139,503	23,496,762	70,325,384	1,066,904,406	1,701,832,724

Income Opportunities Fund GBP	Japan Value Fund JPY	North American Fund US\$	Smart Energy Fund*** US\$	Smart Mobility Fund**** US\$	UK Absolute Equity Fund GBP	UK Value Opportunities Fund GBP	Total US\$
59,679,614	17,953,295,439	1,055,161,717	_	_	_	1,148,193,906	19,835,492,695
3,417,299	7,741,047,267	318,303,304	28,201,501	7,184,214	_	692,866,173	8,211,891,229
_	-	-	-	-	-	-	(80,709,370)
(15,103,394)	(5,570,721,229)	(359,488,828)	(493,118)	-	-	(493,399,757)	(7,244,572,983)
10,059,180	3,544,831,981	237,457,848	(55,712)	191,656	_	260,597,467	1,993,469,219
58,052,699	23,668,453,458	1,251,434,041	27,652,671	7,375,870	-	1,608,257,789	22,715,570,790

# Comparative Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares

For the financial year ended 31 December 2020

## As at 31 December 2020

	Notes	Asian Opportunities Fund US\$	Asian Stars Fund US\$	Automation & Artificial Intelligence Fund US\$	Biotechnology Fund US\$	
Net assets attributable to holders of redeemable participating shares at the beginning of the financial year		29,530,051	7,204,135	432,973,479	545,642,821	
Issue of redeemable shares during the financial year	9	1,022,912	6,900,069	423,128,837	724,138,196	
Fx gain on consolidation	2	-	_	-	_	
Redemption of redeemable shares during the financial year	9	(21,329,256)	(359,205)	(311,106,802)	(314,877,448)	
Change in net assets attributable to holders of redeemable participating shares		(851,344)	3,702,596	208,365,586	301,534,438	
Net assets attributable to holders of redeemable participating shares at the end of the financial year		8,372,363	17,447,595	753,361,100	1,256,438,007	

	Notes	Global Technology Fund US\$	Healthcare Blue Chip Fund US <b>\$</b>	Healthcare Discovery Fund* US <b>\$</b>	Healthcare Opportunities Fund US <b>\$</b>	
Net assets attributable to holders of redeemable participating shares at the beginning of the financial year		3,650,300,379	92,465,732	_	1,628,715,705	
Issue of redeemable shares during the financial year	9	4,640,789,043	38,845,916	38,114,584	664,961,029	
Fx gain on consolidation	2	-	-	-	-	
Redemption of redeemable shares during the financial year	9	(2,523,510,963)	(43,976,917)	(1,648,911)	(504,077,209)	
Change in net assets attributable to holders of redeemable participating shares		2,888,217,370	4,695,516	11,991,123	334,981,820	
Net assets attributable to holders of redeemable participating shares at the end of the financial year		8,655,795,829	92,030,247	48,456,796	2,124,581,345	

\* Healthcare Discovery Fund launched on 31 January 2020.

\*\* UK Absolute Equity Fund terminated on 15 May 2020.

The accompanying notes form an integral part of these Financial Statements.



China Stars Fund US\$	Emerging Markets Income Fund US\$	Emerging Markets Stars Fund US\$	European ex UK Income Fund EUR	Financial Opportunities Fund US\$	Global Absolute Return Fund US\$	Global Convertible Fund US\$	Global Insurance Fund GBP
7,415,096	147,974,671	42,996,000	270,262,166	18,801,517	45,417,356	918,616,595	1,552,466,425
3,207,732	24,573,792	270,313,451	101,405,735	5,575,870	14,576,654	336,588,482	677,780,754
_	-	_	_	_	-	-	_
(419,992)	(56,472,667)	(24,725,824)	(133,659,957)	(10,829,555)	(22,157,080)	(404,812,047)	(527,974,980)
3,771,644	(11,663,327)	82,020,122	(47,029,712)	(2,742,338)	9,229,411	197,436,571	(114,439,768)
13,974,480	104,412,469	370,603,749	190,978,232	10,805,494	47,066,341	1,047,829,601	1,587,832,431

Income Opportunities Fund GBP	Japan Value Fund JPY	North American Fund US\$	UK Absolute Equity Fund** GBP	UK Value Opportunities Fund GBP	Total US\$
164,158,552	40,871,864,753	2,072,514,390	509,468,363	1,266,549,127	14,945,202,724
3,728,959	3,067,091,170	226,981,775	70,466,797	672,390,411	9,392,520,275
_	-	_	_	-	124,308,697
(97,196,753)	(18,717,385,492)	(1,261,371,899)	(444,691,604)	(662,340,261)	(8,053,045,977)
(11,011,144)	(7,268,274,992)	17,037,451	(135,243,556)	(128,405,371)	3,426,506,977
59,679,614	17,953,295,439	1,055,161,717	_	1,148,193,906	19,835,492,696

Statement of Cash Flows For the financial year ended 31 December 2021

## As at 31 December 2021

	Asian Opportunities Fund US\$	Asian Stars Fund US <b>\$</b>	Automation & Artificial Intelligence Fund US\$	Biotechnology Fund US\$	
Cash flows from operating activities					
Purchase of financial assets	(56,395)	(210,468,260)	(343,927,031)	(1,489,781,314)	
Proceeds from sale of financial assets	8,745,483	59,436,090	435,181,694	1,021,032,334	
Inflow/(outflow) from forward foreign currency contracts and futures	17,270	(1,118,940)	1,965,928	(7,526,362)	
Decrease/(increase) in margin accounts	-	_	_	_	
Dividends and interest received	14,681	943,957	5,962,296	790,197	
Operating expenses paid	(173,277)	(109,636)	(13,056,103)	(29,947,798)	
Net cash inflow/(outflow) from operating activities	8,547,762	(151,316,789)	86,126,784	(505,432,943)	
Cash flows from financing activities					
Distributions	_	_	_	_	
Income equalisation	_	27,640	(201,328)	_	
Proceeds from redeemable participating shares	72,598	195,634,836	125,011,860	857,234,986	
Redemptions of redeemable participating shares	(9,035,743)	(41,961,572)	(225,144,291)	(441,747,312)	
Net cash (outflow)/inflow from financing activities	(8,963,145)	153,700,904	(100,333,759)	415,487,674	
Net (decrease)/increase in cash	(415,383)	2,384,115	(14,206,975)	(89,945,269)	
Foreign exchange adjustment on aggregation	_	_	_	_	
Cash at beginning of the financial year	430,296	323,398	31,471,631	100,060,925	
Cash at end of the financial year	14,913	2,707,513	17,264,656	10,115,656	
Supplementary cash flow information					
Cash flows from operating activities include:					
Cash received during the financial year for dividend income	14,686	945,770	6,157,754	815,738	
Cash received during the financial year for bond interest income	_	_	_	_	
Cash received during the financial year for bank interest income	_	_	7,839	83	
Cash paid during the financial year for interest expense	(5)	(1,813)	(203,297)	(25,624)	
	14,681	943,957	5,962,296	790,197	

\* Asian Opportunities Fund terminated on 01 March 2021.

\*\* Emerging Markets Income Fund merged with the Emerging Markets Stars Fund on 08 June 2021.

China Stars Fund US\$	Emerging Markets Income Fund US\$	Emerging Markets Star Fund US\$	European (ex UK) Income Fund EUR	Financial Opportunities Fund US\$	Global Absolute Return Fund US\$	Global Convertible Fund US\$	Global Insurance Fund GBP
(19,504,775)	(20,861,087)	(1,223,068,530)	(22,350,540)	(27,462,184)	(379,977,560)	(4,264,451,756)	(106,897,932)
10,878,989	130,994,162	283,187,097	113,172,207	17,972,220	352,982,824	4,061,237,609	193,389,064
14,805	(78,552)	(4,541,564)	2,190,857	1,866	(5,484,012)	(58,416,675)	(1,424,797)
9	_	_	_	_	(711,785)	_	_
197,593	1,697,973	5,338,831	7,856,374	403,800	1,337,551	45,648,253	29,014,197
(257,568)	(590,010)	(6,071,989)	(2,657,787)	(292,048)	(2,009,629)	(11,146,039)	(18,886,469)
(8,670,947)	111,162,486	(945,156,155)	98,211,111	(9,376,346)	(33,862,611)	(227,128,608)	95,194,063
_	(2,012,462)	_	(5,627,689)	(187,304)	_	(34,011,104)	(11,359,000)
58,924	(1,079,820)	78,741	(965,317)	98,959	161,542	3,523,299	(2,098,029)
12,072,946	3,711,772	1,081,914,332	23,512,624	21,897,548	41,585,735	362,361,951	466,026,981
(3,398,582)	(113,082,426)	(122,932,893)	(117,353,112)	(11,368,643)	(20,114,203)	(228,984,762)	(591,486,723)
8,733,288	(112,462,936)	959,060,180	(100,433,494)	10,440,560	21,633,074	102,889,384	(138,916,771)
62,341	(1,300,450)	13,904,025	(2,222,383)	1,064,214	(12,229,537)	(124,239,224)	(43,722,708)
_	_	_	_	_	_	_	_
924,488	1,426,888	11,697,452	(254,206)	383,063	214,045	(64,087,192)	49,422,268
986,829	126,438	25,601,477	(2,476,589)	1,447,277	(12,015,492)	(188,326,416)	5,699,560
199,727	1,697,812	5,344,271	7,868,335	404,794	1,178,423	37,144,413	29,108,356
_	_	_	_	_	238,983	6,671,125	-
2	164	1,003	154	1	-	1,833,243	_
(2,136)	(3)	(6,443)	(12,115)	(995)	(79,855)	(528)	(94,159)
197,593	1,697,973	5,338,831	7,856,374	403,800	1,337,551	45,648,253	29,014,197

Statement of Cash Flows continued For the financial year ended 31 December 2021

## As at 31 December 2021

	Global Technology Fund US\$	Healthcare Blue Chip Fund US\$	Healthcare Discovery Fund US\$	Healthcare Opportunities Fund US\$	
Cash flows from operating activities					
Purchase of financial assets	(10,913,464,357)	(157,295,808)	(66,811,344)	(1,680,908,650)	
Proceeds from sale of financial assets	11,020,930,683	153,849,098	45,250,023	1,925,258,930	
Inflow/(outflow) from forward foreign currency contracts and futures	(60,572,758)	(48,737)	(147,485)	(5,332,971)	
Decrease/(increase) in margin accounts	(4,403,480)	_	_	20,502,128	
Dividends and interest received	45,444,393	1,074,004	140,701	10,002,287	
Operating expenses paid	(156,285,849)	(938,850)	(670,642)	(23,440,412)	
Net cash inflow/(outflow) from operating activities	(68,351,368)	(3,360,293)	(22,238,747)	246,081,312	
Cash flows from financing activities					
Distributions	_	(465,527)	_	_	
Income equalisation	_	21,016	-	_	
Proceeds from redeemable participating shares	2,945,579,068	21,335,181	28,764,438	476,864,198	
Redemptions of redeemable participating shares	(3,256,746,782)	(17,542,949)	(5,827,197)	(657,281,781)	
Net cash (outflow)/inflow from financing activities	(311,167,714)	3,347,721	22,937,241	(180,417,583)	
Net (decrease)/increase in cash	(379,519,082)	(12,572)	698,494	65,663,729	
Foreign exchange adjustment on aggregation	-	-	-	-	
Cash at beginning of the financial year	784,391,029	4,573,008	3,338,624	1,941,735	
Cash at end of the financial year	404,871,947	4,560,436	4,037,118	67,605,464	
Supplementary cash flow information					
Cash flows from operating activities include:					
Cash received during the financial year for dividend income	45,499,505	1,080,911	141,332	10,283,150	
Cash received during the financial year for bond interest income	-	-	-	_	
Cash received during the financial year for bank interest income	2,481	_	-	_	
Cash paid during the financial year for interest expense	(57,593)	(6,907)	(631)	(280,863)	
	45,444,393	1,074,004	140,701	10,002,287	

\* Smart Energy Fund launched on 30 September 2021.

\*\* Smart Mobility Fund launched on 30 September 2021.

The accompanying notes form an integral part of these Financial Statements.



Total US\$	UK Value Opportunities Fund GBP	UK Absolute Equity Fund GBP	Smart Mobility Fund** US <b>\$</b>	Smart Energy Fund* US <b>\$</b>	North American Fund US\$	Japan Value Fund JPY	Income Opportunities Fund GBP
(22,879,372,534)	(904,250,552)	_	(9,333,364)	(34,398,582)	(452,803,033)	(15,712,558,217)	(17,618,520)
21,257,332,481	695,886,311	_	2,444,901	9,818,753	508,320,394	12,361,844,691	38,967,293
(143,666,400)	50,713	427	2,059	10,216	(9,073,266)	695,010,069	(365,130)
15,376,269	17,670	_	_	_	_	_	(26,323)
239,259,727	39,058,586	(92)	3,964	10,333	8,017,677	557,212,369	2,995,875
(310,052,080)	(15,466,186)	(1,376)	(22,101)	(36,189)	(10,652,208)	(285,363,462)	(1,207,672)
(1,821,122,537)	(184,703,458)	(1,041)	(6,904,541)	(24,595,469)	43,809,564	(2,383,854,550)	22,745,523
(66,515,715)	(4,455,214)	_	_	_	_	_	(1,037,712)
(2,077,691)	(200,135)	_	_	_	1,286	29,975,676	(536,356)
8,223,958,999	693,904,390	_	7,167,701	25,474,142	318,446,475	7,755,167,679	3,406,749
(7,214,536,181)	(489,643,808)	_	_	(491,724)	(359,948,682)	(5,582,228,935)	(15,378,353)
940,829,412	199,605,233	_	7,167,701	24,982,418	(41,500,921)	2,202,914,420	(13,545,672)
(222,222,125)		(1.0.11)		222.2.12	2 2 2 2 4 2	(100.0.10.100)	
(880,293,125)	14,901,775	(1,041)	263,160	386,949	2,308,643	(180,940,130)	9,199,851
313,281,980	-	-	-	-	_	_	_
1,010,461,445	27,314,814	88,976	_	_	25,342,257	255,931,723	617,784
443,450,300	42,216,589	87,935	263,160	386,949	27,650,900	74,991,593	9,817,635
220,000,051	20.050.200		2.000	10,400	0.026.240	FF0 200 F00	1046422
229,898,051	39,059,280	-	3,998	10,488	8,026,218	559,288,590	1,946,133
8,143,793	_	_	-	_	_	-	894,204
2,063,145	5	_	-	-	_	20,271	159,659
(845,262)	(699)	(92)	(34)	(155)	(8,541)	(2,096,492)	(4,121)
239,259,727	39,058,586	(92)	3,964	10,333	8,017,677	557,212,369	2,995,875

Comparative Statement of Cash Flows

For the financial year ended 31 December 2020

## As at 31 December 2020

Cash flows from operating activities           Purchase of financial assets         (10,501,096)         (9,459,051)         (423,642,542)         (1,245,201,213)           Proceeds from sale of financial assets         29,981,063         3,200,155         343,613,991         936,998,207           Inflow/(outflow) from forward foreign currency contracts and futures         69,006         (42,963)         (942,311)         (138,362)           Decrease in margin accounts         -         -         -         -         -           Dividends and interest received         459,381         72,111         4,666,446         439,083           Operating expenses paid         (560,114)         (130,378)         (13,868,614)         (12,534,135)           Net cash inflow/(outflow) from operating activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities         19,448,240         (6,360,096)         422,065,609         726,611,159           Redemptions paid to shareholders         (21,326,774)         (359,205)         (311,120,214)         (325,471,604)           Net cash (outflow)/inflow from financing activities         (20,002,696)         6,539,585         110,828,214         401,139,555           Net (decrease)/increase in cash         (554,456)		Asian Opportunities Fund US\$	Asian Stars Fund US\$	Automation & Artificial Intelligence Fund US\$	Biotechnology Fund US\$	
Proceeds from sale of financial assets         29,981,063         3,200,155         343,613,991         936,998,207           Inflow/(outflow) from forward foreign currency contracts and futures         69,006         (42,963)         (942,311)         (138,362)           Decrease in margin accounts         -         -         -         -         -           Dividends and interest received         459,381         72,141         4,666,446         439,083           Operating expenses paid         (560,114)         (130,378)         (13,868,614)         (12,534,135)           Net cash inflow/(outflow) from operating activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities         19,448,240         (6,360,096)         (91,73,030)         (320,436,420)           Cash flows from financing activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities         19,448,240         (6,360,096)         (91,73,030)         (320,436,420)           Net cash (outflow)/inflow from financing activities         (21,326,774)         (359,205)         (311,120,214) <td< td=""><td>Cash flows from operating activities</td><td></td><td></td><td></td><td></td><td></td></td<>	Cash flows from operating activities					
Inflow/(outflow) from forward foreign currency contracts and futures       69,006       (42,963)       (942,311)       (138,362)         Decrease in margin accounts       -       -       -       -         Dividends and interest received       459,381       72,141       4,666,446       439,083         Operating expenses paid       (560,114)       (130,378)       (13,868,614)       (12,534,135)         Net cash inflow/(outflow) from operating activities       19,448,240       (6,360,096)       (90,173,030)       (320,436,420)         Cash flows from financing activities       19,448,240       (6,360,096)       (90,173,030)       (320,436,420)         Cash flows from financing activities       19,448,240       (6,360,096)       (90,173,030)       (320,436,420)         Cash flows from financing activities       19,448,240       (6,360,096)       (90,173,030)       (320,436,420)         Cash flows from financing activities       19,448,240       (6,360,096)       (90,173,030)       (320,436,420)         Proceeds from redeemable participating shares issued       1,443,986       6,898,790       422,065,609       726,611,159         Redemptions paid to shareholders       (21,326,774)       (359,205)       (311,120,214)       (325,471,604)         Net cash (outflow)/inflow from financing activities       (20,002	Purchase of financial assets	(10,501,096)	(9,459,051)	(423,642,542)	(1,245,201,213)	
Decrease in margin accounts         -         -         -           Dividends and interest received         459,381         72,141         4,666,446         439,083           Operating expenses paid         (560,114)         (130,378)         (13,868,614)         (12,534,135)           Net cash inflow/(outflow) from operating activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Distributions         -         -         -         -         -           Income equalisation         (119,908)         -         (117,181)         -           Proceeds from redeemable participating shares issued         1,443,986         6,898,790         422,065,609         726,611,159           Redeemptions paid to shareholders         (20,002,696)         6,539,585         110,828,214         401,139,555           Net (decrease)/increase in cash         (554,456)         179,489         20,655,184         80,703,135           Foreign exchange adjustment on aggregation         -         -         -         -           Cash at beginning of the financial year         984,752         143,909         3,562,824         19,357,790	Proceeds from sale of financial assets	29,981,063	3,200,155	343,613,991	936,998,207	
Dividends and interest received         459,381         72,141         4,666,446         439,083           Operating expenses paid         (560,114)         (130,378)         (13,868,614)         (12,534,135)           Net cash inflow/(outflow) from operating activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Redemptions paid to shareholders         (119,908)         -         (117,181)         -           Proceeds from redeemable participating shares issued         1,443,986         6,898,790         422,065,609         726,611,159           Redemptions paid to shareholders         (21,326,774)         (359,255         110,828,214         401,139,555           Net (decrease)/increase in cash         (554,456)         179,489         20,655,184         80,703,135	Inflow/(outflow) from forward foreign currency contracts and futures	69,006	(42,963)	(942,311)	(138,362)	
Operating expenses paid         (560,114)         (13,0,378)         (13,868,614)         (12,534,135)           Net cash inflow/(outflow) from operating activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities                Distributions         -         -         -         -         -         -         -           Income equalisation         (119,908)         -         (117,181)         -         -           Proceeds from redeemable participating shares issued         1,443,986         6,898,790         422,065,609         726,611,159           Redemptions paid to shareholders         (21,326,774)         (359,205)         (311,120,214)         (325,471,604)           Net cash (outflow)/inflow from financing activities         (20,002,696)         6,539,585         110,828,214         401,139,555           Net (decrease)/increase in cash         (554,456)         179,489         20,655,184         80,703,135           Foreign exchange adjustment on aggregation         -         -         -         -           Cash at beginning of the financial year         984,752         143,909         3,562,824         19,357,790           Supplementary cash flow i	Decrease in margin accounts	_	_	_	_	
Net cash inflow/(outflow) from operating activities         19,448,240         (6,360,096)         (90,173,030)         (320,436,420)           Cash flows from financing activities <td< td=""><td>Dividends and interest received</td><td>459,381</td><td>72,141</td><td>4,666,446</td><td>439,083</td><td></td></td<>	Dividends and interest received	459,381	72,141	4,666,446	439,083	
Cash flows from financing activitiesDistributionsIncome equalisation(119,908)-(117,181)Proceeds from redeemable participating shares issued1,443,9866,898,790422,065,609726,611,159Redemptions paid to shareholders(21,326,774)(359,205)(311,120,214)(325,471,604)Net cash (outflow)/inflow from financing activities(20,002,696)6,539,585110,828,214401,139,555Net (decrease)/increase in cash(554,456)179,48920,655,18480,703,135Foreign exchange adjustment on aggregationCash at beginning of the financial year984,752143,9093,562,82419,357,790Cash at end of the financial year430,296323,39824,218,008100,060,925Supplementary cash flow informationCash received during the financial year for dividend income458,84672,1974,778,770599,202Cash received during the financial year for bond interest income	Operating expenses paid	(560,114)	(130,378)	(13,868,614)	(12,534,135)	
Distributions         –         –         –           Income equalisation         (119,908)         –         (117,181)         –           Proceeds from redeemable participating shares issued         1,443,986         6,898,790         422,065,609         726,611,159           Redemptions paid to shareholders         (21,326,774)         (359,205)         (311,120,214)         (325,471,604)           Net cash (outflow)/inflow from financing activities         (20,002,696)         6,539,585         110,828,214         401,139,555           Net (decrease)/increase in cash         (554,456)         179,489         20,655,184         80,703,135           Foreign exchange adjustment on aggregation         –         –         –         –           Cash at beginning of the financial year         984,752         143,909         3,562,824         19,357,790           Cash at end of the financial year         430,296         323,398         24,218,008         100,060,925           Supplementary cash flow information         E         –         –         –           Cash received during the financial year for dividend income         458,846         72,197         4,778,770         599,202           Cash received during the financial year for bond interest income         –         –         –         – </td <td>Net cash inflow/(outflow) from operating activities</td> <td>19,448,240</td> <td>(6,360,096)</td> <td>(90,173,030)</td> <td>(320,436,420)</td> <td></td>	Net cash inflow/(outflow) from operating activities	19,448,240	(6,360,096)	(90,173,030)	(320,436,420)	
Income equalisation       (119,908)       -       (117,181)       -         Proceeds from redeemable participating shares issued       1,443,986       6,898,790       422,065,609       726,611,159         Redemptions paid to shareholders       (21,326,774)       (359,205)       (311,120,214)       (325,471,604)         Net cash (outflow)/inflow from financing activities       (20,002,696)       6,539,585       110,828,214       401,139,555         Net (decrease)/increase in cash       (554,456)       179,489       20,655,184       80,703,135         Foreign exchange adjustment on aggregation       -       -       -       -         Cash at beginning of the financial year       984,752       143,909       3,562,824       19,357,790         Cash at end of the financial year       430,296       323,398       24,218,008       100,060,925         Supplementary cash flow information       Cash received during the financial year for dividend income       458,846       72,197       4,778,770       599,202         Cash received during the financial year for bond interest income       -       -       -       -	Cash flows from financing activities					
Proceeds from redeemable participating shares issued       1,443,986       6,898,790       422,065,609       726,611,159         Redemptions paid to shareholders       (21,326,774)       (359,205)       (311,120,214)       (325,471,604)         Net cash (outflow)/inflow from financing activities       (20,002,696)       6,539,585       110,828,214       401,139,555         Net (decrease)/increase in cash       (554,456)       179,489       20,655,184       80,703,135         Foreign exchange adjustment on aggregation       -       -       -       -         Cash at beginning of the financial year       984,752       143,909       3,562,824       19,357,790         Cash at end of the financial year       430,296       323,398       24,218,008       100,060,925         Supplementary cash flow information       -       -       -       -         Cash received during the financial year for dividend income       458,846       72,197       4,778,770       599,202         Cash received during the financial year for bond interest income       -       -       -       -	Distributions	_	_	_	_	
Redemptions paid to shareholders       (21,326,774)       (359,205)       (311,120,214)       (325,471,604)         Net cash (outflow)/inflow from financing activities       (20,002,696)       6,539,585       110,828,214       401,139,555         Net (decrease)/increase in cash       (554,456)       179,489       20,655,184       80,703,135         Foreign exchange adjustment on aggregation       –       –       –       –         Cash at beginning of the financial year       984,752       143,909       3,562,824       19,357,790         Cash at end of the financial year       430,296       323,398       24,218,008       100,060,925         Supplementary cash flow information       –       –       –       –         Cash received during the financial year for dividend income       458,846       72,197       4,778,770       599,202         Cash received during the financial year for dividend income       –       –       –       –         Cash received during the financial year for dividend income       458,846       72,197       4,778,770       599,202         Cash received during the financial year for bond interest income       –       –       –       –       –       –       –	Income equalisation	(119,908)	-	(117,181)	_	
Net cash (outflow)/inflow from financing activities(20,002,696)6,539,585110,828,214401,139,555Net (decrease)/increase in cash(554,456)179,48920,655,18480,703,135Foreign exchange adjustment on aggregationCash at beginning of the financial year984,752143,9093,562,82419,357,790Cash at end of the financial year430,296323,39824,218,008100,060,925Supplementary cash flow informationCash received during the financial year for dividend income458,84672,1974,778,770599,202Cash received during the financial year for bond interest income	Proceeds from redeemable participating shares issued	1,443,986	6,898,790	422,065,609	726,611,159	
Net (decrease)/increase in cash(554,456)179,48920,655,18480,703,135Foreign exchange adjustment on aggregationCash at beginning of the financial year984,752143,9093,562,82419,357,790Cash at end of the financial year430,296323,39824,218,008100,060,925Supplementary cash flow informationCash received during the financial year for dividend income458,84672,1974,778,770599,202Cash received during the financial year for bond interest income	Redemptions paid to shareholders	(21,326,774)	(359,205)	(311,120,214)	(325,471,604)	
Foreign exchange adjustment on aggregationCash at beginning of the financial year984,752143,9093,562,82419,357,790Cash at end of the financial year430,296323,39824,218,008100,060,925Supplementary cash flow informationCash received during the financial year for dividend income458,84672,1974,778,770599,202Cash received during the financial year for bond interest income	Net cash (outflow)/inflow from financing activities	(20,002,696)	6,539,585	110,828,214	401,139,555	
Cash at beginning of the financial year984,752143,9093,562,82419,357,790Cash at end of the financial year430,296323,39824,218,008100,060,925Supplementary cash flow informationCash flows from operating activities include:Cash received during the financial year for dividend income458,84672,1974,778,770599,202Cash received during the financial year for bond interest income	Net (decrease)/increase in cash	(554,456)	179,489	20,655,184	80,703,135	
Cash at end of the financial year430,296323,39824,218,008100,060,925Supplementary cash flow informationCash flows from operating activities include:Cash received during the financial year for dividend income458,84672,1974,778,770599,202Cash received during the financial year for bond interest income	Foreign exchange adjustment on aggregation	-	-	-	_	
Supplementary cash flow information         Cash flows from operating activities include:         Cash received during the financial year for dividend income       458,846       72,197       4,778,770       599,202         Cash received during the financial year for bond interest income       -       -       -       -	Cash at beginning of the financial year	984,752	143,909	3,562,824	19,357,790	
Cash flows from operating activities include:Cash received during the financial year for dividend income458,84672,1974,778,770599,202Cash received during the financial year for bond interest income	Cash at end of the financial year	430,296	323,398	24,218,008	100,060,925	
Cash received during the financial year for dividend income458,84672,1974,778,770599,202Cash received during the financial year for bond interest income	Supplementary cash flow information					
Cash received during the financial year for bond interest income – – – – – –	Cash flows from operating activities include:					
	Cash received during the financial year for dividend income	458,846	72,197	4,778,770	599,202	
Cash received during the financial year for bank interest income 534 – 10,680 3,208	Cash received during the financial year for bond interest income	_	_	_	_	
	Cash received during the financial year for bank interest income	534	-	10,680	3,208	
Cash paid during the financial year for interest expense 1 (56) (123,004) (163,327)	Cash paid during the financial year for interest expense	1	(56)	(123,004)	(163,327)	
459,381 72,141 4,666,446 439,083		459,381	72,141	4,666,446	439,083	

\_\_\_\_\_

Global Insurance Fund GBP	Global Convertible Fund US <b>\$</b>	Global Absolute Return Fund US\$	Financial Opportunities Fund US <b>\$</b>	European ex UK Income Fund EUR	Emerging Markets Stars Fund US\$	Emerging Markets Income Fund US\$	China Stars Fund US\$
(357,869,162)	(3,831,853,787)	(441,759,227)	(7,624,406)	(132,764,828)	(276,876,408)	(25,403,493)	(7,504,259)
220,584,354	3,838,551,642	489,278,040	13,027,731	167,018,399	39,557,425	56,291,639	5,575,743
113,740	4,316,495	(21,161,774)	1,002	(6,224,626)	(1,658,199)	(86,229)	(2,626)
_	8,994,826	3,640,834	_	_	_		
25,781,795	36,210,506	1,408,620	189,618	10,378,596	924,798	5,522,035	121,897
(15,941,264)	(8,523,995)	(571,416)	(165,859)	(3,225,658)	285,180	(1,666,008)	(116,074)
(127,330,537)	47,695,687	30,835,077	5,428,086	35,181,883	(237,767,204)	34,657,944	(1,925,319)
(8,820,811)	(27,795,727)	_	(160,699)	(8,438,293)	_	(5,186,709)	_
(433,302)	(3,839,501)	(18,314)	(25,174)	328,898	21,883	(453,589)	5,246
687,175,601	336,090,402	14,613,019	5,566,395	101,441,181	272,735,384	24,693,006	3,174,240
(535,576,901)	(405,843,988)	(22,157,607)	(10,837,661)	(133,679,316)	(24,086,693)	(55,937,471)	(384,410)
142,344,587	(101,388,814)	(7,562,902)	(5,457,139)	(40,347,530)	248,670,574	(36,884,763)	2,788,606
15,014,050	(53,693,127)	23,272,175	(29,053)	(5,165,647)	10,903,370	(2,226,819)	863,287
-	_	_	-	_	_	_	_
34,408,218	(10,394,065)	(23,058,130)	412,116	4,911,441	794,082	3,653,707	61,201
49,422,268	(64,087,192)	214,045	383,063	(254,206)	11,697,452	1,426,888	924,488
25,917,586	22,682,443	891,833	189,884	10,413,395	935,349	5,526,470	136,288
_	13,978,456	541,240	_	_	_	_	_
22,992	(64,536)	166	151	350	148	345	1,523
(158,783)	(385,857)	(24,619)	(417)	(35,149)	(10,699)	(4,780)	(15,914)
25,781,795	36,210,506	1,408,620	189,618	10,378,596	924,798	5,522,035	121,897

# Comparative Statement of Cash Flows continued For the financial year ended 31 December 2020

## As at 31 December 2020

	Global Technology Fund US\$	Healthcare Blue Chip Fund US <b>\$</b>	Healthcare Discovery Fund* US\$	Healthcare Opportunities Fund US\$
Cash flows from operating activities				
Purchase of financial assets	(9,081,297,226)	(249,008,670)	(64,419,819)	(4,914,728,369)
Proceeds from sale of financial assets	7,602,817,059	257,406,916	31,570,918	4,783,035,552
Inflow/(outflow) from forward foreign currency contracts and futures	48,120,322	(59,478)	(1,433)	(1,621,723)
Decrease/(increase) in margin accounts	22,817,732	_	-	(71,197)
Dividends and interest received	26,955,770	812,991	38,151	12,514,720
Operating expenses paid	(74,432,737)	(883,590)	(219,097)	(23,438,522)
Net cash inflow/(outflow) from operating activities	(1,455,019,080)	8,268,169	(33,031,280)	(144,309,539)
Cash flows from financing activities				
Distributions	_	(652,419)	-	_
Income equalisation	_	12,996	_	2,576
Proceeds from redeemable participating shares issued	4,623,576,050	39,069,659	38,014,563	665,791,946
Redemptions paid to shareholders	(2,508,120,746)	(44,161,871)	(1,644,577)	(496,983,024)
Net cash (outflow)/inflow from financing activities	2,115,455,304	(5,731,635)	36,369,904	168,811,498
Net (decrease)/increase in cash	660,436,224	2,536,534	3,338,624	24,501,959
Foreign exchange adjustment on aggregation	_	_	_	_
Cash at beginning of the financial year	123,954,805	2,036,474	_	(22,560,224)
Cash at end of the financial year	784,391,029	4,573,008	3,338,624	1,941,735
Supplementary cash flow information				
Cash flows from operating activities include:				
Cash received during the financial year for dividend income	26,765,402	834,596	39,453	12,514,405
Cash received during the financial year for bond interest income	_	_	-	-
Cash received during the financial year for bank interest income	190,368	3,015	_	315
Cash paid during the financial year for interest expense	_	(24,620)	(1,302)	-
	26,955,770	812,991	38,151	12,514,720

\* Healthcare Discovery Fund launched on 31 January 2020.

\*\* UK Absolute Equity Fund terminated on 15 May 2020.

The accompanying notes form an integral part of these Financial Statements.



Income Opportunities Fund GBP	Japan Value Fund JPY	North American Fund US\$	UK Absolute Fund** GBP	UK Value Opportunities Fund GBP	Total US\$
(22,928,527)	(15,175,873,003)	(786,314,992)	(136,483,552)	(680,412,251)	(23,206,540,088)
103,883,254	28,181,493,092	1,793,342,485	417,568,011	630,530,616	22,440,623,825
(235,433)	(417,162,500)	2,554,557	8,411,562	452	29,513,567
2,440,108	_	_	36,599,396	22	87,089,569
5,269,466	563,317,865	13,501,811	511,819	17,576,413	183,990,551
(1,177,327)	(363,842,560)	(13,814,783)	(7,266,261)	(7,538,600)	(196,121,925)
87,251,541	12,787,932,894	1,009,269,078	319,340,975	(39,843,348)	(661,444,501)
(1,723,491)	_	_	_	(15,656,304)	(77,058,211)
(2,367,781)	(80,346,555)	(340,848)	_	46,591	(8,785,049)
3,750,570	4,140,447,286	226,060,158	72,700,160	673,275,311	9,405,727,404
(96,992,387)	(18,773,190,074)	(1,277,223,767)	(448,262,552)	(662,764,953)	(8,071,843,242)
(97,333,089)	(14,713,089,343)	(1,051,504,457)	(375,562,392)	(5,099,355)	1,248,040,903
(10,081,548)	(1,925,156,449)	(42,235,379)	(56,221,417)	(44,942,703)	586,596,402
-	_	-	_	-	1,532,425
10,699,332	2,181,088,172	67,577,636	56,310,393	72,257,517	422,332,618
617,784	255,931,723	25,342,257	88,976	27,314,814	1,010,461,445
2,410,082	568,652,885	13,491,855	2,318,511	17,577,064	169,237,627
2,859,384	_	_	_	_	18,219,253
-	_	11,604	349,238	_	423,583
_	(5,335,020)	(1,648)	(2,155,930)	(651)	(3,889,912)
5,269,466	563,317,865	13,501,811	511,819	17,576,413	183,990,551



## 1. Organisation and nature of business

Polar Capital Funds plc (the 'Company') is an open-ended investment company with variable capital and segregated liability between its sub-funds (the 'Funds'), organised under the laws of Ireland. The Company has been authorised by the Central Bank of Ireland (the 'Central Bank') as an Undertaking for Collective Investment in Transferable Securities ('UCITS') pursuant to the UCITS Regulations and structured as an umbrella fund in that different sub-funds thereof may be established with the prior approval of the Central Bank. The redeemable participating shares of the Funds are listed on Euronext Dublin (formerly The Irish Stock Exchange). At 31 December 2021, the Company had twenty active Funds.

The following Funds are currently authorised:

	Date of first issue of share class	Investment management fee	Performance fee
Asian Opportunities Fund*	30/03/2012	Up to 1.00%	10%
Asian Stars Fund	21/12/2018	Up to 1.25%	10%
Automation & Artificial Intelligence Fund	06/10/2017	Up to 1.30%	10%
Biotechnology Fund	31/10/2013	Up to 1.50%	10%
China Stars Fund	31/08/2018	Up to 1.25%	10%
Emerging Markets Income Fund**	21/01/2011	Up to 1.50%	10%
Emerging Markets Stars Fund	29/06/2018	Up to 1.25%	10%
European ex UK Income Fund	01/07/2015	Up to 1.50%	_
Financial Opportunities Fund	03/05/2011	Up to 1.50%	10%
Global Absolute Return Fund	31/12/2018	Up to 1.00%	15%
Global Convertible Fund	30/08/2013	Up to 1.50%	10%
Global Insurance Fund	27/05/2011	Up to 1.25%	10%
Global Technology Fund	22/10/2001	Up to 1.50%	10%
Healthcare Blue Chip Fund	11/09/2014	Up to 0.85%	10%
Healthcare Discovery Fund	31/01/2020	Up to 1.00%	10%
Healthcare Opportunities Fund	03/12/2007	Up to 1.50%	10%
Income Opportunities Fund	30/03/2012	Up to 1.25%	10%
Japan Value Fund	01/11/2012	Up to 1.35%	10%
North American Fund	14/11/2011	Up to 1.25%	_
Smart Energy Fund***	30/09/2021	Up to 1.50%	-
Smart Mobility Fund***	30/09/2021	Up to 1.50%	-
UK Absolute Equity Fund****	29/09/2014	Up to 1.50%	20%
UK Value Opportunities Fund	31/01/2017	Up to 0.75%	10%

\* Asian Opportunities Fund terminated on 1 March 2021.

\*\* Emerging Markets Income Fund merged with Emerging Markets Stars Fund on 8 June 2021.

\*\*\* Smart Energy Fund and Smart Mobility Fund launched on 30 September 2021.

\*\*\*\*UK Absolute Equity Fund terminated on 15 May 2020.

For each fund, share classes are available to both Institutional and Retail investors to which different fee rates may apply. For further information regarding the investment management fee and performance fee relating to each Fund please refer to the Prospectus and Supplements to the Prospectus.

The following table details the investment objectives for each Fund. Investors should note that there can be no guarantee that any Fund will achieve its investment objectives.

Fund Name	Investment Objective
Asian Stars Fund	The investment objective of the Asian Stars Fund is to achieve medium to long term growth and to primarily invest in a diversified portfolio of equity securities and equity related securities of, or relating to companies, which are domiciled, or exercise the predominant part of their economic activity, in Asian developed and emerging markets. The Fund will generally not invest more than 30% of its Net Asset Value in securities issued by companies in Japan or outside of Asia (such as Australia or New Zealand).
Automation & Artificial Intelligence Fund	The investment objective of Automation & Artificial Intelligence Fund is to achieve long-term capital appreciation by primarily investing in a diversified portfolio of global equity securities which may be listed or traded on a Regulated Market. The Fund is not expected to invest more than 20% of its Net Asset Value in emerging markets. The securities in which the Fund will primarily invest will include equity and equity related securities including, but not limited to, ordinary and preference shares and financial derivative instruments.
Biotechnology Fund	The investment objective of the Biotechnology Fund is to preserve capital and achieve long-term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of biotechnology, diagnostics and life sciences tools companies and will invest in transferable securities including shares, equity warrants and other types of equity related securities such as preferred shares, which will be listed and/or traded on a Regulated Market, and issued by biotechnology, diagnostics and life sciences tools companies. The Fund may also invest in Global depository receipts and American and European depository receipts to gain exposure to biotechnology companies. The Fund may invest in unlisted securities subject to a limit of 10% of its Net Asset Value in unlisted securities. The Fund will seek to outperform the NASDAQ Biotechnology Index.
China Stars Fund	The investment objective of China Stars Fund is to achieve long-term capital growth by primarily investing in a diversified portfolio of equity securities and equity related securities of, or relating to companies, which are domiciled, or exercise the predominant part of their economic activity, in The Peoples' Republic of China, Hong Kong and Taiwan (together 'Greater China'). The Fund is not expected to invest more than 40% of its Net Asset Value in securities issued by companies outside of Greater China. The securities in which the Fund will invest will include transferable securities, to include shares, equities, equity warrants, preferred shares, shares in collective investment schemes with investment policies that are consistent with the Fund's investment objective and securities convertible into shares, which may be listed on a Regulated Market or unlisted (subject to a limit of 10% of the Net Asset Value of the Fund in unlisted securities) and issued by companies.
Emerging Markets Income Fund Merged with Emerging Markets Stars Fund on 8 June 2021.	The investment objective of each of the Emerging Markets Income Funds was to achieve both income and long term capital growth by investing in securities of issuers that are incorporated, have their headquarters, or exercise a significant part of their economic activities in markets/countries which are, in the Investment Manager's opinion, emerging markets/developing countries.
Emerging Markets Stars Fund	The investment objective of the Emerging Markets Stars Fund is to achieve long term capital growth. The Fund will seek to achieve its investment objective by primarily investing in a diversified portfolio of equity securities and equity related securities of, or relating to companies, which are domiciled, or exercise the predominant part of their economic activity, in emerging markets. The Fund is not expected to invest more than 30% of its Net Asset Value in securities issued by companies outside of the emerging markets. The securities in which the Fund will invest will include transferable securities, such as shares, equities, equity warrants, preferred shares, and shares in collective investment schemes.
European ex UK Income Fund	The investment objective of the European ex UK Income Fund is to deliver strong long term risk adjusted returns to achieve both income and capital growth by investing in securities of issuers that are incorporated, have their headquarters, or exercise a significant part greater than 20% of their economic activities in European markets/ countries excluding the United Kingdom. It is anticipated to target an overall yield of 10% higher than that of the Index (MSCI Daily Net Total Return Europe ex UK EUR); however, this cannot be guaranteed.
Financial Opportunities Fund	<b>s</b> The investment objective of the Financial Opportunities Fund is to achieve long term capital growth, and in order to achieve its objective the Fund will invest in the securities of financial sector companies and companies related to the financial sector worldwide. These companies primarily include commercial and investment banks, life and non-life insurance and reinsurance companies, asset management and brokerage companies.

# 1. Organisation and nature of business continued

Fund Name	Investment Objective
Global Absolute Return Fund	The investment objective of the Global Absolute Return Fund is to deliver capital growth over rolling 12-month periods, in all market conditions. There is no guarantee the Fund will achieve this objective over any given period.
Global Convertible Fund	The investment objective of the Global Convertible Fund is to generate both income and long term capital growth by investing in a diversified portfolio of convertible bonds (the underlying of which will be equity securities) and financial derivative instruments. Such securities will be listed and/or traded on a Recognised Exchange. The Fund will have a global geographical focus, and may invest more than 20% of its Net Asset Value in emerging markets.
Global Insurance Fund	The investment objective of the Global Insurance Fund is to provide an attractive total return irrespective of broader economic and financial market conditions. In order to achieve its investment objective the Fund will invest primarily in securities of insurance related companies worldwide. These companies include insurance and reinsurance companies, life assurance companies, insurance brokerage companies and other insurance related businesses including, but not limited to, insurance claims administration companies, insurance support service companies and companies that own insurance related assets.
Global Technology Fund	The investment objective of the Global Technology Fund is long term capital appreciation by way of investing in a globally diversified portfolio of technology companies. Although the Fund may receive income in the form of dividends, interest and from other sources, income is not a primary consideration. The Fund will invest at least two thirds of its net asset value in technology-related companies worldwide. The Fund will take a geographically diversified approach and operate within broad asset allocation ranges, but there are no specified limits on investing in any geographical region or single country.
Healthcare Blue Chip Fund	The investment objective of the Healthcare Blue Chip Fund is to achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing in a globally diversified portfolio of healthcare companies. The Fund will invest in transferable securities including, shares, equity warrants and other types of equity related securities such as preferred shares, which will be listed and/or traded on a Regulated Market, and issued by healthcare companies, to include, but not limited to, pharmaceutical, biotechnology, medical device and healthcare services companies. The Healthcare Blue Chip Fund may also invest in Global depository receipts and American and European depository receipts to gain exposure to healthcare companies.
Healthcare Discovery Fund	The investment objective of the Healthcare Discovery Fund is to achieve long term capital appreciation by way of investing in a globally diversified portfolio of healthcare companies which may be listed on traded on a Regulated Market. The securities in which the Fund will primarily invest will include equity and equity related securities including, but not limited to, ordinary and preference shares and financial derivative instruments. The Fund will typically invest in small capitalisation issues depending on market liquidity and as it judges the available opportunities. The Fund will take a geographically diversified approach. There are no specified limits on investing in any geographical region or in any sub-sector of healthcare.
Healthcare Opportunities Fund	The investment objective of the Healthcare Opportunities Fund is to preserve capital and achieve long term capital appreciation by investing in a globally diversified portfolio of healthcare companies. The Fund will seek to outperform the MSCI Global Healthcare Index whilst striving to limit the volatility of the Fund's returns. The Fund will take a geographically diversified approach and operate within broad asset allocation ranges, but there are no specified limits on investing in any geographical region or in any sub-sector of healthcare. Non-healthcare related securities will not exceed one third of the Fund's total assets.
Income Opportunities Fund	The investment objective of the Income Opportunities Fund is to provide an attractive level of income together with capital growth. In order to achieve its objective the Fund will invest primarily in the equity, debt and other securities of listed financial companies. The debt securities in which the Fund will invest will be fixed and floating rate and include, but are not limited to, preference shares, convertible bonds, debentures and bonds with the restriction that unrated debt securities will not be greater than 25% of the Net Asset Value of the Fund. The other securities in which the Fund may invest will be securities with equity characteristics, including but not limited to preferred stocks, as well as depository receipts (including global depositary receipts traded) for such securities.

Fund Name	Investment Objective
Japan Value Fund	The investment objective of the Japan Value Fund is to achieve long term capital appreciation. The Fund will seek to achieve its investment objective by investing primarily in equity securities of issuers that exercise a significant part of their economic activities in Japan or are organised under the laws of Japan. The Fund intends to primarily invest its assets in securities listed on the Tokyo and regional Japanese exchanges that are Regulated Markets. Investment will primarily be concentrated in securities listed on the Tokyo Stock Exchange, however, the Fund may also, to a limited extent, invest in securities listed and/or traded globally on Regulated Markets which securities provide exposure to the Japanese market.
North American Fund	The investment objective of the North American Fund is to achieve long term capital appreciation. The Fund invests in a diversified portfolio of securities of North American companies. The Investment Manager will invest in large, medium and small capitalisation companies depending on market liquidity and as it judges the available opportunities.
Smart Energy Fund Fund launched on 30 September 2021.	The investment objective of the Fund is to provide long-term capital growth. The Fund invests in a global portfolio of selected publicly listed companies with exposure to the themes of smart energy, with at least 51% of its gross assets invested on a continuous basis in Equity Participations. Investments will be made in transferable securities including, but not limited to, shares, equity warrants and other types of securities such as preferred shares, which will be listed on a Regulated Market, and issued by companies, and Global, American and European depository receipts.
Smart Energy Fund Fund launched on 30 September 2021.	The investment objective of the Fund is to provide long-term capital growth. The Fund invests in a global portfolio of selected publicly listed companies with exposure to the themes of smart mobility, with at least 51% of its gross assets invested on a continuous basis in Equity Participations. Investments will be made in transferable securities including, but not limited to, shares, equity warrants and other types of securities such as preferred shares, which will be listed on a Regulated Market, and issued by companies, and Global, American and European depository receipts.
UK Value Opportunities Fund	The investment objective of UK Value Opportunities Fund is to achieve long term capital appreciation. The Fund will seek to achieve its investment objective by primarily investing in a diversified portfolio of equity securities listed in the UK. The securities in which the Fund will invest will primarily include equity securities including, but not limited to ordinary and preference shares and equity warrants. The Fund will aim to outperform the FTSE All-Share Total Return Index by investing in undervalued companies or shares, whilst striving to reduce the volatility of the Fund's return by investing in a diversified portfolio.

## 2. Principal Accounting Policies

The principal accounting policies applied in the preparation of these Financial Statements are set out below.

#### **A. Basis of Preparation**

These Financial Statements have been prepared in accordance with International Financial Reporting Standards as adopted by the European Union ('IFRS'), with Irish Statute comprising the Companies Act 2014 and with the Central Bank UCITS Regulations.

The financial statements have been prepared on a fair value basis for financial assets and financial liabilities at fair value through profit or loss and derivative financial instruments in accordance with the relevant accounting standards. All other assets and liabilities are short term in nature and their carrying value approximates fair value. Redeemable participating shares are stated at redemption amount (redeemable participating shares).

## 2. Principal Accounting Policies continued

#### A. Basis of Preparation continued

The format and certain wording of the financial statements have been adapted from those contained in the Companies Act 2014 so that, in the opinion of the Directors, they more appropriately reflect the nature of the Company's business as an investment fund.

The preparation of financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and the reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. Where applicable, information about assumptions and estimation uncertainties that have an impact on the financial statements are disclosed in note 2 (D) and note 10 and relate to the determination of fair value of financial instruments with significant unobservable inputs. As at 31 December 2021 and 31 December 2020, the Sub-Funds do not hold any financial instruments with significant unobservable inputs.

The UK Absolute Equity Fund financial information has been prepared on a non-going concern basis of accounting where all assets are stated at their estimated recoverable amounts. As the assets of the Funds were already carried at amounts which approximate their recoverable amounts the re-measurement has not resulted in any adjustments to their value.

The Asian Opportunities Fund financial information has been prepared on a non-going concern basis of accounting as the Fund was terminated on 1 March 2021.

The Emerging Markets Income Fund financial information has been prepared on a non-going concern basis of accounting as the Fund merged with the Emerging Markets Stars Fund on 8 June 2021.

#### **International Financial Reporting Standards**

The Company has adopted all applicable International Financial Reporting Standards as endorsed by the European Union.

The Company classifies its redeemable shares as financial liabilities in accordance with IAS 32. The financial statements of the Company also include qualitative disclosure which indicates how the net asset value attributable to redeemable shareholders is calculated.

The combination of the above disclosures is considered, in this instance, to be sufficient to address the requirements of the amendments

#### **IFRIC interpretation 23 Uncertainty or Income Tax Treatment**

On 7 June 2017, the international Accounting Standards Board issued IFRIC Interpretation 23 – uncertainty over Income Tax Treatments (the 'Interpretation'). The Interpretation clarifies application of recognition and measurement requirements in IAS 12 Income Taxes when there is uncertainty over the income tax treatments. The Interpretation specifically addresses the following:

- Whether an entity considers uncertain tax treatments separately
- The assumptions an entity makes about the examination of tax treatments by taxation authorities
- How an entity determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates
- How an entity considers changes in facts and circumstances

#### **IFRIC interpretation 23 Uncertainty or Income Tax Treatment**

The Company determines whether to consider each uncertain tax treatment separately or together with one or more other uncertain tax treatments and uses the approach that better predicts the resolution of the uncertainty.

The Company applies significant judgement in identifying uncertainties over income tax treatments. Since the Company operates in a complex multinational environment, it assessed whether the Interpretation had an impact on its financial statements.

The accounting policies have been applied consistently by the Company.

#### B. Swing pricing/dilution levy

A Fund may suffer dilution of the net asset value per share due to investors buying or selling shares in a Fund at a price that does not reflect dealing and other costs that arise when security trades are undertaken by the Investment Manager to accommodate cash inflows or outflows.

In order to counter this impact, a swing pricing mechanism has been adopted to protect the long-term interests of shareholders of the Funds. If, on any valuation date, the aggregate net capital activity of a Fund exceeds a pre-determined threshold, as established and reviewed by the Board of Directors of the Company, the net asset value per share will be adjusted upwards or downwards to reflect costs associated with the net capital inflows/(outflows) respectively.

The swing factor is impacted by three factors:

- 1. Adjustment for the spread between the bid and offer price of the underlying securities (currently a Fund will only swing to bid on material net redemptions).
- 2. An adjustment for broker fees and other market charges.
- 3. An adjustment for governmental taxes and duties payable on securities transactions

As a result of capital activity at the financial year end on the Income Opportunities Fund and UK Value Opportunities Fund, this Funds' net asset value per share at the financial year end was adjusted to reflect factors two and three above. The level of activity was not sufficiently material to justify applying factor one, or to require adjustment for any other Funds.

For financial reporting purposes, the net assets of each Fund at 31 December 2021 as disclosed in the Statement of Financial Position and Statement of Changes in Net Assets attributable to Holders of Redeemable Participating Shares, does not reflect any swing pricing or duties and charges adjustment. The net asset value per share at 31 December 2021 used for dealing purposes, which is shown in Note 8 and Note 12, includes any swing price adjustments.

The following tables set out a reconciliation of the financial reporting net asset value per share and the dealing Net Asset Value per share for the two Funds affected:

Income Opportunities Fund	Dealing NAV per share	Swing Pricing Adjustment	Financial Statements NAV per share
Class A1 Sterling Distribution	f1.48	£0.00	f1.48
Class A2 Sterling Accumulation	£2.71	f0.00	£2.71
Class B1 Sterling Distribution	£1.57	£0.00	
Class B2 Sterling Accumulation	£2.85	£0.00	£2.85
Class I Euro Accumulation	€3.39	€0.00	€3.39
Class I Euro Distribution	€1.87	€0.00	€1.87
Class I Euro Hedged Accumulation	€16.29	€0.02	€16.27
Class I Euro Hedged Distribution	€12.59	€0.02	€12.57
Class I US Dollar Accumulation	\$3.86	\$0.01	\$3.85
Class I US Dollar Distribution	\$2.13	\$0.00	\$2.13
Class R Euro Accumulation	€3.23	€0.00	€3.23
Class R Euro Distribution	€1.76	€0.00	€1.76
Class R Euro Hedged Accumulation	€15.87	€0.02	€15.85
Class R Euro Hedged Distribution	€12.28	€0.02	€12.26
Class R US Dollar Accumulation	\$3.67	\$0.01	\$3.66
Class R US Dollar Distribution	\$2.00	\$0.00	\$2.00
Class R US Dollar Hedged Accumulation	\$13.89	\$0.02	\$13.87
Class R US Dollar Hedged Distribution	\$11.33	\$0.02	\$11.31
Class Z Sterling Accumulation*	£0.00	£0.00	£0.00
Class Z Sterling Distribution*	£0.00	£0.00	£0.00

\* The swing price adjustment had insignificant impact on NAV per share.

## 2. Principal Accounting Policies continued

## B. Swing pricing/dilution levy continued

UK Value Opportunities Fund	Dealing NAV per share	Swing Pricing Adjustment	Financial Statements NAV per share
Class I Sterling Accumulation	£14.64	£0.07	£14.57
Class I Sterling Distribution	£13.83	£0.06	£13.77
Class R Sterling Accumulation	£12.25	£0.05	£12.20
Class S Sterling Accumulation	£14.72	£0.07	£14.65
Class S Sterling Distribution	£13.86	£0.07	£13.79
Class Z Sterling Accumulation	£13.30	£0.06	£13.24
Class Z Sterling Distribution*	£0.00	£0.00	£0.00

#### C. Foreign exchange translation

#### (i) Presentational currency

Items included in the Company's Financial Statements are measured using the currency of the primary economic environment in which it operates (the 'presentational currency'). The presentation currency for the Company is US Dollars ('\$' or 'US\$'). The functional currency for each Fund is driven by the investment policy of each Fund. This is US\$ for all Funds with the exception of European ex UK Income Fund and European Income Fund, for which the functional currency is Euro ('EUR' or ' $\in$ '), Global Insurance Fund, Income Opportunities Fund, UK Absolute Equity Fund and UK Value Opportunities Fund, the functional currency of which is Sterling ('GBP' or ' $\pm$ ') and Japan Fund and Japan Value Fund, for which the functional currency is Ty').

#### (ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Comprehensive Income. For the purposes of aggregation, the amounts in the financial statements for the European ex UK Income Fund, Global Insurance Fund, Income Opportunities Fund, Japan Value Fund, UK Absolute Equity Fund and UK Value Opportunities Fund have been translated to US\$ at the exchange rate ruling at the financial year end.

The foreign currency translation adjustment of US\$78,418,120 (31 December 2020: US\$124,308,697) included in the Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares is due to the movement in exchange rates between 1 January 2021 and 31 December 2021 and the rate difference arising on the translation of the Statement of Comprehensive Income and the Statement of Changes in Net Assets Attributable to Holders of Redeemable Participating Shares at average rates. The translation is in relation to the notional value for the Company only and has no impact on any individual Fund.

Proceeds from subscriptions and amounts paid on redemption of redeemable participating shares are translated at daily rates, which approximate the rates prevailing at the dates of the transactions.

#### D. Investments at fair value

#### (i) Classification of financial assets

On initial recognition, the Company classifies financial assets as measured at amortised cost or fair value through profit or loss (FVTPL). A financial asset is measured at amortised cost if it meets both of the following conditions and is not designated as at fair value through profit or loss:

- it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are Solely Payments of Principal and Interest ('SPPI').

The Company's financial assets include equity investments, debt securities, investments in unlisted open-ended investment funds and derivatives. These financial assets are managed and their performance is evaluated, on a fair value basis, with frequent sales taking place, other than short term receivables held for collection and which meet the criteria for measurement at amortised cost.

The Company's financial assets and liabilities are measured as follows:

Financial Assets	Measurement
Equities	FVTPL
Debt securities	FVTPL
Investment funds	FVTPL
Financial derivative instruments	FVTPL
Cash and cash equivalents	Amortised cost
Other assets	Amortised cost
Financial Liabilities	
Financial derivative instruments	FVPTL
Other liabilities	Amortised cost
Net assets attributable to unitholders	Amortised cost

#### (ii) Recognition and derecognition of financial liabilities

Purchases and sales of investments are recognised on trade date, which is the date on which the Company commits to purchase or sell the asset. Investments are derecognised when the rights to receive cash flows from the investments have expired or the Company has transferred substantially all risks and rewards of ownership.

A financial liability is derecognised when the obligation specified in the contract is discharged, cancelled or expired.

#### (iii) Measurement

Financial instruments are measured initially at fair value (transaction price). Transaction costs on financial assets and financial liabilities at fair value through profit or loss are expensed immediately. Subsequent to initial recognition, all instruments classified at fair value through profit or loss are measured at fair value with changes in their fair value recognised in the Statement of Comprehensive Income. Other financial assets are carried at amortised cost using the effective interest rate method, less impairment losses, if any.

Financial liabilities, other than those at fair value through profit or loss, are measured at amortised cost using the effective interest rate method. Financial liabilities arising from the redeemable participating shares issued by the Funds are carried at the redemption amount representing the investors' right to a residual interest in the Funds' assets.

#### Gains and losses on investments

Gains and losses arising from changes in the fair value of the 'financial assets at fair value through profit or loss' category are included in the Statement of Comprehensive Income in the period in which they arise.

Investment transactions are accounted for on a trade date basis. Profits and losses on the disposal of investments are calculated by reference to the net proceeds received on disposal and the cost attributable to those investments based on the first in first out basis and are included in the Statement of Comprehensive Income.

#### (iv) Fair value measurement principles

The fair value of financial instruments traded in active markets (such as publicly traded derivatives and trading securities) is based on quoted market prices at the Statement of Financial Position date. The value of financial assets and liabilities which is quoted, listed or normally dealt in on a regulated market shall be the last traded price on such regulated market as at the valuation point or the mid-price, where no trades occurred on such day where relevant.

If a quoted market price is not available on a recognised stock exchange or from a broker/dealer for non-exchange-traded financial instruments, the value of any investment which is not quoted, listed or normally dealt in on a regulated market shall be the probable realisable value estimated with care and in good faith by a competent person, firm or association making a market in such investment (approved for the purpose by the Depositary) and/or any other competent person, in the opinion of the Directors (and approved for the purpose by the Depositary).

## 2. Principal Accounting Policies continued

#### D. Investments at fair value continued

#### (iv) Fair value measurement principles continued

#### Investment funds

Open-ended Investment funds are included in the accounts at the last reported NAV at close of business on the last dealing day of the reporting period. The changes in the daily net asset value of these Units are recognised in the Statement of Comprehensive Income.

#### Contracts for difference and swaps

Contracts for difference and equity swaps are agreements between the Company and third parties which allow the Company to acquire an exposure to the price movement of specific securities without actually purchasing the securities. The changes in contract values are recorded as unrealised gains or losses and the Company recognises a realised gain or loss when the contract is closed. Realised and unrealised gains and losses on contracts for difference and equity swaps are recognised in the Statement of Comprehensive Income.

#### Futures

A futures contract is an agreement between two parties to buy or sell a security, index or currency at a specific price or rate at a future date. Upon entering into a futures contract, the Company is required to deposit with a broker an amount of cash or cash equivalents equal to a certain percentage of the contract amount. This is known as 'initial cash margin'. Subsequent payments ('variation margin') are made or received by the Company each day, depending upon the daily fluctuation in the value of the contract. The daily changes in contract value are recorded as unrealised gains or losses and the Company recognises a realised gain or loss when the contract is closed. Realised and unrealised gains and losses on futures contracts are recognised in the Statement of Comprehensive Income.

#### Forward foreign currency contracts

A forward foreign currency contract ('FFCC') involves an obligation to purchase or sell a specific currency at a future date at a price set at the time the contract is made. FFCCs will be valued by reference to the forward price at which a new FFCC of the same size and maturity could be undertaken at the valuation date. The realised and unrealised gain or loss on open FFCC is calculated as the difference between the contract rate and this FFCC price and the Company recognises a realised gain or loss when the contract is closed. Realised and unrealised gains and losses on FFCCs are recognised in the Statement of Comprehensive Income. Where a FFCC is purchased to hedge the currency risk of a specific class which is issued in a currency other than the measurement currency of the Company, all gains or losses on that contract are allocated to that class.

#### Options

As part of the Company's investment strategy, it enters into options which are recognised in the Statement of Financial Position at fair value. The premium on purchased put options exercised is subtracted from the proceeds of the sale of the underlying security or foreign currency in determining the realised gain or loss. The premium on purchased call options exercised is added to the cost of the securities or foreign currency purchased. Premiums paid on the purchase of options which expire unexercised are treated as realised losses. Unrealised gains or losses on options are included in assets or liabilities on the Statement of Financial Position and movements are dealt with through the Statement of Comprehensive Income.

#### Warrants

Warrants are sometimes used to gain exposure to emerging market equities where custody, liquidity, or other issues make ownership of local shares sub-optimal. The valuation of warrants depends on the level of trading. If the warrants are actively traded in the market then the market price is used. If the warrants are not actively traded in the market then the intrinsic value of the warrant based on the underlying equity price and the warrant strike price is used.

#### E. Other measurement principles

#### Cash and bank overdrafts

Cash, other liquid assets and bank overdrafts are valued at their face value with interest accrued, where applicable. Cash at bank and bank overdraft balances are comprised of cash balances held with The Northern Trust Company (TNTC) and includes investors' money held in collection accounts.

#### Margin cash and margin receivable

Cash provided by the Funds to a counterparty in relation to futures and option contracts is identified in the Statement of Financial Position as Margin Cash. Margin Cash is not included as a component of cash and cash equivalents in the Statement of Financial Position and is not available to the Funds on demand.

Margin receivable or payable is held with or due to Credit Suisse Securities (Europe) Limited ('Credit Suisse') and UBS AG.

#### **Receivables**

Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Receivables are recognised initially at amortised cost plus transaction costs that are directly attributable to their acquisition.

#### **Payables**

Payables are recognised initially at fair value and subsequently stated at amortised cost. The difference between proceeds and amount payable is recognised over the period of the payable using the effective interest method.

#### **Offsetting financial instruments**

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.

The Company has an ISDA Master Agreement (the 'Agreement') with Credit Suisse and UBS AG. Under certain conditions, as set out under the Agreement, amounts payable by one party to the other in respect of derivative contracts covered by the Agreement may be off-set against any other amounts payable by the payee to the payer.

#### **Redeemable participating shares**

Redeemable participating shares are redeemable at the shareholder's option and are classified as financial liabilities. Distributions on these redeemable participating shares are recognised in the Statement of Comprehensive Income as finance costs.

Redeemable participating shares can be put back to the Company at any time for cash equal to a proportionate share of the Company's net asset value. The redeemable participating shares are carried at the present value of the redemption amount that is payable at the Statement of Financial Position date if the shareholders exercised their rights to put the shares back to the Company.

#### **Transaction costs**

Transaction costs are incremental costs that are directly attributable to the acquisition, issue or disposal of a financial asset or financial liability. An incremental cost is one that would not have been incurred if the entity had not acquired, issued or disposed of the financial instrument.

Transaction costs on the purchase and sale of bonds, forward foreign currency contracts, CFDs, investment funds and warrants are included in the purchase and sale price of the investment. They cannot be practically or reliably gathered as they are embedded in the cost of the investment and cannot be separately verified or disclosed.

Transaction costs on purchases and sales of equities, futures and options are included in net gains/(losses) on financial assets at fair value through profit or loss in the Statement of Comprehensive Income for each Fund. These costs are separately identifiable and are disclosed in Note 15.

#### **Income Equalisation**

Income equalisation is a process by which accrued income included in the price of shares purchased and redeemed during the accounting financial year is reported to Shareholders. The subscription price of Shares is deemed to include an equalisation payment calculated by reference to the accrued income of the relevant Fund and the first distribution in respect of any Share will include a payment of income usually equal to or greater than the amount of such equalisation payment. The redemption price of each Share will also include an equalisation payment in respect of the accrued income of the relevant Fund up to the date of redemption. Income equalisation is classified as investment income in the Statement of Comprehensive Income.

#### F. Distribution policy

The share classes of certain Funds have been approved by the United Kingdom HM Revenue and Customs as Reporting Funds in accordance with the UK Offshore Funds (Tax) Regulations 2009. The Directors intend to continue the distribution policy as outlined below unless otherwise specified in the relevant fund supplement. Dividends, if declared, will only be paid out of the Company's net investment income return (i.e. income from dividends, interest or otherwise, less the Company's accrued expenses to be certified for the accounting period), realised and unrealised profits on the disposal/revaluation of investments and other assets less realised and unrealised losses of the Company, although the amount available for distribution in respect of certain Funds may be effectively increased by the charging of expenses to capital. Funds which can avail of this facility are identified in the relevant Fund supplement.

## 2. Principal Accounting Policies continued

## F. Distribution policy continued

Dividends will normally be paid in May of each financial year for all of the Funds except for the Distributing Share Classes of the Emerging Markets Income Fund, European ex UK Income Fund, Global Convertible Fund and Financial Opportunities Fund for which dividends will be paid in July and January and for the Distributing Share Classes of the Global Insurance Fund and Income Opportunities Fund for which dividends are to be declared at the beginning of each calendar quarter in respect of the preceding quarter, and paid by the end of the month in which they are declared. Any dividend paid on a redeemable participating share that is not claimed will not earn interest and, if not claimed within six years of its declaration, shall be forfeited for the benefit of the Company.

#### G. Operating expenses

The Company is responsible for all normal operating expenses including investment management fees, depositary fees, performance fees, administration fees, audit fees, stamp duties and accruals and other duties and charges incurred on the acquisition and realisation of investments. These are accounted for on an accruals basis. The Investment Manager, Polar Capital LLP ('the Investment Manager'), meets all other operating expenses incurred by it in connection with its services.

#### H. Interest and dividend income

Interest income and expense is recognised in the Statement of Comprehensive Income for all the relevant instruments using the effective interest method. The effective interest method is a method of calculating the amortised cost of the financial asset or the financial liability and of allocating the interest income or expense over the relevant period.

Dividends are recognised to the Statement of Comprehensive Income on the dates on which the relevant securities are listed as 'ex-dividend'. Dividend income is recorded gross of irrecoverable dividend withholding tax which is disclosed separately in the Statement of Comprehensive Income. Bank interest income is recognised on an accruals basis.

## 3. Fees and Expenses

The Investment Manager is entitled to receive an investment management fee and a performance fee in respect of each Fund together with any extraordinary out of pocket expenses. The investment management fee is accrued daily and is payable monthly in arrears. Please see note 1 for a breakdown of investment management and performance fee rates for each Fund. Investment management fees are calculated before deduction for any accrued performance fees. An initial payment of the investment management fee based on the most recently published Net Asset Value will be made on the last day of each month, with an adjustment being made where necessary, on the last day of the next month.

In general, the performance fee is calculated separately for each class of shares in a Fund and is equal to a percentage of the amount by which the increase in the Net Asset Value (prior to the provision for a performance fee) during the relevant performance period exceeds the increase in the Indexed Net Asset Value (the specific established index that the respective Fund is aiming to track) over the same period. However, the precise method of calculation may differ in each case. Full details are set out in the Prospectus supplement for each Fund. The performance fee is accrued daily and payable annually on 31 December, where there is a performance fee payable.

All fees paid to the Investment Manager, including any performance fees, are disclosed separately in the Statement of Comprehensive Income. US\$35,487,393 (31 December 2020: US\$78,305,315) was due to the Investment Manager at 31 December 2021, which includes both investment management and performance fees. Please refer to Note 3 for further details.

The Administrator is entitled to receive a fee of 0.09% of the first US\$1.5 billion of the Company's Net Asset Value, 0.07% of the next US\$3.5 billion of the Company's Net Asset Value, 0.04% of the next US\$5 billion of the Company's Net Asset Value and 0.02% of the Company's Net Asset Value thereafter, subject to a monthly minimum fee of US\$3,500 in respect of each Fund, which shall be accrued daily and paid monthly in arrears.

The Administrator shall also be entitled to be repaid out of the assets of the Company or relevant Fund all of its reasonable out-of-pocket expenses incurred on behalf of the Company (which shall include legal fees, couriers' fees and telecommunication costs and expenses).

The Depositary is entitled to an annual fee from the Company accrued daily and paid monthly in arrears of 0.015% of the Company's Net Asset Value, subject to a monthly minimum fee of US\$1,200 in respect of each Fund, which shall be accrued daily and paid monthly in arrears. The Depositary shall also be entitled to be repaid out of the assets of each Fund all reasonable out-of-pocket expenses incurred by it on behalf of the relevant Fund (such as telephone, postage, printing, legal and fax expenses) including stamp duties and registration fees and the fees and expenses of sub-custodians, at normal commercial rates.

The Management Company is entitled to receive an annual management fee from the relevant Fund. This fee will not exceed 0.02% of the Net Asset Value of the relevant Fund.

The Austrian Paying Agent, Meinl Bank AG, is entitled to receive an annual fee of €3,000 and is entitled to receive reimbursement of agreed costs incurred in transmitting dividends, redemption proceeds and documentation to Shareholders in Austria.

The German Paying and Information Agent, Deutsche Bank AG, is entitled to receive an annual fee of €18,000, a proportional handling fee for each new Fund and agreed costs in transmitting dividends, redemption proceeds and documentation to Shareholders in Germany.

The French paying and information agent, BNP Paribas Securities Services, is entitled to receive an annual fee of €7,000, a proportional handling fee for each new Fund and agreed costs in transmitting dividends, redemption proceeds and documentation to Shareholders in France.

BNP Paribas Securities Services also acts as the Swiss Representative and Swiss Paying Agent and for the financial year ended 31 December 2021 was entitled to receive the following fees for this service:

- (i) an annual fee of CHF 34,000;
- (ii) additional hours for extraordinary expenditures which are not covered by the agreement and which are billed at CHF 250 per hour;
- (iii) reimbursement for all external costs, such as the publication of rates or other publication costs, charges levied by the Swiss Financial Market Supervisory Authority ('FINMA') and any amounts charged by external lawyers on behalf of the Company.

The Austrian, German, French and Swiss paying agents are also entitled to receive reimbursement of any reasonable out of pocket expenses incurred by them in the performance of their duties.

The Directors fees are disclosed in the Statement of Comprehensive Income.

#### **Auditor's Remuneration**

The remuneration for all work carried out by the statutory auditors in respect of the financial year is as follows:

	2021 EUR	2020 EUR
Statutory audit fee	187,211	154,000
Other assurance services	7,000	-
Tax advisory services	-	-
Other non audit services	-	-
	194,211	154,000

Amounts payable at the year-end to the Administrator, Depositary, Directors, Auditors and other general expenses are included in sundry creditors on the Statement of Financial Position.

## 4. Bank Overdraft

The Company has an overdraft facility with The Northern Trust Company for liquidity purposes. The assets of the relevant Fund are held as collateral for the overdraft when it is utilised. As at the financial year end the following Funds had bank overdrafts:

Automation & Artificial Intelligence Fund: US\$5,772,695 (31 December 2020: US\$21,259,046) Biotechnology Fund: US\$1,873,888 (31 December 2020: US\$1,994,610) Emerging Markets Income Fund: US\$26,670 (31 December 2020: US\$Nil) European (ex UK) Income Fund: US\$4,427,479 (31 December 2020: US\$Nil) Global Absolute Return Fund: US\$13,015,839 (31 December 2020: US\$3,080,696) Global Convertible Fund: US\$228,309,056 (31 December 2020: US\$116,048,142) Global Insurance Fund: GBP£9,052,423 (31 December 2020: GBP£ Nil) Global Technology Fund: GBP£1,414,870 (31 December 2020: GBP f Nil) Japan Value Fund: JPY¥31,038,624 (31 December 2020: JPY¥75,316,023) North American Fund: US\$1,897,676 (31 December 2020: US\$378,941) Small Energy Fund: US\$84,578 (31 December 2020: US\$Nil) UK Absolute Equity fund: GBP£8,512 (31 December 2020: GBP£8,938) UK Value Opportunities Fund: GBP£40,340 (31 December 2020: GBP£38,779)

## 5. Soft Commissions and investment research

The Investment Manager has committed to the Company that it will bear the cost of all general written research consumed by its investment teams. For certain strategies where the consumption of specialised research is regarded as critical to the investment process, the Company will pay for such costs up to a level pre-agreed with the Directors. These costs are included on the Statement of Comprehensive Income. The Funds that paid for the cost of specialised research are listed below:

Asian Opportunities Fund	Global Insurance Fund
Asian Stars Fund	Global Technology Fund
Automation & Artificial Intelligence Fund	Healthcare Blue Chip Fund
Biotechnology Fund	Healthcare Discovery Fund
China Stars Fund	Healthcare Opportunities Fund
Emerging Markets Income Fund	Income Opportunities Fund
Emerging Markets Stars Fund	Japan Value Fund
Financial Opportunities Fund	Smart Energy Fund
Global Absolute Return Fund	Smart Mobility Fund
Global Convertible Fund	UK Value Opportunities Fund

The Investment Manager received no soft commissions during the year.

# 6. Exchange Rates

The exchange rates used at 31 December 2021 and 31 December 2020 were as follows:

Exchange Rate	31 December 2021 to US\$	31 December 2020 to US\$
Australian dollar	1.3754	1.2959
Brazilian real	5.5700	5.1942
Canadian dollar	1.2632	1.2740
Czech koruna	21.8519	21.4638
Danish krone	6.5403	6.0835
Egyptian pound	15.7100	15.7300
Euro	0.8794	0.8173
Hong Kong dollar	7.7963	7.7539
Hungary forint	324.0987	296.4203
Indian rupee	74.3357	73.0675
Indonesian rupiah	14,252.5000	14,050.0000
Japanese yen	115.1550	103.2450
Korean won	1,188.7500	1,086.3000
Malaysian ringgit	4.1660	4.0225
Mexican peso	20.4650	19.9255
Norwegian krone	8.8183	8.5620
Pakistani rupee	176.5000	159.8000
Philippine peso	50.9925	48.0235
Polish zloty	4.0304	3.7260
Qatari riyal	3.6410	3.6410
Romanian leu	4.3517	3.9782
Singapore dollar	1.3482	1.3217
South Africa rand	15.9600	14.6888
Sri Lanka rupee	202.7850	185.2500
Sterling	0.7383	0.7316
Swedish krona	9.0539	8.2126
Swiss franc	0.9112	0.8840
Taiwan dollar	27.6670	28.0980
Thai baht	33.4050	29.9600
Turkish lira	13.2798	7.4325
UAE dirham	3.6731	3.6732

# 6. Exchange Rates continued

Exchange Rate	31 December 2021 to EUR	31 December 2020 to EUR
Danish krone	7.4376	7.4435
Japanese yen	130.9544	126.3256
Norwegian krone	10.0282	10.4760
Sterling	0.8396	0.8951
Swedish krona	10.2960	10.0485
Swiss franc	1.0362	1.0816
United States dollar	1.1372	1.2236

Exchange Rate	31 December 2021 to GBP	31 December 2020 to GBP
Australian dollar	1.8629	1.7715
Brazilian real	7.5443	7.1002
Canadian dollar	1.7109	1.7415
Danish krone	8.8584	8.3158
Euro	1.1910	1.1172
Hong Kong dollar	10.5597	10.5991
Indian rupee	100.6839	99.8797
Indonesian rupiah	19,304.3002	19,205.6646
Japanese yen	155.9717	141.1309
Malaysian ringgit	5.6426	5.4986
Norwegian krone	11.9439	11.7038
Singapore dollar	1.8260	1.8066
South Africa rand	21.6170	20.0788
Swedish krona	12.2630	11.2262
Swiss franc	1.2341	1.2083
Thai baht	45.2454	40.9539
United States dollar	1.3545	1.3670

Exchange Rate	31 December 2021 to JPY	31 December 2020 to JPY
Euro	0.0076	0.0079
Sterling	0.0064	0.0071
Swiss franc	0.0079	0.0086
United States dollar	0.0087	0.0097

All exchange rates are official rates and come from quoted sources.

## 7. Taxation

Under current Irish law and practice the Company qualifies as an investment undertaking as defined in Section 739B of the Taxes Consolidation Act, 1997, as amended (the 'TCA'). On that basis, it is not chargeable to Irish tax on its income or gains.

However, Irish tax may arise if a 'chargeable event' occurs. A chargeable event includes any distribution payments to shareholders or any encashment, redemption, cancellation, transfer or deemed disposal of shares for Irish tax purposes, arising as a result of holding shares in the Company for a period of eight years or more, or the appropriation or cancellation of shares of a shareholder by the Company for the purposes of meeting the amount of tax payable on a gain arising on a transfer.

No Irish tax will arise on the Company in respect of chargeable events in respect of:

- (iv) transactions by a shareholder who is neither Irish resident nor ordinarily resident in Ireland for tax purposes, at the time of the chargeable event, provided that a relevant declaration is in place (in accordance with Schedule 2b of the TCA) and the Company is not in possession of any information which would reasonably suggest that the information contained therein is no longer materially correct; or
- (v) transactions by a shareholder who is an exempt Irish investor (as defined in Section 739D TCA).

Dividends, interest and capital gains (if any) received on investments made by the Company may be subject to withholding taxes imposed by the country from which the investment income/gains are received and such taxes may not be recoverable by the Company or its shareholders.

During the financial year ended 31 December 2021, the following Funds were subject to Indian and Brazilian capital gain taxes on sale of investments: Asian Opportunities, Automation & Artificial Intelligence, Asian Stars, Emerging Markets Stars fund, Healthcare Discoveries and Healthcare Opportunities. Such charges are included in Net realised and unrealised gain/(loss) on investments in Statement of Comprehensive Income.

## 8. Related Party Transactions

A number of the Directors held interests directly or indirectly in the Funds during the financial year. At the end of the year, their interests were as follows:

			Number o	f Holdings
Director	Fund	Share Class	31 December 2021	31 December 2020
David Astor	Financial Opportunities Fund	Class I Sterling Distribution	4,685	4,685
	Income Opportunities Fund	Class B1 Sterling Distribution	9,531	9,531
	Japan Value Fund	Class S Hedged	1,125	1,125
Charles Scott	Biotechnology Fund	Class I US Dollar Distribution	-	10,707
	Global Insurance Fund	Class R US Dollar Accumulation	69,977	69,977
	Income Opportunites Fund	Class B2 Sterling Accumulation	184,233	184,233
	Emerging Markets Stars	Class I Sterling Accumulation	-	9,275
	Automation and Artificial Intelligence Fund	Class I Sterling Accumulation	-	8,010
Robert Bovet	Biotechnology Fund	Class I US Dollar Distribution	8,000	8,000
Karen Nolan and Richard Dunne	Emerging Markets Stars Fund	Class I Euro Accumulation	3,816	-
	Automation & Artificial Intelligence Fund	Class I Euro Accumulation	2,729	
The Cayzer Trust Company Limited (Jamie Cayzer-Colvin				
listed Director of the Company)	Global Insurance Fund	Class I Sterling Distribution	523,654	-

## 8. Related Party Transactions continued

No other Director had any interest in the redeemable participating shares of the Company during the financial year.

The remuneration of the Directors of the Company may not, in the aggregate, exceed €1,000,000. Directors fees earned during the financial year ended 31 December 2021 and 31 December 2020 are disclosed in the Statement of Comprehensive Income.

James Cayzer-Colvin is a Director of both the Company and the holding company of Polar Capital LLP.

Polar Capital LLP is the Investment Manager of Polar Capital Funds plc and Polar Capital Partners Limited is a controlling partner of Polar Capital LLP. As at 31 December 2021 and 31 December 2020, Polar Capital Partners Limited held shares in the Funds listed below.

Partners, managers, employees and associated persons of the Investment Manager are the holders of the below shares in the Company. The number of Shares in a Fund owned by any of these persons individually is not considered to be material.

	Number of	Number of Shares	
Fund	31 December 2021	31 December 2020	
Asian Opportunities Fund*			
Class A US Dollar Distribution	-	146	
Class I Euro Distribution	-	11	
Class I Euro Hedged Distribution	-	100	
Class I Sterling Distribution	-	12	
Class I Sterling Hedged Distribution	-	100	
Class I US Dollar Distribution	_	108	
Asian Stars Fund			
Class I Euro Accumulation	114	114	
Class I Sterling Accumulation	127	127	
Class I US Dollar Accumulation	100	100	
Class R Euro Accumulation	114	114	
Class R Sterling Accumulation	127	127	
Class R US Dollar Accumulation	100	100	
Class S Euro Accumulation	114	114	
Class S Sterling Accumulation	127	127	
Class S US Dollar Accumulation	-	545,500	
Class S US Dollar Distribution	100	_	
Automation & Artificial Intelligence Fund			
Class I Euro Accumulation	117	117	
Class I Sterling Accumulation	130	130	
Class I US Dollar Accumulation	100	100	
Class R Euro Accumulation	117	117	
Class R US Dollar Accumulation	100	100	
Class S Euro Accumulation	117	117	
Class S Sterling Accumulation	289,417	156,947	
Class S US Dollar Accumulation	11,937	10,867	
Class Z Sterling Accumulation	100	100	

\* Asian Opportunities Fund terminated on 1 March 2021.

	Number of	Number of Shares	
Fund	31 December 2021	31 December 2020	
Biotechnology Fund			
Class I Sterling Distribution	740	-	
Class I Sterling Hedged Distribution	3,125	100	
Class I US Dollar Distribution	856	-	
Class S Sterling Distribution	7,295	4,060	
China Stars Fund			
Class I Euro Accumulation	116	116	
Class I Sterling Accumulation	1,060	130	
Class I US Dollar Accumulation	100	100	
Class R Euro Accumulation	116	116	
Class R Sterling Accumulation	130	130	
Class R US Dollar Accumulation	100	100	
Class S Euro Accumulation	308	404	
Class S Sterling Accumulation	1,736	1,736	
Class S US Dollar Accumulation	842,941	601,196	
Emerging Markets Stars Fund			
Class I Euro Accumulation	12	12	
Class I Sterling Accumulation	13	13	
Class I US Dollar Accumulation	10	10	
Class R Euro Accumulation	12	12	
Class R Sterling Accumulation	13	13	
Class R US Dollar Accumulation	10	10	
Class R US Dollar Distribution*	100	-	
Class S Euro Accumulation	24	12	
Class S Euro Distribution*	116	-	
Class S Sterling Accumulation	121,491	32,035	
Class S US Dollar Accumulation	1,386	21,867	
Class S US Dollar Distribution	100	100	
Class SX Euro Accumulation	100	100	
Class SX Sterling Accumulation	100	100	
Class SX Sterling Distribution*	100	_	
Class SX US Dollar Accumulation	100	100	
Class SX US Dollar Distribution*	100	_	
Class X US Dollar Accumulation	100	100	
Class X Euro Accumulation	113	113	
Class X Swedish Krona Accumulation	11	11	

\* New Share Classes launched during the year.

# 8. Related Party Transactions continued

	Number o	Number of Shares	
Fund	31 December 2021	31 December 2020	
Emerging Markets Income Fund**	-		
Class I Euro Accumulation	-	_	
Class I Euro Distribution	-	_	
Class I Sterling Accumulation	-	_	
Class I Sterling Distribution	-	_	
Class I US Dollar Accumulation	-	-	
Class I US Dollar Distribution	-	_	
Class R Euro Accumulation	-	_	
Class R Euro Distribution	-	_	
Class R Sterling Accumulation	-	_	
Class R Sterling Distribution	-	_	
Class R US Dollar Accumulation	-	_	
Class R US Dollar Distribution	-	_	
Class S Euro Accumulation	-	13	
Class S Euro Distribution	-	19	
Class S Sterling Accumulation	-	103,402	
Class S Sterling Distribution	-	_	
Class S US Dollar Accumulation	-	10	
Class S US Dollar Distribution	-	_	
European ex UK Income Fund			
Class I Euro Accumulation	103	103	
Class I Sterling Distribution	180	173	
Class I Sterling Hedged Accumulation	100	100	
Class I Sterling Hedged Distribution	128	123	
Class S Sterling Accumulation	14,097	28,054	
Class S Sterling Hedged Accumulation	100	100	
Class S Sterling Hedged Distribution	128	123	
Class X Sterling Accumulation	100	100	
Class X Sterling Distribution	110	105	

\*\* Emerging Markets Income Fund merged with the Emerging Markets Stars Fund on 8 June 2021.

Fund	Number of	Number of Shares	
	31 December 2021	31 December 2020	
Financial Opportunities Fund			
Class I Euro Accumulation	11	11	
Class I Euro Distribution	6	6	
Class I US Dollar Accumulation	5	5	
Class I US Dollar Distribution	6	6	
Class R Euro Accumulation	10	10	
Class R Euro Distribution	6	6	
Class R Sterling Accumulation	17	17	
Class R US Dollar Accumulation	11	11	
Class R US Dollar Distribution	9	9	
Class S Sterling Distribution	13	13	
Class S US Dollar Distribution	3,413	10	
Global Absolute Return Fund			
Class I Hedged Euro Accumulation	10	10	
Class I Hedged Sterling Accumulation	10	10	
Class I US Dollar Accumulation	10	10	
Class S Hedged Euro Accumulation	109	10	
Class S Hedged Sterling Accumulation	139,032	99,689	
Class S US Dollar Accumulation	63,952	48,577	
Global Convertible Fund			
Class I Hedged Euro Accumulation	100	100	
Class I Hedged Sterling Accumulation	494	_	
Class I Hedged Swiss Franc Accumulation	50	50	
Class Portfolio Currency Hedged Euro I Accumulation	20,500	20,500	
Class Portfolio Currency Hedged Sterling I Distribution	1,210	1,161	
Class Portfolio Currency Hedged Sterling S Distribution	108	104	
Class R Euro Distribution	182	174	
Class R Sterling Accumulation	155	155	
Class R Sterling Distribution	213	205	
Class R US Dollar Accumulation	100	100	
Class R US Dollar Distribution	138	132	
Class S Euro Accumulation	137	137	
Class S Hedged Sterling Accumulation	36,469	36,469	
Class S Hedged Sterling Distribution	133	128	
Class S Hedged Swiss Franc Accumulation	50	50	
Class S US Dollar Accumulation	100	100	
Class S US Dollar Distribution	135	130	
Class SI Sterling Accumulation	100	100	
Class S Euro Distribution	185	178	

# 8. Related Party Transactions continued

	Number of	Number of Shares	
Fund	31 December 2021	31 December 2020	
Global Insurance Fund			
Class F Sterling Accumulation	2,455	1,064	
Class I Euro Distribution	53	52	
Class I Hedged Euro Accumulation	100	100	
Class I Hedged US Dollar Accumulation	100	100	
Class I Sterling Accumulation	348,630	126,154	
Class R Euro Distribution	53	52	
Class R US Dollar Distribution	37	36	
Global Technology Fund			
Class I Euro Accumulation	11	11	
Class I Euro Distribution	29	44	
Class I Hedged Euro Distribution	100	100	
Class I Hedged Sterling Distribution	1,127	1,127	
Class I Hedged Swiss Franc Distribution	100	100	
Class I Sterling Distribution	19,455	21,086	
Class R Euro Accumulation	11	11	
Class R Hedged Euro Accumulation	100	100	
Class R Hedged Swiss Franc Distribution	100	100	
Healthcare Blue Chip Fund			
Class I Euro Accumulation	65	65	
Class I Euro Distribution	69	68	
Class I US Dollar Distribution	53	53	
Class S Sterling Hedged Distribution	103	102	
Class S US Dollar Accumulation	8	8	
Class S US Dollar Distribution	53	53	
Class SI Sterling Distribution	145	144	
Class SI US Dollar Distribution	102	102	
Healthcare Discovery Fund			
Class I Sterling Accumulation	132	100	
Class I US Dollar Accumulation	100	132	
Class S Sterling Accumulation	213,913	1,556	
Class S US Dollar Accumulation	1,071	206,760	

	Number of	Number of Shares			
Fund	31 December 2021	31 December 2020			
Healthcare Opportunities Fund					
Class I Euro Accumulation	100	100			
Class I Euro Hedged Accumulation	100	100			
Class I Sterling Distribution	17,086	17,763			
Class I US Dollar Distribution	172	343			
Class I US Dollar Accumulation	576	23			
Class R Euro Accumulation	26	26			
Class R Sterling Distribution	2,640				
Class R US Dollar Accumulation	24	24			
Income Opportunities Fund					
Class B2 Sterling Accumulation	222,623	183,462			
Class I Euro Accumulation	414	414			
Class I Euro Distribution	746	714			
Class I Euro Hedged Accumulation	100	100			
Class I Euro Hedged Distribution	128	123			
Class I US Dollar Accumulation	371	371			
Class I US Dollar Distribution	669	641			
Class R Euro Accumulation	424	424			
Class R Euro Distribution	776	743			
Class R Euro Hedged Accumulation	100	100			
Class R Euro Hedged Distribution	129	123			
Class R US Dollar Accumulation	381	381			
Class R US Dollar Distribution	696	667			
Class R US Dollar Hedged Accumulation	100	100			
Class R US Dollar Hedged Distribution	121	115			
Japan Value Fund					
Class I Euro Distribution	1,038	1,038			
Class I Hedged Euro Distribution	100	100			
Class I Hedged Sterling Distribution	5,726	100			
Class I Hedged Swiss Franc Distribution	100	100			
Class I Hedged US Dollar Distribution	100	100			
Class I Japanese Yen Distribution	1,415	1,415			
Class I Sterling Distribution	1,168	1,168			
Class I US Dollar Distribution	846	846			
Class R Euro Distribution	509	509			

## 8. Related Party Transactions continued

	Number of	Shares
Fund	31 December 2021	31 December 2020
Japan Value Fund continued		
Class R Hedged Sterling Distribution	1,288	1,288
Class R Hedged Swiss Franc Distribution	100	100
Class R Hedged US Dollar Distribution	38	38
Class R Japanese Yen Distribution	120	120
Class R Sterling Distribution	575	575
Class R US Dollar Distribution	80	80
Class S Euro Distribution	960	960
Class S Hedged Euro Distribution	4,668	4,668
Class S Hedged Swiss Franc Distribution	100	100
Class S Hedged US Dollar Distribution	3,021	3,021
Class S Japanese Yen Distribution	364	364
Class S Sterling Distribution	10,463	667
Class S US Dollar Distribution	825	825
North American Fund		
Class I Hedged Swiss Franc Distribution	100	100
Class I Sterling Distribution	413	_
Class R Hedged Euro Distribution	100	100
Class S Euro Distribution	14	14
Class S Hedged Euro Distribution	100	100
Class S Hedged Sterling Distribution	-	12,919
Class S Sterling Distribution	18,458	32,383
Class S US Dollar Distribution	1,039	1,732
Smart Energy Fund*		
Class I Euro Accumulation	116	_
Class I Sterling Accumulation	135	_
Class I Swedish Krona Accumulation	11	-
Class I Swiss Franc Accumulation	107	_
Class I US Dollar Accumulation	1,400,090	-
Class R Euro Accumulation	116	_
Class R Sterling Accumulation	135	_
Class R Swedish Krona Accumulation	11	_
Class R Swiss Franc Accumulation	107	_
Class R US Dollar Accumulation	100	_

\* Smart Energy Fund launched on 30 September 2021.

	Number	Number of Shares			
Fund	31 December 2021	31 December 2020			
Smart Mobility Fund*					
Class I Euro Accumulation	116	_			
Class I GBP Accumulation	135	_			
Class I Swedish Krona Accumulation	11	_			
Class I Swiss Franc Accumulation	107	_			
Class I US Dollar Accumulation	500,000	_			
Class R Euro Accumulation	116	-			
Class R GBP Accumulation	135	_			
Class R Swedish Krona Accumulation	11	_			
Class R Swiss Franc Accumulation	107	_			
Class R US Dollar Accumulation	100	-			
UK Value Opportunities Fund					
Class I Sterling Accumulation	100	100			
Class I Sterling Distribution	106	105			
Class R Sterling Accumulation	100	100			
Class S Sterling Accumulation	110,745	82,938			
Class S Sterling Distribution	106	105			
Class Z Sterling Accumulation	100	100			
Class Z Sterling Distribution	-	_			

\* Smart Mobility Fund launched on 30 September 2021.

### 8. Related Party Transactions continued

	Number of	Shares
Fund	31 December 2021	31 December 2020
Asian Opportunities Fund*	_	254
Asian Stars Fund	26,313	23,944
Automation & Artificial Intelligence Fund	170,626	147,728
Biotechnology Fund	90,710	52,317
China Stars Fund	33,320	20,393
Emerging Markets Income Fund**	-	34,859
Emerging Markets Stars Fund	25,592	19,681
European ex UK Income Fund	85,606	83,858
Financial Opportunities Fund	3,918	11,385
Global Absolute Return Fund	16,941	4,827
Global Convertible Fund	74,188	74,190
Global Insurance Fund	286,800	262,294
Global Technology Fund	61,554	42,702
Healthcare Blue Chip Fund	15,212	15,212
Healthcare Discovery Fund	3,498	2,272
Healthcare Opportunities Fund	23,471	23,385
Income Opportunities Fund	309,295	304,236
Japan Value Fund	1,590,839	854,010
North American Fund	96,206	63,763
Smart Energy Fund***	8,644	_
Smart Mobility Fund***	144	-
UK Value Opportunities Fund	183,225	333,784

\* Asian Opportunities Fund terminated on 1 March 2021.

\*\* Emerging Markets Income Fund merged with the Emerging Markets Stars Fund on 8 June 2021

\*\*\* Smart Energy Fund and Smart Mobility Fund launched on 30 September 2021.

### 9. Shareholders' Funds

On incorporation, the authorised share capital of the Company was US\$40,000 divided into 40,000 Subscriber Shares with a par value of US\$1 each and 500,000,000,000 redeemable participating shares of no par value. There are 7 Subscriber Shares currently in issue which are held by the Investment Manager and nominees of the Investment Manager. These subscriber shares do not participate in any of the Company's Funds and are not included as part of the net asset value of the Company. The Directors consider this treatment is appropriate, given the nature of the Company as an investment Fund.

#### Number of redeemable participating shares outstanding and net asset value per redeemable participating share

	31 December 2021		31 December 2020	
Asian Opportunities Fund*	Number of shares	NAV/Share	Number of shares	NAV/Share
Class A US Dollar Distribution	_	\$0.00	15,298	\$456.12
Class I Euro Distribution	_	€0.00	2,811	€13.07
Class I Euro Hedged Distribution	_	€0.00	6,331	€14.50
Class I Sterling Distribution	-	£0.00	12,853	£11.75
Class I Sterling Hedged Distribution	-	£0.00	12,501	£14.87
Class I US Dollar Distribution	-	\$0.00	48,442	\$16.04

	31 Decemb	31 December 2021		31 December 2020	
Asian Stars Fund	Number of shares	NAV/Share	Number of shares	NAV/Share	
Class I Euro Accumulation	50,391	€16.52	3,714	€14.81	
Class I Sterling Accumulation	114,243	£13.87	75,245	£13.26	
Class I US Dollar Accumulation	173,648	\$18.79	98,463	\$18.12	
Class R Euro Accumulation	3,022	€16.30	114	€14.69	
Class R Sterling Accumulation	127	£13.69	127	£13.15	
Class R US Dollar Accumulation	1,083	\$18.54	100	\$17.97	
Class S Euro Accumulation	5,270,403	€16.70	114	€14.91	
Class S Sterling Accumulation	1,274,618	£14.02	127	£13.35	
Class S US Dollar Accumulation	2,065,418	\$18.99	779,575	\$18.24	
Class S US Dollar Distribution	100	\$9.60	_	\$0.00	

\* Asian Opportunities Fund terminated on 1 March 2021.

## 9. Shareholders' Funds continued

	31 Decembe	31 December 2021		r 2020
Automation & Artificial Intelligence Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Euro Accumulation	1,453,941	€18.29	1,165,702	€14.58
Class I Sterling Accumulation	7,099,683	£15.35	6,693,034	£13.05
Class I US Dollar Accumulation	2,958,931	\$20.80	3,962,109	\$17.84
Class R Euro Accumulation	1,456,944	€17.95	1,204,496	€14.38
Class R US Dollar Accumulation	1,735,902	\$20.41	1,648,545	\$17.60
Class S Euro Accumulation	81,174	€18.45	86,228	€14.66
Class S Sterling Accumulation	11,816,416	£15.49	11,988,718	£13.12
Class S US Dollar Accumulation	837,449	\$20.98	921,951	\$17.94
Class Z Sterling Accumulation	7,280,100	£19.99	11,245,919	£16.86

	31 December 2021		31 December 2020	
Biotechnology Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Euro Distribution	4,476,496	€36.15	3,599,872	€32.09
Class I Sterling Distribution	5,740,766	£30.35	5,403,245	£28.73
Class I Sterling Hedged Distribution	6,879,916	£16.79	457,537	£16.06
Class I US Dollar Distribution	11,839,209	\$41.11	10,119,427	\$39.27
Class R Euro Distribution	5,126,666	€34.80	4,066,324	€31.04
Class R Sterling Distribution	273,238	£29.22	230,876	£27.78
Class R US Dollar Distribution	10,791,636	\$39.58	8,549,659	\$37.98
Class S Euro Distribution	16,882	€36.82	13,050	€32.62
Class S Sterling Distribution	49,685	£30.91	11,692	£29.19
Class S US Dollar Distribution	173,425	\$41.87	164,766	\$39.91

	31 Decembe	31 December 2021		31 December 2020		
China Stars Fund	Number of shares	NAV/Share	Number of shares	NAV/Share		
Class I Euro Accumulation	19,919	€12.28	11,409	€13.47		
Class I Sterling Accumulation	101,558	£10.31	136,523	£12.06		
Class I US Dollar Accumulation	1,903	\$13.96	35,461	\$16.49		
Class R Euro Accumulation	14,720	€12.12	8,465	€13.36		
Class R Sterling Accumulation	130	£10.18	130	£11.96		
Class R US Dollar Accumulation	19,739	\$13.78	36,215	\$16.35		
Class S Euro Accumulation	308	€12.38	404	€13.53		
Class S Sterling Accumulation	367,708	£10.39	15,452	£12.11		
Class S US Dollar Accumulation	897,794	\$14.07	601,196	\$16.56		

	31 December	31 December 2021		31 December 2020	
Emerging Markets Income Fund*	Number of shares	NAV/Share	Number of shares	NAV/Share	
Class I Euro Accumulation	_	€0.00	1,655	€10.89	
Class I Euro Distribution	-	€0.00	13,298	€7.30	
Class I Sterling Accumulation	-	£0.00	167,122	£9.75	
Class I Sterling Distribution	-	£0.00	2,702,942	£6.53	
Class I US Dollar Accumulation	-	\$0.00	147,774	\$13.33	
Class I US Dollar Distribution	-	\$0.00	38,469	\$8.93	
Class R Euro Accumulation	_	€0.00	45,420	€10.37	
Class R Euro Distribution	_	€0.00	11,850	€6.98	
Class R Sterling Accumulation	-	£0.00	3,821	£9.29	
Class R Sterling Distribution	_	£0.00	25,060	£6.25	
Class R US Dollar Accumulation	_	\$0.00	432,793	\$12.69	
Class R US Dollar Distribution	-	\$0.00	184,145	\$8.55	
Class S Euro Accumulation	-	€0.00	13	€10.75	
Class S Euro Distribution	_	€0.00	19	€7.54	
Class S Sterling Accumulation	_	£0.00	235,423	£9.62	
Class S Sterling Distribution	-	£0.00	6,561,991	£6.75	
Class S US Dollar Accumulation	_	\$0.00	10	\$13.15	
Class S US Dollar Distribution	_	\$0.00	430,329	\$9.22	

### 9. Shareholders' Funds continued

Number of redeemable participating shares outstanding and net asset value per redeemable participating share continued

	31 December 2021		31 December 2020		
Emerging Markets Stars Fund	Number of shares	NAV/Share	Number of shares	NAV/Share	
Class I Euro Accumulation	3,202,667	€13.23	1,732,431	€12.37	
Class I Sterling Accumulation	1,142,912	£11.11	628,642	£11.07	
Class I US Dollar Accumulation	2,243,693	\$15.05	514,862	\$15.13	
Class R Euro Accumulation	121,061	€13.04	19,841	€12.23	
Class R Sterling Accumulation	15,526	£10.95	13	£10.95	
Class R US Dollar Accumulation	510,872	\$14.83	3,124	\$14.97	
Class R US Dollar Distribution	12,160,942	\$9.53	N/A	N/A	
Class S Euro Accumulation	4,288,829	€13.41	4,728,009	€12.47	
Class S Euro Distribution**	15,378	€10.01	N/A	N/A	
Class S Sterling Accumulation	6,976,574	£11.26	3,708,371	£11.16	
Class S US Dollar Accumulation	11,101,418	\$15.25	6,846,289	\$15.25	
Class S US Dollar Distribution	2,618,729	\$15.47	1,431,129	\$15.48	
Class SX Euro Accumulation	100	€16.91	100	\$15.73	
Class SX Euro Distribution**	8,901,270	€9.36	N/A	N/A	
Class SX Sterling Accumulation	1,424,574	£13.79	1,583,599	\$13.67	
Class SX Sterling Distribution	100	£10.00	N/A	N/A	
Class SX US Dollar Accumulation	12,907,882	\$17.54	430,024	\$17.55	
Class X Swedish Krona Accumulation	13,216,771	SEK 146.16	40,917	SEK 133.81	
Class X Euro Accumulation	1,713,854	€14.20	184,286	€13.32	
Class X US Dollar Accumulation	4,002,611	\$16.14	1,883,479	\$16.29	

\* Launched during the period

\*\* Terminated during the year.

	31 Decem	ber 2021	31 Decem	ber 2020
European ex UK Income Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Euro Accumulation	75,517	€13.66	47,310	€11.50
Class I Sterling Accumulation	657,540	£11.39	2,450,462	£10.22
Class I Sterling Distribution	348,244	£8.94	362,527	£8.37
Class I Sterling Hedged Accumulation	6,434	£14.08	2,500	£11.78
Class I Sterling Hedged Distribution	18,598	£10.95	8,959	£9.56
Class S Sterling Accumulation	954,562	£11.50	758,892	£10.31
Class S Sterling Distribution	3,114,544	£9.01	3,563,707	£8.43
Class S Sterling Hedged Accumulation	100	£14.14	100	£11.83
Class S Sterling Hedged Distribution	64,200	£10.99	3,484,880	£9.60
Class X Sterling Accumulation	100	£11.01	100	£9.95
Class X Sterling Distribution	4,853,942	£10.00	7,509,538	£9.44

	31 Decemb	per 2021	31 Decem	ber 2020
Financial Opportunities Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Euro Accumulation	2,604	€15.46	2,112	€12.01
Class I Euro Distribution	118,199	€14.29	88,378	€11.27
Class I Sterling Accumulation	350,700	£12.98	77,832	£10.75
Class I Sterling Distribution	307,115	£12.00	325,408	£10.09
Class I US Dollar Accumulation	29,862	\$17.59	5	\$14.70
Class I US Dollar Distribution	526	\$16.25	8,715	\$13.79
Class R Euro Accumulation	4,794	€14.85	10,407	€11.58
Class R Euro Distribution	1,163	€13.61	6	€10.78
Class R Sterling Accumulation	12,245	£12.47	395	£10.37
Class R Sterling Distribution	6,550	£11.43	8,073	£9.65
Class R US Dollar Accumulation	13,982	\$16.89	13,982	\$14.17
Class R US Dollar Distribution	9	\$15.48	9	\$13.19
Class S Sterling Distribution	68,053	\$10.96	13	\$9.18
Class S US Dollar Distribution	551,152	\$14.85	266,814	\$12.54

	31 December 2021		31 December 2020	
Global Absolute Return Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Hedged Euro Accumulation	1,747	€123.92	2,222	€119.49
Class I Hedged Sterling Accumulation	33,672	£126.84	28,224	£121.75
Class I US Dollar Accumulation	12,894	\$130.79	7,356	\$125.46
Class S Hedged Euro Accumulation	16,362	€125.04	26,394	€120.10
Class S Hedged Sterling Accumulation	193,929	£127.76	181,321	£122.20
Class S US Dollar Accumulation	202,741	\$131.80	55,229	\$126.06

## 9. Shareholders' Funds continued

	31 Decembe	er 2021	31 December	r 2020
Global Convertible Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Euro Accumulation	3,265,706	€14.16	423,853	€14.23
Class I Euro Distribution	192,609	€10.22	220,828	€10.70
Class I Hedged Euro Accumulation	136,995	€12.07	97,770	€13.18
Class I Hedged Sterling Accumulation	3,303,990	£12.68	987,149	£13.77
Class I Hedged Sterling Distribution	3,002,723	£9.48	2,684,202	£10.72
Class I Hedged Swiss Franc Accumulation	82,200	Sfr. 11.58	687,350	Sfr. 12.70
Class I Sterling Accumulation	1,974,049	£11.89	1,709,492	£12.73
Class I Sterling Distribution	19,234,589	£8.58	16,908,917	£9.58
Class I US Dollar Accumulation	195,449	\$16.10	250,487	\$17.41
Class I US Dollar Distribution	249,115	\$11.63	315,516	\$13.09
Class Portfolio Currency Hedged Euro I Accumulation	702,077	€13.02	2,604,686	€13.83
Class Portfolio Currency Hedged Sterling I Distribution	4,604,353	£10.93	5,693,940	£12.04
Class R Euro Accumulation	73,457	€13.66	56,920	€13.79
Class R Euro Distribution	175,195	€9.83	154,760	€10.34
Class R Sterling Accumulation	12,787	£11.47	17,450	£12.35
Class R Sterling Distribution	23,153	£8.26	11,134	£9.26
Class R US Dollar Accumulation	7,282	\$15.53	100	\$16.88
Class R US Dollar Distribution	86,802	\$11.18	79,412	\$12.66
Class S Euro Accumulation	15,113	€12.51	8,270	€12.52
Class S Euro Distribution	66,622	€9.25	178	€9.65
Class S Hedged Sterling Accumulation	61,909	£12.99	69,516	£14.05
Class S Hedged Sterling Distribution	181,663	£9.69	250,444	£10.92
Class S Hedged Swiss Franc Accumulation	50	Sfr. 11.86	50	Sfr. 12.93
Class S Sterling Accumulation	190,980	£10.50	192,445	£11.21
Class S Sterling Distribution	34,763,757	£7.77	28,803,200	£8.64
Class S US Dollar Accumulation	55,872	\$14.22	48,251	\$15.32
Class S US Dollar Distribution	413,002	\$10.52	257,825	\$11.81
Class SI Sterling Accumulation	5,037,957	£12.05	5,329,419	£12.88
Class Portfolio Currency Hedged Sterling S Distribution	7,320,175	£11.03	7,285,765	£12.11

	31 Decen	nber 2021	31 Decem	ber 2020
	Number		Number	
Global Insurance Fund	of shares	NAV/Share	of shares	NAV/Share
Class A Sterling Distribution	201,481	£6.02	269,148	£5.27
Class B Sterling Accumulation	1,102,791	£8.00	1,370,374	£6.92
Class E Sterling Distribution	96,533,213	£6.35	97,052,757	£5.54
Class F Sterling Accumulation	27,449,439	£8.52	26,963,629	£7.33
Class I Euro Accumulation	6,101,194	€9.85	7,293,177	€7.95
Class I Euro Distribution	1,531,179	€7.40	1,608,411	€6.05
Class I Hedged Euro Accumulation	879,760	€15.73	1,061,608	€13.60
Class I Hedged US Dollar Accumulation	52,697	\$17.06	130,857	\$14.67
Class I Sterling Accumulation	31,572,776	£8.27	41,399,020	£7.11
Class I Sterling Distribution	39,634,630	£6.21	35,407,787	£5.42
Class I US Dollar Accumulation	20,633,607	\$11.20	26,197,610	\$9.72
Class I US Dollar Distribution	2,891,212	\$8.42	2,604,962	\$7.41
Class R Euro Accumulation	661,670	€9.27	719,574	€7.52
Class R Euro Distribution	326,725	€7.03	339,185	€5.78
Class R Sterling Accumulation	535,469	£7.78	815,846	£6.73
Class R Sterling Distribution	3,171,435	£5.90	3,297,184	£5.17
Class R US Dollar Accumulation	5,903,146	\$10.54	7,476,972	\$9.20
Class R US Dollar Distribution	174,033	\$7.99	183,594	\$7.07

	31 Decen	nber 2021	31 Decem	ber 2020
Global Technology Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class A Euro Distribution	207,948	€91.05	271,890	€77.26
Class A Sterling Distribution	313,150	£76.45	365,726	£69.15
Class A US Dollar Distribution	836,519	\$103.55	1,023,143	\$94.53
Class I Euro Accumulation*	4,355,115	€14.14	272,197	€11.94
Class I Euro Distribution	5,223,432	€84.81	7,149,606	€71.61
Class I Hedged Euro Distribution	5,776,799	€26.63	6,259,752	£24.46
Class I Hedged Sterling Distribution	5,084,702	£38.69	5,092,563	Sfr. 35.35
Class I Hedged Swiss Franc Distribution	3,065,483	Sfr. 38.32	2,856,470	£35.35
Class I Sterling Distribution	25,846,912	£71.21	29,653,115	\$64.09
Class I US Dollar Distribution	22,177,694	\$96.45	25,459,261	\$87.61
Class R Euro Accumulation*	236,197	€14.06	74,455	€11.93
Class R Euro Distribution	6,083,280	€80.10	5,861,555	€67.97
Class R Hedged Euro Accumulation	6,935,166	€26.04	8,748,425	€24.05
Class R Hedged Euro Distribution	2,283,150	€38.44	3,104,523	Sfr. 35.50
Class R Hedged Swiss Franc Distribution	933,307	Sfr. 37.27	901,548	£34.54
Class R Sterling Distribution	708,466	£67.25	687,340	\$60.84
Class R US Dollar Distribution	24,093,839	\$91.09	18,263,544	\$83.17

## 9. Shareholders' Funds continued

	31 December 2021		31 December 2020	
Healthcare Blue Chip Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Euro Accumulation	42,306	€17.25	18,456	€13.11
Class I Euro Distribution	5,801	€16.22	41,397	€12.40
Class I Sterling Accumulation	1,066,223	£14.49	946,210	£11.73
Class I Sterling Distribution	242,097	£13.62	195,379	£11.10
Class I US Dollar Accumulation	62,872	\$19.62	116,951	\$16.04
Class I US Dollar Distribution	4,615	\$18.44	3,736	\$15.17
Class S Sterling Accumulation	253,560	£14.63	244,263	£11.83
Class S Sterling Distribution	53,519	£13.76	52,230	£11.20
Class S Sterling Hedged Distribution	103	£17.43	102	£14.37
Class S US Dollar Accumulation	8	\$19.82	8	\$16.18
Class S US Dollar Distribution	53	\$18.63	53	\$15.31
Class SI Sterling Distribution	4,983,528	£12.19	4,882,220	£9.91
Class SI US Dollar Distribution	4,423	\$16.52	11,828	\$13.54

	31 December 2021		31 December 2020	
Healthcare Discovery Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Sterling Accumulation	158,969	\$11.42	113,274	£11.01
Class I US Dollar Accumulation	607,812	\$15.47	88,700	\$15.05
Class S Sterling Accumulation	3,021,074	\$11.47	2,210,967	£11.03
Class S US Dollar Accumulation	884,960	\$15.54	800,940	\$15.08

	31 Decembe	er 2021	31 Decembe	r 2020
Healthcare Opportunities Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class A Euro Distribution	152,178	€40.54	189,856	€34.74
Class A Sterling Distribution	87,455	£34.04	94,007	£31.10
Class A US Dollar Distribution	179,616	\$46.10	207,039	\$42.51
Class I Euro Distribution	3,321,576	€61.90	3,739,430	€52.78
Class I Euro Accumulation	2,654,253	€14.78	2,574,884	€12.61
Class I Euro Hedged Accumulation	243,622	€15.33	188,568	€14.22
Class I Sterling Distribution	18,282,663	£51.97	20,427,500	£47.24
Class I US Dollar Distribution	3,552,582	\$70.39	3,671,756	\$64.58
Class I US Dollar Accumulation	425,238	\$69.38	577,388	€63.66
Class R Euro Distribution	1,466,934	€58.23	1,336,367	€49.91
Class R Euro Accumulation	65,381	€57.31	17,572	€49.12
Class R Sterling Distribution	312,881	£48.89	309,617	£44.68
Class R US Dollar Distribution	2,074,995	\$66.22	1,948,088	\$61.07
Class R US Dollar Accumulation	160,242	\$65.17	92,655	€60.11

	31 Decen	nber 2021	31 Decem	ber 2020
Income Opportunities Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class A1 Sterling Distribution	3,541,057	£1.48	4,548,293	£1.27
Class A2 Sterling Accumulation	914,187	£2.71	1,019,563	£2.22
Class B1 Sterling Distribution	4,839,746	£1.57	5,329,699	£1.34
Class B2 Sterling Accumulation	7,529,199	£2.85	7,629,593	£2.33
Class I Euro Accumulation	29,894	€3.39	414	€2.60
Class I Euro Distribution	746	€1.87	714	€1.50
Class I Euro Hedged Accumulation	17,205	€16.29	15,305	€13.38
Class I Euro Hedged Distribution	928	€12.59	923	€10.81
Class I US Dollar Accumulation	371	\$3.86	371	\$3.18
Class I US Dollar Distribution	309,823	\$2.13	309,795	\$1.83
Class R Euro Accumulation	94,269	€3.23	40,250	€2.48
Class R Euro Distribution	62,319	€1.76	439,628	€1.41
Class R Euro Hedged Accumulation	81,133	€15.87	137,104	€13.09
Class R Euro Hedged Distribution	95,314	€12.28	150,328	€10.60
Class R US Dollar Accumulation	112,106	\$3.67	264,433	\$3.04
Class R US Dollar Distribution	757,003	\$2.00	1,602,402	\$1.73
Class R US Dollar Hedged Accumulation	1,216,806	\$13.89	1,340,957	\$11.39
Class R US Dollar Hedged Distribution	508,048	\$11.33	1,215,267	\$9.72

# 9. Shareholders' Funds continued

	31 Deceml	ber 2021	31 Decemb	er 2020
Japan Value Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Euro Distribution	1,038	€0.99	1,038	€0.89
Class I Hedged Swiss Franc Distribution	100	Sfr. 10.89	100	Sfr. 9.57
Class I Hedged Euro Distribution	100	€9.53	100	€8.36
Class I Hedged Sterling Distribution	5,726	£9.79	100	£8.57
Class I Hedged US Dollar Distribution	37,327	\$10.28	31,684	\$8.96
Class I Japanese Yen Distribution	1,415	¥128.69	3,598,071	¥112.12
Class I Sterling Distribution	96,189	£0.83	96,846	£0.80
Class I US Dollar Distribution	846	\$1.12	3,833	\$1.09
Class R Hedged Swiss Franc Distribution	225,825	Sfr. 10.81	230,196	Sfr. 9.54
Class R Hedged Euro Distribution	2,146,280	¥2.26	3,092,775	¥1.99
Class R Hedged Sterling Distribution	1,317,154	£1.87	2,249,721	£1.65
Class R Hedged US Dollar Distribution	7,710,654	\$3.25	9,302,596	\$2.84
Class R Euro Distribution	49,771	€2.00	166,226	€1.80
Class R Sterling Distribution	3,075	£1.68	4,469	£1.63
Class R Japanese Yen Distribution	4,406,425	¥260.46	5,256,088	¥227.72
Class R US Dollar Distribution	243,833	\$2.26	318,943	\$2.20
Class S Hedged Swiss Franc Distribution	195,757	Sfr. 10.99	221,084	Sfr. 9.62
Class S Hedged Euro Distribution	1,704,815	€2.39	2,236,158	€2.09
Class S Hedged Sterling Distribution	6,044,264	£1.99	7,951,303	£1.73
Class S Hedged US Dollar Distribution	5,252,869	\$3.45	5,613,345	\$2.99
Class S Euro Distribution	5,964,902	€2.12	164,902	€1.89
Class S Japanese Yen Distribution	11,451,031	¥275.45	9,112,220	¥239.03
Class S Sterling Distribution	25,786,556	£1.78	16,046,594	£1.71
Class S US Dollar Distribution	5,504,889	\$2.39	5,682,635	\$2.31

	31 Decen	nber 2021	31 December 2020	
North American Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Euro Distribution	9,953	€34.11	10,580	€25.66
Class I Hedged Euro Distribution	2,379,639	€33.81	1,609,896	€27.58
Class I Hedged Sterling Distribution	1,473,279	£35.19	922,476	£28.63
Class I Hedged Swiss Franc Distribution	105,810	Sfr. 18.81	148,941	Sfr. 15.38
Class I Sterling Distribution	4,114,975	£28.64	5,391,976	£22.96
Class I US Dollar Distribution	10,749,027	\$38.79	10,647,266	\$31.39
Class R Euro Distribution	156,781	€32.19	70,297	€24.36
Class R Hedged Euro Distribution	194,085	€31.86	170,773	€26.15
Class R Hedged Sterling Distribution	48,795	£33.31	47,750	£27.24
Class R Sterling Distribution	20,888	£27.03	20,500	£21.80
Class R US Dollar Distribution	1,583,047	\$36.61	1,391,788	\$29.81
Class S Euro Distribution	37,680	€34.52	38,982	€25.96
Class S Hedged Euro Distribution	21,412	€34.29	195,250	€27.95
Class S Hedged Sterling Distribution	616,053	£35.67	796,893	£28.99
Class S Sterling Distribution	7,248,224	£28.99	8,543,177	£23.23
Class S US Dollar Distribution	3,063,920	\$39.26	3,024,799	\$31.76

	31 December	r 2021	31 Decembe	r 2019
UK Absolute Equity Fund*	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Euro Distribution	-	€0.00	_	€0.00
Class I Hedged Euro Distribution	-	€0.00	_	€0.00
Class I Hedged US Dollar Distribution	-	\$0.00	_	€0.00
Class I Sterling Distribution	-	£0.00	_	€0.00
Class I US Dollar Distribution	-	\$0.00	_	€0.00
Class R Euro Distribution	-	€0.00	_	€0.00
Class R Hedged Euro Distribution	-	€0.00	-	€0.00
Class R Hedged US Dollar Distribution	-	\$0.00	-	€0.00
Class R Sterling Distribution	-	£0.00	_	€0.00
Class R US Dollar Distribution	-	\$0.00	_	€0.00
Class S Euro Distribution	-	€0.00	_	€0.00
Class S Hedged Euro Distribution	-	€0.00	_	€0.00
Class S Hedged US Dollar Distribution	-	\$0.00	_	€0.00
Class S Sterling Distribution	_	£0.00	-	€0.00
Class S US Dollar Distribution	-	\$0.00	_	€0.00

## 9. Shareholders' Funds continued

Number of redeemable participating shares outstanding and net asset value per redeemable participating share continued

	31 December 2021		31 December 2020	
Smart Energy Fund*	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Euro Accumulation	560,105	€9.36	_	€0.00
Class I Sterling Accumulation	108,411	£7.86	_	£0.00
Class I Swedish Krona Accumulation	11	SEK 96.34	_	SEK 0.00
Class I Swiss Franc Accumulation	107	Sfr. 9.70	-	Sfr. 0.00
Class I US Dollar Accumulation	1,505,543	\$10.64	_	\$0.00
Class R Euro Accumulation	63,704	€9.34	_	€0.00
Class R Sterling Accumulation	135	£7.84	_	£0.00
Class R Swedish Krona Accumulation	11	SEK 96.16	_	SEK 0.00
Class R Swiss Franc Accumulation	307	Sfr. 9.68	-	Sfr. 0.00
Class R US Dollar Accumulation	361,283	\$10.62	_	\$0.00

	31 Decem	31 December 2021		31 December 2020	
Smart Mobility Fund*	Number of shares	NAV/Share	Number of shares	NAV/Share	
Class I Euro Accumulation	151,516	€9.30	_	€0.00	
Class I GBP Accumulation	41,848	£7.81	_	£0.00	
Class I Swedish Krona Accumulation	11	SEK 95.74	_	SEK 0.00	
Class I Swiss Franc Accumulation	107	Sfr. 9.63	_	Sfr. 0.00	
Class I US Dollar Accumulation	501,800	\$10.57	_	\$0.00	
Class R Euro Accumulation	1,904	€9.29	_	€0.00	
Class R GBP Accumulation	135	£7.80	_	£0.00	
Class R Swedish Krona Accumulation	11	SEK 95.61	_	SEK 0.00	
Class R Swiss Franc Accumulation	107	Sfr. 9.62	_	Sfr. 0.00	
Class R US Dollar Accumulation	100	\$10.56	_	\$0.00	

	31 Decembe	er 2021	31 Decembe	r 2020
UK Value Opportunities Fund	Number of shares	NAV/Share	Number of shares	NAV/Share
Class I Sterling Accumulation	9,592,295	£14.64	13,925,084	£12.19
Class I Sterling Distribution	11,963,814	£13.83	7,084,022	£11.59
Class R Sterling Accumulation	170,554	£12.25	271,055	£10.23
Class S Sterling Accumulation	16,550,139	£14.72	14,835,024	£12.25
Class S Sterling Distribution	72,814,722	£13.86	50,376,830	£11.61
Class Z Sterling Accumulation	4,126,850	£13.30	12,058,964	£10.97
Class Z Sterling Distribution	-	£0.00	_	£0.00

\* Smart Energy Fund and Smart Mobility Fund launched on 30 September 2021.

### Movement in redeemable participating shares in issue during the financial year

	3	31 December 2021			
Asian Opportunities Fund*	Shares Number Class A USD Distribution	Shares Number Class I EUR Distribution	Shares Number Class I EUR Hedged Distribution		
Shares in issue at 1 January 2021	15,298	2,811	6,331		
Shares issued during financial year	157	_	_		
Shares redeemed during financial year	(15,455)	(2,811)	(6,331)		
Shares in issue at 31 December 2021	-	-	-		
Shares in issue at 31 December 2020	15,298	2,811	6,331		

	31 December 2021			
Asian Opportunities Fund	Shares Number Class I GBP Distribution	Shares Number Class I GBP Hedged Distribution	Shares Number Class I USD Distribution	
Shares in issue at 1 January 2021	12,853	12,501	48,442	
Shares issued during financial year	8	_	_	
Shares redeemed during financial year	(12,861)	(12,501)	(48,442)	
Shares in issue at 31 December 2021	-	-	-	
Shares in issue at 31 December 2020	12,853	12,501	48,442	

	31 December 2021			
Asian Stars Fund*	Shares Number Class I EUR Accumulation	Shares Number Class I GBP Accumulation	Shares Number Class I USD Accumulation	
Shares in issue at 1 January 2021	3,714	75,245	98,463	
Shares issued during financial year	46,677	101,561	79,285	
Shares redeemed during financial year	_	(62,563)	(4,100)	
Shares in issue at 31 December 2021	50,391	114,243	173,648	
Shares in issue at 31 December 2020	3,714	75,245	98,463	

\* Asian Opportunities Fund terminated on 01 March 2021.

### 9. Shareholders' Funds continued

		31 December 2021		
Asian Stars Fund*	Shares Number Class R EUR Accumulation	Shares Number Class R GBP Accumulation	Shares Number Class R USD Accumulation	
Shares in issue at 1 January 2021	114	127	100	
Shares issued during financial year	8,356	_	983	
Shares redeemed during financial year	(5,448)	_	_	
Shares in issue at 31 December 2021	3,022	127	1,083	
Shares in issue at 31 December 2020	114	127	100	

		31 December 2021		
Asian Stars Fund* continued	Shares Number Class S EUR Accumulation	Shares Number Class S GBP Accumulation	Shares Number Class S USD Accumulation	
Shares in issue at 1 January 2021	114	127	779,575	
Shares issued during financial year	6,379,825	1,590,321	1,971,484	
Shares redeemed during financial year	(1,109,537)	(315,831)	(685,641)	
Shares in issue at 31 December 2021	5,270,402	1,274,617	2,065,418	
Shares in issue at 31 December 2020	114	127	779,575	

Asian Stars Fund* continued	31 December 2021 Shares Number Class S USD Distribution
Shares in issue at 1 January 2021	-
Shares issued during financial year	100
Shares redeemed during financial year	-
Shares in issue at 31 December 2021	100
Shares in issue at 31 December 2020	-

31 December 2021 Shares Shares Shares Shares Number Number Number Number **Class I EUR Class I GBP Class I USD Class R EUR** Automation & Artificial Intelligence Fund Accumulation Accumulation Accumulation Accumulation Shares in issue at 1 January 2021 1,165,702 6,693,034 3,962,109 1,204,496 Shares issued during financial year 665,837 1,886,723 766,001 731,627 Shares redeemed during financial year (377,598) (1,480,074) (1,769,179) (479,179) Shares in issue at 31 December 2021 1,453,941 7,099,683 2,958,931 1,456,944 Shares in issue at 31 December 2020 1,165,702 6,693,034 3,962,109 1,204,496

	31 December 2021				
Automation & Artificial Intelligence Fund continued	Shares Number Class R USD Accumulation	Shares Number Class S EUR Accumulation	Shares Number Class S GBP Accumulation	Shares Number Class S USD Accumulation	
Shares in issue at 1 January 2021	1,648,545	86,228	11,988,718	921,951	
Shares issued during financial year	567,173	4,606	1,705,024	66,016	
Shares redeemed during financial year	(479,816)	(9,660)	(1,877,326)	(150,518)	
Shares in issue at 31 December 2021	1,735,902	81,174	11,816,416	837,449	
Shares in issue at 31 December 2020	1,648,545	86,228	11,988,718	921,951	

	31 December 2021
Automation & Artificial Intelligence Fund continued	Shares Number Class Z GBP Accumulation
Shares in issue at 1 January 2021	11,245,919
Shares issued during financial year	149,280
Shares redeemed during financial year	(4,115,099)
Shares in issue at 31 December 2021	7,280,100
Shares in issue at 31 December 2020	11,245,919

## 9. Shareholders' Funds continued

	31 December 2021			
Biotechnology Fund	Shares Number Class I EUR	Shares Number Class I GBP	Shares Number Class I GBP Hedged	Shares Number Class I USD
Shares in issue at 1 January 2021	3,599,872	5,403,245	457,537	10,119,427
Shares issued during financial year	2,015,014	2,278,678	6,625,792	5,880,374
Shares redeemed during financial year	(1,138,390)	(1,941,157)	(203,413)	(4,160,592)
Shares in issue at 31 December 2021	4,476,496	5,740,766	6,879,916	11,839,209
Shares in issue at 31 December 2020	3,599,872	5,403,245	457,537	10,119,427

	3	31 December 2021		
Biotechnology Fund continued	Shares Number Class R EUR	Shares Number Class R GBP	Shares Number Class R USD	
Shares in issue at 1 January 2021	4,066,324	230,876	8,549,659	
Shares issued during financial year	2,582,780	92,536	4,253,168	
Shares redeemed during financial year	(1,522,438)	(50,174)	(2,011,191)	
Shares in issue at 31 December 2021	5,126,666	273,238	10,791,636	
Shares in issue at 31 December 2020	4,066,324	230,876	8,549,659	

	3	31 December 2021		
Biotechnology Fund continued	Shares Number Class S EUR	Shares Number Class S GBP	Shares Number Class S USD	
Shares in issue at 1 January 2021	13,050	11,692	164,766	
Shares issued during financial year	8,699	38,438	16,655	
Shares redeemed during financial year	(4,867)	(445)	(7,996)	
Shares in issue at 31 December 2021	16,882	49,685	173,425	
Shares in issue at 31 December 2020	13,050	11,692	164,766	

		31 December 2021		
China Stars Fund	Shares Number Class I EUR Accumulation	Shares Number Class I GBP Accumulation	Shares Number Class I USD Accumulation	
Shares in issue at 1 January 2021	11,409	136,523	35,461	
Shares issued during financial year	8,654	95,790	9,080	
Shares redeemed during financial year	(144)	(130,755)	(42,638)	
Shares in issue at 31 December 2021	19,919	101,558	1,903	
Shares in issue at 31 December 2020	11,409	136,523	35,461	

		31 December 2021		
China Stars Fund	Shares Number Class R EUR Accumulation	Shares Number Class R GBP Accumulation	Shares Number Class R USD Accumulation	
Shares in issue at 1 January 2021	8,465	130	36,215	
Shares issued during financial year	16,210	_	11,975	
Shares redeemed during financial year	(9,955)	_	(28,451)	
Shares in issue at 31 December 2021	14,720	130	19,739	
Shares in issue at 31 December 2020	8,465	130	36,215	

		31 December 2021		
China Stars Fund	Shares Number Class S EUR Accumulation	Shares Number Class S GBP Accumulation	Shares Number Class S USD Accumulation	
Shares in issue at 1 January 2021	404	15,452	601,196	
Shares issued during financial year	-	352,312	296,598	
Shares redeemed during financial year	(96)	(56)	_	
Shares in issue at 31 December 2021	308	367,708	897,794	
Shares in issue at 31 December 2020	404	15,452	601,196	

	3		
Emerging Markets Income Fund*	Shares Number Class I EUR Accumulation	Shares Number Class I EUR Distribution	Shares Number Class I GBP Accumulation
Shares in issue at 1 January 2021	1,655	13,298	167,122
Shares issued during financial year	30	7,000	5,853
Shares redeemed during financial year	(1,685)	(20,298)	(172,975)
Shares in issue at 31 December 2021	-	-	-
Shares in issue at 31 December 2020	1,655	13,298	167,122

### 9. Shareholders' Funds continued

Movement in redeemable participating shares in issue during the financial year continued

	31 December 2021			
Emerging Markets Income Fund* continued	Shares Number Class I GBP Distribution	Shares Number Class I USD Accumulation	Shares Number Class I USD Distribution	
Shares in issue at 1 January 2021	2,702,942	147,774	38,469	
Shares issued during financial year	22,964	25	281	
Shares redeemed during financial year	(2,725,906)	(147,799)	(38,750)	
Shares in issue at 31 December 2021	-	-	-	
Shares in issue at 31 December 2020	2,702,942	147,774	38,469	

	31 December 2021		
Emerging Markets Income Fund* continued	Shares Number Class R EUR Accumulation	Shares Number Class R EUR Distribution	Shares Number Class R GBP Accumulation
Shares in issue at 1 January 2021	45,420	11,850	3,821
Shares issued during financial year	6,390	_	444
Shares redeemed during financial year	(51,810)	(11,850)	(4,265)
Shares in issue at 31 December 2021	-	-	-
Shares in issue at 31 December 2020	45,420	11,850	3,821

	31 December 2021		
Emerging Markets Income Fund* continued	Shares Number Class R GBP Distribution	Shares Number Class R USD Accumulation	Shares Number Class R USD Distribution
Shares in issue at 1 January 2021	25,060	432,793	184,145
Shares issued during financial year	_	83,537	1,194
Shares redeemed during financial year	(25,060)	(516,330)	(185,339)
Shares in issue at 31 December 2021	-	-	-
Shares in issue at 31 December 2020	25,060	432,793	184,145

	31 December 2021		
Emerging Markets Income Fund* continued	Shares Number Class S EUR Accumulation	Shares Number Class S EUR Distribution	Shares Number Class S GBP Accumulation
Shares in issue at 1 January 2021	13	19	235,423
Shares issued during financial year	_	_	_
Shares redeemed during financial year	(13)	(19)	(235,423)
Shares in issue at 31 December 2021	-	-	-
Shares in issue at 31 December 2020	13	19	235,423

	31 December 2021		
Emerging Markets Income Fund* continued	Shares Number Class S GBP Distribution	Shares Number Class S USD Accumulation	Shares Number Class S USD Distribution
Shares in issue at 1 January 2021	6,561,991	10	430,329
Shares issued during financial year	172,602	_	51,000
Shares redeemed during financial year	(6,734,593)	(10)	(481,329)
Shares in issue at 31 December 2021	-	-	-
Shares in issue at 31 December 2020	6,561,991	10	430,329

	31 December 2021			
Emerging Markets Stars Fund	Shares Number Class I EUR Accumulation	Shares Number Class I GBP Accumulation	Shares Number Class I USD Accumulation	Shares Number Class R EUR Accumulation
Shares in issue at 1 January 2021	1,732,431	628,642	514,862	19,841
Shares issued during financial year	3,560,013	705,377	1,880,915	134,373
Shares redeemed during financial year	(2,089,777)	(191,107)	(152,084)	(33,153)
Shares in issue at 31 December 2021	3,202,667	1,142,912	2,243,693	121,061
Shares in issue at 31 December 2020	1,732,431	628,642	514,862	19,841

	31 December 2021			
Emerging Markets Stars Fund continued	Shares Number Class R GBP Accumulation	Shares Number Class R USD Accumulation	Shares Number Class R USD Distribution	Shares Number Class S EUR Accumulation
Shares in issue at 1 January 2021	13	3,124	_	4,728,009
Shares issued during financial year	16,167	590,356	12,231,374	119,593
Shares redeemed during financial year	(654)	(82,608)	(70,432)	(558,773)
Shares in issue at 31 December 2021	15,526	510,872	12,160,942	4,288,829
Shares in issue at 31 December 2020	13	3,124	_	4,728,009

		31 December 2021		
Emerging Markets Stars Fund continued	Shares Number Class S EUR Distribution	Shares Number Class S GBP Accumulation	Shares Number Class S USD Accumulation	Shares Number Class S USD Distribution
Shares in issue at 1 January 2021	_	3,708,371	6,846,289	1,431,129
Shares issued during financial year	15,378	4,931,393	5,045,690	1,348,920
Shares redeemed during financial year	_	(1,663,190)	(790,561)	(161,320)
Shares in issue at 31 December 2021	15,378	6,976,574	11,101,418	2,618,729
Shares in issue at 31 December 2020	_	3,708,371	6,846,289	1,431,129

### 9. Shareholders' Funds continued

		31 December 2021		
Emerging Markets Stars Fund continued	Shares Number Class SX EUR Accumulation	Shares Number Class SX EUR Distribution	Shares Number Class SX GBP Accumulation	Shares Number Class SX GBP Distribution
Shares in issue at 1 January 2021	100	_	1,583,599	_
Shares issued during financial year	_	9,108,550	378,059	100
Shares redeemed during financial year	_	(207,280)	(537,084)	_
Shares in issue at 31 December 2021	100	8,901,270	1,424,574	100
Shares in issue at 31 December 2020	100	_	1,583,599	

		31 December 2021		
Emerging Markets Stars Fund continued	Shares Number Class SX USD Accumulation	Shares Number Class X SEK Accumulation	Shares Number Class X EUR Accumulation	Shares Number Class X USD Accumulation
Shares in issue at 1 January 2021	430,024	40,917	184,286	1,883,480
Shares issued during financial year	13,167,725	13,419,316	1,530,610	2,290,594
Shares redeemed during financial year	(689,867)	(243,462)	(1,042)	(191,358)
Shares in issue at 31 December 2021	12,907,882	13,216,771	1,713,854	3,982,716
Shares in issue at 31 December 2020	430,024	40,917	184,286	1,883,480

		31 December 2021		
European ex UK Income Fund	Shares Number Class I EUR Accumulation	Shares Number Class I GBP Accumulation	Shares Number Class I GBP Distribution	
Shares in issue at 1 January 2021	47,310	2,450,462	362,527	
Shares issued during financial year	34,319	218,882	107,552	
Shares redeemed during financial year	(6,113)	(2,011,804)	(121,835)	
Shares in issue at 31 December 2021	75,516	657,540	348,244	
Shares in issue at 31 December 2020	47,310	2,450,462	362,527	

		31 December 2021		
European ex UK Income Fund continued	Shares Number Class I GBP Hedged Accumulation	Shares Number Class I GBP Hedged Distribution	Shares Number Class S GBP Accumulation	
Shares in issue at 1 January 2021	2,500	8,959	758,892	
Shares issued during financial year	9,655	21,281	395,218	
Shares redeemed during financial year	(5,721)	(11,642)	(199,548)	
Shares in issue at 31 December 2021	6,434	18,598	954,562	
Shares in issue at 31 December 2020	2,500	8,959	758,892	

	31 December 2021		
European ex UK Income Fund continued	Shares Number Class S GBP Distribution	Shares Number Class S GBP Hedged Accumulation	Shares Number Class S GBP Hedged Distribution
Shares in issue at 1 January 2021	3,563,707	100	3,484,880
Shares issued during financial year	1,204,237	-	23,204
Shares redeemed during financial year	(1,653,400)	_	(3,443,884)
Shares in issue at 31 December 2021	3,114,544	100	64,200
Shares in issue at 31 December 2020	3,563,707	100	3,484,880

	31 Decembe	er 2021
European ex UK Income Fund continued	Shares Number Class X GBP Accumulation	Shares Number Class X GBP Distribution
Shares in issue at 1 January 2021	100	7,509,538
Shares issued during financial year	_	131,004
Shares redeemed during financial year	_	(2,786,600)
Shares in issue at 31 December 2021	100	4,853,942
Shares in issue at 31 December 2020	100	7,509,538

### 9. Shareholders' Funds continued

		31 December 2021	
Financial Opportunities Fund	Shares Number Class I EUR Accumulation	Shares Number Class I EUR Distribution	Shares Number Class I GBP Accumulation
Shares in issue at 1 January 2021	2,112	88,378	77,832
Shares issued during financial year	182,054	29,823	471,569
Shares redeemed during financial year	(181,562)	(2)	(198,701)
Shares in issue at 31 December 2021	2,604	118,199	350,700
Shares in issue at 31 December 2020	2,112	88,378	77,832

		31 December 2021			
Financial Opportunities Fund continued	Shares Number Class I GBP Distribution	Shares Number Class I USD Accumulation	Shares Number Class I USD Distribution		
Shares in issue at 1 January 2021	325,408	5	8,715		
Shares issued during financial year	234,687	30,407	987		
Shares redeemed during financial year	(252,980)	(550)	(9,176)		
Shares in issue at 31 December 2021	307,115	29,862	526		
Shares in issue at 31 December 2020	325,408	5	8,715		

		31 December 2021	021
Financial Opportunities Fund continued	Shares Number Class R EUR Accumulation	Shares Number Class R EUR Distribution	Shares Number Class R GBP Accumulation
Shares in issue at 1 January 2021	10,407	6	395
Shares issued during financial year	626	1,173	12,236
Shares redeemed during financial year	(6,239)	(16)	(386)
Shares in issue at 31 December 2021	4,794	1,163	12,245
Shares in issue at 31 December 2020	10,407	6	395

		31 December 2021		
Financial Opportunities Fund continued	Shares Number Class R GBP Distribution	Shares Number Class R USD Accumulation	Shares Number Class R USD Distribution	
Shares in issue at 1 January 2021	8,073	13,982	9	
Shares issued during financial year	345	765	_	
Shares redeemed during financial year	(1,868)	(765)	_	
Shares in issue at 31 December 2021	6,550	13,982	9	
Shares in issue at 31 December 2020	8,073	13,982	9	

	31 Decembe	r 2021
Financial Opportunities Fund continued	Shares Number Class S GBP Distribution	Shares Number Class S USD Distribution
Shares in issue at 1 January 2021	13	266,814
Shares issued during financial year	89,040	315,804
Shares redeemed during financial year	(21,000)	(31,466)
Shares in issue at 31 December 2021	68,053	551,152
Shares in issue at 31 December 2020	13	266,814

		31 December 2021	
Global Absolute Return Fund	Shares Number Class I Hedged Euro Accumulation Shares	Shares Number Class I Hedged Sterling Accumulation Shares	Shares Number Class I US Dollar Accumulation Shares
Shares in issue at 1 January 2021	2,222	28,224	7,356
Shares issued during financial year	_	8,201	7,184
Shares redeemed during financial year	(475)	(2,753)	(1,646)
Shares in issue at 31 December 2021	1,747	33,672	12,894
Shares in issue at 31 December 2020	2,222	28,224	7,356

### 9. Shareholders' Funds continued

	31 December 2021		
Global Absolute Return Fund continued	Shares Number Class S Hedged Euro Accumulation Shares	Shares Number Class S Hedged Sterling Accumulation Shares	Shares Number Class S US Dollar Accumulation Shares
Shares in issue at 1 January 2021	26,394	181,321	55,229
Shares issued during financial year	6,160	84,797	183,360
Shares redeemed during financial year	(16,192)	(72,189)	(35,848)
Shares in issue at 31 December 2021	16,362	193,929	202,741
Shares in issue at 31 December 2020	26,394	181,321	55,229

	31 December 2021		
Global Convertible Fund	Shares Number Class I EUR Accumulation	Shares Number Class I EUR Distribution	Shares Number Class I Hedged EUR Accumulation
Shares in issue at 1 January 2021	423,853	220,828	97,770
Shares issued during financial year	2,855,348	9,683	41,275
Shares redeemed during financial year	(13,495)	(37,902)	(2,050)
Shares in issue at 31 December 2021	3,265,706	192,609	136,995
Shares in issue at 31 December 2020	423,853	220,828	97,770

	3	31 December 2021		
Global Convertible Fund continued	Shares Number Class I Hedged GBP Accumulation	Shares Number Class I Hedged GBP Distribution	Shares Number Class I Hedged CHF Accumulation	
Shares in issue at 1 January 2021	987,149	2,684,202	687,350	
Shares issued during financial year	2,871,090	1,017,088	228,800	
Shares redeemed during financial year	(554,249)	(698,567)	(833,950)	
Shares in issue at 31 December 2021	3,303,990	3,002,723	82,200	
Shares in issue at 31 December 2020	987,149	2,684,202	687,350	

		31 December 2021		
Global Convertible Fund continued	Shares Number Class I GBP Accumulation	Shares Number Class I GBP Distribution	Shares Number Class I USD Accumulation	
Shares in issue at 1 January 2021	1,709,492	16,908,917	250,487	
Shares issued during financial year	837,231	4,722,039	9,980	
Shares redeemed during financial year	(572,674)	(2,396,367)	(65,018)	
Shares in issue at 31 December 2021	1,974,049	19,234,589	195,449	
Shares in issue at 31 December 2020	1,709,492	16,908,917	250,487	

	31 December 2021		
Global Convertible Fund continued	Shares Number Class I USD Distribution	Shares Number Class Portfolio Currency Hedged EUR I Accumulation	Shares Number Class Portfolio Currency Hedged GBP I Distribution
Shares in issue at 1 January 2021	315,516	2,604,686	5,693,940
Shares issued during financial year	45,058	622,541	1,079,774
Shares redeemed during financial year	(111,459)	(2,525,150)	(2,169,361)
Shares in issue at 31 December 2021	249,115	702,077	4,604,353
Shares in issue at 31 December 2020	315,516	2,604,686	5,693,940

	31 December 2021			
Global Convertible Fund continued	Shares Number Class R EUR Accumulation	Shares Number Class R EUR Distribution	Shares Number Class R GBP Accumulation	Shares Number Class R GBP Distribution
Shares in issue at 1 January 2021	56,920	154,760	17,450	11,134
Shares issued during financial year	70,477	69,996	2,974	21,453
Shares redeemed during financial year	(53,940)	(49,561)	(7,637)	(9,434)
Shares in issue at 31 December 2021	73,457	175,195	12,787	23,153
Shares in issue at 31 December 2020	56,920	154,760	17,450	11,134

\* Healthcare Discovery Fund launched on 31 January 2020.

### 9. Shareholders' Funds continued

		31 December 2021		
Global Convertible Fund continued	Shares Number Class R USD Accumulation	Shares Number Class R USD Distribution	Shares Number Class S EUR Accumulation	Shares Number Class S EUR Distribution
Shares in issue at 1 January 2021	100	79,412	8,270	178
Shares issued during financial year	28,818	26,198	6,843	67,375
Shares redeemed during financial year	(21,636)	(18,808)	_	(931)
Shares in issue at 31 December 2021	7,282	86,802	15,113	66,622
Shares in issue at 31 December 2020	100	79,412	8,270	178

		31 December 2021		
Global Convertible Fund continued	Shares Number Class S Hedged GBP Accumulation	Shares Number Class S Hedged GBP Distribution	Shares Number Class S CHF Hedged Accumulation	Shares Number Class S GBP Accumulation
Shares in issue at 1 January 2021	69,516	250,444	50	192,445
Shares issued during financial year	5,625	85,902	-	37,966
Shares redeemed during financial year	(13,232)	(154,683)	_	(39,431)
Shares in issue at 31 December 2021	61,909	181,663	50	190,980
Shares in issue at 31 December 2020	69,516	250,444	50	192,445

	31 December 2021			
Global Convertible Fund continued	Shares Number Class S GBP Distribution	Shares Number Class S USD Accumulation	Shares Number Class S USD Distribution	Shares Number Class SI GBP Accumulation
Shares in issue at 1 January 2021	28,803,200	48,251	257,825	5,329,419
Shares issued during financial year	9,604,554	8,183	230,154	1,209,910
Shares redeemed during financial year	(3,643,997)	(562)	(74,977)	(1,501,372)
Shares in issue at 31 December 2021	34,763,757	55,872	413,002	5,037,957
Shares in issue at 31 December 2020	28,803,200	48,251	257,825	5,329,419

	31 December 2020
Global Convertible Fund continued	Shares Number Class Portfolio Currency Hedged GBP S Distribution
Shares in issue at 1 January 2021	7,285,765
Shares issued during financial year	784,233
Shares redeemed during financial year	(749,823)
Shares in issue at 31 December 2021	7,320,175
Shares in issue at 31 December 2020	7,285,765

		31 December 2021			
Global Insurance Fund	Shares Number Class A GBP Distribution	Shares Number Class B GBP Accumulation	Shares Number Class E GBP Distribution	Shares Number Class F GBP Accumulation	
Shares in issue at 1 January 2021	269,148	1,370,374	97,052,757	26,963,629	
Shares issued during financial year	310	18,292	21,572,998	6,264,070	
Shares redeemed during financial year	(67,977)	(285,875)	(22,092,542)	(5,778,260)	
Shares in issue at 31 December 2021	201,481	1,102,791	96,533,213	27,449,439	
Shares in issue at 31 December 2020	269,148	1,370,374	97,052,757	26,963,629	

		31 December 2021			
Global Insurance Fund continued	Shares Number Class I EUR Accumulation	Shares Number Class I EUR Distribution	Shares Number Class I Hedged EUR Accumulation	Shares Number Class I Hedged USD Accumulation	
Shares in issue at 1 January 2021	7,293,177	1,608,411	1,061,608	130,857	
Shares issued during financial year	4,493,179	33,705	165,946	9,710	
Shares redeemed during financial year	(5,685,162)	(110,937)	(347,794)	(87,870)	
Shares in issue at 31 December 2021	6,101,194	1,531,179	879,760	52,697	
Shares in issue at 31 December 2020	7,293,177	1,608,411	1,061,608	130,857	

### 9. Shareholders' Funds continued

Global Insurance Fund continued	Shares Number Class I GBP Accumulation	Shares Number Class I GBP Distribution	Shares Number Class I USD Accumulation	Shares Number Class I USD Distribution
Shares in issue at 1 January 2021	41,399,020	35,407,787	26,197,610	2,604,962
Shares issued during financial year	14,203,237	10,285,338	9,490,738	930,351
Shares redeemed during financial year	(24,029,481)	(6,058,495)	(15,054,741)	(644,101)
Shares in issue at 31 December 2021	31,572,776	39,634,630	20,633,607	2,891,212
Shares in issue at 31 December 2020	41,399,020	35,407,787	26,197,610	2,604,962

		31 December 2021		
Global Insurance Fund continued	Shares Number Class R EUR Accumulation	Shares Number Class R EUR Distribution	Shares Number Class R GBP Accumulation	
Shares in issue at 1 January 2021	719,574	339,185	815,846	
Shares issued during financial year	202,925	59,629	104,094	
Shares redeemed during financial year	(260,829)	(72,089)	(384,471)	
Shares in issue at 31 December 2021	661,670	326,725	535,469	
Shares in issue at 31 December 2020	719,574	339,185	815,846	

		31 December 2021		
Global Insurance Fund continued	Shares Number Class R GBP Distribution	Shares Number Class R USD Accumulation	Shares Number Class R USD Distribution	
Shares in issue at 1 January 2021	3,297,184	7,476,972	183,594	
Shares issued during financial year	40,707	1,447,981	31,978	
Shares redeemed during financial year	(166,456)	(3,021,807)	(41,539)	
Shares in issue at 31 December 2021	3,171,435	5,903,146	174,033	
Shares in issue at 31 December 2020	3,297,184	7,476,972	183,594	

31 December 2021 Shares Number Shares Shares Shares Number Number Number **Class I EUR** Accumulation **Global Technology Fund** Class A EUR Class A GBP Class A USD Shares in issue at 1 January 2021 272,197 271,890 365,726 1,023,143 Shares issued during financial year 71,189 34,948 4,824,751 67,132 Shares redeemed during financial year (135,131) (87,524) (253,756) (741,833) Shares in issue at 31 December 2021 207,948 313,150 836,519 4,355,115 1,023,143 Shares in issue at 31 December 2020 271,890 365,726 272,197

	31 December 2021			
Global Technology Fund continued	Shares Number Class I EUR Distribution	Shares Number Class I Hedged EUR Distribution	Shares Number Class I Hedged GBP	Shares Number Class I Hedged CHF
Shares in issue at 1 January 2021	7,149,606	6,259,752	5,092,563	2,856,470
Shares issued during financial year	1,471,842	3,062,038	1,131,091	889,126
Shares redeemed during financial year	(3,398,016)	(3,544,991)	(1,138,952)	(680,113)
Shares in issue at 31 December 2021	5,223,432	5,776,799	5,084,702	3,065,483
Shares in issue at 31 December 2020	7,149,606	6,259,752	5,092,563	2,856,470

		31 December 2021		
Global Technology Fund continued	Shares Number Class I GBP Distribution	Shares Number Class I USD Distribution	Shares Number Class R EUR Accumulation	Shares Number Class R EUR Distribution
Shares in issue at 1 January 2021	29,653,115	25,459,261	74,455	5,861,555
Shares issued during financial year	4,766,793	7,901,905	207,257	1,524,000
Shares redeemed during financial year	(8,572,996)	(11,183,472)	(45,515)	(1,302,275)
Shares in issue at 31 December 2021	25,846,912	22,177,694	236,197	6,083,280
Shares in issue at 31 December 2020	29,653,115	25,459,261	74,455	5,861,555

	31 December 2021			
Global Technology Fund continued	Shares Number Class R Hedged EUR Distribution	Shares Number Class R Hedged CHF Distribution	Shares Number Class R GBP Distribution	Shares Number Class R USD Distribution
Shares in issue at 1 January 2021	8,748,425	3,104,523	901,548	687,340
Shares issued during financial year	2,312,255	427,055	274,444	149,278
Shares redeemed during financial year	(4,125,514)	(1,248,428)	(242,685)	(128,152)
Shares in issue at 31 December 2021	6,935,166	2,283,150	933,307	708,466
Shares in issue at 31 December 2020	8,748,425	3,104,523	901,548	687,340

### 9. Shareholders' Funds continued

	31 December 2021
Global Technology Fund continued	Shares Number Class R USD Distribution
Shares in issue at 1 January 2021	18,263,544
Shares issued during financial year	12,752,279
Shares redeemed during financial year	(6,921,984)
Shares in issue at 31 December 2021	24,093,839
Shares in issue at 31 December 2020	18,263,544

Healthcare Blue Chip Fund	Shares Number Class I EUR Accumulation	Shares Number Class I EUR Distribution	Shares Number Class I GBP Accumulation	Shares Number Class I GBP Distribution
Shares in issue at 1 January 2021	18,456	41,397	946,210	195,379
Shares issued during financial year	35,342	1,005	383,532	117,890
Shares redeemed during financial year	(11,493)	(36,602)	(263,519)	(71,172)
Shares in issue at 31 December 2021	42,305	5,800	1,066,223	242,097
Shares in issue at 31 December 2020	18,456	41,397	946,210	195,379

	:	31 December 2021		
Healthcare Blue Chip Fund continued	Shares Number Class I USD Accumulation	Shares Number Class I USD Distribution	Shares Number Class S GBP Accumulation	
Shares in issue at 1 January 2021	116,951	3,736	244,263	
Shares issued during financial year	55,145	1,265	50,584	
Shares redeemed during financial year	(109,225)	(387)	(41,287)	
Shares in issue at 31 December 2021	62,871	4,614	253,560	
Shares in issue at 31 December 2020	116,951	3,736	244,263	

		31 December 2021		
Healthcare Blue Chip Fund continued	Shares Number Class S GBP Distribution	Shares Number Class S GBP Hedged Distribution	Shares Number Class S USD Accumulation	
Shares in issue at 1 January 2021	52,230	102	8	
Shares issued during financial year	26,772	1	-	
Shares redeemed during financial year	(25,483)	_	_	
Shares in issue at 31 December 2021	53,519	103	8	
Shares in issue at 31 December 2020	52,230	102	8	

		31 December 2021		
Healthcare Blue Chip Fund continued	Shares Number Class S USD Distribution	Shares Number Class SI GBP Distribution	Shares Number Class SI USD Distribution	
Shares in issue at 1 January 2021	53	4,882,220	11,828	
Shares issued during financial year	_	674,183	1,000	
Shares redeemed during financial year	-	(572,875)	(8,405)	
Shares in issue at 31 December 2021	53	4,983,528	4,423	
Shares in issue at 31 December 2020	53	4,882,220	11,828	

		31 December 2021		
Healthcare Discovery Fund	Shares Number Class I GBP Accumulation	Shares Number Class I USD Accumulation	Shares Number Class S GBP Accumulation	Shares Number Class S USD Accumulation
Shares in issue at 1 January 2021	113,274	88,700	2,210,967	800,940
Shares issued during financial year	137,059	592,807	997,162	122,711
Shares redeemed during financial year	(91,364)	(73,695)	(187,055)	(38,691)
Shares in issue at 31 December 2021	158,969	607,812	3,021,074	884,960
Shares in issue at 31 December 2020	113,274	88,700	2,210,967	800,940

		31 December 2021		
Healthcare Opportunities Fund	Shares Number Class A EUR Distribution	Shares Number Class A GBP Distribution	Shares Number Class A USD Distribution	Shares Number Class I EUR Distribution
Shares in issue at 1 January 2020	189,856	94,007	207,039	3,739,430
Shares issued during financial year	22,218	2,075	11,445	763,882
Shares redeemed during financial year	(59,896)	(8,627)	(38,868)	(1,181,736)
Shares in issue at 31 December 2020	152,178	87,455	179,616	3,321,576
Shares in issue at 31 December 2019	189,856	94,007	207,039	3,739,430

## 9. Shareholders' Funds continued

		31 December 2020			
Healthcare Opportunities Fund continued	Shares Number Class I EUR Accumulation	Shares Number Class I EUR Hedged Distribution	Shares Number Class I GBP Distribution	Shares Number Class I USD Distribution	
Shares in issue at 1 January 2020	2,574,884	188,568	20,427,500	3,671,756	
Shares issued during financial year	1,902,677	364,643	3,083,658	1,479,804	
Shares redeemed during financial year	(1,823,308)	(309,589)	(5,228,495)	(1,598,978)	
Shares in issue at 31 December 2020	2,654,253	243,622	18,282,663	3,552,582	
Shares in issue at 31 December 2019	2,574,884	188,568	20,427,500	3,671,756	

		31 December 2020			
Healthcare Opportunities Fund continued	Shares Number Class I USD Accumulation	Shares Number Class R EUR Distribution	Shares Number Class R EUR Accumulation	Shares Number Class R GBP Distribution	
Shares in issue at 1 January 2020	577,388	1,336,367	17,572	309,617	
Shares issued during financial year	184,690	404,491	60,271	64,016	
Shares redeemed during financial year	(336,840)	(273,924)	(12,462)	(60,752)	
Shares in issue at 31 December 2020	425,238	1,466,934	65,381	312,881	
Shares in issue at 31 December 2019	577,388	1,336,367	17,572	309,617	

	31 December	31 December 2020	
Healthcare Opportunities Fund continued	Shares Number Class R USD Distribution	Shares Number Class R USD Accumulation	
Shares in issue at 1 January 2020	1,948,088	92,655	
Shares issued during financial year	543,440	123,683	
Shares redeemed during financial year	(416,533)	(56,096)	
Shares in issue at 31 December 2020	2,074,995	160,242	
Shares in issue at 31 December 2019	1,948,088	92,655	

31 December 2021 Shares Shares Shares Shares Number Number Number Number Class A1 GBP Class A2 GBP Class B1 GBP Class B2 GBP **Income Opportunities Fund** Distribution Accumulation Distribution Accumulation Shares in issue at 1 January 2021 4,548,293 1,019,563 5,329,699 7,629,593 Shares issued during financial year 293,347 274,241 30,516 569,565 Shares redeemed during financial year (1,300,583) (135,892) (1,059,518) (374,635) Shares in issue at 31 December 2021 3,541,057 914,187 4,839,746 7,529,199 1,019,563 Shares in issue at 31 December 2020 4,548,293 5,329,699 7,629,593

	31 December 2021			
Income Opportunities Fund continued	Shares Number Class I EUR Accumulation	Shares Number Class I EUR Distribution	Shares Number Class I EUR Hedged Accumulation	Shares Number Class I EUR Hedged Distribution
Shares in issue at 1 January 2021	414	714	15,305	923
Shares issued during financial year	29,480	32	1,900	5
Shares redeemed during financial year	_	-	_	-
Shares in issue at 31 December 2021	29,894	746	17,205	928
Shares in issue at 31 December 2020	414	714	15,305	923

	31 December 2021			
Income Opportunities Fund continued	Shares Number Class I USD Accumulation	Shares Number Class I USD Distribution	Shares Number Class R EUR Accumulation	Shares Number Class R EUR Distribution
Shares in issue at 1 January 2021	371	309,795	40,250	439,628
Shares issued during financial year	_	28	218,315	33
Shares redeemed during financial year	_	_	(164,296)	(377,342)
Shares in issue at 31 December 2021	371	309,823	94,269	62,319
Shares in issue at 31 December 2020	371	309,795	40,250	439,628

		31 December 2021		
Income Opportunities Fund continued	Class R EUR Hedged Accumulation	Shares Number Class R EUR Hedged Distribution	Shares Number Class R USD Accumulation	Shares Number Class R USD Distribution
Shares in issue at 1 January 2021	137,104	150,328	264,433	1,602,402
Shares issued during financial year	2,934	4,589	_	1,246
Shares redeemed during financial year	(58,905)	(59,603)	(152,327)	(846,645)
Shares in issue at 31 December 2021	81,133	95,314	112,106	757,003
Shares in issue at 31 December 2020	137,104	150,328	264,433	1,602,402

## 9. Shareholders' Funds continued

Movement in redeemable participating shares in issue during the financial year continued

		31 December 2021			
Income Opportunities Fund continued	Shares Number Class R USD Hedged Accumulation	Shares Number Class R USD Hedged Distribution	Shares Number Class Z GBP Accumulation	Shares Number Class Z GBP Distribution	
Shares in issue at 1 January 2021	1,340,957	1,215,267	_	_	
Shares issued during financial year	71,639	13,866	_	_	
Shares redeemed during financial year	(195,790)	(721,085)	_	_	
Shares in issue at 31 December 2021	1,216,806	508,048	0	0	
Shares in issue at 31 December 2020	1,340,957	1,215,267	-	-	

	31 December 2021			
Japan Value Fund	Shares Number Class I EUR Distribution	Shares Number Class I Hedged CHF Distribution	Shares Number Class I Hedged EUR Distribution	Shares Number Class I Hedged GBP Distribution
Shares in issue at 1 January 2021	1,038	100	100	100
Shares issued during financial year	-	-	-	5,626
Shares redeemed during financial year	-	-	-	_
Shares in issue at 31 December 2021	1,038	100	100	5,726
Shares in issue at 31 December 2020	1,038	100	100	100

		31 Decembe	er 2021	
Japan Value Fund continued	Shares Number Class I Hedged USD Distribution	Shares Number Class I JPY Distribution	Shares Number Class I GBP Distribution	Shares Number Class I USD Distribution
Shares in issue at 1 January 2021	31,684	3,598,071	96,846	3,833
Shares issued during financial year	9,836	1,251,583	22,289	2,688
Shares redeemed during financial year	(4,193)	(4,848,239)	(22,946)	(5,675)
Shares in issue at 31 December 2021	37,327	1,415	96,189	846
Shares in issue at 31 December 2020	31,684	3,598,071	96,846	3,833

		31 December 2021			
Japan Value Fund continued	Shares Number Class R Hedged CHF Distribution	Shares Number Class R Hedged EUR Distribution	Shares Number Class R Hedged GBP Distribution	Shares Number Class R Hedged USD Distribution	
Shares in issue at 1 January 2021	230,196	3,092,775	2,249,721	9,302,596	
Shares issued during financial year	3,390	117,456	89,388	264,333	
Shares redeemed during financial year	(7,761)	(1,063,951)	(1,021,955)	(1,856,275)	
Shares in issue at 31 December 2021	225,825	2,146,280	1,317,154	7,710,654	
Shares in issue at 31 December 2020	230,196	3,092,775	2,249,721	9,302,596	

		31 Decembe	<sup>·</sup> 2021			
Japan Value Fund continued	Shares Number Class R EUR Distribution	Shares Number Class R GBP Distribution	Shares Number Class R JPY Distribution	Shares Number Class R USD Distribution		
Shares in issue at 1 January 2021	166,226	4,469	5,256,088	318,943		
Shares issued during financial year	1,584	_	20,562	10,303		
Shares redeemed during financial year	(118,039)	(1,394)	(870,225)	(85,413)		
Shares in issue at 31 December 2021	49,771	3,075	4,406,425	243,833		
Shares in issue at 31 December 2020	166,226	4,469	5,256,088	318,943		

		31 December 2021			
Japan Value Fund continued	Shares Number Class S Hedged CHF Distribution	Shares Number Class S Hedged EUR Distribution	Shares Number Class S Hedged GBP Distribution	Shares Number Class S Hedged USD Distribution	
Shares in issue at 1 January 2021	221,084	2,236,158	7,951,303	5,613,345	
Shares issued during financial year	570	261,505	380,702	894,832	
Shares redeemed during financial year	(25,897)	(792,848)	(2,287,741)	(1,255,308)	
Shares in issue at 31 December 2021	195,757	1,704,815	6,044,264	5,252,869	
Shares in issue at 31 December 2020	221,084	2,236,158	7,951,303	5,613,345	

## 9. Shareholders' Funds continued

Movement in redeemable participating shares in issue during the financial year continued

		31 Decembe	er 2021	
Japan Value Fund continued	Shares Number Class S EUR Distribution	Shares Number Class S JPY Distribution	Shares Number Class S GBP Distribution	Shares Number Class S USD Distribution
Shares in issue at 1 January 2021	164,902	9,112,220	16,046,594	5,682,635
Shares issued during financial year	6,591,869	3,239,441	15,374,552	1
Shares redeemed during financial year	(791,869)	(900,630)	(5,634,590)	(177,747)
Shares in issue at 31 December 2021	5,964,902	11,451,031	25,786,556	5,504,889
Shares in issue at 31 December 2020	164,902	9,112,220	16,046,594	5,682,635

		31 December 2021			
North American Fund	Shares Number Class I EUR Distribution	Shares Number Class I Hedged EUR Distribution	Shares Number Class I Hedged GBP Distribution	Shares Number Class I Hedged CHF Distribution	
Shares in issue at 1 January 2021	10,580	1,609,896	922,476	148,941	
Shares issued during financial year	139,877	1,803,458	1,650,940	24,609	
Shares redeemed during financial year	(140,504)	(1,033,715)	(1,100,137)	(67,740)	
Shares in issue at 31 December 2021	9,953	2,379,639	1,473,279	105,810	
Shares in issue at 31 December 2020	10,580	1,609,896	922,476	148,941	

		31 Decembe	er 2021	2021			
North American Fund continued	Shares Number Class I GBP Distribution	Shares Number Class I USD Distribution	Shares Number Class R EUR Distribution	Shares Number Class R Hedged EUR Distribution			
Shares in issue at 1 January 2021	5,391,976	10,647,266	70,297	170,773			
Shares issued during financial year	560,418	2,894,258	104,224	81,275			
Shares redeemed during financial year	(1,837,419)	(2,792,497)	(17,740)	(57,963)			
Shares in issue at 31 December 2021	4,114,975	10,749,027	156,781	194,085			
Shares in issue at 31 December 2020	5,391,976	10,647,266	70,297	170,773			

31 December 2021 Shares Shares Shares Shares Number Number Number Number Class R GBP Class R GBP **Class R USD Class S EUR** North American Fund continued Distribution Distribution Distribution Distribution Shares in issue at 1 January 2021 20,500 38,982 47,750 1,391,788 Shares issued during financial year 3,106 736 5,321 422,335 Shares redeemed during financial year (2,718) (4,276) (231,076) (2,038) Shares in issue at 31 December 2021 48,795 20,888 1,583,047 37,680 Shares in issue at 31 December 2020 47,750 20,500 1,391,788 38,982

		31 December 2021				
North American Fund continued	Shares Number Class S Hedged EUR Distribution	Shares Number Class S Hedged GBP Distribution	Shares Number Class S GBP Distribution	Shares Number Class S USD Distribution		
Shares in issue at 1 January 2021	195,250	796,893	8,543,177	3,024,799		
Shares issued during financial year	188	13,068	727,753	190,862		
Shares redeemed during financial year	(174,026)	(193,908)	(2,022,706)	(151,741)		
Shares in issue at 31 December 2021	21,412	616,053	7,248,224	3,063,920		
Shares in issue at 31 December 2020	195,250	796,893	8,543,177	3,024,799		

		31 December 2021				
Smart Energy Fund*	Shares Number Class I CHF Accumulation	Shares Number Class I EUR Accumulation	Shares Number Class I GBP Accumulation	Shares Number Class I SEK Accumulation		
Shares in issue at 1 January 2021	_	_	_	_		
Shares issued during financial year	107	560,105	108,413	11		
Shares redeemed during financial year	_	_	(2)	_		
Shares in issue at 31 December 2021	107	560,105	108,411	11		
Shares in issue at 31 December 2020	-	-	-	_		

		31 December 2021			
Smart Energy Fund* continued	Shares Number Class I USD Accumulation	Shares Number Class R CHF Accumulation	Shares Number Class R EUR Accumulation	Shares Number Class R GBP Accumulation	
Shares in issue at 1 January 2021	_	_	_	_	
Shares issued during financial year	1,550,391	307	63,704	135	
Shares redeemed during financial year	(44,848)	_	_	_	
Shares in issue at 31 December 2021	1,505,543	307	63,704	135	
Shares in issue at 31 December 2020	_	-	-	-	

\* Smart Energy Fund launched on 30 September 2021.

### 9. Shareholders' Funds continued

Movement in redeemable participating shares in issue during the financial year continued

	31 Decemb	er 2021
Smart Energy Fund* continued	Shares Number Class R SEK Accumulation	Shares Number Class R USD Accumulation
Shares in issue at 1 January 2021	-	_
Shares issued during financial year	11	361,693
Shares redeemed during financial year	_	(410)
Shares in issue at 31 December 2021	11	361,283
Shares in issue at 31 December 2020	-	_

	31 December 2021			
Smart Mobility Fund*	Shares Number Class I CHF Accumulation	Shares Number Class I EUR Accumulation	Shares Number Class I GBP Accumulation	Shares Number Class I SEK Accumulation
Shares in issue at 1 January 2021	-	_	_	_
Shares issued during financial year	107	151,516	41,848	11
Shares redeemed during financial year	_	_	_	_
Shares in issue at 31 December 2021	107	151,516	41,848	11
Shares in issue at 31 December 2020	-	-	_	-

		31 December 2021			
Smart Mobility Fund* continued	Shares Number Class I USD Accumulation	Shares Number Class R CHF Accumulation	Shares Number Class R EUR Accumulation	Shares Number Class R GBP Accumulation	
Shares in issue at 1 January 2021	_	_	_	-	
Shares issued during financial year	501,800	107	1,904	135	
Shares redeemed during financial year	_	_	_	_	
Shares in issue at 31 December 2021	501,800	107	1,904	135	
Shares in issue at 31 December 2020	_	-	_	-	

\* Smart Energy Fund and Smart Mobility Fund launched on 30 September 2021.

	31 Decemb	er 2021
Smart Mobility Fund* continued	Shares Number Class R SEK Accumulation	Shares Number Class R USD Accumulation
Shares in issue at 1 January 2021	_	_
Shares issued during financial year	11	100
Shares redeemed during financial year	-	_
Shares in issue at 31 December 2021	11	100
Shares in issue at 31 December 2020		_

	31 December 2021			
UK Value Opportunities Fund continued	Shares Number Class I GBP Accumulation	Shares Number Class I GBP Distribution	Shares Number Class R GBP Accumulation	Shares Number Class S GBP Accumulation
Shares in issue at 1 January 2021	13,925,084	7,058,208	271,055	14,835,024
Shares issued during financial year	5,581,606	7,229,116	56,871	8,656,594
Shares redeemed during financial year	(9,914,395)	(2,323,510)	(157,372)	(6,941,479)
Shares in issue at 31 December 2021	9,592,295	11,963,814	170,554	16,550,139
Shares in issue at 31 December 2020	13,925,084	7,058,208	271,055	14,835,024

	31 December 2021				
UK Value Opportunities Fund continued	Shares Number Class S GBP Distribution	Shares Number Class Z GBP Accumulation	Shares Number Class Z GBP Distribution		
Shares in issue at 1 January 2021	50,376,830	12,058,964	_		
Shares issued during financial year	32,766,824	_	_		
Shares redeemed during financial year	(10,328,932)	(7,932,114)	_		
Shares in issue at 31 December 2021	72,814,722	4,126,850	-		
Shares in issue at 31 December 2020	50,376,830	12,058,964	_		

\* Smart Mobility Fund launched on 30 September 2021.

### **10. Financial Risk Management**

In accordance with its investment objectives and policies, the Company holds financial instruments, which at any one time may comprise securities, cash and derivatives, held in accordance with the investment objective and polices of each Fund.

A review of the portfolio activity for the financial year is available in the Investment Manager's Reports and a detailed analysis of the investments is shown in the Portfolio Statements. Investments listed on the Portfolio Statements are stated at fair value as described in Note 2.

#### **Risks**

The following summary is not intended to be a comprehensive summary of all the risks inherent in investing in the Company and investors should refer to the prospectus for a more detailed discussion of these risks.

#### **Strategy in using Financial Instruments**

The Funds are exposed to a variety of financial risks in pursuing their stated investment objectives and policies. These risks are defined for financial reporting purposes by IFRS as credit risk, liquidity risk and market risk (which in turn includes currency risk, interest rate risk and price risk). The Funds take exposure to certain of these risks to generate investment returns on their portfolios, although these risks can also potentially result in a reduction in the Funds' assets. The Investment Manager will use its best endeavours to minimise the potentially adverse effects of these risks on the Funds' performance where it can do so while still managing the investments of the Funds in ways that are consistent with each Fund's investment objectives and policies.

The risks, and the measures adopted by the Company for managing these risks, are detailed below.

### Market price risk

Market price risk is the risk that the fair value of a financial instrument or its future cash flows will fluctuate because of changes in market prices.

The assets of the Funds consist principally of equities, equity related securities, fixed income securities, contracts for difference ('CFDs') and currency derivatives used for hedging purposes. Credit default swaps, interest rate futures and options are also used by certain Funds from time to time.

The values of these instruments are determined by market forces and there is accordingly a risk that market prices can change in a way that is adverse to a Fund's performance.

The Directors have adopted a number of investment restrictions which are set out in the individual Fund supplements to the Company's prospectus and which limit the exposure of the Funds to adverse changes in the price of any individual financial asset. In accordance with Company policy, the Investment Manager monitors the Funds' positions on a daily basis and reports regularly to the Board of Directors. The Board reviews the information on each Fund's overall market exposure provided by the Investment Manager at its periodic meetings.

In addition, the Investment Manager manages the exposure of the portfolios to the risk of adverse changes in the general level of market prices to the extent consistent, in the judgement of the Investment Manager, with each Fund's respective investment objective.

#### **Use of Derivatives and Efficient Portfolio Management**

Depending on the Funds involved, the Company may invest in financial derivative instruments for both speculative and efficient portfolio management purposes, subject to the conditions and within the limits from time to time stipulated by the Central Bank under the UCITS Regulations. A number of the Funds use currency forwards to hedge share class exposures.

Apart from the Global Absolute Return Fund and Global Convertible Fund, and before it was fully redeemed on 5 May 2020, the UK Absolute Equity Fund, the Investment Manager has generally only used financial derivative instruments in the Funds for the purpose of efficient portfolio management and efficient access to markets during the financial year. This includes contracts for difference, option contracts, forward foreign currency contracts and futures contracts. Risks arising from the use of financial derivative instruments at the financial year end are consistent with those set out in the Prospectus.

Open financial derivative instrument contracts at the financial year end are disclosed in the Portfolio Statements, including the relevant counterparty, the underlying securities, currencies or indices, and the market value or unrealised gain/loss on the contract at the financial year end.

At 31 December 2021, market price risks applying to each Fund are affected by two main components: changes in market prices and currency exchange rates.

NAV % Increase/ US\$/share NAV US\$/share (decrease) As at 31 December 2021 31 December 2021 price levels after price impact Asian Opportunities Fund Class I US Dollar Distribution US\$ 0.00 10 Asian Opportunities Fund Class I US Dollar Distribution US\$ 0.00 (10)Asian Stars I USD Accumulation US\$ 18 79 10 20.66 Asian Stars I USD Accumulation US\$ 18.79 16.92 (10)US\$ Automation & AI – I USD Accumulation 20.80 10 22.84 Automation & AI – I USD Accumulation US\$ 20.80 (10)18.76 Biotechnology Fund Class I US Dollar Distribution US\$ 41.11 10 45.22 Biotechnology Fund Class I US Dollar Distribution US\$ 41.11 (10)37.00 China Stars I USD Accumulation US\$ 13 96 15 29 10 China Stars I USD Accumulation US\$ 13.96 (10)12.63 Emerging Markets Income Fund Class I US Dollar Accumulation US\$ 0.00 10 Emerging Markets Income Fund Class I US Dollar Accumulation US\$ 0.00 (10) Emerging Markets Stars I USD Accumulation US\$ 15.05 10 16.53 Emerging Markets Stars I USD Accumulation US\$ 15.05 (10)13.57 Financial Opportunities Fund Class I US Dollar Accumulation US\$ 17.59 10 19.24 Financial Opportunities Fund Class I US Dollar Accumulation US\$ 17.59 (10)15.94 Global Absolute Return I USD Accumulation US\$ 130.79 10 133.51 Global Absolute Return I USD Accumulation US\$ 130.79 (10)128.54 Global Convertible Fund Class I US Dollar Accumulation US\$ 16.10 10 16.78 Global Convertible Fund Class I US Dollar Accumulation US\$ 16.10 (10)15.49 Global Technology Fund Class I US Dollar Distribution US\$ 96 45 10 106 15 Global Technology Fund Class I US Dollar Distribution US\$ 96.45 87.41 (10)Healthcare Blue Chip Fund Class I US Dollar Accumulation US\$ 19.62 10 21.50 Healthcare Blue Chip Fund Class I US Dollar Accumulation US\$ 19.62 (10)17.74 Healthcare Discovery Fund Class I US Dollar Accumulation US\$ 11.42 10 12.51 Healthcare Discovery Fund Class I US Dollar Accumulation US\$ 10.33 11 42 (10)Healthcare Opportunities Fund Class I US Dollar Distribution US\$ 77.19 70 39 10 Healthcare Opportunities Fund Class I US Dollar Distribution US\$ 70.39 63.59 (10)North American Fund Class I US Dollar Distribution US\$ 38.79 10 42.58 North American Fund Class I US Dollar Distribution US\$ 38.79 (10)35.00 Smart Energy Fund Class I US Dollar Accumulation US\$ 10.64 10 11.70 Smart Energy Fund Class I US Dollar Accumulation US\$ 10.64 9.58 (10)Smart Mobility Fund Class I US Dollar Accumulation US\$ 10 57 11 62 10 Smart Mobility Fund Class I US Dollar Accumulation US\$ 10.57 9.52 (10)

The following tables show the sensitivity of each Fund (for a representative share class) to changes in market prices based on a 10% price stress test on the portfolio as at 31 December 2021 and 31 December 2020.

## 10. Financial Risk Management continued

Market price risk continued

As at 31 December 2021		NAV €/share 31 December 2021	% Increase/ (decrease) price levels	NAV €/share after price impact
European Ex UK Income Fund Class I Euro Accumulation	EUR	13.66	10	15.01
European Ex UK Income Fund Class I Euro Accumulation	EUR	13.66	(10)	12.31

As at 31 December 2021		NAV £/share 31 December 2021	% Increase/ (decrease) price levels	NAV £/share after price impact
Global Insurance Fund Class I Sterling Accumulation	GBP	8.27	10	9.10
Global Insurance Fund Class I Sterling Accumulation	GBP	8.27	(10)	7.44
Income Opportunities Fund B2 Sterling Accumulation	GBP	2.85	10	3.03
Income Opportunities Fund B2 Sterling Accumulation	GBP	2.85	(10)	2.67
UK Value Opportunities Fund Class I Sterling Accumulation	GBP	14.64	10	16.07
UK Value Opportunities Fund Class I Sterling Accumulation	GBP	14.64	(10)	13.21

As at 30 December 2021		NAV ¥/share 31 December 2021	% Increase/ (decrease) price levels	NAV ¥/share after price impact
Japan Value Fund Class S Japanese Yen Distribution	JPY¥	275.45	10	302.90
Japan Value Fund Class S Japanese Yen Distribution	JPY¥	275.45	(10)	247.99

As at 31 December 2020		NAV US\$/share 31 December 2020	% Increase/ (decrease) price levels	NAV US\$/share after price impact
Asian Opportunities Fund Class I US Dollar	US\$	16.04	10	17.60
Asian Opportunities Fund Class I US Dollar	US\$	16.04	(10)	14.48
Biotechnology Fund Class I US Dollar	US\$	39.27	10	42.88
Biotechnology Fund Class I US Dollar	US\$	39.27	(10)	35.66
Emerging Markets Income Fund Class I US Dollar Accumulation	US\$	13.33	10	14.64
Emerging Markets Income Fund Class I US Dollar Accumulation	US\$	13.33	(10)	12.02
Financial Opportunities Fund Class I US Dollar Accumulation	US\$	14.70	10	16.11
Financial Opportunities Fund Class I US Dollar Accumulation	US\$	14.70	(10)	13.29
Global Convertible Fund Class I US Dollar Accumulation	US\$	17.41	10	18.26
Global Convertible Fund Class I US Dollar Accumulation	US\$	17.41	(10)	16.61
Global Technology Fund Class I US Dollar	US\$	87.61	10	96.45
Global Technology Fund Class I US Dollar	US\$	87.61	(10)	79.62
Healthcare Blue Chip Fund Class I US Dollar Accumulation	US\$	16.04	10	17.54
Healthcare Blue Chip Fund Class I US Dollar Accumulation	US\$	16.04	(10)	14.54
Healthcare Opportunities Fund Class I US Dollar	US\$	64.58	10	70.96
Healthcare Opportunities Fund Class I US Dollar	US\$	64.58	(10)	58.20
North American Fund Class I US Dollar	US\$	31.39	10	34.45

As at 31 December 2020		NAV US\$/share 31 December 2020	% Increase/ (decrease) price levels	NAV US\$/share after price impact
North American Fund Class I US Dollar	US\$	31.39	(10)	28.33
Automation & AI Fund – I USD Acc	US\$	17.84	10	19.55
Automation & AI Fund – I USD Acc	US\$	17.84	(10)	16.13
Emerging Markets Stars Fund I USD Acc	US\$	15.13	10	16.59
Emerging Markets Stars Fund I USD Acc	US\$	15.13	(10)	13.67
China Stars Fund I USD Acc	US\$	16.49	10	18.04
China Stars Fund I USD Acc	US\$	16.49	(10)	14.94
Asian Stars Fund I USD Acc	US\$	18.12	10	19.90
Asian Stars Fund I USD Acc	US\$	18.12	(10)	16.34
Global Absolute Return Fund I USD Acc	US\$	125.46	10	138.00
Global Absolute Return Fund I USD Acc	US\$	125.46	(10)	112.91
Healthcare Discovery Fund I USD Acc	US\$	11.01	10	12.11
Healthcare Discovery Fund I USD Acc	US\$	11.01	(10)	9.91

As at 31 December 2020		NAV €/share 31 December 2020	% Increase/ (decrease) price levels	NAV €/share after price impact
European ex UK Income Fund Class I Euro Accumulation	EUR	11.50	10	12.64
European ex UK Income Fund Class I Euro Accumulation	EUR	11.50	(10)	10.36

As at 31 December 2020	31 D	NAV £/share ecember 2020	% Increase/ (decrease) price levels	NAV £/share after price impact
Global Insurance Fund Class I Sterling Accumulation	GBP	9.72	10	10.67
Global Insurance Fund Class I Sterling Accumulation	GBP	9.72	(10)	8.78
Income Opportunities Fund B2 Sterling Accumulation	GBP	2.33	10	2.49
Income Opportunities Fund B2 Sterling Accumulation	GBP	2.33	(10)	2.15
UK Absolute Equity Fund Class I Sterling	GBP	_	10	_
UK Absolute Equity Fund Class I Sterling	GBP	_	(10)	_
UK Value Opportunities Fund Class I Accumulation	GBP	12.19	10	13.38
UK Value Opportunities Fund Class I Accumulation	GBP	12.19	(10)	11.00

As at 31 December 2020	31	NAV ¥/share December 2020	% Increase/ (decrease) price levels	NAV ¥/share after price impact
Japan Value Fund Class I Japanese Yen	JPY	239.03	10	260.80
Japan Value Fund Class I Japanese Yen	JPY	239.03	(10)	215.13

Sensitivity analysis is calculated after an adjustment for swing pricing.

### 10. Financial Risk Management continued

### Market price risk continued

Market price risk analysis is based on the dealing NAV per share.

Some limitations of sensitivity analysis are:

- (i) the models are based on historical data and cannot take account of the fact that future market price movements, correlations between markets and levels of market liquidity in conditions of market stress may bear no relation to historical patterns;
- (ii) the market price risk information is a relative estimate of risk rather than a precise and accurate number
- (iii) the market price information represents a hypothetical outcome and is not intended to be predictive; and

(iv) future market conditions could vary significantly from those experienced in the past.

#### **Exposure to derivatives**

In respect of Global Absolute Return Fund and, until it was fully redeemed, the UK Absolute Equity Fund, the Investment Manager uses a Value at Risk ('VaR') based approach to limit the exposure of the Fund to derivatives. In accordance with the UCITS Regulations, derivatives exposure is limited to the extent necessary to keep the Fund's VaR within the limit set out below. VaR is measured using a 99% confidence level.

### **Global Absolute Return Fund**

The VaR limit for the Global Absolute Return Fund is 20% based on a 20-day holding period. The minimum VaR during the financial year was 1.56%.

The maximum VaR during the financial year was 6.88%. The average VaR during the financial year was 2.69%.

The VaR calculated for Global Absolute Return Fund is a 20d Monte Carlo VaR, with a confidence level 99% and using five-year return history with a decay factor of 0.97. The VaR is calculated in Axioma.

Secondly, gross leverage, calculated as the sum of the absolute notional values of the derivatives used in the Global Absolute Return Fund, is not anticipated to exceed 250% of Net Asset Value of the Fund at any given time.

All of the other Funds active during the financial year use the commitment approach to measure derivatives exposure.

#### **Currency risk**

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. Each Fund is exposed to currency risk as the assets and liabilities of each Fund may be denominated in a currency other than the base currency of that Fund.

The fluctuations in the rate of exchange between the currency in which the asset or liability is denominated and the functional currency could result in an appreciation or depreciation in the fair value of that asset when measured in the Fund's base currency. The Investment Manager may attempt to mitigate these risks through the use of financial derivative instruments.

The Investment Manager monitors each Fund's currency exposure, where relevant to the investment strategy for the Fund, on a daily basis and reports regularly to the Board of Directors.

At 31 December 2021 each Fund's currency exposure was as follows:

Asian Opportunities Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Euro	-	_	(33)	_	(33)
Sterling	_	-	227	_	227
	-	-	194	_	194

Asian Stars Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Australian dollar	2,889,828	_	-	_	2,889,828
China Yuan	5,992,512	_	_	_	5,992,512
Euro	-	(50)	(86)	_	(136)
Hong Kong dollar	41,139,932	_	_	(84,771)	41,055,161
Indian rupee	32,507,809	_	80,254	_	32,588,063
Japanese yen	2,705,189	_	-	_	2,705,189
Korean won	33,942,218	_	_	_	33,942,218
Singapore dollar	-	_	8	_	8
Sterling	-	(1)	(741)	_	(742)
Taiwan dollar	32,681,035	_	_	-	32,681,035
Vietnamese dong	5,398,859	-	592,176	_	5,991,035
	151,858,523	(51)	671,611	(84,771)	157,844,171

Automation & Artificial Intelligence Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US <b>\$</b>	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Euro	74,264,021	(17)	(19,613)	_	74,244,391
Hong Kong dollar	15,576,145	_	_	_	15,576,145
Japanese yen	128,357,123	(5,296)	(6,149,875)	_	122,201,952
Korean won	8,667,737	_	_	_	8,667,737
Sterling	22,438,363	_	396,340	-	22,834,703
Swedish krona	43,676,459	_	_	_	43,676,459
Swiss franc	7,394,559	_	_	2,190	7,396,749
Taiwan dollar	50,541,644	-	_	-	50,541,644
	350,916,051	(5,313)	(5,773,148)	2,190	345,139,780

# 10. Financial Risk Management continued

Biotechnology Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Danish krone	93,052,635	(398)	_	_	93,052,237
Euro	216,700,492	(10,446)	(1,116,427)	9,444	215,583,063
Sterling	210,353,497	-	(757,461)	153,066,756	362,662,792
Swedish krona	9,344,091	_	_	_	9,344,091
Swiss franc	_	_	_	4,781	4,781
	529,450,715	(10,844)		153,080,981	680,646,964

China Stars Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US <b>\$</b>	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
China Yuan	4,768,799	_	269,778	-	5,038,577
Euro	326,780	(151)	(175,400)	-	151,229
Hong Kong dollar	9,822,971	(4,206)	_	4,206	9,822,971
Sterling	-	_	33,017	-	33,017
Swiss franc	-	_	_	44	44
Taiwan dollar	761,606	_	243,721	_	1,005,327
Vietnamese dong	-	-	122,861	-	122,861
	15,680,156	(4,357)	493,977	4,250	16,174,026

Emerging Markets Income Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Brazil real	-	_	(35,649)	-	(35,649)
Euro	_	_	2,163	_	2,163
Kuwait dinar	-	_	1	_	1
Malaysian ringgit	-	_	672	-	672
Sterling	-	_	6,143	-	6,143
	-	_	(26,670)	-	(26,670)

Emerging Markets Stars Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Australian dollar	_	_	4	_	4
Brazil real	11,581,637	(15,532)	8,607	_	11,574,712
Canadian dollar	39,395,839	_	_	_	39,395,839
China Yuan	32,147,814	_	_	_	32,147,814
Euro	_	(6)	(643)	_	(649)
Hong Kong dollar	282,840,188	_	616,830	(617,295)	282,839,723
Indian rupee	238,706,970	_	5,685	_	238,712,655
Korean won	241,244,389	_	174	_	241,244,563
Mexican peso	_	_	172	_	172
Polish zloty	_	_	(207)	_	(207)
Sri Lanka rupee	_	_	20,582	_	20,582
South African rand	_	(2)	(458)	_	(460)
Sterling	_	(56)	176,295	(87,936)	88,303
Swedish krona	_	(9)	(3,147)	_	(3,156)
Swiss franc	_	_	_	3,680	3,680
Taiwan dollar	234,072,890	_	20,816	_	234,093,706
Vietnamese dong	36,024,865	_	3,618,398	-	39,643,263
	1,116,014,592	(15,605)	4,463,108	(701,551)	1,119,760,544

European ex UK Income Fund	Non-EUR Currency Assets EUR	Non-EUR Currency Liabilities EUR	Non-EUR Cash Balance EUR	Forward Foreign Currency Contracts EUR	Net Non-EUR Currency Assets EUR
Danish kroner	3,401,857	_	_	_	3,401,857
Sterling	_	(136)	(4,429,470)	5,456,203	1,026,597
Swedish krona	7,182,346	_	_	_	7,182,346
Swiss franc	23,235,721	_	_	(1,679,816)	21,555,905
United States dollar	_	_	1,991	_	1,991
	33,819,924	(136)	(4,427,479)	3,776,387	33,168,696

# 10. Financial Risk Management continued

Financial Opportunities Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Australian dollar	214,447	_	-	-	214,447
Brazil real	_	_	8	_	8
Canadian dollar	657,666	_	_	-	657,666
Euro	2,058,156	(18)	12,771	-	2,070,909
Hong Kong dollar	753,894	_	_	-	753,894
Indian rupee	681,576	_	30,179	-	711,755
Indonesian rupiah	643,667	_	_	-	643,667
Japanese yen	482,795	_	_	-	482,795
Korean won	241,150	_	_	_	241,150
Mexican peso	194,996	-	_	-	194,996
Singapore dollar	253,681	_	182	_	253,863
Sterling	2,461,168	(97)	(63,576)	_	2,397,495
Swedish krona	628,678	_	_	_	628,678
Swiss franc	549,898	(45)	29,713	63	579,629
Taiwan dollar	211,090	_	85,506	_	296,596
Thai baht	536,269	_	-	_	536,269
Vietnamese Dong	251,356	_	3,003	_	254,359
	10,820,487	(160)	97,786	63	10,918,176

Global Absolute Return Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Australian dollar	-	(23)	92,152	_	92,129
Euro	10,499,218	(4,710,684)	(2,730,107)	2,560,729	5,619,156
Hong Kong dollar	1,494,299	(1,526)	(1,025,095)	-	467,678
Japanese yen	2,246,320	(4)	(1,592,353)	_	653,963
Sterling	7,548,037	(4,282,693)	2,812,242	38,784,430	44,862,016
Swedish krona	-	_	(1,143)	-	(1,143)
Swiss franc	2,092,955	_	(1,720,077)	_	372,878
	23,880,829	(8,994,930)	(4,164,381)	41,345,159	52,066,677

Global Convertible Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US <b>\$</b>	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Australian dollar	-	_	(29,960)	_	(29,960)
Canadian dollar	_	_	(39,832)	_	(39,832)
Euro	185,052,482	(73,163,749)	(93,800,741)	(29,815,015)	(11,727,023)
Hong Kong dollar	16,220,563	_	(51,828)	_	16,168,735
Israel shekel	1,482,606	-	_	_	1,482,606
Japanese yen	45,046,894	(11,526,204)	(17,787,675)	(11,919,549)	3,813,466
Singapore dollar	_	-	(62,991)	_	(62,991)
South African rand	_	_	(1,436)	_	(1,436)
Sterling	58,112,836	(29,165,352)	(4,491,852)	275,311,335	299,766,967
Swiss franc	42,906,135	_	1,809,657	1,069,586	45,785,378
	348,821,516	(228,311,963)	(114,456,658)	234,646,357	355,155,910

Global Insurance Fund	Non-GBP Currency Assets GBP	Non-GBP Currency Liabilities GBP	Non-GBP Cash Balance GBP	Forward Foreign Currency Contracts GBP	Net Non-GBP Currency Assets GBP
Canadian dollar	150,331,595	_	-	_	150,331,595
Euro	23,712,449	(40)	61,533	11,822,290	35,596,232
Hong Kong dollar	34,090,743	_	_	_	34,090,743
Swiss franc	_	_	_	4,728	4,728
United States dollar	1,294,092,004	_	(9,113,956)	(1,014,109)	1,283,963,939
	1,502,226,791	(40)	(9,052,423)	10,812,909	1,503,987,237

Global Technology Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Euro	345,123,064	(1,854)	(937,293)	471,073,458	815,257,375
Hong Kong dollar	173,550,138	_	_	_	173,550,138
Indian rupee	_	_	3,260	_	3,260
Japanese yen	297,320,942	(1)	1,837	_	297,322,778
Korean won	218,476,136	_	_	_	218,476,136
Sterling	_	(1,181)	(459,715)	255,411,134	254,951,238
Swiss franc	-	(4)	(23,958)	160,906,586	160,882,624
Taiwan dollar	425,727,355	_	_	_	425,727,355
	1,460,197,635	(3,040)	(1,414,869)	887,391,178	2,346,170,904

# 10. Financial Risk Management continued

Healthcare Blue Chip Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Euro	2,625,560	_	-	-	2,625,560
Japanese yen	2,757,373	_	_	_	2,757,373
Swedish Kronor	10,331,592	(53)	201	-	10,331,740
Sterling	5,502,479	(2)	136,759	2,391	5,641,627
Swiss franc	3,067,007	_	_	(1,243,479)	1,823,528
	24,284,011	(55)	136,960	(1,241,088)	23,179,828

Healthcare Discovery Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Danish krone	2,223,265	-	-	-	2,223,265
Euro	6,628,302	-	26	_	6,628,328
Hungary Forint	1,542,589	-	_	_	1,542,589
Indian Rupee	1,749,054	-	401	_	1,749,455
Japanese yen	2,095,292	_	_	_	2,095,292
Sterling	1,407,557	(10)	_	_	1,407,547
Swiss franc	-	_	_	198	198
	15,646,059	(10)	427	198	15,646,674

Healthcare Opportunities Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Danish krone	116,666,111	_	_	_	116,666,111
Euro	157,589,654	(89)	(52,623)	4,179,962	161,716,904
Hungary Forint	36,064,815	_	_	_	36,064,815
Indian rupee	100,195,539	_	25,637,061	_	125,832,600
Japanese yen	68,244,649	-	409	_	68,245,058
Sterling	114,501,038	(1,309)	(35,217)	_	114,464,512
Swiss franc	54,684,591	(3)	1,695	5,577	54,691,860
	647,946,397	(1,401)	25,551,325	4,185,539	677,681,860

Income Opportunities Fund	Non-GBP Currency Assets GBP	Non-GBP Currency Liabilities GBP	Non-GBP Cash Balance GBP	Forward Foreign Currency Contracts GBP	Net Non-GBP Currency Assets GBP
Canadian dollar	1,133,690	_	-	_	1,133,690
Euro	7,871,341	(401,435)	823,248	1,823,080	10,116,234
Hong Kong dollar	584,079	-	-	_	584,079
Norwegian krone	563,994	_	_	_	563,994
Singapore dollar	873,246	_	_	-	873,246
Swedish krona	2,044,056	_	_	_	2,044,056
United States dollar	1,433,005	_	_	-	1,433,005
Swiss franc	798,310	_	_	165	798,475
Thai baht	860,375	_	_	-	860,375
Sterling	15,773,490	(16,418)	(115,525)	16,610,535	32,252,082
	31,935,586	(417,853)		18,433,780	50,659,236

Japan Value Fund	Non-JPY Currency Assets JPY	Non-JPY Currency Liabilities JPY	Non-JPY Cash Balance JPY	Forward Foreign Currency Contracts JPY	Net Non-JPY Currency Assets JPY
Euro	_	(1,125)	(1,656,786)	1,149,799,136	1,148,141,225
Sterling	-	(6,255)	(6,202,712)	2,203,047,416	2,196,838,449
Swiss franc	_	_	_	563,984,185	563,984,185
United States dollar	_	(19,320)	(23,170,781)	4,897,343,752	4,874,153,651
	_	(26,700)	(31,030,279)	8,814,174,489	8,783,117,510

North American Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Canadian dollar	64,138,477	_	_	_	64,138,477
Euro	-	(652)	(2,013,830)	98,050,906	96,036,424
Hong Kong Dollar	14,620,554	_	_	_	14,620,554
Mexican peso	11,719,029	_	_	_	11,719,029
Sterling	-	(28)	138,161	97,475,132	97,613,265
Swiss franc	_	(5)	(22,007)	2,121,591	2,099,579
	90,478,060	(685)	(1,897,676)	197,647,629	286,227,328

# 10. Financial Risk Management continued

Smart Energy Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US <b>\$</b>	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US <b>\$</b>
Canadian dollar	182,377	_	_	_	182,377
Danish kroner	153,052	-	_	-	153,052
Euro	6,844,551	(552,674)	(84,575)	636,980	6,844,282
Japanese yen	3,322,948	(172,454)	-	172,454	3,322,948
Norwegian krone	788,905	(257,641)	_	257,641	788,905
Sterling	160,096	(2)	(1)	_	160,093
Swedish krona	347,394	(60,550)	_	60,550	347,394
Swiss franc	593,094	(49,804)	_	49,804	593,094
Taiwan dollar	730,292	(46,690)	_	_	683,602
	13,122,709	(1,139,815)	(84,576)	1,177,429	13,075,747

Smart Mobility Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-US\$ Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Euro	1,615,559	(1)	_	_	1,615,558
Hong Kong dollar	102,587	-	_	_	102,587
Japanese yen	1,215,011	(49,180)	_	49,180	1,215,011
Korean won	188,654	_	_	_	188,654
Norwegian krone	51,745	_	_	_	51,745
Sterling	53,366	(11)	_	_	53,355
Swiss franc	398,211	_	_	_	398,211
Taiwan dollar	300,752	_	_	_	300,752
	3,925,885	(49,192)	_	49,180	3,925,873

UK Absolute Equity Fund	Non-GBP Currency Assets GBP	Non-GBP Currency Liabilities GBP	Non-GBP Cash Balance GBP	Forward Foreign Currency Contracts GBP	Net Non-GBP Currency Assets GBP
Euro	_	(3)	(6,392)	_	(6,395)
Swiss franc	_	_	(27)	_	(27)
United States dollar	_	(1)	(2,093)	_	(2,094)
	-	(4)	(8,512)	_	(8,516)

UK Value Opportunities Fund	Non-GBP Currency Assets GBP	Non-GBP Currency Liabilities GBP	Non-GBP Cash Balance GBP	Forward Foreign Currency Contracts GBP	Net Non-GBP Currency Assets GBP
Euro	-	(1)	1,251	_	1,250
United States dollar	_	(42)	(49,725)	_	(49,767)
	_	(43)	(48,474)	_	(48,517)

At 31 December 2020 each Fund's currency exposure was as follows:

Asian Opportunities Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US <b>\$</b>
Australian dollar	78,892	_	_	_	78,892
Euro	_	_	(265)	112,627	112,361
Hong Kong dollar	2,557,902	_	140	_	2,558,042
Indian rupee	1,371,525	_	855	_	1,372,380
Indonesian rupiah	624,341	_	_	_	624,341
Korean won	616,439	_	_	_	616,439
Malaysian ringgit	117,275	_	_	_	117,275
Pakistan rupee	70,787	_	_	_	70,787
Philippine peso	410,310	_	_	_	410,310
Singapore dollar	298,345	_	105,476	_	403,821
Sri Lanka rupee	-	_	15	_	15
Sterling	_	_	(692)	253,409	252,717
Taiwan dollar	834,064	_	_	_	834,064
Vietnamese dong	91,634	_	7,810	_	99,444
Thai baht	431,554	_	_	_	431,554
	7,503,068	_	113,339	366,036	7,982,443

Asian Stars Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
China Yuan	185,437	_	_	_	185,437
Euro	-	_	(121)	_	(121)
Hong Kong dollar	3,674,356	_	_	_	3,674,356
Indian rupee	2,460,765	_	79,029	_	2,539,794
Korean won	3,977,049	_	_	_	3,977,049
Singapore dollar	187,365	-	8	_	187,373
Sterling	-	(3)	(109)	_	(112)
Taiwan dollar	2,757,034	_	_	_	2,757,034
Vietnamese dong	669,785	_	65,858	_	735,643
	13,911,791	(3)	144,665	_	14,056,453

# 10. Financial Risk Management continued

Automation & Artificial Intelligence Fund	Non-USD Currency Assets GBP	Non-USD Currency Liabilities GBP	Non-GBP Cash Balance GBP	Forward Foreign Currency Contracts GBP	Net Non-USD Currency Assets GBP
Euro	76,981,156	(32)	18,196	(35,892)	76,963,428
Hong Kong dollar	13,129,374	_	_	_	13,129,374
Japanese yen	151,122,686	(1,188,483)	(18,748,290)	(4,398,920)	126,786,993
Korean won	10,916,633	_	_	_	10,916,633
Sterling	18,680,719	(195,055)	(2,528,953)	1,174,266	17,130,978
Swedish krona	23,971,765	_	_	_	23,971,765
Swiss franc	12,313,072	_	_	_	12,313,072
Taiwan dollar	50,428,695	_	_	_	50,428,695
	357,544,100	(1,383,570)	(21,259,047)	(3,260,546)	331,640,937

Biotechnology Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Danish krone	27,495,685	(813)	(1,040,123)	(200,044)	170,104,970
Euro	171,345,950	_	_	-	27,495,685
Sterling	77,044,076	(2,246,864)	(954,488)	12,009,355	85,852,079
Swedish krona	8,499,187	_	_	-	8,499,187
	284,384,898	(2,247,677)	(1,994,610)	11,809,311	291,951,922

China Stars Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US <b>\$</b>	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
China Yuan	3,258,926	(27,284)	_	27,284	3,258,926
Euro	263,748	(163)	(188,753)	_	74,832
Hong Kong dollar	6,177,671	(78,435)	_	47,421	6,146,657
Sterling	_	(22,221)	56,281	_	34,060
Taiwan dollar	672,610	(12,291)	239,982	_	900,301
	10,372,955	(140,394)	107,510	74,705	10,414,776

Emerging Markets Income Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Brazil real	1,871,091	_	20	_	1,871,111
Czech koruna	1,900,879	_	_	_	1,900,879
Euro	3,787,499	(1)	(966)	_	3,786,532
Hong Kong dollar	25,337,839	_	_	_	25,337,839
Indian rupee	8,973,937	_	_	_	8,973,937
Indonesian rupiah	3,093,416	_	_	-	3,093,416
Kuwait dinar	2,247,929	_	_	_	2,247,929
Korean won	21,981,228	_	_	_	21,981,228
Malaysian ringgit	_	_	696	_	696
Mexican peso	4,305,063	_	_	_	4,305,063
Polish zloty	868,492	_	_	_	868,492
Romanian leu	3,463,542	_	_	_	3,463,542
South Africa rand	3,132,928	_	_	_	3,132,928
Sterling	_	_	57,189	(391)	56,798
Taiwan dollar	10,507,884	_	2	_	10,507,886
Thai baht	1,601,650	_	_	_	1,601,650
UAE dirham	1,404,256	_	_	_	1,404,256
	94,477,633	(1)	56,941	(391)	94,534,182

Emerging Markets Stars Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Australian dollar	4		_	_	4
Brazil real	4,615,904	_	9,230	-	4,625,134
Canadian dollar	8,267,442	_	_	-	8,267,442
China Yuan	3,658,815	-	_	-	3,658,815
Euro	7,419,139	(31)	258,016	(258,552)	7,418,572
Hong Kong dollar	60,042,930	_	(468)	_	60,042,462
Indian rupee	47,883,548	_	4,637	_	47,888,185
Korean won	76,230,313	_	190	_	76,230,503
Mexican peso	-	-	177	-	177
Polish zloty	2,892,962	(1)	(223)	-	2,892,738
Singapore dollar	3,738,129	-	_	-	3,738,129
South Africa rand	_	(501)	_	-	(501)
Sri Lanka rupee	_	_	22,530	-	22,530
Sterling	-	(3)	83,156	5,749	88,902
Swiss franc	_	(992)	_	-	(992)
Taiwan dollar	51,631,036	_	20,489	_	51,651,525
Vietnamese dong	11,227,303	_	1,896,296	_	13,123,599
	277,607,525	(1,528)	2,294,030	(252,803)	279,647,224

## 10. Financial Risk Management continued

European ex UK Income Fund	Non-EUR Currency Assets EUR	Non-EUR Currency Liabilities EUR	Non-EUR Cash Balance EUR	Forward Foreign Currency Contracts EUR	Net Non–EUR Currency Assets EUR
Danish kroner	6,417,097	_	-	_	6,417,097
Sterling	_	(292)	(120,570)	35,996,473	35,875,611
Swedish krona	9,746,282	_	-	-	9,746,282
Swiss franc	34,478,226	_	-	(770,201)	33,708,024
United States dollar	_	_	1,851	_	1,851
	50,641,605	(292)	(118,719)	35,226,272	85,748,866

Financial Opportunities Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
British Sterling Pound	789,785	_	21,900	(7,108)	804,577
Brazil real	9	_	_	_	9
Canadian dollar	246,930	_	_	_	246,930
Euro	798,603	(2)	(1,758)	_	796,843
Hong Kong dollar	1,043,610	_	-	-	1,043,610
Indian rupee	738,526	_	_	_	738,526
Indonesian rupiah	409,139	_	_	_	409,139
Mexican peso	126,892	_	_	_	126,892
Norwegian krone	239,574	_	-	_	239,574
Philippine peso	130,299	_	-	-	130,299
Singapore dollar	_	_	185	_	185
Swedish krona	97,255	_	_	_	97,255
Swiss franc	157,393	(46)	30,628	_	187,975
Taiwan dollar	165,501	_	32,643	_	198,144
Thai baht	262,028	_	_	_	262,028
Vietnamese dong	119,556	_	5,531	_	125,087
	5,325,100	(48)	89,129	(7,108)	5,407,073

Global Absolute Return Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Australian dollar	896,317	(1,906)	(731,594)	_	162,817
Euro	9,000,926	(3,104,320)	1,329,488	4,184,311	11,410,405
Hong Kong dollar	329,997	(106,456)	_	_	223,541
Japanese yen	527,931	(4,542)	(801,455)	_	(278,066)
Sterling	_	(5)	290,136	34,823,375	35,113,506
Swedish krona	_	_	(1,253)	_	(1,253)
Swiss franc	1,190,887	(87,274)	(720,026)	_	383,587
	11,946,058	(3,304,503)	(634,704)	39,007,686	47,014,537

Global Convertible Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Euro	212,937,716	(74,072,554)	6,133,734	(23,615,792)	121,383,104
Hong Kong dollar	28,608,693	(81,732)	(4,333,004)	-	24,193,957
Israel shekel	1,437,169	_	(19,729,814)	(12,824,231)	(9,275,073)
Japanese yen	23,278,973	(469,588)	(25,550,771)	276,524,417	317,533,033
Singapore dollar	16,518,388	_	(572)	-	(572)
South African rand	-	(272,430)	1,506,289	9,891,339	34,895,630
Sterling	67,028,975	_	_	_	1,437,169
Swedish krona	_	_	_	-	16,518,388
Swiss franc	23,770,432	_	(1,498)	_	(1,498)
	373,580,345	(74,896,304)	(41,975,636)	249,975,733	506,684,138

Global Insurance Fund	Non-GBP Currency Assets GBP	Non-GBP Currency Liabilities GBP	Non-GBP Cash Balance GBP	Forward Foreign Currency Contracts GBP	Net Non-GBP Currency Assets GBP
Canadian dollar	126,141,590	_	_	_	126,141,590
Euro	21,815,119	(32)	(89,923)	12,879,832	34,604,996
Hong Kong dollar	442,484,635	_	_	_	42,484,635
United States dollar	1,145,777,322	(2,077,659)	4,395,689	3,519,687	1,151,615,039
	1,336,218,666	(2,077,691)	4,305,766	16,399,519	1,354,846,260

# 10. Financial Risk Management continued

Global Technology Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US <b>\$</b>	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Euro	463,562,244	(4,320)	2,944,773	553,550,322	1,020,053,019
Hong Kong dollar	268,546,645	_	6,761	_	268,553,406
Indian rupee	-	-	3,316	-	3,316
Japanese yen	506,497,456	_	2,049	_	506,499,505
Korean won	340,437,022	-	_	_	340,437,022
Sterling	66,505,595	(111)	4,862,335	230,305,972	301,673,791
Swiss franc	-	(72)	501,417	142,954,121	143,455,466
Swedish Kronor	44,470,532	_	_	_	44,470,532
Taiwan dollar	334,078,570	_	_	_	334,078,570
	1,336,218,666	(4,503)	8,320,651	926,810,415	2,959,224,627

Healthcare Blue Chip Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Euro	14,380,155	(20)	(2,866)	-	14,377,269
Japanese yen	3,426,980	_	_	(1,052,537)	2,374,443
Swedish Kronor	1,790,775	_	_	_	1,790,775
Sterling	3,646,304	(1,861)	(1,977,137)	(5,379)	1,661,927
Swiss franc	3,322,987	_	_	_	3,322,987
	26,567,201	(1,861)	(1,980,003)	(1,057,916)	23,527,401

Healthcare Discovery Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US\$	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Danish krone	1,116,867	_	_	_	1,116,867
Euro	2,694,448	_	26	-	2,694,474
Hungary Forint	802,958	_	_	_	802,958
Japanese yen	1,433,106	_	_	_	1,433,106
Swedish Kronor	1,847,609	_	_	_	1,847,609
Sterling	963,676	_	_	47	963,723
Swiss franc	261,080	_	_	_	261,080
	9,119,744	_	26	47	9,119,817

Healthcare Opportunities Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US <b>\$</b>	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Danish krone	78,904,060	-	-	_	78,904,060
Euro	113,018,019	(100)	160,098	2,898,815	116,076,832
Hungary Forint	35,621,260	-	_	_	35,621,260
Indian rupee	_	-	6,789	_	6,789
Japanese yen	73,438,345	-	457	-	73,438,802
Sterling	90,163,550	(388)	812,702	(857,130)	90,118,734
Swiss franc	116,863,838	(3)	1,747	_	116,865,582
	508,009,072	(491)	981,793	2,041,685	511,032,059

Income Opportunities Fund	Non-GBP Currency Assets GBP	Non-GBP Currency Liabilities GBP	Non-GBP Cash Balance GBP	Forward Foreign Currency Contracts GBP	Net Non-GBP Currency Assets GBP
Canadian dollar	848,465	_	_	_	848,465
Euro	9,527,047	_	20,879	3,124,459	12,672,385
Hong Kong dollar	557,782	_	_	_	557,782
Norwegian krone	1,225,863	_	_	_	1,225,863
Singapore dollar	779,573	_	_	_	779,573
Swedish krona	1,359,523	_	_	_	1,359,523
United States dollar	25,329,284	(16,126)	26,043	19,054,788	44,393,989
Swiss franc	877,213	_	_	_	877,213
Thai baht	1,428,114	_	_	_	1,428,114
	41,932,864	(16,126)	46,922	22,179,247	64,142,907

Japan Value Fund	Non-JPY Currency Assets JPY	Non-JPY Currency Liabilities JPY	Non-JPY Cash Balance JPY	Forward Foreign Currency Contracts JPY	Net Non-JPY Currency Assets JPY
Euro	-	(1,094)	(6,870,728)	1,352,276,961	1,345,405,139
Sterling	_	(26,080)	(13,625,485)	2,410,435,793	2,396,784,228
Swiss franc	-	_	4	495,854,405	495,854,409
United States dollar	_	(15,218)	(54,819,814)	4,439,966,055	4,385,131,023
	-	(42,392)	(75,316,023)	8,698,533,214	8,623,174,799

## 10. Financial Risk Management continued

Currency risk continued

North American Fund	Non-USD Currency Assets US\$	Non-USD Currency Liabilities US <b>\$</b>	Non-USD Cash Balance US\$	Forward Foreign Currency Contracts US\$	Net Non-USD Currency Assets US\$
Canadian dollar	20,916,488	_	-	_	20,916,488
Euro	-	(606)	(848,877)	65,244,940	64,395,457
Hong Kong Dollar	13,173,218	_	-	_	13,173,218
Sterling	-	_	492,619	67,629,225	68,121,844
Swiss franc	-	(5)	(22,684)	2,543,591	2,520,902
	34,089,706	(611)	(378,942)	135,417,756	169,127,909

UK Value Opportunities Fund	Non-GBP Currency Assets GBP	Non-GBP Currency Liabilities GBP	Non-GBP Cash Balance GBP	Forward Foreign Currency Contracts GBP	Net Non-GBP Currency Assets GBP
Euro	_	_	(761)	-	(761)
United States dollar	_	(40)	(38,018)	_	(38,058)
	_	(40)	(38,779)	-	(38,819)

If the exchange rate at 31 December 2021 between the individual Funds' base currencies and all other relevant currencies had increased or decreased by 5% with all other variables held constant, excluding the effect of the share class hedges, this would have decreased or increased net assets attributable to holders of redeemable participating shares of the Funds as set out below. This does not allow for currency exposure on the underlying share class.

As at 31 December 2021	Net Non-USD Currency Monetary Assets US\$	% Increase/(decrease) in exchange rate	Effect of increase/decrease US\$
Asian Opportunities Fund	194	5	+/- 10
Asian Stars Fund	157,844,171	5	+/- 7,892,209
Automation & Artificial Intelligence Fund	345,139,780	5	+/- 17,256,989
Biotechnology Fund	680,646,964	5	+/- 34,032,348
China Stars Fund	16,174,026	5	+/- 808,701
Emerging Markets Income Fund	(26,670)	5	+/- 1,334
Emerging Markets Stars Fund	1,119,760,544	5	+/- 55,988,027
Financial Opportunities Fund	10,918,176	5	+/- 545,909
Global Absolute Return Fund	52,066,677	5	+/- 2,603,334
Global Convertible Fund	355,155,910	5	+/- 17,757,796
Global Technology Fund	2,346,170,904	5	+/- 117,308,545
Healthcare Blue Chip Fund	23,179,828	5	+/- 1,158,991
Healthcare Discovery Fund	15,646,674	5	+/- 782,334
Healthcare Opportunities Fund	511,032,060	5	+/- 25,551,603
North American Fund	286,227,328	5	+/- 14,311,366
Smart Energy Fund	13,075,747	5	+/- 653,787
Smart Mobility Fund	3,925,873	5	+/- 196,294

As at 31 December 2021	Net Non-JPY Currency Monetary Assets % Increase/(decrease) JPY '000 in exchange rate	Effect of increase/decrease JPY '000
Japan Value Fund	8,783,117,510 5	+/- 439,155,876

As at 31 December 2021	Net Non-GBP Currency Monetary Assets GBP	% Increase/(decrease) in exchange rate	Effect of increase/decrease GBP
Global Insurance Fund	1,503,987,237	5	+/- 75,199,362
Income Opportunities Fund	50,659,236	5	+/- 2,532,962
UK Value Opportunities	(48,517)	5	+/- 2,426

As at 31 December 2021	Net Non-EUR Currency Monetary Assets EUR	% Increase/(decrease) in exchange rate	Effect of increase/decrease EUR
European ex UK Income Fund	33,168,696	5	+/- 1,658,435
European Income Fund	-	5	+/-

As at 31 December 2020	Net Non-USD Currency Monetary Assets US\$	% Increase/(decrease) in exchange rate	Effect of increase/decrease US\$
Asian Opportunities Fund	7,982,442	5	+/- 399,122
Asian Stars Fund	14,056,452	5	+/- 702,823
Automation & Artificial Intelligence Fund	331,640,939	5	+/- 16,582,047
Biotechnology Fund	291,951,921	5	+/- 14,597,596
China Stars Fund	10,414,777	5	+/- 520,739
Emerging Markets Income Fund	94,534,183	5	+/- 4,726,709
Emerging Markets Stars Fund	279,647,224	5	+/- 13,982,361
Financial Opportunities Fund	5,407,074	5	+/- 270,354
Global Absolute Return Fund	47,014,542	5	+/- 2,350,727
Global Convertible Fund	506,684,187	5	+/- 25,334,209
Global Technology Fund	2,959,224,626	5	+/- 147,961,231
Healthcare Blue Chip Fund	23,527,402	5	+/- 1,176,370
Healthcare Discovery Fund	9,119,817	5	+/- 455,991
Healthcare Opportunities Fund	511,032,060	5	+/- 25,551,603
North American Fund	169,127,908	5	+/- 8,456,395

As at 31 December 2020	Net Non-JPY Currency Monetary Assets JPY '000	% Increase/(decrease) in exchange rate	Effect of increase/decrease JPY '000
Japan Value Fund	8,623,174,799	5	+/- 431,158,740

### 10. Financial Risk Management continued

Currency risk continued

As at 31 December 2020	Net Non-GBP Currency Monetary Assets GBP	% Increase/(decrease) in exchange rate	Effect of increase/decrease GBP
Global Insurance Fund	1,354,846,260	5	+/- 67,742,313
Income Opportunities Fund	64,142,908	5	+/- 3,207,145
UK Value Opportunities	9,747,959	5	+/- 487,398

As at 31 December 2020	Net Non-EUR Currency Monetary Assets EUR	% Increase/(decrease) in exchange rate	Effect of increase/decrease EUR
European ex UK Income Fund	85,748,866	5	+/- 4,287,443

### **Interest rate risk**

Most of the Funds' financial assets and liabilities are non-interest bearing and any excess cash and cash equivalents are invested at short term market interest rates. As a result, the Funds are not subject to significant amounts of risk due to fluctuations in the prevailing level of market interest rates.

The three Funds which invest in interest bearing securities are Global Absolute Return Fund, Global Convertible Fund and Income Opportunities Fund and as such their net asset values are exposed to changes in interest rates, the risk being that if interest rates rise, they will cause the value of the interest-bearing securities component of the Funds' portfolio to decline. These portfolios consist of a variety of positions with varying maturity dates; in general, the longer the period to maturity of the securities, the greater the risk that the net asset value will decline as a result of an increase in interest rates. The Investment Manager regularly monitors the portfolio and particularly the spread of maturity dates and portfolio balances to achieve the investment objective in line with change in interest rates.

As part of its monitoring process the Investment Manager, when looking at individual bonds and the portfolios as a whole, will consider their sensitivity to changes in interest rates. This will include taking into account their position in the capital structure, whether they have fixed maturities or are perpetual, and whether they have call dates. If they have call dates, the terms if not called will be considered, whether fixed or floating, and what margin over the relevant risk free rate the bond will yield if not called. The Investment Manager will also compare the yield on corporate bonds relative to government bonds and the impact that this may have in increasing or reducing the sensitivity of the portfolio to moves in interest rates.

### **Global Absolute Return Fund**

31 December 2021	Less than 1 month (US\$)	1 month – 1 year (US\$)	Greater than 1 year (US\$)	Non-Interest bearing (GBP£)	Total US\$
Financial assets at fair value through profit or loss	_	_	49,925,897	32,055,205	81,981,102
Cash at bank	(12,015,492)	-	-	-	(12,015,492)
Margin cash	_	_	-	711,785	711,785
Other debtors	-	_	-	143,896	143,896
Financial derivative instruments	_	_	(459,826)	466,815	6,989
Fees and sundry creditors payable	_	-	-	(502,896)	(502,896)
Total	(12,015,492)	-	49,466,071	32,874,805	70,325,384

31 December 2020	Less than 1 month (US <b>\$</b> )	1 month – 1 year (US\$)	Greater than 1 year (US\$)	Non-Interest bearing (GBP£)	Total US\$
Financial assets at fair value through profit or loss	_	_	37,433,458	14,177,268	51,610,726
Cash at bank	214,045	_	_		214,045
Other debtors	_	_	_	113,209	113,209
Financial derivative instruments	_	_	_	(3,219,817)	(3,219,817)
Fees and sundry creditors payable	_	_	_	(1,651,822)	(1,651,822)
Total	214,045	_	37,433,458	9,418,838	47,066,341

As at 31 December 2021, should interest rates have fallen by 0.25%, with all other variables remaining constant, the increase in net assets attributable to the holders of redeemable shares would amount to approximately 0.53% (31 December 2020: 0.30%). An equal change in interest rates in the opposite direction would have decreased net assets attributable to the holders of redeemable shares by 0.52% (31 December 2020: 0.30%).

### **Global Convertible Fund**

31 December 2021	Less than 1 month (US\$)	1 month – 1 year (US\$)	Greater than 1 year (US\$)	Non-Interest bearing (US\$)	Total US\$
ST December 2021	(033)	(03\$)	(03\$)	(033)	
Financial assets at fair value through profit or loss	-	35,325,870	718,677,255	494,181,215	1,248,184,340
Amounts receivable on sale of redeemable participating shares	_	_	_	661,143	661,143
Cash at bank	(188,288,472)	-	-	_	(188,288,472)
Other debtors	_	_	_	2,957,064	2,957,064
Financial derivative instruments	_	_	(4,598,265)	10,169,068	5,570,803
Fees and sundry creditors payable	_	_	_	(2,180,472)	(2,180,472)
Total	(188,288,472)	35,325,870	714,078,990	505,788,018	1,066,904,406

31 December 2020	Less than 1 month (US\$)	1 month – 1 year (US\$)	Greater than 1 year (US\$)	Non-Interest bearing (US\$)	Total US\$
Financial assets at fair value through profit or loss	_	-	724,444,802	415,875,927	1,140,320,729
Amounts receivable on sale of redeemable participating shares	_	_	_	1,277,215	1,277,215
Amounts receivable on sale of securities	_	-	_	13,694,099	13,694,099
Cash at bank	(64,087,192)	-	-	_	(64,087,192)
Other debtors	_	-	_	3,885,379	(3,885,379)
Financial derivative instruments	_	_	_	(38,093,993)	38,093,993
Fees and sundry creditors payable	_	_	_	(9,166,636)	9,166,636
Total	(64,087,192)	-	724,444,802	387,471,991	1,047,829,601

### 10. Financial Risk Management continued

### Interest rate risk continued

As at 31 December 2021 should interest rates have fallen by 0.25%, with all other variables remaining constant, the increase in net assets attributable to the holders of redeemable shares would amount to approximately 0.38% (31 December 2020: 0.35%). An equal change in interest rates in the opposite direction would have decreased net assets attributable to the holders of redeemable shares for the period by 0.38% (31 December 2020: 0.36%).

### **Income Opportunities Fund**

31 December 2021	Less than 1 month (GBP£)	1 month – 1 year (GBP£)	Greater than 1 year (GBP£)	Non-Interest bearing (GBP£)	Total GBP£
Financial assets at fair value through profit or loss	1,285,639	1,018,325	4,297,311	42,414,010	49,015,285
Amounts receivable on sale of redeemable participating shares	_	_	_	12,750	12,750
Amounts receivable on sale of securities	-	_	_	-	-
Cash at bank	9,817,635	_	_	-	9,817,635
Margin receivable	-			-	-
Margin cash	-	_	_	97,949	97,949
Other debtors	-	_	_	213,083	213,083
Financial derivative instruments	-	_	_	(417,735)	(417,735)
Fees and sundry creditors payable	-	-	_	(686,268)	(686,268)
Total	11,103,274	1,018,325	4,297,311	41,633,789	58,052,699

31 December 2020	Less than 1 month (GBP£)	1 month – 1 year (GBP£)	Greater than 1 year (GBP£)	Non-Interest bearing (GBP£)	Total GBP£
Financial assets at fair value through profit or loss	_	-	15,531,541	44,590,667	60,122,208
Amounts receivable on sale of redeemable participating shares	_	_	_	2,000	2,000
Amounts receivable on sale of securities				210,122	210,122
Cash at bank	617,784	-	_	_	617,784
Margin cash	_	_	_	71,626	71,626
Other debtors	_	-	_	215,450	(215,450)
Financial derivative instruments	_	-	_	(577,225)	577,225
Fees and sundry creditors payable	_	_	_	(982,551)	982,551
Total	617,784	-	15,531,541	43,530,289	59,679,614

As at 31 December 2021, should interest rates have fallen by 0.25%, with all other variables remaining constant, the increase in net assets attributable to the holders of redeemable shares would amount to approximately 0.07% (31 December 2020: 0.23%). An equal change in interest rates in the opposite direction would have decreased net assets attributable to the holders of redeemable shares by 0.05% (31 December 2020: 0.22%).

### Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The majority of the Funds' financial assets are equity securities. As a result, they are not subject to significant amounts of credit risk. The credit rating of the fixed income securities held in the three Funds that do invest in debt securities were as follows at 31 December 2021:

	31 Decem	ber 2021	31 December 2020			
Global Absolute Return Fund	% Holding	Value US\$	% Holding	Value US\$		
A	0.00%	-	2.88%	1,484,975		
A-	3.38%	2,768,295	0.00%	_		
BBB	2.29%	1,874,136	2.37%	1,224,095		
CCC+	0.00%	-	2.93%	1,514,594		
NR	94.34%	77,338,671	91.82%	47,386,094		
Total	100.00%	81,981,102	100.00%	51,609,757		

	31 Decem	1ber 2021	31 December 2020			
Global Convertible Fund	% Holding	Value US\$	% Holding	Value US\$		
A	0.00%	-	2.47%	25,912,102		
A-	0.00%	-	1.512%	15,814,016		
BBB+	0.55%	5,305,501	0.97%	10,172,033		
BBB	2.97%	28,940,290	0.98%	10,282,394		
BBB-	0.00%	-	1.60%	16,719,458		
BB+	1.92%	18,638,438	0.00%	-		
BB	0.00%	_	0.80%	8,389,921		
BB-	0.00%	_	2.24%	23,441,313		
NR	94.56%	919,978,519	87.50%	916,876,689		
Total	100.00%	972,862,748	100.00%	1,027,607,931		

	31 Decen	1ber 2021	31 December 2020			
Income Opportunities Fund	% Holding	Value GBP£	% Holding	Value GBP£		
ААА	12.45%	1,480,395	0.00%	-		
AA+	11.47%	1,363,760	0.00%	-		
BBB+	0.00%	-	13.41%	2,568,983		
BBB	0.00%	-	2.70%	517,933		
BB+	0.00%	_	21.74%	4,164,776		
BB-	0.00%	-	5.08%	973,589		
NR	76.08%	9,045,139	57.07%	10,934,632		
Total	100.00%	11,889,294	100.00%	19,159,913		

### 10. Financial Risk Management continued

### Credit risk continued

### **Credit risk on settlement**

Transactions in securities are generally settled or paid for on delivery or cleared through the appropriate clearing system for the market on which the securities are traded. The risk of default is not considered to be material, as delivery of securities sold is only made once the Depositary has received confirmation of payment. Payment is also only made on a purchase once confirmation of delivery of the securities has been received by the Depositary. The trade will fail if either party fails to deliver the required confirmations.

### Credit risk on cash and receivables

The Company has an exposure for cash at bank, margin cash and margin receivable as an unsecured creditor to either counterparty risk or the Depositary which would involve a significant risk of loss in the event of a default by either. Credit risk for sundry debtors is considered immaterial.

At 31 December 2021 and 31 December 2020, none of the Funds' financial assets were past due or impaired.

The Investment Manager monitors each Fund's credit exposure, where relevant to the Fund's investment strategy, on a daily basis and reports regularly to the Board of Directors, which reviews the information provided by the Investment Manager on significant exposures at its periodic meetings.

#### **Credit risk statement**

The Depositary is responsible for the safe-keeping of assets. The Depositary has appointed The Northern Trust Company ('TNTC') as its global sub-custodian. Both the Depositary and TNTC are wholly owned subsidiaries of Northern Trust Corporation ('NTC'). As at 31 December 2021, NTC had a long-term credit rating from Standard & Poor's of A+ (31 December 2020: A+).

TNTC, in the discharge of its delegated depositary duties, holds in custody (i) all financial instruments that may be registered in a financial instruments account opened on the books of TNTC and (ii) all financial instruments that can be physically delivered to TNTC. TNTC ensures all financial instruments (held in a financial instruments account on the books of TNTC) are held in segregated accounts in the name of the Fund, clearly identifiable as belonging to the Fund, and distinct and separately from the proprietary assets of TNTC, Depositary and NTC.

In addition, TNTC, as banker, holds cash of the Funds on deposit. Such cash is held on the balance sheet of TNTC. In the event of insolvency of TNTC, in accordance with standard banking practice, the Fund will rank as an unsecured creditor of TNTC in respect of any cash deposits.

Insolvency of Depositary and or one of its agents or affiliates may cause the Fund's rights with respect to its assets to be delayed or may result in the Company not receiving the full value of its assets.

As per Note 2 (E), Cash at bank and bank overdraft balances are comprised of cash balances held at TNTC. As at 31 December 2021 cash was held with counterparties and brokers as follows:

China Stars: US\$6,461 (31 December 2020: US\$6,470)

Global Absolute Return Fund: US\$711,785 (31 December 2020: US\$Nil)

Global Technology Fund: GBP14,322,512 (31 December 2020: GBP9,919,032)

Healthcare Opportunities Fund: US\$100 (31 December 2020: US\$20,502,228)

Income Opportunities Fund GBP97,949 (31 December 2020: GBP71,626)

UK Value Opportunities Fund: GBP(2) (31 December 2020: GBP17,668)

The Funds' counterparties and brokers had the following long-term credit ratings from Standard & Poor's as at 31 December 2021:

Credit Suisse Securities (Europe) Limited: A+ (31 December 2020: A+). UBS AG: A+ (31 December 2020: A+).

### Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities as they fall due.

The Funds are exposed to daily cash redemptions of redeemable participating shares. The Funds invest the majority of their assets in securities and other instruments that are traded on an active market and which are considered to be liquid as under normal market conditions, they can be readily disposed of in the event that cash needs to be raised to meet redemptions or to pay expenses.

In accordance with Company policy, the Investment Manager monitors the Funds' liquidity on a daily basis and reports regularly to the Board of Directors, which reviews the information provided by the Investment Manager on significant exposures at its periodic meetings.

The Funds' listed securities are considered to be readily realisable as they are principally listed on major European, Asian and US stock exchanges. At 31 December 2021 and 31 December 2020, the Funds all held liquid assets and liabilities that could be realised in less than one month. The residual contractual maturities of financial liabilities held by the Funds are all within 3 months.

### **Offsetting Financial Instruments**

The Company has not offset any financial assets and financial liabilities in the Statement of Financial Position. Financial assets and financial liabilities which are subject to enforceable master netting arrangements are detailed in the tables below.

	G Gross amounts of recognised assets 2021 US\$	ognised of financial assets position 2021 2021	Net amount presented on the statement of financial position 2021 US\$	Related amounts not set off in the Statement of Financial Position		
Global Absolute Return Fund				Financial instruments 2021 US <b>\$</b>	Cash collateral pledged / received 2021 US\$	Net amount 2021 US\$
Assets						
Contracts for difference	339,352	-	339,352	(339,352)	_	-
Forward foreign currency contracts	938,585	_	938,585	(393)	_	938,192
Total	1,277,937	-	1,277,937	(339,745)	-	938,192
Liabilities						
Contracts for difference	(648,292)	_	(648,292)	339,352	_	(308,940)
Futures contracts	(162,437)	-	(162,437)	_	_	(162,437)
Forward foreign currency contracts	(393)	_	(393)	393	_	-
Swaps	(459,826)	_	(459,826)	_	_	(459,826)
Total	(1,270,948)	-	(1,270,948)	339,745	-	(931,203)

### 10. Financial Risk Management continued

Offsetting Financial Instruments continued

Global Absolute Return Fund	Gross amounts of recognised assets 2020 US\$	Gross amounts offset in the statement of financial position 2020 US\$	Net amount presented on the statement of financial position 2020 US\$	Related amounts not set off in the Statement of Financial Position		
				Financial instruments 2020 US\$	Cash collateral pledged / received 2020 US\$	Net amount 2020 US\$
Assets						
Contracts for difference	176,126	-	176,126	(176,126)	_	_
Futures contracts	-	-	_	_	_	-
Forward foreign currency contracts	882,099	-	882,099	(13,670)	_	868,429
Total	1,058,225	-	1,058,225	(189,796)	-	868,429
Liabilities						
Contracts for difference	(4,223,422)	_	(4,223,422)	176,126	_	(4,047,296)
Futures contracts	(40,950)	_	(40,950)	_	_	(40,950)
Forward foreign currency contracts	(13,670)	-	(13,670)	13,670	_	-
Total	(4,278,042)	_	(4,278,042)	189,796	_	(4,088,246)

Global Convertible Fund	Gross amounts of recognised assets 2021 US\$	Gross amounts offset in the statement of financial position 2021 US\$	Net amount presented on the statement of financial position 2021 US\$	Related amounts not set off in the Statement of Financial Position		
				Financial instruments 2021 US\$	Cash collateral pledged / received 2021 US\$	Net amount 2021 US\$
Assets						
Contracts for difference	5,489,745	_	5,489,745	(2,495,459)	_	2,994,286
Futures contracts	1,753,043	-	1,753,043	(900,607)	-	852,436
Forward foreign currency contracts	6,347,293	-	6,347,293	(24,947)	_	6,322,346
Total	13,590,081	-	13,590,081	(3,421,013)	-	10,169,068
Liabilities						
Contracts for difference	(2,495,459)	_	(2,495,459)	2,495,459	_	-
Futures contracts	(900,607)	_	(900,607)	900,607	_	_
Forward foreign currency contracts	(24,947)		(24,947)	24,947	_	-
Swaps	(4,598,265)	-	(4,598,265)	_	_	(4,598,265)
Total	(8,019,278)	-	(8,019,278)	3,421,013	_	(4,598,265)

		Gross amounts offset in the	Net amount presented on	Related amounts not set off in the Statement of Financial Position		
Global Convertible Fund	of recognised of finan assets posit 2020 2	statement of financial position 2020 US\$	the statement of financial position 2020 US\$	Financial instruments 2020 US\$	Cash collateral pledged / received 2020 US\$	Net amount 2020 US\$
Assets						
Contracts for difference	1,579,155	-	1,579,155	(1,579,155)	_	_
Futures contracts	1,170,550	_	1,170,550	(487,276)	-	683,274
Forward foreign currency contracts	4,503,091	_	4,503,091	(105,865)	_	4,397,226
Total	7,252,796	-	7,252,796	(2,172,296)	-	5,080,500
Liabilities						
Contracts for difference	(44,753,648)	_	(44,753,648)	1,579,155	_	(43,174,493)
Futures contracts	(487,276)	_	(487,276)	487,276	_	-
Forward foreign currency contracts	(105,865)	_	(105,865)	105,865	_	-
Total	(45,346,789)	-	(45,346,789)	2,172,296	-	(43,174,493)

Global Convertible Fund is party to an ISDA Master Agreement with UBS AG, which was signed on 30 August 2013. The existing Agreement was amended by adding Global Absolute Return Fund on 31 December 2018.

#### Fair value hierarchy

Financial assets and financial liabilities at fair value through profit and loss are valued at fair value at the Statement of Financial Position date. Subsequent to initial recognition, all financial assets and financial liabilities at fair value through profit or loss are measured at fair value. Gains and losses arising from changes in the fair value of the 'financial assets or financial liabilities at fair value through profit or loss' category are presented in the Statement of Comprehensive Income within 'Net gain/loss on financial assets and financial liabilities at fair value through profit or loss' in the period in which they arise. Fair value is the price that would be received to sell the asset or paid to transfer the liability in an orderly transaction between market participants at the measurement date.

In determining fair value, securities which are quoted, listed or traded on a recognised exchange will be valued at the last traded price (or, if no last traded price is available, at the mid-market price).

A financial instrument is regarded as quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.

The fair value of financial assets and liabilities that are not traded in an active market is determined by using valuation techniques.

For instruments for which there is no active market, the Company may use internally developed models, which are usually based on valuation methods and techniques generally recognised as standard within the industry.

Valuation models are used primarily to value unlisted equities, for which markets were or have been inactive during the financial year. Some of the inputs to these models may not be market observable and are therefore estimated based on assumptions.

#### 10. Financial Risk Management continued

Fair value hierarchy continued

The table below sets out fair value measurements using the fair value hierarchy:

#### Financial assets and liabilities at fair value through profit or loss as at 31 December 2021

Asian Stars Fund	Total US\$	Level 1 US\$	Level 2 US\$	Level 3 US\$
Assets				
Equity investments	167,959,084	167,959,084	-	-
Total	167,959,084	167,959,084	-	-
Automation & Artificial Intelligence Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	753,389,515	753,389,515	_	_
Forward foreign currency contracts	1,279	-	1,279	-
Total	753,390,794	753,389,515	1,279	-
Biotechnology Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	1,708,169,955	1,708,169,955	_	_
Warrants	3,731,510	_	3,731,510	-
Forward foreign currency contracts	3,649,007	-	3,649,007	-
Total	1,715,550,472	1,708,169,955	7,380,517	-
Liabilities				
Forward foreign currency contracts	(3,664)	_	(3,664)	_
Total	(3,664)	-	(3,664)	-
China Stars Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	19,021,813	19,021,813	_	_
Total	19,021,813	19,021,813	-	-
Emerging Markets Stars Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	1,269,055,378	1,269,055,378	_	-
Forward foreign currency contracts	760	_	760	-
Total	1,269,056,138	1,269,055,378	760	-

European (ex UK) Income Fund	Total EUR€	Level 1 EUR€	Level 2 EUR€	Level 3 EUR€
Assets				
Equity investments	117,939,248	117,939,248	_	-
Warrants	118,951	_	118,951	-
Forward foreign currency contracts	19,171	_	19,171	_
Total	118,077,370	117,939,248	138,122	-
Financial Opportunities Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	22,023,268	22,023,268	_	_
Forward foreign currency contracts	112	-	112	_
Total	22,023,380	22,023,268	112	-
Global Absolute Return Fund	US\$	US\$	US\$	US\$
Assets				
Corporate bonds	84,272,352	_	84,272,352	-
Contracts for difference	339,352	_	339,352	-
Forward foreign currency contracts	938,585	_	938,585	-
Total	85,550,289	-	85,550,289	_
Liabilities				
Corporate bonds	(2,291,250)	_	(2,291,250)	_
Contracts for difference	(648,292)	_	(648,292)	_
Forward foreign currency contracts	(393)	_	(393)	_
Futures contracts	(162,437)	(162,437)	_	-
Swaps	(459,826)	_	(459,826)	-
Total	(3,562,198)	(162,437)	(3,399,761)	-
Global Convertible Fund	US\$	US\$	US\$	US\$
Assets				
Corporate bonds	972,862,748	_	972,862,748	-
Equity investments	275,321,592	275,321,592	_	-
Contracts for difference	5,489,745	_	5,489,745	_
Forward foreign currency contracts	6,347,293	_	6,347,293	_
Futures contracts	1,753,043	1,753,043	-	-
Total	1,261,774,421	277,074,635	984,699,786	-
Liabilities				
Contracts for difference	(2,495,459)	_	(2,495,459)	-
Forward foreign currency contracts	(24,947)	-	(24,947)	-
Futures contracts	(900,607)	(900,607)	-	_
<i>c</i>	(4 500 255)			

(4,598,265)

(8,019,278)

Swaps

Total

(4,598,265)

(7,118,671)

\_

\_

(900,607)

#### 10. Financial Risk Management continued

Fair value hierarchy continued

Financial assets and liabilities at fair value through profit or loss as at 31 December 2021 continued

Global Insurance Fund	Total GBP£	Level 1 GBP£	Level 2 GBP£	Level 3 GBP£
Assets				
Investment funds	31,030,208	_	31,030,208	-
Equity investments	1,670,521,872	1,670,521,872	_	-
Forward foreign currency contracts	255	_	255	-
Total	1,701,552,335	1,670,521,872	31,030,463	-
Liabilities				
Forward foreign currency contracts	(222,337)	_	(222,337)	-
Total	(222,337)	-	(222,337)	-
Global Technology Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	8,679,284,866	8,679,284,866	-	_
Options	25,296,625	_	25,296,625	_
Forward foreign currency contracts	11,628,055	_	11,628,055	_
Total	8,716,209,546	8,679,284,866	36,924,680	-
Liabilities				
Forward foreign currency contracts	(624,035)	_	(624,035)	-
Total	(624,035)	-	(624,035)	-
Healthcare Blue Chip Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	111,068,496	111,068,496	-	_
Forward foreign currency contracts	7,345	_	7,345	_
Total	111,075,841	111,068,496	7,345	-
Liabilities				
Forward foreign currency contracts	(930)	_	(930)	-
Total	(930)	-	(930)	-
Healthcare Discovery Fund	US\$	US\$	US\$	US\$
Assets	69,379,995	69,379,995	_	-
Equity investments	1	_	1	_
Total	69,379,996	69,379,995	1	-
Liabilities				
Forward foreign currency contracts	(1)	-	(1)	-
Total	(1)	-	(1)	-

Healthcare Opportunities Fund	Total US\$	Level 1 US\$	Level 2 US\$	Level 3 US\$
Assets				
Equity investments	2,066,481,371	2,066,481,371	_	-
Forward foreign currency contracts	52,093	_	52,093	_
Total	2,066,533,464	2,066,481,371	52,093	-
Liabilities				
Forward foreign currency contracts	(21,350)	_	(21,350)	-
Total	(21,350)	_	(21,350)	-
la constanta iti co Fund	CDDC	CDDC	CDDC	CDDC
Income Opportunities Fund	GBP£	GBP£	GBP£	GBP£
Assets	0.045 120		0.045 120	
Corporate bonds	9,045,139 37,125,991	-	9,045,139	-
Equity investments Futures contracts	25,852	37,125,991 25,852	_	
Government Bonds	2,844,155	25,652	2 944 165	
Total	49,041,137	37,151,843	2,844,155 11,889,294	
	-5,0+1,157	57,151,045	11,005,254	
Liabilities	(		(	
Forward foreign currency contracts	(443,587)		(443,587)	-
Total	(443,587)	_	(443,587)	-
Japan Value Fund	JPY ¥	JPY ¥	JPY ¥	JPY ¥
Assets				
Equity investments	23,411,300,300	23,411,300,300	_	-
Forward foreign currency contracts	187,441,853	_	187,441,853	-
Total	23,598,742,153	23,411,300,300	187,441,853	_
Liabilities				
Forward foreign currency contracts	(4,935,705)	_	(4,935,705)	-
Total	(4,935,705)	-	(4,935,705)	-
North American Fund	US\$	US\$	US\$	US\$
Assets	\$53		÷20	¢50
Equity investments	1,219,739,666	1,219,739,666		
Forward foreign currency contracts	3,015,040		3,015,040	
	5,015,010			
Total	1,222,754,706	1,219,739,666	3,015,040	-
Total	1,222,754,706	1,219,739,666	3,015,040	_
· ·	1,222,754,706 (18,954)	1,219,739,666	3,015,040 (18,954)	_

#### 10. Financial Risk Management continued

Fair value hierarchy continued

Financial assets and liabilities at fair value through profit or loss as at 31 December 2021 continued

	Total	Level 1	Level 2	Level 3
Smart Energy Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	27,537,578	27,537,578	_	_
Total	27,537,578	27,537,578	-	-
Smart Mobility Fund	US\$	US\$	US\$	US\$
Assets		·		
Equity investments	7,341,000	7,341,000	_	_
Total	7,341,000	7,341,000	-	-
UK Value Opportunities Fund	GBP£	GBP£	GBP£	GBP£
Assets				
Equity investments	1,568,275,932	1,568,275,932	-	_
Total	1,568,275,932	1,568,275,932	_	_

#### Financial assets and liabilities at fair value through profit or loss as at 31 December 2020

Asian Opportunities Fund	Total US\$	Level 1 US\$	Level 2 US\$	Level 3 US\$
Assets				
Equity investments	8,030,649	8,030,649	_	_
Forward foreign currency contracts	6,111	_	6,111	
Total	8,036,760	8,030,649	6,111	-
Liabilities				
Forward foreign currency contracts	(6)	_	(6)	-
Total	(6)	-	(6)	-
Asian Stars Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	17,352,888	17,352,888	_	-
Total	17,352,888	17,352,888	-	-
Automation & Artificial Intelligence Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	728,735,691	728,735,691	-	_
Total	728,735,691	728,735,691	—	-

Biotechnology Fund	Total US <b>\$</b>	Level 1 US\$	Level 2 US\$	Level 3 US\$
Assets				
Equity investments	1,165,403,819	1,165,403,819	_	_
Forward foreign currency contracts	245,891	_	245,891	_
Total	1,165,649,710	1,165,403,819	245,891	-
Liabilities				
Forward foreign currency contracts	(1,171)	_	(1,171)	-
Total	(1,171)	_	(1,171)	_
China Stars Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	13,305,341	13,305,341	_	_
Options	90	_	90	_
Total	13,305,521	13,305,341	90	_
Emerging Markets Income Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	103,152,112	103,152,112	_	_
Forward foreign currency contracts	7,030	_	7,030	-
Total	103,159,142	103,152,112	7,030	_
Liabilities				
Forward foreign currency contracts	(6,893)	_	(6,893)	-
Total	(6,893)	_	(6,893)	-
Emerging Markets Stars Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	362,968,186	362,968,186	_	-
Total	362,968,186	362,968,186	-	_
European ex UK Income Fund	EUR€	EUR€	EUR€	EUR€
Assets				
Equity investments	189,702,354	189,702,354	-	_
Warrants	26,210	_	26,210	-
Forward foreign currency contracts	866,971	_	866,971	-
Total	190,595,535	189,702,354	893,181	-

#### 10. Financial Risk Management continued

Fair value hierarchy continued

Financial assets and liabilities at fair value through profit or loss as at 31 December 2020 continued

	Total	Level 1	Level 2	Level 3
Financial Opportunities Fund	US\$	US\$	US\$	US\$
Assets	40,420,650	40,400,650		
Equity investments	10,420,659	10,420,659	_	_
Total	10,420,659	10,420,659		_
Global Absolute Return Fund	US\$	US\$	US\$	US\$
Assets		·		
Corporate bonds	51,609,757	_	51,609,757	_
Warrants	969	_	969	_
Contracts for difference	176,126	_	176,126	_
Forward foreign currency contracts	882,099	_	882,099	-
Total	52,668,951	-	52,668,951	
Liabilities				
Contracts for difference	(4,223,422)	_	(4,223,422)	_
Forward foreign currency contracts	(13,670)	_	(13,670)	-
Futures contracts	(40,950)	(40,950)	_	-
Total	(4,278,042)	(40,950)	(4,237,092)	_
Global Convertible Fund	US\$	US\$	US\$	US\$
Assets				
Corporate bonds	1,027,607,930	_	1,027,607,931	_
Equity investments	112,712,798	112,712,798	_	_
Contracts for difference	1,579,155		1,579,155	_
Forward foreign currency contracts	4,508,091	_	4,503,091	_
Futures contracts	1,170,550	1,170,550	_	_
Total	1,147,578,525	113,883,348	1,033,690,177	_
Liabilities				
Contracts for difference	(44,753,648)	_	(44,753,648)	_
Forward foreign currency contracts	(105,865)	_	(105,865)	_
Futures contracts	(487,276)	(487,276)	_	-
Total	(45,346,789)	(487,276)	(44,859,513)	_

Global Insurance Fund	Total GBP£	Level 1 GBP£	Level 2 GBP£	Level 3 GBP£
Assets				
Investment funds	24,063,913	_	24,063,913	_
Equity investments	1,520,706,081	1,520,706,081	_	_
Forward foreign currency contracts	1,054	_	1,054	_
Total	1,544,771,048	1,520,706,081	24,064,967	-
Liabilities				
Forward foreign currency contracts	(354,981)	_	(354,981)	_
Total	(354,981)	-	(354,981)	-
Global Technology Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	7,831,220,695	7,831,220,695	_	_
Forward foreign currency contracts	6,590,906	_	6,590,906	-
Options	50,287,000	_	50,287,000	-
Total	7,888,098,601	7,831,220,695	56,877,906	_
Liabilities				
Forward foreign currency contracts	(27,157)	_	(27,157)	-
Total	(27,157)	_	(27,157)	-
Healthcare Blue Chip Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	86,369,420	86,369,420	_	_
Forward foreign currency contracts	48	_	48	_
Total	86,369,468	86,369,420	48	-
Healthcare Discovery Fund	US\$	US\$	US\$	US\$
Assets				
Equity investments	45,272,115	45,272,115	_	_
Total	45,272,115	45,272,115	_	_

### 10. Financial Risk Management continued

Fair value hierarchy continued

Financial assets and liabilities at fair value through profit or loss as at 31 December 2020 continued

Healthcare Opportunities Fund	Total US\$	Level 1 US\$	Level 2 US\$	Level 3 US\$
Assets				
Equity investments	2,104,298,240	2,104,298,240	_	-
Forward foreign currency contracts	92,664	_	92,664	-
Total	2,104,390,904	2,104,298,240	92,664	-
Liabilities				
Forward foreign currency contracts	(7)	_	(7)	_
Total	(7)	-	(7)	-
Income Opportunities Fund	GBP£	GBP£	GBP£	GBP£
Assets		·		
Corporate bonds	19,159,913	-	19,159,913	_
Equity investments	40,962,295	40,962,295	-	-
Total	60,122,208	40,962,295	19,159,913	-
Liabilities				
Forward foreign currency contracts	(563,225)	-	(563,225)	_
Futures contracts	(14,000)	(14,000)	-	-
Total	(577,225)	(14,000)	(563,225)	_
Japan Value Fund	JPY ¥	JPY ¥	JPY ¥	JPY ¥
Assets				
Equity investments	17,653,006,900	17,653,006,900	_	_
Forward foreign currency contracts	39,004,928	_	39,004,928	-
Total	17,692,011,828	17,653,006,900	39,004,928	-
Liabilities				
Forward foreign currency contracts	(6,355,778)		(6,355,778)	
Total	(6,355,778)	_	(6,355,778)	_
North American Fund	US\$	US\$	US\$	US\$

Assets				
Equity investments	1,027,053,531	1,027,053,531	_	_
Forward foreign currency contracts	1,745,802	_	1,745,802	-
Total	1,028,799,333	1,027,053,531	1,745,802	_
Liabilities				
Forward foreign currency contracts	(578)	_	(578)	_
Total	(578)	_	(578)	_
UK Value Opportunities Fund	GBP£	GBP£	GBP£	GBP£
Assets				
Equity investments	1,125,618,319	1,125,618,319	_	-
Total	1,125,618,319	1,125,618,319	-	_

Categorisation within the hierarchy has been determined on the basis of the lowest level input that is significant to the fair value measurement of the relevant asset as follows:

Level 1 - valued using quoted prices in active markets for identical assets.

Level 2 – valued by reference to valuation techniques using observable inputs other than quoted prices included within level 1.

Level 3 – valued by reference to valuation techniques using inputs that are not based on observable market data.

There are no assets held in level 3 at 31 December 2021 (31 December 2020: Nil). In addition, there were no transfers between level 1 and level 2 of the fair value hierarchy during the financial year from 1 January 2021 to 31 December 2021 and 1 January 2020 to 31 December 2020.

The valuation techniques used by the Company are explained in the accounting policies described in note 2.

#### **11. Cross/Segregated Liability**

The Company is an umbrella fund investment company with segregated liability between the Funds of the Company. Under Irish law, being the law applicable to the Company, this should result in any liabilities attributable to any Fund being borne solely by that Fund in the event of any insolvency.

# **12. Comparative Figures**

Asian Opportunities Fund*	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class A US Dollar Distribution	\$0	\$7,032,683	\$27,824,753
Class I Euro Distribution	€0	€36,735	€54,314
Class I Euro Hedged Distribution	€0	€91,806	€384,743
Class I Sterling Distribution	£O	£151,027	£500,701
Class I Sterling Hedged Distribution	£O	£185,888	£334,436
Class I US Dollar Distribution	\$0	\$777,006	\$109,773
	NAV per share	NAV per share	NAV per share
Class A US Dollar Distribution	\$0.00	\$456.12	\$407.25
Class I Euro Distribution	€0.00	€13.07	€12.60
Class I Euro Hedged Distribution	€0.00	€14.50	€13.05
Class I Sterling Distribution	£0.00	£11.75	£10.71
Class I Sterling Hedged Distribution	£0.00	£14.87	£13.46
Class I US Dollar Distribution	\$0.00	\$16.04	\$14.14

Asian Stars Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	€832,454	€55,004	€1,289
Class I Sterling Accumulation	£1,584,551	£1,024,535	£1,853
Class I US Dollar Accumulation	\$3,262,841	\$1,784,145	\$272,940
Class R Euro Accumulation	€49,256	€1,679	€1,282
Class R Sterling Accumulation	£1,744	£1,675	£1,211
Class R US Dollar Accumulation	\$20,078	\$1,797	\$1,259
Class S Euro Accumulation	€88,015,725	€1,704	€1,291
Class S Sterling Accumulation	£17,870,138	£1,701	£1,220
Class S US Dollar Accumulation	\$39,222,288	\$14,219,448	\$6,922,395
	NAV per share	NAV per share	NAV per share
Class I Euro Accumulation	€16.52	€14.81	€11.28
Class I Sterling Accumulation	£13.87	£13.26	£9.56
Class I US Dollar Accumulation	\$18.79	\$18.12	\$12.66
Class R Euro Accumulation	€16.30	€14.69	€11.22
Class R Sterling Accumulation	£13.69	£13.15	£9.51
Class R US Dollar Accumulation	\$18.54	\$17.97	\$12.59
Class S Euro Accumulation	€16.70	€14.91	€11.30
Class S Sterling Accumulation	£14.02	£13.35	£9.58
Class S US Dollar Accumulation	\$18.99	\$18.24	\$12.69

\* Asian Opportunities Fund terminated on 1 March 2021.

Automation & Artificial Intelligence Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	€26,592,589	€16,995,934	€9,822,814
Class I Sterling Accumulation	£108,980,129	£87,407,116	£33,023,912
Class I US Dollar Accumulation	\$61,545,774	\$70,684,023	\$30,103,462
Class R Euro Accumulation	€26,152,140	€17,356,198	€1,406,585
Class R US Dollar Accumulation	\$35,429,763	\$29,014,386	\$17,890,123
Class S Euro Accumulation	€1,497,656	€1,264,103	€1,969,041
Class S Sterling Accumulation	£183,036,287	£157,268,407	£237,703,144
Class S US Dollar Accumulation	\$17,569,687	\$16,539,799	\$11,380,676
Class Z Sterling Accumulation	£145,529,203.04	\$189,606,198	\$1,212
	NAV per share	NAV per share	NAV per share
Class I Euro Accumulation	€18.29	€14.58	€11.43
Class I Sterling Accumulation	£15.35	£13.05	£9.69
Class I US Dollar Accumulation	\$20.80	\$17.84	\$12.83
Class R Euro Accumulation	€17.95	€14.38	€11.33
Class R US Dollar Accumulation	\$20.41	\$17.60	\$12.72
Class S Euro Accumulation	€18.45	€14.66	€11.49
Class S Sterling Accumulation	£15.49	£13.12	£9.73
Class S US Dollar Accumulation	\$20.98	\$17.94	\$12.90
Class Z Sterling Accumulation	£19.99	£16.86	£12.12
Biotechnology Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Distribution	€161,825,336	€115,637,498	€64,169,754
Class I Sterling Distribution	£174,232,241	£155,523,504	£84,209,344
Class I Sterling Hedged Distribution	£115,513,788	£7,405,175	£4,847,709
Class I US Dollar Distribution	\$486,709,900	\$398,816,706	\$156,959,893
Class R Euro Distribution	€178,407,960	€126,483,314	€49,376,939
Class R Sterling Distribution	£7,984,001	£6,413,725	£3,595,457
Class R US Dollar Distribution	\$427,132,963	\$324,759,423	\$137,577,143
Class S Euro Distribution	€621,605	€425,699	€252,834
Class S Sterling Distribution	£1,535,778	£341,291	£106,122

Class S US Dollar Distribution

\$6,575,820

\$7,261,299

\$481,086

Biotechnology Fund continued	NAV per share 31 December 2021	NAV per share 31 December 2020	NAV per share 31 December 2019
Class I Euro Distribution	€36.15	€32.09	€24.84
Class I Sterling Distribution	£30.35	£28.73	£21.05
Class I Sterling Hedged Distribution	£16.79	£16.06	£11.66
Class I US Dollar Distribution	\$41.11	\$39.27	\$27.88
Class R Euro Distribution	€34.80	€31.04	€24.13
Class R Sterling Distribution	£29.22	£27.78	£20.45
Class R US Dollar Distribution	\$39.58	\$37.98	\$27.09
Class S Euro Distribution	€36.82	€32.62	€25.20
Class S Sterling Distribution	£30.91	£29.19	£21.35
Class S US Dollar Distribution	\$41.87	\$39.91	\$28.29

China Stars Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	€244,611	€153,685	€1,177
Class I Sterling Accumulation	£1,047,068	£1,645,723	£93,240
Class I US Dollar Accumulation	\$26,572	\$584,747	\$1,136
Class R Euro Accumulation	€178,404	€115,500	€1,170
Class R Sterling Accumulation	£1,322	£1,553	£1,106
Class R US Dollar Accumulation	\$272,000	\$592,119	\$238,631
Class S Euro Accumulation	€3,807	€5,460	€1,184
Class S Sterling Accumulation	£3,820,482	£187,121	£132,114
Class S US Dollar Accumulation	\$12,631,962	\$9,955,813	\$6,871,675
	NAV per share	NAV per share	NAV per share
Class I Euro Accumulation	€12.28	€13.47	€10.12
Class I Sterling Accumulation	£10.31	£12.06	£8.58
Class I US Dollar Accumulation	\$13.96	\$16.49	\$11.36
Class R Euro Accumulation	€12.12	€13.36	€10.06
Class R Sterling Accumulation	£10.18	£11.96	£8.52
Class R US Dollar Accumulation	\$13.78	\$16.35	\$11.29
Class S Euro Accumulation	€12.38	€13.53	€10.18
Class S Sterling Accumulation	£10.39	£12.11	£8.63
Class S US Dollar Accumulation	\$14.07	\$16.56	\$11.43

Emerging Markets Income Fund*	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	€0	€18,021	€373,989
Class I Euro Distribution	€0	€97,075	€1,328,070
Class I Sterling Accumulation	£0	£1,629,438	£1,694,473
Class I Sterling Distribution	£0	£17,649,050	£35,753,276
Class I US Dollar Accumulation	\$0	\$1,969,828	\$4,708,250
Class I US Dollar Distribution	\$0	\$343,532	\$500,391
Class R Euro Accumulation	€0	€471,007	€684,669
Class R Euro Distribution	€0	€82,713	€83,809
Class R Sterling Accumulation	£0	£35,500	£85,807
Class R Sterling Distribution	£0	£156,627	£245,661
Class R US Dollar Accumulation	\$0	\$5,492,142	\$9,167,883
Class R US Dollar Distribution	\$0	\$1,574,443	\$2,201,709
Class S Euro Accumulation	€0	€141	€153
Class S Euro Distribution	€0	€141	€153
Class S Sterling Accumulation	£0	£2,264,768	£2,087,697
Class S Sterling Distribution	fO	£44,293,439	£56,403,611
Class S US Dollar Accumulation	\$0	\$132	\$131
Class S US Dollar Distribution	\$0	\$3,967,636	\$1,094,278
	NAV per share	NAV per share	NAV per share
Class I Euro Accumulation	€0.00	€10.89	€11.84
Class I Euro Distribution	CO 00	€7.30	
	€0.00	C7.50	€8.33
Class I Sterling Accumulation	€0.00 £0.00	£9.75	€8.33 £10.03
Class I Sterling Accumulation Class I Sterling Distribution			
	£0.00	£9.75	£10.03
Class I Sterling Distribution	£0.00 £0.00	f9.75 f6.53	£10.03 £7.06
Class I Sterling Distribution Class I US Dollar Accumulation	£0.00 £0.00 \$0.00	£9.75 £6.53 \$13.33	£10.03 £7.06 \$13.29
Class I Sterling Distribution Class I US Dollar Accumulation Class I US Dollar Distribution	f0.00 f0.00 \$0.00 \$0.00	f9.75 f6.53 \$13.33 \$8.93	£10.03 £7.06 \$13.29 \$9.36
Class I Sterling Distribution Class I US Dollar Accumulation Class I US Dollar Distribution Class R Euro Accumulation	f0.00 f0.00 \$0.00 \$0.00 €0.00	£9.75 £6.53 \$13.33 \$8.93 €10.37	£10.03 £7.06 \$13.29 \$9.36 €11.33
Class I Sterling Distribution Class I US Dollar Accumulation Class I US Dollar Distribution Class R Euro Accumulation Class R Euro Distribution	<pre>£0.00 £0.00 \$0.00 \$0.00 €0.00 </pre>	f9.75 f6.53 \$13.33 \$8.93 €10.37 €6.98	f10.03 f7.06 \$13.29 \$9.36 €11.33 €8.02
Class I Sterling Distribution Class I US Dollar Accumulation Class I US Dollar Distribution Class R Euro Accumulation Class R Euro Distribution Class R Sterling Accumulation	<pre>f0.00 f0.00 \$0.00 \$0.00 \$0.00 \$0.00 \$0.00 f0.00 f0.00 f0.00</pre>	<pre>f9.75 f6.53 f13.33 \$8.93 €10.37 €6.98 f9.29</pre>	f10.03 f7.06 \$13.29 \$9.36 €11.33 €8.02 f9.60
Class I Sterling Distribution Class I US Dollar Accumulation Class I US Dollar Distribution Class R Euro Accumulation Class R Euro Distribution Class R Sterling Accumulation Class R Sterling Distribution	f0.00 f0.00 \$0.00 \$0.00 €0.00 f0.00 f0.00	f9.75 f6.53 \$13.33 \$8.93 €10.37 €6.98 f9.29 f6.25	f10.03 f7.06 \$13.29 \$9.36 €11.33 €8.02 f9.60 f6.80
Class I Sterling Distribution Class I US Dollar Accumulation Class I US Dollar Distribution Class R Euro Accumulation Class R Euro Distribution Class R Sterling Accumulation Class R Sterling Distribution Class R US Dollar Accumulation	<pre>f0.00 f0.00 f0.00 \$0.00 f0.00 f0.00 f0.00 f0.00 f0.00 f0.00 f0.00 f0.00</pre>	<pre>f9.75 f6.53 f13.33 f3.33 f0.37 f0.37 f0.98 f9.29 f6.25 f12.69</pre>	<pre>f10.03 f7.06 \$13.29 \$9.36 €11.33 €8.02 f9.60 f6.80 \$12.72</pre>
Class I Sterling Distribution Class I US Dollar Accumulation Class I US Dollar Distribution Class R Euro Accumulation Class R Euro Distribution Class R Sterling Accumulation Class R Sterling Distribution Class R US Dollar Accumulation Class R US Dollar Distribution	<pre>f0.00 f0.00 f0.00</pre>	<pre>f9.75 f6.53 f13.33 f8.93 f0.37 f6.98 f9.29 f6.25 f12.69 f8.55</pre>	<pre>f10.03 f7.06 f7.06 \$13.29 \$9.36 €11.33 €8.02 f9.60 f6.80 \$12.72 \$9.00</pre>
Class I Sterling Distribution Class I US Dollar Accumulation Class I US Dollar Distribution Class R Euro Accumulation Class R Euro Distribution Class R Sterling Accumulation Class R Sterling Distribution Class R US Dollar Accumulation Class R US Dollar Distribution Class S Euro Accumulation	<pre>f0.00 f0.00 f0.00</pre>	<pre>f9.75 f6.53 f13.33 fe10.37 fe6.98 f9.29 f6.25 f12.69 fe10.75</pre>	<pre>f10.03 f7.06 f7.06 \$13.29 \$9.36 €11.33 €8.02 f9.60 f6.80 \$12.72 \$9.00 e11.67</pre>
Class I Sterling Distribution Class I US Dollar Accumulation Class I US Dollar Distribution Class R Euro Accumulation Class R Euro Distribution Class R Sterling Accumulation Class R Sterling Distribution Class R US Dollar Accumulation Class R US Dollar Distribution Class S Euro Accumulation Class S Euro Accumulation	<pre>f0.00 f0.00 f0.00&lt;</pre>	<pre>f9.75 f6.53 f6.53 f13.33 f8.93 fe10.37 fe6.98 f9.29 f6.25 f12.69 f8.55 f€10.75 fe10.75</pre>	<pre>f10.03 f7.06 f7.06 \$13.29 \$9.36 €11.33 €8.02 f9.60 f6.80 \$12.72 \$9.00 €11.67 €8.59</pre>
Class I Sterling Distribution Class I US Dollar Accumulation Class I US Dollar Distribution Class R Euro Accumulation Class R Euro Distribution Class R Sterling Accumulation Class R Sterling Distribution Class R US Dollar Accumulation Class R US Dollar Distribution Class S Euro Accumulation Class S Euro Accumulation Class S Euro Distribution Class S Euro Distribution	<pre>f0.00 f0.00 f0.00</pre>	<pre>f9.75 f6.53 f6.53 f0.37 f0.37 f0.29 f6.25 f0.29 f6.25 f0.75 f0.75 f0.75 f7.54 f9.62</pre>	<pre>f10.03 f7.06 f7.06 f313.29 \$9.36 f11.33 f8.02 f9.60 f6.80 f12.72 \$9.00 f1.67 f6.89 f9.69 f6.80 f1.67 f6.89 f9.89</pre>

\* Emerging Markets Income Fund merged with Emerging Markets Stars Fund on 8 June 2021.

# 12. Comparative Figures continued

Emerging Markets Stars Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	€42,371,286	€21,286,003	€3,742,520
Class I Sterling Accumulation	£12,697,758	£7,072,705	£1,900,760
Class I US Dollar Accumulation	\$33,767,572	\$7,789,861	\$800,097
Class R Euro Accumulation	€1,578,632	€242,659	€2,446
Class R Sterling Accumulation	£170,014	£145	£109
Class R US Dollar Accumulation	\$7,576,233	\$46,768	\$109
Class R USD Distribution*	\$115,893,782	N/A	N/A
Class S Euro Accumulation	€57,513,195	€58,958,267	€5,359,749
Class S Euro Distribution*	€153,939	N/A	N/A
Class S Sterling Accumulation	£78,556,222	£41,591,579	£4,139,243
Class S US Dollar Accumulation	\$169,296,625	\$104,406,643	\$23,975,538
Class S US Dollar Distribution	\$40,511,744	£22,153,872	N/A
Class SX Euro Accumulation	€1,691	£1,573	N/A
Class SX Sterling Accumulation	£19,644,873	£21,654,906	N/A
Class SX Sterling Distribution*	£1,000	N/A	N/A
Class SX US Dollar Accumulation	\$226,404,250	£7,546,921	N/A
Class SX US Dollar Distribution*	\$83,315,890	N/A	N/A
Class X Swedish Krona Accumulation	SEK. 1,931,763,256	SEK. 5,318,484	SEK. 1,180
Class X Euro Accumulation	€24,336,722	€2,454,690	€1,170
Class X US Dollar Accumulation	\$64,602,145	\$30,681,946	\$1,164
	NAV per share	NAV per share	NAV per share
Class I Euro Accumulation	€13.23	€12.37	€9.77
Class I Sterling Accumulation	£11.11	£11.07	£8.28
Class I US Dollar Accumulation	\$15.05	\$15.13	\$10.97
Class R Euro Accumulation	€13.04	€12.23	€9.70
Class R Sterling Accumulation	£10.95	£10.95	£8.22
Class R US Dollar Accumulation	\$14.83	\$14.97	\$10.89
Class R USD Distribution*	\$9.53	N/A	N/A
Class S Euro Accumulation	€13.41	€12.47	€9.82
Class S Euro Distribution*	€10.01	N/A	N/A
Class S Sterling Accumulation	£11.26	£11.16	£8.32
Class S US Dollar Accumulation	\$15.25	\$15.25	\$11.02
Class S US Dollar Distribution	\$15.47	£15.48	N/A

\* New Share Classes launched during the year.

Emerging Markets Stars Fund continued	NAV per share 31 December 2021	NAV per share 31 December 2020	NAV per share 31 December 2019
Class SX Euro Accumulation	€16.91	£15.73	N/A
Class SX Sterling Accumulation	£13.79	£13.67	N/A
Class SX Sterling Distribution*	£10.00	N/A	N/A
Class SX US Dollar Accumulation	\$17.54	£17.55	N/A
Class SX US Dollar Distribution*	\$9.36	N/A	N/A
Class X Swedish Krona Accumulation	SEK. 146.16	SEK. 133.81	SEK. 108.99
Class X Euro Accumulation	€14.20	€13.32	£10.37
Class X US Dollar Accumulation	\$16.14	\$16.29	£11.64

European ex UK Income Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	€1,031,557	€544,066	€342,421
Class I Sterling Accumulation	£7,489,383	£25,043,595	£27,804,365
Class I Sterling Distribution	£3,113,304	£3,034,374	£3,694,555
Class I Sterling Hedged Accumulation	£90,585	£29,450	£100,197
Class I Sterling Hedged Distribution	£203,650	£85,651	£253,094
Class S Sterling Accumulation	£10,977,463	£7,823,982	£1,182,379
Class S Sterling Distribution	£28,062,043	£30,050,659	£9,994,524
Class S Sterling Hedged Accumulation	£1,414	£1,183	£1,333
Class S Sterling Hedged Distribution	£705,561	£33,454,843	£120,831,926
Class X Sterling Accumulation	£1,101	£995	£1,066
Class X Sterling Distribution	£48,539,423	£70,890,036	£64,853,634
	NAV per share	NAV per share	NAV per share
Class I Euro Accumulation	€13.66	€11.50	€12.91
Class I Sterling Accumulation	£11.39	£10.22	£10.86
Class I Sterling Distribution	£8.94	£8.37	£9.27
Class I Sterling Hedged Accumulation	£14.08	£11.78	£13.28
Class I Sterling Hedged Distribution	£10.95	£9.56	£11.23
Class S Sterling Accumulation	£11.50	£10.31	£10.96
Class S Sterling Distribution	£9.01	£8.43	£9.34
Class S Sterling Hedged Accumulation	£14.14	£11.83	£13.33
Class S Sterling Hedged Distribution	£10.99	£9.60	£11.28
Class X Sterling Accumulation	£11.01	£9.95	£10.66
Class X Sterling Distribution	£10.00	£9.44	£10.58

\* New Share Classes launched during the year.

Financial Opportunities Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	€40,263	€25,364	€28,406
Class I Euro Distribution	€1,689,066	€996,021	€1,103,972
Class I Sterling Accumulation	£4,552,091	£836,795	£6,894,875
Class I Sterling Accumulation	£3,685,381	£3,283,306	£2,871,305
Class I US Dollar Accumulation	\$525,278	\$79	\$81
Class I US Dollar Distribution		\$120,182	\$4,006,660
Class R Euro Accumulation	\$8,546		
	€71,185	€120,516	€105,634
Class R Euro Distribution	€15,825	€62	€174
Class R Sterling Accumulation	£152,697	£4,101	£27,575
Class R Sterling Distribution	£74,865	£77,905	£68,018
Class R US Dollar Accumulation	\$236,155	\$198,124	\$338,839
Class R US Dollar Distribution	\$136	\$114	\$118
Class S Sterling Distribution	\$745,864	\$120	N/A
Class S US Dollar Distribution	\$8,184,614	\$3,345,848	N/A
	NAV per share	NAV per share	NAV per share
Class I Euro Accumulation	€15.46	€12.01	€13.45
Class I Euro Distribution	€14.29	€11.27	€12.90
Class I Sterling Accumulation	£12.98	£10.75	£11.40
Class I Sterling Distribution	£12.00	£10.09	£10.93
Class I US Dollar Accumulation	\$17.59	\$14.70	\$15.10
Class I US Dollar Distribution	\$16.25	\$13.79	\$14.48
Class R Euro Accumulation	€14.85	€11.58	€13.04
Class R Euro Distribution	€13.61	€10.78	€12.40
Class R Sterling Accumulation	£12.47	£10.37	£11.05
Class R Sterling Distribution	£11.43	£9.65	£10.51
Class R US Dollar Accumulation	\$16.89	\$14.17	\$14.63
Class R US Dollar Distribution	\$15.48	\$13.19	\$13.92
Class S Sterling Distribution	\$10.96	\$9.18	N/A
Class S US Dollar Distribution	\$14.85	\$12.54	N/A

Global Absolute Return Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Hedged Euro Accumulation	€216,536	€265,560	€137,294
Class I Hedged Sterling Accumulation	£4,270,898	£3,436,309	£847,481
Class I US Dollar Accumulation	\$1,686,465	\$922,944	\$3,075,917
Class S Hedged Euro Accumulation	€2,045,937	€3,169,897	€3,882,424
Class S Hedged Sterling Accumulation	£24,776,372	£22,157,413	£24,514,233
Class S US Dollar Accumulation	\$26,721,279	\$6,962,131	\$4,229,429

Global Absolute Return Fund continued	NAV per share 31 December 2021	NAV per share 31 December 2020	NAV per share 31 December 2019
Class I Hedged Euro Accumulation	€123.92	€119.49	€99.83
Class I Hedged Sterling Accumulation	£126.84	£121.75	£101.18
Class I US Dollar Accumulation	\$130.79	\$125.46	\$102.29
Class S Hedged Euro Accumulation	€125.04	€120.10	€100.13
Class S Hedged Sterling Accumulation	£127.76	£122.20	£101.35
Class S US Dollar Accumulation	\$131.80	\$126.06	\$102.57

Global Convertible Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	€46,242,404	€6,031,429	€51,336,753
Class I Euro Distribution	€1,968,468	€2,362,856	€2,024,775
Class I Hedged Euro Accumulation	€1,653,530	€1,288,609	€221,971
Class I Hedged Sterling Accumulation	£41,894,588	£13,593,147	£14,621,231
Class I Hedged Sterling Distribution	£28,465,818	£28,774,641	£22,354,918
Class I Hedged Swiss Franc Accumulation	Sfr. 951,876	Sfr. 8,729,345	Sfr. 6,674,960
Class I Sterling Accumulation	£23,471,443	£21,762,720	£17,432,307
Class I Sterling Distribution	£165,032,770	£162,098,233	£133,660,426
Class I US Dollar Accumulation	\$3,146,734	\$4,360,981	\$8,169,918
Class I US Dollar Distribution	\$2,897,211	\$4,130,100	\$3,159,349
Class Portfolio Currency Hedged Euro I Accumulation	€9,141,039	€36,022,803	€3,466,629
Class Portfolio Currency Hedged Sterling I Distribution	£50,325,577	£68,557,278	£111,879,694
Class R Euro Accumulation	€1,003,421	€784,930	€628,871
Class R Euro Distribution	€1,722,165	€1,600,219	€1,125,370
Class R Sterling Accumulation	£146,667	£215,502	£202,089
Class R Sterling Distribution	£191,243	£103,100	£1,539
Class R US Dollar Accumulation	\$113,083	\$1,688	\$1,338
Class R US Dollar Distribution	\$970,444	\$1,005,361	\$1,092,503
Class S Euro Accumulation	€189,059	€103,541	€117,993
Class S Euro Distribution	€616,249	€1,714	€1,498
Class S Hedged Sterling Accumulation	£804,197	£976,696	£1,555,873
Class S Hedged Sterling Distribution	£1,760,317	£2,729,389	£3,406,749
Class S Hedged Swiss Franc Accumulation	Sfr. 593.00	Sfr. 647	Sfr. 517
Class S Sterling Accumulation	£2,005,289	£2,157,304	£1,923,103
Class S Sterling Distribution	£270,114,392	£249,077,519	£267,473,432
Class S US Dollar Accumulation	\$794,494	\$739,201	\$499,628
Class S US Dollar Distribution	\$4,344,785	\$3,044,915	\$3,328,757
Class SI Sterling Accumulation	£60,707,376	£68,644,680	£40,470,568
Class Portfolio Currency Hedged Sterling S Distribution	£80,741,534	£88,201,998	£10,314,876

Global Convertible Fund continued	NAV per share 31 December 2021	NAV per share 31 December 2020	NAV per share 31 December 2019
Class I Euro Accumulation	€14.16	€14.23	€12.13
Class I Euro Distribution	€10.22	€10.70	€9.51
Class I Hedged Euro Accumulation	€12.07	€13.18	€10.56
Class I Hedged Sterling Accumulation	£12.68	£13.77	£11.03
Class I Hedged Sterling Distribution	£9.48	£10.72	£8.95
Class I Hedged Swiss Franc Accumulation	Sfr. 11.58	Sfr. 12.70	Sfr. 10.19
Class I Sterling Accumulation	£11.89	£12.73	£10.26
Class I Sterling Distribution	£8.58	£9.58	£8.05
Class I US Dollar Accumulation	\$16.10	\$17.41	\$13.61
Class I US Dollar Distribution	\$11.63	\$13.09	\$10.67
Class Portfolio Currency Hedged Euro I Accumulation	€13.02	€13.83	€11.18
Class Portfolio Currency Hedged Sterling I Distribution	£10.93	£12.04	£10.26
Class R Euro Accumulation	€13.66	€13.79	€11.82
Class R Euro Distribution	€9.83	€10.34	€9.24
Class R Sterling Accumulation	£11.47	£12.35	£10.00
Class R Sterling Distribution	£8.26	£9.26	£7.82
Class R US Dollar Accumulation	\$15.53	\$16.88	\$13.27
Class R US Dollar Distribution	\$11.18	\$12.66	\$10.37
Class S Euro Accumulation	€12.51	€12.52	€10.64
Class S Euro Distribution	€9.25	€9.65	€8.54
Class S Hedged Sterling Accumulation	£12.99	£14.05	£11.22
Class S Hedged Sterling Distribution	£9.69	£10.92	£9.09
Class S Hedged Swiss Franc Accumulation	Sfr. 11.86	Sfr. 12.93	Sfr. 10.34
Class S Sterling Accumulation	£10.50	£11.21	£9.01
Class S Sterling Distribution	£7.77	£8.64	£7.23
Class S US Dollar Accumulation	\$14.22	\$15.32	\$11.94
Class S US Dollar Distribution	\$10.52	\$11.81	\$9.59
Class SI Sterling Accumulation	£12.05	£12.88	£10.36
Class Portfolio Currency Hedged Sterling S Distribution	£11.03	£12.11	£10.23

	Net Asset Value Unaudited	Net Asset Value Audited	Net Asset Value Audited
Global Insurance Fund	31 December 2021	31 December 2020	31 December 2019
Class A Sterling Distribution	£1,212,349	£1,419,485	£2,192,020
Class B Sterling Accumulation	£8,823,869	£9,477,097	£11,332,394
Class E Sterling Distribution	£612,956,941	£537,548,317	£341,673,496
Class F Sterling Accumulation	£233,811,579	£197,505,637	£196,920,938
Class I Euro Accumulation	€60,093,102	€57,943,616	€84,608,193
Class I Euro Distribution	€11,330,421	€9,736,031	€10,218,320
Class I Hedged Euro Accumulation	€13,835,724	€14,433,408	€20,690,644
Class I Hedged US Dollar Accumulation	\$899,241	\$1,919,064	\$2,549,571
Class I Sterling Accumulation	£261,091,073	£294,421,553	£343,856,432
Class I Sterling Distribution	£246,245,991	£191,847,242	£198,634,320
Class I US Dollar Accumulation	\$231,110,844	\$254,666,196	\$333,758,414
Class I US Dollar Distribution	\$24,329,549	\$19,423,371	\$17,480,532
Class R Euro Accumulation	€6,133,614	€5,418,959	€9,702,647
Class R Euro Distribution	€2,295,734	€1,959,401	€1,001,350
Class R Sterling Accumulation	£4,167,556	£5,486,204	£7,551,333
Class R Sterling Distribution	£18,709,879	£17,049,078	£21,256,176
Class R US Dollar Accumulation	\$62,229,195	\$68,754,492	\$71,910,584
Class R US Dollar Distribution	\$1,390,626	\$1,297,677	\$1,002,538
	NAV per share	NAV per share	NAV per share
Class A Sterling Distribution	£6.02	£5.27	£5.73
Class B Sterling Accumulation	£8.00	£6.92	£7.38
Class E Sterling Distribution	£6.35	£5.54	£5.98
Class F Sterling Accumulation	£8.52	£7.33	£7.78
Class I Euro Accumulation	€9.85	€7.95	€8.89
Class I Euro Distribution	€7.40	€6.05	€6.90
Class I Hedged Euro Accumulation	€15.73	€13.60	€14.46
Class I Hedged US Dollar Accumulation	\$17.06	\$14.67	\$15.50
Class I Sterling Accumulation	£8.27	£7.11	£7.53
Class I Sterling Distribution	£6.21	£5.42	£5.84
Class I US Dollar Accumulation	\$11.20	\$9.72	\$9.98
Class I US Dollar Distribution	\$8.42	\$7.41	\$7.74
Class R Euro Accumulation	€9.27	€7.52	€8.46
		€5.78	€6.61
Class R Euro Distribution	€7.03		
Class R Euro Distribution Class R Sterling Accumulation	€7.03 £7.78	£6.73	£7.17
			£7.17 £5.60
Class R Sterling Accumulation	£7.78	£6.73	

Global Technology Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class A Euro Distribution	€18,933,704	€21,026,391	€5,681,779
Class A Sterling Distribution	£23,940,322	£25,294,111	£13,370,134
Class A US Dollar Distribution	\$86,621,494	\$96,727,378	\$57,864,482
Class I Euro Accumulation	€61,581,326	€3,250,035	N/A
Class I Euro Distribution	€442,999,275	€512,018,203	€131,049,557
Class I Hedged Euro Distribution	€153,836,170	€153,126,806	€60,935,800
Class I Hedged Sterling Distribution	£196,727,125	£179,945,587	£94,986,655
Class I Hedged Swiss Franc Distribution	Sfr. 117,469,302	Sfr. 101,053,907	Sfr. 34,015,441
Class I Sterling Distribution	£1,840,558,637	£1,900,613,783	£1,063,308,625
Class I US Dollar Distribution	\$2,139,038,560	\$2,231,275,507	\$872,165,059
Class R Euro Accumulation	€3,320,925	€891,317	N/A
Class R Euro Distribution	€487,270,747	€398,778,454	€153,141,681
Class R Hedged Euro Accumulation	€180,591,732	€210,484,996	€52,619,192
Class R Hedged Euro Distribution	€87,764,299	€110,228,317	€56,304,582
Class R Hedged Swiss Franc Distribution	Sfr. 34,784,358	Sfr. 31,139,483	Sfr. 11,128,344
Class R Sterling Distribution	£47,644,324	£41,818,351	£20,259,809
Class R US Dollar Distribution	\$2,194,707,757	£1,519,309,187	£578,573,409
	NAV per share	NAV per share	NAV per share
Class A Euro Distribution	€91.05	€77.26	€53.41
Class A Sterling Distribution	£76.45	£69.15	£45.25
Class A US Dollar Distribution	\$103.55	\$94.53	\$59.95
Class I Euro Accumulation.	€14.14	€11.94	N/A
Class I Euro Distribution	€84.81	€71.61	€49.05
Class I Hedged Euro Distribution	€26.63	€24.46	€15.72
Class I Hedged Sterling Distribution	£38.69	£35.35	£22.72
Class I Hedged Swiss Franc Distribution	Sfr. 38.32	Sfr. 35.35	Sfr. 22.80
Class I Sterling Distribution	£71.21	£64.09	£41.56
Class I US Dollar Distribution	\$96.45	\$87.61	\$55.06
Class R Euro Accumulation	€14.06	€11.93	N/A
Class R Euro Distribution	€80.10	€67.97	€46.72
Class R Hedged Euro Accumulation	€26.04	€24.05	€15.51
Class R Hedged Euro Distribution	€38.44	€35.50	€22.92
Class R Hedged Swiss Franc Distribution	Sfr. 37.27	Sfr. 34.54	Sfr. 22.34
	JII. J7.27		
Class R Sterling Distribution	f67.25	£60.84	£39.58

Healthcare Blue Chip Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	€729,776	€241,965	€8,512
Class I Euro Distribution	€94,096	€513,326	€463,803
Class I Sterling Accumulation	£15,449,569	£11,058,140	£9,571,104
Class I Sterling Distribution	£3,297,356	£2,168,948	£5,407,991
Class I US Dollar Accumulation	\$1,233,544	\$1,873,117	\$1,766,712
Class I US Dollar Distribution	\$85,093	\$56,674	\$22,740
Class S Sterling Accumulation	£3,709,578	£2,889,627	£5,242,226
Class S Sterling Distribution	£736,419	£582,424	£549,416
Class S Sterling Hedged Distribution	£1,790	£1,467	£1,394
Class S US Dollar Accumulation	\$150	\$123	\$114
Class S US Dollar Distribution	\$991	\$809	\$749
Class SI Sterling Distribution	£60,749,208	£48,402,659	£47,169,563
Class SI US Dollar Distribution	\$73,073	\$160,147	\$110,155
	NAV per share	NAV per share	NAV per share
Class I Euro Accumulation	€17.25	€13.11	€13.25
Class I Euro Distribution	€16.22	€12.40	€12.65
Class I Sterling Accumulation	£14.49	£11.73	£11.23
Class I Sterling Distribution	£13.62	£11.10	£10.72
Class I US Dollar Accumulation	\$19.62	\$16.04	\$14.87
Class I US Dollar Distribution	\$18.44	\$15.17	\$14.20
Class S Sterling Accumulation	£14.63	£11.83	£11.31
Class S Sterling Distribution	£13.76	£11.20	£10.80
Class S Sterling Hedged Distribution	£17.43	£14.37	£13.66
Class S US Dollar Accumulation	\$19.82	\$16.18	\$14.98
Class S US Dollar Distribution	\$18.63	\$15.31	\$14.31
Class SI Sterling Distribution	£12.19	£9.91	£9.53
Class SI US Dollar Distribution	\$16.52	\$13.54	\$12.63

Healthcare Discovery Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Sterling Accumulation	£1,815,430	£1,247,146	N/A
Class I US Dollar Accumulation	\$9,402,846	£1,334,935	N/A
Class S Sterling Accumulation	£34,651,717	£24,386,965	N/A
Class S US Dollar Accumulation	\$13,752,278	£12,078,174	N/A
	NAV per share	NAV per share	NAV per share
Class I Sterling Accumulation	£11.42	£11.01	N/A
Class I US Dollar Accumulation	\$15.47	£15.05	N/A
Class S Sterling Accumulation	£11.47	£11.03	N/A
Class S US Dollar Accumulation	\$15.54	£15.08	N/A

Healthcare Opportunities Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class A Euro Distribution	\$6,169,289	£6,595,606	£5,810,432
Class A Sterling Distribution	\$2,976,956	£2,923,616	£2,909,160
Class A US Dollar Distribution	\$8,280,305	£8,801,242	£8,896,760
Class I Euro Distribution	\$205,605,571	£197,367,115	£153,461,338
Class I Euro Accumulation	\$39,229,856	£32,469,292	£1,203,872
Class I Euro Hedged Accumulation	\$3,734,725	£2,681,443	N/A
Class I Sterling Distribution	\$950,150,017	£964,995,112	£814,338,418
Class I US Dollar Distribution	\$250,066,265	£237,121,974	£175,826,922
Class I US Dollar Accumulation	\$29,503,027	£36,756,528	N/A
Class R Euro Distribution	\$85,419,548	£66,698,086	£59,710,465
Class R Euro Accumulation	\$3,746,997	£863,140	N/A
Class R Sterling Distribution	\$15,296,765	£13,833,695	£11,569,737
Class R US Dollar Distribution	\$137,406,194	£118,969,723	£98,745,136
Class R US Dollar Accumulation	\$10,442,946	£5,569,520	N/A

Healthcare Opportunities Fund continued	NAV per share 31 December 2021	NAV per share 31 December 2020	NAV per share 31 December 2019
Class A Euro Distribution	\$40.54	€34.74	€32.05
Class A Sterling Distribution	\$34.04	£31.10	£27.15
Class A US Dollar Distribution	\$46.10	\$42.51	\$35.97
Class I Euro Distribution	\$61.90	€52.78	€48.45
Class I Euro Accumulation	\$14.78	€12.61	€11.57
Class I Euro Hedged Accumulation	\$15.33	€14.22	N/A
Class I Sterling Distribution	\$51.97	£47.24	£41.05
Class I US Dollar Distribution	\$70.39	\$64.58	\$54.39
Class I Euro Hedged Accumulation	\$15.33	€63.66	N/A
Class R Euro Distribution	\$58.23	€49.91	€46.03
Class R Euro Accumulation	\$57.31	€49.12	N/A
Class R Sterling Distribution	\$48.89	£44.68	£39.01
Class R US Dollar Distribution	\$66.22	\$61.07	\$51.67
Class R US Dollar Accumulation	\$65.17	€60.11	N/A

Income Opportunities Fund (based on dealing NAV per share)	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class A1 Sterling Distribution	£5,227,662	£5,759,048	£7,366,727
Class A2 Sterling Accumulation	£2,477,171	£2,266,692	£4,264,708
Class B1 Sterling Distribution	£7,602,273	£7,151,013	£25,190,078
Class B2 Sterling Accumulation	£21,446,170	£17,758,731	£84,374,013
Class I Euro Accumulation	€101,415	€1,076	€1,177
Class I Euro Distribution	€1,396	€1,071	€1,174
Class I Euro Hedged Accumulation	€280,270	€204,801	€234,861
Class I Euro Hedged Distribution	€11,690	€9,975	€58,204
Class I US Dollar Accumulation	\$1,433	\$1,182	\$1,185
Class I US Dollar Distribution	\$659,179	\$568,132	\$1,085,281
Class R Euro Accumulation	€304,243	€90,501	€450,081
Class R Euro Distribution	€109,582	€621,898	€798,978
Class R Euro Hedged Accumulation	€1,287,621	€1,794,911	€2,737,033
Class R Euro Hedged Distribution	€1,170,434	€1,593,118	€3,418,823
Class R US Dollar Accumulation	\$411,451	\$803,612	\$2,072,392
Class R US Dollar Distribution	\$1,513,704	\$2,773,437	\$3,595,686
Class R US Dollar Hedged Accumulation	\$16,898,400	\$15,276,048	\$24,509,687
Class R US Dollar Hedged Distribution	\$5,756,839	\$11,817,260	\$16,982,246
Class Z Sterling Accumulation	-	-	£1,113
Class Z Sterling Distribution	-	_	£1,113

Income Opportunities Fund continued (based on dealing NAV per share)	NAV per share 31 December 2021	NAV per share 31 December 2020	NAV per share 31 December 2019
Class A1 Sterling Distribution	£1.48	£1.27	£1.39
Class A2 Sterling Accumulation	£2.71	£2.22	£2.31
Class B1 Sterling Distribution	£1.57	£1.34	£1.47
Class B2 Sterling Accumulation	£2.85	£2.33	£2.41
Class I Euro Accumulation	€3.39	€2.60	€2.84
Class I Euro Distribution	€1.87	€1.50	€1.73
Class I Euro Hedged Accumulation	€16.29	€13.38	€13.89
Class I Euro Hedged Distribution	€12.59	€10.81	€11.84
Class I US Dollar Accumulation	\$3.86	\$3.18	\$3.19
Class I US Dollar Distribution	\$2.13	\$1.83	\$1.94
Class R Euro Accumulation	€3.23	€2.48	€2.73
Class R Euro Distribution	€1.76	€1.41	€1.64
Class R Euro Hedged Accumulation	€15.87	€13.09	€13.66
Class R Euro Hedged Distribution	€12.28	€10.60	€11.65
Class R US Dollar Accumulation	\$3.67	\$3.04	\$3.06
Class R US Dollar Distribution	\$2.00	\$1.73	\$1.84
Class R US Dollar Hedged Accumulation	\$13.89	\$11.39	\$11.65
Class R US Dollar Hedged Distribution	\$11.33	\$9.72	\$10.47
Class Z Sterling Accumulation	-	_	£11.13
Class Z Sterling Distribution	-	_	£11.13

	Net Asset Value Unaudited	Net Asset Value Audited	Net Asset Value Audited
Japan Value Fund	31 December 2021	31 December 2020	31 December 2019
Class I Euro Distribution	€1,027	€919	€1,910,498
Class I Hedged Swiss Franc Distribution	Sfr. 1,089	Sfr. 957	Sfr. 1,109
Class I Hedged Euro Distribution	€953	€836	€970
Class I Hedged Sterling Distribution	£56,070	£857	£988
Class I Hedged US Dollar Distribution	\$383,554	\$283,971	\$9,092
Class I Japanese Yen Distribution	¥182,091	¥403,407,806	¥181,472
Class I Sterling Distribution	£79,875	£77,564	£36,395
Class I US Dollar Distribution	\$946	\$4,161	\$111,425
Class R Hedged Swiss Franc Distribution	Sfr. 2,440,262	Sfr. 2,195,052	Sfr. 4,311,454
Class R Hedged Euro Distribution	€4,849,304	€6,157,405	€13,882,908
Class R Hedged Sterling Distribution	£2,468,610	£3,703,041	£3,980,429
Class R Hedged US Dollar Distribution	\$25,039,578	\$26,424,023	\$57,208,526
Class R Euro Distribution	€99,602	€298,957	€670,426
Class R Sterling Distribution	£5,168	£7,270	£11,721
Class R Japanese Yen Distribution	¥1,147,693,152	¥1,196,931,572	¥1,994,412,986

Japan Value Fund continued	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class R US Dollar Distribution	\$551,453	\$703,174	\$1,271,346
Class S Hedged Swiss Franc Distribution	Sfr. 2,150,981	Sfr. 2,127,695	Sfr. 4,774,128
Class S Hedged Euro Distribution	€4,072,121	€4,670,439	€19,231,110
Class S Hedged Sterling Distribution	£12,006,326	£13,772,452	£28,631,456
Class S Hedged US Dollar Distribution	\$18,105,065	\$16,799,619	\$49,782,036
Class S Euro Distribution	€12,623,521	€311,301	€1,925,809
Class S Japanese Yen Distribution	¥3,154,136,123	¥2,178,077,521	¥10,884,995,284
Class S Sterling Distribution	£45,830,446	£27,399,558	£28,246,822
Class S US Dollar Distribution	\$13,166,044	\$13,150,187	\$16,390,198
	NAV per share	NAV per share	NAV per share
Class I Euro Distribution	€0.99	€0.89	€1.05
Class I Hedged Swiss Franc Distribution	Sfr. 10.89	Sfr. 9.57	Sfr. 11.09
Class I Hedged Euro Distribution	€9.53	€8.36	€9.70
Class I Hedged Sterling Distribution	£9.79	£8.57	£9.88
Class I Hedged US Dollar Distribution	\$10.28	\$8.96	\$10.23
Class I Japanese Yen Distribution	¥128.69	¥112.12	¥128.25
Class I Sterling Distribution	f0.83	£0.80	£0.90
Class I US Dollar Distribution	\$1.12	\$1.09	\$1.17
Class R Hedged Swiss Franc Distribution	Sfr. 10.81	Sfr. 9.54	Sfr. 11.09
Class R Hedged Euro Distribution	€2.26	€1.99	€2.32
Class R Hedged Sterling Distribution	£1.87	£1.65	£1.91
Class R Hedged US Dollar Distribution	\$3.25	\$2.84	\$3.25
Class R Euro Distribution	€2.00	€1.80	€2.14
Class R Sterling Distribution	£1.68	£1.63	£1.83
Class R Japanese Yen Distribution	¥260.46	¥227.72	¥261.40
Class R US Dollar Distribution	\$2.26	\$2.20	\$2.39
Class S Hedged Swiss Franc Distribution	Sfr. 10.99	Sfr. 9.62	Sfr. 11.11
Class S Hedged Euro Distribution	€2.39	€2.09	€2.41
Class S Hedged Sterling Distribution	£1.99	£1.73	£1.99
Class S Hedged US Dollar Distribution	\$3.45	\$2.99	\$3.40
Class S Euro Distribution	€2.12	€1.89	€2.23
Class S Japanese Yen Distribution	¥275.45	¥239.03	¥272.32
Class S Sterling Distribution	£1.78	£1.71	£1.91
Class S US Dollar Distribution	\$2.39	\$2.31	\$2.49

North American Fund	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Distribution	€339,509	€271,480	€159,967,651
Class I Hedged Euro Distribution	€80,455,582	€44,400,932	€127,357,165
Class I Hedged Sterling Distribution	£51,844,686	£26,410,625	£80,295,758
Class I Hedged Swiss Franc Distribution	Sfr. 1,990,289	Sfr. 2,291,141	Sfr. 2,504,482
Class I Sterling Distribution	£117,852,890	£123,781,952	£248,794,128
Class I US Dollar Distribution	\$416,954,758	\$334,217,691	\$511,068,660
Class R Euro Distribution	€5,046,768	€1,712,431	€1,874,587
Class R Hedged Euro Distribution	€6,183,533	€4,374,506	€9,079,896
Class R Hedged Sterling Distribution	£1,625,361	£1,300,710	£1,247,525
Class R Sterling Distribution	£564,614	£446,906	£394,536
Class R US Dollar Distribution	\$57,955,332	\$41,489,186	\$48,502,643
Class S Euro Distribution	€1,300,722	€1,011,963	€1,130,831
Class S Hedged Euro Distribution	€734,223	€5,457,242	€703,587
Class S Hedged Sterling Distribution	£21,974,628	£23,101,917	£48,096,232
Class S Sterling Distribution	£210,126,020	£198,460,322	£420,748,385
Class S US Dollar Distribution	\$120,289,480	\$96,059,357	\$114,082,854
	NAV per share	NAV per share	NAV per share
Class I Euro Distribution	€34.11	€25.66	€24.29
Class I Hedged Euro Distribution	€33.81	€27.58	€24.60
Class I Hedged Sterling Distribution	£35.19	£28.63	£25.75
Class I Hedged Swiss Franc Distribution	Sfr. 18.81	Sfr. 15.38	Sfr. 13.74
Class I Sterling Distribution	£28.64	£22.96	£20.58
Class I US Dollar Distribution	\$38.79	\$31.39	\$27.26
Class R Euro Distribution	€32.19	€24.36	€23.20
Class R Hedged Euro Distribution	€31.86	€26.15	€23.46
Class R Hedged Sterling Distribution	£33.31	£27.24	£24.66
Class R Sterling Distribution	£27.03	£21.80	£19.66
Class R US Dollar Distribution	\$36.61	\$29.81	\$26.04
Class S Euro Distribution	€34.52	€25.96	€24.56
		627.05	€24.91
Class S Hedged Euro Distribution	€34.29	€27.95	C24.51
Class S Hedged Euro Distribution Class S Hedged Sterling Distribution	€34.29 £35.67	£27.95	£26.07
-			

Smart Energy Fund*	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	\$5,242,579	N/A	N/A
Class I Sterling Accumulation	\$852,111	N/A	N/A
Class I Swedish Krona Accumulation	\$1,101	N/A	N/A
Class I Swiss Franc Accumulation	\$1,040	N/A	N/A
Class I US Dollar Accumulation	\$16,018,982	N/A	N/A
Class R Euro Accumulation	\$594,991	N/A	N/A
Class R Sterling Accumulation	\$1,057	N/A	N/A
Class R Swedish Krona Accumulation	\$1,099	N/A	N/A
Class R Swiss Franc Accumulation	\$2,974	N/A	N/A
Class R US Dollar Accumulation	\$3,836,824	N/A	N/A
	NAV per share	NAV per share	NAV per share
Class I Euro Accumulation	£9.36	N/A	N/A
Class I Sterling Accumulation	£7.86	N/A	N/A
Class I Swedish Krona Accumulation	£96.34	N/A	N/A
Class I Swiss Franc Accumulation	£9.70	N/A	N/A
Class I US Dollar Accumulation	£10.64	N/A	N/A
Class R Euro Accumulation	£9.34	N/A	N/A
Class R Sterling Accumulation	£7.84	N/A	N/A
Class R Swedish Krona Accumulation	£96.16	N/A	N/A
Class R Swiss Franc Accumulation	£9.68	N/A	N/A
Class R US Dollar Accumulation	£10.62	N/A	N/A

Smart Mobility Fund*	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Accumulation	€1,409,097.64	N/A	N/A
Class I GBP Accumulation	£326,829.69	N/A	N/A
Class I Swedish Krona Accumulation	kr 1,094.31	N/A	N/A
Class I Swiss Franc Accumulation	CHF 1,032.15	N/A	N/A
Class I US Dollar Accumulation	\$5,304,026.00	N/A	N/A
Class R Euro Accumulation	€17,687.00	N/A	N/A
Class R GBP Accumulation	£1,051.21	N/A	N/A
Class R Swedish Krona Accumulation	kr 1,092.82	N/A	N/A
Class R Swiss Franc Accumulation	CHF 1,031.08	N/A	N/A
Class R US Dollar Accumulation	\$1,056.00	N/A	N/A

\* Smart Energy Fund and Smart Mobility Fund launched on 30 September 2021.

# 12. Comparative Figures continued

Smart Mobility Fund* continued	NAV per share 31 December 2021	NAV per share 31 December 2020	NAV per share 31 December 2019
Class I Euro Accumulation	€9.30	N/A	N/A
Class I GBP Accumulation	£7.81	N/A	N/A
Class I Swedish Krona Accumulation	kr 95.74	N/A	N/A
Class I Swiss Franc Accumulation	CHF 9.63	N/A	N/A
Class I US Dollar Accumulation	\$10.57	N/A	N/A
Class R Euro Accumulation	€9.29	N/A	N/A
Class R GBP Accumulation	£7.80	N/A	N/A
Class R Swedish Krona Accumulation	kr 95.61	N/A	N/A
Class R Swiss Franc Accumulation	CHF 9.62	N/A	N/A
Class R US Dollar Accumulation	\$10.56	N/A	N/A

UK Absolute Equity Fund*	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Euro Distribution	_	_	€1,701,372
Class I Hedged Euro Distribution	-	_	€238,464,437
Class I Hedged US Dollar Distribution	-	_	\$40,915,302
Class I Sterling Distribution	_	_	£167,547,222
Class I US Dollar Distribution	-	_	\$18,697,704
Class R Euro Distribution	-	_	€873,098
Class R Hedged Euro Distribution	-	_	€30,434,398
Class R Hedged US Dollar Distribution	-	_	\$1,447,597
Class R Sterling Distribution	-	_	£2,511,592
Class R US Dollar Distribution	-	_	\$252,774
Class S Euro Distribution	-	_	€860,779
Class S Hedged Euro Distribution	-	_	€1,132,664
Class S Hedged US Dollar Distribution	-	_	\$2,758,886
Class S Sterling Distribution	-	_	£58,470,670
Class S US Dollar Distribution	-	_	\$181

\* Smart Mobility Fund launched on 30 September 2021.

UK Absolute Equity Fund* continued	NAV per share 31 December 2021	NAV per share 31 December 2020	NAV per share 31 December 2019
Class I Euro Distribution	-	_	€25.99
Class I Hedged Euro Distribution	-	_	€27.25
Class I Hedged US Dollar Distribution	_	_	\$36.76
Class I Sterling Distribution	-	-	£22.09
Class I US Dollar Distribution	-	_	\$29.18
Class R Euro Distribution	_	_	€25.50
Class R Hedged Euro Distribution	_	_	€26.68
Class R Hedged US Dollar Distribution	-	_	\$35.94
Class R Sterling Distribution	_	_	£21.67
Class R US Dollar Distribution	_	_	\$28.63
Class S Euro Distribution	-	_	€26.31
Class S Hedged Euro Distribution	_	_	€27.64
Class S Hedged US Dollar Distribution	_	_	\$37.12
Class S Sterling Distribution	-	_	£22.36
Class S US Dollar Distribution	_	_	\$29.53

<b>UK Value Opportunities Fund</b> (based on dealing NAV per share)	Net Asset Value Unaudited 31 December 2021	Net Asset Value Audited 31 December 2020	Net Asset Value Audited 31 December 2019
Class I Sterling Accumulation	£140,431,200	£169,776,899	£163,235,912
Class I Sterling Distribution	£165,459,543	£82,103,819	£69,565,964
Class R Sterling Accumulation	£2,089,281	£2,772,778	£2,606,083
Class S Sterling Accumulation	£243,618,047	£181,693,640	£384,429,419
Class S Sterling Distribution	£1,009,212,051	£585,158,581	£652,165,547
Class Z Sterling Accumulation	£54,887,100	£132,286,830	£1,178
Class Z Sterling Distribution	-	_	£1,178
	NAV per share	NAV per share	NAV per share
Class I Sterling Accumulation	£14.64	£12.19	£13.21
Class I Sterling Distribution	£13.83	£11.59	£12.82
Class R Sterling Accumulation	£12.25	£10.23	£11.13
Class S Sterling Accumulation	£14.72	£12.25	£13.25
Class S Sterling Distribution	£13.86	£11.61	£12.84
Class Z Sterling Accumulation	£13.30	£10.97	£11.78
Class Z Sterling Distribution	-	-	£11.78

<sup>\*</sup> UK Absolute Equity Fund terminated on 15 May 2020.

#### **13. Distributions**

In the financial year ended 31 December 2021 the following Funds declared and paid distributions as follows:

31 December 2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Emerging Markets Income Fund						· · ·
Class R Distributing Shares					US\$42,619	
Class R US Dollar Distribution	04/01/2021	29/01/2021	\$0.1928	184,145	\$35,503	01/07/2020 – 31/12/2020
Class R Sterling Distribution	04/01/2021	29/01/2021	£0.1410	25,060	£3,534	01/07/2020 – 31/12/2020
Class R Euro Distribution	04/01/2021	29/01/2021	€0.1576	11,850	€1,868	01/07/2020 - 31/12/2020
Class I Distributing Shares					US\$547,601	
Class I US Dollar Distribution	04/01/2021	29/01/2021	\$0.1988	38,469	\$7,648	01/07/2020 – 31/12/2020
Class I Sterling Distribution	04/01/2021	29/01/2021	£0.1454	2,702,764	£392,982	01/07/2020 - 31/12/2020
Class I Euro Distribution	04/01/2021	29/01/2021	€0.1625	13,298	€2,161	01/07/2020 - 31/12/2020
Class S Distributing Shares				U	IS\$1,422,242	
Class S US Dollar Distribution	04/01/2021	29/01/2021	\$0.2034	430,329	\$87,529	01/07/2020 - 31/12/2020
Class S Sterling Distribution	04/01/2021	29/01/2021	£0.1488	6,561,991	£976,424	01/07/2020 - 31/12/2020
Class S Euro Distribution	04/01/2021	29/01/2021	€0.1662	19	€3	01/07/2020 - 31/12/2020

Total Distributions for Emerging Markets Income Fund

US\$2,012,462

31 December 2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
European ex UK Income Fund						
Class I Distribution Shares				G	BP£141,674	
Class I Sterling Distribution	04/01/2021	29/01/2021	£0.0425	362,530	£15,408	01/10/2020 - 31/12/2020
Class I Sterling Distribution	01/04/2021	30/04/2021	£0.0561	347,393	£19,489	01/01/2021 – 31/03/2021
Class I Sterling Distribution	01/07/2021	30/07/2021	£0.2132	383,530	£81,769	01/04/2021 - 30/06/2021
Class I Sterling Distribution	01/10/2021	29/10/2021	£0.0628	398,233	£25,009	01/07/2021 - 30/09/2021
Class S Distribution Shares				GBI	P£1,407,669	
Class S Sterling Distribution	04/01/2021	29/01/2021	£0.0427	3,564,728	£152,214	01/10/2020 - 31/12/2020
Class S Sterling Distribution	01/04/2021	30/04/2021	£0.0566	3,768,028	£213,270	01/01/2021 – 31/03/2021
Class S Sterling Distribution	01/07/2021	30/07/2021	£0.2148	3,811,546	£818,720	01/04/2021 - 30/06/2021
Class S Sterling Distribution	01/10/2021	29/10/2021	£0.0633	3,530,241	£223,464	01/07/2021 – 30/09/2021
Class I Hedged Distribution Shares					GBP£2,376	
Class I Sterling Hedged Distribution	04/01/2021	29/01/2021	£0.0479	8,959	£429	01/10/2020 - 31/12/2020
Class I Sterling Hedged Distribution	01/04/2021	30/04/2021	£0.0663	3,940	£261	01/01/2021 - 31/03/2021
Class I Sterling Hedged Distribution	01/07/2021	30/07/2021	£0.2527	4,679	£1,182	01/04/2021 - 30/06/2021
Class I Sterling Hedged Distribution	01/10/2021	29/10/2021	£0.0752	6,692	£503	01/07/2021 – 30/09/2021

31 December 2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
European ex UK Income Fund continu	ued					
Class S Hedged Distribution Shares				(	GBP£716,518	
Class S Sterling Hedged Distribution	04/01/2021	29/01/2021	£0.0482	3,484,880	£167,971	01/10/2020 - 31/12/2020
Class S Sterling Hedged Distribution	01/04/2021	30/04/2021	£0.0665	1,906,971	£126,814	01/01/2021 – 31/03/2021
Class S Sterling Hedged Distribution	01/07/2021	30/07/2021	£0.2540	1,645,615	£417,986	01/04/2021 - 30/06/2021
Class S Sterling Hedged Distribution	01/10/2021	29/10/2021	£0.0755	49,631	£3,747	01/07/2021 – 30/09/2021
Class X Distribution Shares				GB	P£2,598,404	
Class X Sterling Distribution	04/01/2021	29/01/2021	£0.0479	7,509,538	£359,707	01/10/2020 - 31/12/2020
Class X Sterling Distribution	01/04/2021	30/04/2021	£0.0632	6,709,538	£424,043	01/01/2021 – 31/03/2021
Class X Sterling Distribution	01/07/2021	30/07/2021	€0.2398	6,072,338.91	£1,456,147	01/04/2021 - 30/06/2021
Class X Sterling Distribution	01/10/2021	29/10/2021	£0.0704	5,092,442	£358,508	01/07/2021 – 30/09/2021
Total Distributions for European ex UK Income Fund				EU	R€5,627,689	

#### Total Distributions for European ex UK Income Fund

	Date	Date of	Rate per	No. of		
31 December 2021	declared	payment	share	shares	Amount	Relevant period
Financial Opportunities Fund						
Class R Distributing Shares					US\$2,033	
Class R US Dollar Distribution	04/01/2021	29/01/2021	\$0.0775	9	\$1	01/07/2020 - 31/12/2020
Class R Sterling Distribution	04/01/2021	29/01/2021	£0.0567	8,073	£458	01/07/2020 - 31/12/2020
Class R Euro Distribution	04/01/2021	29/01/2021	€0.0634	6	€0	01/07/2020 - 31/12/2020
Class R US Dollar Distribution	01/07/2021	30/07/2021	\$0.1519	9	\$1	01/04/2021 - 30/06/2021
Class R Sterling Distribution	01/07/2021	30/07/2021	£0.1099	8,092	£889	01/04/2021 - 30/06/2021
Class R Euro Distribution	01/07/2021	30/07/2021	€0.1281	1,163	€149	01/04/2021 - 30/06/2021
Class I Distributing Shares					US\$99,619	
Class I US Dollar Distribution	04/01/2021	29/01/2021	\$0.0810	8,715	\$706	01/07/2020 – 31/12/2020
Class I Sterling Distribution	04/01/2021	29/01/2021	£0.0592	325,402	£19,264	01/07/2020 – 31/12/2020
Class I Euro Distribution	04/01/2021	29/01/2021	€0.0662	88,378	€5,851	01/07/2020 - 31/12/2020
Class I US Dollar Distribution	01/07/2021	30/07/2021	\$0.1588	9,149	\$1,453	01/04/2021 - 30/06/2021
Class I Sterling Distribution	01/07/2021	30/07/2021	£0.1149	313,547	£36,027	01/04/2021 - 30/06/2021
Class I Euro Distribution	01/07/2021	30/07/2021	€0.1339	89,121	€11,933	01/04/2021 - 30/06/2021
Class S Distributing Shares					US\$85,652	
Class S US Dollar Distribution	04/01/2021	29/01/2021	€0.0537	266,814	€14,328	01/07/2020 – 31/12/2020
Class S Sterling Distribution	04/01/2021	29/01/2021	€0.0393	13	€1	01/07/2020 – 31/12/2020
Class S US Dollar Distribution	01/07/2021	30/07/2021	€0.1448	484,663	£70,179	01/04/2021 - 30/06/2021
Class S Sterling Distribution	01/07/2021	30/07/2021	€0.1048	7,903	€828	01/04/2021 - 30/06/2021
Total Distributions for Financial Opportunities Fund     US\$187,304						

### 13. Distributions continued

31 December 2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Global Convertible Fund						
Class R Distributing Shares					US\$135,334	
Class R US Dollar Distribution	04/01/2021	29/01/2021	\$0.1329	79,412	\$10,554	01/10/2020 - 31/12/2020
Class R Sterling Distribution	04/01/2021	29/01/2021	£0.0972	11,134	£1,082	01/10/2020 - 31/12/2020
Class R Euro Distribution	04/01/2021	29/01/2021	€0.1086	154,760	€16,807	01/10/2020 - 31/12/2020
Class R US Dollar Distribution	01/04/2021	30/04/2021	\$0.1213	81,742	\$9,915	01/01/2021 – 31/03/2021
Class R Sterling Distribution	01/04/2021	30/04/2021	£0.0879	21,195	£1,863	01/01/2021 - 31/03/2021
Class R Euro Distribution	01/04/2021	30/04/2021	€0.1032	152,850	€15,774	01/01/2021 - 31/03/2021
Class R US Dollar Distribution	01/07/2021	31/07/2021	\$0.1227	96,723	\$11,868	01/04/2021 - 30/06/2021
Class R Sterling Distribution	01/07/2021	31/07/2021	£0.0888	23,634	£2,099	01/04/2021 - 30/06/2021
Class R Euro Distribution	01/07/2021	31/07/2021	€0.1035	179,130	€18,540	01/04/2021 - 30/06/2021
Class R US Dollar Distribution	01/10/2021	29/10/2021	\$0.1142	104,805	\$11,969	01/07/2021 – 30/09/2021
Class R Sterling Distribution	01/10/2021	29/10/2021	£0.0847	26,124	£2,213	01/07/2021 – 30/09/2021
Class R Euro Distribution	01/10/2021	29/10/2021	€0.0985	175,193	€17,257	01/07/2021 – 30/09/2021
Class I Distributing Shares				ι	JS\$9,331,289	
Class I US Dollar Distribution	04/01/2021	29/01/2021	\$0.1374	315,516	\$43,352	01/10/2020 - 31/12/2020
Class I Sterling Distribution	04/01/2021	29/01/2021	£0.1005	16,920,484	£1,700,509	01/10/2020 - 31/12/2020
Class I Euro Distribution	04/01/2021	29/01/2021	€0.1123	220,828	€24,799	01/10/2020 - 31/12/2020
Class I US Dollar Distribution	01/04/2021	30/04/2021	\$0.1255	326,369	\$40,959	01/01/2021 – 31/03/2021
Class I Sterling Distribution	01/04/2021	30/04/2021	£0.0910	17,501,487	£1,592,635	01/01/2021 - 31/03/2021
Class I Euro Distribution	01/04/2021	30/04/2021	€0.1068	185,127	€19,772	01/01/2021 - 31/03/2021
Class I US Dollar Distribution	01/07/2021	31/07/2021	\$0.1272	326,448	\$41,524	01/04/2021 - 30/06/2021
Class I Sterling Distribution	01/07/2021	31/07/2021	£0.0921	18,239,323	£1,679,842	01/04/2021 - 30/06/2021
Class I Euro Distribution	01/07/2021	31/07/2021	€0.1073	186,092	€19,968	01/04/2021 - 30/06/2021
Class I US Dollar Distribution	01/10/2021	29/10/2021	\$0.1186	262,460	\$31,128	01/07/2021 – 30/09/2021
Class I Sterling Distribution	01/10/2021	29/10/2021	£0.0880	18,814,235	£1,655,653	01/07/2021 – 30/09/2021
Class I Euro Distribution	01/10/2021	29/10/2021	€0.1023	191,823	€19,624	01/07/2021 – 30/09/2021
Class S Distributing Shares				US	\$14,682,837	
Class S US Dollar Distribution	04/01/2021	29/01/2021	\$0.1239	257,825	\$31,945	01/10/2020 - 31/12/2020
Class S Sterling Distribution	04/01/2021	29/01/2021	£0.0906	28,828,417	£2,611,855	01/10/2020 - 31/12/2020
Class S Euro Distribution	04/01/2021	29/01/2021	€0.1013	178	€18	01/10/2020 – 31/12/2020
Class S US Dollar Distribution	01/04/2021	30/04/2021	\$0.1134	267,077	\$30,286	01/01/2021 – 31/03/2021
Class S Sterling Distribution	01/04/2021	30/04/2021	£0.0822	29,915,744	£2,459,074	01/01/2021 – 31/03/2021
Class S Euro Distribution	01/04/2021	30/04/2021	€0.0965	179	€17	01/01/2021 - 31/03/2021
Class S US Dollar Distribution	01/07/2021	31/07/2021	\$0.1147	394,543	\$45,254	01/04/2021 - 30/06/2021
Class S Sterling Distribution	01/07/2021	31/07/2021	£0.0830	33,531,853	£2,783,144	01/04/2021 - 30/06/2021
Class S Euro Distribution	01/07/2021	31/07/2021	€0.0967	61,133	€5,912	01/04/2021 - 30/06/2021
Class S US Dollar Distribution	01/10/2021	29/10/2021	\$0.1075	397,791	\$42,763	01/07/2021 - 30/09/2021
Class S Sterling Distribution	01/10/2021	29/10/2021	£0.0797	34,517,997	£2,751,084	01/07/2021 - 30/09/2021
Class S Euro Distribution	01/10/2021	29/10/2021	€0.0928	65,562	€6,084	01/07/2021 – 30/09/2021

31 December 2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period			
Global Convertible Fund continued									
Class I Hedged Distributing Shares				G	BP£561,870				
Class I Hedged Sterling Distribution	04/01/2021	29/01/2021	£0.1126	2,684,202	£302,241	01/10/2020 - 31/12/2020			
Class I Hedged Sterling Distribution	01/04/2021	30/04/2021	£0.1027	2,528,028	£259,628	01/01/2021 – 31/03/2021			
Class I Hedged Sterling Distribution	01/07/2021	31/07/2021	£0.1039	2,923,761	£303,779	01/04/2021 - 30/06/2021			
Class I Hedged Sterling Distribution	01/10/2021	29/10/2021	£0.0967	2,885,834	£279,060	01/07/2021 - 30/09/2021			
Class S Hedged Distributing Shares				(					
Class S Hedged Sterling Distribution	04/01/2021	29/01/2021	£0.1149	249,944	£28,719	01/10/2020 - 31/12/2020			
Class S Hedged Sterling Distribution	01/04/2021	30/04/2021	£0.1046	171,185	£17,906	01/01/2021 - 31/03/2021			
Class S Hedged Sterling Distribution	01/07/2021	31/07/2021	£0.1059	174,116	£18,439	01/04/2021 - 30/06/2021			
Class S Hedged Sterling Distribution	01/10/2021	29/10/2021	£0.0998	193,089	£19,270	01/07/2021 - 30/09/2021			
Class Portfolio Currency Hedged I Di	ass Portfolio Currency Hedged I Distribution Shares				GBP£1,369,910				
Class Portfolio Currency Hedged Sterling I Distribution	04/01/2021	29/01/2021	£0.1264	5,694,126	£719,738	01/10/2020 – 31/12/2020			
Class Portfolio Currency Hedged Sterling I Distribution	01/04/2021	30/04/2021	£0.1172	5,547,549	£650,173	01/01/2021 – 31/03/2021			
Class Portfolio Currency Hedged Sterling I Distribution	01/07/2021	31/07/2021	£0.1183	5,532,420	£654,485	01/04/2021 – 30/06/2021			
Class Portfolio Currency Hedged Sterling I Distribution	01/10/2021	29/10/2021	£0.1109	4,636,764	£514,217	01/07/2021 – 30/09/2021			
Class Portfolio Currency Hedged S Di	GBP£1,762,282								
Class Portfolio Currency Hedged Sterling S Distribution	04/01/2021	29/01/2021	£0.1272	7,283,402	£926,449	01/10/2020 – 31/12/2020			
Class Portfolio Currency Hedged Sterling S Distribution	01/04/2021	30/04/2021	£0.1181	7,077,336	£835,833	01/01/2021 – 31/03/2021			
Class Portfolio Currency Hedged Sterling S Distribution	01/07/2021	31/07/2021	£0.1191	7,262,785	£864,998	01/04/2021 – 30/06/2021			
Class Portfolio Currency Hedged Sterling S Distribution	01/10/2021	29/10/2021	£0.1118	7,270,043	£812,791	01/07/2021 – 30/09/2021			
Total Distributions for Global Convertible Fund				US	\$34,011,104				

### 13. Distributions continued

Class R Sterling Distribution04/0Class R Euro Distribution04/0Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/0Class R US Dollar Distribution01/0Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/1Class R US Dollar Distribution01/1Class R Sterling Distribution01/1Class R Sterling Distribution01/1	01/2021 01/2021 01/2021 04/2021 04/2021 04/2021 07/2021 07/2021 10/2021 10/2021	29/01/2021 29/01/2021 30/04/2021 30/04/2021 30/04/2021 30/07/2021 30/07/2021 30/07/2021 29/10/2021 29/10/2021	\$0.0158 £0.0116 €0.0129 \$0.0279 £0.0238 €0.0238 \$0.0359 £0.0260 €0.0302 \$0.0240 £0.0240 £0.0178 €0.0207	183,594 3,297,184 339,185 190,626 3,218,559 338,959 184,638 3,215,311 339,655 174,058 3,212,708	GBP£283,735 \$2,901 €38,247 €4,375 \$5,318 f65,337 €8,067 \$6,628 f83,598 €10,258 \$4,177.3858	01/10/2020 – 31/12/2020 01/10/2020 – 31/12/2020 01/10/2020 – 31/12/2020 01/01/2021 – 31/03/2021 01/01/2021 – 31/03/2021 01/04/2021 – 30/06/2021 01/04/2021 – 30/06/2021 01/04/2021 – 30/06/2021		
Class R US Dollar Distribution04/0Class R Sterling Distribution04/0Class R Euro Distribution04/0Class R Euro Distribution01/0Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Sterling Distribution01/0Class R US Dollar Distribution01/1Class R US Dollar Distribution01/1Class R Sterling Distribution01/1Class R Sterling Distribution01/1	01/2021 01/2021 04/2021 04/2021 04/2021 07/2021 07/2021 10/2021 10/2021	29/01/2021 29/01/2021 30/04/2021 30/04/2021 30/07/2021 30/07/2021 30/07/2021 29/10/2021	£0.0116 €0.0129 \$0.0279 £0.0203 €0.0238 \$0.0359 £0.0260 €0.0302 \$0.0240 £0.0178	183,594 3,297,184 339,185 190,626 3,218,559 338,959 184,638 3,215,311 339,655 174,058	\$2,901 £38,247 €4,375 \$5,318 £65,337 €8,067 \$6,628 £83,598 €10,258 \$4,177.3858	01/10/2020 – 31/12/2020 01/10/2020 – 31/12/2020 01/01/2021 – 31/03/2021 01/01/2021 – 31/03/2021 01/01/2021 – 31/03/2021 01/04/2021 – 30/06/2021 01/04/2021 – 30/06/2021		
Class R Sterling Distribution04/CClass R Euro Distribution04/CClass R US Dollar Distribution01/OClass R Sterling Distribution01/OClass R Euro Distribution01/OClass R US Dollar Distribution01/OClass R US Dollar Distribution01/OClass R US Dollar Distribution01/OClass R Sterling Distribution01/OClass R Sterling Distribution01/OClass R Euro Distribution01/OClass R US Dollar Distribution01/OClass R US Dollar Distribution01/OClass R US Dollar Distribution01/OClass R Sterling Distribution01/OClass R Sterling Distribution01/O	01/2021 01/2021 04/2021 04/2021 04/2021 07/2021 07/2021 10/2021 10/2021	29/01/2021 29/01/2021 30/04/2021 30/04/2021 30/07/2021 30/07/2021 30/07/2021 29/10/2021	£0.0116 €0.0129 \$0.0279 £0.0203 €0.0238 \$0.0359 £0.0260 €0.0302 \$0.0240 £0.0178	3,297,184 339,185 190,626 3,218,559 338,959 184,638 3,215,311 339,655 174,058	f38,247 €4,375 \$5,318 f65,337 €8,067 \$6,628 f83,598 €10,258 \$4,177.3858	01/10/2020 – 31/12/2020 01/10/2020 – 31/12/2020 01/01/2021 – 31/03/2021 01/01/2021 – 31/03/2021 01/01/2021 – 31/03/2021 01/04/2021 – 30/06/2021 01/04/2021 – 30/06/2021		
Class R Euro Distribution04/0Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/0Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/1Class R US Dollar Distribution01/1Class R Sterling Distribution01/1	01/2021 04/2021 04/2021 04/2021 07/2021 07/2021 07/2021 10/2021 10/2021	29/01/2021 30/04/2021 30/04/2021 30/07/2021 30/07/2021 30/07/2021 29/10/2021 29/10/2021	€0.0129 \$0.0279 £0.0238 €0.0238 \$0.0359 £0.0260 €0.0302 \$0.0240 £0.0178	339,185 190,626 3,218,559 338,959 184,638 3,215,311 339,655 174,058	€4,375 \$5,318 £65,337 €8,067 \$6,628 £83,598 €10,258 \$4,177.3858	01/10/2020 – 31/12/2020 01/01/2021 – 31/03/2021 01/01/2021 – 31/03/2021 01/01/2021 – 31/03/2021 01/04/2021 – 30/06/2021 01/04/2021 – 30/06/2021		
Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R Euro Distribution01/0Class R Euro Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/1Class R US Dollar Distribution01/1Class R Sterling Distribution01/1	04/2021 04/2021 04/2021 07/2021 07/2021 07/2021 10/2021 10/2021	30/04/2021 30/04/2021 30/07/2021 30/07/2021 30/07/2021 29/10/2021	\$0.0279 £0.0203 €0.0238 \$0.0359 £0.0260 €0.0302 \$0.0240 £0.0178	190,626 3,218,559 338,959 184,638 3,215,311 339,655 174,058	\$5,318 f65,337 €8,067 \$6,628 f83,598 €10,258 \$4,177.3858	01/01/2021 – 31/03/2021 01/01/2021 – 31/03/2021 01/01/2021 – 31/03/2021 01/04/2021 – 30/06/2021 01/04/2021 – 30/06/2021		
Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/1Class R US Dollar Distribution01/1Class R US Dollar Distribution01/1	04/2021 04/2021 07/2021 07/2021 07/2021 10/2021 10/2021	30/04/2021 30/04/2021 30/07/2021 30/07/2021 29/10/2021 29/10/2021	f0.0203 €0.0238 \$0.0359 f0.0260 €0.0302 \$0.0240 f0.0178	3,218,559 338,959 184,638 3,215,311 339,655 174,058	f65,337 €8,067 \$6,628 £83,598 €10,258 \$4,177.3858	01/01/2021 – 31/03/2021 01/01/2021 – 31/03/2021 01/04/2021 – 30/06/2021 01/04/2021 – 30/06/2021 01/04/2021 – 30/06/2021		
Class R Euro Distribution01/0Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/1Class R US Dollar Distribution01/1Class R Sterling Distribution01/1	04/2021 07/2021 07/2021 07/2021 10/2021 10/2021 10/2021	30/04/2021 30/07/2021 30/07/2021 30/07/2021 29/10/2021 29/10/2021	€0.0238 \$0.0359 £0.0260 €0.0302 \$0.0240 £0.0178	338,959 184,638 3,215,311 339,655 174,058	€8,067 \$6,628 £83,598 €10,258 \$4,177.3858	01/01/2021 - 31/03/2021 01/04/2021 - 30/06/2021 01/04/2021 - 30/06/2021 01/04/2021 - 30/06/2021		
Class R US Dollar Distribution01/0Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/1Class R Sterling Distribution01/1	07/2021 07/2021 07/2021 10/2021 10/2021	30/07/2021 30/07/2021 30/07/2021 29/10/2021 29/10/2021	\$0.0359 £0.0260 €0.0302 \$0.0240 £0.0178	184,638 3,215,311 339,655 174,058	\$6,628 £83,598 €10,258 \$4,177.3858	01/04/2021 - 30/06/2021 01/04/2021 - 30/06/2021 01/04/2021 - 30/06/2021		
Class R Sterling Distribution01/0Class R Euro Distribution01/0Class R US Dollar Distribution01/1Class R Sterling Distribution01/1	07/2021 07/2021 10/2021 10/2021 10/2021	30/07/2021 30/07/2021 29/10/2021 29/10/2021	f0.0260 €0.0302 \$0.0240 f0.0178	3,215,311 339,655 174,058	£83,598 €10,258 \$4,177.3858	01/04/2021 - 30/06/2021 01/04/2021 - 30/06/2021		
Class R Euro Distribution01/0Class R US Dollar Distribution01/1Class R Sterling Distribution01/1	07/2021 10/2021 10/2021 10/2021	30/07/2021 29/10/2021 29/10/2021	€0.0302 \$0.0240 £0.0178	339,655 174,058	€10,258 \$4,177.3858	01/04/2021 - 30/06/2021		
Class R US Dollar Distribution01/1Class R Sterling Distribution01/1	10/2021 10/2021 10/2021	29/10/2021 29/10/2021	\$0.0240 £0.0178	174,058	\$4,177.3858			
Class R Sterling Distribution 01/1	10/2021 10/2021	29/10/2021	£0.0178			01/07/2021 – 30/09/2021		
	10/2021			3,212,708				
Class B Euro Distribution 01/1		29/10/2021	€0.0207		£57,186	01/07/2021 – 30/09/2021		
	)1/2021		20.0207	328,788	€6,806	01/07/2021 – 30/09/2021		
Class I Distributing Shares	)1/2021		GBP£3,298,234					
Class I US Dollar Distribution 04/0		29/01/2021	\$0.0166	2,622,512	\$43,534	01/10/2020 - 31/12/2020		
Class I Sterling Distribution 04/0	01/2021	29/01/2021	£0.0121	35,407,929	£428,436	01/10/2020 - 31/12/2020		
Class I Euro Distribution 04/0	01/2021	29/01/2021	€0.0135	1,608,411	€21,714	01/10/2020 - 31/12/2020		
Class I US Dollar Distribution 01/0	)4/2021	30/04/2021	\$0.0294	2,617,357	\$76,950	01/01/2021 - 31/03/2021		
Class I Sterling Distribution 01/0	)4/2021	30/04/2021	£0.0213	36,537,746	£778,254	01/01/2021 – 31/03/2021		
Class I Euro Distribution 01/0	4/2021	30/04/2021	€0.0250	1,576,608	€39,415	01/01/2021 - 31/03/2021		
Class I US Dollar Distribution 01/0	07/2021	30/07/2021	\$0.0377	2,744,285	\$103,460	01/04/2021 - 30/06/2021		
Class I Sterling Distribution 01/0	07/2021	30/07/2021	£0.0273	36,466,034	£995,523	01/04/2021 - 30/06/2021		
Class I Euro Distribution 01/0	07/2021	30/07/2021	€0.0318	1,578,108	€50,184	01/04/2021 - 30/06/2021		
Class I US Dollar Distribution 01/1	10/2021	29/10/2021	\$0.0252	2,885,250	\$72,708.2913	01/07/2021 – 30/09/2021		
Class I Sterling Distribution 01/1	10/2021	29/10/2021	£0.0187	40,326,210	£754,100	01/07/2021 – 30/09/2021		
Class I Euro Distribution 01/1	10/2021	29/10/2021	€0.0218	1,574,358	€34,321	01/07/2021 - 30/09/2021		
Class A Distributing Shares					GBP£17,845			
Class A Sterling Distribution 04/0	01/2021	29/01/2021	£0.0119	269,148	£3,203	01/10/2020 - 31/12/2020		
Class A Sterling Distribution 01/0	4/2021	30/04/2021	£0.0206	269,223	£5,546	01/01/2021 – 31/03/2021		
Class A Sterling Distribution 01/0	07/2021	30/07/2021	£0.0266	203,788	£5,421	01/04/2021 - 30/06/2021		
Class A Sterling Distribution 01/1	10/2021	29/10/2021	£0.0182	201,919	£3,675	01/07/2021 – 30/09/2021		
Class E Distributing Shares				G	BP£7,759,155			
Class E Sterling Distribution 04/0	01/2021	29/01/2021	£0.0125	97,072,435	£1,213,405	01/10/2020 - 31/12/2020		
Class E Sterling Distribution 01/0	)4/2021	30/04/2021	£0.0217	93,920,954	£2,038,085	01/01/2021 - 31/03/2021		
Class E Sterling Distribution 01/0	07/2021	30/07/2021	£0.0279	95,297,630	£2,658,804	01/04/2021 - 30/06/2021		
Class E Sterling Distribution 01/1	0/2021	29/10/2021	£0.0191	96,799,029	£1,848,861	01/07/2021 - 30/09/2021		
Total Distributions for Global Insurance Fu	GBP£11,359,000							

24 De comb en 2024	Date	Date of	Rate per	No. of	A	Delevent needed
31 December 2021	declared	payment	share	shares	Amount	Relevant period
Healthcare Blue Chip Fund						
<b>Class I Distributing Shares</b>					US\$24,029	
Class I US Dollar Distribution	04/01/2021	29/01/2021	\$0.0999	3,736	\$373	01/01/2020 - 31/12/2020
Class I Sterling Distribution	04/01/2021	29/01/2021	£0.0731	195,401	£14,284	01/01/2020 - 31/12/2020
Class I Euro Distribution	04/01/2021	29/01/2021	€0.0817	41,397	€3,382	01/01/2020 - 31/12/2020
Class S Distributing Shares					US\$5,247	
Class S US Dollar Distribution	04/01/2021	29/01/2021	\$0.1008	53	\$5	01/01/2020 - 31/12/2020
Class S Sterling Distribution	04/01/2021	29/01/2021	£0.0737	52,002	£3,833	01/01/2020 - 31/12/2020
Class SI Distributing Shares					US\$436,238	
Class SI US Dollar Distribution	04/01/2021	29/01/2021	\$0.0891	11,828	\$1,054	01/01/2020 - 31/12/2020
Class SI Sterling Distribution	04/01/2021	29/01/2021	£0.0652	4,884,224	£318,451	01/01/2020 - 31/12/2020
Class S Hedged Distribution Shares					US\$13	
Class S Sterling Hedged Distribution	04/01/2021	29/01/2021	0.0900	102	€9	01/01/2020 - 31/12/2020
Total Distributions for Healthcare Bl						

31 December 2021	Date	Date of	Rate per share	No. of shares	<b>A</b>	Delauration
	declared	payment	snare	snares	Amount	Relevant period
Income Opportunities Fund						
Class A1 Distribution Shares				(	GBP£348,236	
Class A1 Sterling Distribution	04/01/2021	29/01/2021	£0.0150	4,548,293	£68,224	01/10/2020 - 31/12/2020
Class R US Dollar Distribution	04/01/2021	29/01/2021	\$0.0205	1,602,402	\$32,849	01/10/2020 - 31/12/2020
Class R Euro Distribution	04/01/2021	29/01/2021	€0.0168	439,628	€7,386	01/10/2020 - 31/12/2020
Class A1 Sterling Distribution	01/04/2021	30/04/2021	£0.0150	4,440,621	£66,609	01/01/2021 - 31/03/2021
Class R US Dollar Distribution	01/04/2021	30/04/2021	\$0.0207	1,448,702	\$29,988	01/01/2021 – 31/03/2021
Class R Euro Distribution	01/04/2021	30/04/2021	€0.0176	375,660	€6,612	01/01/2021 – 31/03/2021
Class A1 Sterling Distribution	01/07/2021	30/07/2021	£0.0152	4,145,387	£62,803	01/04/2021 - 30/06/2021
Class R US Dollar Distribution	01/07/2021	30/07/2021	\$0.0209	856,345	\$17,898	01/04/2021 - 30/06/2021
Class R Euro Distribution	01/07/2021	30/07/2021	€0.0176	375,668	€6,612	01/04/2021 – 30/06/2021
Class A1 Sterling Distribution	01/10/2021	29/10/2021	£0.0152	3,841,326	£58,196.0951	01/07/2021 – 30/09/2021
Class R US Dollar Distribution	01/10/2021	29/10/2021	\$0.0204	856,352	\$17,470	01/07/2021 – 30/09/2021
Class R Euro Distribution	01/10/2021	29/10/2021	€0.0176	62,311	€1,097	01/07/2021 – 30/09/2021

# 13. Distributions continued

31 December 2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Income Opportunities Fund continued	ł					
Class B1 Distribution Shares					GBP£337,131	
Class B1 Sterling Distribution	04/01/2021	29/01/2021	£0.0158	5,330,212	£83,951	01/10/2020 - 31/12/2020
Class I US Dollar Distribution	04/01/2021	29/01/2021	\$0.0215	309,795	\$6,661	01/10/2020 – 31/12/2020
Class I Euro Distribution	04/01/2021	29/01/2021	€0.0176	714	€13	01/10/2020 - 31/12/2020
Class B1 Sterling Distribution	01/04/2021	30/04/2021	£0.0158	5,124,150	£80,705	01/01/2021 - 31/03/2021
Class I US Dollar Distribution	01/04/2021	30/04/2021	\$0.0217	309,802	\$6,723	01/01/2021 – 31/03/2021
Class I Euro Distribution	01/04/2021	30/04/2021	€0.0185	723	€13	01/01/2021 – 31/03/2021
Class B1 Sterling Distribution	01/07/2021	30/07/2021	£0.0163	5,042,411	£81,939	01/04/2021 - 30/06/2021
Class I US Dollar Distribution	01/07/2021	30/07/2021	\$0.0224	309,809	\$6,940	01/04/2021 – 30/06/2021
Class I Euro Distribution	01/07/2021	30/07/2021	€0.0189	731	€14	01/04/2021 - 30/06/2021
Class B1 Sterling Distribution	01/10/2021	29/10/2021	£0.0163	4,996,752	£81,197.2214	01/07/2021 – 30/09/2021
Class I US Dollar Distribution	01/10/2021	29/10/2021	\$0.0219	309,816	\$6,785	01/07/2021 – 30/09/2021
Class I Euro Distribution	01/10/2021	29/10/2021	€0.0189	739	€14	01/07/2021 – 30/09/2021
Class R Hedged Distribution Shares					EUR€61,539	
Class R Euro Hedged Distribution	04/01/2021	29/01/2021	€0.1275	150,328	€19,167	01/10/2020 - 31/12/2020
Class R Euro Hedged Distribution	01/04/2021	30/04/2021	€0.1275	146,810	€18,718	01/01/2021 – 31/03/2021
Class R Euro Hedged Distribution	01/07/2021	30/07/2021	€0.1300	95,311	€12,390	01/04/2021 - 30/06/2021
Class R Euro Hedged Distribution	01/10/2021	29/10/2021	€0.1300	95,312	€12,391	01/07/2021 – 30/09/2021
Class I Hedged Distribution Shares					EUR€465	
Class I Euro Hedged Distribution	04/01/2021	29/01/2021	€0.1275	923	€118	01/10/2020 - 31/12/2020
Class I Euro Hedged Distribution	01/04/2021	30/04/2021	€0.1275	924	€118	01/01/2021 – 31/03/2021
Class I Euro Hedged Distribution	01/07/2021	30/07/2021	€0.1300	926	€120	01/04/2021 - 30/06/2021
Class I Euro Hedged Distribution	01/10/2021	29/10/2021	€0.1300	927	€121	01/07/2021 – 30/09/2021
Class R Hedged Distribution Shares					US\$381,128	
Class R US Dollar Hedged Distribution	04/01/2021	29/01/2021	\$0.1125	1,215,267	\$136,718	01/10/2020 - 31/12/2020
Class R US Dollar Hedged Distribution	01/04/2021	30/04/2021	€0.1125	1,081,194	\$121,634	01/01/2021 – 31/03/2021
Class R US Dollar Hedged Distribution	01/07/2021	30/07/2021	\$0.1175	619,955	\$72,845	01/04/2021 - 30/06/2021
Class R US Dollar Hedged Distribution	01/10/2021	29/10/2021	€0.1175	543,156	\$63,821	01/07/2021 – 30/09/2021
Total Distributions for Income Oppor	rtunities Fund			G	BP£1,037,712	
31 December 2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period

Total Distributions for UK Value Opportunities Fund

04/01/2021

04/01/2021

29/01/2021

29/01/2021

£0.0704

£0.0785

7,084,022

£498,715 01/01/2020 - 31/12/2020

50,401,256 £3,956,499 01/01/2020 - 31/12/2020

GBP£4,455,214

Class I Sterling Distribution

Class S Sterling Distribution

In the financial year ended 31 December 2020 the following Funds declared and paid distributions as follows:

31 December 2020	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Emerging Markets Income Fund						
Class R Distributing Shares					US\$107,813	
Class R US Dollar Distribution	02/01/2020	31/01/2020	\$0.2073	244,634.30	\$50,713	01/07/2019 – 31/12/2019
Class R Sterling Distribution	02/01/2020	31/01/2020	£0.1565	36,126.66	£5,654	01/07/2019 – 31/12/2019
Class R Euro Distribution	02/01/2020	31/01/2020	€0.1847	10,450.00	€1,930	01/07/2019 - 31/12/2019
Class R US Dollar Distribution	01/07/2020	31/07/2020	\$0.1825	219,858.29	\$40,124	01/01/2020 - 30/06/2020
Class R Sterling Distribution	01/07/2020	31/07/2020	£0.1477	28,265.34	£4,175	01/01/2020 - 30/06/2020
Class R Euro Distribution	01/07/2020	31/07/2020	€0.1625	11,850.00	€1,926	01/01/2020 - 30/06/2020
Class I Distributing Shares				ι	JS\$1,882,192	
Class I US Dollar Distribution	02/01/2020	31/01/2020	\$0.2137	53,460.54	\$11,425	01/07/2019 – 31/12/2019
Class I Sterling Distribution	02/01/2020	31/01/2020	£0.1613	5,066,321.13	£817,198	01/07/2019 - 31/12/2019
Class I Euro Distribution	02/01/2020	31/01/2020	€0.1904	159,432.19	€30,356	01/07/2019 – 31/12/2019
Class I US Dollar Distribution	01/07/2020	31/07/2020	\$0.1863	49,050.39	\$9,136	01/01/2020 - 30/06/2020
Class I Sterling Distribution	01/07/2020	31/07/2020	£0.1507	3,832,360.21	£577,537	01/01/2020 - 30/06/2020
Class I Euro Distribution	01/07/2020	31/07/2020	€0.1658	166,822.30	€27,659	01/01/2020 - 30/06/2020
Class S Distributing Shares				ι	JS\$3,196,704	
Class S US Dollar Distribution	02/01/2020	31/01/2020	\$0.2187	113,514.28	\$24,826	01/07/2019 – 31/12/2019
Class S Sterling Distribution	02/01/2020	31/01/2020	£0.1651	7,747,548.81	£1,279,120	01/07/2019 – 31/12/2019
Class S Euro Distribution	02/01/2020	31/01/2020	€0.1948	17.82	€3	01/07/2019 – 31/12/2019
Class S US Dollar Distribution	01/07/2020	31/07/2020	\$0.1892	61,324.28	\$11,603	01/01/2020 - 30/06/2020
Class S Sterling Distribution	01/07/2020	31/07/2020	£0.1531	7,747,779.83	£1,186,185	01/01/2020 - 30/06/2020
Class S Euro Distribution	01/07/2020	31/07/2020	€0.1685	18.24	€3	01/01/2020 - 30/06/2020

Total Distributions for Emerging Markets Income Fund

US\$5,186,709

# 13. Distributions continued

31 December 2020	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
European ex UK Income Fund		1				
Class I Distribution Shares				(	GBP£121,863	
Class I Sterling Distribution	02/01/2020	31/01/2020	£0.0255	399,280.11	£10,182	01/10/2019 - 31/12/2019
Class I Sterling Distribution	01/04/2020	30/04/2020	£0.0658	371,115.71	£24,419	01/01/2020 - 31/03/2020
Class I Sterling Distribution	01/07/2020	31/07/2020	£0.1665	376,120.16	£62,624	01/04/2020 - 30/06/2020
Class I Sterling Distribution	01/10/2020	30/10/2020	£0.0684	360,208.20	£24,638	01/07/2020 – 30/09/2020
Class S Distribution Shares				(	GBP£891,951	
Class S Sterling Distribution	02/01/2020	31/01/2020	£0.0257	1,070,100.45	£27,502	01/10/2019 - 31/12/2019
Class S Sterling Distribution	01/04/2020	30/04/2020	£0.0663	1,124,181.12	£74,533	01/01/2020 - 31/03/2020
Class S Sterling Distribution	01/07/2020	31/07/2020	£0.1676	3,307,479.03	£554,333	01/04/2020 - 30/06/2020
Class S Sterling Distribution	01/10/2020	30/10/2020	£0.0690	3,414,248.10	£235,583	01/07/2020 – 30/09/2020
Class I Hedged Distribution Shares					GBP£8,352	
Class I Sterling Hedged Distribution	02/01/2020	31/01/2020	£0.0306	22,537.28	£690	01/10/2019 - 31/12/2019
Class I Sterling Hedged Distribution	01/04/2020	30/04/2020	£0.0760	25,949.69	£1,972	01/01/2020 - 31/03/2020
Class I Sterling Hedged Distribution	01/07/2020	31/07/2020	£0.1908	25,710.70	£4,906	01/04/2020 - 30/06/2020
Class I Sterling Hedged Distribution	01/10/2020	30/10/2020	£0.0772	10,158.18	£784	01/07/2020 – 30/09/2020
Class S Hedged Distribution Shares				GB	P£3,995,895	
Class S Sterling Hedged Distribution	02/01/2020	31/01/2020	£0.0308	10,712,050.17	£329,931	01/10/2019 - 31/12/2019
Class S Sterling Hedged Distribution	01/04/2020	30/04/2020	£0.0763	10,873,070.10	£829,615	01/01/2020 - 31/03/2020
Class S Sterling Hedged Distribution	01/07/2020	31/07/2020	£0.1917	11,221,955.97	£2,151,249	01/04/2020 - 30/06/2020
Class S Sterling Hedged Distribution	01/10/2020	30/10/2020	£0.0775	8,839,997.72	£685,100	01/07/2020 – 30/09/2020
Class X Distribution Shares				GB	P£2,459,160	
Class X Sterling Distribution	02/01/2020	31/01/2020	£0.0034	6,129,833.08	£20,841	01/10/2019 - 31/12/2019
Class X Sterling Distribution	01/04/2020	30/04/2020	£0.0520	6,059,033.11	£315,070	01/01/2020 - 31/03/2020
Class X Sterling Distribution	01/07/2020	31/07/2020	£0.2640	6,113,033.71	£1,613,841	01/04/2020 - 30/06/2020
Class X Sterling Distribution	01/10/2020	30/10/2020	£0.0776	6,564,536.7	£509,408	01/07/2020 - 30/09/2020
Total Distributions for European ex	Total Distributions for European ex UK Income Fund					

31 December 2020	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Financial Opportunities Fund		payment	Share	of shares	Anount	nelevant period
Class R Distributing Shares					US\$1,928	
Class R US Dollar Distribution	02/01/2020	31/01/2020	\$0.1092	8.46	\$1	01/01/2019 - 31/12/2019
Class R Sterling Distribution	02/01/2020	31/01/2020	£0.0824	6,471.75	£533	01/01/2019 - 31/12/2019
Class R Euro Distribution	02/01/2020	31/01/2020	€0.0973	14.06	€1	01/01/2019 - 31/12/2019
Class R US Dollar Distribution	01/07/2020	31/07/2020	\$0.1455	8.53	\$1	01/01/2020 - 30/06/2020
Class R Sterling Distribution	01/07/2020	31/07/2020	£0.1178	8,364.55	£985	01/01/2020 - 30/06/2020
Class R Euro Distribution	01/07/2020	31/07/2020	€0.1296	5.67	€1	01/01/2020 - 30/06/2020
Class I Distributing Shares					US\$158,770	
Class I US Dollar Distribution	02/01/2020	31/01/2020	\$0.1135	276,703.06	\$31,406	01/01/2019 - 31/12/2019
Class I Sterling Distribution	02/01/2020	31/01/2020	£0.0857	262,699.47	£22,513	01/01/2019 - 31/12/2019
Class I Euro Distribution	02/01/2020	31/01/2020	€0.1011	85,579.26	€8,652	01/01/2019 - 31/12/2019
Class I US Dollar Distribution	01/07/2020	31/07/2020	\$0.1516	254,473.11	\$38,578	01/01/2020 - 30/06/2020
Class I Sterling Distribution	01/07/2020	31/07/2020	£0.1227	238,651.55	£29,283	01/01/2020 - 30/06/2020
Class I Euro Distribution	01/07/2020	31/07/2020	€0.1349	86,262.13	€11,637	01/01/2020 - 30/06/2020

**Total Distributions for Financial Opportunities Fund** 

US\$160,699

31 December 2020	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Global Convertible Fund		payment	Share	of shares	Thround	
Class R Distributing Shares					US\$104,334	
Class R US Dollar Distribution	02/01/2020	31/01/2020	\$0.1037	105,352.27	\$10,925	01/10/2019 - 31/12/2019
Class R Sterling Distribution	02/01/2020	31/01/2020	£0.0782	196.76	£15	01/10/2019 - 31/12/2019
Class R Euro Distribution	02/01/2020	31/01/2020	€0.0924	121,793.28	€11,254	01/10/2019 - 31/12/2019
Class R US Dollar Distribution	01/04/2020	30/04/2020	\$0.0906	91,958.54	\$8,331	01/01/2020 – 31/03/2020
Class R Sterling Distribution	01/04/2020	30/04/2020	£0.0731	198.70	£15	01/01/2020 – 31/03/2020
Class R Euro Distribution	01/04/2020	30/04/2020	€0.0826	140,833.82	€11,633	01/01/2020 – 31/03/2020
Class R US Dollar Distribution	01/07/2020	31/07/2020	\$0.1111	98,259.75	\$10,917	01/04/2020 - 30/06/2020
Class R Sterling Distribution	01/07/2020	31/07/2020	£0.0899	200.57	£18	01/04/2020 - 30/06/2020
Class R Euro Distribution	01/07/2020	31/07/2020	€0.0989	140,756.51	€13,921	01/04/2020 - 30/06/2020
Class R US Dollar Distribution	01/10/2020	30/10/2020	\$0.1165	118,111.06	\$13,760	01/07/2020 – 30/09/2020
Class R Sterling Distribution	01/10/2020	30/10/2020	£0.0901	202.71	£18	01/07/2020 - 30/09/2020
Class R Euro Distribution	01/10/2020	30/10/2020	€0.0993	165,569.19	€16,441	01/07/2020 - 30/09/2020

# 13. Distributions continued

31 December 2020	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Global Convertible Fund continued						
Class I Distributing Shares				l	JS\$7,958,741	
Class I US Dollar Distribution	02/01/2020	31/01/2020	\$0.1067	296,096.42	\$31,593	01/10/2019 - 31/12/2019
Class I Sterling Distribution	02/01/2020	31/01/2020	£0.0804	16,604,638.65	£1,335,013	01/10/2019 - 31/12/2019
Class I Euro Distribution	02/01/2020	31/01/2020	€0.0950	212,910.10	€20,226	01/10/2019 - 31/12/2019
Class I US Dollar Distribution	01/04/2020	30/04/2020	\$0.0927	279,304.90	\$25,892	01/01/2020 - 31/03/2020
Class I Sterling Distribution	01/04/2020	30/04/2020	£0.0748	18,447,384.40	£1,379,864	01/01/2020 - 31/03/2020
Class I Euro Distribution	01/04/2020	30/04/2020	€0.0845	238,770.10	€20,176	01/01/2020 - 31/03/2020
Class I US Dollar Distribution	01/07/2020	31/07/2020	\$0.1146	287,908.51	\$32,994	01/04/2020 - 30/06/2020
Class I Sterling Distribution	01/07/2020	31/07/2020	£0.0927	18,425,349.09	£1,708,030	01/04/2020 - 30/06/2020
Class I Euro Distribution	01/07/2020	31/07/2020	€0.1020	216,827.65	€22,116	01/04/2020 - 30/06/2020
Class I US Dollar Distribution	01/10/2020	30/10/2020	\$0.1204	319,880.65	\$38,514	01/07/2020 - 30/09/2020
Class I Sterling Distribution	01/10/2020	30/10/2020	£0.0931	17,779,149.47	£1,655,239	01/07/2020 - 30/09/2020
Class I Euro Distribution	01/10/2020	30/10/2020	€0.1027	216,827.65	€22,268	01/07/2020 - 30/09/2020
Class S Distributing Shares				US	\$12,209,934	
Class S US Dollar Distribution	02/01/2020	31/01/2020	\$0.0959	347,107.06	\$33,288	01/10/2019 - 31/12/2019
Class S Sterling Distribution	02/01/2020	31/01/2020	£0.0723	37,005,989.75	£2,675,533	01/10/2019 - 31/12/2019
Class S Euro Distribution	02/01/2020	31/01/2020	€0.0854	175.39	€15	01/10/2019 - 31/12/2019
Class S US Dollar Distribution	01/04/2020	30/04/2020	\$0.0845	332,911.84	\$28,131	01/01/2020 - 31/03/2020
Class S Sterling Distribution	01/04/2020	30/04/2020	£0.0681	32,134,219.38	£2,188,340	01/01/2020 - 31/03/2020
Class S Euro Distribution	01/04/2020	30/04/2020	€0.0770	172.37	€13	01/01/2020 - 31/03/2020
Class S US Dollar Distribution	01/07/2020	31/07/2020	\$0.1031	272,899.64	\$28,136	01/04/2020 - 30/06/2020
Class S Sterling Distribution	01/07/2020	31/07/2020	£0.0834	27,221,937.13	£2,270,310	01/04/2020 - 30/06/2020
Class S Euro Distribution	01/07/2020	31/07/2020	€0.0918	173.97	€16	01/04/2020 - 30/06/2020
Class S US Dollar Distribution	01/10/2020	30/10/2020	\$0.1084	275,250.92	\$29,837	01/07/2020 – 30/09/2020
Class S Sterling Distribution	01/10/2020	30/10/2020	£0.0838	27,856,793.15	£2,334,399	01/07/2020 - 30/09/2020
Class S Euro Distribution	01/10/2020	30/10/2020	€0.0924	175.77	€16	01/07/2020 - 30/09/2020
Class I Hedged Distributing Shares				(	GBP£357,986	
Class I Hedged Sterling Distribution	02/01/2020	31/01/2020	£0.0895	2,497,162.29	£223,496	01/10/2019 – 31/12/2019
Class I Hedged Sterling Distribution	01/04/2020	30/04/2020	£0.0769	1,748,889.23	£134,490	01/01/2020 - 31/03/2020
Class I Hedged Sterling Distribution	01/07/2020	31/07/2020	£0.0944	1,667,841.16	£157,444	01/04/2020 - 30/06/2020
Class I Hedged Sterling Distribution	01/10/2020	30/10/2020	£0.0991	1,690,287.81	£167,508	01/07/2020 - 30/09/2020
Class S Hedged Distributing Shares					GBP£61,108	
Class S Hedged Sterling Distribution	02/01/2020	31/01/2020	£0.0909	374,779.89	£34,067	01/10/2019 – 31/12/2019
Class S Hedged Sterling Distribution	01/04/2020	30/04/2020	£0.0784	344,907.30	£27,041	01/01/2020 – 31/03/2020
Class S Hedged Sterling Distribution	01/07/2020	31/07/2020	£0.0961	279,160.74	£26,827	01/04/2020 - 30/06/2020
Class S Hedged Sterling Distribution	01/10/2020	30/10/2020	£0.1007	263,118.18	£26,496	01/07/2020 – 30/09/2020

31 December 2020	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Global Convertible Fund continued						
Class Portfolio Currency Hedged I D	Class Portfolio Currency Hedged I Distribution Shares				3P£1,816,119	
Class Portfolio Currency Hedged Sterling I Distribution	02/01/2020	31/01/2020	£0.1025	10,906,140.91	£1,117,879	01/10/2019 – 31/12/2019
Class Portfolio Currency Hedged Sterling I Distribution	01/04/2020	30/04/2020	£0.0812	8,599,012.52	£698,240	01/01/2020 – 31/03/2020
Class Portfolio Currency Hedged Sterling I Distribution	01/07/2020	31/07/2020	£0.1082	7,100,216.56	£768,243	01/04/2020 – 30/06/2020
Class Portfolio Currency Hedged Sterling I Distribution	01/10/2020	30/10/2020	£0.1123	6,132,825.42	£688,716	01/07/2020 – 30/09/2020
Class Portfolio Currency Hedged S D	istribution Sha	res		(	GBP£185,126	
Class Portfolio Currency Hedged Sterling S Distribution	02/01/2020	31/01/2020	£0.1023	1,008,297.07	£103,149	01/10/2019 – 31/12/2019
Class Portfolio Currency Hedged Sterling S Distribution	01/04/2020	30/04/2020	£0.0891	920,059.61	£81,977	01/01/2020 – 31/03/2020
Class Portfolio Currency Hedged Sterling S Distribution	01/07/2020	31/07/2020	£0.1086	7,472,605.85	£811,525	01/04/2020 – 30/06/2020
Class Portfolio Currency Hedged Sterling S Distribution	01/10/2020	30/10/2020	£0.1128	7,416,711.03	£836,605	01/07/2020 – 30/09/2020
Total Distributions for Global Conve			US	\$27,795,727		

	Date	Date of	Rate per	No.		
31 December 2020	declared	payment	share	of shares	Amount	Relevant period
Global Insurance Fund						
<b>Class R Distributing Shares</b>				GI	3P£333,343	
Class R US Dollar Distribution	02/01/2020	31/01/2020	\$0.0182	135,127.54	\$2,459	01/10/2019 - 31/12/2019
Class R Sterling Distribution	02/01/2020	31/01/2020	£0.0137	3,795,474.58	£51,998	01/10/2019 - 31/12/2019
Class R Euro Distribution	02/01/2020	31/01/2020	€0.0162	152,258.09	€2,467	01/10/2019 - 31/12/2019
Class R US Dollar Distribution	01/04/2020	30/04/2020	\$0.0310	150,043.64	\$4,651	01/01/2020 - 31/03/2020
Class R Sterling Distribution	01/04/2020	30/04/2020	£0.0250	3,742,463.48	£93,562	01/01/2020 - 31/03/2020
Class R Euro Distribution	01/04/2020	30/04/2020	€0.0283	221,378.43	€6,265	01/01/2020 - 31/03/2020
Class R US Dollar Distribution	01/07/2020	31/07/2020	\$0.0255	191,033.91	\$4,871	01/04/2020 - 30/06/2020
Class R Sterling Distribution	01/07/2020	31/07/2020	£0.0206	3,360,607.88	£69,229	01/04/2020 - 30/06/2020
Class R Euro Distribution	01/07/2020	31/07/2020	€0.0227	270,785.58	€6,147	01/04/2020 - 30/06/2020
Class R US Dollar Distribution	01/10/2020	30/10/2020	\$0.0325	192,855.46	\$6,268	01/07/2020 – 30/09/2020
Class R Sterling Distribution	01/10/2020	30/10/2020	£0.0252	3,285,344.18	£82,791	01/07/2020 - 30/09/2020
Class R Euro Distribution	01/10/2020	30/10/2020	€0.0277	324,124.37	€8,978	01/07/2020 – 30/09/2020

# 13. Distributions continued

31 December 2020	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period		
Global Insurance Fund continued						<u> </u>		
<b>Class I Distributing Shares</b>	GBP£3,341,551							
Class I US Dollar Distribution	02/01/2020	31/01/2020	\$0.0189	2,257,854.10	\$42,673	01/10/2019 - 31/12/2019		
Class I Sterling Distribution	02/01/2020	31/01/2020	£0.0143	33,993,700.38	£486,110	01/10/2019 - 31/12/2019		
Class I Euro Distribution	02/01/2020	31/01/2020	€0.0169	1,483,517.11	€25,071	01/10/2019 - 31/12/2019		
Class I US Dollar Distribution	01/04/2020	30/04/2020	\$0.0323	2,182,970.12	\$70,510	01/01/2020 - 31/03/2020		
Class I Sterling Distribution	01/04/2020	30/04/2020	£0.0261	33,457,416.11	£873,239	01/01/2020 – 31/03/2020		
Class I Euro Distribution	01/04/2020	30/04/2020	€0.0295	1,495,123.14	€44,106	01/01/2020 – 31/03/2020		
Class I US Dollar Distribution	01/07/2020	31/07/2020	\$0.0265	2,024,128.71	\$53,639	01/04/2020 - 30/06/2020		
Class I Sterling Distribution	01/07/2020	31/07/2020	£0.0215	34,947,343.66	£751,368	01/04/2020 - 30/06/2020		
Class I Euro Distribution	01/07/2020	31/07/2020	€0.0236	1,553,487.21	€36,662	01/04/2020 - 30/06/2020		
Class I US Dollar Distribution	01/10/2020	30/10/2020	\$0.0340	2,236,726.18	\$76,049	01/07/2020 – 30/09/2020		
Class I Sterling Distribution	01/10/2020	30/10/2020	£0.0263	34,352,673.12	£903,475	01/07/2020 - 30/09/2020		
Class I Euro Distribution	01/10/2020	30/10/2020	€0.0290	1,601,325.43	€46,438	01/07/2020 – 30/09/2020		
Class A Distributing Shares					GBP£29,005			
Class A Sterling Distribution	02/01/2020	31/01/2020	£0.0141	382,738.49	£5,397	01/10/2019 - 31/12/2019		
Class A Sterling Distribution	01/04/2020	30/04/2020	£0.0256	329,970.95	£8,447	01/01/2020 - 31/03/2020		
Class A Sterling Distribution	01/07/2020	31/07/2020	£0.0210	326,993.70	£6,867	01/04/2020 - 30/06/2020		
Class A Sterling Distribution	01/10/2020	30/10/2020	£0.0257	322,752.89	£8,295	01/07/2020 – 30/09/2020		
Class E Distributing Shares				GI	3P£5,116,911			
Class E Sterling Distribution	02/01/2020	31/01/2020	£0.0147	57,112,051.08	£839,547	01/10/2019 - 31/12/2019		
Class E Sterling Distribution	01/04/2020	30/04/2020	£0.0268	56,929,441.51	£1,525,709	01/01/2020 - 31/03/2020		
Class E Sterling Distribution	01/07/2020	31/07/2020	£0.0220	56,557,449.00	£1,244,264	01/04/2020 - 30/06/2020		
Class E Sterling Distribution	01/10/2020	30/10/2020	£0.0269	56,036,844.74	£1,507,391	01/07/2020 – 30/09/2020		
Total Distributions for Global Insur	ance Fund			GB	Pf8.820.811			

**Total Distributions for Global Insurance Fund** 

GBP£8,820,811

	Date	Date of	Rate per	No.		
31 December 2020	declared	payment	share	of shares	Amount	Relevant period
Healthcare Blue Chip Fund						
<b>Class I Distributing Shares</b>					US\$70,734	
Class I US Dollar Distribution	02/01/2020	31/01/2020	\$0.1304	1,601.42	\$209	01/10/2019 - 31/12/2019
Class I Sterling Distribution	02/01/2020	31/01/2020	£0.0984	504,177.50	£49,611	01/10/2019 – 31/12/2019
Class I Euro Distribution	02/01/2020	31/01/2020	€0.1162	36,664.28	€4,260	01/10/2019 - 31/12/2019
Class S Distributing Shares					US\$7,648	
Class S US Dollar Distribution	02/01/2020	31/01/2020	\$0.1315	52.35	\$7	01/10/2019 - 31/12/2019
Class S Sterling Distribution	02/01/2020	31/01/2020	£0.0993	58,106.26	£5,770	01/10/2019 – 31/12/2019
Class SI Distributing Shares					US\$574,036	
Class SI US Dollar Distribution	02/01/2020	31/01/2020	\$0.1158	8,721.73	\$1,010	01/10/2019 - 31/12/2019
Class SI Sterling Distribution	02/01/2020	31/01/2020	£0.0874	4,948,411.75	£432,491	01/10/2019 – 31/12/2019
Total Distributions for Healthcare			US\$652,418			

### Total Distributions for Healthcare Blue Chip Fund

	Date	Date of	Rate per	No.		
31 December 2020	declared	payment	share	of shares	Amount	Relevant period
Income Opportunities Fund						
<b>Class A1 Distribution Shares</b>				G	BP£437,298	
Class A1 Sterling Distribution	02/01/2020	31/01/2020	£0.0150	5,301,710.65	£79,526	01/10/2019 - 31/12/2019
Class R US Dollar Distribution	02/01/2020	31/01/2020	\$0.0199	1,953,433.78	\$38,873	01/10/2019 - 31/12/2019
Class R Euro Distribution	02/01/2020	31/01/2020	€0.0177	487,241.29	€8,624	01/10/2019 - 31/12/2019
Class A1 Sterling Distribution	01/04/2020	30/04/2020	£0.0150	4,696,782.85	£70,452	01/01/2020 - 31/03/2020
Class R US Dollar Distribution	01/04/2020	30/04/2020	\$0.0186	1,827,412.93	\$33,990	01/01/2020 - 31/03/2020
Class R Euro Distribution	01/04/2020	30/04/2020	€0.0170	487,248.90	€8,283	01/01/2020 - 31/03/2020
Class A1 Sterling Distribution	01/07/2020	31/07/2020	£0.0150	5,125,259.16	£76,879	01/04/2020 - 30/06/2020
Class R US Dollar Distribution	01/07/2020	31/07/2020	\$0.0185	1,729,218.75	\$31,991	01/04/2020 - 30/06/2020
Class R Euro Distribution	01/07/2020	31/07/2020	€0.0165	487,258.91	€8,040	01/04/2020 - 30/06/2020
Class A1 Sterling Distribution	01/10/2020	30/10/2020	£0.0150	4,867,613.25	£73,014	01/07/2020 - 30/09/2020
Class R US Dollar Distribution	01/10/2020	30/10/2020	\$0.0194	1,702,777.05	\$33,034	01/07/2020 - 30/09/2020
Class R Euro Distribution	01/10/2020	30/10/2020	€0.0165	487,268.64	€8,040	01/07/2020 - 30/09/2020

# 13. Distributions continued

31 December 2020	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Income Opportunities Fund continued	ł					
Class B1 Distribution Shares					GBP£683,154	
Class B1 Sterling Distribution	02/01/2020	31/01/2020	£0.0158	17,183,141.34	£270,634	01/10/2019 - 31/12/2019
Class I US Dollar Distribution	02/01/2020	31/01/2020	\$0.0209	559,077.36	\$11,685	01/10/2019 - 31/12/2019
Class I Euro Distribution	02/01/2020	31/01/2020	€0.0186	679.03	€13	01/10/2019 - 31/12/2019
Class B1 Sterling Distribution	01/04/2020	30/04/2020	£0.0158	11,055,168.99	£174,119	01/01/2020 - 31/03/2020
Class I US Dollar Distribution	01/04/2020	30/04/2020	\$0.0195	559,084.04	\$10,902	01/01/2020 - 31/03/2020
Class I Euro Distribution	01/04/2020	30/04/2020	€0.0178	686.33	€12	01/01/2020 - 31/03/2020
Class B1 Sterling Distribution	01/07/2020	31/07/2020	£0.0158	6,705,809.83	£105,617	01/04/2020 - 30/06/2020
Class I US Dollar Distribution	01/07/2020	31/07/2020	\$0.0195	559,092.68	\$10,902	01/04/2020 - 30/06/2020
Class I Euro Distribution	01/07/2020	31/07/2020	€0.0173	695.86	€12	01/04/2020 - 30/06/2020
Class B1 Sterling Distribution	01/10/2020	30/10/2020	£0.0158	6,191,640.41	£97,518	01/07/2020 – 30/09/2020
Class I US Dollar Distribution	01/10/2020	30/10/2020	\$0.0204	559,100.63	\$11,406	01/07/2020 - 30/09/2020
Class I Euro Distribution	01/10/2020	30/10/2020	€0.0174	705.13	€12	01/07/2020 - 30/09/2020
Class R Hedged Distribution Shares						
Class R Euro Hedged Distribution	02/01/2020	31/01/2020	€0.1275	293,443.60	€37,414	01/10/2019 - 31/12/2019
Class R Euro Hedged Distribution	01/04/2020	30/04/2020	€0.1275	257,194.88	€32,792	01/01/2020 - 31/03/2020
Class R Euro Hedged Distribution	01/07/2020	31/07/2020	€0.1275	224,466.58	€28,619	01/04/2020 - 30/06/2020
Class R Euro Hedged Distribution	01/10/2020	30/10/2020	€0.1275	208,626.53	€26,600	01/07/2020 - 30/09/2020
Class I Hedged Distribution Shares					EUR€1,489	
Class I Euro Hedged Distribution	02/01/2020	31/01/2020	€0.1275	4,916.76	€627	01/10/2019 - 31/12/2019
Class I Euro Hedged Distribution	01/04/2020	30/04/2020	€0.1275	4,918.02	€627	01/01/2020 – 31/03/2020
Class I Euro Hedged Distribution	01/07/2020	31/07/2020	€0.1275	919.69	€117	01/04/2020 - 30/06/2020
Class I Euro Hedged Distribution	01/10/2020	30/10/2020	€0.1275	921.29	€117	01/07/2020 - 30/09/2020
Class R Hedged Distribution Shares					US\$624,909	
Class R US Dollar Hedged Distribution	02/01/2020	31/01/2020	\$0.1075	1,622,672.94	\$174,437	01/10/2019 - 31/12/2019
Class R US Dollar Hedged Distribution	01/04/2020	30/04/2020	\$0.1075	1,495,928.07	\$160,812	01/01/2020 – 31/03/2020
Class R US Dollar Hedged Distribution	01/07/2020	31/07/2020	\$0.1075	1,404,614.55	\$150,996	01/04/2020 - 30/06/2020
Class R US Dollar Hedged Distribution	01/10/2020	30/10/2020	\$0.1075	1,289,895.98	\$138,664	01/07/2020 - 30/09/2020
Total Distributions for Income Oppor		GI	3P£1,723,491			

31 December 2020	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
UK Value Opportunities Fund						
Class   Sterling Distribution	02/01/2020	31/01/2020	£0.2645	5,430,291.18	£1,436,312	01/01/2019 – 31/12/2019
Class S Sterling Distribution	02/01/2020	31/01/2020	£0.2798	50,821,881.88	£14,219,963	01/01/2019 - 31/12/2019
Class Z Sterling Distribution	02/01/2020	31/01/2020	£0.2931	100.00	£29	01/01/2019 – 31/12/2019
Total Distributions for UK Value O	pportunities Fun	d		GBF	£15,656,304	

The following distributions were declared in respect of the Company on 4 January 2022 and are therefore not accrued in the financial statements for the financial year ended 31 December 2021:

2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
European ex UK Income Fund						
Class I Distribution Shares					GBP£9,368	
Class I Sterling Distribution	04/01/2022	31/01/2022	£0.0269	348,244.34	£9,368	01/10/2021 - 31/12/2021
Class S Distribution Shares					GBP£84,093	
Class S Sterling Distribution	04/01/2022	31/01/2022	£0.0270	3,114,544.16	£84,093	01/10/2021 - 31/12/2021
Class I Hedged Distribution Shares					GBP£603	
Class I Sterling Hedged Distribution	04/01/2022	31/01/2022	£0.0324	18,598.20	£603	01/10/2021 - 31/12/2021
Class S Hedged Distribution Shares					GBP£2,087	
Class S Sterling Hedged Distribution	04/01/2022	31/01/2022	£0.0325	64,200.29	£2,087	01/10/2021 - 31/12/2021
Class X Distribution Shares				G	GBP£146,104	
Class X Sterling Distribution	04/01/2022	31/01/2022	£0.0301	4,853,942.31	£146,104	01/10/2021 - 31/12/2021
Total Distributions for European ex		E	UR€288,533			

2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Financial Opportunities Fund		payment	Share	or shares	, anount	Relevant period
Class R Distributing Shares					US\$1,163	
Class R US Dollar Distribution	04/01/2022	31/01/2022	\$0.1506	8.78	\$1	01/07/2021 - 31/12/2021
Class R Sterling Distribution	04/01/2022	31/01/2022	£0.1112	6,549.91	£728	01/07/2021 - 31/12/2021
Class R Euro Distribution	04/01/2022	31/01/2022	€0.1324	1,162.77	€154	01/07/2021 - 31/12/2021
Class I Distributing Shares					US\$67,242	
Class I US Dollar Distribution	04/01/2022	31/01/2022	\$0.1579	525.90	\$83	01/07/2021 - 31/12/2021
Class I Sterling Distribution	04/01/2022	31/01/2022	£0.1166	307,115.12	£35,810	01/07/2021 - 31/12/2021
Class I Euro Distribution	04/01/2022	31/01/2022	€0.1388	118,199.19	€16,406	01/07/2021 - 31/12/2021
Class S Distributing Shares					US\$89,284	
Class S US Dollar Distribution	04/01/2022	31/01/2022	\$0.1442	551,152.46	\$79,476	01/07/2021 - 31/12/2021
Class S Sterling Distribution	04/01/2022	31/01/2022	£0.1064	68,053.31	£7,241	01/07/2021 – 31/12/2021
Total Distributions for Financial Op			US\$157,689			

# 13. Distributions continued

2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Global Convertible Fund						
Class R Distributing Shares					US\$31,876	
Class R US Dollar Distribution	04/01/2022	31/01/2022	\$0.1118	86,801.78	\$9,704	01/10/2021 - 31/12/2021
Class R Sterling Distribution	04/01/2022	31/01/2022	£0.0825	23,152.95	£1,910	01/10/2021 - 31/12/2021
Class R Euro Distribution	04/01/2022	31/01/2022	€0.0983	175,194.81	€17,222	01/10/2021 - 31/12/2021
Class I Distributing Shares				U	\$\$2,286,619	
Class I US Dollar Distribution	04/01/2022	31/01/2022	\$0.1162	249,115.34	\$28,947	01/10/2021 - 31/12/2021
Class I Sterling Distribution	04/01/2022	31/01/2022	£0.0858	19,234,588.62	£1,650,328	01/10/2021 - 31/12/2021
Class I Euro Distribution	04/01/2022	31/01/2022	€0.1022	192,609.43	€19,685	01/10/2021 - 31/12/2021
Class S Distributing Shares				U	1\$\$3,709,021	
Class S US Dollar Distribution	04/01/2022	31/01/2022	\$0.1052	413,002.35	\$43,448	01/10/2021 - 31/12/2021
Class S Sterling Distribution	04/01/2022	31/01/2022	£0.0777	34,763,756.96	£2,701,144	01/10/2021 - 31/12/2021
Class S Euro Distribution	04/01/2022	31/01/2022	€0.0925	66,621.53	€6,162	01/10/2021 - 31/12/2021
Class I Hedged Distributing Shares				G	BP£284,658	
Class I Hedged Sterling Distribution	04/01/2022	31/01/2022	£0.0948	3,002,723.40	£284,658	01/10/2021 – 31/12/2021
Class S Hedged Distributing Shares					GBP£17,603	
Class S Hedged Sterling Distribution	04/01/2022	31/01/2022	£0.0969	181,663.24	£17,603	01/10/2021 – 31/12/2021
Class Portfolio Currency Hedged I Dis	stribution Shar	es		G	BP£503,256	
Class Portfolio Currency Hedged Sterling I Distribution	04/01/2022	31/01/2022	£0.1093	4,604,352.93	£503,256	01/10/2021 – 31/12/2021
Class Portfolio Currency Hedged S Distribution Shares			GBP£807,415			
Class Portfolio Currency Hedged Sterling S Distribution	04/01/2022	31/01/2022	£0.1103	7,320,175.35	£807,415	01/10/2021 – 31/12/2021
Total Distributions for Global Conve	rtible Fund			U	\$\$8,212,152	

	Date	Date of	Rate per	No.			
2021	declared	payment	share	of shares	Amount	Relevant period	
Global Insurance Fund							
Class R Distributing Shares					GBP£57,288		
Class R US Dollar Distribution	04/01/2022	31/01/2022	\$0.0211	174,032.77	\$3,672	01/10/2021 - 31/12/2021	
Class R Sterling Distribution	04/01/2022	31/01/2022	£0.0156	3,171,434.77	£49,474	01/10/2021 - 31/12/2021	
Class R Euro Distribution	04/01/2022	31/01/2022	€0.0186	326,725.10	€6,077	01/10/2021 - 31/12/2021	
Class I Distributing Shares				(	GBP£722,807		
Class I US Dollar Distribution	04/01/2022	31/01/2022	\$0.0223	2,891,211.96	\$64,474	01/10/2021 - 31/12/2021	
Class I Sterling Distribution	04/01/2022	31/01/2022	£0.0164	39,634,629.71	£650,008	01/10/2021 - 31/12/2021	
Class I Euro Distribution	04/01/2022	31/01/2022	€0.0196	1,531,179.35	€30,011	01/10/2021 - 31/12/2021	
Class A Distributing Shares					GBP£3,204		
Class A Sterling Distribution	04/01/2022	31/01/2022	£0.0159	201,480.59	£3,204	01/10/2021 - 31/12/2021	
Class E Distributing Shares			GBP£1,621,758				
Class E Sterling Distribution	04/01/2022	31/01/2022	£0.0168	96,533,212.78	£1,621,758	01/10/2021 – 31/12/2021	
Total Distributions for Global Ins	urance Fund			GB	P£2,405,056		

2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Healthcare Blue Chip		payment	Share	or shares	Amount	
Class I Distributing Shares					US\$33,717	
Class I US Dollar Distribution	04/01/2022	31/01/2022	\$0.1342	4,614.60	\$619	01/10/2021 - 31/12/2021
Class I Sterling Distribution	04/01/2022	31/01/2022	£0.0991	242,096.64	£23,992	01/10/2021 - 31/12/2021
Class I Euro Distribution	04/01/2022	31/01/2022	€0.1180	5,801.21	€685	01/10/2021 – 31/12/2021
Class S Distributing Shares					US\$7,256	
Class S US Dollar Distribution	04/01/2022	31/01/2022	\$0.1354	53.19	\$7	01/10/2021 - 31/12/2021
Class S Sterling Distribution	04/01/2022	31/01/2022	£0.1000	53,518.84	£5,352	01/10/2021 – 31/12/2021
Class SI Distributing Shares					US\$597,900	
Class SI US Dollar Distribution	04/01/2022	31/01/2022	\$0.1199	4,423.33	\$530	01/10/2021 - 31/12/2021
Class SI Sterling Distribution	04/01/2022	31/01/2022	£0.0885	4,983,528.16	£441,042	01/10/2021 - 31/12/2021
Class S Hedged Distribution Shares					GBP£18	
Class S Sterling Hedged Distribution	04/01/2022	31/01/2022	£0.1307	102.71	£13	01/10/2021 - 31/12/2021
Total Distributions for Healthcare Bl			US\$638,891			

## 13. Distributions continued

2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
Income Opportunities Fund						
Class A1 Distribution Shares				G	BP£221,307	
Class A1 Sterling Distribution	04/01/2022	31/01/2022	£0.0156	3,541,056.74	£55,240	01/10/2021 - 31/12/2021
Class R US Dollar Distribution	04/01/2022	31/01/2022	\$0.0211	757,003.19	\$15,973	01/10/2021 - 31/12/2021
Class R Euro Distribution	04/01/2022	31/01/2022	€0.0186	62,319.17	€1,159	01/10/2021 - 31/12/2021
Class B1 Distribution Shares				G	BP£462,386	
Class B1 Sterling Distribution	04/01/2022	31/01/2022	£0.0168	4,839,746.24	£81,066	01/10/2021 – 31/12/2021
Class I US Dollar Distribution	04/01/2022	31/01/2022	\$0.0227	309,822.85	\$7,033	01/10/2021 - 31/12/2021
Class I Euro Distribution	04/01/2022	31/01/2022	€0.0199	746.14	€15	01/10/2021 - 31/12/2021
Class R Hedged Distribution Shares					EUR€12,724	
Class R Euro Hedged Distribution	04/01/2022	31/01/2022	€0.1335	95,313.80	€12,724	01/10/2021 - 31/12/2021
Class I Hedged Distribution Shares					EUR€124	
Class I Euro Hedged Distribution	04/01/2022	31/01/2022	€0.1335	928.39	€124	01/10/2021 – 31/12/2021
Class R Hedged Distribution Shares					US\$61,728	
Class R US Dollar Hedged Distribution	04/01/2022	31/01/2022	€0.1215	508,047.51	€61,728	01/10/2021 – 31/12/2021
Total Distributions for Income Oppo	rtunities Fund			G	iBP£210,639	
2024	Date	Date of	Rate per	No.		

2021	Date declared	Date of payment	Rate per share	No. of shares	Amount	Relevant period
UK Value Opportunities Fund						
Class I Sterling Distribution	04/01/2022	31/01/2022	£0.2075	11,964,975.33	£2,482,732	01/10/2021 - 31/12/2021
Class S Sterling Distribution	04/01/2021	29/01/2021	£0.2242	72,873,226.57	£16,338,177	01/01/2020 - 31/12/2020
Total Distributions for UK Value	Opportunities Fun	d		GB	P£18,820,910	

## 14. FCA Side Letter Policy

The Financial Conduct Authority (FCA) in the United Kingdom, which regulates the Investment Manager, expects all investment managers authorised and regulated by the FCA to write to investors in the funds managed by them with details of any Side Letter that may have been entered into by the Investment Manager. The FCA considers a Side Letter to be an arrangement which can reasonably be expected to provide an investor with materially more favourable rights than other investors, such as enhanced redemption rights or the provision of portfolio information which are not generally available. The Investment Manager has confirmed to the Company that it is not aware or party to an arrangement whereby an investor has any preferential redemption terms. However in exceptional circumstances, for example where an investor seeds a new Fund, the Investment Manager has provided investors on the Fund's behalf with portfolio information and capacity commitments.

## **15. Transaction Costs**

During the financial year ended 31 December 2021 and 31 December 2020, the Funds incurred transaction costs in the purchase and sale of investments as follows:

	Currency	31 December 2021	31 December 2020
Asian Opportunities Fund	US\$	20,951	84,199
Asian Stars Fund	US\$	340,560.14	18,360
Automation & Artificial Intelligence Fund	US\$	493,749	469,984
Biotechnology Fund	US\$	1,603,433	923,665
China Stars Fund	US\$	43,041	19,064
Emerging Markets Income Fund	US\$	263,335	147,435
Emerging Markets Stars Fund	US\$	1,735,380.00	385,814
European ex UK Income Fund	EUR	56,874	235,378
Financial Opportunities Fund	US\$	46,904	24,586
Global Absolute Return Fund	US\$	99	44
Global Convertible Fund	US\$	-	8,333
Global Insurance Fund	GBP	202,395	549,370
Global Technology Fund	US\$	10,860,987	7,935,186
Healthcare Blue Chip Fund	US\$	156,672	224,789
Healthcare Discovery Fund	US\$	45,118.31	31,174
Healthcare Opportunities Fund	US\$	1,979,690	6,122,316
Income Opportunities Fund	GBP	40,074	54,523
Japan Value Fund	JPY	16,532,923	24,961,267
North American Fund	US\$	414,392	872,064
Smart Energy Fund	US\$	22,891	_
Smart Mobility Fund	US\$	6,893	_
UK Absolute Equity Fund	GBP	_	_
UK Value Opportunities Fund	GBP	4,628,009	3,327,707

For further information regarding the accounting policy for transaction costs please refer to Note 2.

# 16. Reconciliation to US GAAP

The following adjustments would be required to these financial statements in order to reflect the redemptions payable on 1 January 2022, as required by US GAAP. The adjustments relate to the below funds. The effects of the adjustments for the remaining Funds are not material in the context of the financial statements.

	Automation & Artificial Intelligence Fund 2021 US\$	Biotechnology Fund 2021 US\$	China Stars Fund 2021 US\$	Emerging Markets Stars Fund 2021 US\$
Net Assets at 31 December 2021, under IFRS	768,829,307	1,713,904,099	19,979,329	1,288,353,415
Redemptions payable 1 January 2022	_	_	(13,308)	(316,387)
Net Assets at 31 December 2021, under US GAAP	768,829,307	1,713,904,099	19,966,021	1,288,037,028

	European ex UK Fund 2021 EUR€	Financial Opportunities Fund 2021 US\$	Global Convertible Fund 2021 US\$	Global Insurance Fund 2021 GBP£
Net Assets at 31 December 2021, under IFRS	119,139,503	23,496,762	1,066,904,406	1,701,832,724
Redemptions payable 1 January 2022	(17,466)	_	(66,941)	(328,346)
Net Assets at 31 December 2021, under US GAAP	119,122,037	23,496,762	1,066,837,465	1,701,504,378

	Global Technology Fund 2021 US\$	Healthcare Blue Chip Fund 2021 US\$	Healthcare Discovery Fund 2021 US\$	Healthcare Opportunities Fund 2021 US\$
Net Assets at 31 December 2021, under IFRS	9,078,397,146	116,148,125	72,619,592	2,138,223,444
Redemptions payable 1 January 2022	(2,571,457)	(225,603)	(61,556)	(220,882)
Net Assets at 31 December 2021, under US GAAP	9,075,825,689	115,922,522	72,558,036	2,138,002,562

	Income Opportunities Fund 2021 GBP£	Japan Value Fund 2021 JPY ¥	North American Fund 2021 US\$	Smart Energy Fund 2021 GBP£
Net Assets at 31 December 2021, under IFRS	58,052,699	23,668,453,458	1,251,434,041	27,652,671
Redemptions payable 1 January 2022	(4)	(14,618,582)	(84,987)	-
Net Assets at 31 December 2021, under US GAAP	58,052,695	23,653,834,876	1,251,349,054	27,652,671

	Smart Mobility Fund 2021 GBP£	UK Value Opportunities Fund 2021 GBP£
Net Assets at 31 December 2021, under IFRS	7,375,870	1,608,257,789
Redemptions payable 1 January 2022	_	(739,218)
Net Assets at 31 December 2021, under US GAAP	7,375,870	1,607,518,571

The following adjustments would be required to these financial statements in order to reflect the redemptions payable on 1 January 2021, as required by US GAAP. The adjustments relate to the below funds. The effects of the adjustments for the remaining Funds are not material in the context of the financial statements.

	Automation & Artificial Intelligence Fund 2020 US\$	Biotechnology Fund 2020 US\$	China Stars Fund 2020 US\$	Emerging Markets Income Fund 2020 US\$
Net Assets at 31 December 2020, under IFRS	753,361,100	1,256,438,007	13,974,480	104,412,469
Redemptions payable 1 January 2021	(49,810)	(503,850)	(76,907)	(1,588)
Net Assets at 31 December 2020, under US GAAP	753,311,290	1,255,934,157	13,897,573	104,410,881

	Emerging Markets Stars Fund 2020 US\$	European ex UK Fund 2020 EUR€	Financial Opportunities Fund 2020 US\$	Global Convertible Fund 2020 US\$
Net Assets at 31 December 2020, under IFRS	370,603,749	190,978,232	10,805,493	1,047,829,601
Redemptions payable 1 January 2021	(239,856)	(719)	(88)	(142,235)
Net Assets at 31 December 2020, under US GAAP	370,363,893	190,977,513	10,805,405	1,047,687,366

	Global Insurance Fund 2020 GBP£	Global Technology Fund 2020 US\$	Healthcare Blue Chip Fund 2020 US <b>\$</b>	Healthcare Discovery Fund 2020 US\$
Net Assets at 31 December 2020, under IFRS	1,587,832,431	8,655,795,829	92,030,247	48,456,796
Redemptions payable 1 January 2021	(235,056)	(1,217,257)	(76,497)	_
Net Assets at 31 December 2020, under US GAAP	1,587,597,375	8,654,578,572	91,953,750	48,456,796

	Healthcare Opportunities Fund 2020 US\$	Income Opportunities Fund 2020 GBP£	Japan Value Fund 2020 JPY ¥	North American Fund 2020 US\$
Net Assets at 31 December 2020, under IFRS	2,124,581,345	59,679,614	17,953,295,439	1,055,161,717
Redemptions payable 1 January 2021	(316,479)	(8,584)	(2,891,956)	(178,781)
Net Assets at 31 December 2020, under US GAAP	2,124,264,866	59,671,030	17,950,403,483	1,054,982,936

	UK Value Opportunities Fund 2020 GBP£
Net Assets at 31 December 2020, under IFRS	1,148,193,906
Redemptions payable 1 January 2021	(164,178)
Net Assets at 31 December 2020, under US GAAP	1,148,029,728

## 16. Reconciliation to US GAAP continued

The following summarises the Company's financial highlights for the financial year ended 31 December 2021.

### **Financial Highlights**

## For the financial year ended 31 December 2021

	31 December 2021				
	Asian Opportunities Fund Class I USD Distribution US\$	Asian Stars Fund Class I USD Accumulation US\$	Automation & Artificial Intelligence Fund Class I USD Accumulation US\$	Biotechnology Fund Class I USD Distribution US\$	
For a participating share outstanding throughout the financial year ended 31 December 2021					
Net investment loss*	_	0.02	(0.12)	(0.02)	
Net realised and unrealised gain	(16.04)	5.44	5.13	1.86	
Distributions	_	_	_	_	
Less Redemptions	_	_	_	_	
Net increase in net asset value	(16.04)	5.46	5.01	1.84	
Net asset value at beginning of financial year	16.04	12.66	12.83	39.27	
Net asset value at end of financial year	_	18.12	17.84	41.11	
Ratios	%	%	%	%	
Total return:					
Total return before performance fee	(100.00)%	43.94%	39.05%	5.25%	
Performance fee	_	(0.81)%	-	(0.57)%	
Total return after performance fee	(100.00)%	43.13%	39.05%	4.69%	
Ratios to average net assets:					
Expenses to average net assets	(0.57)%	(1.76)%	(1.06)%	(1.25)%	
Performance fee	_	(0.81)%	_	(0.57)%	
Total expenses	(0.57)%	(2.57)%	(1.06)%	(1.82)%	
Net investment loss to average net assets:					
Net investment loss before performance fee	(0.74)%	0.02	(12.01)%	(0.98)%	
Performance fee	_	(0.81)%	_	(0.57)%	
Total net investment loss	(0.74)%	0.02	(12.01)%	(1.55)%	

		31 Decemb	er 2021	
	China Stars Fund Class I USD Accumulation US\$	Emerging Markets Income Fund Class I USD Accumulation US\$	Emerging Markets Stars Fund Class I USD Accumulation US\$	European ex UK Income Fund Class I Euro Accumulation EUR
For a participating share outstanding throughout the financial year ended 31 December 2021				
Net investment income*	_	(0.02)	(0.01)	0.05
Net realised and unrealised gain/(loss)	5.13	(13.31)	(0.07)	2.11
Distributions	_	_	_	_
Less Redemptions	_	_	_	_
Net increase/(decrease) in net asset value	5.13	(13.33)	(0.08)	2.16
Net asset value at beginning of financial year	11.36	13.33	15.13	11.50
Net asset value at end of financial year	16.49	-	15.05	13.66
Ratios	%	%	%	%
Total return:				
Total return before performance fee	45.16%	(100.00)%	(0.16)%	0.19
Performance fee	_	_	(0.36)%	_
Total return after performance fee	45.16%	(100.00)%	(0.53)%	0.19
Ratios to average net assets:				
Expenses to average net assets	(0.12)%	(2.48)%	(1.82)%	(1.13)%
Performance fee	_	_	(0.36)%	_
Total expenses	(0.12)%	(2.48)%	(2.19)%	(1.13)%
Net investment (loss)/income to average net assets:				
Net investment income/(loss) before performance fee	-0.02%	-1.61%	-0.30%	4.77%
Performance fee	_	_	(0.36)%	_
Total net investment (loss)/income	(0.02)%	-1.61%	(0.67)%	4.77%

\* Average month-end shares outstanding were used for this calculation.

## 16. Reconciliation to US GAAP continued

Financial Highlights continued

For the financial year ended 31 December 2021 continued

		31 Decemb	oer 2021	
	Financial Opportunities Fund Class I USD Accumulation US\$	Global Absolute Return Fund Class I USD Accumulation US\$	Global Convertible Fund Class I USD Accumulation US\$	Global Insurance Fund Class I Sterling Accumulation GBP
For a participating share outstanding throughout the financial year ended 31 December 2021				
Net investment income/(loss)*	0.13	0.01	0.03	_
Net realised and unrealised (loss)/ gain	2.76	5.32	(1.34)	1.16
Distributions	_	_	_	_
Less Redemptions	_	_	_	_
Net (decrease)/increase in net asset value	2.89	5.33	(1.31)	1.16
Net asset value at beginning of financial year	14.70	125.46	17.41	7.11
Net asset value at end of financial year	17.59	130.79	16.10	8.27
Ratios	%	%	%	%
Total return:			·	
Total return before performance fee	0.20	5.08%	(0.08)	0.16
Performance fee	(0.00)	(0.83)%	_	0.00%
Total return after performance fee	0.20	4.25%	(0.08)	0.16
Ratios to average net assets:				
Expenses to average net assets	(0.00)%	(1.50)%	(0.47)%	(1.08)%
Performance fee	(0.00)	(0.83)%	_	0.00%
Total expenses	(0.03)%	(2.33)%	(0.47)%	(1.08)%
Net investment (loss)/income to average net assets:				
Net investment income before performance fee	0.13	1.73%	3.41%	0.29%
Performance fee	(0.00)	(0.83)%	_	0.00%
Total net investment (loss)/income	0.13	0.01	3.41%	0.29%

\* Average month-end shares outstanding were used for this calculation.

Technology Fund Chip Fund Discov Class I USD Class I USD Cl	ealthcare ery Fund ass I USD mulation US\$	Healthcare Opportunities Fund Class I USD Distribution USS
the financial year ended 31 December 2021Net investment loss*(0.01)-Net realised and unrealised gain8.853.58DistributionsLess RedemptionsNet increase in net asset value8.843.58Net asset value at beginning of financial year87.6116.04		000
Net realised and unrealised gain8.853.58DistributionsLess RedemptionsNet increase in net asset value8.843.58Net asset value at beginning of financial year87.6116.04		
DistributionsLess RedemptionsNet increase in net asset value8.843.58Net asset value at beginning of financial year87.6116.04	(0.02)	(0.01)
Less RedemptionsNet increase in net asset value8.843.58Net asset value at beginning of financial year87.6116.04	0.51	5.82
Net increase in net asset value8.843.58Net asset value at beginning of financial year87.6116.04	-	_
Net asset value at beginning of financial year 87.61 16.04	-	_
	0.49	5.81
Net asset value at end of financial year96.4519.62	15.05	64.58
	15.54	70.39
Ratios % %	%	%
Total return:		
Total return before performance fee10.09%22.33%	4.43%	9.00%
Performance fee – –	(1.16)%	0.00
Total return after performance fee10.09%22.33%	3.27%	9.00%
Ratios to average net assets:		
Expenses to average net assets(1.31)%(1.64)%	(1.36)%	(1.21)%
Performance fee – –	(1.16)%	_
Total expenses         (1.31)%         (1.64)%	(2.52)%	(1.21)%
Net investment loss to average net assets:		
Net investment loss before performance fee(0.77)%(0.10)%		(0.71)%
Performance fee – –	(1.09)%	
Total net investment loss(0.77)%(0.10)%	(1.09)% (1.16)%	_

\* Average month-end shares outstanding were used for this calculation.

## 16. Reconciliation to US GAAP continued

Financial Highlights continued

For the financial year ended 31 December 2021 continued

31 December 2021				
Income Opportunities Class B2 Sterling Accumulation GBP	Japan Value Fund Class S JPY Distribution JPY	North American Fund Class I USD Distribution US\$	UK Absolute Equity Fund** Class 1 Sterling Distribution GBP	
-	0.02	_	-	
0.52	36.40	4.13	_	
_	_	_	_	
_	_	_	_	
0.52	36.42	4.13	_	
2.33	239.03	27.26	_	
2.85	275.45	31.39	_	
%	%	%	%	
0.22	0.15	15.15%	_	
_	_	_	_	
0.22	0.15	15.15%	-	
_	(1.28)%	(1.03)%	_	
(0.00)	_	_	_	
(0.00)	(1.28)%	(1.03)%	-	
-	1.71%	(0.26%)	-	
_	_	_	_	
-	1.71%	(0.26%)	-	
	Opportunities Class B2 Sterling Accumulation GBP 	Income Opportunities Class B2 Sterling Accumulation GBP         Japan Value Fund Class 5 JPY Distribution JPY           -         0.02           -         0.02           0.52         36.40           -         -           0.52         36.40           -         -           0.52         36.42           2.33         239.03           2.85         275.45           0.22         0.15           -         -           0.22         0.15           -         -           0.22         0.15           -         -           0.22         0.15           -         -           0.22         0.15           -         -           -         -           0.22         0.15           -         -           -         -           -         -           -         -           -         -           -         -           -         -           -         -           -         -           -         -           -         - </td <td>Income Opportunities Class B2 Sterling Accumulation GBP         Japan Value Fund Class S JPY Distribution         North American Fund Class I USD Distribution           -         Class S JPY Distribution         Class I USD Distribution           -         0.02         -           -         0.02         -           -         0.02         -           -         0.52         36.40         4.13           -         -         -         -           0.52         36.42         4.13           2.33         239.03         27.26           0.52         36.42         4.13           2.33         239.03         27.26           0.52         31.39         -           0.22         0.15         15.15%           0.22         0.15         15.15%           0.22         0.15         15.15%           0.22         0.15         15.15%           0.020         -         -           0.020         0.128%         (1.03)%           (0.00)         (1.28)%         (1.03)%</td>	Income Opportunities Class B2 Sterling Accumulation GBP         Japan Value Fund Class S JPY Distribution         North American Fund Class I USD Distribution           -         Class S JPY Distribution         Class I USD Distribution           -         0.02         -           -         0.02         -           -         0.02         -           -         0.52         36.40         4.13           -         -         -         -           0.52         36.42         4.13           2.33         239.03         27.26           0.52         36.42         4.13           2.33         239.03         27.26           0.52         31.39         -           0.22         0.15         15.15%           0.22         0.15         15.15%           0.22         0.15         15.15%           0.22         0.15         15.15%           0.020         -         -           0.020         0.128%         (1.03)%           (0.00)         (1.28)%         (1.03)%	

\* Average net assets held during the financial year end were used for this calculation.

\*\* UK Absolute Equity fund terminated May 15 2020.

	31 Decemb	per 2021
	Smart Mobility Fund Class I USD Accumulation	UK Value Opportunities Fund Class I Sterling Accumulation GBP
For a participating share outstanding throughout the financial year ended 31 December 2021		
Net investment income*	_	_
Net realised and unrealised gain	10.57	2.45
Distributions	_	_
Less Redemptions	-	_
Net decrease in net asset value	10.57	2.45
Net asset value at beginning of financial year	-	12.19
Net asset value at end of financial year	10.57	14.64
Ratios	%	%
Total return:		
Total return before performance fee	_	0.20
Performance fee	-	(0.18)%
Total return after performance fee	-	0.20
Ratios to average net assets:		
Expenses to average net assets	(0.26)%	(0.57)%
Performance fee	_	(0.18)%
Total expenses	(0.26)%	(0.75)%
Net investment income to average net assets:		
Net investment income before performance fee	(0.15)%	1.63%
		(0.10)0/
Performance fee	-	(0.18)%

## 16. Reconciliation to US GAAP continued

Financial Highlights continued

For the financial year ended 31 December 2020

31 December 2020					
Asian Opportunities Fund Class I USD Distribution US\$	Asian Stars Fund Class I USD Accumulation US\$	Automation & Artificial Intelligence Fund Class I USD Accumulation US\$	Biotechnology Fund Class I USD Distribution US\$		
_	(0.02)	(0.02)	(0.03)		
1.90	5.48	5.03	11.42		
_	_	_	_		
_	_	_	_		
1.90	5.46	5.01	11.39		
14.14	12.66	12.83	27.88		
16.04	18.12	17.84	39.27		
%	%	%	%		
13.44%	44.50%	41.30%	42.33%		
_	(1.37)%	(2.25)%	(1.48)%		
13.44%	43.13%	39.05%	40.85%		
(2.13)%	(1.32)%	(1.14)%	(1.26)%		
_	(1.37)%	(2.25)%	(1.48)%		
(2.13)%	(2.69)%	(3.39)%	(2.74)%		
-0.13%	-0.53%	(0.24)%	(1.18)%		
_	(1.37)%	(2.25)%	(1.48)%		
-0.13%	(1.90)%	(2.49)%	(2.66)%		
	Opportunities Fund Class I USD Distribution US\$ 	Asian Opportunities Fund Class I USD Distribution USS         Asian Stars Fund Class I USD Accumulation USS           —         (0.02)           1.90         5.48           —         —           1.90         5.48           —         —           1.90         5.46           14.14         12.66           16.04         18.12           %         %           —         —           13.44%         44.50%           —         —           13.44%         43.13%           (2.13)%         (1.32)%           —         —           —         —           —         —           —         —           13.44%         43.13%           —         —           —         —           —         —           —         —           —         —           —         —           —         —           —         —           —         —           —         —           —         —           —         —           —         — </td <td>Opportunities Fund Class I USD Distribution USS         Asian Stars Fund Class I USD Accumulation USS         &amp; Artificial Intelligence Fund Class I USD Accumulation USS           —         (0.02)         (0.02)           —         (0.02)         (0.02)           —         (0.02)         (0.02)           1.90         5.48         5.03           —         —         —           —         —         —           1.90         5.46         5.01           1.90         5.46         5.01           1.91         12.66         12.83           16.04         18.12         17.84           13.44%         44.50%         41.30%           —         —         —           13.44%         43.13%         39.05%           (2.13)%         (1.32)%         (1.14)%           —         —         (3.39)%           (2.13)%         (2.69)%         (3.39)%           —         —         —           —         —         —           —         —         —           —         —         (3.39)%</td>	Opportunities Fund Class I USD Distribution USS         Asian Stars Fund Class I USD Accumulation USS         & Artificial Intelligence Fund Class I USD Accumulation USS           —         (0.02)         (0.02)           —         (0.02)         (0.02)           —         (0.02)         (0.02)           1.90         5.48         5.03           —         —         —           —         —         —           1.90         5.46         5.01           1.90         5.46         5.01           1.91         12.66         12.83           16.04         18.12         17.84           13.44%         44.50%         41.30%           —         —         —           13.44%         43.13%         39.05%           (2.13)%         (1.32)%         (1.14)%           —         —         (3.39)%           (2.13)%         (2.69)%         (3.39)%           —         —         —           —         —         —           —         —         —           —         —         (3.39)%		

		31 December 2020					
	China Stars Fund Class I USD Accumulation US\$	Emerging Markets Income Fund Class I USD Accumulation US\$	Emerging Markets Stars Fund Class I USD Accumulation US\$	European ex UK Income Fund Class I Euro Accumulation EUR			
For a participating share outstanding throughout the financial year ended 31 December 2020							
Net investment income*	_	0.02	(0.02)	0.05			
Net realised and unrealised (loss)/gain	5.13	0.02	4.18	(1.46)			
Distributions	_	_	_	_			
Less Redemptions	_	_	_	_			
Net (decrease)/increase in net asset value	5.13	0.04	4.16	(1.41)			
Net asset value at beginning of financial year	11.36	13.29	10.97	12.91			
Net asset value at end of financial year	16.49	13.33	15.13	11.50			
Ratios	%	%	%	%			
Total return:							
Total return before performance fee	45.44%	0.30%	40.01%	(10.92)%			
Performance fee	(0.28)%	-	(2.09)%	_			
Total return after performance fee	45.16%	0.30%	37.92%	(10.92)%			
Ratios to average net assets:							
Expenses to average net assets	(1.32)%	(1.55)%	(1.28)%	(1.04)%			
Performance fee	(0.28)%	_	(2.09)%	_			
Total expenses	(1.60)%	(1.55)%	(3.37)%	(1.04)%			
Net investment income/(loss) to average net assets:							
Net investment (loss) before performance fee	0.22%	1.95%	(0.24)%	5.03%			
Performance fee	(0.28)%	_	(2.09)%	_			
Total net investment income	(0.06)%	1.95%	(2.33)%	5.03%			

## 16. Reconciliation to US GAAP continued

Financial Highlights continued

For the financial year ended 31 December 2020 continued

	31 December 2020					
	Financial Opportunities Fund Class I USD Accumulation US\$	Global Absolute Return Fund Class I USD Accumulation US\$	Global Convertible Fund Class I USD Accumulation US\$	Global Insurance Fund Class I Sterling Accumulation GBP		
For a participating share outstanding throughout the financial year ended 31 December 2020						
Net investment income/(loss)*	(0.02)	_	0.02	0.01		
Net realised and unrealised (loss)/ gain	(0.38)	23.17	3.78	(0.43)		
Distributions	_	_	_	_		
Less Redemptions	_	_	_	_		
Net (decrease)/increase in net asset value	(0.40)	23.17	3.80	(0.42)		
Net asset value at beginning of financial year	15.10	102.29	13.61	7.53		
Net asset value at end of financial year	14.70	125.46	17.41	7.11		
Ratios	%	%	%	%		
Total return:						
Total return before performance fee	(2.65)%	24.87%	27.92%	(5.60)%		
Performance fee	_	(2.22)%	_	0.02%		
Total return after performance fee	(2.65)%	22.65%	27.92%	(5.58)%		
Ratios to average net assets:						
Expenses to average net assets	(3.71)%	(1.48)%	(1.03)%	(1.19)%		
Performance fee	_	(2.22)%	_	0.02%		
Total expenses	(3.71)%	(3.70)%	(1.03)%	(1.17)%		
Net investment income/(loss) to average net assets:						
Net investment (loss)/income before performance fee	(1.50)%	1.97%	1.56%	0.71%		
Performance fee	_	(2.22)%	_	0.02%		
Total net investment income	(1.50)%	(0.25)%	1.56%	0.73%		

		31 Decem	ber 2020	
	Global Technology Fund Class I USD Distribution US\$	Healthcare Blue Chip Fund Class I USD Accumulation US\$	Healthcare Discovery Fund Class I USD Accumulation US <b>\$</b>	Healthcare Opportunities Fund Class I USD Distribution US\$
For a participating share outstanding throughout the financial year ended 31 December 2020				
Net investment income/(loss)*	(0.01)	_	(0.03)	(0.01)
Net realised and unrealised gain/(loss)	32.56	1.17	5.08	10.20
Distributions	_	_	_	-
Less Redemptions	_	_	_	_
Net increase/(decrease) in net asset value	32.55	1.17	5.05	10.19
Net asset value at beginning of financial year	55.06	14.87	10.00	54.39
Net asset value at end of financial year	87.61	16.04	15.05	64.58
Ratios	%	%	%	%
Total return:				
Total return before performance fee	59.69%	7.88%	52.32%	18.77%
Performance fee	(0.57)%	-	(1.81)%	(0.03)%
Total return after performance fee	59.12%	7.88%	50.51%	18.74%
Ratios to average net assets:				
Expenses to average net assets	(1.25)%	(1.25)%	(1.86)%	(1.30)%
Performance fee	(0.57)%	_	(1.81)%	(0.03)%
Total expenses	(1.82)%	(1.25)%	(3.67)%	(1.33)%
Net investment (loss)/income to average net assets:				
Net investment (loss)/income before performance fee	(0.77)%	(0.39)%	(1.51)%	(0.63)%
Performance fee	(0.57)%	_	(1.81)%	(0.03)%
Total net investment (loss)/income	(1.34)%	(0.39)%	(3.32)%	(0.66)%

## 16. Reconciliation to US GAAP continued

Financial Highlights continued

For the financial year ended 31 December 2020 continued

	31 December 2020				
	Income Opportunities Class B2 Sterling Accumulation GBP	Japan Value Fund Class S JPY Distribution JPY	North American Fund Class I USD Distribution US\$	UK Absolute Equity Fund** Class I Sterling Distribution GBP	
For a participating share outstanding throughout the financial year ended 31 December 2020					
Net investment income*	_	_	_	_	
Net realised and unrealised loss	(0.08)	(33.29)	4.13	_	
Distributions	_	_	_	_	
Less Redemptions	_	_	_	_	
Net increase/(decrease) in net asset value	(0.08)	(33.29)	4.13	-	
Net asset value at beginning of financial year	2.41	272.32	27.26	-	
Net asset value at end of financial year	2.33	239.03	31.39	-	
Ratios	%	%	%	%	
Total return:					
Total return before performance fee	(2.93)%	(12.22)%	15.15%	-	
Performance fee	(0.49)%	_	_	-	
Total return after performance fee	(3.42)%	(12.22)%	15.15%	-	
Ratios to average net assets:					
Expenses to average net assets	(0.78)%	(0.70)%	(1.14)%	_	
Performance fee	(0.49)%	_	_	_	
Total expenses	(1.27)%	(0.70)%	(1.14)%	-	
Net investment (loss)/income to average net assets:					
Net investment (loss)/income before performance fee	0.49%	0.25%	0.01%	_	
Performance fee	(0.49)%	_	_	-	
Total net investment (loss)/income	_	0.25%	0.01%	-	

\* Average net assets held during the financial year were used for this calculation.

\*\* UK Absolute Equity fund terminated May 15 2020.

	31 December 2020 UK Value Opportunities Fund Class I Sterling Accumulation GBP
For a participating share outstanding throughout the financial year ended 31 December 2020	
Net investment income*	-
Net realised and unrealised loss	(1.02)
Distributions	_
Less Redemptions	
Net decrease in net asset value	(1.02)
Net asset value at beginning of financial year	13.21
Net asset value at end of financial year	12.19
Ratios	%
Total return:	
Total return before performance fee	(7.46)%
Performance fee	(0.25)%
Total return after performance fee	(7.71)%
Ratios to average net assets:	
Expenses to average net assets	(0.87)%
Performance fee	(0.25)%
Total expenses	(1.12)%
Net investment (loss)/income to average net assets:	
Net investment (loss)/income before performance fee	0.99%
Performance fee	(0.25)%
Total net investment (loss)/income	0.74%

\* Average net assets held during the financial year were used for this calculation.

Financial Highlights are based on financial statements NAV per share.

The above shares classes represent the overall performance of each Fund. Other share classes may have a different performance depending on the specific characteristics of the share class.

ASC 740-10 'Accounting for Uncertainty in Income Taxes – an interpretation of ASC 740' clarifies the accounting for uncertainty in income taxes recognised in the Fund's financial statements in conformity with ASC 740 'Accounting for Income Taxes'.

ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken on a tax return.

In conformity with ASC 740-10, the Directors have analysed the Funds' tax positions to be taken for the financial year ended 31 December 2021 and have concluded that no provision for income tax is required in the financial statements.

## 16. Reconciliation to US GAAP continued

For the financial year ended 31 December 2021 and 31 December 2020, the average volume of the Company's derivative activities based on their notional amounts and number of contracts, categorized by primary underlying risk, are as follows:

### **Asian Opportunities Fund**

### Average Balances of Derivative Instruments\*

	For the year ended 31 December 2021 Long Positions Short Positions US\$ US\$		For the yea 31 Decemb	
Primary Underlying Risk			Long Positions US\$	Short Positions US\$
Foreign Currency Exchange Rates				
Forward foreign currency contracts	_	-	135,475	(135,475)

### European ex UK

#### Average Balances of Derivative Instruments\*

	For the year ended 31 December 2021 Long Positions Short Positions EUR€ EUR€		For the yea 31 Decemb	
Primary Underlying Risk			Long Positions EUR€	Short Positions EUR€
Foreign Currency Exchange Rates				
Forward foreign currency contracts	215,229	(215,229)	10,428,653	(10,428,653)

#### **Global Absolute Return Fund**

#### **Average Balances of Derivative Instruments\***

	For the financial year ended 31 December 2021			
Primary Underlying Risk	Long Positions US\$	Short Positions US\$	Long Positions US\$	Short Positions US\$
Equity Price Risk				
Contracts for difference	343,918	(1,051,775)	665,410	(957,108)
Futures contracts	-	(4,304,000)	_	(5,241,283)
Warrants	-	-	21,708	_
Foreign Currency Exchange Rates				
Forward foreign currency contracts	2,527,552	(2,527,552)	1,763,165	(1,763,165)

## **Global Convertible Fund**

#### **Average Balances of Derivative Instruments\***

	For the financia 31 Decem		For the financia 31 Decemb	
Primary Underlying Risk	Long Positions US\$	Short Positions US\$	Long Positions US\$	Short Positions US\$
Equity Price Risk				
Contracts for difference	-	(24,562,462)	3,494,868	(8,682,724)
Futures contracts	138,266,094	(11,694,873)	87,104,208	(28,878,396)
Warrants	-	-	840,000	-
Foreign Currency Exchange Rates				
Forward foreign currency contracts	1,114,870	(1,114,870)	1,341,093	(1,341,093)

### **Global Insurance Fund**

## Average Balances of Derivative Instruments\*

	For the financia 31 Decemb	-	For the financial year ended 31 December 2020	
Primary Underlying Risk	Long Positions GBP£	Short Positions GBP£	Long Positions GBP£	Short Positions GBP£
Foreign Currency Exchange Rates				
Forward foreign currency contracts	467,357	(467,357)	901,714	(901,714)

### **Global Technology Fund**

### **Average Balances of Derivative Instruments\***

	For the financia 31 Decemb		For the financia 31 Decemb	· ·
Primary Underlying Risk	Long Positions US\$	Short Positions US\$	Long Positions US\$	Short Positions US\$
Equity Price Risk				
Options	5,059,325	-	6,477,262	(5,440)
Foreign Currency Exchange Rates				
Forward foreign currency contracts	4,040,358	(4,040,358)	3,051,717	(3,051,717)

## 16. Reconciliation to US GAAP continued

## Healthcare Blue Chip Fund

Average Balances of Derivative Instruments\*

	For the financia 31 Decemb		For the financia 31 Decemb	,
Primary Underlying Risk	Long Positions US\$	Short Positions US\$	Long Positions US\$	Short Positions US\$
Foreign Currency Exchange Rates				
Forward foreign currency contracts	49,001	(49,001)	68,696	(68,696)

#### **Income Opportunities Fund**

#### **Average Balances of Derivative Instruments\***

	For the financi 31 Decem		For the financia 31 Decemb	•
Primary Underlying Risk	Long Positions GBP£	Short Positions GBP£	Long Positions GBP£	Short Positions GBP£
Equity Price Risk				
Futures contracts	-	(1,359,214)	4,612,481	(2,588,779)
Options	-	-	103,949	(77,136)
Foreign Currency Exchange Rates				
Forward foreign currency contracts	2,465,579	(2,465,579)	1,882,401	(1,882,401)

#### Japan Value Fund

#### **Average Balances of Derivative Instruments\***

	For the financial year ended 31 December 2021		For the financia 31 Decemb	,
Primary Underlying Risk	Long Positions JPY¥	Short Positions JPY¥	Long Positions JPY¥	Short Positions JPY¥
Foreign Currency Exchange Rates				
Forward foreign currency contracts	235,247,887	(235,247,887)	142,212,131	(142,212,131)

#### **North American Fund**

**Average Balances of Derivative Instruments\*** 

	For the financia 31 Decemb		For the financial year ended 31 December 2020	
Primary Underlying Risk	Long Positions US\$	Short Positions US\$	Long Positions US\$	Short Positions US\$
Foreign Currency Exchange Rates				
Forward foreign currency contracts	2,099,812	(2,099,812)	6,571,337	(6,571,337)

#### **UK Absolute Equity Fund**

### **Average Balances of Derivative Instruments\***

	For the financia 31 Decemb		For the financia 31 Decemb	•
Primary Underlying Risk	Long Positions GBP£	Short Positions GBP£	Long Positions GBP£	Short Positions GBP£
Equity Price Risk				
Contracts for difference	_	-	19,119,226	(11,430,962)
Futures contracts	_	-	_	(78,475,383)
Options	-	-	2,617,403	-
Foreign Currency Exchange Rates				
Forward foreign currency contracts	-	-	6,893,700	(6,893,700)

# **UK Value Opportunities Fund**

### **Average Balances of Derivative Instruments**

	For the financia 31 Decemb	· ·	For the financia 31 Decemb	· ·
Primary Underlying Risk	Long Positions GBP£	Short Positions GBP£	Long Positions GBP£	Short Positions GBP£
Foreign Currency Exchange Rates				
Forward foreign currency contracts	-	-	1,212	(1,212)

## 16. Reconciliation to US GAAP continued

The following tables identifies the net gain and loss amounts included in the Statement of Comprehensive Income from derivative contracts, categorised by primary underlying risk, for the financial year ended 31 December 2021 and 31 December 2020.

#### **Asian Opportunities Fund**

	For the financia 31 Decemb	•	For the financial 31 Decembe	•
Primary Underlying Risk	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$
Foreign Currency Exchange Rates				
Forward foreign currency contracts	2,087	(2,186)	(45,920)	(2,048)

#### European ex UK

	For the financial year en 31 December 2021		For the financial 31 Decemb	
Primary Underlying Risk	Realised gain/(loss) EUR€	Unrealised appreciation/ (depreciation) EUR€	Realised gain/(loss) EUR€	Unrealised appreciation/ (depreciation) EUR€
Foreign Currency Exchange Rates				
Forward foreign currency contracts	2,168,761	(853,778)	(5,580,665)	(249,740)

#### Healthcare Blue Chip Fund

	For the financial 31 Decembe		For the financial 31 Decemb	
Primary Underlying Risk	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$
Foreign Currency Exchange Rates				
Forward foreign currency contracts	(122,635)	4,399	(164,972)	(5,055)

### **Global Absolute Return Fund**

		For the financial year ended 31 December 2021		For the financial year ended 31 December 2020	
Primary Underlying Risk	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$	
Equity Price Risk					
Contracts for difference	(4,399,431)	3,732,919	_	(2,175,520)	
Futures contracts	(3,909,900)	(121,488)	(2,175,520)	(40,950)	
Foreign Currency Exchange Rates					
Forward foreign currency contracts	(788,995)	76,982	_	347,754	

## **Global Convertible Fund**

		For the financial year ended 31 December 2021		year ended er 2020
Primary Underlying Risk	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$
Equity Price Risk				
Contracts for difference	(40,132,602)	15,968,207	(1,926,228)	(13,151,096)
Futures contracts	(64,693,168)	169,162	(3,041,300)	(186,216)
Foreign Currency Exchange Rates				
Forward foreign currency contracts	319,057	(134,309)	6,282,015	2,109,750

### **Global Insurance Fund**

	For the financial year ended 31 December 2021		For the financial year ended 31 December 2020	
Primary Underlying Risk	Realised gain/(loss) GBP£	Unrealised appreciation/ (depreciation) GBP£	Realised gain/(loss) GBP£	Unrealised appreciation/ (depreciation) GBP£
Foreign Currency Exchange Rates				
Forward foreign currency contracts	(1,042,066)	132,130	1,444,584	(151,874)

# **Global Technology Fund**

	For the financial year ended 31 December 2021		For the financial year ended 31 December 2020	
Primary Underlying Risk	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$
Equity Price Risk				
Options	(146,753,475)	39,170,005	127,158,145	(56,866,113)
Foreign Currency Exchange Rates				
Forward foreign currency contracts	(57,132,277)	4,317,725	49,898,532	2,914,764

# 16. Reconciliation to US GAAP continued

**Income Opportunities Fund** 

		For the financial year ended 31 December 2021		For the financial year ended 31 December 2020	
Primary Underlying Risk	Realised gain/(loss) GBP£	Unrealised appreciation/ (depreciation) GBP£	Realised gain/(loss) GBP£	Unrealised appreciation/ (depreciation) GBP£	
Equity Price Risk					
Futures contracts	19,209	40,033	(695,100)	(110,590)	
Options	(7,368)	-	(130,435)	_	
Foreign Currency Exchange Rates					
Forward foreign currency contracts	(228,574)	119,385	363,969	(20,971)	

### Japan Value Fund

	For the financial year ended 31 December 2021		For the financial year ended 31 December 2020	
Primary Underlying Risk	Realised gain/(loss) JPY¥	Unrealised appreciation/ (depreciation) JPY¥	Realised gain/(loss) JPY¥	Unrealised appreciation/ (depreciation) JPY¥
Foreign Currency Exchange Rates			·	
Forward foreign currency contracts	695,032,790	149,849,218	(514,031,722)	(20,656,494)

### **North American Fund**

Primary Underlying Risk		For the financial year ended 31 December 2021		For the financial year ended 31 December 2020	
	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$	Realised gain/(loss) US\$	Unrealised appreciation/ (depreciation) US\$	
Foreign Currency Exchange Rates					
Forward foreign currency contracts	(8,926,306)	1,256,877	(1,216,484)	(1,780,843)	

## **UK Absolute Equity Fund**

		For the financial year ended 31 December 2021		For the financial year ended 31 December 2020	
Primary Underlying Risk	Realised gain/(loss) GBP£	Unrealised appreciation/ (depreciation) GBP£	Realised gain/(loss) GBP£	Unrealised appreciation/ (depreciation) GBP£	
Equity Price Risk					
Contracts for difference	-	-	(31,394,358)	_	
Futures contracts	-	-	8,704,347	48,775	
Options	-	_	_	_	
Foreign Currency Exchange Rates					
Forward foreign currency contracts	104	-	2,394,377	1,603,613	

#### **UK Value Opportunities Fund**

	For the financial year ended 31 December 2021		For the financial 31 Decembe	·
Primary Underlying Risk	Realised gain/(loss) GBP£	Unrealised appreciation/ (depreciation) GBP£	Realised gain/(loss) GBP£	Unrealised appreciation/ (depreciation) GBP£
Foreign Currency Exchange Rates				
Forward foreign currency contracts	52,395	-	(936)	1,385

For detailed information on the fair value of derivatives by contract type as included in the Statement of Financial Position as of 31 December 2021 please refer to the Portfolio Statements.

#### 17. Significant Events during the Financial year

On 12 February 2021, the Company issued a new Prospectus Supplement for Emerging Markets Stars Fund. The main changes were in relation to the launch of new share classes, Class S Euro Distribution Shares and Class SX US Dollar Distribution Shares.

Barbara Healy resigned as Director of the Company on 16 February 2021.

Karen Nolan was appointed as Director of the Company on 16 February 2021. On 1 March 2021, Asian Opportunities Fund terminated.

The Prospectus and Supplements for each Fund were updated on 9 March 2021 to include the disclosures relating to environmental, social and governance (ESG) matters required by the implementation of EU Regulation 2019/2088 on sustainability-related disclosures in the financial services sector.

On 8 June 2021, Emerging Markets Income Fund merged with Emerging Markets Stars Fund.

On 1 July 2021, Emerging Markets Stars Fund launched the following share class: Class SX GBP Distribution.

On 22 November 2021, Emerging Markets Stars Fund launched the following share class: Class R USD Distribution.

Effective 6th July 2021, Bridge Consulting Limited retired as Governance Services Provider and Bridge Fund Management was appointed as UCITS Management Company.

On 30 September 2021, Smart Energy Fund and Smart Mobility Fund launched.

Throughout the year under review, global financial markets have experienced and may continue to experience significant volatility resulting from the spread of the coronavirus known as COVID-19. The outbreak of COVID-19 has resulted in travel and border restrictions, quarantines, supply chain disruptions, lower consumer demand and general market uncertainty. The effects of COVID-19 have and may continue to adversely affect the global economy, the economies of certain nations and individual issuers.

While the fiscal ramifications of the pandemic are still ongoing, there have been many advances made to curb and control outbreaks, this has meant that many jurisdictions are able to proceed and ease lockdowns with a gradual return to office in both the UK and Ireland. The global economic outlook is much more optimistic than this time last year.

Notes to the Financial Statements continued For the financial year ended 31 December 2021

#### **18. Subsequent Events**

Following Russia's invasion of Ukraine on 24 February 2022, various states have imposed sanctions and restrictions on the Russian state, Russian companies and individuals linked to Russia. The invasion has had a significant impact on markets with increased volatility, supply chain disruption and the potential to create severe disruption to oil, gas, and grain markets in particular.

The Funds have no direct exposure to Russia or Ukraine but the events have potential to impact global markets negatively. The Investment Manager is actively monitoring and continues to manage the Funds' assets within the investment and risk parameters that have been established. The Directors will continue to monitor developments in the region as there is potential for a serious destabilising economic effect which could jeopardise the global economy.

There have been no other events subsequent to the financial year end, which, in the opinion of the Directors of the Company, may have had an impact on the Financial Statements for the financial year ended 31 December 2021.

#### **19. Approval of the Financial Statements**

The Financial Statements were authorised by the Board of Directors on 31 March 2022.

## Asian Opportunities Fund\*

Purchases**	Cost US\$'000	Sales	Proceeds US\$'000
BOC Hong Kong	32	HDFC Bank ADR	602
Oversea-Chinese Banking	24	AIA	497
		Taiwan Semiconductor Manufacturing	462
		Tencent	439
		Bank Central Asia	420
		Housing Development Finance	380
		Alibaba	364
		Hong Kong Exchanges & Clearing	343
		Bajaj Finance	326
		China Merchants Bank	318
		China Construction Bank	314
		Samsung Electronics	304
		Axis Bank	297
		Ping An Insurance Group of China	293
		Bank Rakyat Indonesia Persero	239
		Chailease	206
		Bank of the Philippine Islands	195
		E.Sun Financial Class C	187
		Kasikornbank	181
		Manappuram Finance	180
		Kotak Mahindra Bank	178
		Keppel DC REIT	169
		Oversea-Chinese Banking	163
		Srisawad PCL	158
		KIWOOM Securities	152
		Tisco Financial	146
		NAVER	132
		Security Bank	125
		BOC Hong Kong	118
		Public Bank	116
		Longfor	96
		HDFC Life Insurance	96
		Ayala Land	95
		Bank for Foreign Trade of Vietnam	88

\* Asian Opportunities Fund was terminated on 01 March 2021.

\*\* Includes all purchases.

# Automation & Artificial Intelligence Fund

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Micron Technology	15,192	Meta Platforms	14,764
Thermo Fisher Scientific	13,809	STMicroelectronics	14,598
RELX	11,362	Microsoft	11,071
KLA Corp	10,721	Qualcomm	10,126
Mastercard	9,815	Xilinx	10,022
Amazon.com	9,572	Kulicke & Soffa Industries Inc	9,906
Sandvik AB	8,475	Shimano Inc	9,590
Twitter Inc.	8,305	Advantest Corp	9,084
Volkswagen AG	7,893	AirTAC International	8,753
Guardant Health	7,640	Thermo Fisher Scientific	8,376
Unity Software Inc	7,483	PayPal	8,316
Toyota Industries	7,226	Covestro	8,168
MercadoLibre	6,458	Ocado	7,906
Autodesk Inc	6,281	Spotify Technology	7,743
Meta Platforms	6,274	MarketAxess Holdings Inc	7,620
Seagate Technology	6,211	Avalara	7,469
Shin-Etsu Chemical	6,098	IPG Photonics Corporation	7,442
Equifax Inc.	6,071	Netflix	7,418
Alphabet	5,700	Alibaba ADR	7,275
Qualcomm	5,661	Amazon.com	7,222
Pinduoduo	5,472	Advanced Micro Devices	7,188
Snap	5,410	Equifax Inc.	6,828
Analog Devices	5,315	Samsung Electro-Mechanics	6,789
Man Group plc	5,258	Delivery Hero	6,644
Siemens Healthineers	5,240	MediaTek	6,524
Microsoft	5,153	Analog Devices	6,500
Pagseguro Digital Ltd	5,144	Autodesk Inc	6,239
Alfen	5,000	Adyen	6,154
Adyen	4,875	Twitter Inc.	5,948
LiveRamp	4,864	Volkswagen AG	5,924
NAVER	4,859	Bentley Systems	5,703
Seagate Technology	4,755	Givaudan	5,633
Sysmex Corp.	4,579	Tokyo Electron	5,518
Twilio Inc	4,554	Synopsys	5,506
Sea	4,509	Daifuku	5,397
Zur Rose Group	4,478	Ansys Inc	5,180

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Upstart	4,105	Axon Enterprise inc	5,172
Airbnb Inc.	4,029	Cerence	5,148
10x Genomics	3,934	Taiwan Semiconductor Manufacturing	4,962
M3 Inc	3,927	Intuitive Surgical	4,864
Bentley Systems	3,827	Twilio Inc	4,551
DUERR AG	3,783	Littelfuse	4,372
Netflix	3,691	DexCom Inc	4,367
PayPal	3,504		

## **Biotechnology Fund**

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
AstraZeneca	109,248	Valneva	81,003
Seagen	56,252	Alexion Pharmaceuticals	78,737
Alnylam Pharmaceuticals	54,636	Acceleron Pharma	77,495
NanoString Technologies	51,810	Argenx	60,645
Regeneron Pharmaceuticals	51,574	BioNTech	46,072
Bristol-Myers Squibb	45,664	Novavax	36,305
Biohaven Pharmaceutical	44,200	Bavarian Nordic	35,439
Bavarian Nordic	43,223	Constellation Pharmaceuticals	31,489
Jazz Pharma Plc	43,110	Biogen	30,925
Genmab	39,903	BELLUS Health	22,890
UCB	38,478	Cytokinetics	22,628
Novavax	35,956	Global Blood Therapeutics	22,468
Argenx	35,699	Zentalis Pharmaceuticals	21,141
Insmed	35,561	Synairgen	21,036
Global Blood Therapeutics	32,225	Zai Lab	18,934
Arcutis Biotherapeutics	30,862	BioMarin Pharmaceutical	18,590
Vertex Pharmaceuticals	30,364	Y-mAbs Therapeutics	18,526
Y-mAbs Therapeutics	30,356	Incyte	18,337
United Therapeutics	30,276	Curis	17,445
Xenon Pharmaceuticals	30,189	Oxford Immunotec Global	16,460
Biogen	29,934	Immunovant	15,174
BioNTech	29,541	Celldex Therapeutics	14,919
Valneva	28,647	Cogent Biosciences	14,908
Cytokinetics	28,263	Horizon Therapeutics	13,601
Exelixis	28,134	Atea Pharmaceuticals	13,318
Blueprint Medicines	27,694	Intellia Therapeutics	13,001
Curis	26,059	Travere Therapeutics	12,475
Celldex Therapeutics	25,700	PTC Therapeutics	11,674
Morphic Holding	25,394	Scholar Rock Holdings	11,559
Zai Lab	23,973	Verona Pharma ADR	11,403
Atea Pharmaceuticals	23,438	Alnylam Pharmaceuticals	11,392
Evotec	22,835	UCB	11,360
Horizon Therapeutics	22,162	Vertex Pharmaceuticals	10,578
Adicet Bio	20,533		
Cerevel Therapeutics	18,794		
Akoya Biosciences	17,753		
Supernus Pharmaceuticals	15,963		
BELLUS Health	15,775		
Zentalis Pharmaceuticals	14,910		

## **China Stars Fund**

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Tencent	1,237	iQIYI ADR	648
Alibaba Group	845	JD.com Inc	520
Alibaba ADR	822	NetEase ADR	454
JD.com Inc	780	Ping An Insurance Group of China Class H	432
China Construction Bank	738	Bilibili ADR	426
China Meidong Auto	680	BYD	372
iQIYI ADR	617	China Merchants Bank Class H	359
Meituan Dianping Class B	591	China Meidong Auto	357
BYD	558	Binjiang Service Group Co Ltd	348
Guangdong Kinlong Hardware Products	490	Agora Inc	331
NetEase ADR	469	Meituan Dianping Class B	314
Prosus	431	Guangdong Kinlong Hardware Products	292
Bilibili ADR	426	China Foods	275
Longfor	413	Prosus	273
China State Construction Development	382	C&D International Investment Group Ltd	265
China Resources Sanjiu Medical & Pharmaceutical	377	Longfor	256
ManpowerGreater China	373	China Resources Sanjiu Medical & Pharmaceutical	250
Binjiang Service Group Co Ltd	370	Renrui Human Resources Technology Holdings Ltd	232
51job ADR	342	Alibaba ADR	231
Zhou Hei Ya International Holdings Co Ltd	340	China Resources Beer	227
S.F. Holding Co Ltd	316	Shenzhen Inovance Technology	205
Gree Electric Appliances of Zhuhai	308	51job ADR	195
CLSA OPT Machine Vision Tech	308	Phoenix New Media ADR	186
Phoenix New Media ADR	279	Perfect World	170
Shenzhen Inovance Technology	266	Tencent	162
Xin Point	261	Taiwan Semiconductor Manufacturing	161
JD.com Inc Class A	258	21Vianet ADR	156
Haier Smart Home	251	Vipshop ADR	153
Dadi Early-Childhood Education	245	Microport Scientific	139
China Foods	240	Ping An Insurance Group of China Class A	139
KE Holdings Inc	238	China Resources Pharmaceutical	134
Vipshop ADR	234	Freni Brembo	129
Zhejiang Heda Technology Co Ltd	220	Geely Automobile	126
Venus MedTech (HangZhou) Inc	213	Airtac International	109
Kuaishou Technology	206	Zhou Hei Ya International Holdings Co Ltd	107
Yunnan Baiyao	193		
Foshan Haitian Flavouring & Food	192		
Midea	192		

# Emerging Markets Income Fund\*

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Tencent	2,071	Taiwan Semiconductor Manufacturing	5,978
Alibaba ADR	1,910	Samsung Electronics	4,771
Ping An Insurance	1,663	China Merchants Bank	4,550
China Lesso Group	1,545	Delta Electronics	4,416
Lg	1,375	Samsung Electronics Pref	3,679
NHPC	1,101	NAC Kazatomprom	3,461
Hyundai Motor Pref	1,079	Jiangsu Expressway	3,312
Sea ADR	1,051	КТ	3,286
Lee & Man Paper	993	Minth	3,047
Ivanhoe Mines	909	Haier Smart Home	2,772
Meituan Dianping	889	Topsports International	2,727
JD.com ADR	784	KB Financial	2,688
NetEase ADR	635	Dongbu Insurance	2,659
Prosus	611	Rural Electrification	2,547
MercadoLibre	523	China Mobile	2,499
Sibanye Stillwater	481	KT&G	2,478
Stoneco Ltd	430	LOTTE Reit	2,452
Alibaba Health Information Technology	354	Globaltrans Investment GDR	2,385
EPAM Systems	346	China Construction Bank	2,355
AIA	320	Fondul Proprietatea	2,351
Bilibili ADR	314	Mondi	2,347
Arco Platform	305	AB Ignitis Grupe	2,235
Yandex	282	Humansoft	2,206
Microport Cardioflow Medtech Corp	281	China Lesso Group	2,200
Longfor Group Holdings	231	Moneta Money Bank	2,181
		Macquarie Mexico Real Estate Management	2,128
		Guangdong Investment	1,966
		Tech Mahindra	1,924
		ICICI Bank	1,857
		Telekomunikasi Indonesia Persero	1,783
		Nova Ljubljanska Banka	1,779
		Bolsa Mexicana de Valores	1,766
		Emirates NBD Bank	1,700
		Telefonica Brasil	1,681
		Polyus GDR	1,519

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
		Sberbank of Russia	1,518
		Polycab India	1,513
		Digital Telecommunications Infrastructure	1,497
		OMV Petrom	1,470
		Sinopharm	1,434
		Life Healthcare	1,410
		Chicony Electronics	1,269
		Hyundai Motor Pref	1,263
		China Tower	1,223
		Detsky Mir	1,211

\* Emerging Markets Income Fund merged with the Emerging Markets Stars Fund on 8 June 2021.

## **Emerging Markets Stars Fund**

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Tencent	75,759	Daejoo Electronic Materials	20,891
Samsung Electronics	74,818	Prosus	14,680
Taiwan Semiconductor Manufacturing	74,323	NetEase ADR	14,399
Sea ADR	35,966	Sungrow Power Supply	8,125
Reliance Industries – Restricted	29,831	Agora	6,476
Alibaba Group Holdings	28,746	Afya	6,071
MediaTek	28,216	Glodon	5,940
ICICI Bank	27,890	Ping An Insurance	5,910
SK Hynix	27,582	Win Semiconductors	5,526
Meituan Dianping	27,354	Microport Cardioflow Medtech Corp	5,402
Naver	27,091	21Vianet ADR	5,115
Alibaba ADR	27,027	Prestige Estates Projects	4,997
MercadoLibre	23,434	Stoneco Ltd	4,877
Phoenix Mills	22,307	iqiyi Adr	4,854
Ivanhoe Mines	21,318	KMW	4,790
Housing Development Finance	19,506	Ecopro BM	4,761
eMemory Technology	18,471	JD.Com Inc	4,335
EPAM Systems	18,424	Sea ADR	3,993
JD.Com Inc	18,313	Microport Scientific	3,982
JD Health International	18,092	Leader Harmonious Drive Systems	3,925
Coforge Ltd	17,784	ICICI Bank	3,792
Apollo Hospitals	17,389	Kuaishou Technology	3,710
Sungrow Power Supply	17,354	Bilibili ADR	3,703
Ping An Insurance	16,966	Mail.Ru GDR	3,502
LandMark Optoelectronics	16,677	MediaTek	3,501
Stoneco Ltd	16,573	Alibaba ADR	3,463
Alibaba Health Information Technology	14,965	SK Hynix	3,445
OPT Machine Vision Tech	13,844	eMemory Technology	3,304
Samsung SDI	13,353	LandMark Optoelectronics	3,122
Prestige Estates Projects	13,023	51job ADR	3,055
Leader Harmonious Drive Systems	12,960	Samsung Electronics	3,037
Shenzhen Inovance Technology	12,931	Yoma Strategic	2,701
Andes Technology	12,779	Allegro.eu SA	2,517
Koh Young Technology	12,705	OPT Machine Vision Tech	2,116
Yandex	12,426		
AIA	12,204		
JD.com ADR	12,173		
Microport Cardioflow Medtech Corp	11,915		
Chroma ATE	11,867		
Longfor	11,807		
TCS Group GDR	11,564		

## European ex UK Income Fund

Purchases*	Cost EUR€′000		Proceeds UR€'000
TRYG	3,400	Scandinavian Tobacco	7,632
Nestle	2,826	Naturgy Energy	6,953
UPM-Kymmene	2,631	Pernod Ricard	6,405
Novartis	2,357	Novartis	5,546
Air Liquide	1,872	AXA	5,507
Siemens	1,863	Nestle	5,387
Vinci	1,254	UPM-Kymmene	5,349
Deutsche Telekom	1,231	Cie Financiere Richemont	5,006
Roche	1,004	TotalEnergies	4,799
Danone	841	BASF	4,760
Koninklijke KPN	726	Roche	4,290
Societe BIC	702	Deutsche Telekom	4,120
Unilever Plc	589	Sanofi	3,731
Deutsche Post	533	Danone	3,545
Sanofi	354	Getlink	3,073
Telenet	167	Telenet	3,014
		Societe BIC	2,958
		Swiss Re	2,941
		Koninklijke KPN	2,918
		Brenntag	2,840
		Deutsche Post	2,763
		Red Electrica	2,616
		SCOR	2,498
		Sampo Plc	2,240
		Heineken	2,163
		Unilever Plc	2,030
		NOS	2,007
		Assa Abloy	1,819
		Muenchener Rueckversicherungs-Gesellschaftin Muenchen	1,735
		Anheuser-Busch InBev	1,690
		Orange	1,676
		Cia de Distribucion Integral Logista	1,441

#### \* Includes all purchases.

## **Financial Opportunities Fund**

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
JPMorgan Chase	1,001	Wells Fargo	548
HSBC	826	US Bancorp	499
Bank of America	813	Citigroup	449
Toronto-Dominion Bank	714	Ping An Insurance	437
Sumitomo Mitsui Financial	632	Visa	436
Arch Capital	608	American Express	421
Citizens Financial	589	Bank of America	415
PNC Financial Services Group	585	JPMorgan Chase	380
HDFC Bank ADR	573	HSBC	370
Mastercard	550	Banco Bilbao Vizcaya Argentaria	368
PayPal	531	AIA	353
ING Groep	519	London Stock Exchange Group	351
Nordea Bank Abp	515	Mastercard	347
Chubb	501	Prudential	340
AIA	499	Signature Bank	334
Morgan Stanley	485	Commonwealth Bank of Australia	331
PacWest Bancorp	478	Sberbank of Russia ADR	319
Lancashire	474	Webster Financial	317
Citigroup	473	FinecoBank SPA	310
UBS	465	Arch Capital	305
Webster Financial	425	Prosperity Bancshares	305
Visa	424	Alibaba Group Holdings	286
East West Bancorp	421	Funding Circle	284
Enterprise Financial Services	411	Swedbank	280
OSB	402	Toronto-Dominion Bank	275
Intesa Sanpaolo SPA	397	M&T Bank	268
Alibaba Group Holdings	395	Citizens Financial	258
Sampo	381	PNC Financial Services Group	249
BNP Paribas	377	Axis Bank	248
Western Alliance Bancorp	374	China Merchants Bank	244
Standard Chartered	362	Chailease	242
Banco Bilbao Vizcaya Argentaria	344	HDFC Bank ADR	242
Shinhan Financial	339	Hong Kong Exchanges & Clearing	239
Oversea-Chinese Banking	333	ING Groep	239
Ping An Insurance	328	Comerica Inc	236
Sberbank of Russia ADR	319	PayPal	235
SVB Financial	318	Enterprise Financial Services	231

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Allfunds	317	DNB	227
Commonwealth Bank of Australia	314	Itau Unibanco	225
Pacific Premier Bancorp	308	Bajaj Finance	219
Signature Bank	302	Kasikornbank Public Company	215
Srisawad PCL	299	Chubb	206
Housing Development Finance	298	Sbanken	205
Natwest	291	Allianz	202
Bank Rakyat Indonesia Persero	291	Bank Rakyat Indonesia Persero	202
Manappuram Finance	289	BNP Paribas	197
Hong Kong Exchanges & Clearing	285	КВС	193
M&T Bank	284	Blackstone Group	183
		Housing Development Finance	182

## **Global Absolute Return Fund**

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
BP Capital Markets 1.000% 28/04/2023	11,146	BP Capital Markets 1.000% 28/04/2023	8,308
Umicore 0.000% 23/06/2025	8,184	Illumina 0.000% 15/08/2023	6,959
Ozon 1.875% 24/02/2026	6,792	Ozon 1.875% 24/02/2026	6,745
Mondelez International 0.000% 20/09/2024	5,891	Microstrategy 0.750% 15/12/2025	6,307
Orpar 0.000% 20/06/2024	5,878	Orpar 0.000% 20/06/2024	6,168
J Sainsbury 2.875% 29/12/2049	5,777	Umicore 0.000% 23/06/2025	5,687
Dufry One 0.750% 30/3/2026	5,380	Patrick Industries 1.750% 01/12/2028	4,484
Global Blood Therapeutics 1.875% 15/12/2028	5,000	Par Technology 1.500% 15/10/2027	4,428
Illumina 0.000% 15/08/2023	4,559	Repay 0.000% 01/02/2026	4,200
Patrick Industries 1.750% 01/12/2028	4,500	Marriott Vacations 0.000% 15/01/2026	4,169
Delivery Hero 0.875% 15/07/2025	4,238	Porch 0.750% 15/09/2026	4,002
Repay 0.000% 01/02/2026	4,105	Delivery Hero 0.875% 15/07/2025	3,957
Nutanix 0.250% 01/10/2027	4,000	Engie 0.000% 02/06/2024	3,839
Par Technology 1.500% 15/10/2027	4,000	John Bean Technologies 0.250% 15/05/2026	3,761
Porch 0.750% 15/09/2026	4,000	Peloton Interactive 0.000% 15/02/2026	3,755
Fisker 2.500% 15/09/2026	4,000	Neogenomics Inc 0.250% 15/01/2028	3,724
Shift4 Payments 0.500% 01/08/2027	4,000	Fisker 2.500% 15/09/2026	3,721
Engie 0.000% 02/06/2024	3,794	Li Auto 0.250% 01/05/2028	3,707
JET2 1.625% 10/06/2026	3,528	Mitek Sys. 0.750% 01/02/2026	3,688
Digitalocean 0.000% 01/12/2026	3,500	Sunnova Energy Int 0.250% 01/12/2026	3,644
DraftKings 0.000% 15/03/2028	3,500	Everbridge 0.000% 15/3/2026	3,638
Ford Motor 0.000% 15/03/2026	3,500	BigCommerce 0.250% 01/10/2026	3,591
Unity Software 0.000% 15/11/2026	3,500	Digitalocean 0.000% 01/12/2026	3,574
Marathon Digital 1.000% 01/12/2026	3,500	Bentley Sys. 0.125% 15/01/2026	3,572
MGp Ingredients I 1.875% 15/11/2041	3,500	Greenbrier Companies 2.875% 15/04/2028	3,570
Greenbrier Companies 2.875% 15/04/2028	3,500	ltron 0.000% 15/03/2026	3,565
Smiledirectclub 0.000% 01/02/2026	3,500	Box 0.000% 15/01/2026	3,552
Bentley Sys. 0.125% 15/01/2026	3,500	Mondelez International 0.00% 20/09/2024	3,537
Marriott Vacations 0.000% 15/01/2026	3,500	Alarm.com 0.000% 15/01/2026	3,533
Veritone 1.750% 15/11/2026	3,500	Dynavax Technologies 2.500% 15/05/2026	3,532
Alphatec 0.750% 01/08/2026	3,500	Kaleyra 6.125% 01/06/2026	3,524
Kaleyra 6.125% 01/06/2026	3,500	Ford Motor 0.000% 15/03/2026	3,522
Blackline 0.000% 15/03/2026	3,500	Unity Software 0.000% 15/11/2026	3,519
Box 0.000% 15/01/2026	3,500	Verint Systems 0.250% 15/04/2026	3,500
Array Technologies 1.000% 01/12/2028	3,500	Alphatec 0.750% 01/08/2026	3,495
BigCommerce 0.250% 01/10/2026	3,500	Blackline 0.000% 15/03/2026	3,444
Dynavax Technologies 2.500% 15/05/2026	3,500	Bridgebio Pharma 2.250% 01/02/2029	3,427

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
ltron 0.000% 15/03/2026	3,500	Spirit Airlines 1.000% 15/05/2026	3,420
Alarm.com 0.000% 15/01/2026	3,500	Stem 0.500% 01/12/2028	3,334
Stem 0.500% 01/12/2028	3,500	DraftKings 0.000% 15/03/2028	3,310
John Bean Technologies 0.250% 15/05/2026	3,500	Marathon Digital 1.000% 01/12/2026	3,288
Verint Systems 0.250% 15/04/2026	3,500	Smiledirectclub 0.000% 01/02/2026	3,261
MicroStrategy 0.000% 15/02/2027	3,500	Dufry One 0.750% 30/3/2026	3,258
Peloton Interactive 0.000% 15/02/2026	3,500		
Bridgebio Pharma 2.250% 01/02/2029	3,500		
Cryoport 0.750% 01/12/2026	3,500		
Sunnova Energy Int 0.250% 01/12/2026	3,500		
Spirit Airlines 1.000% 15/05/2026	3,500		
Camtek 0.000% 01/12/2026	3,500		
Li Auto 0.250% 01/05/2028	3,500		
Everbridge 0.000% 15/3/2026	3,500		
Sofi Technologies 0.00% 15/10/2026	3,500		
Mitek Sys. 0.750% 01/02/2026	3,500		
Neogenomics Inc 0.250% 15/01/2028	3,500		
Bigbear Al 6.000% 15/12/2026	3,498		

## **Global Convertible Fund**

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
PG&E	111,825	ArcelorMittal 5.500% 18/05/2023	118,096
Nexi 0.000% 24/02/2028	97,406	Electricite de France 0.000% 14/09/2024	114,613
Electricite de France 0.000% 14/09/2024	93,617	Nexi 0.000% 24/02/2028	95,206
Delivery Hero 0.875% 15/07/2025	93,156	Delivery Hero 0.875% 15/07/2025	86,919
2020 Cash Mandatory Exchangeable Trust	89,614	Deutsche Post 0.050% 30/06/2025	75,154
Deutsche Post 0.050% 30/06/2025	87,176	MorphoSys 0.625% 16/10/2025	71,777
MorphoSys 0.625% 16/10/2025	63,521	Zalando 0.050% 06/08/2025	64,378
Dufry One 0.750% 30/03/2026	62,519	Cellnex Telecom 0.500% 05/07/2028	60,168
Cellnex Telecom 0.500% 05/07/2028	62,197	J Sainsbury	55,635
Zalando 0.050% 06/08/2025	60,119	Colfax	54,163
Ford Motor 0.000% 15/03/2026	58,095	STMicroelectronics 0.000% 04/08/2025	51,877
Capital & Counties Properties 2.000% 30/03/2026	57,743	Safran 0.875% 15/05/2027	50,594
STMicroelectronics 0.000% 04/08/2025	50,538	Capital & Counties Properties 2.000% 30/03/2026	46,039
DISH Network 0.000% 15/12/2025	49,232	JPMorgan Chase Bank NA 0.000% 24/05/2022	43,981
JP Moragan Chase Bank 0.000% 18/02/2024	46,581	Ford Motor 0.000% 15/03/2026	42,609
Safran 0.875% 15/05/2027	44,533	Worldline 0.000% 30/07/2026	41,710
Meituan 0.000% 27/04/2027	44,150	RAG-Stiftung 0.000% 02/10/2024	40,558
Change Healthcare	42,560	Sika 0.150% 05/06/2025	37,824
RAG-Stiftung 0.000% 02/10/2024	40,567	Halozyme Therapeutics 0.250% 01/03/2027	37,063
Halozyme Therapeutics 0.250% 01/03/2027	39,730	GSK Finance No 3 0.000% 22/06/2023	36,241

## **Global Insurance Fund**

Purchases	Cost* GBP £'000	Sales	Proceeds GBP £'000
RenaissanceRe	26,397	Marsh & McLennan Cos	25,300
Kinesis	10,946	Chubb	21,753
Markel	8,968	Arch Capital	16,728
Ryan Specialty Group	8,066	Aon	13,208
Helios Underwriting	7,800	Markel	12,605
AlphaCat Opportunities	7,274	Berkshire Hathaway	11,677
Lodgepine 2021	7,212	Fairfax Financial	11,365
Direct Line Insurance	4,960	Alleghany	10,383
Beazley	4,778	Travelers Cos	9,698
James River	4,187	RenaissanceRe	8,316
Arch Capital	3,871	Essent	8,241
Intact Financial	3,541	WR Berkley	7,609
Reinsurance of America	2,020	Kinesis	5,164
Prudential	1,385	First American Financial	4,232
WR Berkley	1,322	Intact Financial	4,008
Essent	1,090	Reinsurance of America	3,816
Progressive Corp	1,004	Direct Line Insurance	3,520
		Sampo	2,398
		Progressive Corp	1,735
		Lancashire	1,690

\* Includes all purchases.

# Global Technology Fund

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Uber Technologies	233,780	Facebook	343,775
Amazon.com	221,716	PayPal	263,971
Facebook	220,384	Advanced Micro Devices	262,714
Microsoft	216,134	Applied Materials	249,549
Micron Technology	213,753	Analog Devices	220,972
Netflix	213,728	Zoom Video Communications	212,693
Alphabet Class A	212,215	Uber Technologies	207,577
Okta	209,979	NVIDIA	198,759
Alphabet Class C	209,624	Amazon.com	184,760
Snap	201,493	Tencent	172,989
Zoom Video Communications	190,626	DocuSign	171,694
Advanced Micro Devices	184,120	Adobe	169,890
Five9	180,996	Visa	168,703
DocuSign	177,612	Netflix	166,203
Roblox	173,269	Alibaba ADR	165,220
Zillow	167,448	Crowdstrike	155,022
ServiceNow	166,011	STMicroelectronics	154,636
Marvell Technology Inc.	160,147	Peloton Interactive	149,157
Elastic	158,630	Samsung Electronics	143,882
HelloFresh SE	157,293	Zendesk	143,366
Applied Materials	157,138	HubSpot	137,888
Zendesk	150,405	Alphabet Class A	136,132
Workday	145,372	Alphabet Class C	133,275
PayPal	142,027	Mastercard	132,948
Snowflake Inc.	141,606	Tesla Inc	130,270
Crowdstrike	137,171	Match Group	129,798
Western Digital	126,176	ServiceNow	124,570
Twitter Inc.	124,618	Spotify Technology	122,055
NVIDIA	124,441	ASML	120,845
Arista Networks	123,913	salesforce.com	119,139
Airbnb Inc.	122,738	Snowflake Inc.	115,116
ON Semiconductor	118,872	Taiwan Semiconductor Manufacturing	112,172
Seagate Technology	111,607	Etsy Inc.	111,941

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Etsy Inc.	109,441		
HubSpot	109,376		
Seagate Technology	109,165		
Mastercard	108,502		
NAVER	108,411		

# Healthcare Blue Chip Fund

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
UnitedHealth Group Inc	8,684	UnitedHealth Group Inc	8,427
Johnson & Johnson	8,620	Sartorius	6,950
Abbott Laboratories	5,316	Koninklijke Philips	6,260
Thermo Fisher Scientific	5,204	Thermo Fisher Scientific	6,082
Zimmer Biomet	4,910	Amgen	5,422
Align Technology	4,788	Syneos Health	5,300
Ramsay Health Care	4,773	Medtronic	5,216
The Cooper Companies	4,693	Centene	4,877
Boston Scientific	4,555	Siemens Healthineers	4,797
AmerisourceBergen	4,490	Hill-Rom	4,309
UCB	4,419	AmerisourceBergen	4,140
Centene	4,160	Align Technology	4,082
Alcon	4,057	Roche	4,028
STERIS Plc	3,973	Becton Dickinson	3,864
Hologic	3,731	Swedish Orphan Biovitrum	3,374
Biohaven Pharmaceutical	3,692	Zimmer Biomet	3,292
Siemens Healthineers	3,688	EssilorLuxottica	3,284
Sartorius	3,573	Alcon	3,160
Genmab	3,531	Fresenius Medical Care	3,108
AptarGroup	3,522	Eli Lilly	3,067
Molina Healthcare	3,411	Humana	3,049
Koninklijke Philips	3,332	Alnylam Pharmaceuticals	3,009
Argenx	3,291	PRA Health Sciences	3,007
Envista	3,113	Neurocrine Biosciences	2,936
Amedisys	3,043	IQVIA	2,820
Acadia Healthcare	2,889	Bio-Rad Laboratories	2,770
EssilorLuxottica	2,872	Horizon Therapeutics	2,724
Alnylam Pharmaceuticals	2,857	Bristol-Myers Squibb	2,609
AstraZeneca	2,491	PPD	2,527
GN Store Nord	2,485	Chugai Pharmaceutical	2,427
United Therapeutics	2,437	Argenx	2,387
Bio-Rad Laboratories	2,318	Ramsay Health Care	2,259
Amgen	2,238	UCB	2,166
Baxter International	2,237	Incyte	2,072
Bristol-Myers Squibb	2,218	GN Store Nord	2,063

Purchases	Cost U\$\$'000	Sales	Proceeds US\$'000
Seagen	2,075	Biohaven Pharmaceutical	1,845
Horizon Therapeutics	1,980	Baxter International	1,727
PPD	1,972	ACADIA Pharmaceuticals	1,700
AdaptHealth	1,969	Molina Healthcare	1,630
Syneos Health	1,923	Abbott Laboratories	1,599
Sanofi	1,856		

# Healthcare Discovery Fund

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Arrowhead	2,181	Tenet Healthcare	2,683
NanoString Technologies	1,798	Acceleron Pharma	2,609
Quidel	1,653	Hill-Rom	2,376
Acadia Healthcare	1,498	Swedish Orphan Biovitrum	2,110
Hikma Pharmaceuticals	1,461	BRUKER	1,764
Arcutis Biotherapeutics	1,447	Magellan Health	1,386
Zai Lab	1,445	Quidel	1,342
LivaNova	1,428	Medpace	1,286
Natera	1,413	Repligen	1,273
Y-mAbs Therapeutics	1,388	Chemed	1,181
Lantheus	1,208	Syneos Health	1,169
AtriCure	1,189	Horizon Therapeutics	1,160
R1 RCM	1,163	Haemonetics	1,068
Vericel	1,161	Arrowhead	1,061
Kalvista Pharmaceuticals	1,155	Change Healthcare	1,019
Inspire Medical Systems	1,120	AdaptHealth	950
Laboratorios Farmaceuticos Rovi	1,114	Amedisys	901
United Therapeutics	1,112	Renalytix Al	897
Evolent Health	1,094	Vericel	889
Denali Therapeutics	1,088	iRhythm Technologies	868
Pacira BioSciences	1,049	Inspire Medical Systems	847
Penumbra	1,036	Kalvista Pharmaceuticals	826
Korian	1,030	OptimizeRx	815
Haemonetics	1,021	Elekta AB	771
Envista	993	LHC	712
1Life Healthcare	984	Tactile Systems Technology	711
Tenet Healthcare	983	1Life Healthcare	667
Exelixis	979	ACADIA Pharmaceuticals	661
Conmed	954	SeaSpine	627
Mirati Therapeutics	928	NATERA INC.	608
Amedisys	913	uniQure	594
Progyny	897	CONMED Corporation	469
Medley	884	ICU Medical	454

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Globus Medical	851		
Omnicell	830		
IVERIC bio	808		
ALK-Abello	747		
Biohaven Pharmaceutical	714		
Richter Gedeon Nyrt	709		
Repligen	706		
Xenon Pharmaceuticals	702		
Insmed	698		
Tandem Diabetes Care	696		
Valneva	688		

## Healthcare Opportunities Fund

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Bristol-Myers Squibb	85,782	Johnson & Johnson	199,455
Boston Scientific	79,630	EssilorLuxottica	137,966
UCB	79,182	Roche	115,239
CVS Health	63,634	Align Technology	102,776
Zimmer Biomet	62,821	Syneos Health	83,735
Envista	55,862	Bristol-Myers Squibb	79,444
The Cooper Companies	55,737	Humana	66,451
United Therapeutics	54,756	Catalent	62,136
EssilorLuxottica	51,763	Zimmer Biomet	58,294
Hill-Rom	49,029	Bio-Rad Laboratories	58,281
LivaNova	45,157	Hill-Rom	53,738
AtriCure	44,954	Surgery Partners	52,600
Acadia Healthcare	44,864	Teleflex	51,271
Genmab	44,747	Avantor	45,842
Amedisys	44,423	Horizon Therapeutics	39,103
Alcon	43,803	AtriCure	39,012
AngioDynamics	39,319	AdaptHealth	38,940
AptarGroup	34,975	Oxford Immunotec Global	37,054
Centene	31,947	Centene	31,014
Dicerna Pharmaceuticals	31,430	Haemonetics	25,385
Glenmark Life Sciences	29,731	AstraZeneca	24,744
Max Healthcare Institute	27,960	Dicerna Pharmaceuticals	23,102
Encompass Health	27,145	Amedisys	22,719
IVERIC bio	26,226	Cigna	19,890
Surgery Partners	25,793	Trillium Therapeutics	19,810
Horizon Therapeutics	21,777	UCB	19,802
KalVista Pharmaceuticals	21,541	Axonics Modulation Technologies	19,697
Globus Medical	21,521		
Xenon Pharmaceuticals	20,513		
AstraZeneca	19,979		
Ship Healthcare	19,861		
Neuronetics	19,155		
ALK-Abello	18,847		
Krishna Institute of Medical Sciences	18,564		
Revance Therapeutics	16,968		
Johnson & Johnson	16,932		

# Income Opportunities Fund

Purchases	Cost GBP£'000	Sales	Proceeds GBP£'000
Provident Financial	1,100	JPMorgan Chase	2,242
Ground Rents Income Fund	975	ING Groep FRN (Perpetual)	1,679
Singapore Government Bond	842	Bank of America	1,351
Swedbank	814	KBC Bank	1,228
XPS Pensions	747	International Personal Finance FRN 15/06/2022	1,181
Beazley	738	Nationwide Building Society	1,047
Skandinaviska Enskilda Banken	722	First Republic Bank	1,031
Flow Traders	693	National Westminster Bank FRN (Perpetual)	1,007
United States Treasury Inflation Indexed Bonds	691	Blackstone Group	982
International Personal Finance	672	PNC Financial Services Group	973
Shinhan Financial	659	Dresdner Funding Trust I 8.151% 30/06/2031	970
Singapore Government Bond	636	Morgan Stanley FRN 30/04/2032	953
United States Treasury Inflation Indexed Bonds	632	Morses Club	905
3i	613	Lancashire	801
East West Bancorp	468	National Westminster Bank FRN (Perpetual)	787
Sumitomo Mitsui Financial	453	Swedbank	776
HSBC	421	SpareBank 1 SMN	754
Hellenic Bank	401	Wells Fargo	739
Schroders	365	Borealis Finance 7.500% 16/11/2022	737
Banco Comercial Portugues	342	National Westminster Bank 11.500% (Perpetual)	698
Provident Financial	324	Legal & General	680
Distribution Finance Capital	312	Kasikornbank	659
UK Mortgages	295	Provident Financial 8.250% 04/06/2023	655
Esquire Financial	265	Зі	596
Allfunds	240	Bank of NT Butterfield & Son	542
SLR Senior Investment	228	HSBC Bank FRN (Perpetual)	518
International Personal Finance	214	SLR Investment	473
Toronto-Dominion Bank	185	Sumitomo Mitsui Financial	465
National Westminster Bank 11.500% (Perpetual)	174	Bank of Georgia	461

## Income Opportunities Fund continued

Purchases	Cost GBP£'000	Sales	Proceeds GBP£'000
		UK Mortgages	459
		Wachovia Capital Trust III 5.570% 29/03/2049	451
		OSB	445
		Personal	445
		ING Groep	438
		HSBC	420
		Ares Capital	415
		BNP Paribas	410
		Premier Milton Group	405
		Morgan Stanley FRN 30/09/2031	372
		Direct Line Insurance	367

## Japan Value Fund

Purchases	Cost JPY¥'000	Sales	Proceeds JPY¥'000
Suzuki Motor	1,000,355	Secom Joshinetsu	1,298,080
Secom	914,068	HI-LEX	718,321
SoftBank Group	882,232	Mirait	703,911
Honda Motor	703,267	Bridgestone	689,166
Medikit	637,452	Okinawa Cellular Telephone	670,102
Lifedrink	567,029	KDDI	668,118
METAWATER	539,573	Inpex	608,930
Bank of Kyoto	530,152	Mitsui Fudosan	586,537
SK Kaken	510,423	Toppan Forms	556,449
TS Tech	477,705	Nikon	511,699
Shimamura	448,869	Kyocera	474,039
Nohmi Bosai	432,484	Tokio Marine	462,272
Hogy Medical	430,346	NTT Data	446,431
Amuse	424,834	Taisho Pharmaceutical	445,176
Tokio Marine	397,317	Kaga Electronics	439,763
Mabuchi Motor	391,711	Denso	362,684
Vital KSK Holdings	388,452	Kuraray	360,838
Toyo Tire	378,129	H2O Retailing	335,627
Optex	351,982	Mitsubishi UFJ Lease & Finance	299,250
SKY Perfect JSAT	348,271	JAFCO	273,387
Tanseisha	343,741	Suntory Beverage & Food	236,115
Forum Engineering	336,128	Daiwa Industries	148,729
Alps Alpine	298,712	Toshiba	145,077
Benesse Holdings	294,919	Aeon Delight	141,153
Jastec	273,641		
Mitsubishi UFJ Lease & Finance	266,539		
Mitsubishi Research Institute	247,865		
Suntory Beverage & Food	233,854		
Nihon Parkerizing	220,909		
SRA Holdings	220,398		
Ines	218,906		
Tokyo Broadcasting System	172,773		

## North American Fund

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Signature Bank	27,759	Colfax	35,814
Service Corporation International	26,921	Applied Materials	32,904
MKS Instruments	23,876	Markel	28,175
LPL Financial	22,131	IAC/InterActiveCorp	23,947
Zuora	21,117	Wells Fargo	23,472
Cannae	20,957	Altria	22,654
IAC/InterActiveCorp	20,595	Citigroup	21,169
Constellation Software	18,545	eBay	20,141
Littelfuse	18,420	Agilent Technologies	19,484
Wells Fargo	16,832	Marsh & McLennan	16,770
Amazon.com	16,209	Alphabet	16,037
Grupo Cementos de Chihuahua	15,092	Sabre	15,682
ICON	13,968	Mohawk Industries	13,756
United Rentals	13,965	Analog Devices	13,435
Shift Technologies	13,257	Envista	12,511
T-Mobile US	12,351	Centene	12,046
Canadian Natural Resources	11,973	Medtronic	11,727
Meta Platforms	11,138	Anthem	11,562
SS&C Technologies	10,824	Ametek	11,417
еВау	10,240	Lyft	10,351
Visa	9,661	TE Connectivity	9,945
Alphabet	8,947	Accenture	9,798
Uber	8,947	Amazon.com	9,786
Altria	8,168	Stitch Fix	8,538
Centene	7,930	Qualcomm	7,424
Stitch Fix	6,783	LiveRamp Holdings	7,235
TE Connectivity	6,418	Arch Capital	6,266
LiveRamp Holdings	5,295	Fiserv	6,079
Qualcomm	5,022	ICON	5,865
Anthem	4,684	Canadian Natural Resources	5,638
US Foods	4,534	Zuora	5,086

## Smart Energy Fund\*

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Xilinx	1,968	Xilinx	1,228
ON Semiconductor	1,872	Marvell Technology	816
Power Integrations	1,461	Plug Power	771
Marvell Technology	1,448	ON Semiconductor	645
Plug Power	1,421	SolarEdge Technologies	638
Xpeng Motors ADR	1,303	NIO ADR	637
Schneider Electric	1,255	Nordex	575
NIO ADR	1,244	Xpeng Motors ADR	402
Lattice Semiconductor	1,120	Enphase Energy	361
Nordex	1,055	Lattice Semiconductor	324
Infineon Technologies	939	NXP Semiconductors	266
EnerSys	919	7C Solarparken	234
SolarEdge Technologies	905	Albemarle	234
Alstom	899	Varta	218
Rohm	898	Nel	214
Johnson Controls International	891	РТС	207
Qorvo	853	Lumentum	196
Monolithic Power Systems	841	Encavis	191
Air Liquide	811	Wacker Chemie	186
Lumentum	769	Neoen	181
Renesas Electronics	746	Vertiv Holdings	149
STMicroelectronics	674	ITM Power	144
Linde	631	Schneider Electric	116
Albemarle	584	PNE	114
Nexans	561	Alstom	108
Skyworks Solutions	536	Ballard Power System	99
Analog Devices	525		
Fuji Electric	515		
Silergy	511		
Varta	491		
Azbil	477		
Navitas Semiconductor	474		
Enphase Energy	450		
Nel	417		
Vertiv Holdings	408		
SMA Solar Technology	385		
RENOVA	379		

\* Smart Energy Fund launched on 30 September 2021.

# Smart Mobility Fund\*

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
Plug Power	533	Plug Power	420
ON Semiconductor	480	Solaredge Technologies	251
XPeng	439	NIO	242
NIO	427	XPeng	176
Power Integrations	353	Albemarle	160
Alstom	337	Umicore	157
Infineon Technologies	336	ON Semiconductor	141
Uber Technologies	324	Ballard Power Systems	102
Visteon	323	NEL	98
Albemarle	312	Texas Instruments	97
Livent	306	NXP Semiconductors	96
Aptiv	297	Sociedad Quimica y Minera de Chile	84
Rohm	269	Fuji Electric	66
Monolithic Power Systems	248	ITM Power	58
Schneider Electric	244	Power Integrations	56
Solaredge Technologies	241	Delta Electronics	52
Denso	235	Chroma ATE	52
Renesas Electronics	227	Legrand	47
Analog Devices	210	TE Connectivity	39
Sociedad Quimica y Minera de Chile	207	Alstom	35
Umicore	206	Schneider Electric	33
Air Liquide	201		
Panasonic	196		
NXP Semiconductors	195		
Linde	182		
ABB	175		
Fuji Electric	160		
Dassault Systemes	151		
Nidec	145		

Purchases	Cost US\$'000	Sales	Proceed US\$'00
NEL	143		
Hota Industrial Manufacturing	142		
Stadler Rail	135		
STMicroelectronics	125		
ITM Power	122		
Hyundai Mobis	109		
Chroma ATE	101		
Legrand	101		
Texas Instruments	100		
Delta Electronics	100		
Ballard Power System	99		

\* Smart Mobility Fund launched on 30 September 2021.

# **UK Value Opportunities Fund**

Purchases	Cost US\$'000	Sales	Proceeds US\$'000
AstraZeneca	30,885	Watches of Switzerland	43,283
Bellway	28,059	Wm Morrison Supermarkets	39,396
Standard Chartered	27,293	Ultra Electronics	35,074
Rio Tinto	26,512	Stock Spirits	29,698
Natwest	25,572	Barratt Developments	27,897
Taylor Wimpey	25,254	Prudential	27,180
J Sainsbury	24,987	ВНР	23,123
HSBC	23,887	JD Sports Fashion	19,490
Atalaya Mining	23,660	James Fisher & Sons	18,749
Virgin Money UK	23,621	Ashmore	17,725
Greencore	22,730	Persimmon	17,250
SigmaRoc	22,728	Marks & Spencer	17,173
PZ Cussons	22,722	Investec	17,059
Mitchells & Butlers	22,557	Natwest	16,592
BHP	22,141	Marlowe	15,977
Beazley	21,509	Brewin Dolphin	15,285
Marks & Spencer	20,344	Polymetal International	15,183
Kier	19,108	Johnson Service	14,854
WPP	18,819	Rio Tinto	14,699
CMC Markets	18,581	Pennon	13,479
Hikma Pharmaceuticals	17,801	Morgan Sindall	12,420
Inchcape	17,460	On the Beach	12,145
Rathbone Brothers	15,961	Aviva	10,517
Premier Foods	15,774	DiscoverIE	10,063
Spirent Communications	15,142	OSB Group Plc	9,999
Vesuvius	14,567	Severfield	9,968
Morgan Advanced Materials	14,566	Young & Co's Brewery	9,444
Mondi	14,413	SThree	9,396
IG Design	14,004	Hill & Smith	9,337
Tesco	13,609	Grafton	9,239
Pennon	12,162	Morgan Advanced Materials	9,216
QinetiQ	11,788	AstraZeneca	9,112
Grafton	11,709	Reckitt Benckiser	8,746
Hilton Food	11,499	Victorian Plumbing	7,247

Purchases	Cost US\$′000	Sales	Proceeds US\$'000
Cranswick	10,790		
Breedon	10,132		
A.G. Barr	9,646		
Anglo American	9,623		
Dunelm	9,229		
B&M European Value Retail	9,026		

## Information for Investors (unaudited)

#### Information for Investors in the Federal Republic of Germany (unaudited)

The Prospectus, the Key Investor Information Document ('KIID'), the Memorandum and Articles of Association of the Company and the annual and semi-annual reports of the Company and a complete listing of the purchases and sales during the period, each in paper form, as well as the Net Asset Value per Share, issue and redemption prices and any switching prices are available and may be obtained free of charge at the office of the German Paying and Information Agent.

#### Information for Investors in Switzerland (unaudited)

The Company has appointed BNP Paribas Securities Services, Paris, Succursale de Zurich, Selnaustrasse 16, 8002 Zurich, Switzerland as representative and paying agent for Switzerland. For redeemable participating shares distributed in Switzerland, the performance place is at BNP Paribas Securities Services' address. Investors, can obtain free of charge, the prospectus, the simplified prospectus (both also available for potential investors), and the last annual and interim reports, from the representative at the above address and the official publications for the Company are published in www.fundinfo.com.

Following a directive of the Swiss Funds Association dated 27 July 2004, the Company is required to supply performance data in conformity with the said directive. This data can be found under each of the Fund reports.

Please note that all references to a specific index are for comparative purposes only.

Past performance is no indication of current or future performance. The value of an investment can fall as well as rise as a result of market fluctuations and investors may not get back the amount originally invested. The performance data does not take account of the commissions and costs incurred on the issue and redemption of redeemable participating shares.

Investors should contact the Swiss representative at the above address should they require additional information, e.g. on performance including the composition of the relevant indices where applicable.

#### **Total Expense Ratio**

Pursuant to a guideline from the Swiss Funds Association dated January 2006, the Company is required to publish a Total Expense Ratio (TER) for the period ended 31 December 2021.

The TERs for each Fund for the current and prior period are as follows:

	31 Decen	nber 2021	31 December 2020	
Name of Fund	TER (excluding performance fee) in %	TER (including performance fee) in %	TER (excluding performance fee) in %	TER (including performance fee) in %
Asian Opportunities Fund*	-	_	1.19	1.62
Asian Stars Fund	0.53	1.42	0.71	2.48
Automation & Artificial Intelligence Fund	0.61	0.61	0.55	1.91
Biotechnology Fund	1.31	1.61	1.33	2.69
China Stars Fund	0.63	0.63	0.71	1.67
Emerging Markets Income Fund**	1.12	1.12	0.98	0.98
Emerging Markets Stars Fund	1.57	1.83	0.66	2.29
European ex UK Income Fund	1.05	1.05	0.97	0.97
Financial Opportunities Fund	2.04	2.04	1.16	1.23
Global Absolute Return Fund	0.90	1.17	0.90	4.55
Global Convertible Fund	1.02	1.02	0.97	0.97
Global Insurance Fund	0.86	0.86	0.90	0.90
Global Technology Fund	1.28	1.28	1.28	1.81
Healthcare Blue Chip Fund	0.69	0.69	0.75	0.75
Healthcare Discovery Fund	0.81	0.81	0.78	1.65
Healthcare Opportunities Fund	1.17	1.17	1.20	1.24
Income Opportunities Fund	1.10	1.13	1.11	1.71
Japan Value Fund	0.90	0.90	1.00	1.00
North American Fund	0.75	0.75	0.74	0.74
Smart Energy Fund***	0.25	0.25	-	-
Smart Mobility Fund****	0.25	0.25	-	-
UK Value Opportunities Fund	0.67	0.89	0.66	0.66

\* Asian Opportunities Fund terminated on 1 March 2021.

\*\* Emerging Markets Income Fund merged with Emerging Markets Stars Fund on 8 June 2021.

\*\*\* Smart Energy Fund launched on 30 September 2021.

\*\*\*\* Smart Mobility Fund launched on 30 September 2021.

The Total Expense Ratio is calculated after an adjustment for swing pricing.

#### **PEA Compliance (unaudited)**

The European Income Fund is Plan d'Epargne en Actions ('PEA') eligible. For the purpose of eligibility requirement of Article L-221-31 of the French Monetary and Financial Code, the Fund must at all times during the financial year ended 31 December 2021 be invested in more than 75% of PEA eligible assets. PEA eligible assets are defined as equity or equity equivalent securities, which have their registered office in a country which is a member of the EU or the European Economic Area.

	% PEA Eligible Assets – 31 December 2021	5
European Income ex UK Fund	81.03%	81.48%

## Appendix I – Remuneration Disclosures (unaudited)

The below disclosure is made in respect of the remuneration policies of Bridge Fund Management Limited ('Manager') in accordance with the European Union Directive 2014/91/EU as implemented in Ireland by S.I. No. 143/2016 – European Union (Undertakings for Collective Investment in Transferable Securities) (Amendment) Regulations 2016.

The Manager has a business model, policies and procedures, which by their nature do not promote excessive risk taking and take account of the nature, scale and complexity of the Manager and the UCITS. The Remuneration Policy is designed to discourage risk taking that is inconsistent with the risk profile of the UCITS and the Manager is not incentivised or rewarded for taking excessive risk.

The Bridge Remuneration Policy applies to all UCITS for which it acts as manager. All remuneration paid to Identified Staff can be divided into:

- Fixed remuneration (payments or benefits without consideration of any performance criteria); and
- Variable remuneration (additional payments or benefits depending on performance or, in certain cases, other contractual criteria) which is not based on the performance of the UCITS.

The Manager has designated the following persons as Identified Staff:

- Executive and Non-Executive members of the management body of the Manager e.g. CEO, Directors, Executive and Non-Executive partners;
- Senior management;
- Risk takers staff who can exert material influence on the Manager or on the UCITS or AIFs it manages;
- Those in control functions: Operations, HR, Compliance, Finance where applicable;
- Staff whose total remuneration takes them into the bracket of senior management and risk takers, whose professional activities have a
  material impact on the Manager's risk position or those of the UCITS and/or AIFs it manages; and
- Categories of staff of the entities to which portfolio management or risk management activities have been delegated whose professional activities have a material impact on the Manager's risk position or those of the UCITS and/or AIFs it manages.

The Manager is required under the UCITS Regulations to make quantitative disclosures of remuneration. Disclosures are provided in relation to Identified Staff who are employed directly by the Manager and Identified staff who have the ability to materially impact the risk profile of the UCITS including individuals who, although not directly employed by the Manager, are assigned by their employer to carry out services directly by the Manager.

Remuneration details for the Manager are disclosed below:

Description	Number of beneficiaries	Total remuneration paid	Fixed remuneration paid	Variable remuneration paid
Total Staff Remuneration	29	€2,137,652	€1,807,402	€330,250
Senior Management (including executives), risk takers and other identified staff	8	€1,003,801	€760,801	€243,000

Details of the Remuneration Policy, including, but not limited to, a description of how remuneration and benefits are calculated and the identity of persons responsible for awarding the remuneration and benefits is available at the following website:

https://bridgeconsulting.ie/management-company-services/



The Securities Financing Transactions Regulation ('SFTR') came into effect on 12 January 2016. Article 13 requires information to be provided as to the use of securities financing transactions ('SFTs') and Total Return Swaps ('TRSs').

A Securities Financing Transaction ('SFT') is defined as per Article 3 (11) of the SFTR as: a repurchase transaction, securities or commodities lending and securities or commodities borrowing; a buy-sell back transaction or sell-buy back transaction; or a margin lending transaction.

As at 31 December 2021, Polar Capital Funds Plc held the following types of SFTs: Total Return Swaps (including CFDs). The amount of securities and commodities on loan as a proportion of total lendable assets (excluding cash and cash equivalents) was 0.00% as at 31 December 2021.

## **Global Data**

Type of Asset	Absolute Amount	Proportion of AUM (%)
Contracts for difference		
Global Absolute Return Fund	\$30,760,039	17.95%
Global Convertible Fund	\$240,635,970	11.16%
UK Absolute Equity Fund	£O	0.00%

## **Concentration Data**

	Collateral Issuers	Volume of the collateral securities and commodities
1	UBS AG	-\$110,803,425
2	Credit Suisse	£0

The gross volume of outstanding trades with each counterparty across all SFTs is as follows:

	Counterparty	Gross volume of outstanding trades*
Contracts for difference		
Global Absolute Return Fund	UBS AG	\$30,760,039
Global Convertible Fund	UBS AG	\$240,635,970
UK Absolute Equity Fund	Credit Suisse	£O

\* Gross volume of outstanding transactions expressed as market value of open derivative contracts at the reporting date.

## Appendix II – Securities Financing Transactions Regulation (unaudited) continued

## Aggregate transaction data

Contracts for difference	Type/ Quality of collateral	Currency	Maturity tenor (collateral)	Maturity tenor (SFTs/ Total Return Swaps)	Country of counterparty establishment (not collateral)	Settlement and clearing
Global Absolute Return Fund						
UBS AG	Cash	Multiple	>1 year	>1 year	Switzerland	Bilateral
Global Convertible Return						
Fund						
UBS AG	Cash	Multiple	>1 year	>1 year	Switzerland	Bilateral
UK Absolute Equity Fund						
Credit Suisse	Cash	Multiple	>1 year	>1 year	Ireland	Bilateral

The share of collateral that is reused is 0.00%.

## Safekeeping

Prime Broker	Collateral assets safe-kept
Credit Suisse	Cash Collateral
UBS AG	Cash Collateral

The proportion of collateral held in segregated accounts, in pooled accounts or any other accounts is 100.00%.

## Return/(Costs)

	Absolute Re	<b>Overall returns</b>	
Contracts for difference	Return	Cost	%
Global Absolute Return Fund	\$3,732,919	-\$4,660,370	100
Global Convertible Fund	\$15,968,207	-\$42,403,264	100

## Article 8 SFDR Asian Stars Fund Annual Report

### **Description of the Achievement of the Characteristics**

This disclosure should be read in conjunction with the Fund's prospectus and website disclosures under the Sustainable Finance Disclosure Regulation (EU) 2019/2088 ('SFDR').

In accordance with the Fund's prospectus, the Fund will invest in issuers situated in Asia that have the ability to remain competitive and deliver attractive profitability over the long-term due to robust fundamental characteristics only where these robust fundamental characteristics are combined with good or improving environmental, social and governance profiles based on the Investment Manager's proprietary analysis.

The Fund currently has a bias towards issuers with improving sustainability profiles, based on the Investment Manager's proprietary analysis.

The Fund excludes companies that have an unacceptable or controversial environmental, social or governance profile following the application of quantitative and qualitative analysis by the Investment Manager and through the use of exclusions lists.

The five specific areas of sustainability evaluated by the Investment Manager in its proprietary analysis, and the areas which are used as the sustainability indicators to measure the Fund's performance on its characteristics, are how companies in the Fund contribute to future sustainable economic development (their 'Impact on Progress'), how companies in the Fund manage their key risks and opportunities from an ESG perspective ('Material ESG Issues' – each of the environmental, social and governance issues being assessed as individual areas) and how companies in the Fund ensures they act as responsible corporate citizens (their 'Business Ethics').

Each company in the Fund is assigned a quantitative score from 1-10 based on these five areas. These scores are then taken together to provide the Investment Manager with a company's 'Sustainability Delta', which shows both the 'Current Level' and 'Future Direction' of a company from a sustainability perspective.

The Fund achieved its sustainability characteristics across all indicators during the reporting period.

As is consistent with the Fund's investment process and the expectations of the Investment Manager, the sustainability indicator scores shown at a headline, aggregated Fund level have remained relatively stable from the previous reference period to this reference period and no individual indicator has seen an uplift of greater than 0.5 as compared with the previous reference period, with one indicator stable, and no contractions.

There are two ways in which Fund-level indicator scores change from period to period. These are via i) upgrades or downgrades to our scores on existing holdings, and ii) portfolio changes from buying lower scoring, selling higher scoring stocks or vice versa.

In the case of the first type of change, upgrades or downgrades to a company's indicator score for each area are typically incremental. Such upgrades or downgrades are dependent on upgrades or downgrades to a number of sub-indicators that feed into each area's indicator score. In most cases, companies will require a large number of upgrades or downgrades across these sub-indicators for this to have a significant impact on each area's indicator score.

In the case of the second type of change, as the Fund has relatively low turnover and as it is also unlikely that the spread on all new stocks bought versus all stocks sold during a given period will be very wide (in either direction), this driver too is moderate. Over this reporting period we bought 13 new stocks and exited 9 positions.

We therefore expect to continue to see small changes in our sustainability indicators at the Fund level over time, even whilst at the underlying stock level there are a number of investments which have seen multi-point upgrades.

## Article 8 SFDR Asian Stars Fund Annual Report continued

### Description of the Achievement of the Characteristics continued

A summary of the aggregated Fund Level scores for 2020 and 2021, as at the last date of the respective reference periods, is shown below :

	202	1	202	0
	Current Level	Future Direction	Current Level	Future Direction
Impact on progress	7.4	7.7	7.0	7.4
Environmental	6.4	6.8	5.9	6.3
Social	6.7	7.0	6.6	6.8
Governance	7.0	7.2	7.0	7.1
Business ehitcs	6.8	7.0	6.6	6.6

#### **Impact on Progress**

The Fund's 'Current Level' score increased by 0.4 as compared with 2020 and the 'Future Direction' score increased by 0.3, to 7.4 and 7.7 respectively as shown in the summary table above.

In both cases, the majority of this change in the scores was driven by portfolio changes as, particularly on the 'Current Level' score, the new stock purchases had much better ratings on Impact on Progress, with the average new stock bought over the period having a 'Current Level' score of 7.4 and the average stock sold having a 'Current Level' score of 6.0.

The prime reason for this was that the new stocks purchased operate in areas such as solar inverters, healthcare and robotics technologies which score well in this part of our framework.

#### Environmental

The Environmental indicator improved the most of all indicators over the reference period, increasing from 5.9 to 6.4 on the 'Current Level' score and 6.3 to 6.8 on the 'Future Direction' score. In each case, this 0.5 uplift breaks down as 0.2 from existing portfolio upgrades and 0.3 from portfolio changes.

There was a surprisingly large spread in the Environmental scores between newly bought companies, and those we exited. On 'Current Level' and 'Future Direction' scores, the outgoing companies average scores were 5.0 and 5.0 respectively and our new purchases scored 6.4 and 6.8 respectively.

There are a number of reasons for this difference. Firstly, the improvement in the detail of companies' disclosures on this subject, and the number of companies providing them, has been improving with every quarter, allowing us to improve the quality of our scoring. In tandem with this the range of data sources available has been an increasingly valuable input to more meaningful, complete scores, as well as increased engagement. Lastly, we have made enhancements to our own scoring mechanism to promote more rigorous scores.

The largest contributor to the improving scores from current holdings was a significant upgrade to Vietnam's Techcombank's score following a review of their underlying loan book exposure which has little in carbon intensive sectors and is heavily weighted towards high impact sectors.

#### Social

The Social indicator was the only area in which the Fund saw a small deterioration as compared with the previous reference period. On 'Current Level', the score increased 0.1 and on 'Future Direction' the score increased 0.2.

There was no material impact from the spread of portfolio change scores on this indicator. The main effect was a small net upgrade to the social scores for existing holdings on both 'Current Level' and 'Future Direction'. The largest positive change was made to Glodon as the company has made strong improvements to its social disclosures. This offset a downgrade to Naver, due to new information regarding a culture of 'machoism' (see engagement example below).

#### Governance

This indicator was stable on the 'Current Level' score and increased only 0.1 on the 'Future Direction' score, with only very small fluctuations looked at in terms of both upgrades and downgrades and portfolio changes. The 'Current Level' score remained flat at 7.0.

Within existing holdings, positive changes, such as an upgrade to Longfor Properties which announced an internal reorganisation, offset negatives such as a weakened board at Samsung Electronics as a number of executive directors who failed to remove JY Lee won votes to retain their board seats.

The 'Future Direction' score increased very slightly over the reference period owing to a positive spread from portfolio changes, where we exited a number of young companies bought at IPO with less proven records of established governance structures and bought into names that were either more mature or where we had strong understanding and knowledge of a well-aligned founder-led business model.

Changes to the scores of existing scores detracted from this indicator, as the positive future effects from positive changes such as greater clarity on HDFC's succession plan was not enough to offset the larger downgrades from Samsung Electronics again (for reasons stated above), Koh Young Technology which was downgraded owing to the existence of related party transactions with an entity owned by the founder and Alibaba Health Information Technology where the score was reduced after a previously guided improvement in corporate structure between the company and its parent company Alibaba did not materialise.

#### **Business Ethics**

Business Ethics moved up 0.2 on both 'Current Level' and 'Future Direction' scores. All changes at the underlying stock level were de minimis.

The table below displays a summary of all changes, at an aggregated Fund level, that have been described over the reporting period:

	Level 2020	Upgrade/ downgrade	Portfolio change	Level 2021	Direction 2020	Upgrade/ downgrade	Portfolio change	Direction 2021
Impact on progress	7.0	0.10	0.30	7.4	7.4	0.1	0.20	7.7
Environmental	5.9	0.20	0.30	6.4	6.3	0.2	0.30	6.8
Social	6.6	_	0.10	6.7	6.8	0	0.20	7.0
Governance	7.0	_	_	7	7.1	(0.1)	0.20	7.2
Business ethics	6.6	0.20	-	6.8	6.6	0.2	0.20	7.0

### **Describe the Fund's Top 10 Investments**

Holdings	Fund Weight (%)
1) TSMC	9.2%
2) Samsung Electronics	7.8%
3) Tencent	6.6%
4) Alibaba Group Holding	4.0%
5) Reliance Industries	3.4%
6) MediaTek	3.4%
7) SK Hynix	3.3%
8) ICICI Bank	3.1%
9) Sea	3.1%
10) AIA Group	2.9%

## Article 8 SFDR Asian Stars Fund Annual Report continued

#### Description of the Percentage of the Fund's Investments that meet the Characteristics

All investments attained the characteristics of the Fund on an individual basis over the reference period.

The Investment Manager determines a security has met the characteristics of the Fund if its score is equal to or greater than 5 on its proprietary 'Sustainability Delta' scoring framework.

The Investment Manager prefers to invest in securities which display an improving trend with the score for 'Future Direction' improving from the 'Current Level' score, though this is not a requirement for an investment to meet the Fund's characteristics and the Fund may invest in securities where scores are stable across the forecast period.

In cases where scores display a deteriorating trend, with the 'Future Direction' score declining from the 'Current Level' score, the Investment Manager makes a commitment to engage with the company to resolve a path forward.

The current breakdown of the Fund is shown in table below:

	% Fund
Positive Delta: Current Level < Future Direction	74.0%
Stable Delta: Current Level = Future Direction	26.0%
Negative Delta: Current Level > Future Direction	0%

As at the final date of the reference period, the Fund was primarily invested in equities and equity warrants and the balance was held in cash.

As at the end of the reporting period the Fund had an investment in one security with some exposure to fossil fuels. This security, Reliance Industries, represented a 3.44% weight within the Fund as at the end of the reporting period. Reliance Industries' exposure to fossil fuel is less than 10% of its revenue.

Due to the nature of our process and commitment to investing in improving companies with at least good existing ESG, we can occasionally invest in what we term 'higher delta' cases, where at first glance they may seem more 'controversial'. Reliance Industries represents an example of this. We believe this company is on a huge transformational journey from being an old-style industrial refinery and chemicals business to a modern retail/consumer and communication/internet company, as well as now expanding into new materials and renewable energy and transitioning to net carbon zero by 2035. Owing to the complexity of this ambition, and the recognition that this is starting out as a more carbon intensive business, we have become co-lead investors as part of a Climate Action 100+ collective action engagement, to ensure that we are actively involved in our ownership of a company of this kind, monitoring and partnering so that the transition remains on track.

On our current 'Material ESG Issues' analysis, Reliance Industries scores better than many peers within the industry and is already reasonably efficient in terms of its water and energy usage, with annual improvements and a good safety record. It is far from a best-in-class sustainability company, but we believe it has the potential to be a future leader and the ability to make one of the largest differences. We provide greater detail about this investment and our engagement with Reliance Industries in the section that follows.

As at the date of this report, 0% of the Fund's investments fail the Fund's exclusion criteria.

## **Describe Actions Taken to Attain Characteristics**

The assessment of sustainability factors is not a one-time event and does not stop at the point of purchase. Ongoing engagement and monitoring are a constant and valuable part of our work, as we are very focused on how companies see the future and how they allocate capital accordingly to mitigate risk and benefit from revenue opportunities as part of a sustainable future. These are the types of companies that will score highly on our proprietary framework.

In this way, we view engagement as entirely integrated with our ongoing, fundamental dialogue with our investments. We hold hundreds of meetings each year alongside site visits, meetings with competitors, suppliers, customers, industry experts and lower-tier employees as part of our ongoing engagement and due diligence. Engagement can take the form of meetings, calls, emails or voting as a shareholder. We aim to be regular and proactive in our efforts rather than only engaging post an ESG 'event'.

However, we also maintain a record of specific interactions where we engaged with companies on environmental, social and governance issues. We classify these engagements into what we term 'heavy' and 'light' engagements. Heavy engagements are the minority of cases and reserved for situations where we feel there is a either a greater need for action or a greater likelihood that we can affect material change as a minority investor. In light engagement cases, change is expected to be more incremental and our dialogue with companies on these issues less frequent and of lower materiality for the investment case.

Given the rigour we believe is required for quality, 'heavy' engagement work, as well as the reality that there are fewer companies that meet all aspects of our fundamental process and are in need of this kind of interventional stewardship, we guide that the number of heavy investments we will be undertaking in any year is likely to be in the low single digits. Light engagements may range between 10–30% of the portfolio.

In circumstances where a company is involved in a negative material ESG incident which compromises the integrity of the whole business, or, less dramatically, where we lose confidence in our investment thesis owing to an issue related to ESG practices and therefore our belief in a company's ability to generate long-term sustainable EVA, or our comfort with it as a corporate citizen, our policy is to immediately divest.

A summary of all engagements during the reporting period, together with key engagement and divestment examples are given below.

Engagements	
Total Engagements	11
Companies held	10
Companies not-held	1
Type of Engagement	
Collective Action	1
Heavy	3
Light	7
Topic of Engagement	
Environment	1
Social	1
Governance	2
E&S	3
E&G	1
S&G	2
E, S&G	1

Engagements	
Seniority of Meeting	
Management	3
IR	2
Other	6
Method of Engagament	
In Person	2
Video conference	7
Call	2
Email/Letter	0

## Article 8 SFDR Asian Stars Fund Annual Report continued

### Describe Actions Taken to Attain Characteristics continued

#### Key engagement examples

#### **Reliance Industries**

We are pleased to be co-lead investors of the Climate Action 100+ collective engagement on Reliance Industries (from 2021) to seek to gain better understanding and push them further on their net zero 2035 targets. Climate Action 100+ is an investor-led collaborative engagement initiative that aims to tackle the systemic climate change challenge by influencing the behaviour of management of the key global GHG emitting companies to implement strong governance around climate change, take action to reduce emissions, and improve disclosure.

Prior to joining Climate Action 100+, we had ourselves engaged extensively with Reliance Industries, most recently with meetings following the announcement of their new business reorganisation, with the CFO (Alok Agarwal) and Joint-CFO (Srikanth Venkatachari (Energy division) of Reliance Industries – to talk directly with them on investments in the energy division towards renewable energy and new materials and the commitment to become net-carbon zero by 2035.

Our engagement priorities as part of the Climate Action 100+ group are to establish a more definitive roadmap with milestones over the next 13 years toward reaching the net-carbon zero goal, including pushing for better provision of disclosures on current emissions (split by scope and businesses), committing to an annual commentary on emissions, drivers of year on year changes and commentary on targets and more communication on capital expenditure plans and progress.

The company initially planned to spend \$10bn to invest in 4 new energy giga factories, building an integrated solar photovoltaic module factory enabling 100GW of solar energy by 2030, an advanced energy storage battery factory, an electrolyser factory for green hydrogen and a fuel cell factory to work with the green hydrogen factory. Most recently, this has been increased to

\$80bn of investment, over the next 10-15 years, with US67bn going into renewable power plants and green hydrogen. This gives greater confidence in the ability of the company to fund the transition and ambitions and displays the seriousness and confidence of the management team in committing to the plans and to reaching the net zero 2035 target. Reliance Industries is targeting bringing the entire state of Gujarat to net zero by 2035, which would be an incredibly significant achievement for a private company, and perhaps a first globally.

We acknowledge that Reliance Industries is certainly an 'improver' or one of our largest 'Sustainability Delta' cases but are comfortable they are managing their ESG risks and positioning themselves firmly as future solution providers. We continue to engage in a very active way via Climate Action 100+.

#### Naver

Recently Korea has, in general, been hit by a number of cases around a 'macho culture' in the work place – which has a social impact for many younger, particularly female, employees. This 'macho culture issue' has also been hitting Naver and is why we are starting deeper engagement into this social topic. It appears to be very concentrated around a few individuals within Naver, and it does seem to have been addressed very quickly by the board (founder group) – which includes a new female CEO with a better 'young culture' understanding and drive.

We had a very interesting conversation bringing-up factors up like the Korean war and the strong influence of the very harsh military training that all men have to undergo in Korea – and how this military culture has ended up in the work place. Our light, initial engagement here reflects that Naver has responded very fast and with senior management involvement. However, this is an issue that will still hang across most Korean companies, and a large part of our engagement here is also for us to understand this deep-rooted cultural issue.

#### **ITM Semiconductor**

We arranged a call with the company to discuss the recent announcement that they are engaging with IQOS to supply their battery management technology for IQOS' e-cigarettes. We explained that we believe this the wrong direction for the company as they have so many other attractive business opportunities to focus on, and that this move could potentially restrict their access to international institutional investors who could otherwise help unlock the value of the company, which we believe is underappreciated by the market, not to mention our own beliefs about the nature of the product from a health and social point of view. The investor relations manager said he would relay our message to the company management and we hope to continue this engagement and will try and persuade them to reconsider pursuing this client.

#### **HDFC**

As all 3 key, top people in the management team have now been at the company for 12-15 years and are in their 60s, we asked the CEO about the potential to disclose more definitive succession planning steps to smooth the process and reassure that there is strong governance oversight for the next generation. We were informed that there is a clearly laid out plan at both the very top level and in each business line and that this is a key topic for the board that is discussed at all board meetings. HDFC's preference is to promote internally, but they would fill positions from the outside in some cases if that can be done better

#### **Ecopro**

Ecopro BM proposed at their AGM in 2021 to significantly increase the limit on authorized shares from 150m to 500m, as well as the issuance limit on convertible securities from 100 billion South Korean Won ('KRW') to 1 trillion KRW.

We felt this was an issue from a governance perspective as we believed 1) there was still plenty of headroom left under the current limits as the company has no outstanding convertibles and only 14% of the current limit on authorized shares was utilized, and 2) there is no clear reason stated for the proposal.

During our call, management explained that under the current expansion plans could be sourced by bank loans and internal cash flow as the company has said in the past, but if the company wanted to expand capacity in Europe, this would require additional capital they could not source from domestic banks.

#### Liontown (not held)

One of the key focus areas of our engagement was on the company's environmental impact from its proposed lithium mining activities in Kathleen Valley in Australia and its plan to use 60% renewable energy on-site by the start of the project – which seems very ambitious. During our engagement, company management informed us that they felt very confident of reaching the renewable energy target and eventually aim to move to 100% renewable energy for the project.

Further, from a social responsibility perspective, the Kathleen Valley project is located in an important Aboriginal area in Australia, making social engagement an essential factor to its progress. We found, through our engagement, that the Native title holders, the Tjiwarl, have provided their full consent for the signing of the Kathleen Valley Project Native Title Agreement (NTA) and strong co-operation links have been established with the community. Liontown will be a large employer of local people and will bring a significant upgrade in access to water and electrification, whilst having full and clear understanding on all cultural sites.

The negotiations with the native title holders have been on-going for years and the contract and co-operation structure has been met with strong support from both sides. This reflects well on Liontown and significantly reduces 'S risk'.

#### **Key Divestments**

There were no divestments during the reporting period due to reasons related to sustainability, ESG and engagement actions.

#### Disclosure pursuant to the Taxonomy Regulation (EU) 2020/852

Under Article 8 SFDR, this Fund promotes environmental characteristics in the manner outlined above. In accordance with the requirements of Article 6 of the Taxonomy Regulation, the Fund must state that the 'do no significant harm' principle applies only to those investments underlying the Fund that take into account the EU criteria for environmentally sustainable economic activities.

However, the Fund has not elected to invest in sustainable investments, as defined in Article 2(17) SFDR, and, therefore, its investments are not made on the basis of applying the EU criteria for environmentally sustainable economic activities or, as a consequence, the 'do no significant harm' principle.

## Article 8 SFDR China Stars Annual Report

### **Description of the Achievement of the Characteristics**

This disclosure should be read in conjunction with the Fund's prospectus and website disclosures under the Sustainable Finance Disclosure Regulation (EU) 2019/2088 ('SFDR').

In accordance with the Fund's prospectus, the Fund will invest in issuers situated in Greater China or with material business exposure to Greater China that have the ability to remain competitive and deliver attractive profitability over the long-term due to robust fundamental characteristics, only where those robust fundamental characteristics are combined with positive environmental, social and governance profiles based on the Investment Manager's proprietary analysis.

The Fund excludes companies that have an unacceptable or controversial environmental, social or governance profile following the application of quantitative and qualitative analysis by the Investment Manager and through the use of exclusion lists.

The five specific areas of sustainability evaluated by the Investment Manager are how a company contributes to future sustainable economic development (its 'Impact on Progress'), how a company manages its key risks and opportunities from an ESG perspective (its 'Material ESG Issues' – each of the environmental, social and governance issues being assessed as individual areas) and how a company ensures it acts as a responsible corporate citizen (its 'Business Ethics'). Each company is assigned a quantitative score from 1-10 based on these five areas.

The Fund achieved its sustainability characteristics across all indicators during the reporting period.

Each company's scores in these areas are then taken together to provide the Investment Manager with a company's 'Sustainability Delta', which shows the holistic profile of a company from a sustainability perspective.

A summary of the aggregated Fund level scores for 2021 as at the last date of the reference period (31st December 2021) is shown below:

2021	Score
Impact on Progress	6.6
Environmental	6.4
Social	6.4
Governance	6.4
Business ethics	6.9

### **Describe the Fund's Top 10 Investments**

As at the last date of the reference period (31st December 2021), the top 10 holdings of the Fund were:

Holdings	Fund Weight (%)
1) Tencent	9.9%
2) China Construction Bank	4.9%
3) BYD	3.9%
4) Alibaba ADR	3.8%
5) China Resources Sanjiu Medical & Pharmaceutical	3.4%
6) Alibaba Group	3.2%
7) Meituan Dianping Class B	3.2%
8) JD.com Inc	2.9%
9) China Meidong Auto	2.7%
10) ManpowerGreater China	2.5%

## Description of the Percentage of the Fund's Investments that meet the Characteristics

All investments attain the characteristics of the Fund on an individual basis.

The Investment Manager determines a security has met the characteristics of the Fund if its scores equal to or greater than 5 on its proprietary 'Sustainability Delta' scoring framework.

The Investment Manager prefers to invest in securities which display an improving trend, though this is not a requirement for an investment to meet the Fund's characteristics and the Fund may invest in securities where scores are stable across the forecast period.

In cases where score display a deteriorating trend, the Investment Manager makes a commitment to engage with the company to resolve a path forward.

As at the final date of the reference period, the Fund was primarily invested in equities and equity warrants, the balance is held in cash.

## **Describe Actions Taken to Attain Characteristics**

The assessment of sustainability factors is not a one-time event and does not stop at the point of purchase. Ongoing engagement and monitoring are a constant and valuable part of our work, as we are very focused on how companies see the future and how they allocate capital accordingly to mitigate risk and benefit from revenue opportunities as part of a sustainable future. These are the types of companies that will score highly on our proprietary framework.

In this way, we view engagement as entirely integrated with our ongoing, fundamental dialogue with our investments. We hold hundreds of meetings each year alongside site visits, meetings with competitors, suppliers, customers, industry experts and lower-tier employees as part of our ongoing engagement and due diligence. Engagement can take the form of meetings, calls, emails or voting as a shareholder. We aim to be regular and proactive in our efforts rather than only engaging post an ESG 'event'. However, there are a few situations each year where we feel we can add value as minority shareholders through more active forms of engagements.

In circumstances where a company is involved in a negative Material ESG incident which compromises the integrity of the whole business, or, less dramatically, where we lose confidence in our investment thesis owing to an issue related to ESG practices and therefore our belief in a company's ability to generate long-term sustainable EVA, or our comfort with it as a corporate citizen, our policy is to immediately divest.

An example of a highly active engagement during the reporting period is given below.

### **Active ESG engagement**

#### SF Holding

In our belief, SF Holding is China's best-in-class integrated logistics service provider. Through our proprietary research on its business practices and strategy, we are confident that SF is driving innovation through technology investments to reduce the logistic industry's carbon footprint and it is way ahead of its peers, which would give them a cost and productivity advantage in the long-term, boosting its profit margin and return profile. Based on the above, we disagreed with MSCI's CCC ESG rating for the company and decided to invest in SF Holding.

In conjunction with our investment, we engaged with SF Holding senior management to encourage them to engage with MSCI to help improve their ESG score, with the view that having an improved MSCI ESG rating would have a material impact on SF Holding's cost of capital in the future as the company looks to continue to expand its capacity. Through our engagement, we helped management understand the importance and urgency of improving their MSCI ESG rating and identified areas for improved communication and disclosure to address MSCI's concerns.

We were pleased to see a subsequent upgrade in SF Holdings' MSCI ESG rating from CCC to BB and believe that through highly engaged dialogue with MSCI on disclosure and communication, the company proved its ESG credentials and showed that is a positive driving force to improve the carbon footprint, productivity and safety of the logistics industry. As a shareholder, we welcome this outcome.

As at the date of this report, 0% of the Fund's investments fail the Fund's exclusion criteria.

## Article 8 SFDR China Stars Annual Report continued

### **Key Divestments**

There were no divestments during the reporting period due to reasons related to sustainability, ESG and engagement actions.

### Disclosure pursuant to the Taxonomy Regulation (EU) 2020/852

Under Article 8 SFDR, this Fund promotes environmental characteristics in the manner outlined above. In accordance with the requirements of Article 6 of the Taxonomy Regulation, the Fund must state that the 'do no significant harm' principle applies only to those investments underlying the Fund that take into account the EU criteria for environmentally sustainable economic activities.

However, the Fund has not elected to invest in sustainable investments, as defined in Article 2(17) SFDR, and, therefore, its investments are not made on the basis of applying the EU criteria for environmentally sustainable economic activities or, as a consequence, the 'do no significant harm' principle.

## Article 8 SFDR Emerging Markets Stars Annual Report

### **Description of the Achievement of the Characteristics**

This disclosure should be read in conjunction with the Fund's prospectus and website disclosures under the Sustainable Finance Disclosure Regulation (EU) 2019/2088 ('SFDR').

In accordance with the Fund's prospectus, the Fund will invest in issuers situated in emerging markets that have the ability to remain competitive and deliver attractive profitability over the long-term due to robust fundamental characteristics only where these robust fundamental characteristics are combined with good or improving environmental, social and governance profiles based on the Investment Manager's proprietary analysis.

The Fund currently has a bias towards issuers with improving sustainability profiles, based on the Investment Manager's proprietary analysis.

The Fund excludes companies that have an unacceptable or controversial environmental, social or governance profile following the application of quantitative and qualitative analysis by the Investment Manager and through the use of exclusions lists.

The five specific areas of sustainability evaluated by the Investment Manager in its proprietary analysis, and the areas which are used as the sustainability indicators to measure the Fund's performance on its characteristics, are how companies in the Fund contribute to future sustainable economic development ( their 'Impact on Progress'), how companies in the Fund manage their key risks and opportunities from an ESG perspective ('Material ESG Issues' – each of the environmental, social and governance issues being assessed as individual areas) and how companies in the Fund ensure they act as responsible corporate citizens (their 'Business Ethics').

Each company in the Fund is assigned a quantitative score from 1–10 based on these five areas. These scores are then taken together to provide the Investment Manager with a company's 'Sustainability Delta', which shows both the 'Current Level' and 'Future Direction' of a company from a sustainability perspective.

The Fund achieved its sustainability characteristics across all indicators during the reporting period.

As is consistent with the Fund's investment process and the expectations of the Investment Manager, the sustainability indicator scores shown at a headline, aggregated Fund level have remained relatively stable from the previous reference period to this reference period and no individual indicator at Fund level has seen an uplift of greater than 0.5 as compared with the previous reference period, whilst only one indicator has seen a contraction of -0.1.

There are two ways in which Fund-level indicator scores change from period to period. These are via i) upgrades or downgrades to our scores on existing holdings, and ii) portfolio changes from buying lower scoring, selling higher scoring stocks or vice versa.

In the case of the first type of change, upgrades or downgrades to a company's indicator scores are typically incremental. Such upgrades or downgrades are dependent on upgrades or downgrades to a number of sub-indicators that feed into each area's overall indicator score. In most cases, companies will require a large number of upgrades or downgrades across these sub-indicators for this to have a significant impact on each area's overall indicator score.

In the case of the second type of change, as the Fund has relatively low turnover and as it is also unlikely that the spread on all new stocks bought versus all stocks sold during a given period will be very wide (in either direction), this driver too is moderate. Over the reporting period, we bought 12 new stocks and exited 11 positions.

We therefore expect to continue to see small changes in our sustainability indicators at the Fund level over time, even whilst at the underlying stock level there are a number of investments which have seen multi-point upgrades.

## Article 8 SFDR Emerging Markets Stars Annual Report continued

## Description of the Achievement of the Characteristics continued

A summary of the aggregated Fund Level scores for 2020 and 2021 as at the last date of the respective reference periods (31st December) is shown below:

	202	1	202	0
	Current Level	Future Direction	Current Level	Future Direction
Impact on progress	7.4	7.8	7.1	7.6
Environmental	6.5	7.0	6.0	6.5
Social	6.6	7.0	6.7	7.0
Governance	6.9	7.1	6.9	7.1
Business ehitcs	6.7	6.9	6.6	6.6

#### **Impact on Progress**

The Fund's 'Current Level' score increased 0.3 as compared with 2020 and the Fund's 'Future Direction' score increased by 0.2, to 7.4 and 7.8 as shown in the summary table above.

In both cases, the majority of this change in the scores was driven by portfolio changes as, particularly on the 'Current Level' score, the new stock purchases had much better ratings on Impact on Progress, with the average new stock bought over the period having a 'Current Level' score of 7.5, and the average stock sold having a 'Current Level' score of 6.6.

The prime reason for this was that the new stocks purchased operate in areas such as solar inverters, healthcare and robotics technologies which score well in this part of our framework.

#### Environmental

The Environmental indicator improved the most of all indicators over the reference period, increasing from 6.0 to 6.5 on the 'Current Level' score and 6.5 to 7.0 on the 'Future Direction' score. In each case, this 0.5 uplift breaks down as 0.2 from existing portfolio upgrades and 0.3 from portfolio changes.

There was a surprisingly large spread in the Environmental scores between newly bought companies and those we exited. On 'Current Level' and 'Future Direction' scores, the outgoing companies' average scores were 5.3 and 5.3 respectively and our new purchases scored 6.4 and 6.7 respectively.

There are a number of reasons for this difference. Firstly, the improvement in the detail of companies' disclosures on this subject, and the number of companies providing them, has been improving with every quarter, allowing us to improve the quality of our scoring. In tandem with this, the range of data sources available, has been an increasingly valuable input to more meaningful, complete scores, as well as increased engagement. Lastly, we have made enhancements to our own scoring mechanism to promote more rigorous scores.

The largest contributor to the improving scores from current holdings was a significant upgrade to Vietnam's Techcombank's score following a review of their underlying loan book exposure which has little in carbon intensive sectors and is heavily weighted towards high impact sectors.

#### Social

The Social indicator was the only area in which the Fund saw a small deterioration as compared with the previous reference period. On 'Current Level', the score fell 0.1 and on 'Future Direction' the score remained flat.

There was no material impact from the spread of portfolio change scores on this indicator. The main effect, whilst a small negative net movement to the score, was from downgrades to the social scores for existing holdings on both 'Current Level' and 'Future Direction'. The largest changes were made to Naver, due to new information regarding a culture of 'machoism' (see engagement example below) and Alibaba Health Information Technology, following necessary additional enhancements on the back of new regulation.

#### Governance

This was a stable indicator, across both 'Current Level' and 'Future Direction' scores and with only very small fluctuations looked at in terms of both upgrades and downgrades and portfolio changes. The 'Current Level' score remained flat at 6.9.

Within existing holdings, positive changes, such as an upgrade to Brazilian ecommerce company Americanas following a merger which simplified their corporate structure, offset negatives, such as a weakened board at Samsung Electronics as a number of executive directors who failed to remove JY Lee won votes to retain their board seats to remain in place.

The 'Future Direction' score dropped very slightly over the reference period in terms of upgrades and downgrades as the positive future effects from positive changes such as greater clarity on HDFC's succession plan was not enough to offset the larger downgrades from Samsung Electronics again (for reasons stated above). Koh Young Technology was downgraded owing to the existence of related party transactions with an entity owned by the founder and Alibaba Health Information Technology's score was reduced after a previously guided improvement in corporate structure between the company and its parent company Alibaba did not materialise.

#### **Business Ethics**

Business Ethics moved up 0.1 on 'Current Level' and 0.3 on 'Future Direction'. All changes at the underlying stock level were de minimis.

The table below displays a summary of all changes, at an aggregated Fund level, that have been described over the reporting period.

	Level 2020	Upgrade/ downgrade	Portfolio change	Level 2021	Direction 2020	Upgrade/ downgrade	Portfolio change	Direction 2021
Impact on progress	7.1	0.10	0.20	7.4	7.6	0.1	0.10	7.8
Environmental	6.0	0.20	0.30	6.5	6.5	0.2	0.30	7.0
Social	6.7	(0.10)	-	6.6	7	(0.1)	0.10	7.0
Governance	6.9	_	_	6.9	7.1	(0.1)	0.10	7.1
Business ethics	6.6	0.20	(0.10)	6.7	6.6	0.2	0.10	6.9

## Describe the Fund's Top 10 Investments

Holdings	Fund Weight (%)
1) TSMC	8.3%
2) Samsung Electronics	7.6%
3) Tencent	6.7%
4) Alibaba Group Holding	3.7%
5) ICICI Bank	3.1%
6) Reliance Industries	3.1%
7) Ivanhoe Mines	3.1%
8) MediaTek	3.0%
9) eMemory Technology	3.0%
10) Phoenix Mills	2.7%

## Article 8 SFDR Emerging Markets Stars Annual Report continued

#### Description of the Percentage of the Fund's Investments that meet the Characteristics

All investments attained the characteristics of the Fund on an individual basis over the reference period.

The Investment Manager determines a security has met the characteristics of the Fund if its score is equal to or greater than 5 on its proprietary 'Sustainability Delta' scoring framework.

The Investment Manager prefers to invest in securities which display an improving trend with the score for 'Future Direction' improving from 'Current Level' score, though this is not a requirement for an investment to meet the Fund's characteristics and the Fund may invest in securities where scores are stable across the forecast period.

In cases where scores display a deteriorating trend, with the 'Future Direction' score declining from the 'Current Level' score, the Investment Manager makes a commitment to engage with the company to resolve a path forward.

The current breakdown of the Fund is shown in table below:

	% Fund
Positive Delta: Current Level < Future Direction	78.82%
Stable Delta: Current Level = Future Direction	21.2%
Negative Delta: Current Level > Future Direction	0%

As at the final date of the reference period, the Fund was primarily invested in equities and equity warrants, the balance is held in cash.

As at the end of the reporting period, the Fund had an investment in one security with some exposure to fossil fuels. This security, Reliance Industries, represented a 3.08% weight within the Fund as at the end of the reporting period. Reliance Industries' exposure to fossil fuel is less than 10% of its revenue.

Due to the nature of our process and commitment to investing in improving companies with at least good existing ESG, we can occasionally invest in what we term 'higher delta' cases, where at first glance they may seem more 'controversial'. Reliance Industries represents an example of this. We believe this company is on a huge transformational journey from being an old-style industrial refinery and chemicals business to a modern retail/consumer and communication/internet company, as well as now expanding into new materials and renewable energy and transitioning to net carbon zero by 2035. Owing to the complexity of this ambition, and the recognition that this is starting out as a more carbon intensive business, we have become co-lead investors as part of a Climate Action 100+ collective action engagement, to ensure that we are actively involved in our ownership of a company of this kind, monitoring and partnering so that the transition remains on track.

On our current Material ESG Issues analysis, Reliance Industries scores better than many peers within the industry and is already reasonably efficient in terms of its water and energy usage, with annual improvements and a good safety record. It is far from a best-in-class sustainability company, but we believe it has the potential to be a future leader and the ability to make one of the largest differences. We provide greater detail about this investment and our engagement with Reliance Industries in the section that follows.

As at the date of this report, 0% of the Fund's investments fail the Fund's exclusion criteria.

On our current Material ESG Issues analysis, Reliance Industries scores better than many peers within the industry and is already reasonably efficient in terms of its water and energy usage, with annual improvements and a good safety record. It is far from a best-in-class sustainability company, but we believe it has the potential to be a future leader and the ability to make one of the largest differences. We provide greater detail about this investment and our engagement with Reliance Industries in the section that follows.

As at the date of this report, 0% of the Fund's investments fail the Fund's exclusion criteria.

## **Describe Actions Taken to Attain Characteristics**

The assessment of sustainability factors is not a one-time event and does not stop at the point of purchase. Ongoing engagement and monitoring are a constant and valuable part of our work, as we are very focused on how companies see the future and how they allocate capital accordingly to mitigate risk and benefit from revenue opportunities as part of a sustainable future. These are the types of companies that will score highly on our proprietary framework.

In this way, we view engagement as entirely integrated with our ongoing, fundamental dialogue with our investments. We hold hundreds of meetings each year alongside site visits, meetings with competitors, suppliers, customers, industry experts and lower-tier employees as part of our ongoing engagement and due diligence. Engagement can take the form of meetings, calls, emails or voting as a shareholder. We aim to be regular and proactive in our efforts rather than only engaging post an ESG 'event'.

However, we also maintain a record of specific interactions where we engaged with companies on environmental, social and governance issues. We classify these engagements into what we term 'heavy' and 'light' engagements. Heavy engagements are the minority of cases and reserved for situations where we feel there is a either a greater need for action or a greater likelihood that we can affect material change as a minority investor. In light engagement cases, change is expected to be more incremental and our dialogue with companies on these issues less frequent and of lower materiality for the investment case.

Given the rigour we believe is required for quality, 'heavy' engagement work, as well as the reality that there are fewer companies that meet all aspects of our fundamental process and are in need of this kind of interventional stewardship, we guide that the number of heavy investments we will be undertaking in any year is likely to be in the low single digits. Light engagements may range between 10–30% of the portfolio.

In circumstances where a company is involved in a negative, material ESG incident which compromises the integrity of the whole business, or, less dramatically, where we lose confidence in our investment thesis owing to an issue related to ESG practices and therefore our belief in a company's ability to generate long-term sustainable EVA, or our comfort with it as a corporate citizen, our policy is to immediately divest.

A summary of all engagements during the reporting period, together with key engagement and divestment examples are given below.

Engagements	
Total Engagements	13
Companies held	10
Companies not-held	3
Type of Engagement	
Collective Action	1
Неаvy	3
Light	9
Topic of Engagement	
Environment	1
Social	1
Governance	2
E&S	3
E&G	2
S&G	2
E, S&G	2

Engagements	
Seniority of Meeting	
Management	4
IR	2
Other	7
Method of Engagament	
In Person	2
Video conference	9
Call	2
Email/Letter	0

## 

### Describe Actions Taken to Attain Characteristics continued

#### Key engagement examples

#### **Reliance Industries**

We are pleased to be co-lead investors of the Climate Action 100+ collective engagement on Reliance Industries (from 2021) to seek to gain better understanding and push them further on their net zero 2035 targets. Climate Action 100+ is an investor-led collaborative engagement initiative that aims to tackle the systemic climate change challenge by influencing the behaviour of management of the key global GHG emitting companies to implement strong governance around climate change, take action to reduce emissions, and improve disclosure.

Prior to joining Climate Action 100+, we had ourselves engaged extensively with Reliance Industries, most recently with meetings following the announcement of their new business reorganisation, with the CFO (Alok Agarwal) and Joint-CFO (Srikanth Venkatachari (Energy division)) of Reliance Industries – to talk directly with them on investments in the energy division towards renewable energy and new materials and the commitment to become net-carbon zero by 2035.

Our engagement priorities as part of the Climate Action 100+ group are to establish a more definitive roadmap with milestones over the next 13 years toward reaching the net-carbon zero goal, including pushing for better provision of disclosures on current emissions (split by scope and businesses), committing to an annual commentary on emissions, drivers of year on year changes and commentary on targets and more communication on capital expenditure plans and progress.

The company initially planned to spend \$10bn to invest in 4 new energy giga factories, building an integrated solar photovoltaic module factory enabling 100GW of solar energy by 2030, an advanced energy storage battery factory, an electrolyser factory for green hydrogen and a fuel cell factory to work with the green hydrogen factory. Most recently, this has been increased to \$80bn of investment, over the next 10-15 years, with USD67bn going into renewable power plants and green hydrogen. This gives greater confidence in the ability of the company to fund the transition and ambitions and displays the seriousness and confidence of the management team in committing to the plans and to reaching the net zero 2035 target. Reliance Industries is targeting bringing the entire state of Gujarat to net zero by 2035, which would be an incredibly significant achievement for a private company, and perhaps a first globally.

We acknowledge that Reliance Industries is certainly an 'improver' or one of our largest 'Sustainability Delta' cases but are comfortable they are managing their ESG risks and positioning themselves firmly as future solution providers. We continue to engage in a very active way via Climate Action 100+.

#### Naver

Recently Korea has, in general, been hit by a number of cases around a 'macho culture' in the work place – which has a social impact for many younger – particularly female employees. This 'macho culture' issue has also been hitting Naver and is why we are starting deeper engagement into this social topic. It appears to be very concentrated around a few individuals within Naver, and it does seem to have been addressed very fast by the board (founder group) – which includes a new female CEO with a better 'young culture' understanding and drive.

We had a very interesting conversation bringing-up factors up like the Korean war and the strong influence of the very harsh military training that all men have to undergo in Korea – and how this military culture has ended up in the work place. Our light, initial engagement here reflects that Naver has responded very fast and with senior management involvement. However, this is an issue that will still hang across most Korean companies, and a large part of our engagement here is also for us to understand this deep-rooted cultural issue.

#### **ITM Semiconductor**

We arranged a call with the company to discuss the recent announcement that they are engaging with IQOS to supply their battery management technology for their e-cigarettes. We explained that we believe this is the wrong direction for the company as they have so many other attractive business opportunities to focus on, and that this move could potentially restrict their access to international institutional investors who could otherwise help unlock the value of the company, which we believe is underappreciated by the market, not to mention our own beliefs about the nature of the product from a health and social point of view.

The investor relations director said he would relay our message to the company management and we hope to continue this engagement and will try and persuade them to reconsider pursuing this client.

#### **HDFC**

As all 3 key, top people in the management team have now been at the company for 12-15 years and are in their 60s, we asked the CEO about the potential to disclose more definitive succession planning steps to smooth the process and reassure that there is strong governance oversight for the next generation. We were informed that there is a clearly laid out plan at both the very top level and in each business line and that this is a key topic for the board that is discussed at all board meetings. HDFC's preference is to promote internally, but they would fill positions from the outside in some cases if that can be done better.

#### **Ecopro**

Ecopro BM proposed at their AGM in 2021 to significantly increase the limit on authorized shares from 150m to 500m, as well as the issuance limit on convertible securities from 100 billion South Korean Won ('KRW') to 1 trillion KRW.

We felt this was an issue from a governance perspective as we believed 1) there was still plenty of headroom left under the current limits as the company has no outstanding convertibles and only 14% of the current limit on authorized shares was utilized, and 2) there is no clear reason stated for the proposal.

During our call, management explained that under the current expansion plans could be sourced by bank loans and internal cash flow as the company has said in the past, but if the company wanted to expand capacity in Europe, this would required additional capital they could not source from domestic banks.

#### Arco

Arco are starting an initiative to improve their ESG disclosures, map their ESG materiality indicators and build towards publishing their first sustainability report at the end of 2022. They are using MSCI, Sustainability and SASB data as well as bringing consultants RPT on to help them with this process and opportunistically engaging with shareholders.

We were able to describe to them what we find materially important from an ESG perspective in our process and why, and which factors may need more focus, positively and negatively, for a business such as theirs. We are very encouraged to see that Arco are doing this and look forward to greater transparency from the results, particularly around the impact they can have. We also discussed the company's alignment with the UN SDGs, UN Global Compact and UN PRI.

#### Hapvida (not held)

Hapvida is being investigated regarding their drugs prescription practices during the COVID-19 pandemic, specifically the use of the 'COVID kit' including recommendations of drugs such as chloroquine and Hydroychlorquine which are used for rheumatoid arthritis, lupus and malaria, but have not been scientifically proven to fight COVID-19.

The investigation has highlighted evidence from doctors working for Hapvida in 2020 who reported internal pressure to prescribe these drugs despite unknown efficacy. Hapvida confirmed that they had encouraged doctors to use these drugs, though denied any pressure. On average 20% of doctors chose to use it, with the backing that the medical counsel permitted prescription with patient consent. Hapvida withdrew this recommendation in the absence of industry consensus.

On our call management with company management, they did not seem to adequately grasp the seriousness of the issue and felt it would 'blow over'. We view this kind of maltreatment of both employees and customers and the risks it presents as a serious governance and human capital management breach, which render the stock uninvestible. ∖ Article 8 SFDR Emerging Markets Stars Annual Report continued

## Describe Actions Taken to Attain Characteristics continued

#### **Key Divestments**

#### Prosus

We engaged with Prosus in 2020 on governance issues, including the persistent holding company trading discount and management's plans to close this discount to realise more value for shareholders, as well as seeking an explanation of management remuneration and how that has been improved for better alignment of stakeholder interests.

Despite this previous engagement, in 2021 we divested from Prosus as the efforts by management during the year to close the trading discount, to the benefit of minority shareholders, principally by means of an unsatisfactory tender offer to simplify the Naspers-Prosus shareholding structure, to restore confidence and to improve corporate governance and the future prospects of organic company's value creation, if anything, deteriorated.

### Disclosure pursuant to the Taxonomy Regulation (EU) 2020/852

Under Article 8 SFDR, this Fund promotes environmental characteristics in the manner outlined above. In accordance with the requirements of Article 6 of the Taxonomy Regulation, the Fund must state that the 'do no significant harm' principle applies only to those investments underlying the Fund that take into account the EU criteria for environmentally sustainable economic activities.

However, the Fund has not elected to invest in sustainable investments, as defined in Article 2(17) SFDR, and, therefore, its investments are not made on the basis of applying the EU criteria for environmentally sustainable economic activities or, as a consequence, the 'do no significant harm' principle.

## Article 8 SFDR Global Insurance Annual Report

## **Description of the Achievement of the Characteristics**

This disclosure should be read in conjunction with the Fund's prospectus and website disclosures under the EU's Sustainable Finance Disclosure Regulation (EU) 2019/2088 ('SFDR').

In accordance with the Fund's prospectus, the Fund invests broadly in the global insurance industry but predominantly focuses on investing in the non-life sub-sector (also known as property and casualty insurance), which the Investment Manager believes positively impacts most, if not all, of the United Nation's Sustainable Development Goals ('UN SDGs').

In accordance with the Fund's Article 8 SFDR prospectus disclosure, the primary indicator through which the Fund measures its achievement of its Article 8 SFDR characteristics is through the Investment Manager's proprietary Polar Capital Funds plc – Global Insurance Fund UN SDG matrix (the 'UN SDG Matrix').

As at 31 December 2021, the Fund had a portfolio of 33 companies that were exposed to a diversified range of underwriting risks.

The UN SDG matrix sets out the weighting of the Fund in each area of underwriting risk and then demonstrates whether, and to what extent, the Fund's holdings within that underwriting risk area have contributed to each UN SDG over the reference period.

Article 8 SFDR Global Insurance Annual Report continued

## Description of the Achievement of the Characteristics continued

Figure 1 – UN SDG Matrix – 31 December 2021 (draft)

UN Sustainable Development Goals	31 December 2021 Weighting	1	2	3	4	5	6	7	8	9
Portfolio Overview										
Personal Insurance	12%									
Personal Auto	8%									
Homeowners	4%									
Commercial Insurance and Reinsurance	69%									
Property (Re)insurances	21%									
Property Catastrophe Reinsurance	4%									
Other Property Reinsurance	7%									
Property Insurance	7%									
Marine and Energy	3%									
Crop	1%									
Casualty (Re)insurances	36%									
General Casualty (D&O, E&O etc)	14%									
Commercial Multi Peril	4%									
Commercial Auto	2%									
Credit and Surety	1%									
Workers Compensation	3%									
Personal Accident	4%									
Medical Malpractice	1%									
Casualty Reinsurance	7%									
Mortgage and Title	7%									
Critical Illness and Health Insurance and Reinsurance	4%									
Critical Illness and associated healthcare coverages	2%									
life Reinsurance	2%									
Other – including Brokers and Life	19%									
(Re)insurance Brokers	13%									
Life (excluding Critical Illness)	1%									
Other	5%									
Corporate ESG Assessment										
Fund Governance										
Fund Environmental										
Fund Social										
Fund Manager Engagement										
Governance										
nnovation										
Nature Based Solutions										
Sustainable Accounting										
Total Impact	100%	23	20	17	12	14	16	12	28	27
o/w High Impact		12	7	6	3	2	0	0	15	7
o/w Strong Impact		4	1	3	0	1	4	1	7	7
o/w Positive Impact		7	12	8	9	11	12	11	6	13
o/w Adverse Impact		0	0	0	0	0	0	0	0	0

High impact Strong impact Positive impact Do impact



UN Sustainable Development Goals	31 December 2021 Weighting	10	11	12	13	14	15	16	17
Portfolio Overview									
Personal Insurance	12%								
Personal Auto	8%								
Homeowners	4%								
Commercial Insurance and Reinsurance	69%								
Property (Re)insurances	21%								
Property Catastrophe Reinsurance	4%								
Other Property Reinsurance	7%								
Property Insurance	7%								
Marine and Energy	3%								
Crop	1%								
Casualty (Re)insurances	36%								
General Casualty (D&O, E&O etc)	14%								
Commercial Multi Peril	4%								
Commercial Auto	2%								
Credit and Surety	1%								
Workers Compensation	3%								
Personal Accident	4%								
Medical Malpractice	1%								
Casualty Reinsurance	7%								
Mortgage and Title	7%								
Critical Illness and Health Insurance and Reinsurance	4%								
Critical Illness and associated healthcare coverages	2%								
Life Reinsurance	2%								
Other – including Brokers and Life	19%								
(Re)insurance Brokers	13%								
Life (excluding Critical Illness)	1%								
Other	5%								
Corporate ESG Assessment									
Fund Governance									
Fund Environmental									
Fund Social									
Fund Manager Engagement									
Governance									
Innovation									
Nature Based Solutions									
Sustainable Accounting									
Total Impact	100%	23	24	22	17	14	17	20	24
o/w High Impact		5	6	2	6	3	1	10	6
o/w Strong Impact		0	1	2	0	0	1	2	4
o/w Positive Impact		18	17	18	11	11	15	8	14
o/w Adverse Impact		0	0	0	0	0	0	0	0

## Article 8 SFDR Global Insurance Annual Report continued

### Description of the Achievement of the Characteristics continued

As shown in the key at the bottom of Figure 1, the Investment Manager assesses a company's impact on the UN SDGs based on five categorisations namely; (i) high impact ( – dark blue), (ii) strong impact ( – blue), (iii) positive impact ( – light blue), (iv) no impact ( – white) or (v) adverse impact ( – orange, but not shown).

High impact actions are quantifiable actions taken by portfolio companies directly in support of specific UN SDGs, strong impacts reflect that company actions of the reference period have had indirect benefits from a UN SDG perspective and positive impacts reflect harder to quantify or more holistic impacts on the UN SDGs.

Adverse impacts are actions taken by portfolio companies, or occurrences at portfolio companies, that run counter to the intention and spirit of the UN SDGs.

Figure 2 below sets out six case studies in which, according to the Investment Manager's methodology, the Fund's investee companies have had a high impact on one or more UN SDGs.

#### Figure 2 – High UN SDG Impact Case Studies – Fund Investee Companies



The first investee company example given in Figure 2, Travelers, is a US focused insurance business and is a significant provider of personal car insurance, home insurance and small and medium sized business insurance across the US and Canada.

The provision of property coverage to individuals and businesses aligns directly with UN SDG 1 (No Poverty) and UN SDG 11 (Sustainable Cities and Communities) given that claims payments following catastrophes help prevent poverty or financial ruin and reduce direct economic losses to society. The investee companies in the Fund that provide property coverage, including Travelers, have a very strong record of supporting clients and paying claims following adverse events.

However, Travelers supports UN SDG 1 and UN SDG 11 goals beyond the provision of this insurance coverage through their partnership with Habitat for Humanity, a global non-profit housing organisation, and the Insurance Institute for Business and Home Safety, a US based non-profit organisation whose research seeks to provide solutions to avoid insurable losses.

These partnerships support the construction of resilient and sustainable affordable homes for low-income families enhancing societal resilience, reduce the cost of coverage and help tackle the 'protection gap' (the level of economic losses suffered during a given year that were not insured).

Progressive and Direct Line, which are well regarded companies that provide similar insurance products by contrast, are, in the Investment Manager's belief, examples of companies within the portfolio that make a strong (rather than high) impact on one or more of the UN SDGs.

Commentary guidance from the UN on UN SDG 3 (Good Health and Wellbeing) specifically refers to the negative impact of road traffic injuries on society. Personal auto insurance can, in many cases, positively contribute to UN SDG 3 by funding the healthcare and rehabilitation of injured parties following a car accident.

In addition, Progressive use telematics, a technology that monitors driver behaviour, to encourage safer driving and, therefore, lower injuries on the road, while Direct Line has provided data to automotive manufacturers on certain types of claims concerning the manufacturer's vehicles in order to support the development of safer vehicles by those manufacturers. These activities further support UN SDG 3 by helping to prevent road traffic injuries from occurring in the first place.

However, given telematics is not a material part of personal auto insurance at this stage, the occasional nature of insurers communications with car manufacturers and that it is difficult to quantify insurers efforts to educate drivers on road safety, the Investment Manager believes that the steps taken above cannot be classified as high impact on UN SDG 3, and the UN SDGs more broadly.

The Investment Manager defines a Positive Impact as, for example, having robust controls over preventing corruption within supply chains particularly in relation to claims payments supporting UN SDGs, such as UN SDG 16 (Peace, Justice and Strong Institutions). Such controls are generally required by law and are not company specific factors, but a failure to adhere to such regulations and laws potentially would lead to adverse sustainability impacts.

The alignment of the Fund's holdings with the UN SDGs at the corporate level is assessed through the Investment Manager's proprietary ESG scoring process. Individual companies are scored across over 20 ESG factors, which in turns form the basis for discussion with investee company management teams. Based on the ESG scores in aggregate for the Fund's investee companies, the UN SDG matrix indicates the extent to which each UN SDG is impacted.

By assessing and then engaging on the weaker elements of a company's ESG impact the Investment Manager helps promote positive actions to address these areas which contributes positively to the overall portfolio UN SDG impact.

The UN SDG Matrix sets out the four key areas in which the Investment Manager has engaged with investee companies during the reference period and the corresponding impact that the Investment Manager believes this engagement has had on the relevant UN SDGs.

For example the Investment Manager encourages companies to look more at nature based solutions (i.e sustainable management practices and the use of natural features and processes to tackle socio-environmental challenges) as a form of risk prevention. An example of this is the Investment Manager introducing Direct Line to a rewilding charity. Subsequently Direct Line agreed to provide lending to the charity for the purchase of land in part to learn more about how land restoration helps with flood mitigation.

Further details around the Investment Manager's engagements, and the impact of these engagement, are discussed in the section 'Describe the actions taken to attain the characteristics' section.

## Article 8 SFDR Global Insurance Annual Report continued


### Description of the Achievement of the Characteristics continued

The Investment Manager's investment approach, including its sustainability approach, is underpinned by the underwriting spread of the Fund as shown below in Figure 3 at 31 December 2021.

The Fund's alignment with the UN SDGs is closely linked with the insurance coverage and services provided by the insurers held in the Fund, as shown in Figure 3, and how those products are priced and delivered to clients.

From a financial performance perspective, the Investment Manager seeks to flex the Fund's exposure to each underwriting set over time depending on the attractiveness of the market conditions applicable to that underwriting set and seeks to remain diversified to manage volatility that occurs where losses occur in one or more underwriting sub-set. During the reference period there has not been a material change in weightings.

#### Figure 3 – Portfolio Underwriting Mix – at 31 December 2021




In summary, the UN SDG Matrix has aggregated the total impact of the Fund on each specific UN SDG over the reference period based on its investee companies' products and services (as shown in Figure 3), its investee companies' corporate ESG profiles and through Investment Manager's engagement.

The UN SDGs that are most materially supported by the Fund holdings, based on the outputs of the UN SDG Matrix and in order of materiality are; UN SDG 8 (Decent Work and Economic Growth), UN SDG 9 (Industry, Innovation and Infrastructure), UN SDG 11 (Sustainable Cities and Communities), UN SDG 17 (Partnerships for the Goals), UN SDG 1 (No Poverty) and UN SDG 10 (Reduced Inequalities).

The Investment Manager has also performed an assessment to determine whether, according to its methodology, there are any adverse impacts on the UN SDGs. Approximately 30% of Fund interactions with the UN SDGs resulted in a high impact, while 10% had a positive impact and 60% a positive impact. According to the Investment Manager's methodology for the Fund, 0% of the Fund's holdings had an adverse impact on the UN SDGs over the reference period.

### Figure 4 – UN SDG Matrix Integration methodology based on indicative portfolio weightings



Source: Polar Capital, January 2022 and https://sdgs.un.org/goals

Article 8 SFDR Global Insurance Annual Report continued

### Description of the Achievement of the Characteristics continued

Describe the Fund's Top 10 Investments

Holdings	Fund Weight (%)
1) Arch Capital	8.1%
2) Marsh & McLennan Cos	8.0%
3) Chubb	7.8%
4) Markel	5.4%
5) RenaissanceRe	5.2%
6) Fairfax Financial	4.9%
7) Alleghany	4.7%
8) Aon	4.4%
9) Essent	4.3%
10) WR Berkley	4.2%

### Description of the Percentage of the Fund's Investments that meet the Characteristics

As at the 31 December 2021, 100% of the Fund's investments, excluding the Fund's cash and any derivative holdings, have a positive impact on one or more of the UN SDGs, as demonstrated by the UN SDG matrix.

The Fund is primarily invested in listed equities. However, the Fund does have investments in several unlisted retrocession funds which are not listed entities. These retrocession funds are collective investment schemes in which the collective investment proceeds are used to underwrite a range of reinsurance protections, primarily for reinsurers and typically with a term of one year.

The Investment Manager assessed the impact of these retrocession funds on the UN SDGs through the UN SDG matrix. The retrocession funds are considered within the relevant underwriting risk areas set out in the UN SDG matrix, primarily property catastrophe coverage but also in property and marine and energy (re)insurance.

The Fund's direct exposure to fossil fuels is confined to its investment in Berkshire Hathaway, a mid-sized holding in the Fund. Berkshire Hathaway is a diversified conglomerate rather than a pure insurance company and one of its subsidiaries, Berkshire Hathaway Energy, has applicable revenues equating to c.6% of Berkshire Hathaway's total group revenues.

However, the Investment Manager believes that Berkshire Hathaway Energy is transitioning its business model from fossil fuels towards renewable energy at a satisfactory pace and making key investments that will help to facilitate the transition more broadly, particularly in US energy transmission capability. 32% of Berkshire Hathaway Energy's 2020 power generation was from renewables, up from 10% in 2005, which reflects capital investment of\$36bn to September 2021. A further \$4.9bn investment in wind and solar development is budgeted by the end of 2023 and existing plans are expected to achieve a 50% reduction in CO<sub>2</sub> emissions by 2030 from 2005 levels.

The Investment Manager is focused on the eradicating the Fund's exposure to thermal coal, oil sands and arctic exploration and other such activities that contribute to global warming from the underwriting portfolios of its investee companies.

A number of investee companies have committed to specific timetables for phasing out these risks and becoming carbon neutral well before 2050. Many of the Fund's investee companies have not underwritten or invested assets in such risks for many years, given the anticipation of increased liability exposures arising from them, and parts of the insurance market continue to withdraw coverage for these kinds of risks (including the Lloyd's of London Insurance Market).

The withdrawal of this coverage in turn raises the cost of the remaining coverage and materially supports the transition towards more sustainable business practices through pricing penalties.

The Investment Manager believes the reduction of coverage, and the associated increase in the cost of the remaining coverage, is already having an outsized impact, relative to the small size of the insurance sector as a whole, on reducing carbon emissions, particularly within the three most polluting industries; utilities, energy and materiality.

## **Describe Actions Taken to Attain Characteristics**

In seeking to attain the Fund's investment objective and the Fund's characteristics highlighted in the UN SDG Matrix, the Investment Manager actively manages the Fund's look-through underwriting mix and corporate ESG alignment.

While the Fund had low turnover during the reference period, the Investment Manager flexed the weighting of the Fund's positions to reflect the product and market characteristics within each line of business.

The Investment Manager undertook quarterly and deeper dive due diligence work on investee companies as necessary, utilising the Fund's long track record and historical data on areas such as a company's reserves, business mix, experience, incentives, culture, technological capability, innovation, data security, diversity and responsible underwriting integration metrics. This due diligence all fed into the Fund's proprietary scoring and, in turn, the UN SDG Matrix.

Further, given the concentrated nature of the Fund, over the reference period the Investment Manager was able to engage with company management teams on a regular basis through meetings with company management teams, underwriters and market participants, as well as performing site visits and attending investor days.

The Fund also conducted ESG audit engagements on a number of investee companies during the reference period. At meetings with the relevant investee companies, the Investment Manager discussed the rating factors that are included in its proprietary ESG ratings, and any relevant findings, with the management teams, including emphasising the importance that portfolio companies should report under TCFD (over half of the Fund's investee companies currently do) and/or the Sustainability Accounting Standards Board's (SASB) sustainable accounting standards and should look to develop science-based carbon emission reduction targets where appropriate.

Figure 6 below sets out some of the key engagements with investee companies that took place during 2021.


### Figure 6 Engagement Insight

#### **UN SDG Case Studies – Engagement**



Article 8 SFDR Global Insurance Annual Report continued

#### Describe Actions Taken to Attain Characteristics continued



The Investment Manager's corporate ESG assessments reflect industry insight, financial analysis, company visits and management meetings attained over decades. Where ESG-related disclosures are not available from an investee company, or a company within the Fund's investment universe, the Investment Manager proactively reaches out to that company and its management team to obtain the relevant information and uses third party data sources as a starting point.

As shown above in Figure 6, one investee company has acknowledged, through the Investment Manager's engagement, that the level of public disclosure needs to be improved, despite the fact that they are already engaging with many ESG issues internally.

In recent periods, investee companies have become more focused on increasing disclosures to third-party providers, which the Investment Manager continues to encourage. Bringing together disclosure of company practices from a variety of published materials into a more dedicated ESG/Sustainability report or website area helps to narrow the differences in ratings between the Fund and third-party providers, which often rely solely on the availability of easily found company disclosures on company websites.

The Investment Manager reached out to investee companies over the reference period for further ESG insight where external rating agencies highlighted factors of concern or provided a low rating to the company.

The Investment Manager is of the view that third party ESG ratings providers ascribe higher ratings to larger, better resourced companies that are capable of a higher level of disclosure which does not, at present, suit the Fund's mid-cap and US market focus or necessarily correlate with better ESG stewardship.

However, the Investment Manager engaged with the companies that had the lowest 5 ESG ratings according to MSCI, as well as its own proprietary ESG scoring process, to understand whether the issue was a matter of disclosure or indicative of deeper ESG issues.

As a result of this engagement, the Investment Manager found that some investee companies considered matters such as climate change within their operational models and underwriting policies and maintain exclusions on climate related risks or areas, but have not disclosed these policies and procedures publicly.

In the instance of smaller investee companies, the Investment Manager found that given the size and scope of the investee companies' operations, some are yet to consider climate related risks and opportunities more broadly within their business and strategy.

A key engagement during the 2021 proxy voting season was in relation to further engagement actions taken by the Investment Manager on an investee company's remuneration proposals, following failure by the Chairman of the Board and a senior independent director of the Board to take on suggestions made by the Investment Manager during a meeting with them, or to find a mutually acceptable solution to the issues raised by the Investment Manager.

The Investment Manager followed up this meeting with a letter to the investee company's Board expressing the importance of the fiduciary duty the Investment Manager owes to its investors and the Investment Manager's continued disagreement with the proposed approach to remuneration. The investee company has since acknowledged the Investment Manager's concerns and implemented a number of the Investment Manager's recommendations on remuneration for the forthcoming financial year.

Other important votes during the 2021 proxy voting season the Investment Manager voted against management in one instance to support a climate transition and risk review resolution at Berkshire Hathaway and abstained from two votes, firstly in respect of Aon's remuneration report given concerns on director remuneration, and secondly in respect of a business resolution from Chubb relating to Swiss law.

Finally, through its broader engagement activities, the Investment Manager has connected a number of investee companies with industry groups, industry communities and charities, such as Instech London and Heal Rewilding, to raise awareness of nature based solutions and insurance solutions and increase the possible impact that those groups, communities and charities have on the UN SDGs and sustainability more broadly.

#### Disclosure pursuant to the Taxonomy Regulation (EU) 2020/852

Under Article 8 SFDR, this Fund promotes environmental characteristics in the manner outlined above. In accordance with the requirements of Article 6 of the Taxonomy Regulation, the Fund must state that the 'do no significant harm' principle applies only to those investments underlying the Fund that take into account the EU criteria for environmentally sustainable economic activities.

However, the Fund has not elected to invest in sustainable investments, as defined in Article 2(17) SFDR, and, therefore, its investments are not made on the basis of applying the EU criteria for environmentally sustainable economic activities or, as a consequence, the 'do no significant harm' principle.

## Article 9 SFDR Smart Energy Annual Report

### **Description of the Achievement of the Characteristics**

This disclosure should be read in conjunction with the Fund's prospectus and website disclosures under the Sustainable Finance Disclosure Regulation (EU) 2019/2088 ('SFDR').

In accordance with the Fund's prospectus disclosures under Article 9 of the SFDR, this Fund has as its sustainable investment objective investment in a portfolio of companies worldwide that support, through their technology solutions and services, the decarbonization and thereby electrification of the global energy sector.

The Investment Manager measures the Fund's alignment with its sustainable investment objective on a qualitative and quantitative basis by:

- 1. The alignment of the Fund's investments with the Fund's eligible investment universe, as described in the 'Investment Strategy' section of the Fund's prospectus and website SFDR disclosures.
- 2. The alignment of the Fund's investments with the Investment Manager's exclusions list for the Fund, as set out in the 'Investment Strategy' section of the Fund's prospectus and website SFDR disclosures.

During the reference period of this annual report, the Investment Manager's eligible investment universe comprised four main themes:

- 1. Clear Power Generation this theme is comprised of the following sub-areas
  - a. Solar Power Supply Chain companies that procure raw materials to produce solar power infrastructure, that produce solar power cells and modules and solar power inverters, that produce ancillary equipment required for solar power infrastructure or that are solar power service companies
  - b. Wind Power Supply Chain companies that procure the materials required to produce wind power infrastructure or that produce wind turbines and/or the gearboxes for wind turbines
  - c. Renewable Power Producers companies that operate wind, solar, hydro-electric or other renewable energy power sites.
- 2. Energy Transmission and Distribution this theme is comprised of the following sub-areas:
  - a. Smart Grid Equipment companies that produce equipment used in electrical grids that help to manage the energy flows intelligently, making sure that supply always matches demand, with any surplus of electricity supply being stored temporarily.
  - b. Hydrogen Infrastructure Equipment companies that produce equipment for the generation of electricity using hydrogen through electrolysis, or that produce equipment to transport, distribute or store hydrogen.
  - c. Electric Grid and Hydrogen Distribution Operators companies that operate electrical grids or that transmit, distribute, or store hydrogen.
- 3. Energy Conversion and Storage this theme is comprised of the following sub-areas:
  - a. Power Conversion companies that produce or design power semiconductors for the energy, industrial, transport, IT and building sectors and/or for consumer electronics/ appliances.
  - b. Energy Storage companies that supply raw materials or components to battery producers or that produce batteries for industry or consumers, for electric vehicles and/or for grid management purposes.
- 4. Energy Efficiency this theme is comprised of the following sub-areas:
  - a. Buildings companies involved in the production or operation of heating, ventilation and air conditioning systems, efficient lighting, smart home appliances or production/installation of insulation materials for buildings.
  - b. Industrial Processes companies that develop energy efficient solutions for industrial automation (e.g. electric motors, industrial processes, industrial internet of things).
  - c. Transportation companies that engineer and manufacture public transport vehicles (e.g. trains, trams), battery electric and fuel cells electric vehicle manufacturers or their electric components or subsystem suppliers.
  - d. Big Data companies that provide data centres with efficient power and thermal management solutions or the provide energy efficient solutions for high-throughput data processing (for artificial intelligence/machine learning and broadband communications).

To be included in the eligible investment universe, the companies had to derive at least 30% of their current or future revenues from one of the sub-themes set out above. Over the reference period, this resulted in an eligible universe of circa 250 companies.

As at 31 December 2021, the Fund's exposures to each of the four themes were as follows:

Investment Area	Portfolio Weighting	Average Current Revenue Exposure
Clean Power Generation	6.6%	100.0%
Energy Conversion & Storage	35.7%	75.5%
Energy Efficiency	45.1%	76.5%
Energy Transmission & Distribution	12.2%	70.8%
Cash	0.4%	0.0%

During the reference period, the Fund did not invest in any companies that were not aligned with the Fund's sustainable investment objective, by virtue of not meeting the prescribed current or future revenue exposure threshold, or companies that participated in activities linked to the Fund's exclusions criteria.

### **Describe the Fund's Top 10 Investments**

As at the last date of the reference period (31st December 2021), the top 10 holdings of the Fund were:

Holdings	Fund Weight (%)
1) ON Semiconductor	5.2%
2) Power Integrations	5.0%
3) Schneider Electric	4.3%
4) Xpeng Motors ADR	3.4%
5) Johnson Controls International	3.4%
6) EnerSys	3.4%
7) Infineon Technologies	3.2%
8) Rohm	3.1%
9) Xilinx	3.1%
10) Lattice Semiconductor	3.1%

## Description of the Percentage of the Fund's Investments that meet the Characteristics

All of the Fund's equity investments during the reference period contributed to the sustainable investment objective through their exposure to one or more of the sub-themes set out above.

The Fund did have cash and cash equivalents over the reference period. These investments did not contribute towards the sustainable investment objective and there were no environmental or social safeguards in place for these holdings as they are held for liquidity management and hedging purposes only.

As per the Fund's exclusion criteria, investments in fossil fuel exploration and production companies, as well as in utilities with thermal fossil power generation, are prohibited.

## Article 9 SFDR Smart Energy Annual Report continued

# Describe the contribution to the environmental objectives of the Taxonomy Regulation (EU) 2020/852

In accordance with the requirements of Article 5 of the Taxonomy Regulation, where the Fund invests in economic activities that contribute to an environmental objective, it must disclose the environmental objective or objectives set out in Article 9 Taxonomy Regulation to which the Fund's investments contribute and a description of how and to what extent these investments are in environmentally sustainable economic activities under Article 3 of the Taxonomy Regulation.

In implementing the investment strategy of the Fund, the Investment Manager selects investments which it believes contribute to the environmental objective of climate change mitigation under Article 9 of the Taxonomy Regulation.

In assessing whether an investment is considered to be in environmentally sustainable economic activities contributing to climate change mitigation, the Investment Manager must be satisfied that the relevant economic activity (i) contributes substantially to the environmental objective of climate change mitigation, (ii) does not significantly harm any of the environmental objectives outlined in the Taxonomy Regulation; (iii) is carried out in compliance with the minimum safeguards laid down in the Taxonomy Regulation and (iv) complies with the Technical Screening Criteria ('TSC') in respect of climate change mitigation that have been published and approved by the European Commission.

The TSC in respect of climate change mitigation were approved by the European Commission on 9 December 2021 and came into force on 1 January 2022. In addition, there is a lack of reliable, timely and verifiable data publicly reported by issuers or investee companies concerning the Taxonomy eligibility or alignment of their economic activities.

In light of the delay in approving the TSC and the challenges in obtaining data from issuers or investee companies on the Taxonomy eligibility or alignment of their economic activities, the Investment Manager is not currently in a position to assess with certainty (a) whether or not the investments underlying the Fund are in environmentally sustainable activities (b) the extent to which the investments of the Fund are in economic activities that qualify as environmentally sustainable and are aligned with the Taxonomy Regulation; (c) the proportion, as a percentage of the Fund's portfolio, of investments in environmentally sustainable activities which are aligned with the Taxonomy Regulation; and (d) the proportion, as a percentage of the Fund's portfolio, of enabling and transitional activities (as described in the Taxonomy Regulation).

Accordingly, the proportion of investments of the Fund in environmentally sustainable economic activities contributing to climate change mitigation, including in transitional and enabling activities, and aligned with the requirements of the Taxonomy Regulation is 0% of the Fund's net assets.

The Investment Manager shall, once sufficient reliable, timely and verifiable data from issuers or investee companies becomes available, update its regulatory documentation to provide an indication of the proportion of investments of the Fund which are in environmentally sustainable economic activities under the EU Taxonomy Framework.

## Describe how the Fund assessed the 'DNSH' principle for its investments over the reference period

Over the reference period, the Investment Manager carried out a screening process during the construction of its eligible investment universe to exclude any companies that significantly harm environmental or social objectives due to their involvement in a range of controversial business activities. The Investment Manager used external ESG data providers as an initial input for the screen.

The Investment Manager's screening for controversial activities was carried out over the reference period in accordance with the Investment Manager's thematic exclusions for the Fund, which cover, from an environmental perspective, involvement in hydrocarbon exploration and production, fossil and nuclear power generation, natural gas transmission and distribution and first-generation biofuels and palm oil.

Further, the Investment Manager's controversies assessment included evaluating if companies were involved in material issues that would cause harm to the Taxonomy Regulation's environmental objectives. Companies with very severe and significant controversies were excluded.

The Investment Manager screened and excluded companies from the eligible investment universe where they were exposed to involvement in controversial weapons, civilian firearms, military contracting, gambling, adult entertainment, tobacco and alcohol.

Finally, the Investment Manager applied additional exclusions based on companies' controversial products or behaviour which violated the principles of the UN Global Compact, the United Nations Guiding Principles on Business and Human Rights and OECD Guidelines for multinational enterprises.

The Investment Manager's screening process ensured that, to the best of its knowledge and belief, no companies that significantly harm environmental or social objectives were included in the Fund's eligible investment universe and, therefore, the Fund.

### Describe the actions taken to attain the sustainable investment objective

Over the reference period, the Investment Manager constructed the Fund's eligible investment universe according to the four themes set out above and only invested in companies within that eligible investment universe.

Therefore, all the companies in the portfolio passed the necessary minimum thematic threshold and did not breach the SFDR's principles 'do no significant harm' and 'good corporate governance'.

The eligible investment universe serves as a secondary, internal benchmark to the Fund, both in terms of performance and in terms of contribution to the sustainable investment objective. The Investment Manager reconsiders the companies that qualify for the eligible investment universe on a periodic basis. However, the Fund was launched end of September 2021 and the Investment Manager did not undertake the first rebalancing of the eligible investment universe during the reference period.

## Article 9 SFDR Smart Mobility Annual Report

## **Description of the Achievement of the Characteristics**

This disclosure should be read in conjunction with the Fund's prospectus and website disclosures under the Sustainable Finance Disclosure Regulation (EU) 2019/2088 ('SFDR').

In accordance with the Fund's prospectus disclosures under Article 9 of the SFDR, this Fund has as its sustainable investment objective investment in a portfolio of companies worldwide that support, through their technology solutions and services, the decarbonization and thereby electrification of the global energy sector.

The Investment Manager measures the Fund's alignment with its sustainable investment objective on a qualitative and quantitative basis by:

- 1. The alignment of the Fund's investments with the Fund's eligible investment universe, as described in the 'Investment Strategy' section of the Fund's prospectus and website SFDR disclosures.
- 2. The alignment of the Fund's investments with the Investment Manager's exclusions list for the Fund, as set out in the 'Investment Strategy' section of the Fund's prospectus and website SFDR disclosures.

During the reference period of this annual report, the Investment Manager's eligible investment universe comprised of four main themes:

- 1. EV Technologies this theme is comprised of the following sub-areas:
  - a. Batteries the sub-area covers the total electric vehicle ('EV') battery life cycle including companies that operate in the mining of materials, the manufacturing of cells, modules and packages, as well as recycling.
  - b. Electric Powertrain companies that provide materials and electric components for the EV powertrain, i.e. for the electric motor and main inverter, as well as for the on-board charger. In particular, companies that produce high-voltage power semiconductors enabling the energy-efficient conversion of electric power, as well as the control of the electric motor.
  - c. Hydrogen Fuel Cells companies that develop and manufacture hydrogen fuel cells and related components for electric vehicles.
- 2. EV Manufacturing this theme is comprised of the following sub-areas:
  - a. EV Manufacturers companies that are exclusively focused on the development and/or manufacturing of electric vehicles including 2/3 wheelers, passenger cars, commercial delivery vans and trucks, buses and aircrafts.
  - b. EV Suppliers automotive tier-one suppliers offering product solutions dedicated to the electrification of vehicles.
  - c. Process Equipment & Software engineering and software companies that provide technology solutions addressing the development, manufacturing and testing of electric vehicles and subsystems.
- 3. Autonomous Driving this theme is comprised of the following sub-areas:
  - a. Connectivity companies developing data connectivity components and solutions for improved efficiency and safety.
  - b. Sensor Technologies & AI companies developing vision, ultrasound, radar and laser sensor technologies as well as artificial intelligence enhanced data processors to enable automated/autonomous driving.
  - c. Autonomous Driving Solutions companies offering complete autonomous driving platforms including hardware systems, software and artificial intelligence algorithms for improved safety.
- 4. Shared Mobility this theme is comprised of the following sub-areas:
  - a. Public Transport & Vehicle Sharing companies that manufacture or operate electric trains for public transport as well as companies that operate shared mobility platforms
  - b. Smart Grid & Charging companies involved in the equipment, buildout and operation of electric vehicle charging infrastructure.
  - c. Green Hydrogen & Sustainable Fuels companies that are providing equipment for and/or are operating in the production of green hydrogen and sustainable fuels.

To be included in the eligible investment universe, the companies had to derive at least 20% of their current or future revenues from one of the sub-themes set out above. Over the reference period, this resulted in an eligible universe of circa 240 companies.

As at 31 December 2021, the Fund's exposures to each of the four themes were as follows:

Investment Area	Portfolio Weighting	Average Current Revenue Exposure
Autonomous Driving	14.1%	28.0%
EV Manufacturing and Infrastructure	20.5%	45.3%
EV Technologies	40.7%	20.7%
Shared Mobility	24.2%	48.0%
Cash	0.5%	0.0%

During the reference period, the Fund did not invest in any companies that were not aligned with the Fund's sustainable investment objective, by virtue of not meeting the prescribed current or future revenue exposure threshold, or companies that participated in activities linked to the Fund's exclusions criteria.

### **Describe the Fund's Top 10 Investments**

As at the last date of the reference period (31 December 2021), the top 10 holdings of the Fund were:

Holdings	Fund Weight (%)
1) ON Semiconductor	6.0%
2) Infineon Technologies	4.7%
3) Visteon	4.5%
4) Aptiv	4.2%
5) XPeng	4.2%
6) Uber Technologies	4.0%
7) Livent	4.0%
8) Power Integrations	3.9%
9) Alstom	3.9%
10) Denso	3.6%

## Description of the Percentage of the Fund's Investments that meet the Characteristics

All of the Fund's equity investments during the reference period contributed to the sustainable investment objective through their exposure to one or more of the sub-themes set out above.

The Fund did have cash and cash equivalents over the reference period. These investments did not contribute towards the sustainable investment objective and there were no environmental or social safeguards in place for these holdings as they are held for liquidity management and hedging purposes only.

## Article 9 SFDR Smart Mobility Annual Report continued

# Describe the contribution to the environmental objectives of the Taxonomy Regulation (EU) 2020/852

In accordance with the requirements of Article 5 of the Taxonomy Regulation, where the Fund invests in economic activities that contribute to an environmental objective, it must disclose the environmental objective or objectives set out in Article 9 Taxonomy Regulation to which the Fund's investments contribute and a description of how and to what extent these investments are in environmentally sustainable economic activities under Article 3 of the Taxonomy Regulation.

In implementing the investment strategy of the Fund, the Investment Manager selects investments which it believes contribute to the environmental objective of climate change mitigation under Article 9 of the Taxonomy Regulation.

In assessing whether an investment is considered to be in environmentally sustainable economic activities contributing to climate change mitigation, the Investment Manager must be satisfied that the relevant economic activity (i) contributes substantially to the environmental objective of climate change mitigation, (ii) does not significantly harm any of the environmental objectives outlined in the Taxonomy Regulation; (iii) is carried out in compliance with the minimum safeguards laid down in the Taxonomy Regulation and (iv) complies with the Technical Screening Criteria ('TSC') in respect of climate change mitigation that have been published and approved by the European Commission.

The TSC in respect of climate change mitigation were approved by the European Commission on 9 December 2021 and came into force on 1 January 2022. In addition, there is a lack of reliable, timely and verifiable data publicly reported by issuers or investee companies concerning the Taxonomy eligibility or alignment of their economic activities.

In light of the delay in approving the TSC and the challenges in obtaining data from issuers or investee companies on the Taxonomy eligibility or alignment of their economic activities, the Investment Manager is not currently in a position to assess with certainty (a) whether or not the investments underlying the Fund are in environmentally sustainable activities (b) the extent to which the investments of the Fund are in economic activities that qualify as environmentally sustainable and are aligned with the Taxonomy Regulation; (c) the proportion, as a percentage of the Fund's portfolio, of investments in environmentally sustainable activities which are aligned with the Taxonomy Regulation; and (d) the proportion, as a percentage of the Fund's portfolio, of enabling and transitional activities (as described in the Taxonomy Regulation).

Accordingly, the proportion of investments of the Fund in environmentally sustainable economic activities contributing to climate change mitigation, including in transitional and enabling activities, and aligned with the requirements of the Taxonomy Regulation is 0% of the Fund's net assets.

The Investment Manager shall, once sufficient reliable, timely and verifiable data from issuers or investee companies becomes available, update its regulatory documentation to provide an indication of the proportion of investments of the Fund which are in environmentally sustainable economic activities under the EU Taxonomy Framework.

# Describe how the Fund assessed the 'DNSH' principle for its investments over the reference period

Over the reference period, the Investment Manager carried out a screening process during the construction of its eligible investment universe to exclude any companies that significantly harm environmental or social objectives due to their involvement in a range of controversial business activities. The Investment Manager used external ESG data providers as an initial input for the screen.

The Investment Manager's screening for controversies assessment included evaluating if companies were involved in material issues that would cause harm to the Taxonomy Regulation's environmental objectives. Companies with very severe and significant controversies were excluded.

The Investment Manager screened and excluded companies from the eligible investment universe where they were exposed to involvement in controversial weapons, civilian firearms, military contracting, gambling, adult entertainment, tobacco and alcohol.

Finally, the Investment Manager applied additional exclusions based on companies' controversial products or behaviour which violated the principles of the UN Global compact, the United Nations Guiding Principles on Business and Human Rights and OECD Guidelines for multinational enterprises.

The Investment Manager's screening process ensured that, to the best of its knowledge and belief, no companies that significantly harm environmental or social objectives were included in the Fund's eligible investment universe and, therefore, the Fund.

### Describe the actions taken to attain the sustainable investment objective

Over the reference period, the Investment Manager constructed the Fund's eligible investment universe according to the four themes set out above and only invested in companies within that eligible investment universe.

Therefore, all the companies in the portfolio passed the necessary minimum thematic threshold and did not breach the principles 'do-no-significant harm' and 'good corporate governance'.

The eligible investment universe serves as a secondary, internal benchmark to the Fund, both in terms of performance and in terms of contribution to the sustainable investment objective. The Investment Manager reconsiders the companies that qualify for the eligible investment universe on a periodic basis. However, the Fund was launched end of September 2021 and the Investment Manager did not undertake the first rebalancing of the eligible investment universe during the reference period.

The remaining Funds do not have as their objective sustainable investment, nor do they promote environmental or social characteristics. As a result, the remaining Funds do not fall within the scope of the Taxonomy Regulation (EU) 2020/852 of the European Parliament and of the Council on the establishment of a framework to facilitate sustainable investment. The investments underlying these remaining Funds do not take into account the EU criteria for environmentally sustainable economic activities.

## Management and Administration

#### Directors (all non-executive):

David Astor (GB)\* Robert Bovet (MT)\* (Chairman) James Cayzer-Colvin (GB) David Hammond (IE)\* Charles Scott (GB)\* Karen Nolan (IE)\*(Appointed 16 February 2021)

\* Directors independent of the Investment Manager

#### Manager:

#### **Bridge Fund Management Limited**

Ferry House 48–53 Mount Street Lower Dublin D02 PT98 Ireland

#### **Depositary:**

#### Northern Trust Fiduciary Services (Ireland) Limited

Georges Court 54–62 Townsend Street Dublin D02 R156 Ireland

## Independent Auditor:

#### **Deloitte Ireland LLP**

Chartered Accountants & Statutory Audit Firm Deloitte & Touche House Earlsfort Terrace Dublin D02 AY28 Ireland

## Swedish Paying Agent:

#### **SEB Merchant Banking**

Sergel Tog 2 ST H1 10640 Stockholm Sweden

## German Paying and Information Agent:

## Deutsche Bank AG

Taunusanlage 12 60325 Frankfurt am Main Germany

### Austrian Paying Agent: UniCredit Bank Austria AG

Rothschildplatz 1 1020 Vienna Austria

#### **Registered Office:**

Georges Court 54–62 Townsend Street Dublin D02 R156 Ireland

### **Company Registration Number:**

348391

#### **Investment Manager and Global Distributor:**

Polar Capital LLP 16 Palace Street London SW1E 5JD United Kingdom

#### Administrator, Registrar, Transfer Agent and Company Secretary:

#### Northern Trust Fund Administration Services (Ireland) Limited

Georges Court 54–62 Townsend Street Dublin D02 R156 Ireland

#### Legal Adviser:

as to Irish law:

### **Dillon Eustace**

33 Sir John Rogerson's Quay Dublin D02 XK09 Ireland

## Sponsoring Broker:

#### **Davy Stockbroker**

Davy House 49 Dawson Street Dublin D02 PY05 Ireland

#### Swiss Paying Agent/Representative:

#### **BNP Paribas Securities Services Paris**

Succursale de Zurich Selnaustrasse 16 8002 Zürich Switzerland

## French Centralising and Paying Agent:

## **BNP Paribas Securities Services**

66 Rue de la Victoire 75009 Paris France





